

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number
WO 02/092015 A2

(51) International Patent Classification⁷: **A61K**
(21) International Application Number: PCT/US02/15982
(22) International Filing Date: 17 May 2002 (17.05.2002)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/291,311 17 May 2001 (17.05.2001) US
60/353,058 1 February 2002 (01.02.2002) US
60/361,293 4 March 2002 (04.03.2002) US

(71) Applicants (for all designated States except US):
GENOME THERAPEUTICS CORPORATION
[US/US]; 100 Beaver Street, Waltham, MA 02453 (US).
WYETH [US/US]; Five Giralda Farms, Madison, NJ
07928 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALLEN, Kristina**
[US/US]; 11 Oliver Lane, Hopkinton, MA 01748-3108

(US). **ANISOWICZ, Anthony** [US/US]; 50 Upham
Street, West Newton, MA 02465 (US). **BHAT, Bheem, M.**
[IN/US]; 1214 Mayapple Lane, West Chester, PA 19380
(US). **DAMAGNEZ, Veronique** [FR/US]; 125 Water
Street, Framingham, MA 01701 (US). **ROBINSON,**
John, Allen [US/US]; 23 Webb Road, Downingtown, PA
19335 (US). **YAWORSKY, Paul, J.** [US/US]; 13 Hobart
Lane, Rockland, MA 02370 (US).


(74) Agents: **REA, Teresa, Stanek et al.**; Burns, Doane,
Swecker & Mathis L.L.P., P.O. Box 1404, Alexandria, VA
22313-1404 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: REAGENTS AND METHODS FOR MODULATING DKK-MEDIATED INTERACTIONS



(57) Abstract: The present invention provides reagents, compounds, compositions, and methods relating to novel interactions of the extracellular domain of LRP5, HBM (a variant of LRP5), and/or LRP6 with Dkk, including Dkk-1. The various nucleic acids, polypeptides, antibodies, assay methods, diagnostic methods, and methods of treatment of the present invention are related to and impact on Dkk, LRP5, LRP6, HBM, and Wnt signaling. Dkk, LRP5, LRP6, HBM, and Wnt are implicated in bone and lipid cellular signaling. Thus, the present invention provides reagents and methods for modulating lipid levels and/or bone mass and is useful in the treatment and diagnosis of abnormal lipid levels and bone mass disorders, such as osteoporosis.



Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*

REAGENTS AND METHODS FOR MODULATING DKK-MEDIATED INTERACTIONS

FIELD OF THE INVENTION

The present invention relates to signal transduction, bone development, bone
5 loss disorders, modulation of lipid-related conditions, research reagents, methods of
screening drug leads, drug development, treatments for bone and/or lipid disorders,
screening and development of therapies, molecular, cellular, and animal models of
bone and/or lipid development and maintenance, which are mediated by Dkk,
including Dkk-1, and/or LRP5, LRP6, HBM or other members of the Wnt pathway.

BACKGROUND OF THE INVENTION

Two of the most common types of osteoporosis are postmenopausal and
senile osteoporosis. Osteoporosis affects both men and women, and, taken with
other abnormalities of bone, presents an ever-increasing health risk for an aging
15 population. The most common type of osteoporosis is that associated with
menopause. Most women lose between 20-60% of the bone mass in the trabecular
compartment of the bone within 3-6 years after the cessation of menses. This rapid
bone loss is generally associated with an increase of bone resorption and formation.
However, the resorptive cycle is more dominant and the result is a net loss of bone
20 mass. Osteoporosis is a common and serious disease among postmenopausal
women. There are an estimated 25 million women in the United States alone who
are afflicted with this disease. The results of osteoporosis are personally harmful,
and also account for a large economic loss due to its chronicity and the need for
extensive and long-term support (e.g., hospitalization and nursing home care) from
25 disease sequelae. This is especially true in elderly patients. Additionally, while
osteoporosis is generally not thought of as a life-threatening condition, a 20-30%
mortality rate is related to hip fractures in elderly women. A large percentage of this
mortality rate can be directly associated with postmenopausal osteoporosis.

The most vulnerable tissue in the bone to the effects of postmenopausal osteoporosis is the trabecular bone. This tissue is often referred to as spongy bone and is particularly concentrated near the ends of the bone, near the joints, and in the vertebrae of the spine. The trabecular tissue is characterized by small structures which inter-connect with each other as well as the more solid and dense cortical tissue which makes up the outer surface and central shaft of the bone. This criss-cross network of trabeculae gives lateral support to the outer cortical structure and is critical to the biomechanical strength of the overall structure. In postmenopausal osteoporosis, it is primarily the net resorption and loss of the trabeculae which lead to the failure and fracture of the bone. In light of the loss of the trabeculae in postmenopausal women, it is not surprising that the most common fractures are those associated with bones which are highly dependent on trabecular support, e.g., the vertebrae, the neck of the femur, and the forearm. Indeed, hip fracture, Colle's fractures, and vertebral crush fractures are indicative of postmenopausal osteoporosis. Osteoporosis affects cortical as well as trabecular bone. Alterations in endosteal bone resorption and Haversian remodeling with age affect cortical thickness and structural integrity contributing the increased risk for fracture.

One of the earliest generally accepted methods for treatment of postmenopausal osteoporosis was estrogen replacement therapy. Although this therapy frequently is successful, patient compliance is low, primarily due to the undesirable side-effects of chronic estrogen treatment. Frequently cited side-effects of estrogen replacement therapy include reinitiation of menses, bloating, depression, and, potentially, increased risk of breast or uterine cancer. In order to limit the known threat of uterine cancer in women who have not had a hysterectomy, a protocol of estrogen and progestin cyclic therapy is often employed. This protocol is similar to that used in birth control regimens, and often is not tolerated by women because of the side-effects characteristic of progestin. More recently, certain antiestrogens, originally developed for the treatment of breast cancer, have been shown in experimental models of postmenopausal osteoporosis to be efficacious. Among these agents is raloxifene (See, U.S. Patent No. 5,393,763; Black *et al.*, J.

Clin. Invest., 93:63-69 (1994); and Ettinger *et al.*, *JAMA* 282:637-45 (1999)). In addition, tamoxifen, a widely used clinical agent for treating breast cancer, has been shown to increase bone mineral density in post menopausal women suffering from breast cancer (Love *et al.*, *N. Engl. J. Med.*, 326:852-856 (1992)).

5 Another therapy for the treatment of postmenopausal osteoporosis is the use of calcitonin. Calcitonin is a naturally occurring peptide which inhibits bone resorption and has been approved for this use in many countries (Overgaard *et al.*, *Br. Med. J.*, 305:556-561 (1992)). The use of calcitonin has been somewhat limited, however. Its effects are very modest in increasing bone mineral density, and the
10 treatment is very expensive. Another therapy for the treatment of postmenopausal osteoporosis is the use of bisphosphonates. These compounds were originally developed for treating Paget's disease and malignant hypercalcemia. They have been shown to inhibit bone resorption. Alendronate, a bisphosphonate, has been approved for the treatment of postmenopausal osteoporosis. These agents may be
15 helpful in the treatment of osteoporosis, but these agents also have potential liabilities which include osteomalacia, extremely long half-life in bone (greater than 2 years), and possible "frozen bone syndrome," e.g., the cessation of normal bone remodeling.

20 Senile osteoporosis is similar to postmenopausal osteoporosis in that it is marked by the loss of bone mineral density and resulting increase in fracture rate, morbidity, and associated mortality. Generally, it occurs in later life, *i.e.*, after 70 years of age. Historically, senile osteoporosis has been more common in females, but with the advent of a more elderly male population, this disease is becoming a major factor in the health of both sexes. It is not clear what, if any, role hormones
25 such as testosterone or estrogen have in this disease, and its etiology remains obscure. Treatment of this disease has not been very satisfactory. Hormone therapy, estrogen in women and testosterone in men, has shown equivocal results; calcitonin and bisphosphonates may be of some utility.

30 The peak mass of the skeleton at maturity is largely under genetic control. Twin studies have shown that the variance in bone mass between adult monozygotic

twins is smaller than between dizygotic twins (Slemenda *et al.*, *J. Bone Miner. Res.*, 6: 561-567 (1991); Young *et al.*, *J. Bone Miner. Res.*, 6:561-567 (1995); Pocock *et al.*, *J. Clin. Invest.*, 80:706-710 (1987); Kelly *et al.*, *J. Bone Miner. Res.*, 8:11-17 (1993)). It has been estimated that up to 60% or more of the variance in skeletal mass is inherited (Krall *et al.*, *J. Bone Miner. Res.*, 10:S367 (1993)). Peak skeletal mass is the most powerful determinant of bone mass in elderly years (Hui *et al.*, *Ann. Int. Med.*, 111:355-361 (1989)), even though the rate of age-related bone loss in adult and later life is also a strong determinant (Hui *et al.*, *Osteoporosis Int.*, 1:30-34 (1995)). Since bone mass is the principal measurable determinant of fracture risk, the inherited peak skeletal mass achieved at maturity is an important determinant of an individual's risk of fracture later in life. Thus, study of the genetic basis of bone mass is of considerable interest in the etiology of fractures due to osteoporosis.

Recently, a strong interest in the genetic control of peak bone mass has developed in the field of osteoporosis. The interest has focused mainly on candidate genes with suitable polymorphisms to test for association with variation in bone mass within the normal range, or has focused on examination of genes and gene loci associated with low bone mass in the range found in patients with osteoporosis. The vitamin D receptor locus (VDR) (Morrison *et al.*, *Nature*, 367:284-287 (1994)), PTH gene (Howard *et al.*, *J. Clin. Endocrinol. Metab.*, 80:2800-2805 (1995); Johnson *et al.*, *J. Bone Miner. Res.*, 8:11-17 (1995); Gong *et al.*, *J. Bone Miner. Res.*, 10:S462 (1995)) and the estrogen receptor gene (Hosoi *et al.*, *J. Bone Miner. Res.*, 10:S170 (1995); Morrison *et al.*, *Nature*, 367:284-287 (1994)) have figured most prominently in this work. These studies are difficult because bone mass (*i.e.*, the phenotype) is a continuous, quantitative, polygenic trait, and is confounded by environmental factors such as nutrition, co-morbid disease, age, physical activity, and other factors. Also, this type of study design requires large numbers of subjects. In particular, the results of VDR studies to date have been confusing and contradictory (Garnero *et al.*, *J. Bone Miner. Res.*, 10:1283-1288 (1995); Eisman *et al.*, *J. Bone. Miner. Res.*, 10:1289-1293 (1995); Peacock, *J. Bone Miner. Res.*, 10:1294-1297 (1995)).

Furthermore, thus far, the art has not determined the mechanism(s) whereby the genetic influences exert their effect on bone mass.

While it is well known that peak bone mass is largely determined by genetic rather than environmental factors, studies to determine the gene loci (and ultimately the genes) linked to variation in bone mass are difficult and expensive. Study designs which utilize the power of linkage analysis, *e.g.*, sib-pair or extended family, are generally more informative than simple association studies, although the latter do have value. However, genetic linkage studies involving bone mass are hampered by two major problems. The first problem is the phenotype, as discussed briefly above. Bone mass is a continuous, quantitative trait, and establishing a discrete phenotype is difficult. Each anatomical site for measurement may be influenced by several genes, many of which may be different from site to site. The second problem is the age component of the phenotype. By the time an individual can be identified as having low bone mass, there is a high probability that their parents or other members of prior generations will be deceased and therefore unavailable for study, and younger generations may not have even reached peak bone mass, making their phenotyping uncertain for genetic analysis.

Thus, there is a need in the art for additional research tools for the elucidation of the molecular mechanism of bone modulation, for the screening and development of candidate drugs, and for treatments of bone development and bone loss disorders. The present invention is directed to these, as well as other, important ends.

In addition to bone modulation, the present invention relates to modulation of lipid levels. Cardiovascular disease is the most common cause of mortality in the United States, and atherosclerosis is the major cause of heart disease and stroke. It is widely appreciated that cholesterol plays an important role in atherogenesis. Normally, most cholesterol serves as a structural element in the walls of cells, whereas much of the rest is in transit through the blood or functions as the starting material for the synthesis of bile acids in the liver, steroid hormones in endocrine cells and vitamin D in skin. The transport of cholesterol and other lipids through the

circulatory system is facilitated by their packaging into lipoprotein carriers. These spherical particles comprise protein and phospholipid shells surrounding a core of neutral lipid, including unesterified ("free") or esterified cholesterol and triglycerides. Risk for atherosclerosis increases with increasing concentrations of low density lipoprotein (LDL) cholesterol, whereas risk is inversely proportional to levels of high-density lipoprotein (HDL) cholesterol. The receptor-mediated control of plasma LDL levels has been well-defined, and recent studies have now provided new insights into HDL metabolism.

The elucidation of LDL metabolism began in 1974 by Michael Brown and Joseph Goldstein. In brief, the liver synthesizes a precursor lipoprotein (very low density lipoprotein, VLDL) that is converted during circulation to intermediate density lipoprotein (IDL) and then to LDL. The majority of the LDL receptors expressed in the body are on the surfaces of liver cells, although virtually all other tissues ("peripheral tissues") express some LDL receptors. After binding, the receptor-lipoprotein complex is internalized by the cells via coated pits and vesicles, and the entire LDL particle is delivered to lysosomes, wherein it is disassembled by enzymatic hydrolysis, releasing cholesterol for subsequent cellular metabolism. This whole-particle uptake pathway is called "receptor-mediated endocytosis." Cholesterol-mediated feedback regulation of both the levels of LDL receptors and cellular cholesterol biosynthesis help ensure cellular cholesterol homeostasis. Genetic defects in the LDL receptor in humans results in familial hypercholesterolemia, a disease characterized by elevated plasma LDL cholesterol and premature atherosclerosis and heart attacks. One hypothesis for the deleterious effects of excess plasma LDL cholesterol is that LDL enters the artery wall, is chemically modified, and then is recognized by a special class of receptors called macrophage scavenger receptors, that mediate the cellular accumulation of the LDL cholesterol in the artery, eventually leading to the formation of an atherosclerotic lesion.

The major lipoprotein classes include intestinally derived chylomicrons that transport dietary fats and cholesterol, hepatic-derived VLDL, IDL, and LDL that can be atherogenic, and hepatic- and intestinally-derived HDL that are antiatherogenic.

Apoprotein B (ApoB) is necessary for the secretion of chylomicrons (ApoB48) and VLDL, IDL, and LDL (ApoB100). Plasma levels of VLDL triglycerides are determined mainly by the rates of secretion in LDL lipolytic activity. Plasma levels of LDL cholesterol are determined mainly by the secretion of ApoB100 into plasma, the efficacy with which VLDL are converted to LDL and by LDL receptor-mediated clearance. Regulation of HDL cholesterol levels is complex and is affected by rates of synthesis of its Apo proteins, rates of esterification of free cholesterol to cholesterol ester by LCAT, levels of triglyceride-rich lipoproteins and CETP-mediated transfer of cholesterol esters from HDL, and clearance from plasma of HDL lipids and Apo proteins.

Normal lipoprotein transport is associated with low levels of triglycerides and LDL cholesterol and high levels of HDL cholesterol. When lipoprotein transport is abnormal, lipoprotein levels can change in ways that predispose individuals to atherosclerosis and arteriosclerosis (see Ginsburg, *Endocrinol. Metab. Clin. North Am.*, 27:503-19 (1998)).

Several lipoprotein receptors may be involved in cellular lipid uptake. These receptors include: scavenger receptors; LDL receptor-related protein/ α 2-macroglobulin receptor (LRP); LDL receptor; and VLDL receptor. With the exception of the LDL receptor, all of these receptors are expressed in atherosclerotic lesions while scavenger receptors are mostly expressed in macrophages, the LRP and VLDL receptors may play an important role in mediating lipid uptake in smooth muscle cells (Hiltunen *et al.*, *Atherosclerosis*, 137 suppl.:S81-8 (1998)).

A major breakthrough in the pharmacologic treatment of hypercholesterolemia has been the development of the "statin" class of 3-hydroxy-3-methylglutaryl-CoA reductase (HMG CoA reductase) inhibitory drugs. 3-hydroxy-3-methylglutaryl-CoA reductase is the rate controlling enzyme in cholesterol biosynthesis, and its inhibition in the liver stimulates LDL receptor expression. As a consequence, both plasma LDL cholesterol levels and the risk for atherosclerosis decrease. The discovery and analysis of the LDL receptor system has had a profound impact on cell biology, physiology, and medicine.

HDL is thought to remove unesterified, or "free" cholesterol (FC) from peripheral tissues, after which most of the cholesterol is converted to cholesterol ester (CE) by enzymes in the plasma. Subsequently, HDL cholesterol is efficiently delivered directly to the liver and steroidogenic tissues via a selective uptake pathway and the HDL receptor, SR-BI (class B type I scavenger receptor) or, in some species, transferred to other lipoproteins for additional transport in metabolism (see Krieger, *Proc. Natl. Acad. Sci. USA*, 95:4077-4080 (1998)).

These issues illustrate a need in the art for additional research tools for the elucidation of the molecular mechanism of lipid modulation, for the screening and development of candidate drugs, and for treatments of lipid levels and lipid level modulation disorders. The present invention is directed to these, as well as other, important ends.

SUMMARY OF THE INVENTION

The present invention provides reagents, compounds, compositions and methods relating to novel interactions of the extracellular domain of LRP5, HBM (a variant of LRP5), and/or LRP6 with Dkk proteins. LRP5 is also referred to as Zmax1 or Zmax. Thus, when discussing methods, reagents, compounds, and compositions of the invention which relate to the interaction between Dkk and LRP5 (or Zmax1), the invention is also to be understood to encompass embodiments relating to interactions between Dkk and LRP6 and Dkk and HBM. Moreover, where Dkk is discussed herein, it is to be understood that the methods, reagents, compounds, and compositions of the present invention include the Dkk family members, including but not limited to Dkk-1, Dkk-2, Dkk-3, Dkk-4 and Soggy. Furthermore, the invention encompasses novel fragments of Dkk-1 which demonstrate a binding interaction between the ligand binding domain (LBD) of LRP5 and additional proteins and/or which can modulate an interaction between LRP5, or a variant or fragment thereof, and a Dkk protein. The invention provides assays, methods, compositions, and compounds relating to Dkk-Wnt signaling. Numerous Wnt proteins are compatible with the present invention, including Wnt1-Wnt19, and particularly, Wnt1, Wnt3,

Wnt3a, and Wnt10b. The present invention further provides reagents, compounds, compositions and methods modulating interactions between one or more other proteins and Dkk-1. The present invention also provides a series of peptide aptamers which bind to Dkk-1 or to LRP5 (or HBM and/or LRP6).

5 The polypeptides of the invention, for example in the form of peptide oligomers, aptamers, proteins, and protein fragments as well as the nucleic acids of the invention, for example in the form of nucleic acids which encode the polypeptides of the invention as well as antisense, or complimentary nucleic acids, are useful as reagents for the study of bone mass and lipid level modulation. The polypeptides
10 and nucleic acids of the invention are also useful as therapeutic and diagnostic agents.

 The present invention provides useful reagents for the modulation of Dkk proteins with LRP5, LRP6, and/or HBM, the modulation Dkk-1 and/or Dkk-1 interacting protein activity, and modulation of LRP5/Dkk-1, LRP6/Dkk1 and
15 HBM/Dkk-1 interactions and Dkk-1/Dkk-1 interacting protein interactions. The present invention provides a series of peptide aptamers which bind Dkk-1 or LRP5, LRP6, and/or HBM.

 An object of the invention is to provide for a method of regulating LRP5/LRP6/HBM/HBM-like activity in a subject comprising administering a
20 therapeutically effective amount of a composition which modulates Dkk activity. The subject can be a vertebrate or an invertebrate organism, but more preferably the organism is a canine, a feline, an ovine, a primate, an equine, a porcine, a caprine, a camelid, an avian, a bovine, or a rodent organism. A more preferred organism is a human. In a preferred embodiment, the Dkk protein is Dkk-1. In a particularly
25 preferred embodiment, Dkk-1 activity is decreased. In another embodiment, Dkk activity modulates bone mass and/or lipid levels. In a preferred embodiment, bone mass is increased and/or lipid levels are decreased. In another preferred embodiment, the modulation in bone mass is an increase in bone strength determined via one or more of a decrease in fracture rate, an increase in areal bone
30 density, an increase in volumetric mineral bone density, an increase in trabecular

connectivity, an increase in trabecular density, an increase in cortical density or thickness, an increase in bone diameter, and an increase in inorganic bone content. The invention further provides such a method wherein the composition comprises a Dkk, Dkk-1 or a LRP5/LRP6/HBM binding fragment thereof, such as those depicted
5 in Figure 6 or a mimetic of those fragments depicted in Figure 6. The invention further provides such a method wherein the composition comprises one or more of the proteins which interact with Dkk, including Dkk-1, such as those depicted in Figure 5, or a Dkk-binding fragment thereof, or an antisense, siRNA, or shRNA molecule which recognizes and binds to a nucleic acid encoding one or more Dkk
10 interacting or Dkk-1 interacting proteins. The invention further provides such a method wherein the composition comprises an LRP5/LRP6/Zmax1 antibody, Dkk antibody, a Dkk-1 antibody or an antibody to a Dkk-1 interacting protein. The invention further provides such a method wherein the compositions comprise an aptamer of Dkk or Dkk-1, such as those depicted in Figure 3 (SEQ ID NOs:171-188),
15 or a mimetic of such an aptamer. The method further provides that invention further provides such a method wherein the compositions comprise an aptamer of a Dkk interacting or Dkk-1 interacting protein, or a mimetic of such an aptamer.

A composition of the present invention may modulate activity either by enhancing or inhibiting the binding of Dkk to LRP5/LRP6/Zmax1, particularly Dkk-1,
20 or the binding of Dkk-1 to a Dkk-1 interacting protein, such as those shown in Figure 5. A composition of the present invention may comprise an LRP5 peptide aptamer, such as OST262 (SEQ ID NO:208), Figures 4 (SEQ ID NOs:189-192) (particularly, peptide (SEQ ID NO:191) and 13 (including SEQ IDNOs:204-214), or a mimetic of such an aptamer. Preferred compositions of the present invention also comprise
25 LRP5 antibodies.

Another aspect of the invention is to provide for a method of regulating Dkk-Wnt pathway activity in a subject comprising administering a therapeutically effective amount of a composition which modulates Dkk-Wnt pathway activity. In a preferred embodiment, the Dkk protein is Dkk-1. In a particularly preferred embodiment, Dkk-
30 1 activity is decreased. In another embodiment, Dkk activity modulates bone mass

and/or lipid levels. In a preferred embodiment, bone mass is increased and/or lipid levels are decreased. In another preferred embodiment, the modulation in bone mass is an increase in bone strength determined via one or more of a decrease in fracture rate, an increase in areal bone density, an increase in volumetric mineral bone density, an increase in trabecular connectivity, an increase in trabecular density, an increase in cortical density or thickness, an increase in bone diameter, and an increase in inorganic bone content. In another preferred embodiment, the Wnt is Wnt1-Wnt19. In a particularly preferred embodiment, the Wnt is Wnt1, Wnt3, Wnt3a, or Wnt10b. Preferred compositions comprise Dkk-modulating or Dkk-1-modulating compounds or one or more Dkk interacting or Dkk-1 interacting proteins, or a Dkk-binding fragment thereof. Other preferred Dkk modulating compositions comprise a Dkk or Dkk-1 antibody or an antibody to a Dkk interacting or Dkk-1 interacting protein. Also contemplated are antisense, siRNA, and shRNA molecules which recognize and bind to a nucleic acid encoding one or more Dkk-1 interacting proteins. The invention further provides such a method wherein the composition comprises a biologically active or LRP5/LRP6/HBM binding fragment of Dkk, including Dkk-1, such as those depicted in Figure 6 or a mimetic of those fragments depicted in Figure 6. The Dkk modulating composition may also comprise a peptide aptamer of a Dkk interacting or Dkk-1 interacting protein, or a mimetic of such an aptamer. A composition of the present invention may modulate activity either by enhancing or inhibiting the binding of Dkk, including Dkk-1, to LRP5, LRP6, or HBM or the binding of Dkk, including Dkk-1, to a Dkk interacting protein, such as those shown in Figure 5. The invention further provides such a method wherein the composition comprises an aptamer of Dkk or Dkk-1, such as those depicted. A composition of the present invention may comprise an LRP5 peptide aptamer, such as OST262 (SEQ ID NO:208). Preferred compositions of the present invention also comprise LRP5 antibodies.

A further aspect of the invention is to provide for a method of modulating Wnt signaling in a subject comprising administering a therapeutically effective amount of a composition which modulates Dkk activity or modulates Dkk interaction with LRP5

(or LRP6 or HBM). In a preferred embodiment, the Dkk protein is Dkk-1. In a particularly preferred embodiment, Dkk-1 activity is decreased. In another embodiment, Dkk activity modulates bone mass and/or lipid levels. In a preferred embodiment, bone mass is increased and/or lipid levels are decreased. In another preferred embodiment, the modulation in bone mass is an increase in bone strength determined via one or more of a decrease in fracture rate, an increase in areal bone density, an increase in volumetric mineral bone density, an increase in trabecular connectivity, an increase in trabecular density, an increase in cortical density or thickness, an increase in bone diameter, and an increase in inorganic bone content.

In another preferred embodiment, the Wnt is Wnt1-Wnt19. In a particularly preferred embodiment, the Wnt is Wnt1, Wnt3, Wnt3a, or Wnt10b. Preferred Wnt modulating compositions comprise one or more Dkk interacting or Dkk-1 interacting proteins, or a biologically active or LRP5/LRP6/HBM binding fragment thereof. Also contemplated are antisense, siRNA, and shRNA molecules which recognize and bind to a nucleic acid encoding one or more Dkk interacting or Dkk-1 interacting proteins. The invention further provides such a method wherein the composition comprises a biologically active or LRP5/LRP6/HBM binding fragment of Dkk or Dkk-1, such as those depicted in Figure 6 or a mimetic of those fragments depicted in Figure 6. The Dkk modulating composition may also comprise a peptide aptamer of a Dkk interacting or Dkk-1 interacting protein, or a mimetic of such an aptamer. A composition of the present invention may modulate activity either by enhancing or blocking the binding of Dkk, including Dkk-1, to LRP5, LRP6, or HBM or the binding of Dkk or Dkk-1 to a Dkk interacting or Dkk-1 interacting protein, such as those shown in Figure 5. The invention further provides such a method wherein compositions comprising an aptamer of Dkk or Dkk-1, such as those depicted in Figure 3 (SEQ ID NOs:171-188), or a mimetic of such an aptamer. The invention further provides such a method wherein the composition comprises a Dkk or Dkk-1 antibody or an antibody to a Dkk interacting or Dkk-1 interacting protein. The invention further provides such a method wherein compositions of an LRP5 peptide aptamer, such as OST262 (SEQ ID NO:208), Figures 4 (SEQ ID NO:189-192

(particularly peptide (SEQ ID NO:191) and Figure 13 (including SEQ ID NOs:204-214), or a mimetic of such an aptamer. Additional preferred compositions of the present invention also comprise LRP5 antibodies.

5 Additionally, the invention provides for a method of modulating bone mass and/or lipid levels in a subject comprising administering to the subject a composition which modulates Dkk activity or Dkk interaction with LRP5 in an amount effective to modulate bone mass and/or lipid levels, wherein bone mass and/or lipid levels are in need of modulation. In a preferred embodiment, the Dkk protein is Dkk-1. In a particularly preferred embodiment, Dkk-1 activity is decreased. In another
10 embodiment, Dkk activity modulates bone mass and/or lipid levels. In a preferred embodiment, bone mass is increased and/or lipid levels are decreased. In another preferred embodiment, the modulation in bone mass is an increase in bone strength determined via one or more of a decrease in fracture rate, an increase in areal bone density, an increase in volumetric mineral bone density, an increase in trabecular
15 connectivity, an increase in trabecular density, an increase in cortical density or thickness, an increase in bone diameter, and an increase in inorganic bone content. Preferred bone mass and/or lipid modulating compositions comprise one or more Dkk interacting or Dkk-1 interacting proteins, or a biologically active or LRP5/LRP6/HBM binding fragment thereof. Also contemplated are antisense,
20 siRNA, and shRNA molecules which recognize and bind to a nucleic acid encoding one or more Dkk interacting or Dkk-1 interacting proteins. The invention further provides such a method wherein the composition comprises a biologically active or LRP5/LRP6/HBM binding fragment of Dkk, including Dkk-1, such as those depicted in Figure 6 or a mimetic of those fragments depicted in Figure 6. The Dkk
25 modulating composition may also comprise a peptide aptamer of a Dkk interacting or Dkk-1 interacting protein, or a mimetic of such an aptamer. The invention further provides such a method wherein the composition comprises an aptamer of Dkk or Dkk-1, such as those depicted in Figure 3 (SEQ ID NOs:171-188), or a mimetic of such an aptamer. A composition of the present invention may modulate activity
30 either by enhancing or inhibiting the binding of Dkk, including Dkk-1, to LRP5, LRP6,

or HBM or the binding of Dkk, including Dkk-1, to a Dkk interacting protein, such as those shown in Figure 5. The invention further provides such a method wherein the composition comprises a Dkk or Dkk-1 antibody or an antibody to a Dkk interacting or Dkk-1 interacting protein. A composition of the present invention may comprise an LRP5 peptide aptamer, such as OST262 (SEQ ID NO:208), Figures 4 (SEQ ID NOs:189-192 (particularly peptide 13 (SEQ ID NO:191)) and 13 (including SEQ ID NOs:204-214), or a mimetic of such an aptamer. Preferred compositions of the present invention also comprise LRP5 antibodies. It is a further aspect of the invention that such lipid-modulated diseases include a cardiac condition, atherosclerosis, familial lipoprotein lipase deficiency, familial apoprotein CII deficiency, familial type 3 hyperlipoproteinemia, familial hypercholesterolemia, familial hypertriglyceridemia, multiple lipoprotein-type hyperlipidemia, elevated lipid levels due to dialysis and/or diabetes, and an elevated lipid level of unknown etiology.

Bone disorders contemplated for treatment and/or diagnosis by the methods and compositions disclosed herein include a bone development disorder, a bone fracture, age related loss of bone, a chondrodystrophy, a drug-induced bone disorder, high bone turnover, hypercalcemia, hyperostosis, osteogenesis imperfecta, osteomalacia, osteomyelitis, osteoporosis, Paget's disease, osteoarthritis, and rickets.

It is a further object of the invention to provide a method of screening for compounds or compositions which modulates the interaction of Dkk with LRP5, LRP6, HBM, or a Dkk-binding fragment of LRP5, LRP6, or HBM comprising:

- (a) exposing Dkk or a LRP5/LRP6/HBM binding fragment thereof to a compound; and
- (b) determining whether said compound binds to Dkk or the LRP5/LRP6/HBM binding fragment thereof.

In a preferred embodiment, the Dkk is Dkk-1. In a particularly preferred embodiment, the binding of Dkk-1 to LRP5/LRP6/HBM is decreased.

It is a further object of the invention to provide a method of screening compounds or compositions which modulate the interaction of DKK with LRP5, LRP6, HBM, or a DKK-binding fragment thereof comprising:

- (a) exposing DKK or a LRP5/LRP6/HBM binding fragment thereof to a compound; and,
- (b) determining whether said compound modulates the interaction of Dkk with LRP5, LRP6, or HBM, or the Dkk-binding fragment of LRP5/LRP6/HBM.

In a preferred embodiment, the Dkk is Dkk-1. In a particularly preferred embodiment, the interaction of Dkk-1 with LRP5/LRP6/HBM is decreased.

It is a further object of the invention to provide a method of screening for compounds or compositions which modulates the interaction of Dkk with LRP5, LRP6, HBM, or a Dkk-binding fragment of LRP5, LRP6, or HBM comprising:

- (a) exposing Dkk or a LRP5/LRP6/HBM binding fragment thereof to a compound;
- (b) determining whether said compound binds to Dkk or the LRP5/LRP6/HBM binding fragment thereof; and,
- (c) further determining whether said compound modulates the interaction of Dkk with LRP5, LRP6, or HBM, or the Dkk-binding fragment of LRP5/LRP6/HBM.

In preferred embodiments of such methods, Dkk or a biologically active fragment thereof is attached to a solid substrate. In an alternative embodiment of the invention, LRP5/LRP6/HBM, or a biologically active fragment thereof (such as the ligand binding domain), is exposed to the compound. Another aspect of the invention provides for compounds and compositions identified by the disclosed methods. A preferred embodiment of the invention provides that the compound screened in an afore-mentioned method is one or more proteins which interact with Dkk, particularly Dkk-1, as depicted in Figure 5, or a LRP5/LRP6/HBM-binding fragment thereof. Another preferred embodiment provides that the compound comprises a Dkk or Dkk-1 peptide aptamer, such as those depicted in Figure 3 (SEQ

ID NOs:171-188), or a mimetic of such aptamers. The compound may also comprise a peptide aptamer of a Dkk interacting or Dkk-1 interacting protein, or a mimetic of such an aptamer. The method further provides that the compound comprises a Dkk or Dkk-1 antibody or an antibody to a Dkk-1 interacting protein.

5 The invention further provides that the compound may comprise an LRP5 peptide aptamer, such as OST262 (SEQ ID NO:208), Figure 4 (SEQ ID NOs:189-192) (particularly peptide 13 (SEQ ID NO:191)) and Figure 13 (including SEQ ID NOs:204-214), or a mimetic of such an aptamer. Preferred compounds of the present invention also comprise LRP5 antibodies.

10 It is a further object of the invention to provide a method of screening for compounds or compositions which modulate the interaction of Dkk and a Dkk interacting protein comprising:

- (a) exposing a Dkk interacting proteins or a Dkk-binding fragment thereof to a compound; and,
- 15 (b) determining whether said compound binds to a Dkk interacting proteins or the Dkk-binding fragment thereof.

In a preferred embodiment, the Dkk is Dkk-1.

20 It is a further object of the invention to provide a method of screening for compounds or compositions which modulate the interaction of Dkk and a Dkk interacting protein comprising:

- (a) exposing Dkk interacting protein(s) or a Dkk-binding fragment thereof to a compounds; and,
- 25 (b) determining whether said compound modulates the interaction of Dkk and Dkk interacting proteins.

It is a further object of the invention to provide a method of screening for compounds or compositions which modulate the interaction of Dkk and a Dkk interacting protein comprising:

- 30 (a) exposing a Dkk interacting proteins or a Dkk-binding fragment thereof to a compound;

- (b) determining whether said compound binds to a Dkk interacting proteins or the Dkk-binding fragment thereof; and,
- (c) further determining whether said compound modulates the interaction of Dkk and Dkk interacting proteins.

In a preferred embodiment, Dkk is Dkk-1.

In preferred embodiments of such methods, the Dkk interacting proteins, particularly Dkk-1 interacting proteins, or a Dkk-binding fragment thereof are attached to a solid substrate. Another aspect of the invention provides for compounds and compositions identified by the disclosed methods. A preferred embodiment provides that the compound comprises a Dkk or Dkk-1 peptide aptamer, such as those depicted in Figure 3 (SEQ ID NOs:171-188), or a mimetic of such aptamers. The compound may also comprise a peptide aptamer of a Dkk interacting or Dkk-1 interacting protein, or a mimetic of such an aptamer. The compound may also comprise an antibody to a Dkk interacting or Dkk-1 interacting protein.

It is another object of the invention to provide for a composition for treating bone mass disorders comprising a LRP5/LRP6/HBM modulating compound and a pharmaceutically acceptable excipient and/or carrier therefor. Preferred LRP5 (or LRP6 or HBM) modulating compounds include Dkk or Dkk-1 or a LRP5/LRP6/HBM binding fragment thereof. Also contemplated are compounds which comprise monoclonal or polyclonal antibodies or immunologically active fragments thereof which bind to Dkk, including Dkk-1, and a pharmaceutically acceptable excipient and/or carrier. Another preferred embodiment provides that the modulating compound comprises one or more Dkk interacting or Dkk-1 interacting proteins, or a biologically active fragment thereof. Also contemplated are compounds which comprise monoclonal or polyclonal antibodies or immunologically active fragments thereof which bind to Dkk interacting or Dkk-1 interacting proteins, or a biologically active fragment thereof, and a pharmaceutically acceptable excipient and/or carrier.

Another preferred embodiment provides that the modulating compound comprises an antisense, siRNA, and shRNA molecule which recognizes and binds to a nucleic acid encoding a Dkk interacting or Dkk-1 interacting protein. Another preferred embodiment provides that the modulating compound comprises a Dkk or Dkk-1 peptide aptamer, a mimetic of a Dkk or Dkk-1 peptide aptamer, a peptide aptamer of a Dkk interacting or Dkk-1 interacting protein, or a mimetic of such an aptamer. Another embodiment provides that the compound comprises an LRP5 peptide aptamer, such as OST262 (SEQ ID NO:208), Figure 4 (SEQ ID NOs:189-192) (particularly peptide) and Figure 13 (including SEQ ID NOs:204-214), or a mimetic of such an aptamer. Preferred compounds of the present invention also comprise LRP5 antibodies.

It is a further object of the invention to provide a pharmaceutical composition for treating a Dkk-mediated disease or condition comprising a compound which modulates Dkk activity and a carrier therefor, including pharmaceutically acceptable excipients. Such compositions include those wherein the compound comprises an antisense, siRNA, and shRNA molecule or an antibody which binds to Dkk, including Dkk-1, and thereby prevents it from interacting with LRP5, LRP6, or HBM. Other such compositions include one or more of Dkk interacting or Dkk-1 interacting proteins, such as those depicted in Figure 5, or a Dkk-binding fragment thereof, or a monoclonal or polyclonal antibody, or immunologically active fragment thereof, which binds to a Dkk interacting or Dkk-1 interacting protein or Dkk-binding fragment thereof. Other contemplated compositions include antisense, siRNA, and shRNA molecules which recognize and bind to a nucleic acid encoding a Dkk interacting or Dkk-1 interacting protein. Further contemplated compositions include Dkk and Dkk-1 peptide aptamers, such as those depicted in Figure 3 (SEQ ID NOs:171-188), mimetics of such aptamers, a peptide aptamer of a Dkk interacting or Dkk-1 interacting protein, or a mimetic of such an aptamer. Other contemplated compositions comprise an LRP5 peptide aptamer, such as OST262 (SEQ ID NO:208), Figure 4 (SEQ ID NOs:189-192) (particularly peptide 13 (SEQ ID NO:191))

and Figure 13 (including SEQ ID NO:204-214), or a mimetic of such an aptamer. Other preferred compositions of the present invention comprise LRP5 antibodies.

A further object of the invention to provide for a method of modulating the expression of a nucleic acid encoding a Dkk interacting or Dkk-1 interacting protein in an organism, such as those shown in Figure 5, comprising the step of administering to the organism an effective amount of composition which modulates the expression of a nucleic acid encoding a Dkk-1 interacting protein. In a preferred embodiment, said composition comprises an antisense, siRNA, or shRNA molecule which recognizes and binds to a nucleic acid encoding a Dkk interacting or Dkk-1 interacting protein.

One aspect of the invention provides for a method of modulating at least one activity of Dkk or a Dkk-1 interacting protein comprising administering an effective amount of a composition which modulates at least one activity of Dkk or a Dkk-1 interacting protein. The invention provides for a composition comprising a Dkk interacting or Dkk-1 interacting protein, such as those shown in Figure 5, or a biologically active fragment thereof. Other agents contemplated for this method are antisense, siRNA, or shRNA molecules which recognize and bind to a nucleic acid encoding a Dkk interacting or Dkk-1 interacting protein. The method further provides that the composition comprises a Dkk or Dkk-1 antibody or an antibody to a Dkk interacting or Dkk-1 interacting protein. In another preferred embodiment, the composition comprises a Dkk or Dkk-1 peptide aptamer, a mimetic of a Dkk or Dkk-1 peptide aptamer, a peptide aptamer of a Dkk interacting or Dkk-1 interacting protein, or a mimetic of such an aptamer. The method provides that a composition of the present invention may comprise an LRP5 peptide aptamer, such as OST262 (SEQ ID NO:208), Figure 4 (SEQ ID NO:189-192) (particularly peptide including (SEQ ID NO:191)) and Figure including (SEQ ID NOs:204-214), or a mimetic of such an aptamer. Preferred compositions of the present invention also comprise LRP5 antibodies. In a further preferred embodiment, the modulated Dkk activity is lipid modulation or bone mass modulation.

In all of the testing/screening embodiments of the present invention discussed below to obtain compounds or compositions which ultimately impact LRP5/LRP6/HBM signaling, one skilled in the art will recognize that HBM can be used as a control in the absence of a test sample or compound. Further, the effect of a test sample of compound on Wnt signaling through the interaction of Dkk with LRP5/LRP6/HBM does not necessarily require a direct measurement of an association or interaction of Dkk and LRP5/LRP6/HBM. Other positive phenotypes/activities established by the High Bone Mass phenotype or by using HBM as a control.

One aspect of the invention provides for a method of identifying binding partners for a Dkk protein comprising the steps of:

- (a) exposing the Dkk protein(s) or a LRP5/LRP6 binding fragment thereof to a potential binding partner; and
- (b) determining if the potential binding partner binds to a Dkk protein or the LRP5/LRP6 binding fragment thereof.

In a preferred embodiment, the Dkk is Dkk-1.

Another aspect of the invention is to provide for a method of identifying a compound that effects Dkk-mediated activity comprising

- (a) providing a group of transgenic animals having (1) a regulatable one or more Dkk interacting protein genes, (2) a knock-out of one or more Dkk interacting protein genes, or (3) a knock-in of one or more Dkk interacting protein genes;
- (b) providing a second group of control animals respectively for the group of transgenic animals in step (a); and
- (c) exposing the transgenic animal group and the control animal group to a potential Dkk-modulating compound which modulates bone mass or lipid levels; and

- (d) comparing the transgenic animal group and the control animal group and determining the effect of the compound on bone mass or lipid levels in the transgenic animals as compared to the control animals.

5

In a preferred embodiment, the Dkk is Dkk-1.

It is another aspect of the invention to provide for a method for determining whether a compound modulates a Dkk interacting protein, said method comprising the steps of:

10

- (a) mixing the Dkk interacting protein or a Dkk-binding fragment thereof with the ligand binding domain of Dkk in the presence of said at least one compound;

15

- (b) measuring the amount of said binding domain of Dkk bound to said Dkk interacting protein or the Dkk-binding fragment thereof as compared to a control without said at least one compound; and

20

- (c) determining whether the compound reduces the amount of said binding domain of Dkk binding to said Dkk interacting protein or Dkk-binding fragment thereof.

In a preferred embodiment, the Dkk is Dkk-1.

In a preferred embodiment, the binding domain is attached to a solid substrate. The invention further provides for compounds identified by this method.

25

In a preferred embodiment, the invention provides that the Dkk interacting or Dkk-1 interacting protein is detected by antibodies. In another preferred embodiment, the solid substrate is a microarray. Another preferred embodiment provides that the ligand binding domain of Dkk and/or Dkk interacting protein is fused or conjugated to a peptide or protein. The invention also provides that the compounds include Dkk

and Dkk-1 peptide aptamers, mimetics of Dkk and Dkk-1 peptide aptamers, Dkk and Dkk-1 interacting proteins peptide aptamers, or mimetics of such aptamers.

An aspect of the invention provides a composition comprising one or more polypeptide sequences of one or more Dkk-1 interacting proteins, or a biologically active fragment thereof, one or more Dkk proteins, or a biologically active fragment thereof, or LRP5/LRP6/HBM polypeptide sequences or a biologically active fragment thereof (for example, the ligand binding domain) and a pharmaceutically acceptable excipient and/or carrier. Another aspect of the invention provides that the composition comprises a Dkk or Dkk-1 antibody or an antibody to a Dkk interacting or Dkk-1 interacting protein and a pharmaceutically acceptable excipient. A composition of the present invention may comprise an LRP5 peptide aptamer, such as OST262 (SEQ ID NO:208), Figure 4 (SEQ ID NOs:189-192) (particularly peptide 13 (SEQ ID NO:191)) and Figure 13 (including SEQ ID NOs:204-214), or a mimetic of such an aptamer. A composition of the present invention may comprise a Dkk peptide aptamer, for example as shown in Figure 3 (SEQ ID NOs:171-188). Preferred compositions of the present invention also comprise LRP5 antibodies.

Another aspect of the invention is to provide an antibody or immunologically active antibody fragment which recognizes and binds to a Dkk-1 amino acid sequence selected from the group consisting of: Asn34-His266 (SEQ ID NO:110), Asn34-Cys245 (SEQ ID NO:111), Asn34-Lys182 (SEQ ID NO:112), Cys97-His266 (SEQ ID NO:113), Val139-His266 (SEQ ID NO:114), Gly183-His266 (SEQ ID NO:115), Cys97-Cys245 (SEQ ID NO:116), or Val139-Cys245 (SEQ ID NO:117) of human Dkk-1. Additional antibodies may bind to any of the sequences depicted in Figures 3 (SEQ ID NOs:171-188) and Figure 4 (SEQ ID NOs:189-192). Another aspect of the invention is to provide for polyclonal antibodies to one or more amino acid sequences: Peptide 1 -GNKYQTIDNYQPYPYPC (SEQ ID NO:118), Peptide 2 -LDGYSRRTTLSSKMYHTKGQEG (SEQ ID NO:119), Peptide 3 -RIQKDHQASNSSRLHTCQRH (SEQ ID NO:120), Peptide 4 -RGEIETITESFGND (SEQ ID NO:121), and Peptide 5 -EIFQRCYCGEGLSCRIQKD (SEQ ID NO: 122).

It is a further object of the invention to provide a nucleic acid encoding a Dkk protein, e.g. Dkk-1, a Dkk interacting or Dkk-1 interacting protein aptamer, or an LRP5 aptamer comprising a nucleic acid encoding a scaffold protein in-frame with the activation domain of Gal4 or LexA that is in-frame with a nucleic acid which
5 encodes for a Dkk or Dkk-1 or Dkk interacting or Dkk-1 interacting protein amino acid sequence. Preferably the scaffold protein is thioredoxin (trxA), S1 nuclease from *Staphylococcus* or M13. Other preferable embodiments include Dkk-1 amino acid sequences selected from Figure 6.

It is yet a further object of the invention to provide a composition comprising a
10 polypeptide sequence of Figure 3 (SEQ ID NOs:171-188), Figure 4 (SEQ ID NO:189-192), or of Dkk-1 interacting proteins identified in Figure 5 and a pharmaceutically acceptable excipient and/or carrier.

Another aspect of the invention includes a method of detecting the modulatory activity of a compound on the binding interaction of a first peptide and a second
15 peptide of a peptide binding pair that bind through extracellular interaction in their natural environment, comprising:

- (i) culturing at least one eukaryotic cell, wherein the eukaryotic cell comprises;
 - a) a nucleotide sequence encoding a first heterologous
20 fusion protein comprising the first peptide or a segment thereof joined to a DNA binding domain of a transcriptional activation protein;
 - b) a nucleotide sequence encoding a second heterologous
25 fusion protein comprising the second peptide or a segment thereof joined to a transcriptional activation domain of a transcriptional activation protein;

wherein binding of the first peptide or segment thereof and the second peptide or segment thereof reconstitutes a transcriptional activation protein; and

c) a reporter element activated under positive transcriptional control of the reconstituted transcriptional activation protein, wherein expression of the reporter element produces a selected phenotype;

- 5 (ii) incubating a compound with the eukaryotic cell under conditions suitable to detect the selected phenotype; and
- (iii) detecting the ability of the compound to affect the binding interaction of the peptide binding pair by determining whether the compound affects the expression of the reporter element which produces the
- 10 selected phenotype;

wherein (1) said first peptide is a Dkk peptide and said second peptide is a peptide selected from LRP5, HBM, LRP6, and the Dkk-binding portion of LRP5/LRP6/HBM or (2) said first peptide is a Dkk-interacting protein or the Dkk-binding fragment thereof, and said second peptide is a Dkk peptide.

15 In one embodiment, the eukaryotic cell is a yeast cell. In a preferred embodiment, the yeast cell is *Saccharomyces*. In a particularly preferred embodiment, the *Saccharomyces* cell is *Saccharomyces cerevisiae*. The invention further provides that the compound may comprise a Dkk interacting or Dkk-1 interacting protein, or a biologically active fragment thereof. In one embodiment, the

20 Dkk interacting or Dkk-1 interacting protein, or a Dkk-binding fragment thereof, is added directly to the assay. In another embodiment, the Dkk interacting or Dkk-1 interacting protein, or a Dkk-binding fragment thereof, is recombinantly expressed by the eukaryotic cell in addition to the first and second peptides. In a preferred

25 embodiment the compound comprises a Dkk or Dkk-1 aptamer, a mimetic of a Dkk or Dkk-1 peptide aptamer, a Dkk interacting or Dkk-1 interacting protein aptamer, or a mimetic of a Dkk-1 interacting protein aptamer. Other preferred embodiments provide that the compound comprises an LRP5 peptide aptamer, such as OST262 (SEQ ID NO:208), Figure 4 (SEQ ID NOs:189-192) (particularly peptide 13 (SEQ ID NO:191) and Figure 13 (including SEQ ID NOs:204-214), or a mimetic of such an

30 aptamer. Alternatively, the present invention also provides that the compound may

comprise LRP5 antibodies or Dkk antibodies. In another embodiment, the yeast cell further comprises at least one endogenous nucleotide sequence selected from the group consisting of a nucleotide sequence encoding the DNA binding domain of a transcriptional activation protein, a nucleotide sequence encoding the transcriptional activation domain of a transcriptional activation protein, and a nucleotide sequence encoding the reporter element, wherein at least one of the endogenous nucleotide sequences is inactivated by mutation or deletion. In another embodiment, the peptide binding pair comprises a ligand and a receptor to which the ligand binds. In one embodiment, the transcriptional activation protein is Gal4, Gcn4, Hap1, Adr1, Swi5, Ste12, Mcm1, Yap1, Ace1, Ppr1, Arg81, Lac9, Qa1F, VP16, or a mammalian nuclear receptor. In another embodiment, at least one of the heterologous fusion proteins is expressed from an autonomously-replicating plasmid. In one embodiment, the DNA binding domain comprises a heterologous DNA-binding domain of a transcriptional activation protein. In a preferred embodiment, the DNA binding protein is selected from the group consisting of a mammalian steroid receptor and bacterial LexA protein. In another embodiment, the reporter element is selected from the group consisting of *lacZ*, a polynucleotide encoding luciferase, a polynucleotide encoding green fluorescent protein (GFP), and a polynucleotide encoding chloramphenicol acetyltransferase. In a particularly preferred embodiment, the reporter element is *lacZ*.

The invention further provides for a rescue screen for detecting the activity of a compound for modulating the binding interaction of a first peptide and a second peptide of a peptide binding pair, comprising:

- (i) culturing at least one yeast cell, wherein the yeast cell comprises;
 - a) a nucleotide sequence encoding a first heterologous fusion protein comprising the first peptide or a segment thereof joined to a DNA binding domain of a transcriptional activation protein;
 - b) a nucleotide sequence encoding a second heterologous

fusion protein comprising the second peptide or a segment thereof joined to a transcriptional activation domain of a transcriptional activation protein;

wherein binding of the first peptide or segment thereof and the second peptide or segment thereof reconstitutes a transcriptional activation protein; and

c) a reporter element activated under positive transcriptional control of the reconstituted transcriptional activation protein, wherein expression of the reporter gene prevents exhibition of a selected phenotype;

(ii) incubating a compound with the yeast cell under conditions suitable to detect the selected phenotype; and

(iii) detecting the ability of the compound to affect the binding interaction of the peptide binding pair by determining whether the compound affects the expression of the reporter element which prevents exhibition of the selected phenotype,

wherein said first peptide is a Dkk peptide and said second peptide is a peptide selected from LRP5, HBM, LRP6 and a Dkk-binding fragment of LRP5/LRP6/HBM.

In a preferred embodiment, the invention provides that the yeast cell is *Saccharomyces*. In a particularly preferred embodiment, the *Saccharomyces* cell is *Saccharomyces cerevisiae*. In one embodiment, the compound comprises one or more Dkk interacting or Dkk-1 interacting proteins, or a Dkk-binding fragment thereof. Compounds used in the present invention may comprise an LRP5 peptide aptamer, such as OST262 (SEQ ID NO:208), Figure 4 (SEQ ID NOs:189-192) (particularly peptide 13 (SEQ ID NO:191)) and Figure 13 (including SEQ ID NOs:204-214), or a mimetic of such an aptamer. Alternatively, the compound may comprise LRP5 antibodies or Dkk antibodies. In another embodiment, the yeast cell further comprises at least one endogenous nucleotide sequence selected from the group consisting of a nucleotide sequence encoding the DNA binding domain of a

transcriptional activation protein, a nucleotide sequence encoding the transcriptional activation domain of a transcriptional activation protein, and a nucleotide sequence encoding the reporter gene, wherein at least one of the endogenous nucleotide sequences is inactivated by mutation or deletion. In another embodiment, the transcriptional activation protein is Gal4, Gcn4, Hap1, Adr1, Swi5, Ste12, Mcm1, Yap1, Ace1, Ppr1, Arg81, Lac9, Qa1F, VP16, or a mammalian nuclear receptor. In one embodiment, at least one of the heterologous fusion proteins is expressed from an autonomously-replicating plasmid. In another embodiment, the DNA binding domain is a heterologous DNA-binding domain of a transcriptional activation protein.

The invention also provides for a rescue screen for detecting the modulatory activity of a compound on the binding interaction of a first peptide and a second peptide of a peptide binding pair, comprising:

(i) culturing at least one yeast cell, wherein the yeast cell comprises;

- a) a nucleotide sequence encoding a first heterologous fusion protein comprising the first peptide or a segment thereof joined to a DNA binding domain of a transcriptional activation protein;
- b) a nucleotide sequence encoding a second heterologous fusion protein comprising the second peptide or a segment thereof joined to a transcriptional activation domain of a transcriptional activation protein;

wherein binding of the first peptide or segment thereof and the second peptide or segment thereof reconstitutes a transcriptional activation protein; and

- c) a reporter element activated under positive transcriptional control of the reconstituted transcriptional activation protein, wherein expression of the reporter element prevents exhibition of a selected phenotype;

(ii) incubating a compound with the yeast cell under conditions suitable to detect the selected phenotype; and

- (iii) detecting the ability of the compound to affect the binding interaction of the peptide binding pair by determining whether the compound affects the expression of the reporter element which prevents exhibition of the selected phenotype,

5 wherein said first peptide is a Dkk interacting or Dkk-1 interacting protein peptide and said second peptide is a Dkk or Dkk-1 peptide.

In a preferred embodiment of the rescue screen, the yeast cell is

Saccharomyces. In a particularly preferred embodiment, the *Saccharomyces* cell is *Saccharomyces cerevisiae*. In another embodiment, the yeast cell further comprises
10 at least one endogenous nucleotide sequence selected from the group consisting of a nucleotide sequence encoding the DNA binding domain of a transcriptional activation protein, a nucleotide sequence encoding the transcriptional activation domain of a transcriptional activation protein, and a nucleotide sequence encoding the reporter gene, wherein at least one of the endogenous nucleotide sequences is
15 inactivated by mutation or deletion. In one embodiment, the transcriptional activation protein is Gal4, Gcn4, Hap1, Adr1, Swi5, Ste12, Mcm1, Yap1, Ace1, Ppr1, Arg81, Lac9, Qa1F, VP16, or a mammalian nuclear receptor. In another embodiment of the rescue screen, at least one of the heterologous fusion proteins is expressed from an autonomously-replicating plasmid. In another embodiment, the DNA binding domain
20 is a heterologous DNA-binding domain of a transcriptional activation protein.

The invention also provides for a method for identifying potential compounds which modulate Dkk activity comprising:

- a) measuring the effect on binding of one or more Dkk interacting protein, or a Dkk-binding fragment thereof, with Dkk or a
25 LRP5/LRP6/HBM binding fragment thereof in the presence and absence of a compound; and
- b) identifying as a potential Dkk modulatory compound a compound which modulates the binding between one or more Dkk interacting proteins or Dkk-binding fragment thereof and
30 Dkk or LRP5/LRP6/HBM fragment thereof.

In a preferred embodiment, the Dkk is Dkk-1.

The invention further provides for any of the Dkk peptide aptamers of Figure 3 (SEQ ID NOs:171-188). The invention also provides for any of the LRP peptide aptamers of Figure 4 (SEQ ID NOs:189-192).

5 Another aspect of the invention provides for a method of identifying agents which modulate the interaction of Dkk with the Wnt signaling pathway comprising:

(a) injecting mRNA encoding Dkk and an agent into a *Xenopus* blastomere;

(b) assessing axis duplication or analyzing marker gene expression; and

10 (c) identifying agents which elicit changes in axis duplication or marker gene expression as agents which modulate the interaction of Dkk with the Wnt signaling pathway. Wherein the agent may be chosen from among mRNA encoding Dkk interacting proteins, fragments thereof, siRNA, shRNA, antisense nucleotides, and antibodies. In a preferred embodiment, Dkk is Dkk-1. In a further embodiment, mRNA of HBM, LRP5/6, any Wnt (including Wnt1-Wnt19, particularly Wnt1, Wnt3, Wnt3a, and Wnt10b), Wnt antagonist, or combination of these is co-injected into the *Xenopus* blastomere. In another embodiment, the marker gene analyzed could include Siamois, Xnr3, slug, Xbra, HNK-1, endodermin, Xlhx8, BMP2, BMP4, XLRP6, EF-1, or ODC.

20 The present invention provides for a method for identifying agents which modulate the interaction of Dkk with the Wnt signaling pathway comprising:

(a) transfecting cells with constructs encoding Dkk and potential Dkk interacting proteins, mRNA fragments thereof, siRNA, shRNA, or antisense, antibodies to LRP5/HBM/LRP6/Dkk/Dkk-interacting protein;

25 (b) assessing changes in expression of a reporter gene linked to a Wnt-responsive promoter; and,

(c) identifying as a Dkk interacting protein any protein which alters reporter gene expression compared with cells transfected with a Dkk construct alone. In a further preferred embodiment, the cells may be HOB-03-CE6, HEK293, or U2OS cells.

30

In alternative embodiments, the Wnt-responsive promoter is TCF or LEF. In other preferred embodiments, the cells are co-transfected with CMV beta-galactosidase or tk-Renilla.

The present invention further provides for a LRP5/HBM monoclonal or polyclonal antibody to one or more peptides of amino acid sequences MYWTDWVETPRIE (SEQ ID NO:123), MYWTDWGETPRIE (SEQ ID NO:124), KRTGGKRKEILSA (SEQ ID NO:125), ERVEKTTGDKRTRIQGR (SEQ ID NO:126), or KQQCDSFPDCIDGSDE (SEQ ID NO:127).

Additionally, the present invention provides a method for identifying compounds which modulate Dkk and LRP5/LRP6/HBM interactions comprising:

- (a) immobilizing LRP5/LRP6/HBM to a solid surface; and
- (b) treating the solid surface with a secreted Dkk protein or a secreted epitope-tagged Dkk and a test compound; and
- (c) determining whether the compound regulates binding between Dkk and LRP5/LRP6/HBM using antibodies to Dkk or the epitope tag or by directly measuring activity of an epitope tag.

In one embodiment, the Dkk is Dkk-1. In a preferred embodiment, the epitope tag is alkaline phosphatase, histidine, myc, or a V5 tag.

Another embodiment of the present invention provides for a method for identifying compounds which modulate Dkk and LRP5/LRP6/HBM interactions comprising:

- (a) creating an LRP5, LRP6, or HBM fluorescent fusion protein using a first fluorescent tag;
- (b) creating a Dkk fusion protein comprising a second fluorescent tag;
- (c) adding a test compound; and,
- (d) assessing changes in the ratio of fluorescent tag emissions using Fluorescence Resonance Energy Transfer (FRET) or Bioluminescent Resonance Energy Transfer (BRET) to determine whether the compound modulates Dkk and LRP5/LRP6/HBM interactions.

In a preferred embodiment, the Dkk is Dkk-1.

The present invention also provides for a method of diagnosing low or high bone mass and/or low or high lipid levels in a subject comprising examining expression of Dkk, LRP5, LRP6, HBM or HBM-like variant in the subject and determining whether Dkk, LRP5, LRP6, or HBM or a HBM-like variant is over- or under-expressed to determine whether subject has (a) high or low bone mass and/or (b) high or low lipid levels.

The invention further provides for a transgenic animal wherein Dkk is knocked out in a tissue-specific fashion. In a preferred embodiment, the Dkk is Dkk-1. In one preferred embodiment, the tissue specificity is bone tissue. In another preferred embodiment, the tissue specificity is liver or other tissues or cells involved in regulating lipid metabolism or cancer tissue.

The present invention further provides a method of screening for compounds which modulate the interaction of Dkk with LRP5, LRP6, or HBM comprising:

- (a) exposing LRP5, LRP6, or HBM, or a Dkk-binding fragment of LRP5, LRP6, or HBM to a compound; and
- (b) determining whether said compound bound to LRP5, LRP6, or HBM or the Dkk-binding fragment of LRP5, LRP6, or HBM and further determining whether said compound modulates the interaction of Dkk and LRP5, LRP6, or HBM.

In one embodiment, the Dkk is Dkk-1. In a preferred embodiment, the compound comprises an LRP5 peptide aptamer. Other preferred compositions include the peptide aptamer, OST262 (SEQ ID NO:208), Figure 4 (SEQ ID NOs:189-192) (particularly peptide 13 (SEQ ID NO:191) and Figure 13 (including SEQ ID NOs:204-214), or a mimetic of such an aptamer, and an LRP5 antibody.

The present invention also provides a method for identifying compounds which modulate Dkk and LRP5/LRP6/HBM interactions comprising:

- (a) immobilizing LRP5/LRP6/HBM to a solid surface; and
- (b) treating the solid surface with a secreted Dkk protein or a secreted epitope-tagged Dkk and a test compound; and

- (c) determining whether the compound regulates binding between Dkk and LRP5/LRP6/HBM using antibodies to Dkk or the epitope tag or by directly measuring activity of an epitope tag. In a preferred embodiment, the epitope tag is alkaline phosphatase, histidine, myc or a V5 tag.

In a preferred embodiment, the Dkk is Dkk-1.

The invention also provides for a method for identifying compounds which modulate the interaction of Dkk with the Wnt signaling pathway comprising:

- (a) transfecting cells with constructs containing Dkk and Wnt proteins;
(b) assessing changes in expression of a reporter element linked to a Wnt-responsive promoter; and
(c) identifying as a Dkk/Wnt interaction modulating compound any compound which alters reporter gene expression compared with cells transfected with a Dkk construct alone.

In one embodiment, the Dkk is Dkk-1. In another embodiment, the Wnt is any of Wnt1-Wnt19. In a preferred embodiment, the Wnt is Wnt1, Wnt3, Wnt3a, or Wnt10b. In a particularly preferred embodiment, the Wnt construct contains Wnt3a. In another particularly preferred embodiment, the Wnt construct contains Wnt1. In another preferred embodiment, the Wnt construct encodes for a Wnt that signals through the canonical Wnt pathway. In a particularly preferred embodiment, both Wnt3a and Wnt1 constructs are co-transfected into the cells. In another embodiment, the cells may be U2-OS, HOB-03-CE6, or HEK293 cells. In another embodiment, the reporter element used is TCF-luciferase, tk-Renilla, or a combination thereof.

The invention also provides for a method of testing compounds that modulate Dkk-mediated activity in a mammal comprising:

- (a) providing a group of transgenic animals having (1) a regulatable one or more Dkk genes, (2) a knock-out of Dkk genes, or (3) a knock-in of one or more Dkk genes;

- (b) providing a second group of control animals respectively for the group of transgenic animals in step (a); and
- (c) exposing the transgenic animal group and control animal group to a potential Dkk-modulating compound which modulates bone mass or lipid levels; and
- (d) comparing the transgenic animals and the control group of animals and determining the effect of the compound on bone mass or lipid levels in the transgenic animals as compared to the control animals.

In a preferred embodiment, the Dkk is Dkk-1.

The invention further provides variants of LRP5 which demonstrate HBM biological activity, i.e., that are "HBM-like." In preferred embodiments, variants G171F, M282V, G171K, G171Q, A65V, G171V, G171I, and A214V of LRP5 are provided. The invention further provides for the use any of these variants in the forgoing methods.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows a schematic of the components of the Wnt signal transduction pathway. Schematic obtained from:

<http://www.stanford.edu/~rnusse/pathways/cell2.html>

Figure 2 (A-C) show bait sequences (SEQ ID NOs:168-170) utilized in yeast two hybrid (Y2H) screens for protein-protein interactions.

Figure 3 shows a table of peptide aptamer insert sequences (SEQ ID NOs: 171-192) identified in Y2H screen with a Dkk-1 bait sequence.

Figure 4 shows a table of peptide aptamer insert sequences identified in a Y2H screen using a LRP5 ligand binding domain bait sequence.

Figure 5 shows a table of proteins identified in a Y2H screen using a Dkk-1 bait sequence. These proteins are identified by both their nucleic acid and amino acid accession numbers.

Figure 6 shows the results of a minimum interaction domain mapping screen of Dkk-1 with LRP5. At the top, a map of Dkk-1 showing the location of the signal

sequence, and cysteine rich domains 1 and 2. Below, the extent of domains examined using LRP5 LBD baits, LBD1 and LBD4, of Figure 2. To the right, scoring of the binding results observed in the experiment.

Figure 7 shows a diagram of the *Xenopus* Embryo Assay for Wnt activity.

5 Figure 8 shows the effects of Zmax/LRP5 and HBM on Wnt signaling in the *Xenopus* embryo assay.

Figure 9 shows the effects of Zmax/LRP5 and HBM on induction of secondary axis formation in the *Xenopus* embryo assay.

10 Figure 10 shows the effects of human Dkk-1 on the repression of the canonical Wnt pathway.

Figure 11 shows the effects of human Dkk-1 on Zmax/LRP5 and HBM-mediated Wnt signaling.

15 Figure 12 shows pcDNA3.1 construct names with nucleotide sequences (including SEQ ID NOs:193-203) for LRP5-binding peptide aptamers, Dkk-1 peptides and control constructs.

Figure 13 shows the amino acid sequences (including SEQ ID NOs:204-214) for the corresponding LRP5-binding peptides, Dkk-1 peptide aptamers and control constructs in Figure 12.

20 Figure 14 shows the effects of Dkk-1 and Dkk-2 on Wnt1 signaling with coreceptors LRP5, HBM, and LRP6 in HOB03CE6 cells.

Figure 15 shows the effects of Dkk-1 and Dkk-2 on Wnt3a signaling with coreceptors LRP5, HBM, and LRP6 in HOB03CE6 cells.

Figure 16 demonstrates that the LRP5-LBD peptide aptamer 262 activates Wnt signaling in the presence of Wnt3a in U2OS cells.

25 Figure 17 shows the differential binding of an antibody generated to a sequence (a.a. 165-177) containing the HBM mutation in LRP5 in LRP5 and HBM virus-infected cells.

30 Figure 18 shows data generated from a Y2H interaction trap where a mutant Dkk-1 (C220A) is unable to bind to LRP5 and demonstrating the window of capability of detecting small molecule effects on LRP and Dkk interactions.

Figure 19 shows that Dkk-1 represses Wnt3a-mediated Wnt signaling in U2OS bone cells using the cell-based reporter gene assay for high throughput screening.

Figure 20 demonstrates that Wnt1-HBM generated signaling is not efficiently inhibited by Dkk-1 in U2OS bone cells while LRP5 and LRP6-mediated signaling are using the cell-based reporter gene assay for high throughput screening.

Figure 21 shows that the TCF signal in the cell-based reporter gene assay for high throughput screening can be modulated by Dkk-1 and Dkk-1-AP without Wnt DNA transfection.

Figure 22 shows the morphological results in the Xenopus assay using aptamers 261 and 262 from the LRP5-LBD to activate Wnt signaling.

Figure 23 demonstrates that LRP5-LBD aptamers 261 and 262 induce Wnt signaling over other LRP5 aptamers.

Figure 24 shows that the mutation G171F in LRP5 produces a greater activation of the Wnt pathway than LRP5 which is consistent with HBM activity.

Figure 25 shows that the mutation M282V in LRP5 produces an activation of the Wnt pathway which is consistent with HBM activity in U2OS cells.

Figure 26 shows the amino acid sequence of the various peptides of dkk-1 selected to generate polyclonal antibodies, their relationship to the Dkk-1 amino acid sequence and identities of polyclonal antibodies generated.

Figure 27 shows a Western blot demonstrating that polyclonal antibody #5521 to amino acids 165-186 of Dkk-1 was able to detect Dkk1-V5 and Dkk1-AP from conditioned medium.

Figure 28 shows a Western blot demonstrating that polyclonal antibody #74397 to amino acids 147-161 was able to detect Dkk1-V5 in both conditioned medium and immunoprecipitated conditioned medium.

DETAILED DESCRIPTION OF THE INVENTION

1. Definitions

In general, terms in the present application are used consistent with the manner in which those terms are understood in the art. To aid in the understanding of the specification and claims, the following definitions are provided.

"Gene" refers to a DNA sequence that encodes through its template or messenger RNA a sequence of amino acids characteristic of a specific peptide. The term "gene" includes intervening, non-coding regions, as well as regulatory regions, and can include 5' and 3' ends.

By "nucleic acid" is meant to include single stranded and double stranded nucleic acids including, but not limited to DNAs, RNAs (e.g., mRNA, tRNAs, siRNAs), cDNAs, recombinant DNA (rDNA), rRNAs, antisense nucleic acids, oligonucleotides, and oligomers, and polynucleotides. The term may also include hybrids such as triple stranded regions of RNA and/or DNA or double stranded RNA:DNA hybrids. The term also is contemplated to include modified nucleic acids such as, but not limited to biotinylated nucleic acids, tritylated nucleic acids, fluorophor labeled nucleic acids, inosine, and the like.

"Gene sequence" refers to a nucleic acid molecule, including DNA which contains a non-transcribed or non-translated sequence, which comprises a gene. The term is also intended to include any combination of gene(s), gene fragment(s), non-transcribed sequence(s) or non-translated sequence(s) which are present on the same DNA molecule.

The nucleic acid sequences of the present invention may be derived from a variety of sources including DNA, cDNA, synthetic DNA, synthetic RNA or combinations thereof. Such sequences may comprise genomic DNA which may or may not include naturally occurring introns. Moreover, such genomic DNA may be obtained in association with promoter regions and/or poly (A) sequences. The sequences, genomic DNA or cDNA may be obtained in any of several ways. Genomic DNA can be extracted and purified from suitable cells by means well

known in the art. Alternatively, mRNA can be isolated from a cell and used to produce cDNA by reverse transcription or other means.

"cDNA" refers to complementary or copy DNA produced from an RNA template by the action of RNA-dependent DNA polymerase (reverse transcriptase).

5 Thus, a "cDNA clone" means a duplex DNA sequence for which one strand is complementary to an RNA molecule of interest, carried in a cloning vector or PCR amplified. cDNA can also be single stranded after first strand synthesis by reverse transcriptase. In this form, it is a useful PCR template and does not need to be carried in a cloning vector. This term includes genes from which the intervening
10 sequences have been removed. Thus, the term "gene", as sometimes used generically, can also include nucleic acid molecules comprising cDNA and cDNA clones.

"Recombinant DNA" means a molecule that has been engineered by splicing
15 *in vitro* a cDNA or genomic DNA sequence or altering a sequence by methods such as PCR mutagenesis.

"Cloning" refers to the use of *in vitro* recombination techniques to insert a particular gene or other DNA sequence into a vector molecule. In order to successfully clone a desired gene, it is necessary to use methods for generating DNA fragments, for joining the fragments to vector molecules, for introducing the
20 composite DNA molecule into a host cell in which it can replicate, and for selecting the clone having the target gene from amongst the recipient host cells.

"cDNA library" refers to a collection of recombinant DNA molecules containing cDNA inserts which together comprise the entire or a partial repertoire of genes expressed in a particular tissue or cell source. Such a cDNA library can be prepared
25 by methods known to one skilled in the art and described by, for example, Cowell and Austin, "cDNA Library Protocols," *Methods in Molecular Biology* (1997).

"Cloning vehicle" refers to a plasmid or phage DNA or other DNA sequence which is able to replicate in a host cell. This term can also include artificial chromosomes such as BACs and YACs. The cloning vehicle is characterized by one
30 or more endonuclease recognition sites at which such DNA sequences may be cut in

a determinable fashion without loss of an essential biological function of the DNA, which may contain a marker suitable for use in the identification of transformed cells.

"Expression" refers to the process comprising transcription of a gene sequence and subsequent processing steps, such as translation of a resultant mRNA to produce the final end product of a gene. The end product may be a protein (such as an enzyme or receptor) or a nucleic acid (such as a tRNA, antisense RNA, or other regulatory factor). The term "expression control sequence" refers to a sequence of nucleotides that control or regulate expression of structural genes when operably linked to those genes. These include, for example, the lac systems, the trp system, major operator and promoter regions of the phage lambda, the control region of fd coat protein and other sequences known to control the expression of genes in prokaryotic or eukaryotic cells. Expression control sequences will vary depending on whether the vector is designed to express the operably linked gene in a prokaryotic or eukaryotic host, and may contain transcriptional elements such as enhancer elements, termination sequences, tissue-specificity elements and/or translational initiation and termination sites.

"Expression vehicle" refers to a vehicle or vector similar to a cloning vehicle but which is capable of expressing a gene which has been cloned into it, after transformation into a host. The cloned gene is usually placed under the control of (i.e., operably linked to) an expression control sequence.

"Operator" refers to a DNA sequence capable of interacting with the specific repressor, thereby controlling the transcription of adjacent gene(s).

"Promoter" refers to a DNA sequence that can be recognized by an RNA polymerase. The presence of such a sequence permits the RNA polymerase to bind and initiate transcription of operably linked gene sequences.

"Promoter region" is intended to include the promoter as well as other gene sequences which may be necessary for the initiation of transcription. The presence of a promoter region is sufficient to cause the expression of an operably linked gene sequence. The term "promoter" is sometimes used in the art to generically indicate a promoter region. Many different promoters are known in the art which direct

expression of a gene in a certain cell types. Tissue-specific promoters can comprise nucleic acid sequences which cause a greater (or decreased) level of expression in cells of a certain tissue type.

"Operably linked" means that the promoter controls the initiation of expression of the gene. A promoter is operably linked to a sequence of proximal DNA if upon introduction into a host cell the promoter determines the transcription of the proximal DNA sequence(s) into one or more species of RNA. A promoter is operably linked to a DNA sequence if the promoter is capable of initiating transcription of that DNA sequence.

"Prokaryote" refers to all organisms without a true nucleus, including bacteria.

"Eukaryote" refers to organisms and cells that have a true nucleus, including mammalian cells.

"Host" includes prokaryotes and eukaryotes, such as yeast and filamentous fungi, as well as plant and animal cells. The term includes an organism or cell that is the recipient of a replicable expression vehicle.

The term "animal" is used herein to include all vertebrate animals, except humans. It also includes an individual animal in all stages of development, including embryonic and fetal stages. Preferred animals include higher eukaryotes such as avians, rodents (e.g., mice, rabbits, rats, chinchillas, guinea pigs, hamsters and the like), and mammals. Preferred mammals include bovine, equine, feline, canine, ovine, caprine, porcine, buffalo, humans, and primates.

A "transgenic animal" is an animal containing one or more cells bearing genetic information received, directly or indirectly, by deliberate genetic manipulation or by inheritance from a manipulated progenitor at a subcellular level, such as by microinjection or infection with a recombinant viral vector (e.g., adenovirus, retrovirus, herpes virus, adeno-associated virus, lentivirus). This introduced DNA molecule may be integrated within a chromosome, or it may be extra-chromosomally replicating DNA.

"Embryonic stem cells" or "ES cells" as used herein are cells or cell lines usually derived from embryos which are pluripotent meaning that they are un-

differentiated cells. These cells are also capable of incorporating exogenous DNA by homologous recombination and subsequently developing into any tissue in the body when incorporated into a host embryo. It is possible to isolate pluripotent cells from sources other than embryonic tissue by methods which are well understood in the art.

Embryonic stem cells in mice have enabled researchers to select for transgenic cells and perform gene targeting. This allows more genetic engineering than is possible with other transgenic techniques. For example, mouse ES cells are relatively easy to grow as colonies *in vitro*. The cells can be transfected by standard procedures and transgenic cells clonally selected by antibiotic resistance. See, for example, Doetschman *et al.*, 1994, *Gene transfer in embryonic stem cells*. In Pinkert (Ed.) Transgenic Animal Technology: A Laboratory Handbook. Academic Press Inc., New York, pp.115-146. Furthermore, the efficiency of this process is such that sufficient transgenic colonies (hundreds to thousands) can be produced to allow a second selection for homologous recombinants. Mouse ES cells can then be combined with a normal host embryo and, because they retain their potency, can develop into all the tissues in the resulting chimeric animal, including the germ cells. The transgenic modification can then be transmitted to subsequent generations.

Methods for deriving embryonic stem (ES) cell lines *in vitro* from early preimplantation mouse embryos are well known. See for example, Evans *et al.*, 1981 *Nature* 29: 154-6 and Martin, 1981, *Proc. Nat. Acad. Sci. USA*, 78: 7634-8. ES cells can be passaged in an undifferentiated state, provided that a feeder layer of fibroblast cells or a differentiation inhibiting source is present.

The term "somatic cell" indicates any animal or human cell which is not a sperm or egg cell or is capable of becoming a sperm or egg cell. The term "germ cell" or "germ-line cell" refers to any cell which is either a sperm or egg cell or is capable of developing into a sperm or egg cell and can therefore pass its genetic information to offspring. The term "germ cell-line transgenic animal" refers to a transgenic animal in which the genetic information was incorporated in a germ line cell, thereby conferring the ability to transfer the information to offspring. If such

offspring in fact possess some or all of that information, then they, too, are transgenic animals.

The genetic alteration of genetic information may be foreign to the species of animal to which the recipient belongs, or foreign only to the particular individual recipient. In the last case, the altered or introduced gene may be expressed differently than the native gene.

"Fragment" of a gene refers to any portion of a gene sequence. A "biologically active fragment" refers to any portion of the gene that retains at least one biological activity of that gene. For example, the fragment can perhaps hybridize to its cognate sequence or is capable of being translated into a polypeptide fragment encoded by the gene from which it is derived.

"Variant" refers to a gene that is substantially similar in structure and biological activity or immunological characteristics to either the entire gene or to a fragment of the gene. Provided that the two genes possess a similar activity, they are considered variant as that term is used herein even if the sequence of encoded amino acid residues is not identical. Preferentially, as used herein (unless otherwise defined) the variant is one of LRP5, HBM or LRP6. The variant preferably is one that yields an HBM-like phenotype (i.e., enhances bones mass and/or modulates lipid levels). These variants include missense mutations, single nucleotide polymorphisms (SNPs), mutations which result in changes in the amino acid sequence of the protein encoded by the gene or nucleic acid, and combinations thereof, as well as com in the exon domains of the *HBM* gene and mutations in LRP5 or LRP6 which result in an HBM like phenotype.

"Amplification of nucleic acids" refers to methods such as polymerase chain reaction (PCR), ligation amplification (or ligase chain reaction, LCR) and amplification methods based on the use of Q-beta replicase. These methods are well known in the art and described, for example, in U.S. Patent Nos. 4,683,195 and 4,683,202. Reagents and hardware for conducting PCR are commercially available. Primers useful for amplifying sequences from the HBM region are preferably complementary to, and hybridize specifically to sequences in the HBM region or in

regions that flank a target region therein. HBM sequences generated by amplification may be sequenced directly. Alternatively, the amplified sequence(s) may be cloned prior to sequence analysis.

"Antibodies" may refer to polyclonal and/or monoclonal antibodies and fragments thereof, and immunologic binding equivalents thereof, that can bind to the HBM proteins and fragments thereof or to nucleic acid sequences from the HBM region, particularly from the HBM locus or a portion thereof. Preferred antibodies also include those capable of binding to LRP5, LRP6 and HBM variants. The term antibody is used both to refer to a homogeneous molecular entity, or a mixture such as a serum product made up of a plurality of different molecular entities. Proteins may be prepared synthetically in a protein synthesizer and coupled to a carrier molecule and injected over several months into rabbits. Rabbit sera is tested for immunoreactivity to the HBM protein or fragment. Monoclonal antibodies may be made by injecting mice with the proteins, or fragments thereof. Monoclonal antibodies will be screened by ELISA and tested for specific immunoreactivity with HBM protein or fragments thereof. Harlow *et al.*, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1988) and *Using Antibodies: A Laboratory Manual*, Harlow, Ed and Lane, David (Cold Spring Harbor Press, 1999). These antibodies will be useful in assays as well as pharmaceuticals. By "antibody" is meant to include but not limited to polyclonal, monoclonal, chimeric, human, humanized, bispecific, multispecific, primatized™ antibodies.

"HBM protein" refers to a protein that is identical to a Zmax1 (LRP5) protein except that it contains an alteration of glycine 171 to a valine. An HBM protein is defined for any organism that encodes a Zmax1 (LRP5) true homolog. For example, a mouse HBM protein refers to the mouse Zmax1 (LRP5) protein having the glycine 170 to valine substitution.

By "HBM-like" is meant a variant of LRP5, LRP6 or HBM which when expressed in a cell is capable of modulating bone mass, lipid levels, Dkk activity, and/or Wnt activity.

In one embodiment of the present invention, "*HBM* gene" refers to the genomic DNA sequence found in individuals showing the HBM characteristic or phenotype, where the sequence encodes the protein indicated by SEQ ID NO: 4. The *HBM* gene and the *Zmax1* (*LRP5*) gene are allelic. The protein encoded by the *HBM* gene has the property of causing elevated bone mass, while the protein encoded by the *Zmax1* (*LRP5*) gene does not. The *HBM* gene and the *Zmax1* (*LRP5*) gene differ in that the *HBM* gene has a thymine at position 582, while the *Zmax1* gene has a guanine at position 582. The *HBM* gene comprises the nucleic acid sequence shown as SEQ ID NO: 2. The *HBM* gene may also be referred to as an "HBM polymorphism." Other *HBM* genes may further have silent mutations, such as those discussed in Section 3 below.

In alternative embodiments of the present invention, "HBM gene" may also refer to any allelic variant of *Zmax1* (*LRP5*) or *LRP6* which results in the HBM phenotype. Such variants may include alteration from the wild-type protein coding sequence as described herein and/or alteration in expression control sequences of *Zmax1* (*LRP5*) or contains an amino acid mutation in *LRP5* or *LRP6*, such that the resulting protein produces a phenotype which enhances bone mass and/or modulates lipid levels. A preferred example of such a variant is an alteration of the endogenous *Zmax1* (*LRP5*) promoter region resulting in increased expression of the *Zmax1* (*LRP5*) protein.

"Normal," "wild-type," "unaffected", "*Zmax1*", "*Zmax*", "*LR3*" and "*LRP5*" all refer to the genomic DNA sequence that encodes the protein indicated by SEQ ID NO: 3. *LRP5* has also been referred to *LRP7* in mouse. *Zmax1*, *LRP5* and *Zmax* may be used interchangeably throughout the specification and are meant to be the same gene, perhaps only relating to the gene in a different organism. The *Zmax1* gene has a guanine at position 582 in the human sequence. The *Zmax1* gene of human comprises the nucleic acid sequence shown as SEQ ID NO: 1. "Normal," "wild-type," "unaffected", "*Zmax1*" and "*LRP5*" also refer to allelic variants of the genomic sequence that encodes proteins that do not contribute to elevated bone

mass. The *Zmax1* (*LRP5*) gene is common in the human population, while the *HBM* gene is rare.

"Bone development" generally refers to any process involved in the change of bone over time, including, for example, normal development, changes that occur during disease states, and changes that occur during aging. This may refer to structural changes and dynamic rate changes such as growth rates, resorption rates, bone repair rates, and etc. "Bone development disorder" particularly refers to any disorders in bone development including, for example, changes that occur during disease states and changes that occur during aging. Bone development may be progressive or cyclical in nature. Aspects of bone that may change during development include, for example, mineralization, formation of specific anatomical features, and relative or absolute numbers of various cell types.

"Bone modulation" or "modulation of bone formation" refers to the ability to affect any of the physiological processes involved in bone remodeling, as will be appreciated by one skilled in the art, including, for example, bone resorption and appositional bone growth, by, *inter alia*, osteoclastic and osteoblastic activity, and may comprise some or all of bone formation and development as used herein.

Bone is a dynamic tissue that is continually adapting and renewing itself through the renewal of old or unnecessary bone by osteoclasts and the rebuilding of new bone by osteoblasts. The nature of the coupling between these processes is responsible for both the modeling of bone during growth as well as the maintenance of adult skeletal integrity through remodeling and repair to meet the everyday needs of mechanical usage. There are a number of diseases that result from an uncoupling of the balance between bone resorption and formation. With aging there is a gradual "physiologic" imbalance in bone turnover, which is particularly exacerbated in women due to menopausal loss of estrogen support, that leads to a progressive loss of bone. As bone mineral density falls below population norms there is a consequent increase in bone fragility and susceptibility to spontaneous fractures. For every 10 percent of bone that is lost, the risk of fracture doubles. Individuals with bone mineral density (BMD) in the spine or proximal femur 2.5 or

more standard deviations below normal peak bone mass are classified as osteoporotic. However, osteopenic individuals with BMD between 1 and 2.5 standard deviations below the norm are clearly at risk.

Bone is measured by several different forms of X-ray absorptiometry. All of the instruments measure the inorganic or bone mineral content of the bone. Standard DXA measurements give a value that is an areal density, not a true density measurement by the classical definition of density (mass/unit volume). Nevertheless, this is the type of measurement used clinically to diagnose osteoporosis. However, while BMD is a major contributing factor to bone strength, as much as 40% of bone strength stems from other factors including: 1) bone size (*i.e.*, larger diameters increase organ-level stiffness, even in the face of lower density); 2) the connectivity of trabecular structures; 3) the level of remodeling (remodeling loci are local concentrators of strain); and 4) the intrinsic strength of the bony material itself, which in turn is a function of loading history (*i.e.*, through accumulated fatigue damage) and the extent of collagen cross-linking and level of mineralization. There is good evidence that all of these strength/fragility factors play some role in osteoporotic fractures, as do a host of extraskkeletal influences as well (such as fall patterns, soft tissue padding, and central nervous system reflex responsiveness).

Additional analytical instruments can be used to address these features of bone. For example, the pQCT allows measurement of separate trabecular and cortical compartments for size and density and the μ CT provides quantitative information on architectural features such as trabecular connectivity. The μ CT also gives a true bone density measurement. With these tools, the important non-BMD parameters can be measured for diagnosing the extent of disease and the efficacy of treatments. Current treatments for osteoporosis are based on the ability of drugs to prevent or retard bone resorption. Although newer anti-resorptive agents are proving to be useful in the therapy of osteoporosis, they are viewed as short-term solutions to the more definitive challenge to develop treatments that will increase bone mass and/or the bone quality parameters mentioned above.

Thus, bone modulation may be assessed by measuring parameters such as bone mineral density (BMD) and bone mineral content (BMC) by pDXA X-ray methods, bone size, thickness or volume as measured by X-ray, bone formation rates as measured for example by calcien labeling, total, trabecular, and mid-shaft density as measured by pQCT and/or μ CT methods, connectivity and other histological parameters as measured by μ CT methods, mechanical bending and compressive strengths as preferably measured in femur and vertebrae respectively. Due to the nature of these measurements, each may be more or less appropriate for a given situation as the skilled practitioner will appreciate. Furthermore, parameters and methodologies such as a clinical history of freedom from fracture, bone shape, bone morphology, connectivity, normal histology, fracture repair rates, and other bone quality parameters are known and used in the art. Most preferably, bone quality may be assessed by the compressive strength of vertebra when such a measurement is appropriate. Bone modulation may also be assessed by rates of change in the various parameters. Most preferably, bone modulation is assessed at more than one age.

"Normal bone density" refers to a bone density within two standard deviations of a Z score of 0 in the context of the HBM linkage study. In a general context, the range of normal bone density parameters is determined by routine statistical methods. A normal parameter is within about 1 or 2 standard deviations of the age and sex normalized parameter, preferably about 2 standard deviations. A statistical measure of meaningfulness is the P value which can represent the likelihood that the associated measurement is significantly different from the mean. Significant P values are $P < 0.05$, 0.01 , 0.005 , and 0.001 , preferably at least $P < 0.01$.

"HBM" refers to "high bone mass" although this term may also be expressed in terms of bone density, mineral content, and size.

The "HBM phenotype" and "HBM-like phenotype" may be characterized by an increase of about 2 or more standard deviations, preferably 2, 2.5, 3, or more standard deviations in 1, 2, 3, 4, 5, or more quantitative parameters of bone modulation, preferably bone density and mineral content and bone strength

parameters, above the age and sex norm for that parameter. The HBM phenotype and HBM-like phenotype are characterized by statistically significant increases in at least one parameter, preferably at least 2 parameters, and more preferably at least 3 or more parameters. The HBM phenotype and the HBM-like phenotype may also be characterized by an increase in one or more bone quality parameters and most preferably increasing parameters are not accompanied by a decrease in any bone quality parameters. Most preferably, an increase in bone modulation parameters and/or bone quality measurements is observed at more than one age. The HBM phenotype and HBM-like phenotype also includes changes of lipid levels, Wnt activity and/or Dkk activity.

The terms "isolated" and "purified" refer to a substance altered by hand of man from the natural environment. An isolated peptide may be for example in a substantially pure form or otherwise displaced from its native environment such as by expression in an isolated cell line or transgenic animal. An isolated sequence may for example be a molecule in substantially pure form or displaced from its native environment such that at least one end of said isolated sequence is not contiguous with the sequence it would be contiguous with in nature.

"Biologically active" refers to those forms of proteins and polypeptides, including conservatively substituted variants, alleles of genes encoding a protein or polypeptide fragments of proteins which retain a biological and/or immunological activity of the wild-type protein or polypeptide. Preferably the activity is one which induces a change in Dkk activity, such as inhibiting the interaction of Dkk with a ligand binding partner (e.g., LRP5 or LRP6 or Dkk-1 with a Dkk-1 interacting protein such as those shown in Figure 5). By biologically active is also meant to include any form which modulates Wnt signaling.

By "modulate" and "regulate" is meant methods, conditions, or agents which increase or decrease the wild-type activity of an enzyme, inhibitor, signal transducer, receptor, transcription activator, co-factor, and the like. This change in activity can be an increase or decrease of mRNA translation, mRNA or DNA transcription, and/or

mRNA or protein degradation, which may in turn correspond to an increase or decrease in biological activity.

By "modulated activity" is meant any activity, condition, disease or phenotype which is modulated by a biologically active form of a protein. Modulation may be effected by affecting the concentration or subcellular localization of biologically active protein, *i.e.*, by regulating expression or degradation, or by direct agonistic or antagonistic effect as, for example, through inhibition, activation, binding, or release of substrate, modification either chemically or structurally, or by direct or indirect interaction which may involve additional factors.

By "effective amount" or "dose effective amount" or "therapeutically effective amount" is meant an amount of an agent which modulates a biological activity of the polypeptide of the invention.

By "immunologically active" is meant any immunoglobulin protein or fragment thereof which recognizes and binds to an antigen.

By "Dkk" is meant to refer to the nucleic acids and proteins of members of the Dkk (Dickkopf) family. This includes, but is not limited to, Dkk-1, Dkk-2, Dkk-3, Dkk-4, Soggy, and related Dkk proteins. Dkk-1 is a preferred embodiment of the present invention. However, the Dkk proteins have substantial homology and one skilled in the art will appreciate that all of the embodiments of the present invention utilizing Dkk-1 may also be utilized with the other Dkk proteins.

By "Dkk-1" is meant to refer to the Dkk-1 protein and nucleic acids which encode the Dkk-1 protein. Dkk-1 refers to Dickkopf-1, and in *Xenopus* it is related to at least Dkk-2, Dkk-3, and Dkk-4 (see Krupnik *et al.*, *Gene* 238:301-313 (1999)). Dkk-1 was first identified in *Xenopus* (Glinka *et al.*, *Nature* 391:357-62 (1998)). It was recognized as a factor capable of inducing ectopic head formation in the presence of inhibition of the BMP pathway. It was then also found to inhibit the axis-inducing activity of several *Xenopus* Wnt molecules by acting as an extracellular antagonist of Wnt signaling. Mammalian homologs have been found including Dkk-1, Dkk-2, Dkk-3, Dkk-4 and soggy (Fedi *et al.*, 1999 and Krupnick *et al.* 1999). Human Dkk-1 was also referred to as sk (Fedi *et al.* 1999). As used herein, Dkk-1 is

meant to include proteins from any species having a Wnt pathway in which Dkk-1 interacts. Particularly preferred are mammalian species (e.g., murine, caprine, canine, bovine, feline, equine, primate, ovine, porcine and the like), with particularly preferred mammals being humans. Nucleic acid sequences encoding Dkk-1 include, but are not limited to human Dkk-1 (GenBank Accession Nos. AH009834, XM_005730, AF261158, AF261157, AF177394, AF127563 and NM_012242), *Mus musculus* dickkopf homolog 1 (GenBank Accession No. NM_010051), and *Danio rerio* dickkopf-1 (GenBank Accession Nos. AF116852 and AB023488). The genomic sequences with exon annotation are GenBank Accession Nos. AF261157 and AF261158. Also contemplated are homologs of these sequences which have Dkk-1 activity in the Wnt pathway. Dkk-1 amino acid sequences include, but are not limited to human dickkopf homolog 1 (GenBank Accession Nos. AAG15544, BAA34651, NP_036374, AAF02674, AAD21087, and XP_005730), *Danio rerio* (zebrafish) dickkopf1 (GenBank Accession Nos. BAA82135 and AAD22461) and murine dickkopf-1 (GenBank Accession Nos. O54908 and NP_034181). Variants and homologs of these sequences which possess Dkk-1 activity are also included when referring to Dkk-1.

By "Dkk mediated" disorder, condition or disease is any abnormal state that involves Dkk activity. The abnormal state can be induced by environmental exposure or drug administration. Alternatively, the disease or disorder can be due to a genetic defect. Dkk mediated diseases, disorders and conditions include but are not limited to bone mass disorders or conditions and lipid disorders and conditions. For example, bone mass disorders/conditions/diseases, which may be mediated by Dkk, include but are not limited to age related loss of bone, bone fractures (e.g., hip fracture, Colle's fracture, vertebral crush fractures), chondrodystrophies, drug-induced disorders (e.g., osteoporosis due to administration of glucocorticoids or heparin and osteomalacia due to administration of aluminum hydroxide, anticonvulsants, or glutethimide), high bone turnover, hypercalcemia, hyperostosis, osteogenesis imperfecta, osteomalacia, osteomyelitis, osteoporosis, Paget's disease, osteoarthritis, and rickets.

Lipid disorders/diseases/conditions, which may be mediated by Dkk, include but are not limited to familial lipoprotein lipase deficiency, familial apoprotein CII deficiency, familial type 3 hyperlipoproteinemia, familial hypercholesterolemia, familial hypertriglyceridemia, multiple lipoprotein-type hyperlipidemia, elevated lipid levels due to dialysis and/or diabetes, and elevated lipid levels of unknown etiologies

The term "recognizes and binds," when used to define interactions of antisense nucleotides, siRNAs (small inhibitory RNA), or shRNA (short hairpin RNA) with a target sequence, means that a particular antisense, siRNA, or shRNA sequence is substantially complementary to the target sequence, and thus will specifically bind to a portion of an mRNA encoding polypeptide. As such, typically the sequences will be highly complementary to the mRNA target sequence, and will have no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 base mismatches throughout the sequence. In many instances, it may be desirable for the sequences to be exact matches, i.e. be completely complementary to the sequence to which the oligonucleotide specifically binds, and therefore have zero mismatches along the complementary stretch. As such, highly complementary sequences will typically bind quite specifically to the target sequence region of the mRNA and will therefore be highly efficient in reducing, and/or even inhibiting the translation of the target mRNA sequence into polypeptide product.

Substantially complementary oligonucleotide sequences will be greater than about 80 percent complementary (or '% exact-match') to the corresponding mRNA target sequence to which the oligonucleotide specifically binds, and will, more preferably be greater than about 85 percent complementary to the corresponding mRNA target sequence to which the oligonucleotide specifically binds. In certain aspects, as described above, it will be desirable to have even more substantially complementary oligonucleotide sequences for use in the practice of the invention, and in such instances, the oligonucleotide sequences will be greater than about 90 percent complementary to the corresponding mRNA target sequence to which the oligonucleotide specifically binds, and may in certain embodiments be greater than about 95 percent complementary to the corresponding mRNA target sequence to

which the oligonucleotide specifically binds, and even up to and including 96%, 97%, 98%, 99%, and even 100% exact match complementary to the target mRNA to which the designed oligonucleotide specifically binds.

Percent similarity or percent complementary of any of the disclosed sequences may be determined, for example, by comparing sequence information using the GAP computer program, version 6.0, available from the University of Wisconsin Genetics Computer Group (UWGCG). The GAP program utilizes the alignment method of Needleman and Wunsch (1970). Briefly, the GAP program defines similarity as the number of aligned symbols (i.e., nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences. The preferred default parameters for the GAP program include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) for nucleotides, and the weighted comparison matrix of Gribskov and Burgess (1986), (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.

By "mimetic" is meant a compound or molecule that performs the same function or behaves similarly to the compound mimicked.

By "reporter element" is meant a polynucleotide that encodes a polypeptide capable of being detected in a screening assays. Examples of polypeptides encoded by reporter elements include, but are not limited to, lacZ, GFP, luciferase, and chloramphenicol acetyltransferase.

2. Introduction

A polymorphism in LRP5 (Zmax), G171V, designated as HBM, has been identified as conferring a high bone mass phenotype in a population of related subjects as described in co-pending applications International Patent Application PCT/US 00/16951, and U.S. Patent Application Nos. 09/543,771 and 09/544,398, which are hereby incorporated by reference in their entirety (Little *et al.*, *Am J Hum Genet.* 70:11-19 (2002)). LRP5 is also described in International Patent Application WO 98/46743, which is incorporated by reference in its entirety. Loss of LRP5

function has been shown to have a deleterious effect on bone (Gong *et al.*, *Cell* 107:513-523 (2001)). Additionally, the HBM polymorphism and LRP5 may also be important in cardiac health and lipid-mediated disorders. Thus, methods of regulating their activity can serve as methods of treating and/or preventing cardiac and lipid-mediated disorders.

Recent studies have indicated that LRP5 participates in the Wnt signal transduction pathway. The Wnt pathway is critical in limb early embryological development. A recently published sketch of the components of Wnt signaling is shown in Figure 1 (Nusse, 2001 <http://www.stanford.edu/~rnusse/pathways/cell2.html>) (see also, Nusse, *Nature* 411:255-6 (2001); and Mao *et al.*, *Nature* 411:321-5 (2001)). Briefly summarized, Wnt proteins are secreted proteins which interact with the transmembrane protein Frizzled (Fz). LRP proteins, such as LRP5 and LRP6, are believed to modulate the Wnt signal in a complex with Fz (Tamai *et al.*, *Nature* 407:530-5 (2000)). The Wnt pathway acts intracellularly through the Disheveled protein (Dsh) which in turn inhibits glycogen synthetase kinase-3 (GSK3) from phosphorylating β -catenin. Phosphorylated β -catenin is rapidly degraded following ubiquitination. However, the stabilized β -catenin accumulates and translocates to the nucleus where it acts as a cofactor of the T-cell factor (TCF) transcription activator complex.

The protein dickkopf-1 (Dkk-1) is reported to be an antagonist of Wnt pathway. Dkk-1 is required for head formation in early development. Dkk-1 and its function in the Wnt pathway are described in e.g., Krupnik, *et al.*, *Gene* 238:301-13 (1999); Fedi *et al.*, *J. Biol. Chem.* 274:19465-72 (1999); see also for Dkk-1 and the Wnt pathway, Wu *et al.*, *Curr. Biol.* 10:1611-4 (2000), Shinya *et al.*, *Mech. Dev.* 98:3-17 (2000), Mukhopadhyay *et al.*, *Dev Cell* 1:423-434 (2001) and in PCT Patent Application No. WO 00/52047, and in references cited in each. It has been known that Dkk-1 acts upstream of Dsh, however the nature of the mechanism of inhibition by Dkk-1 is just beginning to be elucidated. Dkk-1 is expressed in the mouse embryonic limb bud and its disruption results in abnormal limb morphogenesis, among

other developmental defects (Gotewold *et al.*, *Mech. Dev.* 89:151-3 (1999); and, Mukhopadhyay *et al.*, *Dev Cell* 1:423-434 (2001)).

Related U.S. provisional application 60/291,311 disclosed a novel interaction between Dkk-1 (GenBank Accession No. XM 005730) and LRP5. The interaction
5 between Dkk-1 and LRP5 was discovered by a yeast two hybrid (Y2H) screen for proteins which interact with the ligand binding domain of LRP5, as described in Example 1. The two-hybrid screen is a common procedure in the art, which is described, for example, by Gietz *et al.*, *Mol. Cell. Biochem.* 172:67-79 (1997); Young, *Biol. Reprod.* 58:302-11 (1998); Brent and Finley, *Ann. Rev. Genet.* 31:663-
10 704 (1997); and Lu and Hannon, eds., Yeast Hybrid Technologies, Eaton Publishing, Natick MA, (2000). More recently, other studies confirm that Dkk-1 is a binding partner for LRP and modulates the Wnt pathway via direct binding with LRP (R. Nusse, *Nature* 411:255-256 (2001); A. Bafico *et al.*, *Nat. Cell Biol.* 3:683-686 (2001); M. Semenov, *Curr. Biol.* 11:951-961 (2001); B. Mao, *Nature* 411:321-325 (2001),
15 Zorn, *Curr. Biol.* 11:R592-5 (2001)); and, L. Li *et al.*, *J. Biol Chem.* 277:5977-81 (2002)).

Mao and colleagues (2001) identified Dkk-1 as a ligand for LRP6. Mao *et al.* suggest that Dkk-1 and LRP6 interact antagonistically where Dkk proteins inhibit the Wnt coreceptor functions of LRP6. Using co-immunoprecipitation, the group verified
20 that the Dkk-1/LRP6 interaction was direct. Dkk-2 was also found to directly bind LRP6. Contrary to data contained in provisional application 60/291,311, Mao *et al.* report that no interaction was detected between any Dkk protein and LRP5, as well as no interaction with LDLR, VLDLR, ApoER, or LRP). Additionally, Mao *et al.* demonstrated that LRP6 can titrate Dkk-1's effects of inhibiting Wnt signaling using
25 the commercial TCF-luciferase reporter gene assay (TOPFLASH). A similar conclusion was drawn from analogous studies in *Xenopus* embryos. Deletion analyses of LRP6 functional domains revealed that EGF repeats (beta-propellers) 3 and 4 were necessary for Dkk-1 binding and that the ligand binding domains of LRP6 had no effect on Dkk-1 binding. The findings of Mao *et al.* contrast with data
30 obtained by the present inventors indication that the ligand binding domains of LRP5

were necessary and sufficient for Dkk-1 binding in yeast. Using classical biochemical ligand-receptor studies, Mao *et al.* determined a $K_d=0.34$ nM for Dkk-1/LRP6 and a $K_d=0.73$ nM for Dkk-2/LRP6.

5 Semenov *et al.* (2001) verified the Mao group's results and confirmed by coimmunoprecipitation that Dkk-1 does not directly bind to Wnt or Frizzled but rather interacts with LRP6. Their Scatchard analyses found a $K_d=0.5$ nM for Dkk-1/LRP6. Semenov *et al.* also demonstrated that Dkk-1 could abolish an LRP5/Frizzled8 complex implying that Dkk-1 can also repress Wnt signaling via interactions with LRP5. A Dkk-1 mutant where cysteine 220 was changed to alanine abolished LRP6
10 binding and was unable to repress Wnt signaling. Studies in *Xenopus* embryos confirmed the results and revealed a functional consequence of Dkk-1/LRP6: repression of Wnt signaling. Their *Xenopus* work also suggested that LRP6/Dkk-1 may be specific for the canonical, β -catenin-mediated, Wnt pathways as opposed to the Wnt Planar Cell Polarity pathway.

15 Bafico *et al.* (2001) employed a ^{125}I -labeled Dkk-1 molecule to identify LRP6 as its sole membrane receptor with a $K_d=0.39$ nM. Again, the functional consequences of the Dkk-1/LRP6 interaction was a repression of the canonical Wnt signaling even when Dkk-1 was added at extremely low concentrations (30 pM).

20 Not wishing to be bound by theory, it is believed that the present invention provides an explanation for the mechanism of Dkk-1 inhibition of the Wnt pathway and provides a mechanism whereby the Wnt pathway may be modulated. The present application and related provisional application 60/291,311 describe Dkk-1/LRP5 interactions and demonstrate that the interaction between LRP5/LRP6/HBM and Dkk can be used in a method as an intervention point in the Wnt pathway for an
25 anabolic bone therapeutic or a modulator of lipid metabolism.

30 As detailed below, in the section "Methods to Identify Binding Partners" and Examples 6 and 7, Dkk-1 is able to repress LRP5-mediated Wnt signaling but not HBM-mediated Wnt signaling. This observation is of particular interest because the HBM mutation in LRP5 is a gain of function or activation mutation. That is, Wnt signaling, via the canonical pathway, is enhanced with HBM versus LRP5. The

present data suggest the mechanism of this functional activation: the inability of Dkk-1 to repress HBM-mediated Wnt signaling. Further investigations of other Wnt or Dkk family members show differential activities in the canonical Wnt pathway that demonstrate the complexity and variability in Wnt signaling that can be achieved depending on the LRP/Dkk/Wnt/Frizzled repertoire that is expressed in a particular cell or tissue. This may attest to the apparent bone specificity of the HBM phenotype in humans and in the HBM transgenic animals.

Furthermore, the present data reveal the importance and functional consequence for the potential structural perturbation of the first beta-propeller domain of LRP5. Our data identified the ligand binding domain of LRP5 as the interacting region with Dkk-1 while the Mao *et al.* publication demonstrated the functional role of propellers 3 and 4 in their LRP6/Dkk-1 studies. In the present invention, we implicate the first beta propeller domain, via the HBM mutation at residue 171, as having a functional consequence in the Dkk-1-mediated Wnt pathway. The involvement of position 171 of propeller 1 may be direct or indirect with Dkk-1. Direct involvement could arise from perturbations of the 3-dimensional structure of the HBM extracellular domain that render Dkk-1 unable to bind. Alternatively, residue 171 of propeller 1 may directly interact with Dkk-1; however, by itself, it is insufficient to bind and requires other LRP5 domains. Potential indirect candidate molecules may be among the proteins identified the Dkk-1 yeast-two-hybrid experiments.

It may be that the disruption of Dkk activity is not necessarily mediated by enhancing or preventing the binding of Dkk to LRP5/LRP6/HBM. More than one mechanism may be involved. Indeed, the inventors have observed that Dkk-1 binds LRP5, LRP6, and HBM. It is able to effectively inhibit LRP6, and to a slightly lesser extent, LRP5 activity. Further, has been observed that different members of the Dkk family differentially affect LRP5/LRP6/HBM activity. For example, Dkk-1 inhibits LRP5/LRP6/HBM activity while another Dkk may enhance LRP5/LRP6/HBM activity. An endpoint to consider is the modulation of the LRP5/LRP6/HBM activity, not simply binding.

The present disclosure shows that targeting the disruption of the Dkk-1/LRP5 interaction is a therapeutic intervention point for an HBM mimetic agent. A therapeutic agent of the invention may be a small molecule, peptide or nucleic acid aptamer, antibody, or other peptide/protein, etc. Methods of reducing Dkk-1 expression may also be therapeutic using methodologies such as: RNA interference, antisense oligonucleotides, morpholino oligonucleotides, PNAs, antibodies to Dkk-1 or Dkk-1 interacting proteins, decoy or scavenger LRP5 or LRP6 receptors, and knockdown of Dkk-1 or Dkk-1 interactor transcription.

In an embodiment of the present invention, the activity of Dkk-1 or the activity of a Dkk-1 interacting protein may be modulated for example by binding with a peptide aptamer of the present invention. In another embodiment, LRP5 activity may be modulated by a reagent provided by the present invention (e.g., a peptide aptamer). In another embodiment, the Dkk-1/LRP5 interaction may be modulated by a reagent of the present invention (e.g., a Dkk-1 interacting protein such as those identified in Figure 5). In another embodiment, the Wnt signal transduction pathway may be modulated by use of one or more of the above methods. In a preferred embodiment of the present invention, the Dkk-1 mediated activity of the Wnt pathway may be specifically modulated by one or more of the above methods. In another preferred embodiment of the present invention, the Wnt signal transduction pathway may be stimulated by down-regulating Dkk-1 interacting protein activity; such down-regulation could, for example, yield greater LRP5 activity. In a more preferred embodiment, by stimulating LRP5 activity, bone mass regulation may be stimulated to restore or maintain a more optimal level. In another preferred embodiment, by stimulating LRP5 activity, lipid metabolism may be stimulated to restore or maintain a more optimal level. Alternative embodiments provide methods for screening candidate drugs and therapies directed to correction of bone mass disorders or lipid metabolism disorders. And, preferred embodiments of the present invention provide drugs and therapies developed by the use of the reagents and/or methods of the present invention. One skilled in the art will understand that the present invention provides important research tools to develop an effective model of

osteoporosis, to increase understanding of bone mass and lipid modulation, and to modulate bone mass and lipid metabolism.

Previous investigation of a large family in which high bone mass is inherited as a single gene (autosomal dominant) trait (HBM-1) has provided important insight into the mechanism by which bone density might be modulated. Members of this family have significantly increased spinal and hip BMD (>3 standard deviations above the norm) which affects young adults as well as elderly family members into the ninth decade. The bones of affected members, while appearing very dense radiographically, have normal external shape and outer dimensions. Cortical bone is thickened on endosteal surfaces and "affected" individuals are asymptomatic without any other phenotypic abnormalities. Assays of biochemical markers that reflect skeletal turnover suggest that the disorder is associated with a normal rate of bone remodeling. Affected individuals have achieved a balance in bone turnover at a density that is significantly greater than necessary for normal skeletal stresses. Importantly, the bones most affected are load-bearing bones which are subjected to the greatest mechanical and gravitational stresses (spine and hip). These are the most important bones to target for therapeutic interventions in osteoporosis. The gene identified as being responsible for this phenotype, Zmax or LRP5, was not previously associated with bone physiology. The fact that modification of this gene, such as that produced by the polymorphism leading to the autosomal dominant inheritance of the HBM family phenotype, identifies Zmax/LRP5 and the pathway by which it is regulated, including Dkk/Wnt pathways discussed above, as an important target for developing modulators of bone density. Modulation of Zmax/LRP5 to mimic the gain in function provided by the HBM polymorphism would be expected to provide an important therapy for bone wasting conditions. Additionally, such modulation in young adults could enhance peak bone mass and prevent or delay fracture risk later in life. Alternatively, modulation to reduce function could be employed to treat conditions where bone is being inappropriately produced.

3. Polypeptides

Polypeptides contemplated for use in this invention include those which modulate Dkk and Dkk interacting protein activities. Preferred polypeptides and peptides include those which modulate the Wnt pathway. Examples of preferred sequences include the Y2H baits exemplified in Figure 2, peptide aptamers of Figure 3 (SEQ ID NOs:171-188) and Figure 4 (SEQ ID NOs:189-192), the polypeptides of the Dkk-1 interacting proteins identified in Figure 5, those polypeptides shown in Figure 6, the LRP binding domain of Dkk (amino acids 138-266 of hDkk1), the cysteine-rich domain 2 (a.a. 183-245 of hDkk-1), the cysteine-rich domain 1 (a.a. 97-138 of hDkk), and LRP5 binding aptamers of Figure 13 (including SEQ ID NOs:204-213). Although Dkk-1 is exemplified, the other Dkk proteins contain substantially similar regions and may also be used according to the present invention.

For example, the baits depicted in Figure 2 were used in a yeast two hybrid (Y2H) screen. The Y2H screen was performed as described in Example 2 to determine the minimum required binding domain for Dkk-1 to bind LRP5. The minimum binding domain constructs (*i.e.*, residues 139-266 in bold below and residues 97-245 which are underlined, of Dkk-1) include the second cysteine rich domain which has sequence homology to a colipase fold.

mmalgaagat rvfvamvaaa lgghp1lgvs atlnsvlnsn aiknlppplg gaaghpgsav 60
saapgilypg gnkyqtidny qpypcaedee cgtdeycasp trqgdagvqi clacrkrkr 120
cmrhamccpg nyckngicvs sdqnhfrgei eetitesfgn dhstldgyar rttlsskmyh 180
tkgqegsvcl rssdcasqlc carhfwskic kpvlkeggvc tkhrrkgshq leifqrcycq 240
eglscriqkd hhqasnssrl htcgrh (GenBank Accession No. XP_005730) (SEQ ID NO:128).

This homology suggests a lipid-binding function and may facilitate Dkk-1 interactions at the plasma membrane (van Tilbeurgh, H., *Biochim. Biophys. Acta.* 1441:173-84 (1999)). An interaction domain of Dkk-1 that is able to interact with the ligand binding domain (LBD) of LRP5 is a useful reagent in the modulation of LRP5 activity

and modulation of Dkk-1/LRP5 complex formation. Similar screens can be prepared for Dkk-1 and Dkk-1 interacting proteins or polypeptides.

A set of peptide aptamers was identified from a library of random peptides constrained and presented in a thioredoxin A (trxA) scaffold as described in Example 3. Peptide aptamers are powerful new tools for molecular medicine as reviewed by Hoppe-Seyler & Butz, *J. Mol. Med.*, 78:426-430 (2000); Brody and Gold, *Rev. Mol. Biotech.*, 74:5-13 (2000); and Colas, *Curr. Opin. in Chem. Biol.* 4:54-9 (2000) and the references cited therein. Briefly, peptide aptamers have been shown to be highly specific reagents capable of binding *in vivo*. As such, peptide aptamers provide a method of modulating the function of a protein and may serve as a substitute for conventional knock-out methods, knock-down or complete loss of function. Peptide aptamers are also useful reagents for the validation of targets for drug development and may be used as therapeutic compounds directly or provide the necessary foundation for drug design. Once identified, the peptide insert may be synthesized and used directly or incorporated into another carrier molecule. References reviewed and cited by Brody and Gold (2000, *supra*) describe demonstrated therapeutic and diagnostic applications of peptide aptamers and would be known to the skilled artisan.

The peptide aptamers of the present invention are useful reagents in the binding of Dkk-1 to its ligands and thereby modulation of the Wnt pathway and may be used to prevent Dkk-1 from inhibiting LRP5 modulation or Dkk-1 interacting protein modulation of the Wnt pathway. The sequence of these peptide aptamers is shown in Figure 3 (SEQ ID NOs:171-188). The peptide aptamers refers to the peptide constrained by the thioredoxin scaffold. The aptamers are also contemplated as therapeutic agents to treat Dkk-1 mediated diseases and conditions. Such aptamers are useful structural guides to chemists, for the design of mimetic compounds of the aptamers.

Peptide aptamers were likewise developed to the LRP5 ligand binding domain (LBD) bait sequences. The sequences of these peptide aptamers is shown in Figure 4 (SEQ ID NOs:189-192). These are useful reagents which may be used to disrupt

the Dkk-1/LRP5 binding interface while leaving Dkk-1 undisturbed. These can be used as comparative controls for Wnt signaling, thus, a control is provided for the specificity of any drug or therapy screened. The aptamers are also useful therapeutic agents to treat LRP mediated diseases and conditions. Such aptamers may also be used as structural guides to chemists, for the design of mimetic compounds of the aptamers.

Thirty proteins were identified which interact with Dkk-1, Dkk-1 interacting proteins, were identified in a yeast-two-hybrid screen using the Dkk-1 bait and are shown in Figure 5. It was noted that these results suggest an interaction of Dkk-1 with Notch-2. It has been suggested that cross-talk exists between the Wnt and Notch signaling pathways. For instance, Presenilin1 (Ps1) is required for Notch processing and inhibits the downstream Wnt pathway. The extracellular domain of Notch is thought to interact with Wnt. Furthermore, the Notch intracellular domain is thought to interact with disheveled and in signal induced processing, the intracellular domain is thought to interact with presenilin. (Soriano *et al.*, *J. Cell Biol.* 152:785-94 (2001)). For additional information regarding the relationships between Notch and Wnt signaling, see Wesley, *Mol. Cell. Biol.* 19:5743-58 (1999) and Axelrod *et al.*, *Science* 271:1826-32 (1996).

An interaction between Dkk-1 and chordin has also been noted; suggesting that cross-talk exists between the Wnt and TGF-beta/BMP signaling pathways (Letamendia *et al.*, *J. Bone Joint Surg. Am.* 83A:S31 (2001); Labbe *et al.*, *Proc. Natl. Acad. Sci. USA* 97:8358-63 (2000); Nishita *et al.*, *Nature* 403:781-5 (2000); DeRobertis *et al.*, *Int. J. Dev. Biol.* 45:1389-97 (2001); and Saint-Jeannet *et al.*, *Proc. Natl. Acad. Sci. USA* 94:13713-8 (1997)). The BMP signaling pathway has an established role in bone and connective tissue development, repair and homeostasis (review in Rosen and Wozney "Bone Morphogenetic Proteins" In: *Principles of Bone Biology*, 2nd Edition, Eds. J. Bilezikian, L. Raisz and G. Rodan, Academic Press, pp. 919-28 (2002)). Chordin is an important molecule during development which also modulates BMP signaling in adults by sequestering BMPs in latent complexes (Piccolo *et al.*, *Cell* 86:589-98 (1996) reviewed in Reddi, *Arthritis Res.* 3:1-5 (2001);

DeRobertis *et al.*, *Int. J. Dev. Biol.* 45:189-97 (2001)). It may be that Dkk effects bone mass modulation through both the Wnt signaling pathway via LRP and the BMP pathway via chordin.

Moreover, a number of putative growth factors, growth factor related proteins, and extracellular matrix proteins have been identified as Dkk-1 interacting proteins. Additional information regarding Dkk-1 interacting proteins identified in the Y2H assay may be obtained from publicly available databases such as PubMed via the use of the accession numbers provided in the present application. In a preferred embodiment of the invention, the amino acid sequences of these Dkk-1 interacting proteins or biologically active fragments thereof be used to modulate Dkk, Dkk-1, LRP5, LRP6, HBM, or Wnt activity. Although these proteins were identified as interacting with Dkk-1, due to the substantial homology between the various Dkk proteins, such interacting proteins are contemplated to interact with the other Dkk family members.

4. Aptamer Mimetics

The present invention further provides for mimetics of Dkk, particularly Dkk-1, and LRP5 peptide aptamers. Such aptamers may serve as structural guides to chemists for the design of mimetic compounds of the aptamers. The aptamers and their mimetics are useful as therapeutic agents to treat LRP- or Dkk-mediated diseases and conditions.

5. Nucleic Acid Molecules

The present invention further provides nucleic acid molecules that encode polypeptides and proteins which interact with Dkk and Dkk interacting proteins, and/or LRP5 (also LRP6 and HBM) to modulate biological activities of these proteins. Preferred embodiments provide nucleic acids encoding for fragments of Dkk-1 protein, including the nucleic acids of Figure 7, the Dkk-1 interacting proteins listed in Figure 5, polypeptide aptamers of Dkk-1 (Figure 3 - SEQ ID NOs:171-188), LRP5 (Figure 4 - SEQ ID NOs:189-192), Figure 13 peptide aptamers (including SEQ

ID NO:204-214) encoded by Figure 12 polynucleotides (including SEQ ID NO:193-203), LRP6 and HBM and the related fusion proteins herein described, preferably in isolated or purified form. As used herein, "nucleic acid" is defined as RNA, DNA, or cDNA that encodes a peptide as defined above, or is complementary to a nucleic acid sequence encoding such peptides, or hybridizes to either the sense or antisense strands of the nucleic acid and remains stably bound to it under appropriate stringency conditions. The nucleic acid may encode a polypeptide sharing at least about 75% sequence identity, preferably at least about 80%, and more preferably at least about 85%, with the peptide sequences; at least about 90%, 95%, 96%, 97%, 98%, and 99% or greater are also contemplated. Specifically contemplated are genomic DNA, cDNA, mRNA, antisense molecules, enzymatically active nucleic acids (e.g., ribozymes), as well as nucleic acids based on an alternative backbone or including alternative bases, whether derived from natural sources or synthesized. Such hybridizing or complementary nucleic acids, however, are defined further as being novel and nonobvious over any prior art nucleic acid including that which encodes, hybridizes under appropriate stringency conditions, or is complementary to a nucleic acid encoding a protein according to the present invention.

As used herein, the terms "hybridization" (hybridizing) and "specificity" (specific for) in the context of nucleotide sequences are used interchangeably. The ability of two nucleotide sequences to hybridize to each other is based upon the degree of complementarity of the two nucleotide sequences, which in turn is based on the fraction of matched complementary nucleotide pairs. The more nucleotides in a given sequence that are complementary to another sequence, the greater the degree of hybridization of one to the other. The degree of hybridization also depends on the conditions of stringency which include temperature, solvent ratios, salt concentrations, and the like. In particular, "selective hybridization" pertains to conditions in which the degree of hybridization of a polynucleotide of the invention to its target would require complete or nearly complete complementarity. The complementarity must be sufficiently high so as to assure that the polynucleotide of

the invention will bind specifically to the target nucleotide sequence relative to the binding of other nucleic acids present in the hybridization medium. With selective hybridization, complementarity will be about 90-100%, preferably about 95-100%, more preferably about 100%.

5 "Stringent conditions" are those that (1) employ low ionic strength and high temperature for washing, for example: 0.015 M NaCl, 0.0015 M sodium titrate, 0.1% SDS at 50°C; or (2) employ during hybridization a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 50 mM sodium phosphate buffer at pH 6.5
10 with 750 mM NaCl, 75 mM sodium citrate at 42°C. Another example is use of 50% formamide, 5X SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5X Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2X SSC and 0.1% SDS. A skilled artisan can readily determine
15 and vary the stringency conditions appropriately to obtain a clear and detectable hybridization signal.

As used herein, a nucleic acid molecule is said to be "isolated" or "purified" when the nucleic acid molecule is substantially separated from contaminant nucleic acid encoding other polypeptides from the source of nucleic acid. Isolated or purified
20 is also meant to include nucleic acids which encode Dkk or fragments thereof which lack surrounding genomic sequences that flank the *Dkk* gene. Isolated or purified is further intended to include nucleic acids which encode Dkk interacting proteins or biologically active fragments thereof which lack surrounding genomic sequences that flank the Dkk interacting protein genes.

25 The present invention further provides fragments of the encoding nucleic acid molecule. As used herein, a fragment of an encoding nucleic acid molecule refers to a small portion of the entire protein encoding sequence. The size of the fragment will be determined by the intended use. For example, if the fragment is chosen so as to encode an active portion of the protein, the fragment will need to be large enough
30 to encode the functional region(s) of the protein. If the fragment is to be used as a

nucleic acid probe or PCR primer, then the fragment length is chosen so as to obtain a relatively small number of false positives during probing/priming.

Fragments of the encoding nucleic acid molecules of the present invention (*i.e.*, synthetic oligonucleotides) that are used as probes or specific primers for the polymerase chain reaction (PCR), or to synthesize gene sequences encoding proteins of the invention can easily be synthesized by chemical techniques, for example, the phosphotriester method of Matteucci *et al.* (*J. Am. Chem. Soc.* 103:3185-3191 (1981)) or using automated synthesis methods. In addition, larger DNA segments can readily be prepared by well known methods, such as synthesis of a group of oligonucleotides that define various modular segments of the gene, followed by ligation of oligonucleotides to build the complete modified gene.

The polypeptide encoding nucleic acid molecules of the present invention may further be modified to contain a detectable label for diagnostic and probe purposes. A variety of such labels are known in the art and can readily be employed with the encoding molecules herein described. Suitable labels include, but are not limited to, biotin, radiolabeled nucleotides and the like. A skilled artisan can employ any of the art known labels to obtain a labeled encoding nucleic acid molecule.

Modifications to the primary structure itself by deletion, addition, or alteration of the amino acids incorporated into the protein sequence during translation can be made without destroying the activity of the protein. Such substitutions or other alterations result in proteins having an amino acid sequence encoded by a nucleic acid falling within the contemplated scope of the present invention.

Antisense molecules corresponding to the polypeptide coding or complementary sequence may be prepared. Methods of making antisense molecules which bind to mRNA, form triple helices or are enzymatically active and cleave TSG RNA and single stranded DNA (ssDNA) are known in the art. See, *e.g.*, Antisense and Ribozyme Methodology: Laboratory Companion (Ian Gibson, ed., Chapman & Hall, 1997) and Ribozyme Protocols: Methods in Molecular Biology (Phillip C. Turner, ed., Humana Press, Clifton, NJ, 1997).

Also contemplated is the use of compounds which mediate postranscriptional gene silencing (PTGS), quelling and RNA interference (RNAi). These compounds typically are about 21 to about 25 nucleotides and are also known as short interfering RNAs or short inhibitory RNAs (siRNAs). The siRNAs are produced from an initiating double stranded RNA (dsRNA). Although the full mechanism by which the siRNAs function is not fully elucidated, it is known that these siRNAs transform the target mRNA into dsRNA, which is then degraded. Preferred forms are 5' phosphorylated siRNAs, however, hydroxylated forms may also be utilized. For additional background regarding the preparation and mechanism of siRNAs generally, see, e.g., Lipardi *et al.*, *Cell* 107(3): 297-307 (2001); Boutla *et al.*, *Curr. Biol.* 11(22): 1776-80 (2001); Djikeng *et al.*, *RNA* 7(11): 1522-30 (2001); Elbashir *et al.*, *EMBO J.* 20(23): 6877-88 (2001); Harborth *et al.*, *J. Cell. Sci.* 114(Pt. 24): 4557-65 (2001); Hutvagner *et al.*, *Science* 293(5531): 811-3 (2001); and Elbashir *et al.*, *Nature* 411:494-98 (2001).

Also contemplated are short hairpin RNAs (shRNAs). shRNAs are a modification of the siRNA method described above. Instead of transfecting exogenously synthesized dsRNA into a cell, sequence-specific silencing can be achieved by stabling expressing siRNA from a DNA template as a fold-back stem-loop, or hairpin. This approach is known as shRNA. This method permits the analysis of loss of function phenotypes due to sequence-specific gene silencing in mammalian cells by avoiding many of the problems associated with siRNAs, such as RNase degradation of the reagents, expensive chemical synthesis, etc. For additional background regarding the preparation and mechanism of shRNAs generally, see, e.g., Yu *et al.*, *PNAS* 99:6047-6052 (2002); Paddison *et al.*, *Genes and Devel.* 16:948-58 (2002); and Brummelkamp *et al.*, *Science* 296:550-553 (2002). For additional background on the use of this method in mammalian gene knockdown methodologies, see Tuschl, *Nature Biotech.* 20:446-448 (2002) (and references therein).

In one preferred embodiment, the siRNA or shRNA is directed to a Dkk encoding mRNA, wherein a preferred Dkk is Dkk-1. In another embodiment, the

siRNA or shRNA is directed towards a protein which binds to and modulates the activity of or is modulated by a Dkk; these proteins include LRP5, LRP6 and HBM as well as other members of the Wnt pathway.

6. Isolation of Other Related Nucleic Acid Molecules

The identification of the nucleic acid molecule of Dkk allows a skilled artisan to isolate nucleic acid molecules that encode other members of the Dkk family (see, Krupnik *et al.*, 1999). Further, the presently disclosed nucleic acid molecules allow a skilled artisan to isolate nucleic acid molecules that encode Dkk-1-like proteins, in addition to Dkk-1. The presently disclosed Dkk-1 interacting proteins and their corresponding nucleic acid molecules allows a skilled artisan to further isolate other related protein family members which interact with Dkk-1.

A skilled artisan can readily use the amino acid sequence of Dkk and Dkk interacting proteins to generate antibody probes to screen expression libraries prepared from appropriate cells. Typically, polyclonal antiserum from mammals such as rabbits immunized with the purified protein (as described below) or monoclonal antibodies can be used to probe a mammalian cDNA or genomic expression library, such as a human macrophage library, to obtain the appropriate coding sequence for other members of the protein family. The cloned cDNA sequence can be expressed as a fusion protein, expressed directly using its own control sequences, or expressed by constructions using control sequences appropriate to the particular host used for expression of the desired protein.

Alternatively, a portion of the coding sequence herein described can be synthesized and used as a probe to retrieve DNA encoding a member of the protein family from any mammalian organism. Oligomers containing approximately 18-20 nucleotides (encoding about a 6-7 amino acid stretch) are prepared and used to screen genomic DNA or cDNA libraries to obtain hybridization under stringent conditions or conditions of sufficient stringency to eliminate an undue level of false positives.

Additionally, pairs of oligonucleotide primers can be prepared for use in a polymerase chain reaction (PCR) to selectively clone an encoding nucleic acid

molecule. A PCR denature/anneal/extend cycle for using such PCR primers is well known in the art and can readily be adapted for use in isolating other encoding nucleic acid molecules. For example, degenerate primers can be utilized to obtain sequences related to Dkk-1 or Dkk-1 interacting proteins. Primers can be designed that are not perfectly complementary and can still hybridize to a portion of a target sequence or flanking sequence and thereby provide for amplification of all or a portion of a target sequence. Primers of about 20 nucleotides or less, preferably have about one to three mismatches located at the 5' and/or 3' ends. Primers of about 20 to 30 nucleotides have up to about 30% mismatches and can still hybridize to a target sequence.

Hybridization conditions for primers with mismatch can be determined by the method described in Maniatis *et al.*, Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982) or by reference to known methods. The ability of the primer to hybridize to a sequence of either Dkk-1, a Dkk-1 interacting protein, or a related sequence under varying conditions can be determined using this method. Because a target sequence is known, the effect of mismatches can be determined by methods known to those of skill in the art. Degenerate primers would be based on putative conserved amino acid sequences of the Dkk-1 and Dkk-1 interacting protein genes.

7. rDNA Molecules for Polypeptide Expression

The present invention further provides recombinant DNA molecules (rDNAs) that contain a polypeptide coding sequence. As used herein, a rDNA molecule is a DNA molecule that has been subjected to molecular manipulation *in situ*. Methods for generating rDNA molecules are well known in the art, for example, see Sambrook *et al.*, Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989). In the preferred rDNA molecules, a coding DNA sequence is operably linked to expression control sequences and/or vector sequences.

The choice of vector and/or expression control sequences to which one of the protein family encoding sequences of the present invention is operably linked depends directly, as is well known in the art, on the functional properties desired, *e.g.*, protein

expression, and the host cell to be transformed. A vector contemplated by the present invention is at least capable of directing the replication and/or insertion into the host chromosome, and preferably also expression, of the structural gene included in the rDNA molecule.

5 Expression control elements that are used for regulating the expression of an operably linked protein encoding sequence are known in the art and include, but are not limited to, inducible promoters, constitutive promoters, secretion signals, and other regulatory elements. Preferably, the inducible promoter is readily controlled, such as being responsive to a nutrient in the host cell's medium. Preferred promoters include
10 yeast promoters, which include promoter regions for metallothionein, 3-phosphoglycerate kinase or other glycolytic enzymes such as enolase or glyceraldehyde-3-phosphate dehydrogenase, enzymes responsible for maltose and galactose utilization, and others. Vectors and promoters suitable for use in yeast expression are further described in EP 73,675A. Appropriate non-native mammalian
15 promoters might include the early and late promoters from SV40 (Fiers et al, *Nature*, 273:113 (1978)) or promoters derived from Moloney murine leukemia virus, mouse tumor virus, avian sarcoma viruses, adenovirus II, bovine papilloma virus or polyoma. In addition, the construct may be joined to an amplifiable gene (e.g., DHFR) so that multiple copies of the gene may be made. For appropriate enhancer and other
20 expression control sequences, see also Enhancers and Eukaryotic Gene Expression (Cold Spring Harbor Press, Cold Spring Harbor, NY, 1983). Preferred bone related promoters include CMVbActin or type I collagen promoters to drive expression of the human HBM, Zmax1/LRP5 or LRP6 cDNA. Other preferred promoters for mammalian expression are from cytomegalovirus (CMV), Rous sarcoma virus (RSV), Simian virus
25 40 (SV40), and EF-1a (human elongation factor 1a-subunit).

 In one embodiment, the vector containing a coding nucleic acid molecule will include a prokaryotic replicon, i.e., a DNA sequence having the ability to direct autonomous replication and maintenance of the recombinant DNA molecule extrachromosomally in a prokaryotic host cell, such as a bacterial host cell, transformed
30 therewith. Such replicons are well known in the art. In addition, vectors with a

prokaryotic replicon may also include a gene whose expression confers a detectable marker such as a drug resistance. Typical bacterial drug resistance genes are those that confer resistance to ampicillin or tetracycline.

5 Vectors that include a prokaryotic replicon can further include a prokaryotic or bacteriophage promoter capable of directing the expression (transcription and translation) of the coding gene sequences in a bacterial host cell, such as *E. coli*. A promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur. Promoter sequences compatible with bacterial hosts are typically provided in plasmid vectors containing
10 convenient restriction sites for insertion of a DNA segment of the present invention. Typical of such vector plasmids are pUC8, pUC9, pBR322 and pBR329 available from Biorad Laboratories, (Richmond, CA), and pPL and pKK223 available from Pharmacia (Piscataway, NJ).

15 Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, can also be used to form a rDNA molecule that contains a coding sequence. Eukaryotic cell expression vectors are well known in the art and are available from several commercial sources. Typically, such vectors are provided containing convenient restriction sites for insertion of a desired DNA segment. Typical of such vectors are pSVL and pKSV-10 (Pharmacia), pBPV-1/pML2d (International
20 Biotechnologies, Inc.), vector systems that include Histidine Tags and periplasmic secretion, or other vectors described in the art.

Eukaryotic cell expression vectors used to construct the rDNA molecules of the present invention may further include a selectable marker that is effective in an eukaryotic cell, preferably a drug resistance selection marker. A preferred drug
25 resistance marker is the gene whose expression results in neomycin resistance, *i.e.*, the neomycin phosphotransferase (*neo*) gene (Southern *et al.*, *J. Mol. Anal. Genet.* 1:327-341 (1982)). Alternatively, the selectable marker can be present on a separate plasmid, and the two vectors introduced by co-transfection of the host cell, and selected by culturing in the appropriate drug for the selectable marker.

8. Host Cells Containing an Exogenously Supplied rDNA Nucleic Acid

Molecule

The present invention further provides host cells transformed with a nucleic acid molecule that encodes a polypeptide or protein of the present invention. The host cell
5 can be either prokaryotic or eukaryotic. Eukaryotic cells useful for expression of a protein of the invention are not limited, so long as the cell line is compatible with cell culture methods and compatible with the propagation of the expression vector and expression of the gene product. Preferred eukaryotic host cells include, but are not limited to, yeast, insect and mammalian cells, preferably vertebrate cells such as those
10 from a mouse, rat, monkey or human cell line but also can include invertebrates with, for example, cartilage. Preferred eukaryotic host cells include but are not limited to Chinese hamster ovary (CHO) cells (ATCC No. CCL61), NIH Swiss mouse embryo cells NIH/3T3 (ATCC No. CRL 1658), baby hamster kidney cells (BHK), HOB-03-CE6 osteoblast cells, and other like eukaryotic tissue culture cell lines.

15 Any prokaryotic host can be used to express a rDNA molecule encoding a protein of the invention. A preferred prokaryotic host is *E. coli*.

Transformation of appropriate cell hosts with a recombinant DNA (rDNA) molecule of the present invention is accomplished by well known methods that typically depend on the type of vector used and host system employed. With regard to
20 transformation of prokaryotic host cells, electroporation and salt treatment methods are typically employed; see, for example, Cohen *et al.*, *Proc. Natl. Acad. Sci. USA* 69: 2110 (1972); Maniatis *et al.* (1982); and Sambrook *et al.* (1989). With regard to transformation of vertebrate cells with vectors containing rDNAs, electroporation, cationic lipid or salt treatment methods are typically employed; see, for example,
25 Graham *et al.*, *Viol.* 52: 456 (1973); Wigler *et al.*, *Proc. Natl. Acad. Sci. USA* 76: 1373-76 (1979).

Successfully transformed cells, *i.e.*, cells that contain a rDNA molecule of the present invention, can be identified by well known techniques including the selection for a selectable marker. For example, cells resulting from the introduction of an rDNA of
30 the present invention can be cloned to produce single colonies. Cells from those

colonies can be harvested, lysed and their DNA content examined for the presence of the rDNA using a method such as that described by Southern, *J. Mol. Biol.* 98: 503 (1975), or Berent *et al.*, *Biotech.* 3: 208 (1985). Alternatively, the cells can be cultured to produce the proteins encoded by the rDNA and the proteins harvested and assayed, using for example, any suitable immunological method. See, e.g., Harlow *et al.*, (1988).

Recombinant DNA can also be utilized to analyze the function of coding and non-coding sequences. Sequences that modulate the translation of the mRNA can be utilized in an affinity matrix system to purify proteins obtained from cell lysates that associate with the Dkk-1 or Dkk-1 interacting protein or expression control sequence. Synthetic oligonucleotides would be coupled to the beads and probed with the lysates, as is commonly known in the art. Associated proteins could then be separated using, for example, a two dimensional SDS-PAGE system. Proteins thus isolated could be further identified using mass spectroscopy or protein sequencing. Additional methods would be apparent to the skilled artisan.

9. Production of Recombinant Peptides and Proteins using a cDNA or Other Recombinant Nucleic Acids

The invention also relates to nucleic acid molecules which encode a Dkk protein and polypeptide fragments thereof, and proteins and polypeptides which bind to Dkk (e.g., LRP5, LRP6 and HBM, Dkk interacting proteins such as the proteins of Figure 5) and molecular analogues. The polypeptides of the present invention include the full length Dkk and polypeptide fragments thereof, Dkk binding proteins and polypeptides thereof. Preferably these proteins are mammalian proteins, and most preferably human proteins and biologically active fragments thereof. Alternative embodiments include nucleic acid molecules encoding polypeptide fragments having a consecutive amino acid sequence of at least about 3, 5, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, or 200 amino acid residues from a common polypeptide sequence; amino acid sequence variants of a common polypeptide sequence wherein an amino acid residue has been inserted N- or C-terminal to, or within, the polypeptide sequence or its fragments; and amino acid sequence variants of the common

polypeptide sequence or its fragments, which have been substituted by another conserved residue. Recombinant nucleic acid molecules which encode polypeptides include those containing predetermined mutations by, e.g., homologous recombination, site-directed or PCR mutagenesis, and recombinant Dkk proteins or polypeptide fragments of other animal species, including but not limited to vertebrates (e.g., rabbit, rat, murine, porcine, camelid, reptilian, caprine, avian, fish, bovine, ovine, equine and non-human primate species) as well as invertebrates, and alleles or other naturally occurring variants and homologs of Dkk binding proteins of the foregoing species and of human sequences. Also contemplated herein are derivatives of the commonly known Dkk, Dkk interacting proteins, or fragments thereof, wherein Dkk, Dkk interacting proteins, or their fragments have been covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid (for example a detectable moiety such as an enzyme or radioisotope) and soluble forms of Dkk. It is further contemplated that the present invention also includes nucleic acids with silent mutations which will hybridize to the endogenous sequence and which will still encode the same polypeptide.

The nucleic acid molecules encoding Dkk binding proteins, the LRP5 binding domain fragment of Dkk, or other polypeptides of the present invention are preferably those which share a common biological activity (e.g., mediate Dkk activity such as its interaction with LRP5, HBM or LRP6). The polypeptides of the present invention include those encoded by a nucleic acid molecule with silent mutations, as well as those nucleic acids encoding a biologically active protein with conservative amino acid substitutions, allelic variants, and other variants of the disclosed polypeptides which maintain at least one Dkk activity.

The amino acid compounds of the invention are polypeptides which are partially defined in terms of amino acid residues of designated classes. Polypeptide homologs would include conservative amino acid substitutions within the amino acid classes described below. Amino acid residues can be generally sub-classified into four major subclasses as follows:

Acidic: The residue has a negative charge due to loss of H^+ ion at physiological pH, and the residue is attracted by aqueous solution so as to seek the surface positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium, at physiological pH.

5 Basic: The residue has a positive charge due to association with H^+ ion at physiological pH, and the residue is attracted by aqueous solution so as to seek the surface positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium at physiological pH.

10 Neutral/non-polar: The residues are not charged at physiological pH, but the residue is repelled by aqueous solution so as to seek the inner positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium. These residues are also designated "hydrophobic."

15 Neutral/polar: The residues are not charged at physiological pH, but the residue is attracted by aqueous solution so as to seek the outer positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium.

20 It is understood, of course, that in a statistical collection of individual residue molecules some molecules will be charged, and some not, and there will be an attraction for or repulsion from an aqueous medium to a greater or lesser extent. To fit the definition of "charged", a significant percentage (at least approximately 25%) of the individual molecules are charged at physiological pH. The degree of attraction or repulsion required for classification as polar or nonpolar is arbitrary and, therefore, amino acids specifically contemplated by the invention have been classified as one or the other. Most amino acids not specifically named can be classified on the basis of known behavior.

25 Amino acid residues can be further subclassified as cyclic or noncyclic, and aromatic or non-aromatic, self-explanatory classifications with respect to the side chain substituent groups of the residues, and as small or large. The residue is considered small if it contains a total of 4 carbon atoms or less, inclusive of the carboxyl carbon. Small residues are, of course, always nonaromatic.

The gene-encoded secondary amino acid proline, although technically within the group neutral/nonpolar/large/cyclic and nonaromatic, is a special case due to its known effects on the secondary conformation of peptide chains, and is not, therefore, included in this defined group.

5 Other amino acid substitutions of those encoded in the gene can also be included in peptide compounds within the scope of the invention and can be classified within this general scheme according to their structure.

All of the compounds of the invention may be in the form of the pharmaceutically acceptable salts or esters. Salts may be, for example, Na^+ , K^+ , Ca^{+2} , Mg^{+2} and the like;
10 the esters are generally those of alcohols of 1-6 carbons.

The present invention further provides methods for producing a protein of the invention using nucleic acid molecules herein described. In general terms, the production of a recombinant form of a protein typically involves the following steps.

First, a nucleic acid molecule is obtained that encodes Dkk, such as a nucleic acid molecule encoding human Dkk or any other Dkk sequence, or that encodes a Dkk binding protein, a Dkk aptamer or a biologically active fragment thereof. Particularly for Dkk binding peptides, the nucleotides encoding the peptide are incorporated into a nucleic acid in the form of an in-frame fusion, insertion into or appended to a thioredoxin coding sequence. The coding sequence (ORF) is directly suitable for expression in any
15 host, as it is not interrupted by introns.

These DNAs can be transfected into host cells such as eukaryotic cells or prokaryotic cells. Eukaryotic hosts include mammalian cells and vertebrate (e.g., osteoblasts, osteosarcoma cell lines, Drosophila S2 cells, hepatocytes, tumor cell lines and other bone cells of any mammal, as well as insect cells, such as Sf9 cells using recombinant baculovirus). For example, a DNA expressing an open reading frame (ORF) under control of a type I collagen promoter, or such osteoblast promoters as osteocalcin histone, type I collagen, $\text{TGF}\beta 1$, MSX2 , c-fos/c-Jun and Cbfa1 , can be used
25 to regulate the Dkk in animal cells. Alternatively, the nucleic acid can be placed downstream from an inducible promoter, which can then be placed into vertebrate or
30 invertebrate cells or be used in creating a transgenic animal model.

Alternatively, proteins and polypeptides of the present invention can be expressed in an heterologous system. The human cell line GM637, SV-40 transformed human fibroblasts, can be transfected, with a plasmid containing a Dkk ligand binding domain coding sequence under the control of the chicken actin promoter (Reis *et al.*,
5 EMBO J. 11: 185-193 (1992)). Such transfected cells could be used as a source of Dkk binding domain in functional assays. Alternatively, polypeptides encoding only a portion of Dkk or any of the disclosed Dkk binding peptides Dkk aptamers or a polypeptide encoding a Dkk interacting protein can be expressed alone or in the form of a fusion protein. For example, Dkk derived peptides can be expressed in bacteria (e.g.,
10 *E. coli*) as GST- or His-Tag fusion proteins. These fusion proteins are then purified and can be used to generate polyclonal antibodies or can be used to identify other Dkk ligands.

The nucleic acid coding sequence is preferably placed in operable linkage with suitable control sequences, as described above, to form an expression unit containing
15 the protein encoding open reading frame. The expression unit is used to transform a suitable host and the transformed host is cultured under conditions that allow the production of the recombinant protein. Optionally the recombinant protein is isolated from the medium or from the cells; recovery and purification of the protein may not be necessary in some instances where some impurities may be tolerated.

Each of the foregoing steps can be done in a variety of ways. For example, the
20 desired coding sequences may be obtained from genomic fragments and used directly in appropriate hosts. The construction of expression vectors that are operable in a variety of hosts is accomplished using appropriate replicons and control sequences, as set forth above. The control sequences, expression vectors, and transformation
25 methods are dependent on the type of host cell used to express the gene and were discussed in detail earlier. Suitable restriction sites can, if not normally available, be added to the ends of the coding sequence so as to provide an excisable gene to insert into these vectors. A skilled artisan can readily adapt any host/expression system known in the art for use with the nucleic acid molecules of the invention to produce
30 recombinant protein.

10. Methods to Identify Binding Partners

Another embodiment of the present invention provides methods for use in isolating and identifying binding partners of Dkk or Dkk interacting proteins. Dkk or a Dkk interacting protein or a polypeptide fragment thereof can be mixed with a potential binding partner or an extract or fraction of a cell under conditions that allow the association of potential binding partners with Dkk or with Dkk interacting proteins. After mixing, the peptides, polypeptides, proteins or other molecules that have become associated with Dkk or a Dkk interacting protein are separated from the mixture. The binding partner that bound to the polypeptide then can be purified and further analyzed. Determination of binding partners of Dkk and Dkk interacting proteins as well as agents which prevent the interaction of Dkk with one of its interacting proteins (e.g., LRP5, LRP6, HBM, or those proteins listed in Figure 5) can be performed using a variety of different competition assays as are known in the art. For example, the minimal sequence of Dkk, as described herein, can be used to identify antibodies which compete with LRP5 (or LRP6, HBM or other ligand binding partners) for binding to Dkk-1 and vice versa. The minimal Dkk sequence can be bound to the bottom of a 96-well plate (or other solid substrate), and antibodies or other potential binding agents (e.g., polypeptides, mimetics, homologs, antibody fragments and the like) can be screened in a competition assay to identify agents with binding affinities, for example, greater than the natural ligand binding partner of Dkk.

In the present invention, suitable cells are used for preparing assays, for the expression of a LRP and/or Dkk or proteins that interact therewith. The cells may be made or derived from mammals, yeast, fungi, or viruses. A suitable cell for the purposes of this invention is one that includes but is not limited to a cell that can exhibit a detectable Dkk-LRP (or HBM) interaction, and preferably, the differential interaction between Dkk-1-LRP5 and Dkk-1-HBM. For the desired assay, the cell type may vary. In several embodiments, bone cells are preferred, for example, a human osteoblast cell (e.g. hOB-03-CE6) or osteosarcoma cell (e.g. U2OS). Additional hOB cells are hOB-03-C5, hOB-02-02 and, an immortalized pre-osteocytic cell line referred to as hOB-01-C1-PS-09 cells (which are deposited with American Type Culture Collection in

Manassas, Va. with the designation PTA-785), Examples of osteosarcoma cells would include SaoS2, MG63 and HOS TE85. Immortalized refers to a substantially continuous and permanently established cell culture with substantially unlimited cell division potential. That is, the cells can be cultured substantially indefinitely, i.e., for at least about 6 months under rapid conditions of growth, preferably much longer under slower growth conditions, and can be propagated rapidly and continually using routine cell culture techniques. Alternatively stated, preferred cells can be cultured for at least about 100, 150 or 200 population doublings. These cells produce a complement of proteins characteristic of normal human osteoblastic cells and are capable of osteoblastic differentiation. They can be used in cell culture studies of osteoblastic cell sensitivity to various agents, such as hormones, cytokines, and growth factors, or in tissue therapy. Certain non bone cells such as HEK 293 cells that exhibit detectable Dkk-LRP (or HBM) interaction are also be useful for the assays of this invention.

To identify and isolate a binding partner, the entire Dkk protein (e.g., human Dkk-1, GenBank Accession No. BAA34651) or a Dkk interacting protein (Genbank Accession Nos. for some Dkk-1 interacting proteins are given in Figure 5) can be used. Alternatively, a polypeptide fragment of the protein can be used. Suitable fragments of the protein include at least about 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150 or more contiguous amino acid residues of any Dkk or Dkk interactor sequence. Preferable sequences of Dkk include portions or all of one or both of the cysteine rich domains (e.g., Cys-1 and Cys-2 of Dkk-1) or the conserved sequences at the amino terminus of Dkk-1 (See Krupnik *et al.*, *Gene* 238: 301-313 (1999)). Alternatively, portions of LRP5, LRP6, HBM and other Dkk interacting proteins such as those in Figure 5 that interact with Dkk-1 can be used to identify and isolate agents which modulate Dkk activity. Alternatively, peptide aptamers of LRP5, LRP6, HBM, Dkk and other Dkk interacting proteins such as those in Figure 5 that interact with Dkk-1 can be used to identify and isolate agents which modulate Dkk activity.

As used herein, a cellular extract refers to a preparation or fraction which is made from a lysed or disrupted cell. A variety of methods can be used to obtain cell

extracts. Cells can be disrupted using either physical or chemical disruption methods. Examples of physical disruption methods include, but are not limited to, sonication and mechanical shearing. Examples of chemical lysis methods include, but are not limited to, detergent lysis and enzyme lysis. A skilled artisan can readily adapt methods for preparing cellular extracts in order to obtain extracts for use in the present methods.

Once an extract of a cell is prepared, the extract is mixed with the protein of the invention under conditions in which association of the protein with the binding partner can occur. A variety of conditions can be used, the most preferred being conditions that closely resemble conditions found in the cytoplasm of a human cell. Features such as osmolarity, pH, temperature, and the concentration of cellular extract used, can be varied to optimize the association of the protein with the binding partner.

After mixing under appropriate conditions, the bound complex is separated from the mixture. A variety of techniques can be utilized to separate the mixture. For example, antibodies specific to a protein of the invention can be used to immunoprecipitate the binding partner complex. Alternatively, standard chemical separation techniques such as chromatography and density/sediment centrifugation can be used. For example, a protein of the invention is expressed with an affinity tag such as a His tag. The His labeled protein and any bound molecule may be retained and selectively eluted from a Ni-NTA column.

After removal of non-associated cellular constituents found in the extract, the binding partner can be dissociated from the complex using conventional methods. For example, dissociation can be accomplished by altering the salt concentration or pH of the mixture.

To aid in separating associated binding partner pairs from the mixed extract, the protein of the invention can be immobilized on a solid support. For example, the protein can be attached to a nitrocellulose matrix or acrylic beads. Attachment of the protein to a solid support aids in separating peptide/binding partner pairs from other constituents found in the extract. The identified binding partners can be either a single protein or a complex made up of two or more proteins.

Alternatively, the nucleic acid molecules of the invention can be used in a Y2H system. The Y2H system has been used to identify other protein partner pairs and can readily be adapted to employ the nucleic acid molecules herein described. Methods of performing and using Y2H systems are known. See, e.g., Finley *et al.*, "Two-Hybrid Analysis of Genetic Regulatory Networks," in The Yeast Two-Hybrid System (Paul L. Bartel *et al.*, eds., Oxford, 1997); Meijia Yang, "Use of a Combinatorial Peptide Library in the Two-Hybrid Assay," in The Yeast Two-Hybrid System (Paul L. Bartel *et al.*, eds., Oxford, 1997); Gietz *et al.*, "Identification of proteins that interact with a protein of interest: Applications of the yeast two-hybrid system," *Mol. & Cell. Biochem.* 172: 67-9 (1997); K. H. Young, "Yeast Two-Hybrid: So Many Interactions,(in) so Little Time," *Biol. Reprod.* 58: 302-311 (1998); R. Brent *et al.*, "Understanding Gene and Allele Function with Two-Hybrid Methods," *Annu. Rev. Genet.* 31:663-704 (1997) and U.S. Patent No. 5,989,808. The Dkk-1 interacting proteins identified in Figure 5 were identified using the Y2H interacting system using Dkk-1 as bait.

One preferred *in vitro* binding assay for Dkk modulators would comprise a mixture of a LRP binding domain of Dkk and one or more candidate binding targets or substrates. After incubating the mixture under appropriate conditions, one would determine whether Dkk or a fragment thereof bound with the candidate modulator present. For cell-free binding assays, one or more of the components usually comprises or is coupled to a label. The label may provide for direct detection, such as radioactivity, luminescence, optical or electron density, *etc.*, or indirect detection such as an epitope tag, an enzyme, *etc.* A variety of methods may be employed to detect the label depending on the nature of the label and other assay components. For example, the label may be detected bound to the solid substrate or a portion of the bound complex containing the label may be separated from the solid substrate, and the label thereafter detected. Fluorescence resonance energy transfer may be utilized to monitor the interaction of two labeled molecules. For example, a fluorescence label on Dkk and another label on LRP5 or a soluble fragment thereof such as the extracellular domain will exchange fluorescence resonance energy when in close proximity indicating that the two molecules are bound. A preferred binding partner for Dkk will

increase or decrease the affinity between Dkk and LRP5 which will be readily observable in a fluorescence spectrometer. Alternatively, an instrument, such as a surface plasmon resonance detector manufactured by BIAcore (Uppsala, Sweden), may be used to observe interactions with a fixed target. One skilled in the art knows of many other methods which may be employed for this purpose.

Thereby, the present invention provides methods for screening candidates including polypeptides of the present invention for activity which identifies these candidates as valuable drug leads. Other suitable methods are also known in the art and are suitable for use herein, including *Xenopus* oocyte injection studies and TCF luciferase assays.

Additional assays can be used to identify the activity of Dkk and Dkk interacting proteins in the Wnt pathway, as well as the impact of modulators of Dkk and Dkk interacting proteins on the Wnt pathway. These include, for example, a *Xenopus* embryo assay and a TCF-luciferase reporter gene assay to monitor Wnt signaling modulation.

Xenopus embryos are an informative *in vivo* assay system to evaluate the modulation of Wnt signaling. Ectopic expression of certain Wnts or other activators of the Wnt signaling pathway results in a bifurcation of the anterior neural plate. This bifurcation results in a duplicated body axis, which suggests a role for Wnt signaling during embryonic development (McMahon *et al.*, *Cell* 58: 1075-84 (1989); Sokol *et al.*, *Cell* 67: 741-52 (1991)). Since these original observations, the *Xenopus* embryo assay has been extensively used as an assay system for evaluating modulation of the Wnt signaling pathway. One preferred embodiment of the present invention is demonstrated in Example 6.

Constructs for *Xenopus* expression can be prepared as would be known in the art. For example, a variety of cDNAs have been engineered into the vector pCS2+ (Turner *et al.*, *Genes Devel.* 8: 1434-1447 (1994)) to facilitate the *in vitro* generation of mRNA for use in *Xenopus* embryo injection experiments. DNA inserts are subcloned in the sense orientation with respect to the vector SP6 promoter. Downstream of the insert, the vector provides an SV40 virus polyadenylation signal and a T3 promoter

sequence (*i.e.*, for the generation of antisense mRNA). Constructs can be generated for various Dkk family members, LRP5, LRP6, HBM, Dkk-1 interactors, etc. Constructs could be generated in pCS2⁺ that contain the nucleic acid sequence encoding for the peptide aptamers that were identified in yeast screens. These sequences would be fused to a 5' synthetic translation initiation sequence followed by a canonical signal sequence to ensure that the peptide aptamer would be translated and secreted from the cell.

Once these constructs are made then mRNA can be synthesized and injected into *Xenopus* oocytes. mRNA for microinjection into *Xenopus* embryos is generated by *in vitro* transcription using the cDNA constructs in the pCS2⁺ vector described above as template. Various amounts of RNA can be injected into the ventral blastomere of the 4- or 8-cell *Xenopus* embryo substantially as described in Moon *et al.*, *Technique-J. of Methods in Cell and Mol. Biol.* 1: 76-89 (1989), and Peng, *Meth. Cell. Biol.* 36: 657-62 (1991).

Previous data has shown that expression of LRP5, in the presence of Wnt5a, results in a Wnt-induced duplicated axis formation in *Xenopus* embryos (Tamai *et al.*, *Nature* 407: 530-535 (2000)). The roles of Dkk-1 and Dkk-2, and Dkk-1 interacting proteins, in modulating the LRP5-mediated Wnt response *in vivo* can be analyzed using, for example, the *Xenopus* embryo. In addition, the peptide aptamers, Dkk interacting proteins, or combinations of the above can be evaluated in a similar manner.

Experiments can also be conducted wherein RNA is injected into the dorsal blastomere to ensure the specificity of the observed phenotypes. Lineage tracing experiments can be performed where a marker gene such as green fluorescent protein (GFP) or LacZ is co-injected with the experimental RNAs. Detecting marker gene expression would identify the targeted cells of the microinjection and aid in elucidating the mechanism of action. In addition to the Wnt signaling components listed above, the point at which HBM acts upon the Wnt pathway can also be analyzed. This can be done by co-injections of various dominant-negative constructs. For example, a dominant negative TCF-3 construct would be useful to demonstrate that the observed axis duplication (and Wnt activation) is mediated via the β -catenin-TCF response. If so,

such a construct would be expected to abolish the observed duplicated axis phenotype. Another example would include a dominant negative Dsh construct. Since Dsh is far upstream in the Wnt signaling pathway, a dominant negative construct should abolish the activation of the Wnt response and the observed axis duplication. If it does not, this would suggest that axis duplication is being induced via a different signaling pathway.

The marker genes of the injected *Xenopus* embryos can be analyzed as follows. Representative embryos are collected at stage 10.5 (11 hours post fertilization) for marker gene analysis. RNA is extracted and purified from the embryos following standard protocols (Sambrook *et al.*, 1989 at 7.16). Marker genes could include the following: Siamese (*i.e.*, Wnt responsive gene), Xnr3 (*i.e.*, Wnt responsive gene), slug (*i.e.*, neural crest marker), Xbra (*i.e.*, early mesoderm marker), HNK-1 (*i.e.*, ectodermal/neural marker), endodermin (*i.e.*, endoderm), Xlhx8 (*i.e.*, pancreatic), BMP2 and BMP4 (*i.e.*, early mesoderm), XLRP6 (*i.e.*, maternal and zygotic expression, it is also the LRP6 homolog in the frog), EF-1 (*i.e.*, control) and ODC (*i.e.*, control). Induction of marker genes is analyzed and quantitated by RT-PCR/TaqMan®.

This type of marker analysis is excellent to monitor changes in gene expression that result very early in the embryo as a direct result of signaling perturbation. Other experiments could be designed that would monitor changes in gene expression in a more tissue or spatially-restricted fashion. Examples would include the generation of a transgenic *Xenopus* model. For example, Zmax/LRP5 and HBM expression could be under the control of the brachyury or cardiac-actin promoters directing gene expression transiently in the mesoderm or in the somites, respectively. Phenotype analyses of these transgenic *Xenopus* animals would include marker gene analysis/transcriptional profiling (from a restricted tissue source) and histologic examination of the tissue.

A TCF-luciferase assay system such as that described in Example 7 can also be used to monitor Wnt signaling activity, Dkk activity and Dkk interacting protein activity. Constructs for the TCF-luciferase assays can be prepared as would be known in the art. For example, Dkk and Dkk interacting protein peptides, LRP5/LRP6, among others, can be expressed in pcDNA3.1, using Kozak and signal sequences to target peptides for secretion.

Once constructs have been prepared, cells such as osteoblasts and HEK293 cells are seeded in well plates and transfected with construct DNA, CMV beta-galactosidase plasmid DNA, and TCF-luciferase reporter DNA. The cells are then lysed and assayed for beta-galactosidase and luciferase activity to determine whether Dkk, Dkk interacting proteins, or other molecules such as antibodies affect Wnt signaling.

Additional assays for monitoring Wnt signaling activity, Dkk activity, and Dkk interacting protein activity include:

Modulation of another Wnt-responsive transcription factor, LEF, as visualized by a reporter gene activity. One example includes the activation of the LEF1 promoter region fused to the luciferase reporter gene (Hsu *et al.*, *Mol. Cell. Biol.* 18: 4807-18 (1999)).

Alterations in cell proliferation, cell cycle or apoptosis. There are numerous examples describing Wnt-mediated cellular transformations including Shimizu *et al.*, *Cell. Growth Differ.* 8: 1349-58 (1997).

Stabilization and cellular localization of de-phosphorylated β -catenin as an indicator of Wnt activation (Shimizu *et al.*, 1997).

Additional methods of assaying Wnt signaling, through either the canonical or non-canonical pathways, would be apparent to the artisan of ordinary skill.

11. Methods to Identify Agents that Modulate the Expression of a Nucleic Acid Encoding the Dkk and/or LRP5 Proteins and/or Dkk interacting proteins

Another embodiment of the present invention provides methods for identifying agents that modulate the expression of a nucleic acid encoding Dkk. Such assays may utilize any available means of monitoring for changes in the expression level of the nucleic acids of the invention. As used herein, an agent is said to modulate the expression of Dkk, if it is capable of up- or down-regulating expression of the nucleic acid in a cell (e.g., mRNA).

In one assay format, cell lines that contain reporter gene fusions between the nucleic acid encoding Dkk (or proteins which modulate the activity of Dkk) and any

assayable fusion partner may be prepared. Numerous assayable fusion partners are known and readily available, including but not limited to the firefly luciferase gene and the gene encoding chloramphenicol acetyltransferase (Alam *et al.*, *Anal. Biochem.* 188: 245-254 (1990)). Cell lines containing the reporter gene fusions are then exposed to the agent to be tested under appropriate conditions and time. Differential expression of the reporter gene between samples exposed to the agent and control samples identifies agents which modulate the expression of a nucleic acid encoding Dkk or other protein which modulates Dkk activity. Such assays can similarly be used to determine whether LRP5 and even LRP6 activity is modulated by regulating Dkk activity.

Additional assay formats may be used to monitor the ability of the agent(s) to modulate the expression of a nucleic acid encoding Dkk, alone or Dkk and LRP5, and/or Dkk interacting proteins such as those identified in Figure 5. For instance, mRNA expression may be monitored directly by hybridization to the nucleic acids of the invention. Cell lines are exposed to the agent to be tested under appropriate conditions and time and total RNA or mRNA is isolated by standard procedures such those disclosed in Sambrook *et al.* (1989); Ausubel *et al.*, Current Protocols in Molecular Biology (Greene Publishing Co., NY, 1995); Maniatis *et al.*, Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982); and Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology (Frederick M. Ausubel *et al.*, April 1999).

Probes to detect differences in RNA expression levels between cells exposed to the agent and control cells may be prepared from the nucleic acids of the invention. It is preferable, but not necessary, to design probes which hybridize only with target nucleic acids under conditions of high stringency. Only highly complementary nucleic acid hybrids form under conditions of high stringency. Accordingly, the stringency of the assay conditions determines the amount of complementarity which should exist between two nucleic acid strands in order to form a hybrid. Stringency should be chosen to maximize the difference in stability between the probe:target hybrid and potential probe:non-target hybrids.

Probes may be designed from the nucleic acids of the invention through methods known in the art. For instance, the G+C content of the probe and the probe length can affect probe binding to its target sequence. Methods to optimize probe specificity are commonly available. See for example, Sambrook *et al.* (1989) or
5 Ausubel *et al.* (Current Protocols in Molecular Biology, Greene Publishing Co., NY, 1995).

Hybridization conditions are modified using known methods, such as those described by Sambrook *et al.* (1989) and Ausubel *et al.* (1995), as suitable for each probe. Hybridization of total cellular RNA or RNA enriched for polyA RNA can be
10 accomplished in any available format. For instance, total cellular RNA or RNA enriched for polyA RNA can be affixed to a solid support and the solid support exposed to at least one probe comprising at least one, or part of one of the nucleic acid sequences of the invention under conditions in which the probe will specifically hybridize.

Alternatively, nucleic acid fragments comprising at least one, or part of one of the
15 sequences of the invention can be affixed to a solid support, such as a porous glass wafer. The glass or silica wafer can then be exposed to total cellular RNA or polyA RNA from a sample under conditions in which the affixed sequences will specifically hybridize. Such glass wafers and hybridization methods are widely available, for example, those disclosed by Beattie (WO 95/11755). By examining for the ability of a
20 given probe to specifically hybridize to an RNA sample from an untreated cell population and from a cell population exposed to the agent, agents which up- or down-regulate the expression of a nucleic acid encoding Dkk, a Dkk interacting protein, and/or LRP5 can be identified.

Microarray technology and transcriptional profiling are examples of methods
25 which can be used to analyze the impact of putative Dkk or Dkk interacting protein modulating compounds. For transcriptional profiling, mRNA from cells exposed *in vivo* to a potential Dkk modulating agent, such as the Dkk interacting proteins identified in the present invention (*e.g.*, those identified in Figure 5), agents which modulate Dkk interacting proteins, and mRNA from the same type of cells that were not exposed to
30 the agent could be reverse transcribed and hybridized to a chip containing DNA from

numerous genes, to thereby compare the expression of genes in cells treated and not treated with the agent. If, for example a putative Dkk modulating agent down-regulates the expression of Dkk in the cells, then use of the agent may be undesirable in certain patient populations. For additional methods of transcriptional profiling and the use of microarrays, refer to, for example, U.S. Patent No. 6,124,120 issued to Lizardi (2000).

Additional methods for screening the impact of Dkk and Dkk interacting protein modulating compounds or the impact of Dkk or Dkk interacting proteins on modulation of LRP5, LRP6, HBM or the Wnt pathway include the use of TaqMan PCR, conventional reverse transcriptase PCR (RT-PCR), changes in downstream surrogate markers (*i.e.*, Wnt responsive genes), and anti-Dkk Western blots for protein detection. Other methods would be readily apparent to the artisan of ordinary skill.

12. Methods to Identify Agents that Modulate at Least One Activity of Dkk, a Dkk Interacting Protein, or LRP5/LRP6/HBM

Another embodiment of the present invention provides methods for identifying agents that modulate at least one activity of Dkk, Dkk interacting proteins, and/or LRP5/LRP6/HBM proteins or preferably which specifically modulate an activity of a Dkk/Dkk interacting protein complex or an LRP5(or LRP6/HBM)/Dkk complex, or a biologically active fragment of Dkk (*e.g.*, comprising the domain which binds LRP5/LRP6/HBM) or a Dkk interacting protein complex. Such methods or assays may utilize any means of monitoring or detecting the desired activity as would be known in the art (See, *e.g.*, Wu *et al.*, *Curr. Biol.* 10:1611-4 (2000); Fedi *et al.*, *J. Biol. Chem.* 274:19465-72 (1991); Grotewold *et al.*, *Mech. Dev.* 89:151-3 (1999); Shibata *et al.*, *Mech. Dev.* 96:243-6 (2000); Wang *et al.*, *Oncogene* 19:1843-8 (2000); and Glinka *et al.*, *Nature* 391:357-62 (1998)). Potential agents which modulate Dkk include, for example, p53, the tumor suppressor protein, which can induce Dkk-1. Damage to DNA has also been observed to up-regulate Dkk-1 expression via a stabilization and activation of p53 (Wang *et al.*, *Oncogene* 19:1843-48 (2000)); and, Shou *et al.*, *Oncogene* 21:878-89 (2002)). Additionally, Fedi *et al.* (1999) purportedly showed that Dkk-1 can block the Wnt2-induced oncogenic transformation of NIH-3T3 cells.

Furthermore, it has been suggested that Dkk expression can be modulated by BMP signaling in the developing skeleton (Mukhopadhyay *et al.*, *Dev. Cell.* 1:423-34 (2001); and Grotewold *et al.*, *EMBO J.* 21:966-75 (2002)). Grotewold *et al.* additionally describe altered Dkk expression levels in response to stress signals including UV irradiation and other genotoxic stimuli. They propose that Dkk expression is pro-apoptotic. In animals expressing HBM constructs conferring high bone mass, a reduced osteoblast apoptosis effect was observed. Thus, HBM and HBM-like variants may control/alter Dkk's role in programmed cell death. Other agents which potentially modulate Dkk activity include the Dkk interacting proteins identified in Figure 5.

In one embodiment, the relative amounts of Dkk or a Dkk interacting protein of a cell population that has been exposed to the agent to be tested is compared to an unexposed control cell population. Antibodies can be used to monitor the differential expression of the protein in the different cell populations. Cell lines or populations are exposed to the agent to be tested under appropriate conditions and time. Cellular lysates may be prepared from the exposed cell line or population and a control, unexposed cell line or population. The cellular lysates are then analyzed with the probe, as would be known in the art. See, *e.g.*, Ed Harlow and David Lane, Antibodies: A Laboratory Manual (Cold Spring Harbor, NY, 1988) and Ed Harlow and David Lane, Using Antibodies: A Laboratory Manual (Cold Spring Harbor, NY 1998).

For example, N- and C- terminal fragments of Dkk can be expressed in bacteria and used to search for proteins which bind to these fragments. Fusion proteins, such as His-tag or GST fusion to the N- or C-terminal regions of Dkk (or to biologically active domains of Dkk-1) or a whole Dkk protein can be prepared. These fusion proteins can be coupled to, for example, Talon or Glutathione-Sepharose beads and then probed with cell lysates to identify molecules which bind to Dkk. Prior to lysis, the cells may be treated with purified Wnt proteins, RNA, or drugs which may modulate Wnt signaling or proteins that interact with downstream elements of the Wnt pathway. Lysate proteins binding to the fusion proteins can be resolved by SDS-PAGE, isolated and identified by, for example protein sequencing or mass spectroscopy, as is known in the art. See, *e.g.*, Protein Purification Applications: A Practical Approach (Simon Roe, ed., 2nd ed.

Oxford Univ. Press, 2001) and "Guide to Protein Purification" in *Meth. Enzymology* vol. 182 (Academic Press, 1997).

The activity of Dkk, a Dkk interacting protein, or a complex of Dkk with LRP5/LRP6/HBM may be affected by compounds which modulate the interaction
5 between Dkk and a Dkk interacting protein (such as those shown in Figure 5) and/or Dkk and LRP5/LRP6/HBM. The present invention provides methods and research tools for the discovery and characterization of these compounds. The interaction between Dkk and a Dkk interacting protein and/or Dkk and LRP5/6/HBM may be monitored *in vivo* and *in vitro*. Compounds which modulate the stability of a Dkk -
10 LRP5/LRP6/HBM complex are potential therapeutic compounds. Example *in vitro* methods include: Binding LRP5/6/HBM, Dkk, or a Dkk interacting protein to a sensor chip designed for an instrument such as made by Biacore (Uppsala, Sweden) for the performance of an plasmon resonance spectroscopy observation. In this method, the chip with one of Dkk, a Dkk interacting protein, or LRP5/6 is first exposed to the other
15 under conditions which permit them to form the complex. A test compound is then introduced and the output signal of the instrument provides an indication of any effect exerted by the test compound. By this method, compounds may be rapidly screened. Another, *in vitro*, method is exemplified by the SAR-by-NMR methods (Shuker *et al.*, *Science*. 274:1531-4 (1996)). Briefly, a Dkk-1 binding domain and/or LRP 5 or 6 LBD
20 are expressed and purified as ¹⁵N labeled protein by expression in labeled media. The labeled protein(s) are allowed to form the complex in solution in an NMR sample tube. The heteronuclear correlation spectrum in the presence and absence of a test compound provides data at the level of individual residues with regard to interactions with the test compound and changes at the protein-protein interface of the complex.
25 One of skill in the art knows of many other protocols, e.g. affinity capillary electrophoresis (Okun *et al. J Biol Chem* 276:1057-62 (2001); Vergun and Chu, *Methods*, 19:270-7 (1999)), fluorescence spectroscopy, electron paramagnetic resonance, etc. which can monitor the modulation of a complex and/or measure binding affinities for complex formation.

In vitro protocols for monitoring the modulation of a Dkk/LRP5/LRP6/HBM complex include the yeast two hybrid protocol. The yeast two hybrid method may be used to monitor the modulation of a complex in vivo by monitoring the expression of genes activated by the formation of a complex of fusion proteins of Dkk and LRP ligand binding domains. Nucleic acids according to the invention which encode the interacting Dkk and LRP LBD domains are incorporated into bait and prey plasmids. The Y2H protocol is performed in the presence of one or more test compounds. The modulation of the complex is observed by a change in expression of the complex activated gene. It will be appreciated by one skilled in the art that test compounds can be added to the assay directly or, in the case of proteins, can be coexpressed in the yeast with the bait and prey compounds. Similarly, fusion proteins of Dkk and Dkk interacting proteins can also be used in a Y2H screen to identify other proteins which modulate the Dkk/Dkk interacting protein complex.

Assay protocols such as these may be used in methods to screen for compounds, drugs, treatments which modulate the Dkk/Dkk interacting protein and/or Dkk/LRP5/6 complex, whether such modulation occurs by competitive binding, or by altering the structure of either LRP 5/6 or Dkk at the binding site, or by stabilizing or destabilizing the protein-protein interface. It may be anticipated that peptide aptamers may competitively bind, although induction of an altered binding site structure by steric effects is also possible.

12.1 Antibodies and Antibody Fragments

Polyclonal and monoclonal antibodies and fragments of these antibodies which bind to Dkk or LRP5/LRP6/HBM can be prepared as would be known in the art. For example, suitable host animals can be immunized using appropriate immunization protocols and the peptides, polypeptides or proteins of the invention. Peptides for use in immunization are typically about 8-40 residues long. If necessary or desired, the polypeptide immunogens can be conjugated to suitable carriers. Methods for preparing immunogenic conjugates with carriers such as bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH), or other carrier proteins are well known in the art (See,

Harlow *et al.*, 1988). In some circumstances, direct conjugation using, for example, carbodiimide reagents, may be effective; in other instances linking reagents such as those supplied by Pierce Chemical Co., Rockford, IL, may be desirable to provide accessibility to the polypeptide or hapten. The hapten peptides can be extended at either the amino or carboxy terminus with a cysteine residue or interspersed with cysteine residues, for example, to facilitate linking to a carrier. Administration of the immunogens is conducted generally by injection over a suitable time period and with use of suitable adjuvants, as is generally understood in the art. During the immunization schedule, titers of antibodies are taken to determine adequacy of antibody formation.

Anti-peptide antibodies can be generated using synthetic peptides, for example, the peptides derived from the sequence of any Dkk, including Dkk-1, or LRP5/LRP6/HBM. Synthetic peptides can be as small as 2-3 amino acids in length, but are preferably at least 3, 5, 10, or 15 or more amino acid residues long. Such peptides can be determined using programs such as DNASTar. The peptides are coupled to KLH using standard methods and can be immunized into animals such as rabbits. Polyclonal anti-Dkk or anti-LRP5/LRP6/HBM peptide antibodies can then be purified, for example using Actigel beads containing the covalently bound peptide.

While the polyclonal antisera produced in this way may be satisfactory for some applications, for pharmaceutical compositions, use of monoclonal preparations is preferred. Immortalized cell lines which secrete the desired monoclonal antibodies may be prepared using the standard method of Kohler and Milstein or modifications which effect immortalization of lymphocytes or spleen cells, as is generally known (See, e.g., Harlow *et al.*, 1988 and 1998). The immortalized cell lines secreting the desired antibodies can be screened by immunoassay in which the antigen is the peptide hapten, polypeptide or protein. When the appropriate immortalized cell culture secreting the desired antibody is identified, the cells can be cultured either *in vitro* or by production in ascites fluid.

The desired monoclonal antibodies are then recovered from the culture supernatant or from the ascites supernatant. Fragments of the monoclonal antibodies

which contain the immunologically significant portion can be used as agonists or antagonists of Dkk activity. Use of immunologically reactive fragments, such as the Fab, scFV, Fab', of F(ab')₂ fragments are often preferable, especially in a therapeutic context, as these fragments are generally less immunogenic than the whole immunoglobulin.

The antibodies or fragments may also be produced, using current technology, by recombinant means. Regions that bind specifically to the desired regions of Dkk or LRP5/LRP6/HBM can also be produced in the context of chimeras with multiple species origin. Antibody reagents so created are contemplated for use diagnostically or as stimulants or inhibitors of Dkk activity.

In one embodiment, antibodies against Dkk, bind Dkk with high affinity, i.e., ranging from 10⁻⁵ to 10⁻⁹ M. Preferably, the anti-Dkk antibody will comprise a chimeric, primate, Primatized®, human or humanized antibody. Also, the invention embraces the use of antibody fragments, e.g., Fab's, Fv's, Fab's, F(ab)₂, and aggregates thereof.

Another embodiment contemplates chimeric antibodies which recognize Dkk or LRP5/LRP6/HBM. A chimeric antibody is intended to refer to an antibody with non-human variable regions and human constant regions, most typically rodent variable regions and human constant regions.

A "primatized® antibody" refers to an antibody with primate variable regions, e.g., CDR's, and human constant regions. Preferably, such primate variable regions are derived from an Old World monkey.

A "humanized antibody" refers to an antibody with substantially human framework and constant regions, and non-human complementarity-determining regions (CDRs). "Substantially" refers to the fact that humanized antibodies typically retain at least several donor framework residues (i.e., of non-human parent antibody from which CDRs are derived).

Methods for producing chimeric, primate, primatized®, humanized and human antibodies are well known in the art. See, e.g., U.S. Patent 5,530,101, issued to Queen *et al.*; U.S. Patent 5,225,539, issued to Winter *et al.*; U.S. Patents 4,816,397 and

4,816,567, issued to Boss *et al.* and Cabilly *et al.* respectively, all of which are incorporated by reference in their entirety.

The selection of human constant regions may be significant to the therapeutic efficacy of the subject anti-Dkk or LRP5/LRP6/HBM antibody. In a preferred embodiment, the subject anti-Dkk or LRP5/LRP6/HBM antibody will comprise human, gamma 1, or gamma 3 constant regions and, more preferably, human gamma 1 constant regions.

Methods for making human antibodies are also known and include, by way of example, production in SCID mice, and *in vitro* immunization.

The subject anti-Dkk or LRP5/LRP6/HBM antibodies can be administered by various routes of administration, typically parenteral. This is intended to include intravenous, intramuscular, subcutaneous, rectal, vaginal, and administration with intravenous infusion being preferred.

The anti-Dkk or LRP5/LRP6/HBM antibody will be formulated for therapeutic usage by standard methods, e.g., by addition of pharmaceutically acceptable buffers, e.g., sterile saline, sterile buffered water, propylene glycol, and combinations thereof.

Effective dosages will depend on the specific antibody, condition of the patient, age, weight, or any other treatments, among other factors. Typically effective dosages will range from about 0.001 to about 30 mg/kg body weight, more preferably from about 0.01 to 25 mg/kg body weight, and most preferably from about 0.1 to about 20 mg/kg body weight.

Such administration may be effected by various protocols, e.g., weekly, bi-weekly, or monthly, depending on the dosage administered and patient response. Also, it may be desirable to combine such administration with other treatments.

Antibodies to Dkk-1 interacting proteins, such as those identified in Figure 5, are also contemplated according to the present invention, and can be used similarly to the Dkk-1 antibodies mentioned in the above methodology.

The antibodies of the present invention can be utilized in experimental screening, as diagnostic reagents, and in therapeutic compositions.

12.2 Chemical Libraries

Agents that are assayed by these methods can be randomly selected or rationally selected or designed. As used herein, an agent is said to be randomly selected when the agent is chosen randomly without considering the specific sequences involved in the association of Dkk-1 alone, Dkk-1 interacting proteins alone, or with their associated substrates, binding partners, etc. An example of randomly selected agents is the use of a chemical library or a peptide combinatorial library, or a growth broth of an organism.

The agents of the present invention can be, as examples, peptides, small molecules, vitamin derivatives, as well as carbohydrates. A skilled artisan can readily recognize that there is no limit as to the structural nature of the agents of the present invention.

12.3 Peptide Synthesis

The peptide agents of the invention can be prepared using standard solid phase (or solution phase) peptide synthesis methods, as is known in the art. In addition, the DNA encoding these peptides may be synthesized using commercially available oligonucleotide synthesis instrumentation and produced recombinantly using standard recombinant production systems. The production of polypeptides using solid phase peptide synthesis is necessitated if non-nucleic acid-encoded amino acids are to be included.

13. Uses for Agents that Modulate at Least One Activity of Dkk, a Dkk Interacting Protein, a Dkk/Dkk Interacting Protein Complex, or a Dkk/LRP5 or Dkk/LRP6 Complex

The proteins and nucleic acids of the invention, such as the proteins or polypeptides containing an amino acid sequence of LRP5, Dkk, and Dkk interacting proteins are involved in bone mass modulation and lipid modulation of other Wnt pathway mediated activity. Agents that modulate (*i.e.*, up and down-regulate) the expression of Dkk or Dkk interacting proteins, or agents, such as agonists and

antagonists respectively, of at least one activity of Dkk or a Dkk interacting protein may be used to modulate biological and pathologic processes associated with the function and activity of Dkk or a Dkk interacting protein.

As used herein, a subject can be preferably any mammal, so long as the mammal is in need of modulation of a pathological or biological process modulated by a protein of the invention. The term "mammal" means an individual belonging to the class *Mammalia*. The invention is particularly useful in the treatment of human subjects.

As used herein, a biological or pathological process modulated by Dkk or a Dkk interacting protein may include binding of Dkk to a Dkk interacting protein, Dkk to LRP5 or LRP6 or release therefrom, inhibiting or activating Dkk or a Dkk interacting protein mRNA synthesis or inhibiting Dkk or Dkk interacting protein modulated inhibition of LRP5 or LRP6 mediated Wnt signaling. Further bone-related markers may be observed such as alkaline phosphatase activity, osteocalcin production, or mineralization.

Pathological processes refer to a category of biological processes which produce a deleterious effect. For example, expression or up-regulation of expression of LRP5 or LRP6 and/or Dkk and/or a Dkk interacting protein may be associated with certain diseases or pathological conditions. As used herein, an agent is said to modulate a pathological process when the agent statistically significantly ($p < 0.05$) alters the process from its base level in the subject. For example, the agent may reduce the degree or severity of the process mediated by that protein in the subject to which the agent was administered. For instance, a disease or pathological condition may be prevented, or disease progression modulated by the administration of agents which reduce or modulate in some way the expression or at least one activity of a protein of the invention.

As LRP5/6 and Dkk are involved both directly and indirectly in bone mass modulation, one embodiment of this invention is to use Dkk or Dkk interacting protein expression as a method of diagnosing a bone condition or disease. Certain markers are associated with specific Wnt signaling conditions (e.g., *TCF/LEF* activation).

Diagnostic tests for bone conditions may include the steps of testing a sample or an

extract thereof for the presence of Dkk or Dkk interacting protein nucleic acids (*i.e.*, DNA or RNA), oligomers or fragments thereof or protein products of TCF/LEF regulated expression. For example, standard *in situ* hybridization or other imaging techniques can be utilized to observe products of Wnt signaling.

5 This invention also relates to methods of modulating bone development or bone loss conditions. Inhibition of bone loss may be achieved by inhibiting or modulating changes in the LRP5/6 mediated Wnt signaling pathway. For example, absence of LRP5 activity may be associated with low bone mass. Increased activity LRP5 may be associated with high bone mass. Therefore, modulation of LRP5 activity will in turn
10 modulate bone development. Modulation of the Dkk/LRP5/6 or Dkk/Dkk interacting protein complex via agonists and antagonists is one embodiment of a method to regulate bone development. Such modulation of bone development can result from inhibition of the activity of, for example, a Dkk/LRP(5/6) protein complex, a Dkk/Dkk interacting protein complex, upregulated transcription of the *LRP5* gene or inhibited
15 translation of Dkk or Dkk interacting protein mRNA.

 The agents of the present invention can be provided alone, or in combination with other agents that modulate a particular pathological process. As used herein, two agents are said to be administered in combination when the two agents are administered simultaneously or are administered independently in a fashion such that
20 the agents will act at the same time.

 The agents of the present invention can be administered via parenteral, subcutaneous (sc), intravenous (iv), intramuscular (im), intraperitoneal (ip), transdermal or buccal routes. Alternatively, or concurrently, administration may be by the oral route. The dosage administered will be dependent upon the age, health, and weight of the
25 recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

 The present invention further provides compositions containing one or more agents which modulate expression or at least one activity of a protein of the invention. While individual needs vary, determination of optimal ranges of effective amounts of
30 each component is within the skill of the art. Typical dosages of the active agent which

mediate Dkk or Dkk interacting protein activity comprise from about 0.0001 to about 50 mg/kg body weight. The preferred dosages comprise from about 0.001 to about 50 mg/kg body weight. The most preferred dosages comprise from about 0.1 to about 1 mg/kg body weight. In an average human of 70 kg, the range would be from about 7
5 µg to about 3.5 g, with a preferred range of about 0.5 mg to about 5 mg.

In addition to the pharmacologically active agent, the compositions of the present invention may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically for delivery to the site of action.

10 Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water-soluble salts. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, (e.g., ethyl oleate or triglycerides). Aqueous
15 injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol and/or dextran. Optionally, the suspension may also contain stabilizers. Liposomes and other non-viral vectors can also be used to encapsulate the agent for delivery into the cell.

The pharmaceutical formulation for systemic administration according to the
20 invention may be formulated for enteral, parenteral, or topical (top) administration. Indeed, all three types of formulations may be used simultaneously to achieve systemic administration of the active ingredient.

Suitable formulations for oral administration include hard or soft gelatin capsules, pills, tablets, including coated tablets, elixirs, suspensions, syrups or inhalations and
25 controlled release forms thereof.

Potentially, any compound which binds Dkk or a Dkk interacting protein or modulates the Dkk/LRP5 or Dkk/LRP6 or Dkk/Dkk interacting protein complex may be a therapeutic compound. In one embodiment of the invention, a peptide or nucleic acid aptamer according to the invention is used in a therapeutic composition. Such
30 compositions may comprise an aptamer, or a LRP5 or LRP6 fragment unmodified or

modified. In another embodiment, the therapeutic compound comprises a Dkk-1 interacting protein, or biologically active fragment thereof.

Nucleic acid aptamers have been used in compositions for example by chemical bonding to a carrier molecule such as polyethylene glycol (PEG) which may facilitate uptake or stabilize the aptamer. A di-alkylglycerol moiety attached to an RNA will embed the aptamer in liposomes, thus stabilizing the compound. Incorporating chemical substitutions (i.e. changing the 2'OH group of ribose to a 2'NH in RNA confers ribonuclease resistance) and capping, etc. can prevent breakdown. Several such techniques are discussed for RNA aptamers in Brody and Gold (*Rev. Mol. Biol.* 74:3-13 (2000)).

Peptide aptamers may be used in therapeutic applications by the introduction of an expression vector directing aptamer expression into the affected tissue such as for example by retroviral delivery, by encapsulating the DNA in a delivery complex or simple by naked DNA injection. Or, the aptamer itself or a synthetic analog may be used directly as a drug. Encapsulation in polymers and lipids may assist in delivery. The use of peptide aptamers as therapeutic and diagnostic agents is reviewed by Hoppe-Syler and Butz (*J. Mol. Med.* 78:426-430 (2000)).

In another aspect of the invention. The structure of a constrained peptide aptamer of the invention may be determined such as by NMR or X-ray crystallography. (Cavanagh et al., Protein NMR Spectroscopy: Principles and Practice, Academic Press, 1996; Drenth, Principles of Protein X-Ray Crystallography, Springer Verlag, 1999) Preferably the structure is determined in complex with the target protein. A small molecule analog is then designed according to the positions of functional elements of the 3D structure of the aptamer. (Guidebook on Molecular Modeling in Drug Design, Cohen, Ed., Academic Press, 1996; Molecular Modeling and Drug Design (Topics in Molecular and Structural Biology), Vinter and Gardner Eds., CRC Press, 1994) Thus the present invention provides a method for the design of effective and specific drugs which modulate the activity of Dkk, Dkk interacting proteins, Dkk/Dkk interacting protein complex and the Dkk/LRP complex. Small molecule mimetics of the peptide aptamers of the present invention are encompassed within the scope of the invention.

In practicing the methods of this invention, the compounds of this invention may be used alone or in combination, or in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of this invention may be co-administered along with other compounds typically prescribed for these conditions according to generally accepted medical practice. For example, the compounds of this invention can be administered in combination with other therapeutic agents for the treatment of bone loss. Bone loss mediating agents include bone resorption inhibitors such as bisphosphonates (e.g., alendronic acid, clodronic acid, etidronic acid, pamidronic acid, risedronic acid and tiludronic acid), vitamin D and vitamin D analogs, cathepsin K inhibitors, hormonal agents (e.g., calcitonin and estrogen), and selective estrogen receptor modulators or SERMs (e.g., raloxifene). And bone forming agents such as parathyroid hormone (PTH) and bone morphogenetic proteins (BMP).

Additionally contemplated are combinations of agents which regulate Dkk-1 and agents which regulate lipid levels such as HMG-CoA reductase inhibitors (i.e., statins such as Mevacor®, Lipitor® and other inhibitors such as Baycol®, Lescol®, Pravachol® and Zocor®), bile acid sequestrants (e.g., Colestid® and Welchol®), fibric acid derivatives (Atromid-S®, Lopid®, Tricor®), and nicotinic acid.

[0001] The compounds of this invention can be utilized *in vivo*, ordinarily in vertebrates and preferably in mammals, such as humans, sheep, horses, cattle, pigs, dogs, cats, rats and mice, or *in vitro*.

14. Transgenic Animals

Transgenic animal models can be created which conditionally express Dkk and/or LRP5 or LRP6 and/or Dkk interacting proteins, such as those shown in Figure 5. These animals can be used as research tools for the study of the physiological effects of the Dkk-1/Dkk-1 interacting protein interaction and/or the LRP5 / Dkk interaction. Alternatively, transgenic animals can be created which express a transgenic form of Dkk alone or in addition to a transgenic form of HBM or express Dkk interacting proteins alone or in addition to a transgenic form of Dkk. Transgenic animals expressing HBM or LRP5 can be crossed with transgenic animals expressing Dkk or

Dkk interacting proteins to obtain heterozygote as well as homozygote animals which express both desired genes.

Animal models may be created to directly modulate the Dkk/Dkk interacting protein or Dkk/ LRP5 interaction activity *in vivo* to serve as a research tool for determining the efficacy of candidate compounds which modulate the Dkk/Dkk interacting protein or LRP5 / Dkk interaction activity *in vitro*. Animals, such as transgenic mice, can be created using the techniques employed to make transgenic mice that express for example, human Dkk or a Dkk interacting protein, or knockouts (KO), which may be conditional, of the gene encoding mouse Dkk or Dkk interacting protein. Knock-in animals include animals wherein genes have been introduced and animals wherein a gene that was previously knocked-out is reintroduced into the animal. Other transgenic animals can be created with inducible forms of Dkk or a Dkk interacting protein to study the effects of the gene on bone mass development and loss as well as lipid level regulation. These animals can also be used to study long term effects of Dkk or Dkk interacting protein modulation. Transgenic animals may be created to express peptide aptamers, or produce RNA aptamers. The transgenic vectors may direct expression in a tissue specific manner by the use of tissue specific promoters. In a preferred embodiment, a peptide aptamer fusion protein is expressed using a bone specific promoter. Such systems can provide a tissue specific knock-out of Dkk or Dkk interacting protein activity.

General methods for creating transgenic animals are known in the art, and are described in, for example, Strategies in Transgenic Animal Science (Glenn M. Monastersky and James M. Robl eds., ASM Press; Washington, DC, 1995); Transgenic Animal Technology: A Laboratory Handbook (Carl A. Pinkert ed., Academic Press 1994); Transgenic Animals (Louis Marie Houdebine, ed., Harwood Academic Press, 1997); Overexpression and Knockout of Cytokines in Transgenic Mice (Chaim O. Jacob, ed., Academic Press 1994); Microinjection and Transgenesis: Strategies and Protocols (Springer Lab Manual) (Angel Cid-Arregui and Alejandro Garcia-Carranca, eds., Springer Verlag 1998); and Manipulating the Mouse Embryo: A Laboratory Manual (Brigid Hogan *et al.*, eds., Cold Spring Harbor Laboratory Press 1994).

15. Peptide and Nucleotide Aptamers and Peptide Aptamer Mimetics

Another embodiment contemplates the use of peptide and nucleotide aptamer technology to screen for agents which interact with Dkk, which block Dkk from interacting with LRP5 or LRP6, or which block any other Dkk ligand interaction, or which interact with Dkk interacting proteins, such as those shown in Figure 5. Peptide aptamers are molecules in which a variable peptide domain is displayed from a scaffold protein. Thioredoxin A (trxA) is commonly used for a scaffold. The peptide insert destroys the catalytic site of trxA. It is recognized that numerous proteins may also be used as scaffolding proteins to constrain and/or present a peptide aptamer. Other scaffold proteins that could display a constrained peptide aptamer could include staphylococcal nuclease, the protease inhibitor eglin C, the *Streptomyces tendea* alpha-amylase inhibitor Tendamistat, Sp1, and green fluorescent protein (GFP) (reviewed in Hoppe-Seyler *et al.*, *J. Steroid Biochem Mol. Biol.* 78:105-11 (2001)), and the S1 nuclease from *Staphylococcus* or M13 for phage display. Any molecule to which the aptamer could be anchored and presented in its bioactive conformation would be suitable.

Aptamers can then specifically bind to a given target protein *in vitro* and *in vivo* and have the potential to selectively block the function of their target protein. Peptide aptamers are selected from randomized expression libraries on the basis of their *in vivo* binding capacity to the desired target protein. Briefly, a target protein (e.g., Dkk, a Dkk interacting protein, or LRP5/6) is linked to a heterologous DNA binding domain (BD) and expressed as bait in a yeast test strain. Concomitantly, a library coding for different peptides (e.g., 16-mers) of randomized sequence inserted in a scaffold protein sequence, which are linked to a heterologous transcriptional activation domain (AD) is expressed as prey. If a peptide binds to a target protein, a functional transcription factor is reconstituted, in which the BD and AD are bridged together by interacting proteins. This transcription factor is then able to activate the promoter of a marker gene which can be monitored by colorimetric enzymatic assays or by growth selection. Additional variation, methods of preparing and screening methodologies are described in, for example, Hoppe-Seyler *et al.*, *J. Mol. Med.* 78: 426-430 (2000).

Nucleotide aptamers are described for example in Brody *et al.*, *Trends Mol. Biotechnol.* 74: 5-13 (2000). Additional methods of making and using nucleotide aptamers include SELEX, *i.e.*, Systematic Evolution of Ligands by Exponential Enrichment. SELEX is a process of isolating oligonucleotide ligands of a chosen target molecule (see Tuerk and Gold, *Science* 249:505-510 (1990); U.S. Pat. Nos. 5,475,096, 5,595,877, and 5,660,985). SELEX, as described in Tuerk and Gold, involves admixing the target molecule with a pool of oligonucleotides (*e.g.*, RNA) of diverse sequences; retaining complexes formed between the target and oligonucleotides; recovering the oligonucleotides bound to the target; reverse-transcribing the RNA into DNA; amplifying the DNA with polymerase chain reactions (PCR); transcribing the amplified DNA into RNA; and repeating the cycle with ever increasing binding stringency. Three enzymatic reactions are required for each cycle. It usually takes 12-15 cycles to isolate aptamers of high affinity and specificity to the target. An aptamer is an oligonucleotide that is capable of binding to an intended target substance but not other molecules under the same conditions.

In another reference, Bock *et al.*, *Nature* 355:564-566 (1990), describe a different process from the SELEX method of Tuerk and Gold in that only one enzymatic reaction is required for each cycle (*i.e.*, PCR) because the nucleic acid library in Bock's method is comprised of DNA instead of RNA. The identification and isolation of aptamers of high specificity and affinity with the method of Bock *et al.* still requires repeated cycles in a chromatographic column.

Other nucleotide aptamer methods include those described by Conrad *et al.*, *Meth. Enzymol.* 267:336-367 (1996). Conrad *et al.* describe a variety of methods for isolating aptamers, all of which employ repeated cycles to enrich target-bound ligands and require a large amount of purified target molecules. More recently described methods of making and using nucleotide aptamers include, but are not limited to those described in U.S. Patent Nos. 6,180,348; 6,051,388; 5,840,867; 5,780,610, 5,756,291 and 5,582,981.

Potentially, any compound which binds Dkk or a Dkk interacting protein or modulates the Dkk/Dkk interacting protein or Dkk/LRP5 or Dkk/LRP6 complex may be

a therapeutic compound. In one embodiment of the invention, a peptide or nucleic acid aptamer according to the invention is used in a therapeutic composition. Such compositions may comprise an aptamer, or a LRP5 or LRP6 fragment unmodified or modified.

5 Nucleic acid aptamers have been used in compositions for example by chemical bonding to a carrier molecule such as polyethylene glycol (PEG) which may facilitate uptake or stabilize the aptamer. A di-alkylglycerol moiety attached to an RNA will embed the aptamer in liposomes, thus stabilizing the compound. Incorporating chemical substitutions (*i.e.*, changing the 2'-OH group of ribose to a 2'-NH in RNA
10 confers ribonuclease resistance) and capping, etc. can prevent breakdown. Several such techniques are discussed for RNA aptamers in Brody and Gold *Rev. Mol. Biol.* 74:3-13 (2000).

Peptide aptamers may be used in therapeutic applications by the introduction of an expression vector directing aptamer expression into the affected tissue such as for
15 example by retroviral delivery, by encapsulating the DNA in a delivery complex or simple by naked DNA injection. Or, the aptamer itself or a synthetic analog may be used directly as a drug. Encapsulation in polymers and lipids may assist in delivery. The use of peptide aptamers as therapeutic and diagnostic agents is reviewed by Hoppe-Syler and Butz *J. Mol. Med.* 78:426-430 (2000).

20 In another aspect of the invention, the structure of a constrained peptide aptamer of the invention may be determined such as by NMR or X-ray crystallography. (Cavanagh et al., Protein NMR Spectroscopy : Principles and Practice, Academic Press, 1996; Drenth, Principles of Protein X-Ray Crystallography, Springer Verlag, 1999) Preferably the structure is determined in complex with the target protein. A
25 small molecule analog is then designed according to the positions of functional elements of the 3D structure of the aptamer. (Guidebook on Molecular Modeling in Drug Design, Cohen, Ed., Academic Press, 1996; Molecular Modeling and Drug Design (Topics in Molecular and Structural Biology), Vinter and Gardner Eds., CRC Press, 1994) Thus, a method is provided for the design of effective and specific drugs which
30 modulate the activity of Dkk, Dkk interacting proteins, Dkk/Dkk interacting protein

complex, and the Dkk/LRP complex. Small molecule mimics of the peptide aptamers of the present invention are also encompassed within the scope of the invention.

16. Alternative Variants of LRP5/LRP6 Having HBM Activity

5 A structural model of the LRP5/Zmax1 first beta-propeller module was generated based on a model prediction in Springer et al., (1998) *J. Molecular Biology*, 283:837-862. Based on the model, certain amino acid residues were identified as important variants of LRP5/HBM/Zmax1. The following three categories provide examples of such variants:

10 The shape of the beta-propeller resembles a disk with inward-sloping sides and a hole down the middle. Residue 171 is in a loop on the outer or top surface of the domain in blade 4 of propeller module 1. Thus, variants comprising changed residues in structurally equivalent positions in other blades; as well as residues that are slightly more interior to the binding pocket, but still accessible to the surface, are important
15 embodiments of the present invention for the study of bone mass modulation by LRP5/HBM, for the development of pharmaceuticals and treatments of bone mass disorders, and for other objectives of the present invention. The following are examples of such variants:

20 A214V (a position equivalent to 171 in blade 5; alanine is not conserved in other propellers),

E128V (a position equivalent to 171 in blade 3; glutamate is not conserved in other propellers),

A65V (a position equivalent to 171 in blade 2; alanine is conserved in propellers 1-3 but not 4),

25 G199V (an accessible interior position in blade 5; glycine is conserved in propellers 1-3 but not 4), and

M282V (accessible interior position in blade 1; methionine is conserved in propellers 1-3 but not 4).

30 LRP5/Zmax1 has four beta-propeller structures; the first three beta-propeller modules conserve a glycine in the position corresponding to residue 171 in human

LRP5/Zmax1. Therefore, variants bearing a valine in the equivalent positions in the other propellers are important embodiments of the present invention. The following variants are useful for the study of bone mass modulation by LRP5/HBM, for the development of pharmaceuticals and treatments of bone mass disorders, and for other objectives of the present invention: G479V, G781V, and Q1087V.

The G171V HBM polymorphism results in "occupied space" of the beta-propeller 1, with the side-chain from the valine residue sticking out into an open binding pocket and potentially altering a ligand/protein interaction. The glycine residue is conserved in LRP5/Zmax1 propellers 1, 2 and 3 but is a glutamine in propeller 4. Therefore, the following variants of LRP5/HBM are important embodiments of the present invention for the study of bone mass modulation by LRP5/HBM, for the development of pharmaceuticals and treatments of bone mass disorders, and for other objectives of the present invention:

G171K (which introduces a charged side-chain),
G171F (which introduces a ringed side-chain),
G171I (which introduces a branched side-chain), and
G171Q (which introduces the propeller 4 residue).

Furthermore, LRP6 is the closest homolog of LRP5/Zmax1. LRP6 has a beta-propeller structure predicted to be similar, if not identical to Zmax1. The position corresponding to glycine 171 in human LRP5/Zmax1 is glycine 158 of human LRP6. Thus, corresponding variants of LRP6 are an important embodiment of the present invention for the study of the specificity of LRP5/Zmax1 versus its related family member, for the development of pharmaceuticals and treatments of bone mass disorders, and for other objectives of the present invention. Specifically, for example, a glycine to valine substitution at the structurally equivalent position, residue 158, of human LRP6 and similar variants of other species' LRP6 homologs represent important research tools.

Site-directed mutants of LRP5 were generated in the full-length human LRP5 cDNA using the QuikChange XL-Site-Directed Mutagenesis Kit (catalog #200516,

Stratagene, La Jolla, CA) following the manufacturer's protocol. The mutant sequences were introduced using complementary synthetic oligonucleotides:

A65V: TGGTCAGCGGCCTGGAGGATGTGGCCGCAGTGGACTTCC (SEQ ID NO:129) and

5 GGAAGTCCACTGCGGCCACATCCTCCAGGCCGCTGACCA (SEQ ID NO:130)

E128V: AAGCTGTACTGGACGGACTCAGTGACCAACCGCATCGAGG (SEQ ID NO:131) and

10 CCTCGATGCGGTTGGTCACTGAGTCCGTCCAGTACAGCTT (SEQ ID NO:132)

G171K: ATGTACTGGACAGACTGGAAGGAGACGCCCCGGATTGAGCG (SEQ ID NO: 133) and

CGCTCAATCCGGGGCGTCTCCTTCCAGTCTGTCCAGTACAT (SEQ ID NO:134)

15 G171F: ATGTACTGGACAGACTGGTTTGAGACGCCCCGGATTGAGCG (SEQ ID NO:135) and

CGCTCAATCCGGGGCGTCTCAAACCAGTCTGTCCAGTACAT (SEQ ID NO:136)

20 G171I: ATGTACTGGACAGACTGGATTGAGACGCCCCGGATTGAGCG (SEQ ID NO:137) and

CGCTCAATCCGGGGCGTCTCAATCCAGTCTGTCCAGTACAT (SEQ ID NO:138)

G171Q: ATGTACTGGACAGACTGGCAGGAGACGCCCCGGATTGAGCG (SEQ ID NO:139) and

25 CGCTCAATCCGGGGCGTCTCCTGCCAGTCTGTCCAGTACAT (SEQ ID NO:140)

G199V: CGGACATTTACTGGCCCAATGTACTGACCATCGACCTGGAGG (SEQ ID NO:141) and

30 CCTCCAGGTCGATGGTCAGTACATTGGGCCAGTAAATGTCCG (SEQ ID NO:142)

A214V: AGCTCTACTGGGCTGACGTCAAGCTCAGCTTCATCCACCG (SEQ ID NO: 143) and

CGGTGGATGAAGCTGAGCTTGACGTCAGCCCAGTAGAGCT (SEQ ID NO:144)

5 M282V: GAGTGCCCTCTACTCACCCGTGGACATCCAGGTGCTGAGCC (SEQ ID NO:145) and

GGCTCAGCACCTGGATGTCCACGGGTGAGTAGAGGGCACTC (SEQ ID NO:146)

10 G479V: CATGTACTGGACAGACTGGGTAGAGAACCCTAAAATCGAGTGTGC (SEQ ID NO:147) and

GCACACTCGATTTTAGGGTTCTCTACCCAGTCTGTCCAGTACATG (SEQ ID NO:148)

G781V: CATCTACTGGACCGAGTGGGTGCGCAAGCCGAGGATCGTGCG (SEQ ID NO:149) and

15 CGCACGATCCTCGGCTTGCCGACCCACTCGGTCCAGTAGATG (SEQ ID NO:150)

Q1087V: GTACTTCACCAACATGGTGGACCGGGCAGCCAAGATCGAACG (SEQ ID NO:151) and

20 CGTTCGATCTTGGCTGCCCGGTCCACCATGTTGGTGAAGTAC (SEQ ID NO:152)

LRP6 G158V:

GTACTGGACAGACTGGGTAGAAGTGCCAAAGATAGAACGTGC (SEQ ID NO:153) and

25 GCACGTTCTATCTTTGGCACTTCTACCCAGTCTGTCCAGTAC (SEQ ID NO:154).

All constructs were sequence verified to ensure that only the engineered modification was present in the gene. Once verified, each variant was functionally evaluated in the TCF-luciferase assay in U2OS cells (essentially as described in Example 7. Other functional evaluations could also be performed, such as the Xenopus embryo assay (essentially as described in Example 6), or other assays to evaluate Wnt

30

signaling, Dkk modulation, or anabolic bone effect. Binding of these mutants to Dkk, LRP-interacting proteins, Dkk-interacting proteins, or peptide aptamers to any of the preceding could also be investigated in a variety of ways such as in a two-hybrid system (such as in yeast as described in this application), or other methods.

5 Figure 24 shows the effects of the G171F mutation in propeller 1 of LRP5. This mutation is at the same position as HBM's G171V substitution. Expression of G171F results in an HBM effect. That is, in the presence of Wnt, G171F is able to activate the TCF-luciferase reporter construct. In fact, it may activate the reporter to a greater extent than either LRP5 or HBM. Furthermore, in the presence of Dkk1 and Wnt1, 10 G171F is less susceptible than LRP5 to modulation by Dkk. These data exemplify that the G171F variant modulates Wnt signaling in a manner similar to HBM. In addition, this data confirms that HBM's valine residue at 171 is not the only modification at 171 that can result in an HBM effect. Together these data support an important role for LRP5 propeller 1 in modulating Wnt pathway activity; in responding to Dkk modulation; 15 and, in the ability to generate an HBM effect.

 Figure 25 shows the effects of the M282V mutation in propeller 1 of LRP5. M282 expression results in an HBM-effect. That is, in the presence of Wnt, M282 is able to activate the TCF-luciferase reporter construct. Furthermore, in the presence of Dkk1 and Wnt1, M282V is less susceptible than LRP5 to modulation by Dkk. These 20 data show that the M282V variant modulates Wnt signaling in a manner similar to HBM. In addition, this data confirms that modifications of other residues in propeller 1 of LRP5 can result in an HBM effect.

 These data support an "occupied space" model of the HBM mutation in propeller 1 and show that multiple mutations of propeller 1 are capable of generating an HBM 25 effect; the original G171V HBM mutation is not unique in this ability. Moreover, various perturbations in propeller 1 can modulate Dkk activity.

 These data illustrate the molecular mechanism of Dkk modulation of LRP signaling. Using the methods disclosed herein and in U.S. Application 60/290,071, generation of a comprehensive mutant panel will reveal residues in LRP that function in 30 Dkk modulation of Wnt signaling. Such variants of LRP5 and LRP6 that modulate Dkk

activity and the residues which distinguish them from LRP5 and LRP6 are points for therapeutic intervention by small molecule compound, antibody, peptide aptamer, or other agents. Furthermore, models of each HBM-effect mutation/polymorphism may be used in rational drug design of an HBM mimetic agent.

5 These are only a few illustrative examples presented to better describe the present invention. Variants of LRP5 which have demonstrated HBM activity in assays include G171F, M282V, G171K, G171Q and A214V. Clearly, other variants may be contemplated within the scope of the present invention. Furthermore, wherever HBM is recited in the methods of the invention, it should be understood that any such
10 alternative variant of LRP which demonstrates HBM biological activity is also encompassed by those claims.

17. Screening Assays

The two-hybrid system is extremely useful for studying protein:protein
15 interactions. See, e.g., Chien *et al.*, *Proc. Natl Acad. Sci. USA* 88:9578-82 (1991); Fields *et al.*, *Trends Genetics* 10:286-92 (1994); Harper *et al.*, *Cell* 75:805-16 (1993); Vojtek *et al.*, *Cell* 74:205-14 (1993); Luban *et al.*, *Cell* 73:1067-78 (1993); Li *et al.*, *FASEB J.* 7:957-63 (1993); Zang *et al.*, *Nature* 364:308-13 (1993); Golemis *et al.*, *Mol. Cell. Biol.* 12:3006-14 (1992); Sato *et al.*, *Proc. Natl Acad. Sci. USA* 91:9238-42 (1994);
20 Coghlan *et al.*, *Science* 267:108-111 (1995); Kalpana *et al.*, *Science* 266:2002-6 (1994); Helps *et al.*, *FEBS Lett.* 340:93-8 (1994); Yeung *et al.*, *Genes & Devel.* 8:2087-9 (1994); Durfee *et al.*, *Genes & Devel.* 7:555-569 (1993); Paetkau *et al.*, *Genes & Devel.* 8:2035-45; Spaargaren *et al.*, 1994 *Proc. Natl. Acad. Sci. USA* 91:12609-13 (1994); Ye *et al.*, *Proc. Natl Acad. Sci. USA* 91:12629-33 (1994); and U.S. Patent Nos.
25 5,989,808; 6,251,602; and 6,284,519.

Variations of the system are available for screening yeast phagemid (see, e.g., Harper, Cellular Interactions and Development: A Practical Approach, 153-179 (1993); Elledge *et al.*, *Proc. Natl Acad. Sci. USA* 88:1731-5 (1991)) or plasmid (Bartel, 1993 and Bartel, *Cell* 14:920-4 (1993)); Finley *et al.*, *Proc. Natl Acad. Sci. USA* 91:12980-4

(1994)) cDNA libraries to clone interacting proteins, as well as for studying known protein pairs.

The success of the two-hybrid system relies upon the fact that the DNA binding and polymerase activation domains of many transcription factors, such as GAL4, can be separated and then rejoined to restore functionality (Morin *et al.*, *Nuc. Acids Res.* 21:2157-63 (1993)). While these examples describe two-hybrid screens in the yeast system, it is understood that a two-hybrid screen may be conducted in other systems such as mammalian cell lines. The invention is therefore not limited to the use of a yeast two-hybrid system, but encompasses such alternative systems.

Yeast strains with integrated copies of various reporter gene cassettes, such as for example GAL.fwdarw.LacZ, GAL.fwdarw.HIS3 or GAL.fwdarw.URA3 (Bartel, in Cellular Interactions and Development: A Practical Approach, 153-179 (1993); Harper *et al.*, *Cell* 75:805-16 (1993); Fields *et al.*, *Trends Genetics* 10:286-92 (1994)) are co-transformed with two plasmids, each expressing a different fusion protein. One plasmid encodes a fusion between protein "X" and the DNA binding domain of, for example, the GAL4 yeast transcription activator (Brent *et al.*, *Cell* 43:729-36 (1985); Ma *et al.*, *Cell* 48:847-53 (1987); Keegan *et al.*, *Science* 231:699-704 (1986)), while the other plasmid encodes a fusion between protein "Y" and the RNA polymerase activation domain of GAL4 (Keegan *et al.*, 1986). The plasmids are transformed into a strain of the yeast that contains a reporter gene, such as lacZ, whose regulatory region contains GAL4 binding sites. If proteins X and Y interact, they reconstitute a functional GAL4 transcription activator protein by bringing the two GAL4 components into sufficient proximity to activate transcription. It is well understood that the role of bait and prey proteins may be alternatively switched and thus the embodiments of this invention contemplate and encompass both alternative arrangements.

Either hybrid protein alone must be unable to activate transcription of the reporter gene, the DNA-binding domain hybrid, because it does not provide an activation function, and the activation domain hybrid, because it cannot localize to the GAL4 binding sites. Interaction of the two test proteins reconstitutes the function of GAL4 and results in expression of the reporter gene. The reporter gene cassettes

consist of minimal promoters that contain the GAL4 DNA recognition site (Johnson *et al.*, *Mol. Cell. Biol.* 4:1440-8 (1984); Lorch *et al.*, *J. Mol. Biol.* 186:821-824 (1984)) cloned 5' to their TATA box. Transcription activation is scored by measuring either the expression of β -galactosidase or the growth of the transformants on minimal medium lacking the specific nutrient that permits auxotrophic selection for the transcription product, e.g., URA3 (uracil selection) or HIS3 (histidine selection). See, e.g., Bartel, 1993; Durfee *et al.*, *Genes & Devel.* 7:555-569 (1993); Fields *et al.*, *Trends Genet.* 10:286-292 (1994); and U.S. Pat. No. 5,283,173.

Generally, these methods include two proteins to be tested for interaction which are expressed as hybrids in the nucleus of a yeast cell. One of the proteins is fused to the DNA-binding domain (DBD) of a transcription factor and the other is fused to a transcription activation domain (AD). If the proteins interact, they reconstitute a functional transcription factor that activates one or more reporter genes that contain binding sites for the DBD. Exemplary two-hybrid assays which have been used for Dkk-1 or Dkk-1/LRP5 are presented in the Examples below.

Additional methods of preparing two hybrid assay systems for Dkk-1 interactors would be evident to one of ordinary skill in the art. See for example, Finley *et al.*, "Two-Hybrid Analysis of Genetic Regulatory Networks," in The Yeast Two-Hybrid System (Paul L. Bartel *et al.*, eds., Oxford, 1997); Meijia Yang, "Use of a Combinatorial Peptide Library in the Two-Hybrid Assay," in The Yeast Two-Hybrid System (Paul L. Bartel *et al.*, eds., Oxford, 1997); Gietz *et al.*, "Identification of proteins that interact with a protein of interest: Applications of the yeast two-hybrid system," *Mol. & Cell. Biochem.* 172:67-9 (1997); K. H. Young, "Yeast Two-Hybrid: So Many Interactions,(in) so Little Time," *Biol. Reprod.* 58:302-311 (1998); R. Brent *et al.*, "Understanding Gene and Allele Function with Two-Hybrid Methods," *Annu. Rev. Genet.* 31:663-704 (1997). It will be appreciated that protein networks can be elucidated by performing sequential screens of activation domain-fusion libraries.

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The

following working examples therefore, specifically point out preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

5

EXAMPLES

The present invention is described by reference to the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner. Standard techniques well-known in the art or the techniques specifically described below were utilized.

10 For routine practice of the protocols referenced below, one of skill in the art is directed to the references cited in this application as well as the several Current Protocol guides, which are continuously updated, widely available and published by John Wiley and Sons, (New York). In the life sciences, Current Protocols publishes comprehensive manuals in Molecular Biology, Immunology, Human Genetics, Protein
15 Science, Cytometry, Neuroscience, Pharmacology, Cell Biology, Toxicology, and Nucleic Acid Chemistry. Additional sources are known to one of skill in the art.

Example 1

Yeast Two Hybrid Screen Using LRP5 Ligand Binding Domain (LBD) Bait Sequences

20 In a screen against human osteoblast library (*i.e.*, HOB03C5, a custom Gibco generated Y2H compatible cDNA library from a human osteoblast cell line as described by Bodine and Komm, *Bone* 25:535-43 (1999)), an interaction with Dkk-1 was identified. The LRP5 ligand binding domain (LBD) baits used for this screen are depicted in Figures 2B and C. The basic protocol is as follows:

25 An overnight culture of the yeast strain containing the bait of interest is grown in 20 ml of appropriate selective medium containing 2% glucose at 30°C. The overnight culture is diluted by a 10 fold factor into YPDmedia supplemented with 40 mg/l of adenine, and grown for 4 hours at 30°C.

30 For each mating event, an aliquot of the frozen prey library is grown in 150 ml YAPD medium for 5 hours at 30°C.

Appropriate volumes calculated by measuring the OD600 of each culture are combined into a tube. The number of diploids to be screened is typically ten times the number of clones originally present in the prey library of interest. Assuming a mating efficiency of 20% minimum, fifty times (*i.e.*, ten times coverage multiplied by 20% mating efficiency) as many haploid cells containing the bait and as many cells containing the prey are used in any given mating event. The mixture is filtered over a 47 mm, 0.45 mm sterile Metrical filter membrane (Gelman).

Using sterile forceps, the filter is transferred onto a 100 mm² YAPD agar plate with the cell side up, removing all air bubbles underneath the filter. The plate is incubated overnight at room temperature.

The filter is transferred into a 50 ml Falcon tube using sterile forceps and 10 ml SD medium containing 2% glucose are added to resuspend the cells. The filter, once free of cells, is removed and the cell suspension is spun for 5 min. at 2,000 xg.

The cells are resuspended in 10 ml SD medium containing 2% glucose. An aliquot of 100 μ l is set aside for titration.

The cells are plated onto large square plates containing appropriate selective media and incubated at 30°C for three to five days.

To calculate the mating efficiency and to determine the total number of diploid cells screened, the 100 μ l aliquot set aside for titration is diluted and plated onto different selective media. The mating efficiency is calculated by dividing the number of diploids/ml by the lowest number of haploids/ml, either bait or prey, and multiplied by 100. For example, if 2 million diploids were obtained by mating 10 million of haploids containing a bait and 12 million of haploids containing a prey, then the mating efficiency is calculated by dividing 2 million by 10 million, which equals 0.2 and multiplied by 100 which equals 20%. Typical mating efficiencies under the above conditions are within about 20 to about 40%. The total number of diploids screened in a mating event is obtained by multiplying the number of diploids/ml by the total number of ml plated, typically about 10.

Isolation of colonies containing pairs of interacting proteins.

Yeast colonies from the interaction selection (large square) plates are picked with a sterile toothpick and patched onto plates containing the appropriate selective media and incubated at 30°C for two days.

5 To further ensure purity of the yeast, the plates are replicated onto another plate containing the same media and incubated at 30°C for another two days.

Yeast patches are scraped using a sterile toothpick and placed into a 96-well format plate containing 100 μ l SD –L –W –H with 2% glucose liquid medium.

10 Half the volume of the plate is transferred to a 96-well plate containing 50 μ l of 40% glycerol for storage. The other half is set aside for replication and galactosidase-activity assay (see below).

Cells are replicated onto a SD –L –W –H plate with 2% glucose plate to create a master plate, and incubated two days at 30°C. The master plate is replicated onto different selective media to score the strength of each interaction.

15 Cells are also replicated onto media selecting for the prey vector only for colony PCR and incubated two days at 30°C.

Galactosidase activity assay

20 Ten microliters from the 96-well plate (set aside from above) are transferred into another 96-well plate containing 100 μ l SD and 2% glucose media. The cell density is measured at OD₆₀₀ using a spectrophotometer, the OD₆₀₀ is usually between 0.03 and 0.1. Fifty microliters of Galactosidase reaction mixture (Tropix) are added to microplates (Marsh) specifically designed for the luminometer (Hewlett Packard Lumicount). Fifty microliters of the diluted cells are then added and mixed by pipetting.

25 The reaction is incubated sixty to one hundred twenty minutes at room temperature. Relative Light Units (RLUs) are read by the luminometer. Each plate contains a negative control, constituted by diploid yeast containing the bait of interest and an empty prey vector. To be scored as positive, the diploids tested have to have an RLU number at least twice as high as the negative control.

30

Example 2

Minimum interaction domain mapping

Further analysis of yeast two hybrid (Y2H) interacting proteins includes the dissection of protein motifs responsible for the interaction. Sequence alignment of multiple clones identified in the Y2H screens can help identify the smallest common region responsible for the interaction. In the absence of appropriate clones, deletion mapping of interacting domains is necessary.

PCR primers containing restriction sites suitable for cloning are designed to cover multiple sub-domains of the protein of interest (bait or prey). The methods involved in cloning, sequencing, yeast transformation, mating, and scoring of interactions are readily performed by one of ordinary skill in the art of molecular biology and genetic engineering.

Materials and Methods

Minimum interaction domain: primers were designed for PCR of the Dkk-1 clone isolated by screening a primary osteoblast cell strain (HOB03C5) library with pooled Zmax1/LRP5 ligand binding domain (LBD) baits: LBD1 (Leu969-Pro1376) and LBD4 (Arg1070-Pro1376). The primers, which are presented in 5' to 3' orientation, were as follows:

<u>SEQ ID NO</u>	<u>Primer</u>	<u>Sequence</u>
155	Forward 1	TTTTTTGTCGACCAATTCCAACGCTATCAAG
156	Forward 2	TTTTTTGTCGACCTGCGCTAGTCCCACCCGC
157	Forward 3	TTTTTTGTCGACCGTGTCTTCTGATCAAAATC
158	Forward 4	TTTTTTGTCGACCGGACAAGAAGGTTCTGTTTG
159	Reverse 1	TTTTTTGCGGCCGCTTATTTGGTGTGATACATTTTGG
160	Reverse 2	TTTTTTGCGGCCGCTTAGCAAGACAGACCTTCTCC
161	Reverse 3	TTTTTTGCGGCCGCTTAGTGTCTCTGACAAGTGTG

PCR was performed using PfuTurbo® polymerase (Stratagene). The PCR products were gel purified, digested with *Sa*II/ *Not*I and ligated to pPC86 (Gibco/BRL) which had been linearized with *Sa*II/*Not*I. Clones were recovered and sequenced to ascertain that the structure was as expected and that the Gal4 activation domain and Dkk-1 were in-frame. The ORF of Dkk-1 was Met1-His266, as in human Dkk-1 (GenBank Accession No. XM_005730).

The clones used were as follows: D5 (F1/R3: Asn34-His266), D4 (F1/R2: Asn34-Cys245), D3 (F1/R1: Asn34-Lys182), D9 (F2/R3: Cys97-His266), D12 (F3/R3, Val139-His266), D14 (F4/R3: Gly183-His266), D8 (F2/R2: Cys97-Cys245), and D11 (F3/R2: Val139-Cys245). F1, F2, F3 and F4 refer respectively to Forward primers 1, 2, 3 and 4. R1, R2 and R3 refer respectively to reverse primers 1, 2 and 3.

These clones were transformed into yeast and mated with each of three yeast strains containing pDBleu (Gibco/BRL), pDBleuLBD1, and pDBleuLBD4. Positive interactions were detected by growth of the hybrids on appropriate selective media.

Results

Minimum interaction domain: Figure 6 shows that while growth was observed in diploids of D4, D5, D8, D9, and D12, no growth was observed in hybrids of D3, D11, and D12. Carboxy terminal (C-terminal) deletions indicated that while the C-terminal amino acids of Dkk-1 containing the potential N-glycosylation site (Arg246-His266) are not required for interaction with Zmax1/LRP5 LBD baits, the Cys2 domain, Gly183-Cys245, is required. N-terminal deletions also demonstrated that the region between the two cysteine domains, *i.e.* Val139 to Lys182, is also required. Two minimum interaction domain constructs were isolated: D12 (Val139-His266) and D8 (Cys97-Cys245). Similar constructs could be prepared for Dkk-1 interactors.

Example 3

Yeast-2 Hybrid screen for peptide aptamer sequences to Dkk-1

Peptide aptamer library construction

A peptide aptamer library, Tpep, was constructed, which provides a means to identify chimeric proteins that bind to a protein target (or bait) of interest using classic yeast two hybrid (Y2H) assays. The Tpep library is a combinatorial aptamer library composed of constrained random peptides, expressed within the context of the disulfide
5 loop of *E. coli* thioredoxin (trxA), and as C-termini fusion to the *S. cerevisiae* Gal4 activation domain. The Tpep library was generated using a restriction enzyme modified recombinant Y2H prey vector, pPC86 (Gibco), which contains the trxA scaffold protein.

Generation of aptamer-encoding sequences

10 Aptamer-encoding sequences were produced as follows. DNA encoding random stretches of approximately sixteen amino acids surrounded by appropriate restriction sites were generated by semi-random oligonucleotide synthesis. The synthetic oligonucleotides were PCR-amplified, restriction digested, and cloned into the permissive sites within the trxA scaffold protein. The cloning strategy was to insert the
15 random oligonucleotide sequence is in-frame with the scaffold protein coding sequence, resulting in expression of a scaffold protein-aptamer chimera. The scaffold protein is itself in-frame with the activation domain of Gal4, within the pPC86 vector that is appropriate for the aptamer to be expressed and functional in a regular Y2H assay. Additional methods of preparing aptamers would be apparent to the skilled artisan.

Generation of a permissive recombinant pPC86 vector containing the trxA coding sequence

First the *RsrII* restriction site located within the Gal4 activation domain of pPC86 (Gibco) was eliminated by site-directed mutagenesis (Quickchange™ kit, Stratagene).
25 The amino acid sequence of the Gal4 activation domain was unchanged by this modification. The strength of different control interactions was verified to be unchanged by the modification.

Second, the *E. coli* trxA coding sequence was cloned into the *SalI* and *NotI* sites of the *RsrII*-modified pPC86. *EcoRI* and *SpeI* sites were then introduced within the trxA

RsrII site. The oligonucleotides encoding the peptide aptamers were cloned into the *EcoRI* and *SpeI* sites of the resulting vector.

Example 4

Yeast-2 Hybrid screen for Dkk-1 interacting proteins

A Dkk-1 bait sequence was utilized in a yeast two hybrid screen to identify Dkk-1 interacting proteins. The procedure for the Y2H was carried out similarly to that employed in Example 1, except that the Dkk-1 bait from Figure 2C was used instead of LRP baits. The screen was performed using Hela and fetal brain libraries (Invitrogen Corporation, Carlsbad, CA). Multiple libraries were used to identify additional Dkk-1 interacting proteins and to confirm interactions found in other libraries.

The list of Dkk-1 interacting proteins uncovered in these Y2H screens are listed in Figure 5.

The interacting proteins identified in the Dkk-1 bait screen can be used in other Y2H screens with LRP baits and other Dkk-1 interacting proteins to determine more complex interactions which may modulate Dkk-1/LRP interactions and/or Wnt signaling.

Example 5

Generation of antibodies

In each of the following antibody-generating examples, the synthesis of these linear peptides is followed by injection into two New Zealand Rabbits. Subsequent boosts and bleeds are taken according to a standard ten-week protocol. The end-user receives back 5 mgs of peptide, aliquots of pre-bleeds, roughly 80 ml of crude sera from each of the two rabbits and, and ELISA titration data is obtained.

Generation of LRP5 Polymorphism-specific antibodies

Antibodies were generated to the following peptides to obtain antibodies which distinguish the HBM polymorphism versus wild-type LRP5/Zmax: MYWTDWVETPRIE

(SEQ ID NO:123) (mutant peptide) and MYWTDWGETPRIE (SEQ ID NO:124) (wild-type peptide for negative selection). Immunofluorescence data confirmed that the antibody, after affinity purification, is specific for HBM and does not recognize LRP5 (Figure 17).

5

Generation of LRP5 Monospecific antibodies

LRP5 monospecific polyclonal antibodies were generated to the following amino acid sequences of LRP5: Peptide 1 (a.a. 265-277) - KRTGGKRKEILSA (SEQ ID NO:125), Peptide 2 (a.a. 1178-1194) - ERVEKTTGDKRTRIQGR (SEQ ID NO:126), and Peptide 3 (a.a. 1352-1375) - KQQCDSFPDCIDGSDE (SEQ ID NO:127).

10

Immunofluorescence confirmed that the antibody generated detects LRP5.

Generation of Dkk-1 monospecific polyclonal antibodies

Dkk-1 monospecific polyclonal antibodies were generated to the following amino acid sequences of Dkk-1: Peptide 1 (a.a. 71-85) - GNKYQTIDNYQPYPYPC (SEQ ID NO:118), Peptide 2 (a.a. 165-186) - LDGYSRRTLSSKMYHTKGQEG (SEQ ID NO:119), Peptide 3 (a.a. 246-266) - RIQKDHHQASNSSRLHTCQRH (SEQ ID NO:120), Peptide 4 (a.a. 147-161) - RGEIETITESFGND (SEQ ID NO:121), and Peptide 5 (232-250) - EIFQRCYCGEGLSCRIQKD (SEQ ID NO:122) of human Dkk-1.

15

20

Figure 26 shows the location of the various peptides selected, their relationship to the Dkk-1 amino acid sequence and polyclonal antibodies generated.

Western blots demonstrated that the antibodies generated against peptides 2 (Antibody #5521) (Figure 27) and 4 (Antibody #74397) (Figure 28) are specific toward Dkk-1. Figure 27 shows Western blots using 500 μ l of conditioned medium (CM) from non-transfected 293 cells or from 293 cells transfected with Dkk1-V5 that were immunoprecipitated by anti-V5 antibody. Bead elutes were separated by non-reducing SDS-PAGE (lanes #4, 5 of Figure 27). 20 μ l of conditioned medium from both samples (lanes #2, 3 of Figure 27) and from Dkk1-AP transfected 293 cells (lane #6 of Figure 27) were additionally separated on the gel. The Western was performed using

25

antibodies Anti-V5/AP (1:10,000) and Ab#5521 (10 μ g/ml). Ab#5521 detected Dkk1-V5 and Dkk1-AP from conditioned medium.

Figure 28 shows Western blot results using Ab#74397. Anti-V5/AP was tested at a 1:4000 dilution and Ab#74397 was tested at a 1:500 dilution. Ab#74397 was able to detect Dkk1-V5 in both conditioned medium and immunoprecipitated conditioned medium.

The results obtained with antibodies #5521 and #74397 are summarized in the following table:

Rabbit No.	Peptide Position	Peptide Sequence	Purified (Y/N)	Western	Immuno-precipitation	Location
5521	165-186	LDGYSR RTTLSSK MYHTKG QEG	Y (Protein G purified)	Y	N/A	Between Cy1 and Cys2 domain
74397	147-161	RGEIEETI TESFGN D	N	Y	N/A	Between Cy1 and Cys2 domain

Example 6

Effects of exogenous Dkk-1 on Wnt-mediated signaling in the *Xenopus* embryo assay

Xenopus embryos are an informative and well-established *in vivo* assay system to evaluate the modulation of Wnt signaling (McMahon *et al.*, *Cell* 58: 1075-84 (1989); Smith and Harland, 1991; reviewed in Wodarz and Nusse 1998) .

Modification of the Wnt signaling pathway can be visualized by examining the embryos for a dorsalization phenotype (duplicated body axis) after RNA injection into the ventral blastomere at the 4- or 8-cell stage. On the molecular level, phenotypes can be analyzed by looking for expression of various marker genes in stage 10.5 embryos. Such markers would include general endoderm, mesoderm, and ectoderm markers as well as a variety of tissue-specific transcripts.

Analysis can be done by RT-PCR/TaqMan® and can be done on whole embryo tissue or in a more restricted fashion (microdissection). Because this system is very flexible and rapid, by injecting combinations of transcripts, such as HBM and different Wnts or Wnt antagonists, the mechanism of HBM in the Wnt pathway can thereby be dissected. Furthermore, investigations are conducted to determine whether Zmax/LRP5 and HBM differentially modulate Wnt signaling either alone, or in combination with other components. Previous studies have demonstrated that LRP6 alone or LRP5 + Wnt5a were able to induce axis duplication (dorsalization) in this system (Tamai *et al.*, *Nature* 407: 530-35 (2000)).

Constructs for *Xenopus* Expression (Vector pCS2*)

Constructs were prepared using the vector pCS2*. DNA inserts were subcloned in the sense orientation with respect to the vector SP6 promoter. The pCS2* vector contains an SV40 virus polyadenylation signal and T3 promoter sequence (for generation of antisense mRNA) downstream of the insert.

Full length Zmax/LRP5 and HBM ORF cDNA: Insert cDNA was isolated from the full length cDNA retrovirus constructs (with optimized Kozak sequences) by *Bgl*II-*Eco*RI digestion and subcloned into the *Bam*HI-*Eco*RI sites of the pCS2* vector.

Full length XWnt8: This cDNA was PCR amplified from a *Xenopus* embryo cDNA library using oligos 114484 (SEQ ID NO:162) (5'-CAGTGAATTCACCATGCAAAACACCACTTTGTTC-3') and 114487 (SEQ ID NO:163) (5'-CAGTTGCGGCCGCTCATCTCCGGTGGCCTCTG-3'). The oligos were designed to amplify the ORF with a consensus Kozak sequence at the 5' end as determined from GenBank #X57234. PCR was carried out using the following conditions: 96°C, 45 sec.; 63°C, 45 sec.; 72°C, 2 min. for 30 cycles. The resulting PCR product was purified, subcloned into pCRII-TOPO (Invitrogen Corp.), sequence verified, and digested with *Bam*HI/*Xho*I. This insert was subcloned into the vector at the *Bam*HI-*Xho*I sites.

Full length Wnt5a: A murine Wnt5a cDNA clone was purchased from Upstate Biotechnology (Lake Placid, NY) and subcloned into the *Eco*RI site of the vector.

Sequencing confirmed insert orientation.

Full length human Dkk-1: A human cDNA with GenBank accession number AF127563 was available in the public database. Using this sequence, PCR primers were designed to amplify the open reading frame with a consensus Kozak sequence immediately upstream of the initiating ATG. Oligos 117162 (SEQ ID NO:164) (5'-CAATAGTCGACGAATTCACCATGGCTCTGGGCGCAGCGG-3') and 117163 (SEQ ID NO:165) (5'-GTATTGCGGCCGCTCTAGATTAGTGTCTCTGACAAGTGTGAA-3') were used to screen a human uterus cDNA library by PCR. The resulting PCR product was purified, subcloned into pCRII-TOPO (Invitrogen Corp.), sequence verified, and digested with *EcoRI/XhoI*. This insert was subcloned into the pCS2⁺ vector at the *EcoRI-XhoI* sites.

Full length human Dkk-2: A full length cDNA encoding human Dkk-2 was isolated to investigate the specificity of the Zmax/LRP5/HBM interaction with the Dkk family of molecules. Dkk-1 was identified in yeast as a potential binding partner of Zmax/LRP5/HBM. Dkk-1 has also been shown in the literature to be an antagonist of the Wnt signaling pathway, while Dkk-2 is not (Krupnik *et al.*, 1999). The Dkk-2 full length cDNA serves as a tool to discriminate the specificity and biological significance of Zmax/LRP5/HBM interactions with the Dkk family (e.g., Dkk-1, Dkk-2, Dkk-3, Dkk-4, Soggy, their homologs and variant, etc.). A human cDNA sequence for Dkk-2 (GenBank Accession No. NM_014421) was available in the public database. Using this sequence, PCR primers were designed to amplify the open reading frame with a consensus Kozak sequence immediately upstream of the initiating ATG. Oligos 51409 (SEQ ID NO:166) (5'-CTAACGGATCCACCATGGCCGCGTTGATGCGG-3') and 51411 (SEQ ID NO:167) (5'-GATTCTGAATTCTCAAATTTCTGACACACATGG-3') were used to screen human embryo and brain cDNA libraries by PCR. The resulting PCR product was purified, subcloned into pCRII-TOPO, sequence verified, and digested with *BamHI/EcoRI*. This insert was subcloned into the pCS2⁺ vector at the *BamHI-EcoRI* sites.

Full length LRP6 was isolated from the pED6dpc4 vector by *XhoI-XbaI* digestion. The full length cDNA was reassembled into the *XhoI-XbaI* sites of pCS2⁺. Insert orientation was confirmed by DNA sequencing.

mRNA Synthesis and Microinjection Protocol

mRNA for microinjection into *Xenopus* embryos is generated by *in vitro* transcription using the cDNA constructs in the pCS2⁺ vector described above as template. RNA is synthesized using the Ambion mMessage mMachine high yield capped RNA transcription kit (Cat. #1340) following the manufacturer's specifications for the Sp6 polymerase reactions. RNA products were brought up to a final volume of 50 µl in sterile, glass-distilled water and purified over Quick Spin Columns for Radiolabelled RNA Purification G50-Sephadex (Roche, Cat. #1274015) following the manufacturer's specifications. The resulting eluate was finally extracted with phenol:chloroform:isoamyl alcohol and isopropanol precipitated using standard protocols (Sambrook *et al.*, 1989). Final RNA volumes were approximately 50 µl. RNA concentration was determined by absorbance values at 260 nm and 280 nm. RNA integrity was visualized by ethidium bromide staining of denaturing (formaldehyde) agarose gel electrophoresis (Sambrook *et al.*, 1989). Various amounts of RNA (2 pg to 1 ng) are injected into the ventral blastomere of the 4- or 8-cell *Xenopus* embryo. These protocols are described in Moon *et al.*, *Technique-J. of Methods in Cell and Mol. Biol.* 1: 76-89 (1989), and Peng, *Meth. Cell. Biol.* 36: 657-62 (1991).

Screening for Duplicated Body Axis

In vitro transcribed RNA is purified and injected into a ventral blasomere of the 4- or 8-cell *Xenopus* embryo (approx. 2 hours post-fertilization). At stage 10.5 (approx. 11 hours post-fertilization), the injected embryos are cultured for a total of 72 hours and then screened for the presence of a duplicated body axis (dorsalization) (Figure 7). Using XWnt8-injected (2-10 pg) as a positive control (Christian *et al.* (1991)) and water-injected or non-injected embryos as negative controls, we replicated the published observation that Zmax(LRP5) + Wnt5a (500 and 20 pg, respectively) could induce axis duplication. Wnt5a (20 pg) alone could not induce axis duplication (as previously reported by Moon *et al.* (1993)). We have also injected GFP RNA (100-770 pg) as a negative control to show that the amount of RNA injected is not perturbing embryo development (not shown). Strikingly, HBM + Wnt5a (500 and 20 pg, respectively)

yielded an approximately 3.5 fold more robust response of the phenotype ($p=0.043$ by Fisher's exact test) compared to Zmax(LRP5) + Wnt5a, suggesting that the HBM mutation is activating the Wnt pathway (Figures 8 and 9). The HBM/Wnt5a embryos also appear to be more "anteriorized" than the Zmax(LRP5)/Wnt5a embryos, again suggestive of a gain-of-function mutation.

The role of Dkk-1 as a modulator of Zmax/LRP5- and HBM-mediated Wnt signaling was investigated. Literature reports have previously characterized *Xenopus* and murine Dkk-1 as antagonists of the canonical Wnt pathway in the *Xenopus* system (Glinka *et al.*, *Nature* 391:357-362 (1998)). Using the human Dkk-1 construct, a dose-response assay was performed to confirm that our construct was functional and to identify the optimal amount of RNA for microinjection. Using 250 pg/embryo of hDkk-1 RNA, over 90% ($p<0.001$) of the embryos were observed to display enlarged anterior structures (big heads) as anticipated from the published reports (Figure 10).

The mechanism of hDkk-1 modulation of Wnt signaling in the presence of Zmax/LRP5 or HBM was also investigated. Without any hDkk-1 present, it was confirmed that HBM + Wnt5a was a more potent activator of Wnt signaling than Zmax/LRP5 + Wnt5a ($p<0.05$). Interestingly, in the presence of hDkk-1 (250 pg), Zmax/LRP5-mediated Wnt signaling was repressed ($p<0.05$) but hDkk-1 was unable to repress HBM-mediated Wnt signaling ($p<0.01$) (Figure 11). The specificity of this observation can be further addressed by investigating other members of the Dkk family, other Wnt genes, LRP6, additional Zmax/LRP5 mutants, and the peptide aptamers.

Example 7

Effects of exogenous Dkk and LRP5 on Wnt signaling in the TCF-luciferase Assay

Wnt activity can be antagonized by many proteins including secreted Frizzled related proteins (SFRPs), Cerberus, Wnt Inhibitory Factor-1 and Dkk-1 (Krupnik *et al.*, 1999). The Dkk family of proteins consists of Dkk-1-4 and Soggy, a Dkk-3-like protein. Dkk-1 and Dkk-4 have been shown to antagonize Wnt mediated *Xenopus* embryo development, whereas Dkk-2, Dkk-3, and Soggy do not. Unlike many of these proteins

that antagonize Wnt activity by directly interacting with Wnt proteins, Dkk-1 acts by binding to two recently identified Wnt coreceptors, LRP5 and LRP6. (Mao *et al.*, 2001; Bafico *et al.*, 2001). The details of this interaction have been examined by the present inventors and Mao *et al.* using deletion constructs of LRP6, which demonstrated that EGF repeats 3 and 4 are important for Dkk-1 interaction. Accordingly, the activity of two Dkk proteins, Dkk-1 and Dkk-2, were investigated with various Wnt members, LRP5, LRP6, and the mutant form of LRP5, designated HBM. The present invention explores whether there is any functional difference between LRP5 and HBM with regard to Dkk action on Wnt mediated signaling. Various reagents were developed, including Dkk-1 peptides, constrained LRP5 peptide aptamers, constrained Dkk-1 peptide aptamers and polyclonal antibodies to Dkk-1 (in Example 5 above) to identify factors that mimic HBM mediated Wnt signaling.

Methods

Various LRP5 constrained peptides were developed. Specifically, four peptides that interact with the LBD of LRP5 (Figure 4, constructs OST259-262 in Figure 12) and three peptides that interact with the cytoplasmic domain of LRP5 (constructs OST266-OST268 in Figure 12). In addition two Dkk-1 peptides were developed: constructs OST264 and OST265 in Figure 12, corresponding to Dkk-1 amino acids 139-266 and 96-245, containing the smallest region of Dkk-1 that interacts with LRP5 (Figure 6). The cDNA clones encoding the LRP5 LBD interacting peptides and the Dkk-1 peptides were subcloned into pcDNA3.1 with the addition of a Kozak and signal sequence to target the peptide for secretion. The constructs encoding the three peptides interacting with the cytoplasmic domain of LRP5 were also subcloned into pcDNA3.1. However, these latter constructs do not contain a signal sequence.

HOB-03-CE6 osteoblastic cells developed by Wyeth Ayerst (Philadelphia, PA) were seeded into 24-well plates at 150,000 cells per well in 1 ml of the growth media (D-MEM/F12 phenol red-free) containing 10% (v/v) heat-inactivated FBS, 1X penicillin streptomycin, and 1X Glutamax-1, and incubated overnight at 34°C. The following day, the cells were transfected using Lipofectamine 2000® (as described by the

manufacturer, Invitrogen) in OptiMEM (Invitrogen) with 0.35 μ g /well of LRP5, HBM, or control plasmid DNA (empty vector pcDNA3.1) and either Wnt1 or Wnt3a plasmid DNA. Similar experiments were performed with LRP6 plasmid DNA (0.35 μ g/well) or a control pEDdpc4 empty vector. Furthermore, each of these groups were then divided
5 into three groups, those receiving 0.35 μ g/well Dkk-1, Dkk-2, or pcDNA3.1 control DNA. All wells were transfected with 0.025 μ g/well of CMV beta-galactosidase plasmid DNA and 0.35 μ g/well 16X TCF(AS)-luciferase reporter DNA (developed by Ramesh Bhat, Wyeth-Ayerst (Philadelphia, PA)). After 4 hours of incubation, the cells were rinsed and 1 ml of fresh growth media was added to each well. The cells were cultured overnight
10 at 34°C, followed by a wash and a change of media. Cells were cultured for an additional 18-24 hours at 37°C. Cells were then lysed with 50 μ l/well of 1X lysis buffer. The extracts were assayed for beta-galactosidase activity (Galacto Reaction Buffer Diluent & Light Emission Accelerator, Tropix) using 5 μ l extract + 50 μ l beta-galactosidase diluent and luciferase activity (Luciferase Assay Reagent, Promega)
15 using 20 μ l extract.

U2OS human osteosarcoma cells were also utilized. U2OS cells (ATCC) were seeded into 96-well plates at 30,000 cells per well in 200ul of the growth media (McCoy's 5A) containing 10% (v/v) heat-inactivated FBS, 1X penicillin streptomycin, and 1X Glutamax-1, and incubated overnight at 37°C. The following day, the media
20 was replaced with OptiMEM (Invitroge) and cells were transfected using Lipofectamine 2000® (as described by the manufacturer, Invitrogen) with 0.005 μ g/well of LRP5, HBM, LRP6 or control plasmid DNA (empty vector pcDNA3.1) and either Wnt1 (.0025 μ g/well) or Wnt3a (.0025 μ g/well) plasmid DNA. In addition, the 16x-(AS) TCF-TK-firefly-luciferase (Ramesh Bhat, WHRI, Wyeth) and control TK-renilla luciferase (Promega Corp.) were co-transfected at 0.3 μ g/well and 0.06 μ g/well respectively in all
25 experiments. Furthermore, each of these groups was then divided into different groups, those receiving 0.05 μ g/well Dkk-1, Dkk-2, Dkk3, Dkk1-Alkaline Phosphatase (AP), mutant Dkk-1 (C220A), Soggy or pcDNA3.1 control DNA. In other experiments, cells were co-transfected with 0.005 μ g/well of LRP5, 0.0025 μ g/well of Wnt1 or Wnt3a (using
30 0.0025 μ g/well of a control pcDNA3.1) with LRP5-interacting aptamers (0.05 μ g/well).

Cells were cultured for an additional 18-20 hours at 37°C. Culture medium was removed. Cells were cultured for an additional 18-20 hours at 37°C. Culture medium was removed. Cells were then lysed with 100 μ l/well of 1X Passive Lysis Buffer (PLB) of Dual Luciferase Reagent kit (DLR-kit-Promega Corp.) 20 μ l of the lysates were
5 combined with LARII reagent of DLR-kit and assayed for TCF-firefly luciferase signal in Top Count (Packard) instrument. After measuring the Firefly readings, 100 μ l of the "Stop and Glo" reagent of DLR kit that contains a quencher and a substrate for renilla luciferase was added into each well. Immediately the renilla luciferase reading was measured using the Top Count (Packard) Instrument. The ratios of the TCF-firefly
10 luciferase to control renilla readings were calculated for each well and the mean ratio of triplicate or more wells was expressed in all data.

Results

The results of these experiments demonstrate that Dkk-1, in the presence of
15 Wnt1 and LRP5, significantly antagonized TCF-luciferase activity (Figure 14). In marked contrast, Dkk-1 had no effect on HBM/Wnt1 mediated TCF-luciferase activity (Figure 14). In similar experiments, Dkk-1 was also able to antagonize LRP5/Wnt3a but not HBM/Wnt3a mediated TCF-luciferase activity (Figure 15). These results indicate that the HBM mutation renders Dkk-1 inactive as an antagonist of Wnt1 and
20 Wnt3a signaling in HOB03CE6 osteoblastic cells. In other experiments with Wnt1, Dkk-1 had no effect on LRP5 or HBM mediated TCF-luciferase activity (Figure 14). In contrast, with either LRP5 or HBM in the presence of Wnt3a, Dkk-2 was able to antagonize the TCF-luciferase activity (Figure 15). These latter results indicate that the HBM mutation has no effect on Dkk-2 action in the presence of Wnt3a. Experiments
25 were also performed using the closely related LRP6 cDNA in HOB-03-CE6 cells. In these experiments, LRP6/Wnt1 and LRP6/Wnt3a mediated TCF-luciferase were regulated in the same manner as LRP5. Specifically, Dkk-1 antagonized LRP6/Wnt1 mediated TCF-luciferase activity, whereas Dkk-2 had no effect (Figure 14). However, similar to the action of Dkk-2 with LRP5/Wnt3a, Dkk-2 was able to antagonize
30 LRP6/Wnt3a mediated TCF-luciferase activity (Figure 15).

The results in the U2OS cells show a robust effect of the OST262 LRP5 peptide aptamer activation of Wnt signaling in the presence of Wnt3a (Figure 16). These functional results are confirmed by the results shown below in Example 11 using LRP5 peptide aptamers in the Xenopus assay. Such results affirmatively demonstrate that the effects of small molecules on LRP5/LRP6/HBM signaling can be detected using the TCF-luciferase assay.

These data demonstrate that there is a functional difference between LRP5 and HBM regarding the ability of Dkk-1 to antagonize Wnt1 and Wnt3a signaling. These data and previous data showing that Dkk-1 directly interacts with LRP5 suggests that the inability of Dkk-1 to antagonize HBM/Wnt signaling may in part contribute to the HBM phenotype. These experiments further demonstrate the ability to test various molecules (e.g., small molecules, aptamers, peptides, antibodies, LRP5 interacting proteins or Dkk-1 interacting proteins, and the like) for a LRP5 ligand that mimics HBM mediated Wnt signaling or factors that block Dkk-1 interaction with LRP5.

Example 8

Yeast-2 Hybrid Interaction Trap

Small molecule inhibitors (or partial inhibitors) of the Dkk-LRP interaction may be an excellent osteogenic therapeutic. One way to investigate this important protein-protein interaction is using Y2H techniques substantially as described above and as is well known in the art. Regions of LRP5, such as LRP5 LBD, have been found to functionally interact with Dkk. This interaction is quantitated using a reporter element known in the art, e.g., LacZ or luciferase, which is only activated when bait and prey interact. The Y2H assay is used to screen for compounds which modulate the LRP-Dkk interaction. Such a modulation would be visualized by a reduction in reporter element activation signifying a weaker or disrupted interaction, or by an enhancement of the reporter element activation signifying a stronger interaction. Thus, the Y2H assay can be used as a high-throughput screening technique to identify compounds which disrupt or enhance Dkk interaction with LRP5/LRP6/HBM, which may serve as potential therapeutics.

For example, the Interaction Trap methodology can be used as follows. The LRP5 LBD, for example, was fused with LexA and Dkk-1 was fused with either Gal4-AD or B42. With the LRP5LBD-LexA bait and the Gal4AD-Dkk prey, over a 20-fold activation of a lacZ reporter (under the control of a single LexA operator) was detected over the background. Using a Dkk-1 mutant (C220A) that is unable to bind to LRP, the interaction was reduced in yeast, showing the specificity of this interaction and system (Figure 18). As a result, small molecules may be identified that modulate this interaction between LRP and Dkk.

Example 9

Cell-Based Functional High-Throughput Assay

To develop a high throughput assay, the TCF-luciferase assay described in Example 7 was modified utilizing low level expression of endogenous LRP5/6 in U2OS and HEK293 cells. However, HOB-03-CE6 cells and any other cells which show a differential response to Dkk depending on whether LRP5, LRP6 or HBM are expressed. Using U2OS (human osteosarcoma) and HEK293 (ATCC) cells, the TCF-luciferase and tk-Renilla reporter element constructs were co-transfected along with Wnt3a/1 and Dkk. Wnt3a alone, by using endogenous LRP5/6, was able to stimulate TCF reporter gene activation. When Dkk, is co-transfected with Wnt3a/Wnt 1 and reporters (TCF-luci and tk-Renilla), Dkk represses reporter element activity. In addition, the TCF-luci signal is activated by Wnt3a/Wnt1 can be repressed by the addition of Dkk-enriched conditioned media to the cells containing Wnt3a/Wnt1 and reporters. The assay is further validated by the lack of TCF-reporter inhibition by a point mutant construct (C220A) of Dkk1.

The Dkk-mediated repression of the reporter is dependent upon the concentration of transfected Dkk cDNA or on the amount of Dkk-conditioned media added. In addition, the Dkk-mediated reporter suppression can be altered by the co-transfection of LRP5, LRP6, and HBM cDNAs in the U2OS or HEK293 cells. In general, U2OS cells show greater sensitivity to Dkk-mediated reporter suppression than that in HEK-293 cells. In U2OS cells, the transfection of LRP5/LRP6/HBM cDNA leads

to moderate activation of TCF-luci in the absence of Wnt3a/Wnt1 transfection. This activation presumably utilizes the endogenous Wnts present in U2OS cells. Under this condition, Dkk1 can repress TCF-luci and shows a differential signal between LRP5 and HBM. By co-transfecting Wnt3a/Wnt1, there is a generalized increase in the TCF-luci signal in the assay. Further, one can detect Dkk-mediated differential repression of the reporter due to LRP5 and HBM cDNA expression as well as between LRP5 and LRP6 cDNA. The repression is maximal with LRP6, moderate with LRP5, and least with HBM cDNA expression. In addition, the assay can detect the functional impact of the LRP5 interacting peptide aptamers (Figure 4), Dkk1 interacting aptamers and binding domains of Dkk-1 (Figure 6; OST264 and OST265 of Figures 12 and 13).

Using this system with a suppressed Wnt-TCF signal due to the presence of both Dkk and Wnt3a, one can screen for compounds that could alter Dkk modulation of Wnt signaling, by looking for compounds that activate or the TCF-luciferase reporter, and thereby relieve the Dkk-mediated repression of the Wnt pathway. Such compounds identified may potentially serve as HBM-mimetics and be useful, for example, as osteogenic therapeutics. Data generated from this high throughput screen are demonstrated in Figures 19-21. Figure 19 shows that Dkk1 represses Wnt3a-mediated signaling in U2OS bone cells. Figure 20 demonstrates the functional differences between LRP5, LRP6, and HBM. Dkk-1 represses LRP6 and LRP5 but has little or no effect on HBM-generated Wnt1 signaling in U2OS cells. Figure 21 demonstrates the differential effects of various Dkk family members and modified Dkks, including Dkk-1, a mutated Dkk-1 (C220A), Dkk-1-AP (modified with alkaline phosphatase), Dkk-3, and Soggy.

Example 10

DKK/LRP5/6/HBM ELISA Assay

A further method to investigate Dkk binding to LRP is via ELISA assay. Two possible permutations of this assay are exemplified. LRP5 is immobilized to a solid surface, such as a tissue culture plate well. One skilled in the art will recognize that other supports such as a nylon or nitrocellulose membrane, a silicon chip, a glass slide,

beads, etc. can be utilized. In this example, the form of LRP5 used is actually a fusion protein where the extracellular domain of LRP5 is fused to the Fc portion of human IgG. The LRP5-Fc fusion protein is produced in CHO cell extracts from stable cell lines. The LRP5-Fc fusion protein is immobilized on the solid surface via anti-human Fc antibody or by Protein-A or Protein G-coated plates, for example. The plate is then washed to remove any non-bound protein. Conditioned media containing secreted Dkk protein or secreted Dkk-epitope tagged protein (or purified Dkk or purified Dkk-epitope tagged protein) is incubated in the wells and binding of Dkk to LRP is investigated using antibodies to either Dkk or to an epitope tag. Dkk-V5 epitope tagged protein would be detected using an alkaline phosphatase tagged anti-V5 antibody.

Alternatively, the Dkk protein could be directly fused to a detection marker, such as alkaline phosphatase. Here the detection of the Dkk-LRP interaction can be directly investigated without subsequent antibody-based experiments. The bound Dkk is detected in an alkaline phosphatase assay. If the Dkk-alkaline phosphatase fusion protein is bound to the immobilized LRP5, alkaline phosphatase activity would be detected in a colorimetric readout. As a result, one can assay the ability of small molecule compounds to alter the binding of Dkk to LRP using this system.

Compounds, when added with Dkk (or epitope-tagged Dkk) to each well of the plate, can be scored for their ability to modulate the interaction between Dkk and LRP based on the signal intensity of bound Dkk present in the well after a suitable incubation time and washing. The assay can be calibrated by doing cold competition experiments with unlabeled Dkk or with a second type of epitope-tagged Dkk. Any small molecule that is able to modulate the Dkk-LRP interaction may be a suitable therapeutic candidate, more preferably an osteogenic therapeutic candidate.

Example 11

Functional Evaluation of Peptide Aptamers in Xenopus

The constrained peptide aptamers constructs OST258-263 (where 258 contains the signal sequence by itself and 263 contains an irrelevant constrained peptide) (Figures 12 and 13) were used to generate RNA substantially as described in Example

7, except the vector was linearized by restriction endonuclease digestion and RNA was generated using T7 RNA polymerase.

Aptamer RNA was injected at 250 pg per blastomere using the protocol of Example 7. Wnt signaling was activated, as visualized by embryo dorsalization (duplicated body axis) with aptamers 261 and, more strongly, 262. The results of this assay are shown in Figures 22 and 23. These results suggest that aptamers 261 and 262 are able to activate Wnt signaling possibly by binding to the LBD of LRP, thereby preventing the modulation of LRP-mediated signaling by Dkk.

The aptamers of the present invention can serve as HBM-mimetics. In the *Xenopus* system they are able to induce Wnt signaling all by themselves. They may also serve as tools for rational drug design by enhancing the understanding of how peptides are able to interact with LRP and modulate Wnt signaling at the specific amino acid level. Thus, one would be able to design small molecules to mimic their effects as therapeutics. In addition, the aptamers identified as positives in this assay may be used as therapeutic molecules themselves.

Example 12

Homogenous Assay

An excellent method to investigate perturbations in protein-protein interactions is via Fluorescence Resonance Energy Transfer (FRET). FRET is a quantum mechanical process where a fluorescent molecule, the donor, transfers energy to an acceptor chromophore molecule which is in close proximity. This system has been successfully used in the literature to characterize the intermolecular interactions between LRP5 and Axin (Mao et al., *Molec. Cell Biol.* 7:801-809). There are many different fluorescent tags available for such studies and there are several ways to fluorescently tag the proteins of interest. For example, CFP (cyan fluorescent protein) and YFP (yellow fluorescent protein) can be used as donor and acceptor, respectively. Fusion proteins, with a donor and an acceptor, can be engineered, expressed, and purified.

For instance, purified LRP protein, or portions or domains thereof, fused to CFP and purified Dkk protein, or portions or domains thereof that interact with Dkk or LRP

respectively, fused to YFP can be generated and purified using standard approaches. If LRP-CFP and Dkk-YFP are in close proximity, the transfer of energy from CFP to YFP will result in a reduction of CFP emission and an increase in YFP emission. Energy is supplied with an excitation wavelength of 450 nm and the energy transfer is recorded at emission wavelengths of 480 nm and 570 nm. The ratio of YFP emission to CFP emission provides a gauge for changes in the interaction between LRP and Dkk. This system is amenable for screening small molecule compounds that may alter the Dkk-LRP protein-protein interaction. Compounds that disrupt the interaction would be identified by a decrease in the ratio of YFP emission to CFP emission. Such compounds that modulate the LRP-Dkk interaction would then be considered candidate HBM mimetic molecules. Further characterization of the compounds can be done using the TCF-luciferase or Xenopus embryo assays to elucidate the effects of the compounds on Wnt signaling.

While the above example describes a cell-free, solution-phase assay using purified components, a similar cell-based assay could also be performed. For example, LRP-CFP fusion protein can be expressed in cells. The Dkk-YFP fusion protein then could be added to the cells either as purified protein or as conditioned media. The interaction of LRP and Dkk is then monitored as described above.

All references cited herein are hereby incorporated by reference in their entirety for all purposes. The following applications are also incorporated by reference in their entirety herein for all purposes: U.S. Application No. 60/290,071, filed May 11, 2001; U.S. Application No. 09/544,398, filed on April 5, 2000; U.S. Application No. 09/543,771, filed April 5, 2000; 09/578,900; U.S. Application No. 09/229,319, filed January 13, 1999; U.S. Provisional Application 60/071,449, filed January 13, 1998; and International Application PCT/US00/16951, filed June 21, 2000; International PCT Application entitled "HBM Variants That Modulate Bone Mass and Lipid Levels," filed May 13, 2002; and International PCT Application entitled "Transgenic Animal Model of Bone Mass Modulation," filed May 13, 2002. Additionally, this application claims priority to U.S. provisional applications 60/291,311, filed May 17, 2001; 60/353,058, filed

February 1, 2002; and 60/361,293, filed March 4, 2002; the texts of which are herein incorporated by reference in their entirety for all purposes.

CLAIMS

We claim:

1. A method of regulating LRP5, LRP6, or HBM activity in a subject
5 comprising administering a composition which modulates a Dkk activity in an
amount effective to regulate LRP5, LRP6, or HBM activity.
2. The method of any of Claims 1, 24, 28, 33, 36, 37, 48, 64, 65, 93,
98, 101, 105, 107, 111, or 112, wherein the Dkk is Dkk-1.
10
3. The method of any of Claims 1, 24, 28, or 33, wherein the Dkk is
Dkk-1 and the Dkk activity is inhibited.
4. The method of Claims 1 or 24, wherein the Dkk activity modulates
15 bone mass and/or lipid levels.
5. The method of Claim 4, wherein bone mass is increased and/or
lipid levels are decreased.
- 20 6. The method of Claim 5, wherein the increase in bone mass is
determined via one or more of a decrease in fracture rate, an increase in bone
strength, an increase in bone density, an increase in bone mineral density, an
increase in trabecular connectivity, an increase in trabecular density, an increase
in cortical density, an increase in bone diameter, and an increase in inorganic
25 bone content.
7. The method of any of Claims 1, 24, 28, or 33, wherein said
composition comprises one or more compounds selected from the group
consisting of Dkk interacting proteins, or a Dkk-binding fragment thereof.
30

8. The method of any of Claims 1, 24, 28, or 33, wherein said composition comprises an antisense, a siRNA, or shRNA molecule which recognizes and binds to a nucleic acid encoding one or more Dkk interacting proteins.

5

9. The method of any of Claims 1, 24, 28, or 33, and wherein said composition comprises a Dkk peptide aptamer.

10. The method of any of Claims 1, 24, 28, or 33, wherein said composition comprises a mimetic of a Dkk peptide aptamer.

10

11. The method of any of Claims 1, 24, 28, or 33, wherein said composition inhibits Dkk binding to LRP5, LRP6, or HBM.

15

12. The method of any of Claims 1, 24, 28, or 33, wherein said composition enhances binding of Dkk to LRP5, LRP6, or HBM.

13. The method of any of Claims 1, 24, 28, or 33, wherein said composition comprises a Dkk interacting protein peptide aptamer.

20

14. The method of any of Claims 1, 24, 28, or 33, wherein said composition comprises a mimetic of a Dkk interacting protein peptide aptamer.

15. The method of any of Claims 1, 24, 28 or 33, wherein said composition inhibits Dkk interacting protein or Dkk-binding fragment thereof binding to Dkk.

25

16. The method of any of Claims 1, 24, 28, or 33, wherein said composition enhances binding of Dkk interacting protein or Dkk-binding fragment thereof to Dkk.

30

17. The method of any of Claims 1, 24, 28, or 33, wherein said subject is a vertebrate or an invertebrate organism.

5 18. The method of any of Claims 1, 24, 28, or 33, wherein said subject is a mammal.

19. The method of any of Claims 1, 24, 28, or 33, wherein said subject is a canine, a feline, an ovine, a primate, an equine, a porcine, a caprine, a camelid, an avian, a bovine, or a rodent.

10 20. The method of Claim 19, wherein said primate is a human.

21. The method of any of Claims 1, 24, 28, or 33, wherein said composition comprises an LRP5 peptide aptamer.

15 22. The method of Claim 21, wherein said peptide aptamer is OST262 (SEQ ID NO:208).

20 23. The method of any of Claims 1, 24, 28 or 33, wherein the composition comprises an LRP5 antibody or an immunologically active fragment thereof.

25 24. A method of regulating Dkk-Wnt pathway activity in a subject comprising administering a composition which modulates Dkk activity in an amount effective to regulate Dkk-Wnt pathway activity.

25. The method of Claims 24, 101, or 107, wherein the Wnt is one or more of Wnt1-Wnt19.

26. The method of Claim 25, wherein the Wnt is Wnt1, Wnt3, Wnt3a, or Wnt10b.

5 27. The method of Claim 24 wherein said composition which modulates Dkk activity or modulates Dkk interaction with LRP5/LRP6/HBM is administered in an amount effective to modulate Wnt signaling.

10 28. A method of modulating bone mass in a subject comprising administering to the subject a composition which modulates Dkk activity or Dkk interaction with LRP5, LRP6, or HBM in an amount effective to modulate bone mass in the subject.

29. The method of Claim 28, wherein bone mass is increased.

15 30. The method of the previous claim, wherein the increase in bone mass is determined via one or more of a decrease in fracture rate, an increase in bone strength, an increase in bone density, an increase in bone mineral density, an increase in trabecular connectivity, an increase in trabecular density, an increase in cortical density, an increase in bone diameter, and an increase in
20 inorganic bone content.

25 31. The method of Claims 28 or 36, wherein said subject has a bone mass disorder selected from the group consisting of a bone development disorder, a bone fracture, age-related loss of bone, chrondrodystrophy, drug-induced bone disorder, high bone turnover, hypercalcemia, hyperostosis, osteogenesis imperfecta, osteomalacia, osteomyelitis, osteoporosis, Paget's disease, osteoarthritis, and rickets.

30 32. The method of Claim 28, wherein the composition which modulates Dkk activity or Dkk interaction with LRP5, LRP6, or HBM is

administered in an amount effective to modulate the amount of trabecular and/or cortical tissue.

5 33. A method of modulating lipid levels in a subject comprising administering to the subject a composition which modulates Dkk activity or Dkk interaction with LRP5, LRP6, or HBM in an amount effective to modulate lipid levels in the subject.

10 34. The method of Claim 33, wherein lipid levels are decreased.

 35. The method of Claim 33 or 36, wherein the subject has a lipid-modulated disorder and wherein the lipid-modulated disorder is selected from the group consisting of a cardiac condition, atherosclerosis, familial lipoprotein lipase deficiency, familial apoprotein CII deficiency, familial type 3
15 hyperlipoproteinemia, familial hypercholesterolemia, familial hypertriglyceridemia, multiple lipoprotein-type hyperlipidemia, elevated lipid levels due to dialysis and/or diabetes, and elevated lipid levels of unknown etiology.

20 36. A method of diagnosing low or high bone mass and/or high or low lipid levels in a subject comprising examining expression of Dkk, LRP5, LRP6, HBM, or and HBM-like variant in the subject and determining whether Dkk, LRP5, LRP6, HBM, or an HBM-like variant is over- or under-expressed to
25 determine whether subject has (a) high or low bone mass and/or (b) has high or low lipid levels.

 37. A method of screening for a compound which modulates the interaction of Dkk with LRP5, LRP6, HBM, or a Dkk-binding fragment of LRP5, LRP6, or HBM comprising:

(a) exposing Dkk and a LRP5, LRP6, and/or HBM binding fragment thereof to a compound; and

(b) determining whether said compound modulates Dkk interaction with the LRP5/LRP6/HBM binding fragment.

5

38. The method of Claim 37, wherein said modulation is determined by whether said compound binds to Dkk or the LRP5, LRP6, or HBM binding fragment thereof.

10

39. The method of Claim 37, wherein Dkk or a LRP-binding fragment thereof is attached to a substrate.

15

40. The method of Claim 37, wherein said compound comprises one or more compounds selected from the group consisting of Dkk interacting proteins, or a Dkk-binding fragment thereof.

41. The method of Claim 37 or 48, wherein said compound comprises a Dkk peptide aptamer.

20

42. The method of Claim 37 or 48, wherein said compound comprises a mimetic of a Dkk peptide aptamer.

43. The method of Claim 37 or 48, wherein said compound comprises a Dkk interacting protein peptide aptamer.

25

44. The method of Claim 37 or 48, wherein the compound comprises an LRP5 peptide aptamer.

45. The method of Claim 44, wherein the peptide aptamer is OST262 (SEQ ID NO:208).

30

46. The method of Claim 37 or 48, wherein the compound comprises an LRP5 antibody.

47. The method of Claim 37 or 48, wherein said compound is a mimetic of a Dkk interacting protein peptide aptamer.

48. A method of screening for a compound which modulates the interaction of Dkk with a Dkk interacting protein comprising:

- (a) exposing a Dkk interacting protein or a Dkk-binding fragment thereof to a compound; and
- (b) determining whether said compound bound to a Dkk interacting protein or the Dkk-binding fragment thereof; and
- (c) further determining whether said compound modulates the interaction of Dkk interacting protein and Dkk.

49. The method of Claim 48, wherein the Dkk interacting protein or a Dkk-binding fragment thereof is attached to a substrate.

50. A composition comprising a LRP5, LRP6, or HBM activity-modulating compound and a pharmaceutically acceptable carrier therefor.

51. The composition of Claim 50, wherein said LRP5, LRP6, or HBM activity-modulating compound comprises a compound which binds to Dkk thereby modulating the interaction of Dkk with LRP5, LRP6, or HBM.

52. The composition of Claim 50, wherein said LRP5, LRP6, or HBM modulating compound comprises one or more Dkk interacting proteins and Dkk-binding fragments thereof.

53. The composition of Claim 50, wherein said LRP5, or LRP6, or HBM modulating compound is a monoclonal antibody or an immunologically active fragment thereof which binds to a Dkk interacting protein, or a Dkk-binding fragment thereof.

5

54. The composition of Claim 53, wherein the monoclonal antibody is human, chimeric, humanized, primatized®, or bispecific.

55. The composition of Claim 50, wherein said LRP5, LRP6, or HBM modulating compound comprises an antisense, a siRNA, or shRNA molecule which recognizes and binds to a nucleic acid encoding one or more Dkk interacting proteins.

10

56. The composition of Claim 50, wherein said LRP5, LRP6, or HBM modulating compound comprises a Dkk peptide aptamer.

15

57. The composition of Claim 50, wherein said LRP5, LRP6, or HBM modulating compound comprises a mimetic of a Dkk peptide aptamer.

20

58. The composition of Claim 50, wherein said LRP5, LRP6, or HBM modulating compound comprises a Dkk interacting protein peptide aptamer.

59. The composition of Claim 50, wherein said LRP5, LRP6, or HBM modulating compound comprises a mimetic of a Dkk interacting protein peptide aptamer.

25

60. The composition of Claim 50, wherein the compound comprises an LRP5 peptide aptamer.

61. The composition of Claim 60, wherein the peptide aptamer is OST262.

5 62. The composition of Claim 50, wherein the compound comprises an LRP5 antibody.

63. A pharmaceutical composition comprising a compound which modulates Dkk activity and a pharmaceutically acceptable carrier therefor.

10 64. A method for identifying compounds which modulate Dkk and LRP5/LRP6/HBM interactions comprising:
(a) creating an LRP5, LRP6, or HBM fluorescent fusion protein using a first fluorescent tag; and
(b) creating a Dkk fusion protein comprising a second fluorescent tag;
15 (c) adding a test compound; and
(d) assessing changes in the ratio of fluorescent tag emissions using Fluorescence Resonance Energy Transfer (FRET) or Bioluminescence Resonance Energy Transfer (BRET) to determine whether the compound modulates Dkk and LRP5/LRP6/HBM interactions.

20

65. A method of identifying binding partners for a Dkk protein comprising the steps of:

(a) exposing the Dkk protein(s) or a LRP5/LRP6 binding fragment thereof to a potential binding partner; and
25 (b) determining if the potential binding partner binds to a Dkk protein or the LRP5/LRP6 binding fragment thereof.

66. A nucleic acid encoding a Dkk interacting protein peptide aptamer comprising a nucleic acid encoding a scaffold protein in-frame with the activation

domain of Gal4 or LexA that is in-frame with a nucleic acid that encodes a Dkk interacting protein amino acid sequence.

67. A vector comprising the nucleic acid of Claim 66.

5

68. The nucleic acid of Claim 66, wherein the scaffold protein is trxA.

69. A method of detecting a modulatory activity of a compound on the binding interaction of a first peptide and a second peptide of a peptide binding pair that bind through extracellular interaction in their natural environment, comprising:

10

(i) culturing at least one eukaryotic cell comprising:

a) a nucleotide sequence encoding a first heterologous fusion protein comprising the first peptide or a segment thereof joined to a transcriptional activation protein DNA binding domain;

15

b) a nucleotide sequence encoding a second heterologous fusion protein comprising the second peptide or a segment thereof joined to a transcriptional activation protein transcriptional activation domain;

20

wherein binding of the first peptide or segment thereof and the second peptide or segment thereof reconstitutes a transcriptional activation protein; and

c) a reporter element activated under positive transcriptional control of the reconstituted transcriptional activation protein, wherein expression of the reporter element produces a selected phenotype;

25

(ii) incubating the eukaryotic cell in the presence of a compound under conditions suitable to detect the selected phenotype; and

- (iii) detecting the ability of the compound to affect the binding interaction of the peptide binding pair by determining whether the compound affects the expression of the reporter element which produces the selected phenotype;

5 wherein (1) said first peptide is a Dkk peptide and the second peptide is a peptide selected from LRP5, HBM, LRP6 and the Dkk-binding portion of LRP5/LRP6/HBM or (2) said first peptide is a Dkk interacting protein or the Dkk-binding fragment thereof and said second peptide is a Dkk peptide.

10 70. The method of Claim 69, wherein the eukaryotic cell is a yeast cell.

71. The method of Claim 70, wherein the yeast cell is *Saccharomyces*.

15 72. The method of Claim 71, wherein the *Saccharomyces* cell is *Saccharomyces cerevisiae*.

73. The method of Claim 69, wherein the Dkk is Dkk-1 and wherein
20 the compound comprises one or more Dkk interacting proteins or a Dkk-binding fragment thereof.

74. The method of Claim 73, wherein the compound is directly added
to assay.

25 75. The method of Claim 73, wherein the compound is recombinantly expressed by said eukaryotic cell in addition to said first and second peptides.

76. The method of Claim 69, wherein the compound comprises a Dkk
30 peptide aptamer.

77. The method of Claim 69, wherein the compound comprises a mimetic of a Dkk peptide aptamer.

78. The method of Claim 69, wherein the compound comprises a Dkk interacting protein peptide aptamer.

79. The method of Claim 69, wherein the compound comprises a mimetic of a Dkk interacting protein peptide aptamer.

80. The method of Claim 69, wherein the eukaryotic cell further comprises at least one endogenous nucleotide sequence selected from the group consisting of a nucleotide sequence encoding the DNA binding domain of a transcriptional activation protein, a nucleotide sequence encoding the transcriptional activation domain of a transcriptional activation protein, and a nucleotide sequence encoding the reporter element, wherein at least one of the endogenous nucleotide sequences is inactivated by mutation or deletion.

81. The method of Claim 69, wherein the peptide binding pair comprises a ligand and a receptor to which the ligand binds.

82. The method of Claim 69, wherein the transcriptional activation protein is Gal4, Gcn4, Hap1, Adr1, Swi5, Ste12, Mcm1, Yap1, Ace1, Ppr1, Arg81, Lac9, Qa1F, VP16, or a mammalian nuclear receptor.

83. The method of Claim 69, wherein at least one of the heterologous fusion proteins is expressed from an autonomously-replicating plasmid.

84. The method of Claim 69, wherein the DNA binding domain is a heterologous DNA-binding domain of a transcriptional activation protein.

85. The method of Claim 84, wherein the DNA binding protein is selected from the group consisting of a mammalian steroid receptor and bacterial LexA protein.

5 86. The method of Claim 69, wherein the reporter element is selected from the group consisting of *lacZ*, a polynucleotide encoding luciferase, a polynucleotide encoding green fluorescent protein (GFP), and a polynucleotide encoding chloramphenicol acetyltransferase.

10 87. The method of Claim 86, wherein the reporter element is LacZ.

88. The method of Claim 69, wherein the test sample comprises an LRP5 peptide aptamer.

15 89. The method of Claim 88, wherein the peptide aptamer is OST262 (SEQ ID NO:208).

90. The method of Claim 69, wherein the test sample comprises an LRP5 antibody.

20

91. A transgenic animal wherein Dkk-1 is knocked out in a tissue-specific fashion.

92. The transgenic animal of Claim 91, wherein the tissue specificity is bone tissue, cancer tissue, or liver tissue.

25

93. A method for identifying potential compounds which modulate Dkk activity comprising:

30 a) measuring the effect on binding of one or more Dkk interacting proteins, or a Dkk-binding fragment thereof, with Dkk or a

fragment thereof in the presence and absence of a compound;
and

b) identifying as a potential Dkk modulatory compound a
compound which modulates the binding between one or more Dkk
interacting proteins or Dkk-binding fragment thereof and Dkk or
fragment thereof.

94. A peptide aptamer of Figure 3 (SEQ ID NOs:171-188) or Figure 4
(SEQ ID NOs:189-192).

95. An antibody or antibody fragment which recognizes and binds to
one or more peptides of amino acid sequences GNKYQTIDNYQPYPYPC (SEQ ID
NO:118), LDGYSRRTTLSSKMYHTKGQEG (SEQ ID NO:119),
RIQKDHQASNSSRLHTCQRH (SEQ ID NO:120), RGEIETITESFGND (SEQ
ID NO:121), EIFQRCYCGEGLSCRIQKD (SEQ ID NO:122),
MYWTDWVETPRIE (SEQ ID NO:123), MYWTDWGETPRIE (SEQ ID NO:124),
KRTGGKRKEILSA (SEQ ID NO:125), ERVEKTTGDKRTRIQGR (SEQ ID
NO:126), KQQCDSFPDCIDGSDE (SEQ ID NO:127), or a Dkk-1 amino acid
sequence selected from the group consisting Asn34-His266 (SEQ ID NO:110),
Asn34-Cys245 (SEQ ID NO:111), Asn34-Lys182 (SEQ ID NO:112), Cys97-
His266 (SEQ ID NO:113), Val139-His266 (SEQ ID NO:114), Gly183-His266
(SEQ ID NO:115), Cys97-Cys245 (SEQ ID NO:116), or Val139-Cys245 (SEQ ID
NO:117).

96. The antibody or antibody fragment of Claim 95, wherein the
antibody is a monoclonal antibody.

97. The antibody or antibody fragment of Claim 95, wherein the
antibody is a polyclonal antibody

98. A method of identifying Dkk interacting proteins which modulate the interaction of Dkk with the Wnt signaling pathway comprising:

(a) injecting Dkk and potential Dkk interacting protein mRNA into a *Xenopus* blastomere; and

(b) assessing axis duplication or analyzing marker gene expression; and

(c) identifying compositions which elicit changes in axis duplication or marker gene expression as Dkk interacting proteins which modulate the interaction of Dkk with the Wnt signaling pathway.

99. The method of Claim 98, wherein the mRNA of HBM, LRP5/6, any Wnt, Wnt antagonist, Wnt pathway modulator, or combination of these is co-injected into the *Xenopus* blastomere.

100. The method of Claim 98, wherein the marker gene analyzed is Siamese, Xnr3, slug, Xbra, HNK-1, endodermin, Xlhx8, BMP2, BMP4, XLRP6, EF-1, or ODC.

101. A method for identifying Dkk interacting proteins which modulate the interaction of Dkk with the Wnt signaling pathway comprising:

(a) transfecting cells with constructs containing Dkk and potential Dkk interacting proteins; and

(b) assessing changes in expression of a reporter gene linked to a Wnt-responsive promoter; and

(c) identifying as a Dkk interacting protein any protein which alters reporter gene expression compared with cells transfected with a Dkk construct alone.

102. The method of Claim 101, wherein the cells are HOB-03-CE6, HEK293, or U2OS cells.

103. The method of Claim 101, wherein the Wnt-responsive promoter is TCF or LEF.

104. The method of Claim 101, wherein the cells are co-transfected with CMV β -galactosidase.

105. A method for identifying compounds which modulate Dkk and LRP5/LRP6/HBM interactions comprising:

- (a) immobilizing LRP5/LRP6/HBM to a solid surface; and
- (b) treating the solid surface with a secreted Dkk protein or a secreted epitope-tagged Dkk and a test compound; and
- (c) determining whether the compound regulates binding between Dkk and LRP5/LRP6/HBM using antibodies to Dkk or the epitope tag or by directly measuring activity of an epitope tag.

106. The method of Claim 105, wherein the epitope tag is alkaline phosphatase, histidine, or a V5 tag.

107. A method for identifying compounds which modulate the interaction of Dkk with the Wnt signaling pathway comprising:

- (a) transfecting cells with constructs containing Dkk and Wnt proteins;
- (b) assessing changes in expression of a reporter element linked to a Wnt-responsive promoter; and
- (c) identifying as a Dkk/Wnt interaction modulating compound any compound which alters reporter gene expression compared with cells transfected with a Dkk construct alone.

108. The method according to Claim 107, wherein Wnt3a and Wnt1 constructs are co-transfected into the cells.

109. The method according to Claim 107, wherein the cells are U2-OS, HOB-03-CE6, or HEK293 cells.

5 110. The method according to Claim 107, wherein the reporter element used is TCF-luciferase, tk-Renilla, or a combination thereof.

111. A method of testing compounds that modulate Dkk-mediated activity in a mammal comprising

- 10 (a) providing a group of transgenic animals having (1) a regulatable one or more Dkk genes, (2) a knock-out of Dkk genes, or (3) a knock-in of one or more Dkk genes;
- (b) providing a second group of control animals respectively for the group of transgenic animals in step (a); and
- 15 (c) exposing the transgenic animal group and control animal group to a potential Dkk-modulating compound which modulates bone mass or lipid levels; and
- (d) comparing the transgenic animals and the control group of animals and determining the effect of the compound on bone mass or lipid levels in the transgenic animals as compared to the control animals.

20


112. A method of screening for compounds or compositions which modulate the interaction of Dkk and a Dkk interacting protein comprising:

- (a) exposing a Dkk interacting proteins or a Dkk-binding fragment thereof to a compound; and
- 25 (b) determining whether said compound binds to a Dkk interacting proteins or the Dkk-binding fragment thereof.

113. The method of Claim 112, wherein said modulation is determined by whether said compound binds to the Dkk interacting protein or the Dkk-binding fragment thereof.

5 114. An antibody or antibody fragment which recognizes and binds to a sequence depicted in Figure 3 (SEQ ID NOs:171-188) or Figure 4 (SEQ ID NOs:189-192).

1/30



Model of Wnt signaling

FIG. 1

2/30

Sequence of baits used in Y2H screens

>DKK1 (SEQ ID NO: 168)

AATTCCAACGCTATCAAGAACCTGCCCCACCGCTGGGGCGGCGCTG
CGGGGCACCCAGGCTCTGCAGTCAGCGCCGCGCCGGGAATCCTGTA
CCCGGGCGGGAATAAGTACCAGACCATGACAACCTACCAGCCGTAC
CCGTGCGCAGAGGACGAGGAGTGCGGCACTGATGAGTACTGCGCT
AGTCCCACCCGCGGAGGGGACGCGGGCGTGCAAATCTGTCTCGCCT
GCAGGAAGCGCCGAAAACGCTGCATGCGTCACGCTATGTGCTGCCC
CGGGAATTACTGCAAAAATGGAATATGTGTGTCTTCTGATCAAAAT
CATTTCCGAGGAGAAATTGAGGAAACCATCACTGAAAGCTTTGGTA
ATGATCATAGCACCTTGGATGGGTATTCCAGAAGAACCACCTTGTC
TTCAAAAATGTATCACACCAAAGGACAAGAAGGTTCTGTTTGTCTC
CGGTCATCAGACTGTGCCTCAGGATTGTGTTGTGCTAGACACTTCTG
GTCCAAGATCTGTAAACCTGTCCTGAAAGAAGGTCAAGTGTGTACC
AAGCATAGGAGAAAAGGCTCTCATGGACTAGAAATATTCCAGCGTT
GTTACTGTGGAGAAGGTCTGTCTTGCCGGATACAGAAAGATCACCA
TCAAGCCAGTAATTCTTCTAGGCTTCACACTTGTCAGAGACACTAA

FIG. 2A

3/30

>zmax1 LBD1 (SEQ ID NO: 169)

CTCATCCTGCCCCTGCATGGACTGAGGAACGTCAAAGCCATCGACTAT
GACCCACTGGACAAGTTCATCTACTGGGTGGATGGGCGCCAGAACATC
AAGCGAGCCAAGGACGACGGGACCCAGCCCTTTGTTTTGACCTCTCTG
AGCCAAGGCCAAAACCCAGACAGGCAGCCCCACGACCTCAGCATCGA
CATCTACAGCCGGACACTGTTCTGGACGTGCGAGGGCCACCAATACCAT
CAACGTCCACAGGCTGAGCGGGGAAGCCATGGGGGTGGTGCTGCGTG
GGGACCGCGACAAGCCCAGGGCCATCGTCGTCAACGCGGAGCGAGGG
TACCTGTACTTCACCAACATGCAGGACCGGGCAGCCAAGATCGAACGC
GCAGCCCTGGACGGCACCAGCGCGAGGTCTTCAACCACCGGCCTC
ATCCGCCCTGTGGCCCTGGTGGTAGACAACACACTGGGCAAGCTGTTT
TGGGTGGACGCGGACCTGAAGCGCATTGAGAGCTGTGACCTGTCAGG
GGCCAACCGCCTGACCCTGGAGGACGCCAACATCGTGCAGCCTCTGGG
CCTGACCATCCTTGGCAAGCATCTCTACTGGATCGACCGCCAGCAGCA
GATGATCGAGCGTGTGGAGAAGACCACCGGGGACAAGCGGACTCGCA
TCCAGGGCCGTGTCGCCCACCTCACTGGCATCCATGCAGTGGAGGAAG
TCAGCCTGGAGGAGTTCTCAGCCCACCCATGTGCCCCGTGACAATGGTG
GCTGCTCCACATCTGTATTGCCAAGGGTGATGGGACACCACGGTGCT
CATGCCCAGTCCACCTCGTGCTCCTGCAGAACCTGCTGACCTGTGGAG
AGCCGCCACCTGCTCCCCGGACCAAGTTTGCATGTGCCACAGGGGAGA
TCGACTGTATCCCCGGGGCCTGGCGCTGTGACGGCTTTCCCGAGTGCG
ATGACCAGAGCGACGAGGAGGGCTGCCCCGTGTGCTCCGCCGCCAGT
TCCCCTGCGCGCGGGGTGAGTGTGTGGACCTGCGCCTGCGCTGCGACG
GCGAGGCAGACTGTCAGGACCGCTCAGACGAGGCGGACTGTGACGCC
ATCTGCCTGCCCAACCAGTTCCGGTGTGCGAGCGGCCAGTGTGTCTC
ATCAAACAGCAGTGCGACTCCTTCCCCGACTGTATCGACGGCTCCGAC
GAGCTCATGTGTGAAATCACCAAGCCGCCC

FIG. 2B

4/30

>zmax1 LBD4 (SEQ ID NO: 170)

AGGGCCATCGTCGTCAACGCGGAGCGAGGGTACCTGTACTTCACCAA
CATGCAGGACCGGGCAGCCAAGATCGAACGCGCAGCCCTGGACGGCA
CCGAGCGCGAGGTCCTCTTCACCACCGGCCTCATCCGCCCTGTGGCCC
TGGTGGTAGACAACACACTGGGCAAGCTGTTCTGGGTGGACGCGGAC
CTGAAGCGCATTGAGAGCTGTGACCTGTCAGGGGGCCAACCGCCTGAC
CCTGGAGGACGCCAACATCGTGCAGCCTCTGGGCCTGACCATCCTTGG
CAAGCATCTCTACTGGATCGACCGCCAGCAGCAGATGATCGAGCGTG
TGGAGAAGACCACCGGGGACAAGCGGACTCGCATCCAGGGGCCGTGTC
GCCACCTCACTGGCATCCATGCAGTGGAGGAAGTCAGCCTGGAGGA
GTTCTCAGCCCACCCATGTGCCCCGTGACAATGGTGGCTGCTCCCACAT
CTGTATTGCCAAGGGTGATGGGACACCACGGTGCTCATGCCCAGTCCA
CCTCGTGCTCCTGCAGAACCTGCTGACCTGTGGAGAGCCGCCACCTG
CTCCCCGGACCAAGTTTGCATGTGCCACAGGGGAGATCGACTGTATCCC
CGGGGCCTGGCGCTGTGACGGCTTTCCCGAGTGCGATGACCAGAGCG
ACGAGGAGGGCTGCCCCGTGTGCTCCGCCGCCAGTTCCCCTGCGCGC
GGGGTCAGTGTGTGGACCTGCGCCTGCGCTGCGACGGCGAGGCAGAC
TGTCAGGACCGCTCAGACGAGGCGGACTGTGACGCCATCTGCCTGCC
CAACCAGTTCCGGTGTGCGAGCGGCCAGTGTGTCCTCATAAACAGC
AGTGCGACTCCTTCCCCGACTGTATCGACGGCTCCGACGAGCTCATGT
GTGAAATCACCAAGCCGCCCTAAGCGGCCGC

FIG. 2C

5/30

Screen of DKK1 X
Peptide Library

name	motif	# hits	SEQ ID NO:
252-1	SVGCLLCAGLGVWSLS	3	171
252-2	WCCCGLFRGVCVWSCGAD D	2	172
252-3	GWRRCDWCGCVSWCWV	1	173
252-4	MPGSVSHCWGGICEAL	8	174
252-15	SCCAVDVCLRCGGWFR	1	175
252-16	SVLGTCCCCGGWILCE	2	176
252-17	VLSVCEVCGGVFVRRRC	1	177
252-18	GMWYWWSGRDCALCWL	1	178
252-19	CTAVMWGVGSAVAYLGE	1	179
252-20	WCWWCGCRGVVWR	1	180
252-21	CVCASFCCCVCGLRLL	1	181
252-23	TYEVCEECEGGRVVMWV	6	182
252-25	VVVCASCGQVWHGSGA	2	183
252-26	CCRCCHCWDCEWHMCV	1	184
252-27	FCASCCWCGCDCFGWV	2	185
252-32	CDYCWSCGVWCPSSWL	3	186
252-47	VYLCVWCGAARFGCYG	1	187
252-48	FCVCGCCWCWCAACWC	1	188

FIG. 3

peptide #	peptide seq	# hits	SEQ ID NO:
9	VVLCSRCGRLWRWSCG	1	189
12	EVRQVTCIRCRRGFL	1	190
13	GGGGMWEAWSCYACG	1	191
14	GWRWCGRCGALWWRRV	3	192

FIG. 4

6/30

Gene	Genbank Accession #	Protein Accession #
granulin	M75161	AAA58617
similar to cys/His rich protein	BC004544	AAH04544
IGF-BINDING PROTEIN 6	M69054	AAA88070
latent TGFb binding protein 4	AF051344	AAC39879
NOTCH 2	AF315356	AAG37073
fibulin 1	X53743	CAA37772
MDC15 (ADAM15)	U46005	AAC51112
DKFZp761G02121(notch1 Ca++ binding like)	AL137311	CAB70690
chordin	AF076612	AAC69835
fibronectin 1	U42594	AAD00019
MG50(melanoma associated antigen)	AF200348	AAF06354
unknown (notch 4-like)	AX068260	CAC27245
Slit 1	AB017167	BAA35184
tomoregulin (agarin repeat homology)	AB004064	BAA90820
sprouty 1	AF041037	AAC39566
sprouty 2	AF039843	AAC04258
NOV1	X96584	CAA65403
agrin	AF016903	AAC39776
fibrillin 1	L13923	AAB02036
thrombospondin1	X04665	CAA28370
ADAM19	AF134707	AAF22162
Nafl alpha	AJ011895	CAA09855
laminin alpha 5	Z95636	CAB09137
CRIM1	AF167706	AAF34409
nidogen	M30269	AAA59932
fibulin-2	X82494	CAA57876
thrombospondin 2	L12350	AAA03703
KIAA1323	AB037744	BAA92561
fibrillin-2	U03272	AAA18950
MEGF9	AB011542	BAA32470
integrin beta 1	X07979	CAA30790
matrilin-2 precursor	U69263	AAC51260
tenascin	X56160	A32160

FIG. 5




FIG. 6

8/30

Xenopus Embryo Assay for Wnt Activity




FIG. 7

In the Presence of Wnt5a, HBM1 is More Potent than
Zmax as a Stimulator of Wnt Signaling




FIG. 8

Both Zmax and HBM1, in the presence of Wnt5a, induce secondary axis formation in Xenopus (photos at 48 hrs post-injection)





FIG. 9

11/30

Human Dkk-1 Represses the Canonical Wnt Pathway



- Confirms our human construct is active.
- Reproduces reported dose-response.

FIG. 10

hDkk1 Represses Zmax- but Not HBM1-Mediated Wnt Signaling

scored at 72 hrs post injection.

p<0.05

p<0.001




FIG. 11

Listed are the pcDNA3.1 construct names followed by the DNA sequence
OST258 (control for OST 259-OST262 and OST264,OST265)

AAGCTTGCCACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTTCCACTGGTGACGG
ATCC

OST259 (SEQ ID NO: 193)

AAGCTTGCCACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTTCCACTGGTGACGG
ATCCATGAGCGATAAAATTATTACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGGGGCGATCC
TCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGAATTCGGTGGTCTGTGTTTCGCGTTGTGGGCGTTTGTGGCGGTGG
TCGTGTGGGACTAGTGGTCCGTGCAAAATGATCGCCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAAC
GACCGTTGCAAACTGAACATCGATCAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTATCCCGACTCTGC
TGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGTGCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGAC
GCTAACCTGGCGTAAGCGGCCGC

OST260 (SEQ ID NO: 194)

AAGCTTGCCACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTTCCACTGGTGACGG
ATCCATGAGCGATAAAATTATTACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGGGGCGATCC
TCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGAATTCGGGTGGCGGTGGTGTGGTTCGGTGTGGGGCTTTGTGGTGG
CGCGTGTACTAGTGGTCCGTGCAAAATGATCGCCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAAC
GACCGTTGCAAACTGAACATCGATCAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTATCCCGACTCTGC
TGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGTGCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGAC
GCTAACCTGGCGTAAGCGGCCGC

OST261 (SEQ ID NO: 195)

AAGCTTGCCACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTTCCACTGGTGACGG
ATCCATGAGCGATAAAATTATTACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGGGGCGATCC
TCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGAATTCGGGTGGCGGTGGTGTGGTTCGGTGTGGGGCTTTGTGGTGG
TTTCTGTTGACTAGTGGTCCGTGCAAAATGATCGCCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAAC
GACCGTTGCAAACTGAACATCGATCAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTATCCCGACTCTGC
TGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGTGCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGAC
GCTAACCTGGCGTAAGCGGCCGC

OST262 (SEQ ID NO: 196)

AAGCTTGCCACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTTCCACTGGTGACGG
ATCCATGAGCGATAAAATTATTACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGGGGCGATCC
TCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGAATTCGGTGGTGGGGGGATGATTTGGGAGGCTTGGAGTTGTTAT
GCGTGTGGGACTAGTGGTCCGTGCAAAATGATCGCCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAAC
GACCGTTGCAAACTGAACATCGATCAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTATCCCGACTCTGC
TGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGTGCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGAC
GCTAACCTGGCGTAAGCGGCCGC

OST263 (SEQ ID NO: 197)

AAGCTTGCCACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTTCCACTGGTGACGG
ATCCATGAGCGATAAAATTATTACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGGGGCGATCC
TCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGAATTCCTGTGGATTGGGCCGGTGATCAGGCTCTGTTTCGGCGT
TTTGTTTTTACTAGTGGTCCGTGCAAAATGATCGCCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAAC
GACCGTTGCAAACTGAACATCGATCAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTATCCCGACTCTGC
TGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAAGTGGGTGCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGAC
GCTAACCTGGCGTAAGCGGCCGC

FIGURE 12A

OST264 (SEQ ID NO: 198)

AAGCTTGCCACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTCCAGGTTCCACTGGTGACGG
ATCCGTGTCTTCTGATCAAAATCATTTCCGAGGAGAAATTGAGGAAACCATCACTGAAAGCTTTGGTAATGATCATA
GCACCTTGGATGGGTATTCCAGAAAGAACACCTTGTCTTCAAAAATGTATCACACCAAGGACAAGAAGGTTCTGTT
TGTCTCCGGTCACTCAGACTGTGCCCTCAGGATTGTGTTGTGCTAGACACTTCTGGTCCAAGATCTGTAAACCTGTCT
GAAAGAAGGTCAAGTGTGTACCAAGCATAGGAGAAAAGGCTCTCATGGACTAGAAATATTCCAGCGTTGTTACTGTG
GAGAAGGTCTGTCTGCCGGATACAGAAAGATCACCATCAAGCCAGTAATTCTTCTAGGCTTCACACTTGTGAGAGA
CACTAAGCGGCEGC

OST265 (SEQ ID NO: 199)

AAGCTTGCCACCATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTCCAGGTTCCACTGGTGACGG
ATCCTGCGCTAGTCCCACCCGCGAGGGGACGCGGGCGTGCAAAATCTGTCTCGCCTGCAGGAAGCGCGGAAAACGCT
GCATGCGTCACGCTATGTGCTGCCCGGGAATTACTGCAAAAATGGAATATGTGTGCTTCTGATCAAAATCATTTTC
CGAGGAGAAATTGAGGAAACCATCACTGAAAGCTTTGGTAATGATCATAGCACCTTGGATGGGTATTCCAGAAGAAC
CACCTTGTCTTCAAAAATGTATCACACCAAGGACAAGAAGGTTCTGTTTGTCTCCGGTCACTCAGACTGTGCCTCAG
GATTGTGTTGTGCTAGACACTTCTGGTCCAAGATCTGTAAACCTGTCTGAAAGGAGGTCAAGTGTGTACCAAGCAT
AGGAGAAAAGGCTCTCATGGACTAGAAATATTCCAGCGTTGTTACTGTGGAGAAGGTCTGTCTTGCTAAGCGGCCGC

OST266 (SEQ ID NO: 200)

AAGCTTGCCACCATGGGCGATAAAATTATTACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGG
GGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGAATTCCTATGCGTGGTTGTTTTCTGTAGTAGGTGTA
GGTGGTGGTTGCTTGGACTAGTGGTCCGTGCAAAATGATCGCCCCGATTCTGGATGAAATCGCTGACGAATATCAG
GGCAAACTGACCGTTGCAAACTGAACATCGATCAAAACCTGGCACTGCGCCGAAATATGGCATCCGTGGTATCCC
GACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAGTGGGTGCACTGTCTAAAGGTCAGTTGAAAGAGT
TCCTCGACGCTAACCTGGCGTAAGCGGCCGC

OST267 (SEQ ID NO: 201)

AAGCTTGCCACCATGGGCGATAAAATTATTACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGG
GGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGAATTCCTATGCGTGGTTGTTTTCTGTAGTAGGTGTA
ATCCTTGGTCTTGGGTGACTAGTGGTCCGTGCAAAATGATCGCCCCGATTCTGGATGAAATCGCTGACGAATATCAG
GGCAAACTGACCGTTGCAAACTGAACATCGATCAAAACCTGGCACTGCGCCGAAATATGGCATCCGTGGTATCCC
GACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAGTGGGTGCACTGTCTAAAGGTCAGTTGAAAGAGT
TCCTCGACGCTAACCTGGCGTAAGCGGCCGC

OST268 (SEQ ID NO: 202)

AAGCTTGCCACCATGGGCGATAAAATTATTACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGG
GGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGAATTCGGTTGTACTAGTGCGGTGTGTGGTGCTTGGG
CTGAGGCGGGTAGGTTTTATTGTACTAGTGGTCCGTGCAAAATGATCGCCCCGATTCTGGATGAAATCGCTGACGAA
TATCAGGGCAAACCTGACCGTTGCAAACTGAACATCGATCAAAACCTGGCACTGCGCCGAAATATGGCATCCGTGG
TATCCGACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAGTGGGTGCACTGTCTAAAGGTCAGTTGA
AAGAGTTCTCTGACGCTAACCTGGCGTAAGCGGCCGC

OST269 (SEQ ID NO: 203)

(irrelevant control peptide for OST266-OST268)

AAGCTTGCCACCATGGGCGATAAAATTATTACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGG
GGCGATCCTCGTCGATTTCTGGGCAGAGTGGTGCGGTCCGAATTCCTTGTGGATTGGGCGGGGTGATCAGGGTCTGT
TTCGGCGTTTTGTTTTTACTAGTGGTCCGTGCAAAATGATCGCCCCGATTCTGGATGAAATCGCTGACGAATATCAG
GGCAAACTGACCGTTGCAAACTGAACATCGATCAAAACCTGGCACTGCGCCGAAATATGGCATCCGTGGTATCCC
GACTCTGCTGCTGTTCAAAAACGGTGAAGTGGCGGCAACCAAGTGGGTGCACTGTCTAAAGGTCAGTTGAAAGAGT
TCCTCGACGCTAACCTGGCGTAAGCGGCCGC

FIGURE 12B

Listed below are the amino acid sequences corresponding to the pcDNA3.1 constructs in Appendix 1A

OST258

METDTLLLWVLLLVPGSTGDGS

OST259 (SEQ ID NO: 204)

METDTLLLWVLLLVPGSTGDGSMDSKIIHLTDDSFDTDLVKADGAILVDFWAEWCGPNSVVLCSRCGRLLWRWSCGT
SGPCKMIAPILDEIADEYQGKLTVAKLNIQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQLKEFLDANLA

OST260 (SEQ ID NO: 205)

METDTLLLWVLLLVPGSTGDGSMDSKIIHLTDDSFDTDLVKADGAILVDFWAEWCGPNSGWRNCGRCGALWWRVT
SGPCKMIAPILDEIADEYQGKLTVAKLNIQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQLKEFLDANLA

OST261 (SEQ ID NO: 206)

METDTLLLWVLLLVPGSTGDGSMDSKIIHLTDDSFDTDLVKADGAILVDFWAEWCGPNSEVRQVTCIRCRRGFLLT
SGPCKMIAPILDEIADEYQGKLTVAKLNIQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQLKEFLDANLA

OST262 (SEQ ID NO: 207)

METDTLLLWVLLLVPGSTGDGSMDSKIIHLTDDSFDTDLVKADGAILVDFWAEWCGPNSGGGGMIWEAWSYACGT
SGPCKMIAPILDEIADEYQGKLTVAKLNIQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQLKEFLDANLA

OST263 (SEQ ID NO: 208)

METDTLLLWVLLLVPGSTGDGSMDSKIIHLTDDSFDTDLVKADGAILVDFWAEWCGPNSLWIGPGDQGLFRRFVFT
SGPCKMIAPILDEIADEYQGKLTVAKLNIQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQLKEFLDANLA

OST264 (SEQ ID NO: 209)

METDTLLLWVLLLVPGSTGDGSVSSDQNHFRGEIEETITESFGNDHSTLDGYSRRTTLSSKMYHTKGQEGSVCLRS
SDCASGLCCARHFWSKICKPVLKEGQVCTKHRRKGSHGLEIFQRCYCGEGLSCRIQKDHQASNSSRLHTCQRH

OST265 (SEQ ID NO: 210)

METDTLLLWVLLLVPGSTGDGSCASPTRGGDAGVQICLACRKRKRRCMRHAMCCPGNYCKNGICVSSDQNHFRGEI
EETITESFGNDHSTLDGYSRRTTLSSKMYHTKGQEGSVCLRSSDCASGLCCARHFWSKICKPVLKEGQVCTKHRRKG
SHGLEI
FQRCYCGEGLSC.

OST266 (SEQ ID NO: 211)

MGDKIIHLTDDSFDTDLVKADGAILVDFWAEWCGPNSYAWLFSCSRCRWLPTWISGPCKMIAPILDEIADEYQGKLT
VAKLNIQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQLKEFLDANLA

OST267 (SEQ ID NO: 212)

MGDKIIHLTDDSFDTDLVKADGAILVDFWAEWCGPNSICEVRLWSRYFWSWVTSGPCKMIAPILDEIADEYQGKLT
VAKLNIQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQLKEFLDANLA

OST268 (SEQ ID NO: 213)

MGDKIIHLTDDSFDTDLVKADGAILVDFWAEWCGPNSGCTSAVCGAWAEAGRFYCTSGPCKMIAPILDEIADEYQGK
LTVAKLNIQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQLKEFLDANLA

OST269 (SEQ ID NO: 214)

MGDKIIHLTDDSFDTDLVKADGAILVDFWAEWCGPNSLWIGPGDQGLFRRFVFTSGPCKMIAPILDEIADEYQGKLT
VAKLNIQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQLKEFLDANLA

FIGURE 13

Effect of Dkks on Wnt1 signaling
with Coreceptors LRP5, HBM or LRP6
HOB03CE6 Cells




FIG. 14

Effect of Dkks on Wnt3a Signaling
with Coreceptors LRP5, HBM or LRP6
HOB03CE6 Cells




FIG. 15

LRP5-LBD Peptide Aptamer 262 Activates Wnt
Signaling in the presence of Wnt3a






FIG. 16

FIG. 17
Affinity Purified 69546/47



Antibody to: aa 165-177 (Mutation)

EGY188 strain, 1 LexAop:LacZ reporter



- A mutant DKK1, C220A, unable to bind to LRP5, was cloned in GalAD and B42 and tested for its ability to bind to LBD in Y2H
- Interaction LBD-DKK1 20 fold above background
- Interaction LBD-DKK1 C220A 2 to 3 fold above background
- Interaction LBD-DKK1 10 fold above LBD-DKK1 C220A mutant

FIG. 18

Dkk1 Represses Wnt3a-Mediated Wnt Signaling in U2-OS Bone Cells





FIG. 20

Wnt1 - HBM generated TCF-luci is not efficiently inhibited by Dkk1 in U2-OS bone cells.



- With Wnt1 the TCF-signal generated by LRP5 is greater than that of LRP6.
- LRP5/6 -Wnt1 induced TCF- is efficiently blocked byDkk1

In U2-OS cells TCF-signal can be modulated by Dkk1, Dkk1-AP,
without Wnt DNA transfection.




FIG. 21

FIG. 22

Aptamers 261 and 262 from the LRP5-LBD Activate Wnt Signaling in *Xenopus*



263 - Negative Control



261 - LBD-Binding Peptide



262 - LBD-Binding Peptide





262 - LBD-Binding Peptide

FIG. 23

LRP5 Peptide Aptamers 261 and 262

Induce Wnt Signaling






• G171F mutation involves the ringed R group (F) alteration and leads to marginally greater TCF-luc activation than that with HBM1 mutation G171V.

FIG. 24

LRP5-blade1 Mutant M282V leads to HBM1 type TCF-signal
with Wnt1 and Dkk1 in U2-OS cells



- In blade 1, propeller 1, M282 is at the accessible interior position.
- It is conserved in propellers 1-3

FIG. 25

DKK1 Protein
Polyclonal Antibodies



* Sigma/Genosys
† ResGen

FIG. 26




FIG. 27B




FIG. 27A




FIG. 28

032796-132.ST25

SEQUENCE LISTING

<110> Allen, Kristina M.
 Anisowicz, Anthony
 Bhat, Bheem
 Damagnez, Veronique
 Robinson, John
 Yaworsky, Paul

<120> Reagents and Method for Modulating DKK-Mediated Interactions

<130> 032796-132

<150> US 60/291,311

<151> 2001-05-17

<150> US 60/353,058

<151> 2002-02-01

<150> US 60/361,293

<151> 2002-03-04

<160> 214

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 5120

<212> DNA

<213> Homo sapiens

<400> 1

```

actaaagcgc cgccgccgcg ccatggagcc cgagtgcgcg cggcgcgggc ccgtccggcc      60
gccggacaac  atg gag gca gcg ccg ccc ggg ccg ccg tgg ccg ctg ctg      109
              Met Glu Ala Ala Pro Pro Gly Pro Pro Trp Pro Leu Leu
              1          5          10
ctg ctg ctg ctg ctg ctg ctg gcg ctg tgc ggc tgc ccg gcc ccc gcc      157
Leu Leu Leu Leu Leu Leu Leu Ala Leu Cys Gly Cys Pro Ala Pro Ala
15          20          25
gcg gcc tcg ccg ctc ctg cta ttt gcc aac cgc cgg gac gta cgg ctg      205
Ala Ala Ser Pro Leu Leu Leu Phe Ala Asn Arg Arg Asp Val Arg Leu
30          35          40          45
gtg gac gcc ggc gga gtc aag ctg gag tcc acc atc gtg gtc agc ggc      253
Val Asp Ala Gly Gly Val Lys Leu Glu Ser Thr Ile Val Val Ser Gly
50          55          60
ctg gag gat gcg gcc gca gtg gac ttc cag ttt tcc aag gga gcc gtg      301
Leu Glu Asp Ala Ala Ala Val Asp Phe Gln Phe Ser Lys Gly Ala Val
65          70          75
tac tgg aca gac gtg agc gag gag gcc atc aag cag acc tac ctg aac      349
Tyr Trp Thr Asp Val Ser Glu Glu Ala Ile Lys Gln Thr Tyr Leu Asn
80          85          90
cag acg ggg gcc gcc gtg cag aac gtg gtc atc tcc ggc ctg gtc tct      397

```

032796-132.ST25

Gln	Thr	Gly	Ala	Ala	Val	Gln	Asn	Val	Val	Ile	Ser	Gly	Leu	Val	Ser		
95						100					105						
ccc	gac	ggc	ctc	gcc	tgc	gac	tgg	gtg	ggc	aag	aag	ctg	tac	tgg	acg		445
Pro	Asp	Gly	Leu	Ala	Cys	Asp	Trp	Val	Gly	Lys	Lys	Leu	Tyr	Trp	Thr		
110					115					120					125		
gac	tca	gag	acc	aac	cgc	atc	gag	gtg	gcc	aac	ctc	aat	ggc	aca	tcc		493
Asp	Ser	Glu	Thr	Asn	Arg	Ile	Glu	Val	Ala	Asn	Leu	Asn	Gly	Thr	Ser		
				130					135					140			
cgg	aag	gtg	ctc	ttc	tgg	cag	gac	ctt	gac	cag	ccg	agg	gcc	atc	gcc		541
Arg	Lys	Val	Leu	Phe	Trp	Gln	Asp	Leu	Asp	Gln	Pro	Arg	Ala	Ile	Ala		
			145					150					155				
ttg	gac	ccc	gct	cac	ggg	tac	atg	tac	tgg	aca	gac	tgg	ggt	gag	acg		589
Leu	Asp	Pro	Ala	His	Gly	Tyr	Met	Tyr	Trp	Thr	Asp	Trp	Gly	Glu	Thr		
		160					165					170					
ccc	cgg	att	gag	cgg	gca	ggg	atg	gat	ggc	agc	acc	cgg	aag	atc	att		637
Pro	Arg	Ile	Glu	Arg	Ala	Gly	Met	Asp	Gly	Ser	Thr	Arg	Lys	Ile	Ile		
		175					180					185					
gtg	gac	tcg	gac	att	tac	tgg	ccc	aat	gga	ctg	acc	atc	gac	ctg	gag		685
Val	Asp	Ser	Asp	Ile	Tyr	Trp	Pro	Asn	Gly	Leu	Thr	Ile	Asp	Leu	Glu		
				195					200						205		
gag	cag	aag	ctc	tac	tgg	gct	gac	gcc	aag	ctc	agc	ttc	atc	cac	cgt		733
Glu	Gln	Lys	Leu	Tyr	Trp	Ala	Asp	Ala	Lys	Leu	Ser	Phe	Ile	His	Arg		
			210					215					220				
gcc	aac	ctg	gac	ggc	tcg	ttc	cgg	cag	aag	gtg	gtg	gag	ggc	agc	ctg		781
Ala	Asn	Leu	Asp	Gly	Ser	Phe	Arg	Gln	Lys	Val	Val	Glu	Gly	Ser	Leu		
			225				230						235				
acg	cac	ccc	ttc	gcc	ctg	acg	ctc	tcc	ggg	gac	act	ctg	tac	tgg	aca		829
Thr	His	Pro	Phe	Ala	Leu	Thr	Leu	Ser	Gly	Asp	Thr	Leu	Tyr	Trp	Thr		
		240					245					250					
gac	tgg	cag	acc	cgc	tcc	atc	cat	gcc	tgc	aac	aag	cgc	act	ggg	ggg		877
Asp	Trp	Gln	Thr	Arg	Ser	Ile	His	Ala	Cys	Asn	Lys	Arg	Thr	Gly	Gly		
		255				260					265						
aag	agg	aag	gag	atc	ctg	agt	gcc	ctc	tac	tca	ccc	atg	gac	atc	cag		925
Lys	Arg	Lys	Glu	Ile	Leu	Ser	Ala	Leu	Tyr	Ser	Pro	Met	Asp	Ile	Gln		
				275						280					285		
gtg	ctg	agc	cag	gag	cgg	cag	cct	ttc	ttc	cac	act	cgc	tgt	gag	gag		973
Val	Leu	Ser	Gln	Glu	Arg	Gln	Pro	Phe	Phe	His	Thr	Arg	Cys	Glu	Glu		
			290						295					300			
gac	aat	ggc	ggc	tgc	tcc	cac	ctg	tgc	ctg	ctg	tcc	cca	agc	gag	cct		1021
Asp	Asn	Gly	Gly	Cys	Ser	His	Leu	Cys	Leu	Leu	Ser	Pro	Ser	Glu	Pro		
			305					310					315				
ttc	tac	aca	tgc	gcc	tgc	ccc	acg	ggt	gtg	cag	ctg	cag	gac	aac	ggc		1069
Phe	Tyr	Thr	Cys	Ala	Cys	Pro	Thr	Gly	Val	Gln	Leu	Gln	Asp	Asn	Gly		
		320					325					330					
agg	acg	tgt	aag	gca	gga	gcc	gag	gag	gtg	ctg	ctg	ctg	gcc	cgg	cgg		1117
Arg	Thr	Cys	Lys	Ala	Gly	Ala	Glu	Glu	Val	Leu	Leu	Leu	Ala	Arg	Arg		
		335				340					345						
acg	gac	cta	cgg	agg	atc	tcg	ctg	gac	acg	ccg	gac	ttc	acc	gac	atc		1165
Thr	Asp	Leu	Arg	Arg	Ile	Ser	Leu	Asp	Thr	Pro	Asp	Phe	Thr	Asp	Ile		
		350			355					360					365		
gtg	ctg	cag	gtg	gac	gac	atc	cgg	cac	gcc	att	gcc	atc	gac	tac	gac		1213
Val	Leu	Gln	Val	Asp	Asp	Ile	Arg	His	Ala	Ile	Ala	Ile	Asp	Tyr	Asp		
			370						375					380			
ccg	cta	gag	ggc	tat	gtc	tac	tgg	aca	gat	gac	gag	gtg	cgg	gcc	atc		1261
Pro	Leu	Glu	Gly	Tyr	Val	Tyr	Trp	Thr	Asp	Asp	Glu	Val	Arg	Ala	Ile		
			385					390					395				
cgc	agg	gcg	tac	ctg	gac	ggg	tct	ggg	gcg	cag	acg	ctg	gtc	aac	acc		1309

032796-132.ST25

Arg	Arg	Ala	Tyr	Leu	Asp	Gly	Ser	Gly	Ala	Gln	Thr	Leu	Val	Asn	Thr		
		400					405					410					
gag	atc	aac	gac	ccc	gat	ggc	atc	gcg	gtc	gac	tgg	gtg	gcc	cga	aac	1357	
Glu	Ile	Asn	Asp	Pro	Asp	Gly	Ile	Ala	Val	Asp	Trp	Val	Ala	Arg	Asn		
		415				420					425						
ctc	tac	tgg	acc	gac	acg	ggc	acg	gac	cgc	atc	gag	gtg	acg	cgc	ctc	1405	
Leu	Tyr	Trp	Thr	Asp	Thr	Gly	Thr	Asp	Arg	Ile	Glu	Val	Thr	Arg	Leu		
		430			435					440					445		
aac	ggc	acc	tcc	cgc	aag	atc	ctg	gtg	tcg	gag	gac	ctg	gac	gag	ccc	1453	
Asn	Gly	Thr	Ser	Arg	Lys	Ile	Leu	Val	Ser	Glu	Asp	Leu	Asp	Glu	Pro		
				450					455					460			
cga	gcc	atc	gca	ctg	cac	ccc	gtg	atg	ggc	ctc	atg	tac	tgg	aca	gac	1501	
Arg	Ala	Ile	Ala	Leu	His	Pro	Val	Met	Gly	Leu	Met	Tyr	Trp	Thr	Asp		
			465				470						475				
tgg	gga	gag	aac	cct	aaa	atc	gag	tgt	gcc	aac	ttg	gat	ggg	cag	gag	1549	
Trp	Gly	Glu	Asn	Pro	Lys	Ile	Glu	Cys	Ala	Asn	Leu	Asp	Gly	Gln	Glu		
		480				485					490						
cgg	cgt	gtg	ctg	gtc	aat	gcc	tcc	ctc	ggg	tgg	ccc	aac	ggc	ctg	gcc	1597	
Arg	Arg	Val	Leu	Val	Asn	Ala	Ser	Leu	Gly	Trp	Pro	Asn	Gly	Leu	Ala		
		495			500						505						
ctg	gac	ctg	cag	gag	ggg	aag	ctc	tac	tgg	gga	gac	gcc	aag	aca	gac	1645	
Leu	Asp	Leu	Gln	Glu	Gly	Lys	Leu	Tyr	Trp	Gly	Asp	Ala	Lys	Thr	Asp		
		510			515				520						525		
aag	atc	gag	gtg	atc	aat	gtt	gat	ggg	acg	aag	agg	cgg	acc	ctc	ctg	1693	
Lys	Ile	Glu	Val	Ile	Asn	Val	Asp	Gly	Thr	Lys	Arg	Arg	Thr	Leu	Leu		
				530				535						540			
gag	gac	aag	ctc	ccg	cac	att	ttc	ggg	ttc	acg	ctg	ctg	ggg	gac	ttc	1741	
Glu	Asp	Lys	Leu	Pro	His	Ile	Phe	Gly	Phe	Thr	Leu	Leu	Gly	Asp	Phe		
			545				550						555				
atc	tac	tgg	act	gac	tgg	cag	cgc	cgc	agc	atc	gag	cgg	gtg	cac	aag	1789	
Ile	Tyr	Trp	Thr	Asp	Trp	Gln	Arg	Arg	Ser	Ile	Glu	Arg	Val	His	Lys		
		560				565					570						
gtc	aag	gcc	agc	cgg	gac	gtc	atc	att	gac	cag	ctg	ccc	gac	ctg	atg	1837	
Val	Lys	Ala	Ser	Arg	Asp	Val	Ile	Ile	Asp	Gln	Leu	Pro	Asp	Leu	Met		
		575			580						585						
ggg	ctc	aaa	gct	gtg	aat	gtg	gcc	aag	gtc	gtc	gga	acc	aac	ccg	tgt	1885	
Gly	Leu	Lys	Ala	Val	Asn	Val	Ala	Lys	Val	Val	Gly	Thr	Asn	Pro	Cys		
		590			595				600					605			
gcg	gac	agg	aac	ggg	ggg	tgc	agc	cac	ctg	tgc	ttc	ttc	aca	ccc	cac	1933	
Ala	Asp	Arg	Asn	Gly	Gly	Cys	Ser	His	Leu	Cys	Phe	Phe	Thr	Pro	His		
			610					615						620			
gca	acc	cgg	tgt	ggc	tgc	ccc	atc	ggc	ctg	gag	ctg	ctg	agt	gac	atg	1981	
Ala	Thr	Arg	Cys	Gly	Cys	Pro	Ile	Gly	Leu	Glu	Leu	Leu	Ser	Asp	Met		
			625				630						635				
aag	acc	tgc	atc	gtg	cct	gag	gcc	ttc	ttg	gtc	ttc	acc	agc	aga	gcc	2029	
Lys	Thr	Cys	Ile	Val	Pro	Glu	Ala	Phe	Leu	Val	Phe	Thr	Ser	Arg	Ala		
		640				645						650					
gcc	atc	cac	agg	atc	tcc	ctc	gag	acc	aat	aac	aac	gac	gtg	gcc	atc	2077	
Ala	Ile	His	Arg	Ile	Ser	Leu	Glu	Thr	Asn	Asn	Asn	Asp	Val	Ala	Ile		
		655			660						665						
ccg	ctc	acg	ggc	gtc	aag	gag	gcc	tca	gcc	ctg	gac	ttt	gat	gtg	tcc	2125	
Pro	Leu	Thr	Gly	Val	Lys	Glu	Ala	Ser	Ala	Leu	Asp	Phe	Asp	Val	Ser		
		670			675					680					685		
aac	aac	cac	atc	tac	tgg	aca	gac	gtc	agc	ctg	aag	acc	atc	agc	cgc	2173	
Asn	Asn	His	Ile	Tyr	Trp	Thr	Asp	Val	Ser	Leu	Lys	Thr	Ile	Ser	Arg		
			690					695					700				
gcc	ttc	atg	aac	ggg	agc	tcg	gtg	gag	cac	gtg	gtg	gag	ttt	ggc	ctt	2221	

032796-132.ST25

Ala	Phe	Met	Asn	Gly	Ser	Ser	Val	Glu	His	Val	Val	Glu	Phe	Gly	Leu	
			705					710					715			
gac	tac	ccc	gag	ggc	atg	gcc	gtt	gac	tgg	atg	ggc	aag	aac	ctc	tac	2269
Asp	Tyr	Pro	Glu	Gly	Met	Ala	Val	Asp	Trp	Met	Gly	Lys	Asn	Leu	Tyr	
			720					725					730			
tgg	gcc	gac	act	ggg	acc	aac	aga	atc	gaa	gtg	gcg	cgg	ctg	gac	ggg	2317
Trp	Ala	Asp	Thr	Gly	Thr	Asn	Arg	Ile	Glu	Val	Ala	Arg	Leu	Asp	Gly	
			735				740					745				
cag	ttc	cgg	caa	gtc	ctc	gtg	tgg	agg	gac	ttg	gac	aac	ccg	agg	tcg	2365
Gln	Phe	Arg	Gln	Val	Leu	Val	Trp	Arg	Asp	Leu	Asp	Asn	Pro	Arg	Ser	
							755				760				765	
ctg	gcc	ctg	gat	ccc	acc	aag	ggc	tac	atc	tac	tgg	acc	gag	tgg	ggc	2413
Leu	Ala	Leu	Asp	Pro	Thr	Lys	Gly	Tyr	Ile	Tyr	Trp	Thr	Glu	Trp	Gly	
							770								780	
ggc	aag	ccg	agg	atc	gtg	cgg	gcc	ttc	atg	gac	ggg	acc	aac	tgc	atg	2461
Gly	Lys	Pro	Arg	Ile	Val	Arg	Ala	Phe	Met	Asp	Gly	Thr	Asn	Cys	Met	
								790							795	
acg	ctg	gtg	gac	aag	gtg	ggc	cgg	gcc	aac	gac	ctc	acc	att	gac	tac	2509
Thr	Leu	Val	Asp	Lys	Val	Gly	Arg	Ala	Asn	Asp	Leu	Thr	Ile	Asp	Tyr	
							805								810	
gct	gac	cag	cgc	ctc	tac	tgg	acc	gac	ctg	gac	acc	aac	atg	atc	gag	2557
Ala	Asp	Gln	Arg	Leu	Tyr	Trp	Thr	Asp	Leu	Asp	Thr	Asn	Met	Ile	Glu	
							820								825	
tcg	tcc	aac	atg	ctg	ggt	cag	gag	cgg	gtc	gtg	att	gcc	gac	gat	ctc	2605
Ser	Ser	Asn	Met	Leu	Gly	Gln	Glu	Arg	Val	Val	Ile	Ala	Asp	Asp	Leu	
							835								845	
ccg	cac	ccg	ttc	ggt	ctg	acg	cag	tac	agc	gat	tat	atc	tac	tgg	aca	2653
Pro	His	Pro	Phe	Gly	Leu	Thr	Gln	Tyr	Ser	Asp	Tyr	Ile	Tyr	Trp	Thr	
							850								860	
gac	tgg	aat	ctg	cac	agc	att	gag	cgg	gcc	gac	aag	act	agc	ggc	cgg	2701
Asp	Trp	Asn	Leu	His	Ser	Ile	Glu	Arg	Ala	Asp	Lys	Thr	Ser	Gly	Arg	
								870							875	
aac	cgc	acc	ctc	atc	cag	ggc	cac	ctg	gac	ttc	gtg	atg	gac	atc	ctg	2749
Asn	Arg	Thr	Leu	Ile	Gln	Gly	His	Leu	Asp	Phe	Val	Met	Asp	Ile	Leu	
								885							890	
gtg	ttc	cac	tcc	tcc	cgc	cag	gat	ggc	ctc	aat	gac	tgt	atg	cac	aac	2797
Val	Phe	His	Ser	Ser	Arg	Gln	Asp	Gly	Leu	Asn	Asp	Cys	Met	His	Asn	
							900								905	
aac	ggg	cag	tgt	ggg	cag	ctg	tgc	ctt	gcc	atc	ccc	ggc	ggc	cac	cgc	2845
Asn	Gly	Gln	Cys	Gly	Gln	Leu	Cys	Leu	Ala	Ile	Pro	Gly	Gly	His	Arg	
							915								925	
tgc	ggc	tgc	gcc	tca	cac	tac	acc	ctg	gac	ccc	agc	agc	cgc	aac	tgc	2893
Cys	Gly	Cys	Ala	Ser	His	Tyr	Thr	Leu	Asp	Pro	Ser	Ser	Arg	Asn	Cys	
							930								940	
agc	ccg	ccc	acc	acc	ttc	ttg	ctg	ttc	agc	cag	aaa	tct	gcc	atc	agt	2941
Ser	Pro	Pro	Thr	Thr	Phe	Leu	Leu	Phe	Ser	Gln	Lys	Ser	Ala	Ile	Ser	
								950							955	
cgg	atg	atc	ccg	gac	gac	cag	cac	agc	ccg	gat	ctc	atc	ctg	ccc	ctg	2989
Arg	Met	Ile	Pro	Asp	Asp	Gln	His	Ser	Pro	Asp	Leu	Ile	Leu	Pro	Leu	
								965							970	
cat	gga	ctg	agg	aac	gtc	aaa	gcc	atc	gac	tat	gac	cca	ctg	gac	aag	3037
His	Gly	Leu	Arg	Asn	Val	Lys	Ala	Ile	Asp	Tyr	Asp	Pro	Leu	Asp	Lys	
								980							985	
ttc	atc	tac	tgg	gtg	gat	ggg	cgc	cag	aac	atc	aag	cga	gcc	aag	gac	3085
Phe	Ile	Tyr	Trp	Val	Asp	Gly	Arg	Gln	Asn	Ile	Lys	Arg	Ala	Lys	Asp	
							995				1000				1005	
gac	ggg	acc	cag	ccc	ttt	gtt	ttg	acc	tct	ctg	agc	caa	ggc	caa	aac	3133

032796-132.ST25

Asp Gly Thr Gln Pro Phe Val Leu Thr Ser Leu Ser Gln Gly Gln Asn	
1010 1015 1020	
cca gac agg cag ccc cac gac ctc agc atc gac atc tac agc cgg aca	3181
Pro Asp Arg Gln Pro His Asp Leu Ser Ile Asp Ile Tyr Ser Arg Thr	
1025 1030 1035	
ctg ttc tgg acg tgc gag gcc acc aat acc atc aac gtc cac agg ctg	3229
Leu Phe Trp Thr Cys Glu Ala Thr Asn Thr Ile Asn Val His Arg Leu	
1040 1045 1050	
agc ggg gaa gcc atg ggg gtg gtg ctg cgt ggg gac cgc gac aag ccc	3277
Ser Gly Glu Ala Met Gly Val Val Leu Arg Gly Asp Arg Asp Lys Pro	
1055 1060 1065	
agg gcc atc gtc gtc aac gcg gag cga ggg tac ctg tac ttc acc aac	3325
Arg Ala Ile Val Val Asn Ala Glu Arg Gly Tyr Leu Tyr Phe Thr Asn	
1070 1075 1080 1085	
atg cag gac cgg gca gcc aag atc gaa cgc gca gcc ctg gac ggc acc	3373
Met Gln Asp Arg Ala Ala Lys Ile Glu Arg Ala Ala Leu Asp Gly Thr	
1090 1095 1100	
gag cgc gag gtc ctc ttc acc acc ggc ctc atc cgc cct gtg gcc ctg	3421
Glu Arg Glu Val Leu Phe Thr Thr Gly Leu Ile Arg Pro Val Ala Leu	
1105 1110 1115	
gtg gtg gac aac aca ctg ggc aag ctg ttc tgg gtg gac gcg gac ctg	3469
Val Val Asp Asn Thr Leu Gly Lys Leu Phe Trp Val Asp Ala Asp Leu	
1120 1125 1130	
aag cgc att gag agc tgt gac ctg tca ggg gcc aac cgc ctg acc ctg	3517
Lys Arg Ile Glu Ser Cys Asp Leu Ser Gly Ala Asn Arg Leu Thr Leu	
1135 1140 1145	
gag gac gcc aac atc gtg cag cct ctg ggc ctg acc atc ctt ggc aag	3565
Glu Asp Ala Asn Ile Val Gln Pro Leu Gly Leu Thr Ile Leu Gly Lys	
1150 1155 1160 1165	
cat ctc tac tgg atc gac cgc cag cag cag atg atc gag cgt gtg gag	3613
His Leu Tyr Trp Ile Asp Arg Gln Gln Gln Met Ile Glu Arg Val Glu	
1170 1175 1180	
aag acc acc ggg gac aag cgg act cgc atc cag ggc cgt gtc gcc cac	3661
Lys Thr Thr Gly Asp Lys Arg Thr Arg Ile Gln Gly Arg Val Ala His	
1185 1190 1195	
ctc act ggc atc cat gca gtg gag gaa gtc agc ctg gag gag ttc tca	3709
Leu Thr Gly Ile His Ala Val Glu Glu Val Ser Leu Glu Glu Phe Ser	
1200 1205 1210	
gcc cac cca tgt gcc cgt gac aat ggt ggc tgc tcc cac atc tgt att	3757
Ala His Pro Cys Ala Arg Asp Asn Gly Gly Cys Ser His Ile Cys Ile	
1215 1220 1225	
gcc aag ggt gat ggg aca cca cgg tgc tca tgc cca gtc cac ctc gtg	3805
Ala Lys Gly Asp Gly Thr Pro Arg Cys Ser Cys Pro Val His Leu Val	
1230 1235 1240 1245	
ctc ctg cag aac ctg ctg acc tgt gga gag ccg ccc acc tgc tcc ccg	3853
Leu Leu Gln Asn Leu Leu Thr Cys Gly Glu Pro Pro Thr Cys Ser Pro	
1250 1255 1260	
gac cag ttt gca tgt gcc aca ggg gag atc gac tgt atc ccc ggg gcc	3901
Asp Gln Phe Ala Cys Ala Thr Gly Glu Ile Asp Cys Ile Pro Gly Ala	
1265 1270 1275	
tgg cgc tgt gac ggc ttt ccc gag tgc gat gac cag agc gac gag gag	3949
Trp Arg Cys Asp Gly Phe Pro Glu Cys Asp Asp Gln Ser Asp Glu Glu	
1280 1285 1290	
ggc tgc ccc gtg tgc tcc gcc gcc cag ttc ccc tgc gcg cgg ggt cag	3997
Gly Cys Pro Val Cys Ser Ala Ala Gln Phe Pro Cys Ala Arg Gly Gln	
1295 1300 1305	
tgt gtg gac ctg cgc ctg cgc tgc gac ggc gag gca gac tgt cag gac	4045

032796-132.ST25

Cys Val Asp Leu Arg Leu Arg Cys Asp Gly Glu Ala Asp Cys Gln Asp	
1310 1315 1320 1325	
cgc tca gac gag gtg gac tgt gac gcc atc tgc ctg ccc aac cag ttc	4093
Arg Ser Asp Glu Val Asp Cys Asp Ala Ile Cys Leu Pro Asn Gln Phe	
1330 1335 1340	
cgg tgt gcg agc ggc cag tgt gtc ctc atc aaa cag cag tgc gac tcc	4141
Arg Cys Ala Ser Gly Gln Cys Val Leu Ile Lys Gln Gln Cys Asp Ser	
1345 1350 1355	
ttc ccc gac tgt atc gac ggc tcc gac gag ctc atg tgt gaa atc acc	4189
Phe Pro Asp Cys Ile Asp Gly Ser Asp Glu Leu Met Cys Glu Ile Thr	
1360 1365 1370	
aag ccg ccc tca gac gac agc ccg gcc cac agc agt gcc atc ggg ccc	4237
Lys Pro Pro Ser Asp Asp Ser Pro Ala His Ser Ser Ala Ile Gly Pro	
1375 1380 1385	
gtc att ggc atc atc ctc tct ctc ttc gtc atg ggt ggt gtc tat ttt	4285
Val Ile Gly Ile Ile Leu Ser Leu Phe Val Met Gly Gly Val Tyr Phe	
1390 1395 1400 1405	
gtg tgc cag cgc gtg gtg tgc cag cgc tat gcg ggg gcc aac ggg ccc	4333
Val Cys Gln Arg Val Val Cys Gln Arg Tyr Ala Gly Ala Asn Gly Pro	
1410 1415 1420	
ttc ccg cac gag tat gtc agc ggg acc ccg cac gtg ccc ctc aat ttc	4381
Phe Pro His Glu Tyr Val Ser Gly Thr Pro His Val Pro Leu Asn Phe	
1425 1430 1435	
ata gcc ccg ggc ggt tcc cag cat ggc ccc ttc aca ggc atc gca tgc	4429
Ile Ala Pro Gly Gly Ser Gln His Gly Pro Phe Thr Gly Ile Ala Cys	
1440 1445 1450	
gga aag tcc atg atg agc tcc gtg agc ctg atg ggg ggc cgg ggc ggg	4477
Gly Lys Ser Met Met Ser Ser Val Ser Leu Met Gly Gly Arg Gly Gly	
1455 1460 1465	
gtg ccc ctc tac gac ccg aac cac gtc aca ggg gcc tcg tcc agc agc	4525
Val Pro Leu Tyr Asp Arg Asn His Val Thr Gly Ala Ser Ser Ser Ser	
1470 1475 1480 1485	
tcg tcc agc acg aag gcc acg ctg tac ccg ccg atc ctg aac ccg ccg	4573
Ser Ser Ser Thr Lys Ala Thr Leu Tyr Pro Pro Ile Leu Asn Pro Pro	
1490 1495 1500	
ccc tcc ccg gcc acg gac ccc tcc ctg tac aac atg gac atg ttc tac	4621
Pro Ser Pro Ala Thr Asp Pro Ser Leu Tyr Asn Met Asp Met Phe Tyr	
1505 1510 1515	
tct tca aac att ccg gcc act gcg aga ccg tac agg ccc tac atc att	4669
Ser Ser Asn Ile Pro Ala Thr Ala Arg Pro Tyr Arg Pro Tyr Ile Ile	
1520 1525 1530	
cga gga atg gcg ccc ccg acg acg ccc tgc agc acc gac gtg tgt gac	4717
Arg Gly Met Ala Pro Pro Thr Thr Pro Cys Ser Thr Asp Val Cys Asp	
1535 1540 1545	
agc gac tac agc gcc agc cgc tgg aag gcc agc aag tac tac ctg gat	4765
Ser Asp Tyr Ser Ala Ser Arg Trp Lys Ala Ser Lys Tyr Tyr Leu Asp	
1550 1555 1560 1565	
ttg aac tcg gac tca gac ccc tat cca ccc cca acg ccc cac agc	4813
Leu Asn Ser Asp Ser Asp Pro Tyr Pro Pro Pro Thr Pro His Ser	
1570 1575 1580	
cag tac ctg tcg gcg gag gac agc tgc ccg ccc tcg ccc gcc acc gag	4861
Gln Tyr Leu Ser Ala Glu Asp Ser Cys Pro Pro Ser Pro Ala Thr Glu	
1585 1590 1595	
agg agc tac ttc cat ctc ttc ccg ccc cct ccg tcc ccc tgc acg gac	4909
Arg Ser Tyr Phe His Leu Phe Pro Pro Pro Pro Ser Pro Cys Thr Asp	
1600 1605 1610	
tca tcc tgacctcggc cgggccactc tggcttctct gtgccctgt aaatagtttt	4965

032796-132.ST25

Ser Ser
1615
aaatatgaac aaagaaaaaa atatatttta tgatttaaaa aataaatata attgggattt 5025
taaaaacatg agaaatgtga actgtgatgg ggtgggcagg gctgggagaa ctttgtacag 5085
tggagaaata ttataaaact taattttgta aaaca 5120

<210> 2
<211> 5120
<212> DNA
<213> Homo sapiens

<400> 2
actaaagcgc cgccgccgcg ccatggagcc cgagtgcgcg cggcgcgggc ccgtccggcc 60
gccggacaac atg gag gca gcg ccg ccc ggg ccg ccg tgg ccg ctg ctg 109
Met Glu Ala Ala Pro Pro Gly Pro Pro Trp Pro Leu Leu
1 5 10
ctg ctg ctg ctg ctg ctg ctg gcg ctg tgc gcc tgc ccg gcc ccc gcc 157
Leu Leu Leu Leu Leu Leu Leu Ala Leu Cys Gly Cys Pro Ala Pro Ala
15 20 25
gcg gcc tcg ccg ctc ctg cta ttt gcc aac cgc cgg gac gta cgg ctg 205
Ala Ala Ser Pro Leu Leu Leu Phe Ala Asn Arg Arg Asp Val Arg Leu
30 35 40 45
gtg gac gcc ggc gga gtc aag ctg gag tcc acc atc gtg gtc agc ggc 253
Val Asp Ala Gly Gly Val Lys Leu Glu Ser Thr Ile Val Val Ser Gly
50 55 60
ctg gag gat gcg gcc gca gtg gac ttc cag ttt tcc aag gga gcc gtg 301
Leu Glu Asp Ala Ala Ala Val Asp Phe Gln Phe Ser Lys Gly Ala Val
65 70 75
tac tgg aca gac gtg agc gag gag gcc atc aag cag acc tac ctg aac 349
Tyr Trp Thr Asp Val Ser Glu Glu Ala Ile Lys Gln Thr Tyr Leu Asn
80 85 90
cag acg ggg gcc gcc gtg cag aac gtg gtc atc tcc ggc ctg gtc tct 397
Gln Thr Gly Ala Ala Val Gln Asn Val Val Ile Ser Gly Leu Val Ser
95 100 105
ccc gac ggc ctc gcc tgc gac tgg gtg ggc aag aag ctg tac tgg acg 445
Pro Asp Gly Leu Ala Cys Asp Trp Val Gly Lys Lys Leu Tyr Trp Thr
110 115 120 125
gac tca gag acc aac cgc atc gag gtg gcc aac ctc aat ggc aca tcc 493
Asp Ser Glu Thr Asn Arg Ile Glu Val Ala Asn Leu Asn Gly Thr Ser
130 135 140
cgg aag gtg ctc ttc tgg cag gac ctt gac cag ccg agg gcc atc gcc 541
Arg Lys Val Leu Phe Trp Gln Asp Leu Asp Gln Pro Arg Ala Ile Ala
145 150 155
ttg gac ccc gct cac ggg tac atg tac tgg aca gac tgg gtt gag acg 589
Leu Asp Pro Ala His Gly Tyr Met Tyr Trp Thr Asp Trp Val Glu Thr
160 165 170
ccc cgg att gag cgg gca ggg atg gat ggc agc acc cgg aag atc att 637
Pro Arg Ile Glu Arg Ala Gly Met Asp Gly Ser Thr Arg Lys Ile Ile
175 180 185
gtg gac tcg gac att tac tgg ccc aat gga ctg acc atc gac ctg gag 685
Val Asp Ser Asp Ile Tyr Trp Pro Asn Gly Leu Thr Ile Asp Leu Glu
190 195 200 205
gag cag aag ctc tac tgg gct gac gcc aag ctc agc ttc atc cac cgt 733
Glu Gln Lys Leu Tyr Trp Ala Asp Ala Lys Leu Ser Phe Ile His Arg

032796-132.ST25

																210																	215																	220																	
gcc	aac	ctg	gac	ggc	tcg	ttc	cgg	cag	aag	gtg	gtg	gag	ggc	agc	ctg																	781																																			
Ala	Asn	Leu	Asp	Gly	Ser	Phe	Arg	Gln	Lys	Val	Val	Glu	Gly	Ser	Leu																																																				
																225																	230																	235																	
acg	cac	ccc	ttc	gcc	ctg	acg	ctc	tcc	ggg	gac	act	ctg	tac	tgg	aca																	829																																			
Thr	His	Pro	Phe	Ala	Leu	Thr	Leu	Ser	Gly	Asp	Thr	Leu	Tyr	Trp	Thr																																																				
																240																	245																	250																	
gac	tgg	cag	acc	cgc	tcc	atc	cat	gcc	tgc	aac	aag	cgc	act	ggg	ggg																	877																																			
Asp	Trp	Gln	Thr	Arg	Ser	Ile	His	Ala	Cys	Asn	Lys	Arg	Thr	Gly	Gly																																																				
																255																	260																	265																	
aag	agg	aag	gag	atc	ctg	agt	gcc	ctc	tac	tca	ccc	atg	gac	atc	cag																	925																																			
Lys	Arg	Lys	Glu	Ile	Leu	Ser	Ala	Leu	Tyr	Ser	Pro	Met	Asp	Ile	Gln																																																				
																270																	275																	280																	285
gtg	ctg	agc	cag	gag	cgg	cag	cct	ttc	ttc	cac	act	cgc	tgt	gag	gag																	973																																			
Val	Leu	Ser	Gln	Glu	Arg	Gln	Pro	Phe	Phe	His	Thr	Arg	Cys	Glu	Glu																																																				
																290																	295																	300																	
gac	aat	ggc	ggc	tgc	tcc	cac	ctg	tgc	ctg	ctg	tcc	cca	agc	gag	cct																	1021																																			
Asp	Asn	Gly	Gly	Cys	Ser	His	Leu	Cys	Leu	Leu	Ser	Pro	Ser	Glu	Pro																																																				
																305																	310																	315																	
ttc	tac	aca	tgc	gcc	tgc	ccc	acg	ggt	gtg	cag	ctg	cag	gac	aac	ggc																	1069																																			
Phe	Tyr	Thr	Cys	Ala	Cys	Pro	Thr	Gly	Val	Gln	Leu	Gln	Asp	Asn	Gly																																																				
																320																	325																	330																	
agg	acg	tgt	aag	gca	gga	gcc	gag	gag	gtg	ctg	ctg	ctg	gcc	cgg	cgg																	1117																																			
Arg	Thr	Cys	Lys	Ala	Gly	Ala	Glu	Glu	Val	Leu	Leu	Leu	Ala	Arg	Arg																																																				
																335																	340																	345																	
acg	gac	cta	cgg	agg	atc	tcg	ctg	gac	acg	ccg	gac	ttc	acc	gac	atc																	1165																																			
Thr	Asp	Leu	Arg	Arg	Ile	Ser	Leu	Asp	Thr	Pro	Asp	Phe	Thr	Asp	Ile																																																				
																350																	355																	360																	365
gtg	ctg	cag	gtg	gac	gac	atc	cgg	cac	gcc	att	gcc	atc	gac	tac	gac																	1213																																			
Val	Leu	Gln	Val	Asp	Ile	Arg	His	Ala	Ile	Ala	Ile	Asp	Tyr	Asp																																																					
																370																	375																	380																	
ccg	cta	gag	ggc	tat	gtc	tac	tgg	aca	gat	gac	gag	gtg	cgg	gcc	atc																	1261																																			
Pro	Leu	Glu	Gly	Tyr	Val	Tyr	Trp	Thr	Asp	Asp	Glu	Val	Arg	Ala	Ile																																																				
																385																	390																	395																	
cgc	agg	gcg	tac	ctg	gac	ggg	tct	ggg	gcg	cag	acg	ctg	gtc	aac	acc																	1309																																			
Arg	Arg	Ala	Tyr	Leu	Asp	Gly	Ser	Gly	Ala	Gln	Thr	Leu	Val	Asn	Thr																																																				
																400																	405																	410																	
gag	atc	aac	gac	ccc	gat	ggc	atc	gcg	gtc	gac	tgg	gtg																																																							

032796-132.ST25

Leu	Asp	Leu	Gln	Glu	Gly	Lys	Leu	Tyr	Trp	Gly	Asp	Ala	Lys	Thr	Asp	
510					515					520					525	
aag	atc	gag	gtg	atc	aat	gtt	gat	ggg	acg	aag	agg	cgg	acc	ctc	ctg	1693
Lys	Ile	Glu	Val	Ile	Asn	Val	Asp	Gly	Thr	Lys	Arg	Arg	Thr	Leu	Leu	
				530					535					540		
gag	gac	aag	ctc	ccg	cac	att	ttc	ggg	ttc	acg	ctg	ctg	ggg	gac	ttc	1741
Glu	Asp	Lys	Leu	Pro	His	Ile	Phe	Gly	Phe	Thr	Leu	Leu	Gly	Asp	Phe	
			545					550					555			
atc	tac	tgg	act	gac	tgg	cag	cgc	cgc	agc	atc	gag	cgg	gtg	cac	aag	1789
Ile	Tyr	Trp	Thr	Asp	Trp	Gln	Arg	Arg	Ser	Ile	Glu	Arg	Val	His	Lys	
		560					565					570				
gtc	aag	gcc	agc	cgg	gac	gtc	atc	att	gac	cag	ctg	ccc	gac	ctg	atg	1837
Val	Lys	Ala	Ser	Arg	Asp	Val	Ile	Ile	Asp	Gln	Leu	Pro	Asp	Leu	Met	
	575				580					585						
ggg	ctc	aaa	gct	gtg	aat	gtg	gcc	aag	gtc	gtc	gga	acc	aac	ccg	tgt	1885
Gly	Leu	Lys	Ala	Val	Asn	Val	Ala	Lys	Val	Val	Gly	Thr	Asn	Pro	Cys	
590					595				600						605	
gcg	gac	agg	aac	ggg	ggg	tgc	agc	cac	ctg	tgc	ttc	ttc	aca	ccc	cac	1933
Ala	Asp	Arg	Asn	Gly	Gly	Cys	Ser	His	Leu	Cys	Phe	Phe	Thr	Pro	His	
			610						615					620		
gca	acc	cgg	tgt	ggc	tgc	ccc	atc	ggc	ctg	gag	ctg	ctg	agt	gac	atg	1981
Ala	Thr	Arg	Cys	Gly	Cys	Pro	Ile	Gly	Leu	Glu	Leu	Leu	Ser	Asp	Met	
			625					630					635			
aag	acc	tgc	atc	gtg	cct	gag	gcc	ttc	ttg	gtc	ttc	acc	agc	aga	gcc	2029
Lys	Thr	Cys	Ile	Val	Pro	Glu	Ala	Phe	Leu	Val	Phe	Thr	Ser	Arg	Ala	
		640					645					650				
gcc	atc	cac	agg	atc	tcc	ctc	gag	acc	aat	aac	aac	gac	gtg	gcc	atc	2077
Ala	Ile	His	Arg	Ile	Ser	Leu	Glu	Thr	Asn	Asn	Asn	Asp	Val	Ala	Ile	
	655				660					665						
ccg	ctc	acg	ggc	gtc	aag	gag	gcc	tca	gcc	ctg	gac	ttt	gat	gtg	tcc	2125
Pro	Leu	Thr	Gly	Val	Lys	Glu	Ala	Ser	Ala	Leu	Asp	Phe	Asp	Val	Ser	
670					675				680						685	
aac	aac	cac	atc	tac	tgg	aca	gac	gtc	agc	ctg	aag	acc	atc	agc	cgc	2173
Asn	Asn	His	Ile	Tyr	Trp	Thr	Asp	Val	Ser	Leu	Lys	Thr	Ile	Ser	Arg	
			690						695					700		
gcc	ttc	atg	aac	ggg	agc	tgc	gtg	gag	cac	gtg	gtg	gag	ttt	ggc	ctt	2221
Ala	Phe	Met	Asn	Gly	Ser	Ser	Val	Glu	His	Val	Val	Glu	Phe	Gly	Leu	
			705					710					715			
gac	tac	ccc	gag	ggc	atg	gcc	gtt	gac	tgg	atg	ggc	aag	aac	ctc	tac	2269
Asp	Tyr	Pro	Glu	Gly	Met	Ala	Val	Asp	Trp	Met	Gly	Lys	Asn	Leu	Tyr	
		720					725					730				
tgg	gcc	gac	act	ggg	acc	aac	aga	atc	gaa	gtg	gcg	cgg	ctg	gac	ggg	2317
Trp	Ala	Asp	Thr	Gly	Thr	Asn	Arg	Ile	Glu	Val	Ala	Arg	Leu	Asp	Gly	
	735				740					745						
cag	ttc	cgg	caa	gtc	ctc	gtg	tgg	agg	gac	ttg	gac	aac	ccg	agg	tgc	2365
Gln	Phe	Arg	Gln	Val	Leu	Val	Trp	Arg	Asp	Leu	Asp	Asn	Pro	Arg	Ser	
750					755				760						765	
ctg	gcc	ctg	gat	ccc	acc	aag	ggc	tac	atc	tac	tgg	acc	gag	tgg	ggc	2413
Leu	Ala	Leu	Asp	Pro	Thr	Lys	Gly	Tyr	Ile	Tyr	Trp	Thr	Glu	Trp	Gly	
			770					775						780		
ggc	aag	ccg	agg	atc	gtg	cgg	gcc	ttc	atg	gac	ggg	acc	aac	tgc	atg	2461
Gly	Lys	Pro	Arg	Ile	Val	Arg	Ala	Phe	Met	Asp	Gly	Thr	Asn	Cys	Met	
			785					790					795			
acg	ctg	gtg	gac	aag	gtg	ggc	cgg	gcc	aac	gac	ctc	acc	att	gac	tac	2509
Thr	Leu	Val	Asp	Lys	Val	Gly	Arg	Ala	Asn	Asp	Leu	Thr	Ile	Asp	Tyr	
		800					805					810				
gct	gac	cag	cgc	ctc	tac	tgg	acc	gac	ctg	gac	acc	aac	atg	atc	gag	2557

032796-132.ST25

Ala	Asp	Gln	Arg	Leu	Tyr	Trp	Thr	Asp	Leu	Asp	Thr	Asn	Met	Ile	Glu		
815						820					825						
tcg	tcc	aac	atg	ctg	ggt	cag	gag	cgg	gtc	gtg	att	gcc	gac	gat	ctc		2605
Ser	Ser	Asn	Met	Leu	Gly	Gln	Glu	Arg	Val	Val	Ile	Ala	Asp	Asp	Leu		
830					835					840					845		
ccg	cac	ccg	ttc	ggt	ctg	acg	cag	tac	agc	gat	tat	atc	tac	tgg	aca		2653
Pro	His	Pro	Phe	Gly	Leu	Thr	Gln	Tyr	Ser	Asp	Tyr	Ile	Tyr	Trp	Thr		
				850					855						860		
gac	tgg	aat	ctg	cac	agc	att	gag	cgg	gcc	gac	aag	act	agc	ggc	cgg		2701
Asp	Trp	Asn	Leu	His	Ser	Ile	Glu	Arg	Ala	Asp	Lys	Thr	Ser	Gly	Arg		
			865					870					875				
aac	cgc	acc	ctc	atc	cag	ggc	cac	ctg	gac	ttc	gtg	atg	gac	atc	ctg		2749
Asn	Arg	Thr	Leu	Ile	Gln	Gly	His	Leu	Asp	Phe	Val	Met	Asp	Ile	Leu		
	880					885						890					
gtg	ttc	cac	tcc	tcc	cgc	cag	gat	ggc	ctc	aat	gac	tgt	atg	cac	aac		2797
Val	Phe	His	Ser	Ser	Arg	Gln	Asp	Gly	Leu	Asn	Asp	Cys	Met	His	Asn		
	895					900					905						
aac	ggg	cag	tgt	ggg	cag	ctg	tgc	ctt	gcc	atc	ccc	ggc	ggc	cac	cgc		2845
Asn	Gly	Gln	Cys	Gly	Gln	Leu	Cys	Leu	Ala	Ile	Pro	Gly	Gly	His	Arg		
910					915					920					925		
tgc	ggc	tgc	gcc	tca	cac	tac	acc	ctg	gac	ccc	agc	agc	cgc	aac	tgc		2893
Cys	Gly	Cys	Ala	Ser	His	Tyr	Thr	Leu	Asp	Pro	Ser	Ser	Arg	Asn	Cys		
			930					935						940			
agc	ccg	ccc	acc	acc	ttc	ttg	ctg	ttc	agc	cag	aaa	tct	gcc	atc	agt		2941
Ser	Pro	Pro	Thr	Thr	Phe	Leu	Leu	Phe	Ser	Gln	Lys	Ser	Ala	Ile	Ser		
			945					950					955				
cgg	atg	atc	ccg	gac	gac	cag	cac	agc	ccg	gat	ctc	atc	ctg	ccc	ctg		2989
Arg	Met	Ile	Pro	Asp	Asp	Gln	His	Ser	Pro	Asp	Leu	Ile	Leu	Pro	Leu		
	960					965						970					
cat	gga	ctg	agg	aac	gtc	aaa	gcc	atc	gac	tat	gac	cca	ctg	gac	aag		3037
His	Gly	Leu	Arg	Asn	Val	Lys	Ala	Ile	Asp	Tyr	Asp	Pro	Leu	Asp	Lys		
	975					980				985							
ttc	atc	tac	tgg	gtg	gat	ggg	cgc	cag	aac	atc	aag	cga	gcc	aag	gac		3085
Phe	Ile	Tyr	Trp	Val	Asp	Gly	Arg	Gln	Asn	Ile	Lys	Arg	Ala	Lys	Asp		
990					995					1000					1005		
gac	ggg	acc	cag	ccc	ttt	gtt	ttg	acc	tct	ctg	agc	caa	ggc	caa	aac		3133
Asp	Gly	Thr	Gln	Pro	Phe	Val	Leu	Thr	Ser	Leu	Ser	Gln	Gly	Gln	Asn		
			1010					1015						1020			
cca	gac	agg	cag	ccc	cac	gac	ctc	agc	atc	gac	atc	tac	agc	cgg	aca		3181
Pro	Asp	Arg	Gln	Pro	His	Asp	Leu	Ser	Ile	Asp	Ile	Tyr	Ser	Arg	Thr		
			1025					1030					1035				
ctg	ttc	tgg	acg	tgc	gag	gcc	acc	aat	acc	atc	aac	gtc	cac	agg	ctg		3229
Leu	Phe	Trp	Thr	Cys	Glu	Ala	Thr	Asn	Thr	Ile	Asn	Val	His	Arg	Leu		
			1040				1045					1050					
agc	ggg	gaa	gcc	atg	ggg	gtg	gtg	ctg	cgt	ggg	gac	cgc	gac	aag	ccc		3277
Ser	Gly	Glu	Ala	Met	Gly	Val	Val	Leu	Arg	Gly	Asp	Arg	Asp	Lys	Pro		
	1055					1060					1065						
agg	gcc	atc	gtc	gtc	aac	gcg	gag	cga	ggg	tac	ctg	tac	ttc	acc	aac		3325
Arg	Ala	Ile	Val	Val	Asn	Ala	Glu	Arg	Gly	Tyr	Leu	Tyr	Phe	Thr	Asn		
1070					1075					1080					1085		
atg	cag	gac	cgg	gca	gcc	aag	atc	gaa	cgc	gca	gcc	ctg	gac	ggc	acc		3373
Met	Gln	Asp	Arg	Ala	Ala	Lys	Ile	Glu	Arg	Ala	Ala	Leu	Asp	Gly	Thr		
			1090					1095						1100			
gag	cgc	gag	gtc	ctc	ttc	acc	acc	ggc	ctc	atc	cgc	cct	gtg	gcc	ctg		3421
Glu	Arg	Glu	Val	Leu	Phe	Thr	Thr	Gly	Leu	Ile	Arg	Pro	Val	Ala	Leu		
			1105					1110					1115				
gtg	gtg	gac	aac	aca	ctg	ggc	aag	ctg	ttc	tgg	gtg	gac	gcg	gac	ctg		3469

032796-132.ST25

Val	Val	Asp	Asn	Thr	Leu	Gly	Lys	Leu	Phe	Trp	Val	Asp	Ala	Asp	Leu		
		1120					1125					1130					
aag	cgc	att	gag	agc	tgt	gac	ctg	tca	ggg	gcc	aac	cgc	ctg	acc	ctg		3517
Lys	Arg	Ile	Glu	Ser	Cys	Asp	Leu	Ser	Gly	Ala	Asn	Arg	Leu	Thr	Leu		
		1135				1140					1145						
gag	gac	gcc	aac	atc	gtg	cag	cct	ctg	ggc	ctg	acc	atc	ctt	ggc	aag		3565
Glu	Asp	Ala	Asn	Ile	Val	Gln	Pro	Leu	Gly	Leu	Thr	Ile	Leu	Gly	Lys		
		1150			1155				1160					1165			
cat	ctc	tac	tgg	atc	gac	cgc	cag	cag	cag	atg	atc	gag	cgt	gtg	gag		3613
His	Leu	Tyr	Trp	Ile	Asp	Arg	Gln	Gln	Gln	Met	Ile	Glu	Arg	Val	Glu		
			1170				1175							1180			
aag	acc	acc	ggg	gac	aag	cgg	act	cgc	atc	cag	ggc	cgt	gtc	gcc	cac		3661
Lys	Thr	Thr	Gly	Asp	Lys	Arg	Thr	Arg	Ile	Gln	Gly	Arg	Val	Ala	His		
			1185				1190						1195				
ctc	act	ggc	atc	cat	gca	gtg	gag	gaa	gtc	agc	ctg	gag	gag	ttc	tca		3709
Leu	Thr	Gly	Ile	His	Ala	Val	Glu	Glu	Val	Ser	Leu	Glu	Glu	Phe	Ser		
		1200				1205					1210						
gcc	cac	cca	tgt	gcc	cgt	gac	aat	ggt	ggc	tgc	tcc	cac	atc	tgt	att		3757
Ala	His	Pro	Cys	Ala	Arg	Asp	Asn	Gly	Gly	Cys	Ser	His	Ile	Cys	Ile		
		1215			1220				1225								
gcc	aag	ggt	gat	ggg	aca	cca	cgg	tgc	tca	tgc	cca	gtc	cac	ctc	gtg		3805
Ala	Lys	Gly	Asp	Gly	Thr	Pro	Arg	Cys	Ser	Cys	Pro	Val	His	Leu	Val		
		1230			1235				1240					1245			
ctc	ctg	cag	aac	ctg	ctg	acc	tgt	gga	gag	ccg	ccc	acc	tgc	tcc	ccg		3853
Leu	Leu	Gln	Asn	Leu	Leu	Thr	Cys	Gly	Glu	Pro	Pro	Thr	Cys	Ser	Pro		
			1250				1255							1260			
gac	cag	ttt	gca	tgt	gcc	aca	ggg	gag	atc	gac	tgt	atc	ccc	ggg	gcc		3901
Asp	Gln	Phe	Ala	Cys	Ala	Thr	Gly	Glu	Ile	Asp	Cys	Ile	Pro	Gly	Ala		
		1265			1270								1275				
tgg	cgc	tgt	gac	ggc	ttt	ccc	gag	tgc	gat	gac	cag	agc	gac	gag	gag		3949
Trp	Arg	Cys	Asp	Gly	Phe	Pro	Glu	Cys	Asp	Asp	Gln	Ser	Asp	Glu	Glu		
		1280			1285						1290						
ggc	tgc	ccc	gtg	tgc	tcc	gcc	gcc	cag	ttc	ccc	tgc	gcg	cgg	ggt	cag		3997
Gly	Cys	Pro	Val	Cys	Ser	Ala	Ala	Gln	Phe	Pro	Cys	Ala	Arg	Gly	Gln		
		1295			1300				1305								
tgt	gtg	gac	ctg	cgc	ctg	cgc	tgc	gac	ggc	gag	gca	gac	tgt	cag	gac		4045
Cys	Val	Asp	Leu	Arg	Leu	Arg	Cys	Asp	Gly	Glu	Ala	Asp	Cys	Gln	Asp		
		1310			1315				1320					1325			
cgc	tca	gac	gag	gtg	gac	tgt	gac	gcc	atc	tgc	ctg	ccc	aac	cag	ttc		4093
Arg	Ser	Asp	Glu	Val	Asp	Cys	Asp	Ala	Ile	Cys	Leu	Pro	Asn	Gln	Phe		
			1330				1335							1340			
cgg	tgt	gcg	agc	ggc	cag	tgt	gtc	ctc	atc	aaa	cag	cag	tgc	gac	tcc		4141
Arg	Cys	Ala	Ser	Gly	Gln	Cys	Val	Leu	Ile	Lys	Gln	Gln	Cys	Asp	Ser		
		1345			1350								1355				
ttc	ccc	gac	tgt	atc	gac	ggc	tcc	gac	gag	ctc	atg	tgt	gaa	atc	acc		4189
Phe	Pro	Asp	Cys	Ile	Asp	Gly	Ser	Asp	Glu	Leu	Met	Cys	Glu	Ile	Thr		
		1360			1365						1370						
aag	ccg	ccc	tca	gac	gac	agc	ccg	gcc	cac	agc	agt	gcc	atc	ggg	ccc		4237
Lys	Pro	Pro	Ser	Asp	Asp	Ser	Pro	Ala	His	Ser	Ser	Ala	Ile	Gly	Pro		
		1375			1380						1385						
gtc	att	ggc	atc	atc	ctc	tct	ctc	ttc	gtc	atg	ggt	ggt	gtc	tat	ttt		4285
Val	Ile	Gly	Ile	Ile	Leu	Ser	Leu	Phe	Val	Met	Gly	Gly	Val	Tyr	Phe		
		1390			1395				1400					1405			
gtg	tgc	cag	cgc	gtg	gtg	tgc	cag	cgc	tat	gcg	ggg	gcc	aac	ggg	ccc		4333
Val	Cys	Gln	Arg	Val	Val	Cys	Gln	Arg	Tyr	Ala	Gly	Ala	Asn	Gly	Pro		
			1410				1415						1420				
ttc	ccg	cac	gag	tat	gtc	agc	ggg	acc	ccg	cac	gtg	ccc	ctc	aat	ttc		4381

032796-132.ST25

```

Phe Pro His Glu Tyr Val Ser Gly Thr Pro His Val Pro Leu Asn Phe
      1425      1430      1435
ata gcc ccg ggc ggt tcc cag cat ggc ccc ttc aca ggc atc gca tgc      4429
Ile Ala Pro Gly Gly Ser Gln His Gly Pro Phe Thr Gly Ile Ala Cys
      1440      1445      1450
gga aag tcc atg atg agc tcc gtg agc ctg atg ggg ggc cgg ggc ggg      4477
Gly Lys Ser Met Met Ser Ser Val Ser Leu Met Gly Gly Arg Gly Gly
      1455      1460      1465
gtg ccc ctc tac gac cgg aac cac gtc aca ggg gcc tcg tcc agc agc      4525
Val Pro Leu Tyr Asp Arg Asn His Val Thr Gly Ala Ser Ser Ser Ser
      1470      1475      1480      1485
tcg tcc agc acg aag gcc acg ctg tac ccg ccg atc ctg aac ccg ccg      4573
Ser Ser Ser Thr Lys Ala Thr Leu Tyr Pro Pro Ile Leu Asn Pro Pro
      1490      1495      1500
ccc tcc ccg gcc acg gac ccc tcc ctg tac aac atg gac atg ttc tac      4621
Pro Ser Pro Ala Thr Asp Pro Ser Leu Tyr Asn Met Asp Met Phe Tyr
      1505      1510      1515
tct tca aac att ccg gcc act gcg aga ccg tac agg ccc tac atc att      4669
Ser Ser Asn Ile Pro Ala Thr Ala Arg Pro Tyr Arg Pro Tyr Ile Ile
      1520      1525      1530
cga gga atg gcg ccc ccg acg acg ccc tgc agc acc gac gtg tgt gac      4717
Arg Gly Met Ala Pro Pro Thr Thr Pro Cys Ser Thr Asp Val Cys Asp
      1535      1540      1545
agc gac tac agc gcc agc cgc tgg aag gcc agc aag tac tac ctg gat      4765
Ser Asp Tyr Ser Ala Ser Arg Trp Lys Ala Ser Lys Tyr Tyr Leu Asp
      1550      1555      1560      1565
ttg aac tcg gac tca gac ccc tat cca ccc cca ccc acg ccc cac agc      4813
Leu Asn Ser Asp Ser Asp Pro Tyr Pro Pro Pro Pro Thr Pro His Ser
      1570      1575      1580
cag tac ctg tcg gcg gag gac agc tgc ccg ccc tcg ccc gcc acc gag      4861
Gln Tyr Leu Ser Ala Glu Asp Ser Cys Pro Pro Ser Pro Ala Thr Glu
      1585      1590      1595
agg agc tac ttc cat ctc ttc ccg ccc cct ccg tcc ccc tgc acg gac      4909
Arg Ser Tyr Phe His Leu Phe Pro Pro Pro Pro Ser Pro Cys Thr Asp
      1600      1605      1610
tca tcc tgacctcggc cgggccactc tggcttctct gtgccctgt aaatagtttt      4965
Ser Ser
      1615
aaatatgaac aaagaaaaaa atatatttta tgatttaaaa aataaatata attgggattt      5025
taaaaacatg agaaatgtga actgtgatgg ggtgggcagg gctgggagaa ctttgtacag      5085
tggagaaata ttataaaact taattttgta aaaca      5120

```

<210> 3

<211> 1615

<212> PRT

<213> Homo sapiens

<400> 3

```

Met Glu Ala Ala Pro Pro Gly Pro Pro Trp Pro Leu Leu Leu Leu Leu
  1           5           10           15
Leu Leu Leu Leu Ala Leu Cys Gly Cys Pro Ala Pro Ala Ala Ala Ser
      20           25           30
Pro Leu Leu Leu Phe Ala Asn Arg Arg Asp Val Arg Leu Val Asp Ala
      35           40           45
Gly Gly Val Lys Leu Glu Ser Thr Ile Val Val Ser Gly Leu Glu Asp

```

032796-132.ST25

	50					55					60					
Ala 65	Ala	Ala	Val	Asp	Phe 70	Gln	Phe	Ser	Lys	Gly 75	Ala	Val	Tyr	Trp	Thr 80	
Asp	Val	Ser	Glu	Glu 85	Ala	Ile	Lys	Gln	Thr 90	Tyr	Leu	Asn	Gln	Thr 95	Gly	
Ala	Ala	Val	Gln	Asn	Val	Val	Ile	Ser	Gly 105	Leu	Val	Ser	Pro	Asp	Gly	
Leu	Ala	Cys 115	Asp	Trp	Val	Gly	Lys 120	Lys	Leu	Tyr	Trp	Thr 125	Asp	Ser	Glu	
Thr	Asn 130	Arg	Ile	Glu	Val	Ala 135	Asn	Leu	Asn	Gly	Thr 140	Ser	Arg	Lys	Val	
Leu 145	Phe	Trp	Gln	Asp	Leu 150	Asp	Gln	Pro	Lys	Ala 155	Ile	Ala	Leu	Asp	Pro 160	
Ala	His	Gly	Tyr	Met 165	Tyr	Trp	Thr	Asp	Trp	Gly 170	Glu	Thr	Pro	Arg	Ile	
Glu	Arg	Ala	Gly 180	Met	Asp	Gly	Ser	Thr	Arg	Lys	Ile	Ile	Val	Asp	Ser	
Asp	Ile	Tyr 195	Trp	Pro	Asn	Gly	Leu 200	Thr	Ile	Asp	Leu	Glu	Glu	Gln	Lys	
Leu	Tyr 210	Trp	Ala	Asp	Ala	Lys 215	Leu	Ser	Phe	Ile	His	Arg	Ala	Asn	Leu	
Asp 225	Gly	Ser	Phe	Arg	Gln 230	Lys	Val	Val	Glu	Gly 235	Ser	Leu	Thr	His	Pro 240	
Phe	Ala	Leu	Thr	Leu 245	Ser	Gly	Asp	Thr	Leu	Tyr	Trp	Thr	Asp	Trp	Gln	
Thr	Arg	Ser	Ile 260	His	Ala	Cys	Asn	Lys	Arg	Thr	Gly	Gly	Lys	Arg	Lys	
Glu	Ile	Leu 275	Ser	Ala	Leu	Tyr	Ser	Pro	Met	Asp	Ile	Gln	Val	Leu	Ser	
Gln	Glu 290	Arg	Gln	Pro	Phe	Phe 295	His	Thr	Arg	Cys	Glu	Glu	Asp	Asn	Gly	
Gly 305	Trp	Ser	His	Leu	Cys 310	Leu	Leu	Ser	Pro	Ser	Glu	Pro	Phe	Tyr	Thr 320	
Cys	Ala	Cys	Pro	Thr 325	Gly	Val	Gln	Met	Gln	Asp	Asn	Gly	Arg	Thr	Cys	
Lys	Ala	Gly	Ala 340	Glu	Glu	Val	Leu	Leu	Leu	Ala	Arg	Arg	Thr	Asp	Leu	
Arg	Arg	Ile 355	Ser	Leu	Asp	Thr	Pro	Asp	Phe	Thr	Asp	Ile	Val	Leu	Gln	
Val	Asp 370	Asp	Ile	Arg	His	Ala 375	Ile	Ala	Ile	Asp	Tyr	Asp	Pro	Leu	Glu	
Gly 385	Tyr	Val	Tyr	Trp	Thr 390	Asp	Asp	Glu	Val	Arg	Ala	Ile	Arg	Arg	Ala	
Tyr	Leu	Asp	Gly	Ser 405	Gly	Ala	Gln	Thr	Leu	Val	Asn	Thr	Glu	Ile	Asn	
Asp	Pro	Asp	Gly 420	Ile	Ala	Val	Asp	Trp	Val	Ala	Arg	Asn	Leu	Tyr	Trp	
Thr	Asp	Thr 435	Gly	Thr	Asp	Arg	Ile	Glu	Val	Thr	Arg	Leu	Asn	Gly	Thr	
Ser	Arg 450	Lys	Ile	Leu	Val	Ser	Glu	Asp	Leu	Asp	Glu	Pro	Arg	Ala	Ile	
Ala 465	Leu	His	Pro	Val	Met	Gly	Leu	Met	Tyr	Trp	Thr	Asp	Trp	Gly	Glu	
Asn	Pro	Lys	Ile	Glu 485	Cys	Ala	Asn	Leu	Asp	Gly	Gln	Glu	Arg	Arg	Val	
Leu	Val	Asn	Ala 500	Ser	Leu	Gly	Trp	Pro	Asn	Gly	Leu	Ala	Leu	Asp	Leu	

032796-132.ST25

Gln	Glu	Gly	Lys	Leu	Tyr	Trp	Gly	Asp	Ala	Lys	Thr	Asp	Lys	Ile	Glu
		515					520					525			
Val	Ile	Asn	Val	Asp	Gly	Thr	Lys	Arg	Arg	Thr	Leu	Leu	Glu	Asp	Lys
	530					535					540				
Leu	Pro	His	Ile	Phe	Gly	Phe	Thr	Leu	Leu	Gly	Asp	Phe	Ile	Tyr	Trp
545					550					555					560
Thr	Asp	Trp	Gln	Arg	Arg	Ser	Ile	Glu	Arg	Val	His	Lys	Val	Lys	Ala
			565						570					575	
Ser	Arg	Asp	Val	Ile	Ile	Asp	Gln	Leu	Pro	Asp	Leu	Met	Gly	Leu	Lys
			580					585					590		
Ala	Val	Asn	Val	Ala	Lys	Val	Val	Gly	Thr	Asn	Pro	Cys	Ala	Asp	Arg
		595					600					605			
Asn	Gly	Gly	Cys	Ser	His	Leu	Cys	Phe	Phe	Thr	Pro	His	Ala	Thr	Arg
	610					615					620				
Cys	Gly	Cys	Pro	Ile	Gly	Leu	Glu	Leu	Leu	Ser	Asp	Met	Lys	Thr	Cys
625					630					635					640
Ile	Val	Pro	Glu	Ala	Phe	Leu	Val	Phe	Thr	Ser	Arg	Ala	Ala	Ile	His
			645						650					655	
Arg	Ile	Ser	Leu	Glu	Thr	Asn	Asn	Asn	Asp	Val	Ala	Ile	Pro	Leu	Thr
			660					665					670		
Gly	Val	Lys	Glu	Ala	Ser	Ala	Leu	Asp	Phe	Asp	Val	Ser	Asn	Asn	His
	675						680					685			
Ile	Tyr	Trp	Thr	Asp	Val	Ser	Leu	Lys	Asn	Ile	Ser	Arg	Ala	Phe	Met
	690					695					700				
Asn	Gly	Ser	Ser	Val	Glu	His	Val	Val	Glu	Phe	Gly	Leu	Asp	Tyr	Pro
705					710				715						720
Glu	Gly	Met	Ala	Val	Asp	Trp	Met	Gly	Lys	Asn	Leu	Tyr	Trp	Ala	Asp
			725					730						735	
Thr	Gly	Thr	Asn	Arg	Ile	Glu	Val	Ala	Arg	Leu	Asp	Gly	Gln	Phe	Arg
			740					745					750		
Gln	Val	Leu	Val	Trp	Arg	Asp	Leu	Asp	Asn	Pro	Arg	Ser	Leu	Ala	Leu
	755						760					765			
Asp	Pro	Thr	Lys	Gly	Tyr	Ile	Tyr	Trp	Thr	Glu	Trp	Gly	Gly	Lys	Pro
	770					775					780				
Arg	Ile	Val	Arg	Ala	Phe	Met	Asp	Gly	Thr	Asn	Cys	Met	Thr	Leu	Val
785					790					795					800
Asp	Lys	Val	Gly	Arg	Ala	Asn	Asp	Leu	Thr	Ile	Asp	Tyr	Ala	Asp	Gln
			805					810						815	
Arg	Leu	Tyr	Trp	Thr	Asp	Leu	Asp	Thr	Asn	Met	Ile	Glu	Ser	Ser	Asn
			820					825					830		
Met	Leu	Gly	Gln	Glu	Arg	Val	Val	Ile	Ala	Asp	Asp	Leu	Pro	His	Pro
	835						840					845			
Phe	Gly	Leu	Thr	Gln	Tyr	Ser	Asp	Tyr	Ile	Tyr	Trp	Thr	Asp	Trp	Asn
	850					855					860				
Leu	His	Ser	Ile	Glu	Arg	Ala	Asp	Lys	Thr	Ser	Gly	Arg	Asn	Arg	Thr
865					870					875					880
Leu	Ile	Gln	Gly	His	Leu	Asp	Phe	Val	Met	Asp	Ile	Leu	Val	Phe	His
			885					890						895	
Ser	Ser	Arg	Gln	Asp	Gly	Leu	Asn	Asp	Cys	Met	His	Asn	Asn	Gly	Gln
			900					905					910		
Cys	Gly	Gln	Leu	Cys	Leu	Ala	Ile	Pro	Gly	Gly	His	Arg	Cys	Gly	Cys
	915						920					925			
Ala	Ser	His	Tyr	Thr	Leu	Asp	Pro	Ser	Ser	Arg	Asn	Cys	Ser	Pro	Pro
	930					935					940				
Thr	Thr	Phe	Leu	Leu	Phe	Ser	Gln	Lys	Ser	Ala	Ile	Ser	Arg	Met	Ile
945					950					955					960
Pro	Asp	Asp	Gln	His	Ser	Pro	Asp	Leu	Ile	Leu	Pro	Leu	His	Gly	Leu

Arg	Asn	Val	Lys	Ala	Ile	Asp	Tyr	Asp	Pro	Leu	Asp	Lys	Phe	Ile	Tyr	
			980					985					990			
Trp	Val	Asp	Gly	Arg	Gln	Asn	Ile	Lys	Arg	Ala	Lys	Asp	Asp	Gly	Thr	
		995					1000					1005				
Gln	Pro	Phe	Val	Leu	Thr	Ser	Leu	Ser	Gln	Gly	Gln	Asn	Pro	Asp	Arg	
	1010					1015					1020					
Gln	Pro	His	Asp	Leu	Ser	Ile	Asp	Ile	Tyr	Ser	Arg	Thr	Leu	Phe	Trp	
1025					1030					1035					1040	
Thr	Cys	Glu	Ala	Thr	Asn	Thr	Ile	Asn	Val	His	Arg	Leu	Ser	Gly	Glu	
				1045					1050					1055		
Ala	Met	Gly	Val	Val	Leu	Arg	Gly	Asp	Arg	Asp	Lys	Pro	Arg	Ala	Ile	
			1060					1065					1070			
Val	Val	Asn	Ala	Glu	Arg	Gly	Tyr	Leu	Tyr	Phe	Thr	Asn	Met	Gln	Asp	
		1075					1080					1085				
Arg	Ala	Ala	Lys	Ile	Glu	Arg	Ala	Ala	Leu	Asp	Gly	Thr	Glu	Arg	Glu	
	1090					1095					1100					
Val	Leu	Phe	Thr	Thr	Gly	Leu	Ile	Arg	Pro	Val	Ala	Leu	Val	Val	Asp	
1105					1110					1115					1120	
Asn	Thr	Leu	Gly	Lys	Leu	Phe	Trp	Val	Asp	Ala	Asp	Leu	Lys	Arg	Ile	
				1125					1130					1135		
Glu	Ser	Cys	Asp	Leu	Ser	Gly	Ala	Asn	Arg	Leu	Thr	Leu	Glu	Asp	Ala	
			1140					1145					1150			
Asn	Ile	Val	Gln	Pro	Leu	Gly	Leu	Thr	Ile	Leu	Gly	Lys	His	Leu	Tyr	
		1155					1160					1165				
Trp	Ile	Asp	Arg	Gln	Gln	Gln	Met	Ile	Glu	Arg	Val	Glu	Lys	Thr	Thr	
	1170					1175					1180					
Gly	Asp	Lys	Arg	Thr	Arg	Ile	Gln	Gly	Arg	Val	Ala	His	Leu	Thr	Gly	
1185					1190				1195						1200	
Ile	His	Ala	Val	Glu	Glu	Val	Ser	Leu	Glu	Glu	Phe	Ser	Ala	His	Pro	
				1205					1210					1215		
Cys	Ala	Arg	Asp	Asn	Gly	Gly	Cys	Ser	His	Ile	Cys	Ile	Ala	Lys	Gly	
			1220					1225					1230			
Asp	Gly	Thr	Pro	Arg	Cys	Ser	Cys	Pro	Val	His	Leu	Val	Leu	Leu	Gln	
		1235					1240					1245				
Asn	Leu	Leu	Thr	Cys	Gly	Glu	Pro	Pro	Thr	Cys	Ser	Pro	Asp	Gln	Phe	
	1250					1255						1260				
Ala	Cys	Ala	Thr	Gly	Glu	Ile	Asp	Cys	Ile	Pro	Gly	Ala	Trp	Arg	Cys	
1265					1270					1275					1280	
Asp	Gly	Phe	Pro	Glu	Cys	Asp	Asp	Gln	Ser	Asp	Glu	Glu	Gly	Cys	Pro	
				1285					1290					1295		

032796-132.ST25

Glu Tyr Val Ser Gly Thr Pro His Val Pro Leu Asn Phe Ile Ala Pro
 1425 1430 1435 1440
 Gly Gly Ser Gln His Gly Pro Phe Thr Gly Ile Ala Cys Gly Lys Ser
 1445 1450 1455
 Met Met Ser Ser Val Ser Leu Met Gly Gly Arg Gly Gly Val Pro Leu
 1460 1465 1470
 Tyr Asp Arg Asn His Val Thr Gly Ala Ser Ser Ser Ser Ser Ser
 1475 1480 1485
 Thr Lys Ala Thr Leu Tyr Pro Pro Ile Leu Asn Pro Pro Pro Ser Pro
 1490 1495 1500
 Ala Thr Asp Pro Ser Leu Tyr Asn Met Asp Met Phe Tyr Ser Ser Asn
 1505 1510 1515 1520
 Ile Pro Ala Thr Ala Arg Pro Tyr Arg Pro Tyr Ile Ile Arg Gly Met
 1525 1530 1535
 Ala Pro Pro Thr Thr Pro Cys Ser Thr Asp Val Cys Asp Ser Asp Tyr
 1540 1545 1550
 Ser Ala Ser Arg Trp Lys Ala Ser Lys Tyr Tyr Leu Asp Leu Asn Ser
 1555 1560 1565
 Asp Ser Asp Pro Tyr Pro Pro Pro Thr Pro His Ser Gln Tyr Leu
 1570 1575 1580
 Ser Ala Glu Asp Ser Cys Pro Pro Ser Pro Ala Thr Glu Arg Ser Tyr
 1585 1590 1595 1600
 Phe His Leu Phe Pro Pro Pro Pro Ser Pro Cys Thr Asp Ser Ser
 1605 1610 1615

<210> 4

<211> 1615

<212> PRT

<213> Homo sapiens

<400> 4

Met Glu Ala Ala Pro Pro Gly Pro Pro Trp Pro Leu Leu Leu Leu Leu
 1 5 10 15
 Leu Leu Leu Leu Ala Leu Cys Gly Cys Pro Ala Pro Ala Ala Ala Ser
 20 25 30
 Pro Leu Leu Leu Phe Ala Asn Arg Arg Asp Val Arg Leu Val Asp Ala
 35 40 45
 Gly Gly Val Lys Leu Glu Ser Thr Ile Val Val Ser Gly Leu Glu Asp
 50 55 60
 Ala Ala Ala Val Asp Phe Gln Phe Ser Lys Gly Ala Val Tyr Trp Thr
 65 70 75 80
 Asp Val Ser Glu Glu Ala Ile Lys Gln Thr Tyr Leu Asn Gln Thr Gly
 85 90 95
 Ala Ala Val Gln Asn Val Val Ile Ser Gly Leu Val Ser Pro Asp Gly
 100 105 110
 Leu Ala Cys Asp Trp Val Gly Lys Lys Leu Tyr Trp Thr Asp Ser Glu
 115 120 125
 Thr Asn Arg Ile Glu Val Ala Asn Leu Asn Gly Thr Ser Arg Lys Val
 130 135 140
 Leu Phe Trp Gln Asp Leu Asp Gln Pro Lys Ala Ile Ala Leu Asp Pro
 145 150 155 160
 Ala His Gly Tyr Met Tyr Trp Thr Asp Trp Val Glu Thr Pro Arg Ile
 165 170 175
 Glu Arg Ala Gly Met Asp Gly Ser Thr Arg Lys Ile Ile Val Asp Ser
 180 185 190

032796-132.ST25

Asp	Ile	Tyr	Trp	Pro	Asn	Gly	Leu	Thr	Ile	Asp	Leu	Glu	Glu	Gln	Lys
	195						200					205			
Leu	Tyr	Trp	Ala	Asp	Ala	Lys	Leu	Ser	Phe	Ile	His	Arg	Ala	Asn	Leu
	210					215					220				
Asp	Gly	Ser	Phe	Arg	Gln	Lys	Val	Val	Glu	Gly	Ser	Leu	Thr	His	Pro
225					230					235					240
Phe	Ala	Leu	Thr	Leu	Ser	Gly	Asp	Thr	Leu	Tyr	Trp	Thr	Asp	Trp	Gln
				245					250					255	
Thr	Arg	Ser	Ile	His	Ala	Cys	Asn	Lys	Arg	Thr	Gly	Gly	Lys	Arg	Lys
			260					265					270		
Glu	Ile	Leu	Ser	Ala	Leu	Tyr	Ser	Pro	Met	Asp	Ile	Gln	Val	Leu	Ser
		275					280					285			
Gln	Glu	Arg	Gln	Pro	Phe	Phe	His	Thr	Arg	Cys	Glu	Glu	Asp	Asn	Gly
	290					295					300				
Gly	Trp	Ser	His	Leu	Cys	Leu	Leu	Ser	Pro	Ser	Glu	Pro	Phe	Tyr	Thr
305				310						315					320
Cys	Ala	Cys	Pro	Thr	Gly	Val	Gln	Met	Gln	Asp	Asn	Gly	Arg	Thr	Cys
				325					330					335	
Lys	Ala	Gly	Ala	Glu	Glu	Val	Leu	Leu	Ala	Arg	Arg	Thr	Asp	Leu	
			340				345					350			
Arg	Arg	Ile	Ser	Leu	Asp	Thr	Pro	Asp	Phe	Thr	Asp	Ile	Val	Leu	Gln
		355					360					365			
Val	Asp	Asp	Ile	Arg	His	Ala	Ile	Ala	Ile	Asp	Tyr	Asp	Pro	Leu	Glu
	370					375					380				
Gly	Tyr	Val	Tyr	Trp	Thr	Asp	Asp	Glu	Val	Arg	Ala	Ile	Arg	Arg	Ala
385					390					395					400
Tyr	Leu	Asp	Gly	Ser	Gly	Ala	Gln	Thr	Leu	Val	Asn	Thr	Glu	Ile	Asn
				405					410					415	
Asp	Pro	Asp	Gly	Ile	Ala	Val	Asp	Trp	Val	Ala	Arg	Asn	Leu	Tyr	Trp
			420				425						430		
Thr	Asp	Thr	Gly	Thr	Asp	Arg	Ile	Glu	Val	Thr	Arg	Leu	Asn	Gly	Thr
		435					440					445			
Ser	Arg	Lys	Ile	Leu	Val	Ser	Glu	Asp	Leu	Asp	Glu	Pro	Arg	Ala	Ile
	450					455					460				
Ala	Leu	His	Pro	Val	Met	Gly	Leu	Met	Tyr	Trp	Thr	Asp	Trp	Gly	Glu
465					470					475					480
Asn	Pro	Lys	Ile	Glu	Cys	Ala	Asn	Leu	Asp	Gly	Gln	Glu	Arg	Arg	Val
				485					490					495	
Leu	Val	Asn	Ala	Ser	Leu	Gly	Trp	Pro	Asn	Gly	Leu	Ala	Leu	Asp	Leu
			500					505					510		
Gln	Glu	Gly	Lys	Leu	Tyr	Trp	Gly	Asp	Ala	Lys	Thr	Asp	Lys	Ile	Glu
		515					520					525			
Val	Ile	Asn	Val	Asp	Gly	Thr	Lys	Arg	Arg	Thr	Leu	Leu	Glu	Asp	Lys
	530					535					540				
Leu	Pro	His	Ile	Phe	Gly	Phe	Thr	Leu	Leu	Gly	Asp	Phe	Ile	Tyr	Trp
545					550					555					560
Thr	Asp	Trp	Gln	Arg	Arg	Ser	Ile	Glu	Arg	Val	His	Lys	Val	Lys	Ala
				565					570					575	
Ser	Arg	Asp	Val	Ile	Ile	Asp	Gln	Leu	Pro	Asp	Leu	Met	Gly	Leu	Lys
			580					585					590		
Ala	Val	Asn	Val	Ala	Lys	Val	Val	Gly	Thr	Asn	Pro	Cys	Ala	Asp	Arg
		595					600					605			
Asn	Gly	Gly	Cys	Ser	His	Leu	Cys	Phe	Phe	Thr	Pro	His	Ala	Thr	Arg
	610					615					620				
Cys	Gly	Cys	Pro	Ile	Gly	Leu	Glu	Leu	Leu	Ser	Asp	Met	Lys	Thr	Cys
625					630					635					640
Ile	Val	Pro	Glu	Ala	Phe	Leu	Val	Phe	Thr	Ser	Arg	Ala	Ala	Ile	His

032796-132.ST25

				645					650					655		
Arg	Ile	Ser	Leu	Glu	Thr	Asn	Asn	Asn	Asp	Val	Ala	Ile	Pro	Leu	Thr	
			660					665					670			
Gly	Val	Lys	Glu	Ala	Ser	Ala	Leu	Asp	Phe	Asp	Val	Ser	Asn	Asn	His	
		675					680					685				
Ile	Tyr	Trp	Thr	Asp	Val	Ser	Leu	Lys	Asn	Ile	Ser	Arg	Ala	Phe	Met	
	690					695				700						
Asn	Gly	Ser	Ser	Val	Glu	His	Val	Val	Glu	Phe	Gly	Leu	Asp	Tyr	Pro	
705					710					715					720	
Glu	Gly	Met	Ala	Val	Asp	Trp	Met	Gly	Lys	Asn	Leu	Tyr	Trp	Ala	Asp	
				725					730					735		
Thr	Gly	Thr	Asn	Arg	Ile	Glu	Val	Ala	Arg	Leu	Asp	Gly	Gln	Phe	Arg	
			740					745					750			
Gln	Val	Leu	Val	Trp	Arg	Asp	Leu	Asp	Asn	Pro	Arg	Ser	Leu	Ala	Leu	
		755					760					765				
Asp	Pro	Thr	Lys	Gly	Tyr	Ile	Tyr	Trp	Thr	Glu	Trp	Gly	Gly	Lys	Pro	
	770					775					780					
Arg	Ile	Val	Arg	Ala		Phe	Met	Asp	Gly	Thr	Asn	Cys	Met	Thr	Leu	Val
785						790					795					800
Asp	Lys	Val	Gly	Arg	Ala	Asn	Asp	Leu	Thr	Ile	Asp	Tyr	Ala	Asp	Gln	
				805					810					815		
Arg	Leu	Tyr	Trp	Thr	Asp	Leu	Asp	Thr	Asn	Met	Ile	Glu	Ser	Ser	Asn	
			820					825					830			
Met	Leu	Gly	Gln	Glu	Arg	Val	Val	Ile	Ala	Asp	Asp	Leu	Pro	His	Pro	
		835					840					845				
Phe	Gly	Leu	Thr	Gln	Tyr	Ser	Asp	Tyr	Ile	Tyr	Trp	Thr	Asp	Trp	Asn	
	850					855					860					
Leu	His	Ser	Ile	Glu	Arg	Ala	Asp	Lys	Thr	Ser	Gly	Arg	Asn	Arg	Thr	
865					870					875					880	
Leu	Ile	Gln	Gly	His	Leu	Asp	Phe	Val	Met	Asp	Ile	Leu	Val	Phe	His	
				885					890					895		
Ser	Ser	Arg	Gln	Asp	Gly	Leu	Asn	Asp	Cys	Met	His	Asn	Asn	Gly	Gln	
			900					905					910			
Cys	Gly	Gln	Leu	Cys	Leu	Ala	Ile	Pro	Gly	Gly	His	Arg	Cys	Gly	Cys	
		915					920					925				
Ala	Ser	His	Tyr	Thr	Leu	Asp	Pro	Ser	Ser	Arg	Asn	Cys	Ser	Pro	Pro	
						935					940					
Thr	Thr	Phe	Leu	Leu	Phe	Ser	Gln	Lys	Ser	Ala	Ile	Ser	Arg	Met	Ile	
945					950					955					960	
Pro	Asp	Asp	Gln	His	Ser	Pro	Asp	Leu	Ile	Leu	Pro	Leu	His	Gly	Leu	
				965					970					975		
Arg	Asn	Val	Lys	Ala	Ile	Asp	Tyr	Asp	Pro	Leu	Asp	Lys	Phe	Ile	Tyr	
			980</													

032796-132.ST25

Val Leu Phe Thr Thr Gly Leu Ile Arg Pro Val Ala Leu Val Val Asp
 1105 1110 1115 1120
 Asn Thr Leu Gly Lys Leu Phe Trp Val Asp Ala Asp Leu Lys Arg Ile
 1125 1130 1135
 Glu Ser Cys Asp Leu Ser Gly Ala Asn Arg Leu Thr Leu Glu Asp Ala
 1140 1145 1150
 Asn Ile Val Gln Pro Leu Gly Leu Thr Ile Leu Gly Lys His Leu Tyr
 1155 1160 1165
 Trp Ile Asp Arg Gln Gln Gln Met Ile Glu Arg Val Glu Lys Thr Thr
 1170 1175 1180
 Gly Asp Lys Arg Thr Arg Ile Gln Gly Arg Val Ala His Leu Thr Gly
 1185 1190 1195 1200
 Ile His Ala Val Glu Glu Val Ser Leu Glu Glu Phe Ser Ala His Pro
 1205 1210 1215
 Cys Ala Arg Asp Asn Gly Gly Cys Ser His Ile Cys Ile Ala Lys Gly
 1220 1225 1230
 Asp Gly Thr Pro Arg Cys Ser Cys Pro Val His Leu Val Leu Leu Gln
 1235 1240 1245
 Asn Leu Leu Thr Cys Gly Glu Pro Pro Thr Cys Ser Pro Asp Gln Phe
 1250 1255 1260
 Ala Cys Ala Thr Gly Glu Ile Asp Cys Ile Pro Gly Ala Trp Arg Cys
 1265 1270 1275 1280
 Asp Gly Phe Pro Glu Cys Asp Asp Gln Ser Asp Glu Glu Gly Cys Pro
 1285 1290 1295
 Val Cys Ser Ala Ala Gln Phe Pro Cys Ala Arg Gly Gln Cys Val Asp
 1300 1305 1310
 Leu Arg Leu Arg Cys Asp Gly Glu Ala Asp Cys Gln Asp Arg Ser Asp
 1315 1320 1325
 Glu Val Asp Cys Asp Ala Ile Cys Leu Pro Asn Gln Phe Arg Cys Ala
 1330 1335 1340
 Ser Gly Gln Cys Val Leu Ile Lys Gln Gln Cys Asp Ser Phe Pro Asp
 1345 1350 1355 1360
 Cys Ile Asp Gly Ser Asp Glu Leu Met Cys Glu Ile Thr Lys Pro Pro
 1365 1370 1375
 Ser Asp Asp Ser Pro Ala His Ser Ser Ala Ile Gly Pro Val Ile Gly
 1380 1385 1390
 Ile Ile Leu Ser Leu Phe Val Met Gly Gly Val Tyr Phe Val Cys Gln
 1395 1400 1405
 Arg Val Val Cys Gln Arg Tyr Ala Gly Ala Asn Gly Pro Phe Pro His
 1410 1415 1420
 Glu Tyr Val Ser Gly Thr Pro His Val Pro Leu Asn Phe Ile Ala Pro
 1425 1430 1435 1440
 Gly Gly Ser Gln His Gly Pro Phe Thr Gly Ile Ala Cys Gly Lys Ser
 1445 1450 1455
 Met Met Ser Ser Val Ser Leu Met Gly Gly Arg Gly Gly Val Pro Leu
 1460 1465 1470
 Tyr Asp Arg Asn His Val Thr Gly Ala Ser Ser Ser Ser Ser Ser
 1475 1480 1485
 Thr Lys Ala Thr Leu Tyr Pro Pro Ile Leu Asn Pro Pro Pro Ser Pro
 1490 1495 1500
 Ala Thr Asp Pro Ser Leu Tyr Asn Met Asp Met Phe Tyr Ser Ser Asn
 1505 1510 1515 1520
 Ile Pro Ala Thr Ala Arg Pro Tyr Arg Pro Tyr Ile Ile Arg Gly Met
 1525 1530 1535
 Ala Pro Pro Thr Thr Pro Cys Ser Thr Asp Val Cys Asp Ser Asp Tyr
 1540 1545 1550
 Ser Ala Ser Arg Trp Lys Ala Ser Lys Tyr Tyr Leu Asp Leu Asn Ser

032796-132.ST25

1555	1560	1565
Asp Ser Asp Pro Tyr Pro Pro Pro Thr Pro His Ser Gln Tyr Leu		
1570	1575	1580
Ser Ala Glu Asp Ser Cys Pro Pro Ser Pro Ala Thr Glu Arg Ser Tyr		
1585	1590	1595
Phe His Leu Phe Pro Pro Pro Pro Ser Pro Cys Thr Asp Ser Ser		
1605	1610	1615

<210> 5
 <211> 3096
 <212> DNA
 <213> Homo sapiens

<400> 5

catcttctca	cacgatctct	cgttcgcac	tccttccttt	gattgggttt	caccatttac	60
tcagacgacg	gtccttcttc	gatctttgca	cattcttcta	tcattctacta	ccttcataacc	120
cagctccgtc	ccctaataatt	catgcgcgga	tggcccatte	cgtgggtgaaa	attcccttct	180
actctgctaa	tctgctgttc	tctctccctc	ccgtcgggtt	ctgctcctgc	cacgttctcc	240
cctctcccca	ccaaaggtcg	ggttttcttt	gtcagggttc	ctttccctt	tggaagaagg	300
ggggctgtat	ggccttggtg	cgaggccctc	cagtgcacagg	atcccccatc	acccagagtt	360
ccacaggccc	tggtagggag	gagggggagc	agaagaggag	gtgccatctt	tgctgtctgg	420
ggaagggcag	gggccaccca	cacagagctc	tcccatattg	tgtggaccct	ggggccactg	480
cccagttcct	tccaaaggaa	agccagctcc	ccagggtggtg	ggagagtgat	atggcttctt	540
cttaaactta	gggaattgag	tgtgtggttg	cttctaagtg	ccttagaagc	cgggagcggc	600
tcctggaaag	agcctgcctg	ccacagcggg	ccttaccctg	gctgtgccca	cagatgtccc	660
tggggcctgc	cgtcctgcgc	cggtctctct	ggcctccccc	ggtgtgggtt	gggaaaagca	720
cagcaaatta	aaaaacacct	ccatctctgg	cctttgaaga	atgcatctga	acagccgaga	780
gtgtaaaaccg	tggtgaaatg	tggtctttcc	agtttgggga	gaagcagggg	agagctgggg	840
cttttggtacc	cagggtttcc	aagagctcct	gcctccctcg	gctgggctgg	ccaggggccc	900
ccgctgggac	ctccagctgt	aatagggaag	gttttactgg	gttgctggcc	actgtggact	960
gcccctaagg	gcaggatatg	ctgcctttac	ccgggttccc	ctcctgcctg	gaagatacag	1020
cccatgggag	gcctgttgtc	tgtgggatcc	tccagcatca	gagacactgg	ggccagcgtc	1080
tgctgtgtga	ggtgcaggcc	tggcaggccc	ggtccccccac	ctgcttgagc	acccacgggtg	1140
gtgggggctc	gctgcctccc	gagacaatct	atgtcattgt	tgtccaagga	agctaattta	1200
gagtagaaag	ttccgtgtcc	agtcccactc	tgtgcgtgtg	ttagcagggg	actctcgggc	1260
cgaagctggg	tccaccctgg	tagggggact	tcattggggc	tgggcgacag	cactgtgtat	1320
ttgtgtgtgt	gtgtgtttgt	gtgtgtgtgt	gtctgaggag	gtggaccagt	ttctcaaaag	1380
gcctgtgacc	ccaagaacca	aggaatttca	gcctgggtgg	atcacacctt	cactgggtgag	1440
tgggacaagc	tgggggccct	cgccacagga	gcagccaggg	catggggcac	agttggcctc	1500
attcacaaaa	tgggagtata	agtgatccct	gctctggcgg	ccaggacgat	gagtgggaac	1560
acaccgtgtg	ggggctgcct	ggcctgggtg	tgccgcgggt	gtccttgttg	gtgatggttc	1620
cacctgcttg	tgccaccagt	gccctctggg	tctcacacac	aactctcttc	ccagcgaagg	1680
cccctcctgc	cctcaggcct	cagtgtctgt	tccgtctcgg	aaggccccag	gagctcctgc	1740
atcctgggcg	tgattcctgt	gtgcctgcag	accccctcgc	ggctgccatc	tcatactttg	1800
gtgcacctgt	tggccagacc	tcctggtagc	gggtgctgca	ctcccctgaa	tgtgccgggg	1860
cctgggggca	gggacctggg	ctcctccctc	actgagtggg	gggaactcag	tgtcttgagg	1920
ttgggggtgc	tgcaggctgg	gtgggtgcagg	tgaaatgcag	acctctcagc	tgggtgtcca	1980
gagcagctgc	cttccccgcg	ccgagggaact	tcacccgcag	cccagtcagg	ggtggcgcct	2040
gggtgcacgc	cccgcaggct	gggtaggggt	ggagcctggg	tggccctgcc	tgtgagctgc	2100
atagttgtcg	cctttgaccc	tgagttttct	tcgttatctg	tttggaacctg	tttggggcag	2160
gcaggggatg	agatctgaag	ataaatgcct	tagctgtgac	catctccttt	tgtgagaggt	2220
caatgtccag	ttccgctgca	gttataacat	cccatttttt	gatttctttt	tattttttcc	2280
tttttctttt	tgagatggag	tctcgtctcg	tcaccagggc	tggagtgcaa	tggggtgacc	2340
tcagctcact	gcaacctcca	cttctcgggt	tcaagtgatt	ctcctgcctc	agcctcctga	2400

032796-132.ST25

ctagcagggg	ttacaggcgt	gagccaccac	gcccagctaa	tttttgtatt	tttagtagag	2460
gcaaggtttc	gtcatgttg	ccaggctggt	ctcaaactcc	tggccttaag	tgatctgccc	2520
gcctcggcct	cccaaagtgc	tgagatgaca	ggtgtgagcc	accgtgccc	gcccagaact	2580
ctttaattcc	cacctgaaac	ttgccgcctt	aagcaggctc	ccagtctccc	tcccctagtc	2640
cctgggccca	ccattctgct	ttctgtctca	atgaatttgc	ctaccgtaag	tacctcatat	2700
aaattgaatc	ataaagtatt	tgtcttttta	tatctggctt	atttcactta	gcataacatt	2760
cttaagtttc	atccatgttg	tagcatgtgt	cagaatctct	ctcttttttt	tttttttttt	2820
tttttttttt	ttttgcagac	agagtctcgc	tctgtcatct	agactggagt	tcagtggcac	2880
gatctcgggt	cactgcaaca	tctgcctcct	gggtccaagc	aattctcctg	cctcagcctc	2940
cttagcagct	ggaactacag	gcgcgtgcc	ccatgccttg	ctaatttttg	tatttttatg	3000
tggaggcagg	gtttcaccat	cttggccagg	ctggtctcga	attcctggtc	ttcaccacgg	3060
gggcccgaa	gacccgggca	aagcgtggag	gggagg			3096

<210> 6

<211> 26928

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (12044), (12489), (26433), (26434), (26435), (26436), (26439), (26441)

<223> Identity of nucleotide sequences at the above locations are unknown.

<400> 6

gaagaccaag	ggcacacagc	gaggcagttt	cagggcgggc	agcctggggc	cccacggggc	60
ggccccggac	acttgttctc	acctgtggag	ggcagagaag	ggaacaggga	gagaagtggc	120
cggctgggag	tggagggtgg	tttgagggtt	tactgtaaac	taaatgtgta	ccctctacct	180
tagttatgaa	ttatgagaca	cgaagactgc	gaaacagaca	cactcctcta	aaagtgcctc	240
taggtgaca	gggagaaaag	cccgcaggc	tcccagagc	cacctttgag	tccttcaaca	300
agcccgccag	ggcctcttgc	ccaccgggtg	cagctcagcc	actgaaccct	ccagggaagaa	360
gacgtgctgg	taggagaaga	atctcaccoc	ggcacagcct	ggaaggggca	cagaaggggc	420
tccggaacca	gcaagcccaa	gttggaactc	ccagtctgct	actttctaga	acgactgtgc	480
ccttggcggg	tctaagtaga	acctctccgc	gcactctttc	ctcctttgta	aagtggggac	540
agcaatggcc	accttgcagg	ttcagagagg	gcttgcagta	cctcacagaa	ctgagtggcc	600
gtgaacgtgt	gtgttcctcc	agatttgtga	cagctttgcc	aggctggagt	caggctgaac	660
gcctctgccc	tcattggggt	tatattctag	gaagaccaac	aaaaacaaga	agacggaaaa	720
ttaaaacaac	aaaagcccca	ttgacaggcc	gtgaagaatg	ccatgaaaaa	tgaatggcgt	780
tgtgctgca	tctttgggga	aacgggctta	cggaaagaag	gacacttgag	ctgctaccac	840
tgagcagccg	tccgggtggga	gggcagttca	ggaagagcag	acatccactg	aggaggcgct	900
ggggcagagg	gcagcctggt	cgctggattc	gggggaggaa	ccacatcagg	ccatgagctg	960
gagctggtgg	tagaatgtac	aggagaggcc	agccaggggc	agctcatgtc	agacctcaag	1020
cggggaagat	gaatcgagaa	tgcacccac	gagcaatggg	aagccagtct	acgatttaag	1080
cagcaaaaat	attttccctt	cttccaccct	gcattccagct	ctaccagcac	agcctggggt	1140
tctattttca	agatagaata	gacccagact	cccagctctt	cttacacttc	tactactgcc	1200
acctgtcacc	cactcatcg	tccccacttg	cagctctgac	ccccttccac	ctgatctcat	1260
ggcagccagg	gaagctccag	ggctcgtgag	ggctgccatc	taggaaaga	agcaaaaagc	1320
ttcggcacct	gcagggcgctg	ctccaaccac	acttcttctt	tgacctctca	gcttctctag	1380
ccactccctt	cccacatctc	accctgctcc	agccacagtg	gtgtctctgt	gggttctcaa	1440
acacaccagg	tgcactcctg	cctcagggcc	tttgtgcttg	ctgttctctg	ctgggactct	1500
tttttttttt	tttttttttg	agacagggtc	tactctgtg	gcccaggctg	gagtgtagt	1560
gtgtgatcgt	agctcattgc	aacctcaaac	tcctgggctc	aagcaatcct	cccacctcag	1620
cctctcaagt	agttagcttt	tgttgttttg	ttttgagatg	ggatctcact	ctgttgccca	1680
ggctggagtg	cagtggggca	atcttggtct	accacaacct	ctgcctccca	ggctcaagca	1740
attctcctgc	ctcagcctcc	caagtagctg	ggattacagg	catgtgccac	cacgcccagc	1800

032796-132.ST25

ttatttttgt	atTTTTtagta	gagacaggg	ttcaccatgt	tggctctggct	ggtcttgaac	1860
tectggcctc	agatgatcca	cctgcctcgg	cctcccaaag	tgctgggatg	acaggcatga	1920
gcctgtctct	agtagttagg	actacagaga	ggggccatca	tgcttgggtga	tectcccacc	1980
ttttctgctc	caactctttc	accccactta	gcctcgtggc	tcactctctt	acctcttcag	2040
ctcctcagtc	aggcctgagg	acccctgttg	aaaattgcaa	accacacccc	ccaccaccac	2100
caccactat	tgccagcact	ttctactcca	tttctctgct	ttacttttct	cctttgtact	2160
catcaccacc	tgactcatta	catgtttacg	tatctttctt	ctctccacta	gcatggaagc	2220
tccaggagag	cagagagtgt	agttttatct	cctgatgtgt	ttcctgtgcc	cgtaccaggg	2280
cctagcacac	agtaggtgct	cagtaaatgt	gtgttggtatg	aacaaatata	gtgaaaggat	2340
ctgatctaca	tttataaaga	aggcactctg	gctgctgagt	gggatgaga	ctgtcaggag	2400
gaaagaggcc	cctgtggggg	cctggccagc	agggtgggtac	aatggtagca	gccaggagag	2460
agggcctctt	ggactcaagt	ggatggggcc	tgctcagggc	tccggccaca	ggaacaaagg	2520
gaagggggcc	caggatggcc	tgctcatagag	gacacattac	aactggccca	aagttcaagt	2580
caggtttcta	aatttgggaa	gggatacaga	aaaactaaag	actctactgg	acagtcaagt	2640
attgaaatga	ttacatagaa	aatgtaccaa	gaattaaaaa	aaaaaaaaaa	aagcattatg	2700
aaggggccac	cagagactcc	cagagaggaa	agggactatg	ggctggatgc	ggtgactcac	2760
acctataatc	ccagcacttt	gggaggccga	ggagggtgga	tcacgaggtc	aggagttcaa	2820
aaccagccta	ggcaactctg	taaaaccccc	gtttctacta	aaaatacaaa	aaattagctg	2880
ggcatggcag	actgtgcctg	taatcccagc	tactcgggag	gctgaggcag	gagagtgtgt	2940
agaaccagag	aggcagaggt	tgacgtgagc	cgagattgag	ccactatgct	ccagcttggg	3000
cgacagagca	agactccgtc	tctaaaaaaa	agaaaaaaa	ggccagatga	ggtggctcat	3060
gcctgtaatc	ccagcacttt	gggaggccga	ggtgggtgga	tcacgaggtc	aggagatcga	3120
gacctcctg	gctaacatgg	tgaaactcca	tctctactta	aaatacaaaa	aattagccgg	3180
gcgtggtggc	gggcacctgt	agtcccagct	acttgggagg	ctgaggcagg	agaatggcgt	3240
gaacctggga	ggcggagctt	gcagtgagcc	gagattgcgc	cactgcactc	catccagcct	3300
ggcgacaga	gttagactcc	gtctcaaaaa	aaaaaaaaaa	aaaaaaatta	gctgattagt	3360
tgggcttgg	ggcggggcgc	tgtaatccca	actactcggg	aggctgaggc	gggagaatca	3420
cttgaacccg	ggaggcagag	gttgcaatga	gccgatatca	cgccactaca	ctccagcctg	3480
ggcgacagag	caagactcca	tctcaaaaaa	gaaaaaaa	aagaaagggg	ctgtgctgtg	3540
gcctgggacc	caaagcacac	tactgcaagg	tcccagggtg	cctgactcca	accggagcct	3600
tgagaacatt	catttgcaaa	gaatgaatta	aaattcagca	ctattttatt	ctgcaggatt	3660
ccagcacccc	aaggacagtc	atTTTTtagac	ccttcagtaa	cgtaataagt	aaccggagga	3720
tgtgtgagc	ttccacttcc	ccagacgggt	gcctgtcaca	gctcatcagg	ccaacaaact	3780
tttcttaggc	ctcaaatTTg	gaaatgttca	ctctcagttc	gttccttaga	tgcaagtcca	3840
tcccaatgaa	gtaacagggg	ctcagcacct	gtccaatctc	attgcttccg	gggacagggg	3900
cccatgagga	tgctgTTTTca	gcccgggtgac	acttgggcaa	agtgcctttt	ggtttccctc	3960
ccaggctgga	acgtgctggc	tctgtgaagt	tacgtctggc	acaagagccc	cccccaaccc	4020
ggcaggactg	actgctgtgg	tcagaggcgc	ccctggggct	ttgggagcca	cagaatcttc	4080
ctgaggggcag	cgccggagga	ggccccagtg	agagtgccca	ctgccaggct	cattcctcag	4140
gctgccgcag	gcctctcccc	aaaacaggca	atgcttctca	gcaacctgcc	ccaggagcag	4200
gccagggaag	gccgccatcg	gcctacagtg	ctgggctctg	gagggcttgg	ttggtaacag	4260
gccatggttt	ctatgagcca	gctgggggtg	gaaggacaca	ggctggattc	acctctctgg	4320
gcctcagttt	ctgcattcaa	aaagtgggaa	tcatgatata	tgctctatct	cttatctctc	4380
agtgtctgat	tgaacctcca	ataagacttt	taaaaatact	ctttctacct	tacttttatt	4440
tttcatttat	tttaagataa	tgtctagctg	tctcaccag	gctggagtgc	agtgggtgtga	4500
ttacggctca	ctacagcctt	aacctcccag	gctcaagtga	tcttctacc	acagcctccc	4560
aagtagctgg	aactacaggc	atgcaccacc	gcacctggat	aattttttct	tttgagacaa	4620
ggtttcactc	tgttgcccag	gctggagtgc	agtgggtgcac	tcttggtcca	ctgcagcctc	4680
aacctccctg	ggctttagtg	atcctcacac	tacagtctcc	caagtagctg	ggactacagg	4740
taatgtccag	tacacccagc	taatatTTTT	gaaggatggg	gtttcactat	attgccagg	4800
ctggctctga	actccagggt	ttaaagcaatc	taccttcttc	agcctgccaa	agtgtctagga	4860
ttataggtat	gagccacccc	ccggcctata	atcctaccac	tttaaaaaag	cctgtaattt	4920
tagcacttta	aaaaattttt	ctaaattttt	tatagagatg	ggggacagct	gtggctctcac	4980
tgtgttgccc	aggctgggtct	tgaactccta	ggatcaagcc	atcctcctgg	cctggcctcc	5040
caaagtgttg	ggattataag	cataagcctt	accttacctt	ttttttttga	gttgcaagttt	5100
tgttcttgtt	gctcaggctg	gagtgcattg	gcaagatctt	ggctcactgc	aacctccacc	5160
tcccgggttc	aagcaattct	cctgcctcag	cctcccaggt	agctgggatt	acaggcatgc	5220

032796-132.ST25

gccaccacac	ccagctaatt	ttgtatTTTT	agtagagatg	gggtttctct	atatacctta	5280
atttttaaagc	actgcattca	tgtaaattgt	gattaacatg	gattcaagag	agggagttag	5340
gatgaatgag	ccaggcagtc	acctcggtctg	tcaccctcca	cttctctcct	ccttctgaca	5400
gtcatcgtcc	atccgtttct	gcagctgttt	gtttgactct	cctgatcatt	ttgcttgcca	5460
cataacttgc	ctcctgggaa	agaatgcctt	gggcaggccc	acatgagtag	tgaaaaataa	5520
tctgcagtga	aaaataaaaac	taagtagtct	ggtccacaga	gcagtcttat	tttttactg	5580
cagatgaagg	agttgacatt	caggcttcat	tctcatttat	aagtgtttta	aagacacata	5640
cagtggattg	aacagtggcc	ttcaaaaaga	tgtatctaca	tcctaatacc	tgggacctgt	5700
gaatgttaac	caagttagga	aaagggtctt	cccgggtgtc	attaagttag	agatcttgag	5760
atgaggagct	catcgtggat	tatccaggtg	gaccctgcat	ccaaggacaa	atggtcctta	5820
gaaaagaaaa	gcagaggctg	ggcacagtgg	ctcaagcctg	taatcccagc	actttgagag	5880
gccgaggtgg	gtggatcacc	taaggatcatg	agttcgagag	cagcctggcc	aacatgatga	5940
aatcccatct	ctactaaaaa	tacaaaaatt	agcaaggcat	ggtggcgggt	gcctataatc	6000
ccagctactc	aggaagctga	ggcaggagaa	tggcttgac	ctgggaggcg	gaggttgacg	6060
tgagccaaga	tcgcgccact	gcaactccagc	ctgagggaga	aaagtgaac	tctgtctcat	6120
aaaagaaaaag	aaaagcagac	agagatctga	gacagaagag	gagagtgaag	gaaaaaaggc	6180
catgtgaaga	tgaggcagag	gttggagcca	tgcagccaca	agccaaggaa	tacctggagc	6240
cccagaagtt	gcaagaggta	ggaagaagcc	tcccctagag	cctccagacg	gagcacagcc	6300
ctgccaacac	ctccacctca	gacttctggc	ctccagcact	gtgagataat	caactgctgt	6360
tgttttaaac	cattcaattt	gtggtaattt	gttatggcag	ccacaggaaa	ctaatacagt	6420
acctaattctt	cacaaaccca	tcttacagaa	aaggaaactg	aagtcagaga	ggtagtggct	6480
tgtgcagtgt	gttaggccat	tcttgtatta	ctataaagaa	atacctgagg	ccgggcatgg	6540
tggctcacgc	ctgtaatccc	agcaactttg	gaggccaagg	tgagtggatc	acttgagggtc	6600
aggagttaa	gaccagcctg	gacaacatgg	tgaaccccca	tttctactga	aaatatgaaa	6660
attagccagg	catggtggcg	tgcactctgta	gtcccagcta	ctcaggaggc	tgaggcagga	6720
gaatcacttg	cgcccgagg	gaggagggtg	tagtgagcca	agattgtgcc	actgcactcc	6780
agcctgggag	acaagagaga	aaccctgtct	caaaaataat	aaaaaacaaa	taaacacctg	6840
agactgggta	gtttataaag	aaaggggtta	actggctccc	ggttctgcag	gctgtacaag	6900
catggtgccg	gcatctgctt	ggttgctggg	aaggcttcag	ggagttttac	tcatcgtgga	6960
aggcagagcc	agagcaggtg	catcacacag	caaaagcagg	agcgagagag	agagagagca	7020
gggaggtgtg	cacactttta	aatgagcaga	tctcacgaga	actcaccatt	gcaaggacag	7080
caccaagcca	cgaggggtct	gcccccatga	cccaaacctc	ccactaggcc	ccacccccaa	7140
cattgggaat	tacagttcaa	catgagggtt	ggggggacaa	atatccaaac	tatatcattc	7200
caccctgggc	ccccagatc	tcatgttctt	ctcacattgc	aaaatatagt	catgccttcc	7260
cagtggtccc	ccaaagtctt	aactcatccc	agcattaact	caaaaatccc	attcccaagt	7320
ccaacgtctc	atctgaagat	gagttccttt	cacctacaag	actgtaaaaa	tgaaaacagt	7380
tatttactgc	tgagatacaa	tgggggcata	ggcattaggt	aaacattcct	gttccaaaag	7440
ggagaaatcg	gtcaaaaaga	aggggctata	ggccccaagc	aagtccaaaa	cccagcagag	7500
caatcattca	atcttaaagc	tccaaaataa	cctccttaaa	ctccatgtcc	catagccagg	7560
gcacactggg	gcaaggggca	ggctcccaag	gccttgggca	gctctattcc	tgcggttttg	7620
cagaattcag	tccccatggc	tgtctttaca	gattggagat	gagggcctgc	ggcttttcca	7680
ggtgcagggg	gcaagctgct	ggtgatctac	cattctgggg	tgtggatggg	ggcggtcccc	7740
tcccgcagct	ccactaggca	ttgtcccagt	ggggactcta	tgtggggcct	ccaacccccc	7800
atttccccctc	caatgggaag	gctctgcccc	tgcagcagcc	ttcttccttg	gctcccaggc	7860
tttctcatatc	atcctctgac	atctaggtgg	atggtgtcaa	gcttccttca	ctcttgcaact	7920
ctgcacacct	acaggcttaa	caccacatgg	aagctgccaa	ggtgtatggc	tggaaacctc	7980
tgaagcagca	gcctgagctg	tgactatggc	cctttgagcc	aaggctggag	ctggaacagt	8040
ctagatgcag	gcagggagca	gtgtcctgag	gctgtgcaga	gcagcagggc	cctgtgcttg	8100
gacaatgaaa	ccattctttc	ctcctcatcc	tctgggcctg	tgatgggagg	ggtgtggaag	8160
atctctgaaa	tgccttttgc	gcctttttgc	ctctgagggc	tatttcctat	tgtctcagtt	8220
attggcagtc	ggctcctttt	tagttatgca	aatcctctag	caagaggtta	ctccactgcc	8280
ggcttgaaact	cctctcctga	aaaagctttt	tctttctttg	tcacatggcc	aggctgcaaa	8340
ttttccaaac	ttttatgctc	tgttttacct	ttaaataataa	cttctaactt	taattcattt	8400
atttgctcct	gcatttgagc	ataggggaatt	caaagaagct	gggccacatc	ttgaatgctt	8460
tgctgcttca	aaatttatgg	ccacgcttgg	tggctcacac	ctgtaatccc	agcactttgg	8520
gaggcctagg	tgggcagatc	acgagatcag	gagatcgaga	ccatcctggt	caacatgggt	8580
aaacccatct	ctactaaaaa	tacaaaaaaa	ttagcttggt	gtggtggcgc	agacctgtag	8640

032796-132.ST25

tcccagctac	tggagaggct	gaggcaggag	aattacttga	acctgggagg	cagaggttgc	8700
agtgaagccca	gatcatgcca	ctgcactcca	gcctggtgac	agaataagat	ttgatctcga	8760
aaggaaggaa	ggaaggagga	agggaaagaa	tgtcttcccc	ccagatgtcc	tgggtcatcc	8820
ctcttatggt	caaacttcaa	catatcccta	gggcatgaaa	ataatacagc	caaattatct	8880
gctaaggcat	aacgaaagt	acctttgtct	cagttcccaa	taagtccctc	atttccatct	8940
gagactcatc	accctggcct	tggcttgctc	atatcactgt	cagcattttg	gtcacatca	9000
tttaaccagc	taatcgggag	gctgaggcaa	gaggatcact	tgaacccagg	aggttgaggc	9060
tgcagtgagc	tgtgatcaca	tcactgcagt	ccagcttggt	caacagagca	agatcctgtc	9120
tcaataaata	aataaataaa	tacataaata	acttaagttt	atttaaagct	gcatctttgc	9180
caccatggag	aaaggccagg	ccagctcctt	ctctctttct	gcacgtgttc	ctcccacctc	9240
agctgcctct	gctcctcaag	gaggaacaga	gggagtagga	aaggccatcc	caggaggccc	9300
agcaccatcat	gacctggctc	tggggccttg	tgggtttatg	gattcccagt	gctgagtcac	9360
ccctcacagg	ctcttggtgg	caccttggtg	attggtcaga	agcatgtggt	ccccgggaac	9420
acaccttttc	ctgatcatct	gggaagggca	gcttggtgcca	gcgaggccac	ctgttcagcg	9480
ccacggcccc	ccagacagct	gcagccacag	ccttgccctt	gatcagagca	aacaccagac	9540
atgtgtgtca	tgcccccaac	ccatctccag	gggacacatg	tcctttcttg	ccaggcctga	9600
gatgaacaag	agagggacaa	gtcccccaag	ctctctctcc	ttcctgcctc	acccactccg	9660
ctgttagatt	ctcaagggtg	atgggtggct	aactagggca	accgaccatc	ctgggtttacc	9720
tagaactgag	ggggcatttt	caggaataaa	actgcaaaa	tctggagcaa	acaggagcaa	9780
gttggtcact	ctggggcttg	tggagtcagg	tttctctctg	caggccccct	ccccgcaagc	9840
atgggtggaa	cccaggacag	gaacacagag	caggccccag	gaccgggctt	gtcacttaca	9900
agtctttttt	tttttttttt	ttttgagatg	gagtccttgc	ctgtcatcag	ggctggagta	9960
cagtgggtgcc	atcttagctc	actgcaacct	ctgccttctg	ggttcaagtg	atccccctgc	10020
ctcagcctcc	tgagttagctg	ggactacagg	tggcaccacc	acgcccagct	aattttttgt	10080
atttctagta	gagatgagat	ggccaggctg	gtcttgaact	cctgacctca	agtgatctgc	10140
ccgccttggt	ctcccaaagt	gctgggatta	cagggtgtgag	ccactgtgcc	tggccccact	10200
cacaagtctt	aaacatgcc	tcagcacatc	aatgccattt	acaaaaaggt	agagggtatt	10260
tccaggcaaa	aatagatgaa	agacatagga	tgattgatca	tgtcctgctt	aaacataggt	10320
ctgatgctat	taagaattga	gggctgggag	cggtggctca	cgctgtaat	cccagcactt	10380
tgggaggccg	aggcgggcg	atcacgaggt	caggagatcg	agaccatcct	ggctaacacg	10440
gtgaaacccc	atctctacta	aaaatacaaa	aaatggccgc	gcgcggtgac	tcacgcctgt	10500
aatcccagca	ctttgggagg	ccaaggcggt	cggtacacga	ggtcaggaga	tcgagaccat	10560
cctggctaac	acagtgaagc	ccgctctcta	ctaaaaaata	caaaaaaat	tagccaggga	10620
tgggtggcgg	cgctgtagt	cccagcaact	tgggaggctg	aggcaggaga	agaatggtgt	10680
gaacctggga	gggtgagctt	ccagtgaacc	gagatcacac	cactgcactc	cagcctgggc	10740
gacagagtga	aactccatct	caaaaaaaat	ataataaat	aaataagaat	tgtagtatt	10800
ttgcagggtg	gacaaatgat	tctgtttctg	tggcagaatg	ttctcaggag	atctcttttg	10860
aactctcatg	gaaagcatca	tgtgtttggc	aacatcacat	ttatttttat	ttatttatta	10920
tttttttagag	acagggtctt	gctctgttgc	ccaggctgga	gtgcagtggc	acaatcacag	10980
ctcactgcag	cctcaacctc	ctgggtcaa	gcaatcctcc	tgcctcagcc	tcccaaagta	11040
gctgggacca	caggcgtgag	ccactgcact	cagcccaatg	taccttcaat	atttacattt	11100
ctggcaaaag	tagcaaaacc	ttaacaaatt	ttgaatctag	ataataaaat	tatgaggctg	11160
ggtgcagtgg	ccctgacagg	gatggctcac	atctgtaatc	tcaacatttt	gggaggccaa	11220
ggtaggcgga	tcacctgagg	ccaggagttt	gagaccagcc	tggccaacat	ggtgtaaccc	11280
tgtctctaac	aaaaatacaa	aaaaattagc	cagacgtggt	ggtgcacgtc	tgtcatccca	11340
gctactaggg	aggctgaggc	aggagaattg	cttgaacccg	agaggcagag	gttgtgatga	11400
gccgagatcg	cgctattgca	ctccagcctg	ggcaaaaagca	agagcgaaac	tctctctcca	11460
aaaaataaaa	aaaaataaaa	ttaatgaatt	aattaaaata	aaataaaata	atggatagtc	11520
actgtaaaga	aaaaataaat	gtatatatca	gccaacaagt	gatggaatag	agcaccatcc	11580
ctccctggct	ggacagatac	atcccacaac	acctggaagg	cggctccatg	tagaactttc	11640
tggactgctt	gctggagcac	ggtgacagag	gagctggacc	atggacctcc		11700
cccgggcccc	accaaggcg	aggccccctt	gtggtgggtc	tgaaggaggc	atccgtatgg	11760
cctctgcggc	ttgggcaggg	aatttggggt	ccaagtactt	ggtgcaaaagc	ctggaaagag	11820
ggtttgggtg	ctgagggcag	atccccctgg	ccacatgggg	gcagaagtgg	ggccccctga	11880
agcttgagg	cctgggcagg	ggcatctatt	ttgctgtctg	aggccttcag	tacttgaagc	11940
aaaatggagg	cagaatgtcc	caccttaatg	cccctgatcc	ctccaaacca	attccagaga	12000
cagcaagggc	cagaacaggg	atggccctgc	ccagggtcat	gcancgagga	agtggccagg	12060

032796-132.ST25

ctgggatctg	aacccaggct	aatccccctcc	cttgtcctcc	tccaggccct	caccctgca	12120
tagagccctc	cagctcactc	atcctcggcc	agctccatct	cctcagcttg	taaaccctcc	12180
cgggattttc	ctttcttaaa	aaacaaaggc	ttggccaggc	acggtggctc	acgcctgtac	12240
tttgggggtg	gctcccagca	ctttggggagg	ccaaggtggg	cggatcatga	ggtcaagaga	12300
ttgagaccat	tctggccagc	atggtgaaac	cctgtattta	ctaaaaaaa	aaaaattaac	12360
tgggcatggt	ggctagctac	ttaggaggct	gaggcaggag	aatcgcttga	acctgggaga	12420
aagaggttgc	agtgagccaa	gatcgcgcca	ctccacttta	acctggcaac	agaacaagat	12480
tccgtttcna	aaaacaaaca	aacaaacaaa	taaacaaaaa	aaggcggagc	gcgatggctc	12540
gcgcctgcaa	tcccagcact	ttgggaggct	gaggcgggag	gatcacttga	ggttaggagt	12600
ttgagaccag	cttgccaac	atggtgaaac	cccatttcca	ctaaaagtac	aaaaatcagc	12660
caggtgtggt	ggtgggtgcc	tgtaatccca	gctactcagg	aggctgaggc	aggagaatcg	12720
cttgaaccca	tgacctggag	gctacagtga	gctgagattg	cgccactgta	ctccagcttg	12780
ggcaacaaga	tttgtttctc	taaaaaaaaa	aaaaaaaaaga	ctggcccttc	cccttcagct	12840
cttcctcagg	gtccctgagc	actctacacc	cccgtctaca	ctgagcactc	caccctgctg	12900
tctacactga	gcactccacc	ctgccatcta	cactgaggac	tccacccccc	tgtctacact	12960
ggctgcctcc	cgccctcacc	tctgtctaag	gccattcccc	gctgcatctg	tcttctagat	13020
tctgcagcct	tcagcacgct	gggcccctcc	tttgtcccct	tgagccacct	ccagcctccc	13080
cctgagctgc	tactcctctc	ccagcagcct	ccaccaagc	ccctccagtc	cccaagctgt	13140
cccttgcac	cagcactgcc	cttccacgtg	ccccttccct	ccagcttcac	agcagggtgg	13200
ggcctccagg	ccctgcccac	tgtgcccctc	cacaagtgtg	ggtgggagct	ccgaggggag	13260
gcaggggtgt	gcatggactt	gggacgtcca	agtctgggac	caggggcagc	tgggtggtgg	13320
agtgtggagg	gggataggga	ctttcaggta	gagaggctgt	aggggcaaga	tcgggacggc	13380
ggatgtccct	aaggagggtc	ctgacctggg	aaatattgtg	cagcttcctc	tttgccattc	13440
ctggagctca	gacactggcc	ggctctcacc	ccgcccttcc	tgaggagcac	agctccatcc	13500
cagtgagttc	ctagtgtaga	catctccagc	agcacggatg	ggaaaggag	tcataaaagg	13560
tgcccaggac	cggaggcttt	ttctggaggt	ggcagaggag	ggtgtgggtc	tcagggtctc	13620
ggctgagggc	aagcgtggga	ggtcttaggt	ctgcaccagc	cccgtgaagg	cccctcctgc	13680
tccctggtgg	agtcctagag	ggaacagcag	cccctaggct	ctagcaggag	tgggtagggg	13740
cttttctggc	ttcctactgt	gccagcagga	tagctgggcc	tggcactgag	cccaaagatc	13800
acatgccggg	gcattggcgc	agtgaggaac	agacccttgc	caaagctggc	aaagaagacc	13860
ccatgggggtg	cagctgggtga	agctgagagc	tcaatgtttg	ggggagcctg	gcaaaagggg	13920
tccctcccctc	cctctgcagg	ccaggatcgc	aggttttccc	tacatgttgg	taattctcaa	13980
acaatcccat	ggccactgga	gcaaagatca	cagtgggcgg	cggcctcggg	agcagtggac	14040
agggcacgca	gtgcctttga	tgccagagcc	ctcgcccaa	agtcaacaaa	ctctgcagcg	14100
gactttgcac	cgggactttg	ttttcaccat	acaaggaaag	ggacagatca	caggccctct	14160
cgctgccctc	gctgagccgg	aagctgcagc	gtgagctctc	tcaagcccca	tttctaggtt	14220
ccccaggcgc	acccctgagc	ccctactcgc	ctattaagtt	ctcctaatag	cccttcaagg	14280
tcttaatgta	tgtccattag	acagagggga	aaactgaggc	gagggcaagt	gacttgaccg	14340
aggttcctcg	gcgagcaggg	cgtggagctg	agaacctcgt	tattactgct	ccccacacaa	14400
ccctctggcc	gttcttggaa	gaaggctgag	ccccgggggg	gccagagtga	cccaaacacc	14460
atgggcccgc	tgcggttaaca	cgtgcggcca	cgaaggggca	gcagtttccc	gcccggccgg	14520
gctctctccg	gcgctcagta	tccgtcccag	gccaagaaga	agaaactcgg	ggaggagggc	14580
ggaggggggt	gcgtgggagg	gcgtggaaga	tggacgtggc	caggggagtg	gcagctgcac	14640
acagtggatg	ctgttaagat	gaagggaag	aacgtgggct	ccgagatcac	tggacacggt	14700
tccacctttc	ttcccgtca	ctgcatggcc	ctgggcgggt	tgttgaaccc	ttggaaacct	14760
gtttttcctt	ttttcctttt	tttttgagac	agggtcttgc	tctgtggccc	agactggagt	14820
gocgtggcac	gatcttggct	cactgctgcc	tcccaggttc	aagtgatect	cccagctcag	14880
cctcctgcgt	agctgggacc	ccaggatatg	gtcaccacag	ccggctaatt	tttgtatttt	14940
tttgtagaga	cgggatttcg	ccgtattgcc	caggctggte	tcaaactcct	gagttcaccc	15000
gatcttctcg	cctcagcctc	ccaaagtgtc	gggattactg	gcatgagcca	ccgcacccag	15060
cagagacctc	agttttctaa	cctgtgccag	caggaataat	gatagctgcc	tagcttggtc	15120
gtgctgggaa	ttaagtaaga	tgaccgggta	gacaaatatga	agtattactg	gacacagagg	15180
gccccaggct	gggttagcag	cgggtggtcag	ggctgctgct	tcctggcctg	agctcgaagg	15240
agggccctca	ttaccacctg	ggtgagtcct	cgtccaaagg	tggcactgct	gcgtgggaat	15300
aacttctgcc	acccaagttg	gcagattgtg	tgcaaagtta	agtcctgact	ctgtgggggtg	15360
gacttcgagg	cctcttcate	ggacctgctt	ccggtgactg	cattcgcaac	tcctcctggt	15420
cctggtttaa	cacagcccag	ctttcctcct	gctgagccct	ccctgggcct	gctgtcacc	15480

032796-132.ST25

tcgtgccgct	gtgcctcgca	gtgccactcc	ctgtaccctg	aatactttgc	cctgcctctc	15540
cacccagctg	agagtcaggg	cccctgtgag	gctctgcca	gcccgtctc	cgggtttctg	15600
cctctgctga	gcacttccct	gcatgattgc	ttctgagagt	ccccccagcc	tgtgagcttc	15660
tcaggactgg	gacagcttct	caggaccgag	gcttccgtgt	ctgcttgcaa	ttttacaggc	15720
gggcacattt	tcccttggcc	aacatcagag	actggacatc	tgcagatctg	tgctagccac	15780
tgagcaccca	ggcaccccag	caggtagctc	tgtaaccaac	ccattctgta	aagctgaggc	15840
tcagagaggt	gaagcgccct	gcctggggcc	acagcctgcg	tcagctgcag	agccaggagc	15900
tgagatatgc	acctgoggct	ctgctcacag	ggtcctgcac	agactgctgc	tggagccacc	15960
tatgtagagt	caagagagtt	catgttaact	ccctctcaca	tccctcagcc	aggggtggggg	16020
ctgacgatag	acactcaggg	atggcctacc	ctccccaaca	acccccgtca	ggtttgccgg	16080
atctccttgg	aagaaaagtt	ctgggcagaa	ttccaccgtt	ggcctggcct	acactctcct	16140
tagtggttta	ggaccctcag	cggtggataa	gttgtgggca	gaagagatgc	aatcaggatt	16200
ctcaccctact	cacccttgc	cagccccaat	aagctcaata	agctgggctc	ggtctgagga	16260
agtgtccagg	aaatgtgcaa	atggcctggg	acagccctgt	gttcctttca	gtaaggttgc	16320
tgaaggtgag	gctgaaagtt	ggagaaacag	aagccagtgc	ttatggtttt	aattaagata	16380
atggaatgta	tgtatgtatg	tatgtatgta	tgtatgtatt	tatgtattta	tcttttagaga	16440
tagagtctca	ctctgttgcc	caggctggaa	tgcggtgaca	caatcatagc	tccttgccagc	16500
ctogacttcc	tatgcccaca	tgatcctcct	acctcagcct	cctgagtagc	tgggactaca	16560
gacacacgcc	aactatgcct	agctaatttt	ttttctattt	ttttgtggag	actgggttct	16620
cactttgttg	cccaggctgg	tcttgaaccc	ctagcttcaa	gcaatcctcc	tgccctcagcc	16680
tcccaaagtg	gagggattac	aggtgtgagc	caccacacct	ggcctggaat	ttattttgtat	16740
tctgcttata	aaattaatac	attcttattg	cagaaaagtt	tgaaaataaa	agaaaaggaca	16800
agaacaaaa	agcgtatata	atttcacagc	tcagatctca	ctgctattaa	cattttttatt	16860
tactttcagg	cttttttctt	tctaggtaca	tatgcagaga	ttattttatt	ttattttattt	16920
tattttatat	tttattttat	attttttatt	tcattatttt	attttatttt	attttatttat	16980
tttttagagac	agggcctcac	tctgtcaccc	aggctggagt	acaatggagt	gatcatagct	17040
cactgcagcc	tcaaacacct	gggctcaagc	aatcccccca	ctcagccttc	tgagttagttg	17100
ggactaaagt	gtgagtcctg	ctaatttttt	ttactttttg	tattgacaga	ggtctcacta	17160
tgttgccccag	gctgatctca	aactcctggg	ttcaagcgat	cctcccacct	tggactccca	17220
aagtgtctgg	attacaggca	tgagccacca	tgccctggcct	aaaatgccac	tttttgtcat	17280
ttactaaaaat	cccattggaca	ctttgacatg	tctgtattct	atgctattga	tctgactggt	17340
ggcatctaca	tcattatggc	catctatcat	ctatcataat	ccattttaac	attaaaaattg	17400
tgcctgtgct	tagattttct	tggcctgtct	cctatttcta	ttcttccaga	taaaattttag	17460
aatcatttta	tcaaattccc	cttgacagaa	aagccctatt	ggatttttgt	tgaaaaatac	17520
tgaattttta	cattaactta	ggaaagggtc	gggcacggtg	gctcacgcct	gtaatcccta	17580
cacttttcga	ggccaaggca	gggtgatcac	ttgaggttgg	gagtttgaga	ccagcctggc	17640
caacatggtg	aaactcggtc	tttactaaaa	atacaaaaaat	tgccaggcgc	attggctcac	17700
ctgtaatccc	agcactttgg	gaggccgagg	tgggtggatc	acgaggtcag	gagatagaga	17760
ccatcctggc	taacacggtg	caaccccgtc	tctcctaaaa	atacaaaaaa	ttagccaggc	17820
gtggtggtgg	gogcctgtgg	tctcagctac	ttaggaggct	gaggcaggag	aatgggtgtga	17880
accagggagg	cggagcttgc	agttagccaa	gatcgcgcca	ctgcactcca	gcctgggcga	17940
cagagtgaga	ctccatctca	aaaaaaaaata	ataataataa	tacaaaaaatt	agccgggggt	18000
cgtggcgtgc	acctataatc	ccagttactt	gggaggctga	ggcaggagaa	tcgcttgaat	18060
ccaggagggtg	gaggttgcaa	tgagcagaga	tcgtgccact	gtactccagc	ctgggtgaca	18120
gagtgcact	ctgtgaaaaa	aaaaaaaaaaa	ttctgaagga	ttgagactct	tagactctta	18180
ggtcttccta	tccaagagca	caatatagct	tttcatgtat	tcaagccttt	ttcaatgcat	18240
caacagaatt	ttacagtttt	tttcatgata	tcctgctatt	tcttataaaa	tgtattccta	18300
gatattctgc	atgttttccg	gttggttgggt	aataaatatt	tttcatttgt	cattatttcc	18360
taatttggctg	ttatttggat	atatgacatc	tgttgaattt	tttgattact	ttgaaaatgg	18420
ccattctttt	gtgttttttt	tttaactttct	attttgagat	aattttgact	tacagaagat	18480
ttgcaaaaaat	agtagacaga	gttcctgttt	cccccttatg	tttaaccagt	ttctccttat	18540
gttaacatct	tacataacta	cagaacaatt	gtcaaatcta	agaatcaacc	tgggcacaaat	18600
gctattaaact	aaactgcaga	agctgttcag	atctcaccag	ttcttctact	gctccccttt	18660
tctcttccag	tgttcaatcc	ggaatcctac	attatattta	gttgctcattt	ctctttgggtg	18720
tcttccaatc	tgtgacagtt	cctcagctct	tctttgtctt	tcatgacttt	catttttttta	18780
tacttttgaa	aaatactggc	cggttggttt	gtagaacgcc	ctcagtttgg	gtttgcctga	18840
agtttttttgt	gattagatcg	aggtcatgca	ttattggaga	gggtgccacc	gcctcgatgt	18900

032796-132.ST25

gcaagctcaa	tgcatacat	cagagggttt	gtaatgtcag	tttataccgc	cggagaccct	18960
aacctggagc	atttcgtgaa	ggtgctgtct	gccaggattc	tccactagaa	agttactatt	19020
tttccctttt	taattactga	atgtctgagg	ggaaatactt	tgagactatg	caaatacctt	19080
gtttctgtct	taacttcggc	tcactaagtt	tagcattcat	ctatggatct	cgcttatagc	19140
aagtattact	gtggagtctt	aatggtaatt	ttctgtttct	ctcattcctt	caacctttat	19200
taatattgctt	cttcctcaact	tattcatttt	gtttcagttg	tttataccaa	catggatttg	19260
tggatattgg	ttttattctt	tgggttgcaa	ttgaatccta	tcattatttt	gttagtcagt	19320
tgttccatcc	gaccttggtc	attaggagcc	cttgaaattt	ggctcccatg	cctttttttt	19380
tttttttgag	accgagtctc	actctgtcac	ccaggtttga	gtgcagtggc	atgatcttgg	19440
cttctgcaa	cctccgcctc	ccaggttcaa	gcaattctcc	tgccctcagc	tcctgagtag	19500
ctggtattat	aggcgctcca	ccaccttgcc	cggctaattt	tttgtatttt	tagtagagat	19560
ggggttttat	tatgttggcc	aggctggtct	caaactcctg	acctcagggtg	atctgcccgc	19620
ctcggcctcc	caaagtgtctg	ggactacagg	cgtgagccac	cacacctggc	ctcctatgcc	19680
attttaacat	gcccgtcttt	tctttttctt	tcctactttc	tgtgactgta	agaagctcca	19740
ggatacattt	ttgctgccct	agacttagcc	tcaatcagtt	ctcagaaaag	ctctggttct	19800
ttttatggga	tacttagaaa	actagctctg	tatggcctgg	cgcggtggct	cacgcctgta	19860
atcccagtag	tttgggaggc	cgagggtggc	agatcacaga	tcacgaagtc	aggagatcaa	19920
gacctactctg	gctaactatg	tgaaactctg	tctctactaa	acatacaaaa	aattagtcca	19980
ggcgcggtgg	cgggcgctctg	tagtcccagc	tactcaggag	gctgaggcag	gagaacggca	20040
tgaacccggg	aggcgagct	tgtagtgagc	cgagatcggc	agccactgca	ctccagcctg	20100
ggccacagag	cgagactccg	tctcaaaaaa	aaaaaaagga	aaaagaaaaa	agaaaactag	20160
ctctgtatgc	tagttttttt	tttaagacag	ggtctctctt	gccccagctg	gagtgtagca	20220
gcacgatcac	agctcaactgt	agcctcaacc	ttctgggctc	aagcaatcct	cctgcctcag	20280
tctcctaagt	agctgggtct	acaggcatgc	accaccgtac	gtggcaattt	ttaaaaactg	20340
ttttagagaga	tggagtctcc	ctatgttgcc	tggcttgga	ctcctggcct	caagtgatcc	20400
tcctgcctcg	gcctcccaaa	gtgctgagat	tacaggcatg	agccactgta	cctggcctgg	20460
ccaaggtctg	tcttttttta	aaagaagttg	ttgtatagtt	gttttttttt	ttattttttt	20520
ttctgagacg	gagtctcgct	ctgtcgccca	ggctggagtg	cagtgggtcg	atctcggtct	20580
actgcaagct	ccgcctccca	ggttcacgcc	attctcctgc	ctcagcctcc	cgagtagctg	20640
ggcctacagg	cgcccgctac	cacgcccggc	taattttttg	catttttagt	agagacgggg	20700
tttcaccgtg	ttagccagga	tggctctgat	ctcctgacct	cgtgatccgc	ccgcctcggc	20760
ctcccaaagt	gctgggatta	caggcgtgag	ccaccgcgcc	cggcctgttg	tatagttttt	20820
atctcgagtt	ttctagcgat	ttaatcatat	tggttacaaa	aaaggatgat	tttactacct	20880
cctttccaat	gtttctacat	attttttcat	tttatctaac	tgcattttta	aataaaacttt	20940
taatttttaga	atggtttcat	atttacagaa	aatgtgcaaa	gatagtacag	agagttcctg	21000
tgtactccac	acccggtttc	cttattatta	tcttaacgtg	atacacaatt	aataaaaccag	21060
taacattatt	attcaactgaa	gtccacactt	tctttttttt	tttttctgag	acggagtcta	21120
cttctgtcac	ccaggctgga	gtgcagtggc	gcaatctcgg	ctcactgcaa	cctccacctc	21180
ctgggttcag	gcaattctgt	ggctcagcat	cccaagtagc	tgggaatata	ggtgcccggc	21240
accacgcccg	gctaattttt	tgtattttta	gtagagatgg	ggtttcacca	tgttagccag	21300
gatggtcttg	aactcctgac	ctcgtgatct	gcctgcctca	gcctcccaaa	gtgctgggat	21360
tacaggcggtg	agccaccgcg	ccggcggtcc	atactttctt	tagatatcct	tcctttttac	21420
ctaacgtcct	tcttctggtt	caggatccca	tccagaaagc	aacattaccc	ctcgccatca	21480
cgtcttcaca	ggctcccctt	gacgggaaga	gttcctcaga	ctttccttgt	ttttgttgac	21540
cttgacagtt	ttgaggagga	ctggtatctt	agtctgtttt	gtgctgctat	cacagactag	21600
ctgagaccga	tacatgatac	atgaaaaaaa	atgtattctt	acagttgtgg	aggctgggaa	21660
gttcaagacg	aagttgctgg	ttggtttggt	ctctggtttc	aagatggcgc	cttgctgctg	21720
catcctctgg	agaagaagaa	tgcggtgtcc	tctcactgca	gaagatggaa	gcgctaaaag	21780
gaatgaactc	cctttgccaa	gccattttat	aatgggcatt	aatccacaaa	ggatgaaacc	21840
ctgagaaaca	tcaagcttta	aagcactggt	tctcaacctt	tttgggtctc	ggagcccttt	21900
atactcttaa	aacgttttga	ggaatccaaa	aaaaggcttc	tacaggttcc	atcttttaat	21960
atttaccata	tcaaaaatta	aactgaaaaa	atttttaaatt	atttattcat	ttaaaaataac	22020
aaggataaac	ccattacatg	ctaacataaa	tcattgtattt	tatgaaaaat	agctatatatt	22080
atcaaaaaca	aaattagtga	gaagagtggc	atgtataatt	ttttttgttt	attttttgtt	22140
tttagatgga	atcttattct	gtcggccagg	ctggagtgca	gtgggtgtgat	ctcggctcac	22200
tgaagctct	gcctcccagg	ttcacaccat	tctcctgcct	cagcctcctg	agtagctggg	22260
actgcagggtg	cctgccacca	cgcccggtca	attttttgta	tttttagtag	agatggagtt	22320

032796-132.ST25

tcaccgtgtt	agccaggatg	gtcttgcctt	cctgaccttg	tgatccaccc	gcctcagcct	22380
cccaaagtgc	tgggattaca	ggcttgagcc	actgcgtctg	gcctaaattt	ttgtgaatgt	22440
ctttaatgcc	tgccttctca	tatttgtttc	tgcatccaag	ttattgcaaa	atgttggtgt	22500
ggttgaagtt	tgtaaagaaa	atgtggcctc	atacagttgt	gtagttggaa	aggcaagagt	22560
attttgattc	tctcttcaaa	caactatgga	caacctgctg	ttacaaaacc	agaatgcaaa	22620
aagttgtagt	aaatacaggt	taggtgtagt	gtggaatctg	aaagcatgtg	aatgaacttt	22680
ctgagttttg	taacattaaa	gtccagttgc	gttaagctac	tgtgatagca	tatagcattg	22740
tcctaatact	ggaattagta	tcagaagtgg	ggtgctactg	ttaataaata	aaaagaaata	22800
aataaatcat	gtgatactgg	ctcagaagtc	aggcagtagg	ctgtgtggaa	cctgacatca	22860
cgccatgtaa	tacattggca	accatttgat	ccagctgtct	gtcatgatga	cttggaaagt	22920
caaccacata	cttacagagc	ctgtagacat	aggggaaaat	agtataaaac	agaataactaa	22980
cagtggacct	tggttcttgc	cagttgcatt	tagccaaata	ttaaacaaaa	gagatattct	23040
tgggcagcaa	ctggaccatc	ttcaagtaaa	agtgaagagt	aataaacaga	gtccagacat	23100
ttgtgcccac	gcgggttaag	aaaaatccag	ttgcttctag	acaccgtata	tgaaaaacaac	23160
gctgaaaaca	agcctttgag	tggtaaaggc	cgattaacac	tcagcgcggt	aacaaagacc	23220
aggtgggcta	acccgaaatg	aaatgagaag	cctgtggtga	tgaggaggca	gagaagtaaa	23280
atcaagtttg	agcatttcgt	ttaggagagt	ttgggctctg	attacttgca	catgcaaacg	23340
aaactggaaa	aaacagatca	gatgtctacc	acttcttcga	gggaattgca	ttgccaaaga	23400
agtcatgaaa	gcagactcta	tactgattag	gcattaaaaac	aaaaacaatc	tttaggcccc	23460
taaacttgca	tgggcaggaa	gtgggctgtc	aaagctgttc	atcctctaag	gtggacctag	23520
ttcctagtcc	ccagtataca	cttcagatgt	ggccttgag	gacactggac	atggaggacc	23580
tcccagagga	tgaggctagg	gcttcatttc	tccaatgacc	tcagctgcct	ctatttcccc	23640
ttcttcctct	ggaagtccca	tcatcggtat	tattattatt	atcatcattt	ttattttgag	23700
ataaggtctc	gctctgttgc	ccaggctgga	gtgcagtgac	atgatcatgg	ctcactgcag	23760
ccctcccagg	ctcaagtgat	cctcctgcct	cagcctcctg	agtagctggg	agtacaggca	23820
catgccacca	tgcttggtca	tttttttttt	cagtagagat	agggctctca	ctatgttgcc	23880
agggctgatc	tcaacctcct	gggttcaaga	gatcctccta	cctcagctcc	tgagtagctg	23940
ggattcgggt	gcacaccacc	atgccaaacta	atttttaatt	tttttttgta	tggacaggat	24000
gtacagtgtt	agaaatggat	tgcttgacaga	ggcaggagga	tcacttgagc	ccaggagtgt	24060
gatcacactg	tgaaccatga	tcgcacccct	gcactccaat	ctgggcaaca	gagtgagacc	24120
ttgtctcaaa	aaaaaaaaaa	aagagagaga	gagagagact	caaagatagg	caaaaaagtg	24180
ggaaagtctt	atagtggaca	aaaaggaacg	ctctaagctc	gccctattgg	catggtgctg	24240
aagtggggct	aactagagat	aggggggtac	atgtggttga	ctatgggtgc	atctttggct	24300
ttccctgggt	tgccttaagt	tgggaagcagg	gacaaaattt	aggggaagctg	ttagtatttc	24360
atcacgttct	ggcagtagtg	gactgggtgt	gatagaagtt	attgttttgg	ccagggtcgg	24420
tggctcatgc	ctgtaatcct	agccctttca	gagttcaacg	tgggtggatc	aggaaggagg	24480
gaggatttgg	gaggtcagga	gttagcctgg	ctaacctggc	gaaatcccat	ctctactaaa	24540
aatacaaaaa	ttagctgggc	gtggtggtgc	atgcctataa	tcccagctac	tcgggacgct	24600
gaggcaggag	aatcagttga	acctggggag	gaggaggttg	cagtgaacca	agatcgtgcc	24660
caatttcata	tcaaaaaaaa	aaaaaaagtt	atcgtttagc	ttcctcgatt	gttactggac	24720
gtagtaatct	ggcttcctgc	aagtctaact	ttcagcagac	tggctacatg	ggctgtgtac	24780
tgtagataag	gcagtaagta	aagcaaaaat	tgatagagca	tcaaggataa	atagaaaatc	24840
cgtaatcaag	cagaagattt	gaacacttca	ctttcagtaa	ctgataaaaac	aagtagacaa	24900
aaaaaatcag	taaggatgta	gaagatttga	acaacgtaat	taacaaactt	gacttgattt	24960
acacgtctag	aaccctgcag	aacacacact	ttttcaagca	tactcagaac	atttatataa	25020
agtgaccata	tgggtggacca	taaagcagtt	tcaacaaatc	tcacaggagt	aaaataacag	25080
accgtgtttt	ctgaccgtaa	gtacagttaa	cctagaaaatt	gaaaacaaaa	agctagaaaa	25140
accccatgta	tctggaaatt	ttaatatata	ctttgaaata	acaaatggat	cagagattaa	25200
ttcaaatagg	aatttagaaa	taccttgaac	tgaataataa	tgagaataact	ataccccaaa	25260
actgtggggt	gcagctgaac	agtatataga	cgaaaagtat	actcatatgt	gcatacctta	25320
aggagcgggg	aggattgaaa	gttaatggga	ggcaaaaagca	ggtggatcac	ttgagggttag	25380
gagttcaaga	tcagcctggc	taacagggtg	aaaccccatc	tctactaaaa	atacaaaaaa	25440
ttatccaggc	gtagtggagg	tgaggcaaga	gaatcggttg	aacccaggag	gcagagggtg	25500
cagtgaagccg	cgattgcgcc	actgcacccc	agcctgggag	acagagcgag	actccatctc	25560
aagaaagaaa	aaaaaaaaag	aaaaggccag	gcgcggtggc	tcatgcctgt	aatcccagca	25620
ttttgggagg	ccgaggtggg	cggatcacga	ggtcaggaga	tcgagactat	cctggctagc	25680
acggtgaaac	cccgcctcta	ctaaaaatac	aaaaaaatta	gccaggcgtg	gtggcgggtg	25740

032796-132.ST25

cctgtagtcc	cagctactca	ggaggctgag	gcaggagaat	gtcatgaacc	caggaggcag	25800
agcttgacgt	gagccgagat	cgcgccactg	tactccagcc	tgggcaacag	agagagactc	25860
tgtctcaaaa	aaaaaaaaaa	gttaatggga	taaacaatcca	tctcaagaag	ttagaaagga	25920
atgacaaata	aacccaaaaa	aaaaaaatca	aaagaagaaa	atcataaggt	caagactata	25980
aagagagtgg	ctgggtgcag	tggctcaggc	ctgtaatctc	agcatttttg	gaagcagagg	26040
tgggcagatc	acttgagccc	aggagttcaa	gaccagcctg	agtaacatag	agagacctca	26100
tctttgctga	aaataaaaaa	aaaaaattag	ccaggcatgg	tggtagtgag	gtgggaggat	26160
cacttgagcc	taggaggttg	aggctgcagt	aagccatgat	tgtgccactg	cacttcagcc	26220
tgggtgacag	agtgggaccc	tgtctctaaa	aaactaaaat	aaggctgggc	gcggtggctc	26280
aaatctgtaa	tcccaccact	ttgggaggcc	aaggctgagg	tcagcagttt	gagaacagct	26340
tggccaacaa	gatgaaacct	catctctact	aaaaatacaa	aaaattagtt	gggtgtggtg	26400
gcatgtgcct	gtaatcccag	ctacttagga	ggnnnnctnt	ngattatatt	ttctccttcc	26460
tacgtcgtaa	ttggactgaa	ttcagaatga	tgactctcat	tggagctctt	cctgtctcct	26520
aactacagtg	gcttccgacc	ccactctggt	tttcaacttca	cccctctgct	gctcatacga	26580
gtagatactt	ccttccttct	ttctcacttg	ttgctcttcc	tcaaccccc	ccgttggtgt	26640
ccctcctct	ttatcttttt	ctcgcgacac	ctgcgttctc	ttgccctctt	atcatccctt	26700
tctcgaggcg	gtccttttct	ttatccagct	taaataacct	ctcctctgtt	tatttggggg	26760
ttgggttttt	atctctcacc	ctccctctaa	tttcttctct	ctttccgcac	ccatcaagcc	26820
tctcgtgggt	tctcttctct	tactctcggg	tccccccctt	ctccccctct	ttttttcttc	26880
acccccccaa	gcgctttgcc	ttttttttct	ttgcccttta	ttcccccc		26928

<210> 7

<211> 29430

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (4336), (4345), (4349), (4392), (4447), (4490)

<223> Identity of nucleotide sequences at the above locations are unknown.

<400> 7

aggggaagg	ccggtccgt	agctcacacc	tataatccca	gcactttccg	aggagagagg	60
atcatctcag	gccaggagtt	caagaccagc	ctgggcaaca	cagcaagacc	gcatctctac	120
aaaaacttct	tttaaagctt	aaaaaaaaaa	aaaaaagcaa	agaggacagt	tcaggagaaa	180
agcctgtaga	ggcagcacac	taaggaggag	acgcagccca	ggcaccagga	ggggctggcc	240
atgggcactc	actcctccag	caggcgagtg	cccagcacca	gctggccccc	ccagacaccc	300
aggacacggc	ctgaatggct	ccgtattcac	gtgggtggtg	ataaacaagc	aatacacata	360
gccaataaag	acaccttagt	aatgttacat	cataaacgct	gcagatcagg	gaaatggtgc	420
agggtgaagt	gggttggggg	gctgcatgct	acatgagaag	tgggtcgggg	ggctgcatgc	480
tacctgagac	agagcaggcc	ttgctgggaa	agaaggagcc	ggcaggcctg	ggcaaaggctc	540
ctgggtgagg	agcacactgg	agcagagtgt	gggggtagca	tggcgggtgc	tggctcctctg	600
ggcgcttcc	caccacgtca	tgtgcccatg	tgcccaaggt	ctctcgtttc	acagccccct	660
gaagctcagg	ggtcacagct	acacagcccc	cagatacctt	ggcctgcccc	aggtcattcc	720
atccagtgat	ggacctgctg	acctctagcc	tgacctctgg	gcagcgtaat	ttgagaagga	780
ggagaaggga	gggcaacaga	cctggggcga	tgagggatgc	acagggtggc	agacacctga	840
ggctgcacct	tgggacctca	gttctgggtg	tgggtggggg	atggacaggc	tgagggtctga	900
agcagctggg	cccggccacc	atcacacccc	aggaccacc	agatcaccat	gaaaaaccga	960
atgtcaactg	gcagcccaga	gtgcagaaca	aacctttcag	aaacacgggtg	gtgactgccg	1020
catcatgaac	ataaaataat	tacgccctct	ccccagggat	cacccttgca	ggagtgtgtc	1080
ccaagaaaca	ccagaaagaa	ggaaaacgtc	tgagtcacaa	tatttgctga	ggccttattt	1140
gtaatagcaa	aaaaaaaaaa	aaaaaaagaa	caatctccag	cggcaggggt	aactagacta	1200
ttgtctccgt	ggaaaggtag	caccaattaa	ctagtaacaa	aatgactgcg	gtaacaacaa	1260
aacgttcgac	atgtcaacac	caaaaaccac	acaccagca	taaccgtgaa	ccatgatttc	1320

032796-132.ST25

tactagaatg	aatggcagtt	atgagaaagc	accagcggag	acaaagattg	aaaaagtaaa	1380
ggtggcctca	ttagggagac	aagtctctgg	gtaatatatt	gtaatactgg	taaatatata	1440
gtttttaata	tattttttaa	ttccaaattc	catatatgtt	cctatgaagc	tattttctgca	1500
aatatttttt	tcaggaccgt	acatcacaaa	ggcaaaaggg	ccaggtcagc	tctccagctg	1560
agagtggcca	cttcagagca	gacggcagac	tccagggtta	gcaagcctgg	ctgagacctg	1620
gccccagaca	atcactcaac	ccctctgacc	tcaacatcct	gtctgtgaaa	tggggataat	1680
tactgcacct	ccacatcaca	gagtgcgagg	cttaaacagg	atgcttcata	gaaaagcgct	1740
caagaggtaa	cagccgggag	ggggtagtgg	ttttcattaa	ttaaatgttg	ccttcattcca	1800
gccctgggcc	agctccaaca	caaagcacac	accatccact	cagactcagt	tgcttgatt	1860
caaagcccgg	cctggcctcc	agctgtgaga	ttccgggcag	gatttcccat	ctcccagagc	1920
ctcagtttcc	tcattcatga	aacaggaagt	gatcattcct	tttattttta	tttttatttt	1980
tattttgaga	cggagtttca	ctctagtgtc	ccaggctgga	gtatgatggc	gcaatctcag	2040
ctcactgcaa	cctcggcctc	ccagtttcaa	gcgattctcc	cacctcagtc	tcctgagtag	2100
ctgggattac	aggcacacgc	caccacgccc	agctaatttt	gtatttttag	tagagacggg	2160
gttttgccat	gttggtcagg	ctggtctcga	actcctgacc	tcagggtgatc	cgccccgctt	2220
ggcatcccaa	agtgtctgga	ttacagggtg	gagccaccaa	gcccagttga	caactgcttt	2280
taaagacacc	tctggctgct	gtggaaaaca	gcctggtagt	gcctcaaaaa	gttacacata	2340
gaatgatcct	atgaccagta	attccactcc	tacatatata	cccaaaagaa	ctgaaccctt	2400
ctactcatgt	atgtacacat	acaggtacac	gcatgttaac	agcagtgttc	acaaagccaa	2460
aacatggaaa	cagctcaaat	gtccataacc	gatgaacgga	taaataaaac	gtagtctatt	2520
caccacctga	cggaggtgag	agggggcata	aaaaggaatg	atgcataaaa	acgaatatta	2580
tggccaggta	tgggtggtca	cgctgtaat	cccaggactt	tgggaggctg	aggcgggagg	2640
atcacgaggt	aaggagtctg	agaccagcct	ggccaacacg	gtgaaacccc	atctctacta	2700
aaaatacaca	aattagctgg	gcatggtgga	gggcgcctgt	aataccagct	actccggagg	2760
ctgaggcaag	agaatccctt	gaacctggga	aacagaggtt	gcagtgagct	gagattgcac	2820
cactgcactc	cagcctgggc	gacagaccaa	aactccgttt	cggaaaaaaa	agaaaaaatt	2880
agccaggtgt	ggtggcgggt	gggtccctgt	aatcccagct	ctacttggga	tactgaggca	2940
ggagaaccac	ttgaacccgg	gaggtggagg	tagcggtgag	ctgagattgt	gccactgcgc	3000
tccagcctgt	gtgacagaag	gagactctgt	ctctaaaaaa	caaaaaacaaa	aaaggcccca	3060
cgcggtgtct	tacacctgta	atgccaacac	tttggaagc	caaggcaggc	agatcatctg	3120
aggtcaggag	tttgagagca	gcctgggcaa	cacggtgaaa	ccccatctct	actaaaaata	3180
cagaaattag	ccagggtgtg	tggcacatgc	ctgtaatccc	agctactcgg	gaggctgagg	3240
caggagaatc	gcttgaaccc	aggaagcgga	ggttgacagt	agccgacatt	gcaccattat	3300
actccagcct	gggtgacaga	gtgagattct	gtctcaaaaa	aaaaaaaaaa	aaaaaaaaaa	3360
ctaaaaaaa	gcaaaaaaac	caatgagtaa	tgtgtcaag	tgaacttcat	cccaatggga	3420
atgcagataa	tttgtttaaa	aggcaccatg	cacactgggc	aggctggcct	cccctgggaa	3480
cgtcttcttt	tgcttgatt	cccagttggt	ttaatcgggc	gtagaacact	ttcttcaatc	3540
cgggattcag	gcacccctgc	tcagcacaaa	ctcagtacac	cccgactctt	gctgtgggtt	3600
cttggcacta	ttaggagaat	gtgaggggtg	gattcagatc	tatctctagt	gggtgcatgt	3660
ctgccactcc	caggaacgcc	cacttctggc	aagtcagtgt	cagagaaagg	ccagctcgtg	3720
gcccctcctg	ccttgagtcc	caggaccctg	gatcagtcct	accgggagca	gaatcaggag	3780
tttgaiaacc	caagtgccaa	caatctcatt	ttaacccatg	taagcatatc	caatatttat	3840
atatagaatt	cataacagat	gtctgggctt	ccattccaat	agcctatatt	ttactactgt	3900
tattttacatg	gttacaccaa	acaagactca	attcaaggta	acccaatcct	ttgctactat	3960
acaaaaataa	gcaacathtt	cagtccatgc	cttatatata	ttaccaagc	attactactag	4020
gcctccaact	gctcatcgga	gcaagctgca	gcctggacac	aagctagaga	ttaatcagtc	4080
aggaatgatc	ctgcgtccag	tgccagcatg	atggaagaga	cagagaaaca	gaagacatca	4140
gggctccaga	gtcaaggagc	ctgcagggtta	gttgggcagg	atatacacac	atacacacac	4200
acacgcacac	acaaaaccac	ccaagaagaa	aaggtgggat	gaatgcatgg	acaggtaatg	4260
cctggagcct	ggggatggat	aagctgactg	caggtggccc	aggcaggctt	cctggaggaa	4320
gaagacctgg	ctgtangtgg	ggtangcang	ctttctaagt	ggggaaaatc	tggctgtggg	4380
tggagtggc	angtttccga	aaagaagaaa	agctgactat	gggtacacct	ggctgttggg	4440
ggaacangca	ggcttcttgg	aagaagaaaa	tctggctgtg	ggtggatcan	gcaagcttct	4500
tggaagaagt	aaacctgact	atgggtggac	caggcaggct	tcctagagga	agaagaccgg	4560
ctgtgggtga	accaggcagg	cttcctagac	agaggaagat	ctggctgcgg	ttagagtggg	4620
caggcttcta	agaagaggaa	gggctgactg	tgggtagacc	tggctgtggg	tagactgggc	4680
aggcttcctg	gaggagggaag	agctggagca	ttgaaaaaca	aacatgactt	ggtgaatgtt	4740

032796-132.ST25

gagcatgccc	aggcctgac	cccagaggca	attacgcact	caagttactt	aattctactc	4800
acaatgcctc	acaaacaact	tctctgacac	ctaacacagc	tctgggcacc	ttctagcttc	4860
agctcctcaa	agcagttatt	cacgctacta	ccctgcacac	ctcctcacac	cccaacccca	4920
gggacaggag	ttctgccaga	tgccaaagct	cctgatgcc	aagcctgggt	ctgcttccgg	4980
gctcctcttg	gtctaactgt	ccaccccgca	tcggcatgat	gtgcaaaaac	aaggctttgc	5040
aatctgccct	gatgcctggc	ggagcgagtc	cctcccgatt	cgtctccttc	agaaacacct	5100
gggctgccct	ggtcctgtta	tacccccaac	acattctaca	gtcagctccg	caagttccac	5160
aaagatcaac	gctggcggtt	ttatggcatt	ttattttacag	tttttacaat	ataaaaaagg	5220
aaggatgcca	cagctcagcc	agcaggacag	acagagatct	atgatgcttc	tgctgcacca	5280
ttgtttgtgg	tcaagaaagt	ctgttttcaa	tgatttatta	aattgtgggt	ggagatggat	5340
ggtggcagtg	gttaccagca	acatgaatgt	tcttaatgcc	actgaacttc	acacttacia	5400
atggttacga	cgataagtgt	tatatgtatt	ttaccacaat	taaaaacagg	taaatgcagg	5460
ccgggcacgg	tggctcacga	ctgtaatctc	agcacttttg	gaggccaagg	caggcagatc	5520
acctgaggtc	aggggttcga	gaccagtctc	gccaacacgg	tgaaactctg	tctctattaa	5580
aaatacaaaa	attagccaga	tgtggtgggt	catgcctgta	atcccagctt	ctcaggaggc	5640
tgaggcagga	aaatagcttg	aaaccgggag	gcagaggttg	ccatgagctg	agattgtacc	5700
attgcactcc	agcctgggtg	acaaaagcaa	aactctgtct	caaaaaata	aaataaaaa	5760
aaaataggta	aatgcaaa	tatggtatag	taatattatg	ggctattatg	agctacaaaa	5820
aagaatgact	tgggactaca	gttacagccc	tcattcagg	atttgtttta	aatgtgggtt	5880
ggtcgctaag	gcatgtacac	aacattttga	cgttcaaata	ttcctagatt	tggacagtga	5940
gcacccctct	aagctggctc	ttctgtccca	gaggtcccca	ccagtcctcc	agaacttctt	6000
tgctttctta	cacaataaga	tgcccatg	tcggcttgta	cctttccttg	ccccagccct	6060
agaaccagct	tcttcgtgga	caagctctga	ctcctttggg	tggagaatgg	tattcagaaa	6120
cccagacctg	ggctctgggt	tgctcactgc	tacttgggg	cattgttctt	aggcctctct	6180
gctgatggag	gtaggtatata	cacgtacagt	cttcctctt	cccagattcc	gtacttgagc	6240
tcgcctactt	gctaacattt	atttatatcc	cccaaattaa	acctcacagc	acttctgcaa	6300
tcactcactg	acttgacagag	tgtgaaaaaa	ctgagtcacc	atcacacgtt	ccaaactgag	6360
gtcaactgag	gccacaacgc	cccatcttct	tgctccggct	gtcgagatgt	aagcaagtgt	6420
ccttctctcg	gtctagctag	tgccatgctt	tccacatcac	tgtgcttttt	gtgggcaatt	6480
ttgctgtata	aaatgtcccc	tgacatatg	ctgctgtgta	gtgctcctag	gtgcatgagg	6540
ctgccccacg	ccttacagag	agaatatgca	tgagagctt	tattcaggta	tgagttatag	6600
cgtagttggc	catgaattca	atgttaattga	atcaacaata	tacagtaa	aagggtgctt	6660
ttagagacag	ggctcactc	tgtcacccag	cgcttagagt	ccagtgggtg	gaccttggct	6720
cactgccgcc	tcaacctcct	gggtcaagt	gatcctccca	cctcagcctc	ccaaactggt	6780
gggattacag	gcgtgagcta	ctgcactcag	cctaaataag	gtgtcttaga	aacacacata	6840
agacaagggt	atgggctgag	tgcggtggct	catgcctgta	atcccaacac	tttgggaggc	6900
caagggtggga	ggttcacttg	aggccagaag	tttgagacta	gcctgggcaa	catggcaaga	6960
cctcatctgt	atattttttt	aaatcagaca	ggtgtgggtg	tgcatgccta	tagtcccagc	7020
tactggagag	gctgaggcag	gaaaatggcc	tgagcccagg	aggtcaaggc	tgcatgacc	7080
catgattgta	ccactgcatt	ccagcctggg	gtgacacagc	aagacgctgt	cttaaaaaaa	7140
aaaaaaaaaa	aagccagggtc	aggtatcgaa	cagttggcaa	aaacgttgtg	acctgaggct	7200
cacaggaacc	tagcccgatg	tttcccctag	gagcaatggt	tcagtattca	ataattcagg	7260
gttcccagtg	actttatgga	gcataacttt	caagaataac	aagaaccaac	tgtacgtgtg	7320
tatgtatact	cacactttta	ttttatttta	ttttattttt	tgagacagag	tctcactctg	7380
tcacccaggc	tggagtaaaa	tggcgtgac	tcgactcact	gcaacctccg	cctcccagggt	7440
tcaagtgatt	ctcagcctcc	caagttagctg	ggattacagg	tgtgccccca	caaccggcta	7500
atttctgtat	ttttagttag	gacggagttt	cgccacattg	gccacgctgg	tctcaaactc	7560
ctaactcaca	gtgatccacc	cacctcagcc	tcccaaagtg	ctggaattac	aggcatgagc	7620
tgccgtgcct	agctacata	cacttttata	cacacatgca	tctatgacta	tttctctatt	7680
tctgtgcatg	tgtgctggc	agtacctaca	gtttcagcta	tgtgtctggg	tactgtctcg	7740
tccaagtttg	taagcacctt	ctccaaagtg	caaagcctgg	cttgtgttac	tatccatag	7800
tttacttatt	tgtcaatca	atttacttat	tagctccata	accagcttcc	catctgctcc	7860
agtagcctct	gctgtcagtc	acctctgcac	cctacccac	cttgcttccg	gatgctggat	7920
gccaatcacc	cccgacacct	ctacatagca	ccaccctcga	catgctgctt	ctttatttct	7980
tatttatttg	tttgagatgg	agtcttactc	tgttgcccag	gctggagtgc	agtggcacga	8040
tccaggctca	ctgcaacgtc	cgctcctgg	gttcaagtga	ttctcctgcc	tcagcttctc	8100
aaatagctgg	gattacaggt	gccaccacc	acgccagct	aatttttgta	tttttagtag	8160

032796-132.ST25

agatgggggt	tcaccatggt	ggccaggctg	gtctcgaact	cctgacctca	agtgatccac	8220
cttggcctct	caaagtgcgt	ggattacagg	tgtgagccac	cgcgccctgg	ctgcttcttt	8280
aaatgccagg	caccaacatt	tgtgcaatgg	ggtgggagga	aagaacaggg	aggagagcac	8340
actgccggcc	cctgcactga	atccactgat	caatctgggg	gcaactgcc	tctccatctc	8400
ctgtcttcct	atccgtgaac	atctactgca	gtcctctcca	atgtccttct	gtaaaagtgt	8460
attatgtttt	gcatacaggc	cttgcatatt	agttctcaga	tataatccat	atactttata	8520
taaaattcaa	accacattta	aaaaaataaa	actagcatga	ctataacgga	gtctgcaaca	8580
ttctcacaga	ctttatgata	aaacatgaaa	cttcaaagat	acttaggggtg	gggcagggac	8640
aatgtttaag	gctgcctgga	agcctcccca	tccctgagcc	agaaagtcct	atctcccctt	8700
caaggggaaa	tgcttgaaaa	agcactgatc	aggctaaaat	gacagggatc	agggagtaat	8760
caaagtacaa	gtgagctggg	ctcctccatt	ctgagcacag	caaagttcag	tctctccaag	8820
tccaagaatc	atacacctgt	ttgccaaгаа	tgaagttcag	gtgtctacaa	gtggctgaaa	8880
atattcattg	ctgggccatt	aacaacattc	ttggcaaaac	cataaccttag	cttctcgtgg	8940
aaatttctta	aggtagaaga	aacaggaaac	acccaggctc	gcttttatgt	agacagttcc	9000
atgaagccag	ggaccttccc	cacatccacg	tttcaattac	ctgcacgcag	ctcacagtgt	9060
attcaacatc	tacgcgtctc	tctactggg	gtggcggtgg	ccactcaaac	cctcatgcag	9120
ctacgatgac	cgcaattttg	gcaacataat	ttcatgtttt	tccttggggt	tttacccaag	9180
tcagtgcac	aattctgcag	ttgtctaaag	attcaaaaatg	agggacttga	catttacaac	9240
aataataaaa	tcttgggttt	cctttaacca	agcacatgtt	ctgcctttta	gagaaagctc	9300
tgcaaactca	agctggagtg	ggatacttgc	tgacatcttc	aagcacccca	ggaatagctc	9360
tactcccca	tttccacctt	ggctgaacca	tctatatccc	accaattccc	ccaacatccc	9420
tccatccgtc	catccatcca	cccaaggacc	tgctaagcca	ggaggtctct	cccactctacc	9480
ccacagcctg	gcctcagccc	acaagggtc	tctctacatg	aatcccaccg	caccagagta	9540
gaccaagtct	cccgtagact	ccaccctgac	cacctccatg	cctccagcca	ttcccacccc	9600
taaaaaccct	ccctggtctc	tacaccacgc	tgatgaatac	ttgggtgaat	gtgacctggc	9660
ctcctggacc	caggtgaagc	ccacgtcctc	cgtaagcccg	ccagctcacc	ctgcctctgc	9720
accttcaactg	gagagagccc	gcacttcacc	tcctcagggc	aggcatggct	gatgccaccc	9780
agtggaaatct	ggtgcaaagc	agggcccggg	gcagagcagg	gctgcctgca	gagcaaggcc	9840
ctggtgctgg	ggccgagcac	ctccaatgct	ggcgtggaa	ccatccctcc	cattccagggt	9900
gctgtctcca	tcaagaatga	gcgagctgct	gacatttgca	tgacaataat	gaataaatac	9960
catattttgc	ttcaaatacca	gaatagatgt	ggccagggtt	ggcatatgac	tggtgggaaa	10020
ggacagtttg	ctctctccca	aaccaacttg	gattataaaa	agcttttctt	aacgaccaca	10080
agagcggagg	agctcagggg	cagacaaaag	gaaggctggc	tgcaagaagg	gggagagtgg	10140
ggccttcagg	ggcggtggg	gagagagaaa	gcctggagct	gcacccccaa	ggtctgtgta	10200
catcaggtgc	tacagaataa	caccacctct	tccagcttgg	ccccacctg	ccctctccca	10260
gcccagtcac	ccagacagca	ccccactccc	cacacacacc	tcacatctgc	ccgcctcaca	10320
ctcaccagct	tgggtctctc	atgcaacctg	gaacctgccc	ttggcctctc	agctcagcca	10380
ccccatttcc	tgttggtccc	tggtccccca	tcgaattctc	tctaattccta	atgcacacac	10440
ttgcacactc	aaacacacac	acacacacac	acacacacag	cccagaggaa	aaccataatt	10500
gactgaggtc	caggcaagtt	tcccgagcag	ggaccacatt	tcaaaggtca	gggaagcagg	10560
cgaaacaggaa	acatacaggg	ggcacgtttg	ggggtggagc	aggaaataag	aaatcacttg	10620
caaaagataa	aaagaaaatg	aggtagctgg	tttcagacac	ctcggagcac	acagaacagg	10680
acaggcgcct	ccgggtcttc	cctcaacagg	gagatgggcc	aggcagggtcc	ctgctgctcc	10740
accgcagagc	tgggggtctat	ggccctgaca	ccaaggccct	ggggcaggcg	gggaggcagc	10800
tgttctcctg	cctgtgctcc	cgggcagggc	ctggcccccac	aagggaactg	gccgaaggct	10860
ctgcttggct	actccgaaa	gtcctgggag	acaagcaaa	gacttgctag	gtcactccaa	10920
acggcccaga	tgtgacaact	gtgaagaagc	cacaccaaa	caaggtgaca	gaacaatgtt	10980
ggtgacgtca	ggttatcagc	ttacgtctca	ctccacttac	ccgactcac	ccgtaacctg	11040
ccgtctcttc	ccaaccagta	aaggatgcct	aggtagaggg	gcacaaggcc	tgagagcata	11100
ttaccatttt	aaagtcctg	agaagtcctg	cggtagaggaa	gcctagtcca	ctttctctcc	11160
cctaggatttt	cccaactgcg	cctgatcaca	gaacattttt	tcatttccac	tcaggaaaca	11220
tattttgaaa	aacactggcc	tagaggcaga	agtgaatgg	aaaacacaaa	agtaaaaactg	11280
aacaggaggc	actgggcaga	gaacggctcag	aggcgccctg	aatcctggac	cgggtggagat	11340
ccccagcttg	gcatgctccc	ctccctgggc	ccagaccgcc	tccccccatt	tcttgataa	11400
gaaggcta	gcgcacagc	gtgaagggtc	tgcttgggtc	acacccccag	gctcgcccca	11460
caccaatcgc	gctcctgcga	gagccagtga	ctttcttgat	ttggctactg	tggaattgtt	11520
tgaactaac	cacccagat	acagatacaa	atgacaggat	gatcagatgt	aaaggaccca	11580

032796-132.ST25

caggtctctg	tgatacggct	tcatgcagcc	agcatggcta	gtgccgtgca	gaatgagaat	11640
gacccagggc	aagtecttgc	ctcccagacc	cagaacccca	tggagcccac	cagggctggt	11700
tcacaagcac	tgtctgggtc	gggcagagat	tccagcaaga	ggagggaaaca	tccatgcacc	11760
ggagccagtt	accagaagca	aatcgccctc	tccaaaaccc	aggctattaa	tggagtccac	11820
tgttgagtgg	agctggggtc	tagctatgga	atactgcaca	gcagagatct	tcctgagaga	11880
aagcagtttt	ccctgaaagc	catgtgtcct	ccactaactg	tgttttaatt	gggcgaacgt	11940
ctgtatctca	ttgcagtggc	cgcgcagtgt	ctgacaaggg	gctggggggcg	gggtggggag	12000
cagaagctca	ggggcctggg	aggggaaggaa	acaggccacc	agggctcccc	agaaggcatg	12060
tatctctctc	acaaacacac	gcatgcacac	acacgtgcac	acatactctg	caagccctga	12120
gttagcaact	gtggaatgtg	accagctcag	tgatcccagg	acaagctgct	agggaatatg	12180
acatttgatt	gatgtctgca	aatgtgcgtt	ttcactaatt	agaaggttta	gggcagagca	12240
gagaaaaata	tgtatttcag	agtcccagtt	tgacctgcca	gaaaccagcc	cattactaac	12300
attcttattt	tcaacaaaat	atagcattct	gattacatac	catcttggtt	ccacgcctcc	12360
tgccttgcca	agcccccgga	agcggcccaa	ggccatggca	aatagtgaga	gaaacagttc	12420
cagggaggag	actgactcag	gggtgtcagt	cagtggggcg	ctgatggccg	gtgggaggcc	12480
agcagtcac	accctctcct	tgggacagtt	gagtagctct	ccccagggt	catgtggcca	12540
ctcaggttca	tatgggaggc	gagaggagt	gcagagtcca	ggagagtggc	tccgaagtca	12600
ctgttccctc	caggcctcag	tgtcttcac	cattaaattg	gtaggctgag	gtctgggatg	12660
acaaggaggg	cttgcaacta	ctgaaaccca	tgggaggtcg	ttcgccgatt	tcttttattg	12720
atggaagaaa	acactcgtat	aattcaagta	ccaattaaaa	ggcaggcact	ggaaccaccg	12780
tctgccaatt	cctagttttg	cctataccaa	atttgagcaa	gttaattgac	ctctcccagc	12840
ctcagtttct	tctgtctgta	aatgagggtg	gggatggccc	ccagcccaca	gggcagctgg	12900
aaggattaaa	gaaatcaaac	atctcttaga	gccacctgg	cacactgtga	tacacaacaa	12960
atgttagcta	tttttgtcta	tgaagtctag	attttatatc	ttgggtgttc	taaagcagga	13020
tacatttatt	taaaaacaag	gattttcatt	aaacacgtac	cccacagaca	gcaaccccat	13080
ggagactgct	cttaattcag	gccagtatcg	aaacgactct	aactacaagc	tttatacagg	13140
tctcttggtc	gtccttcaaa	tccaactaag	gtggtacttc	tgaagcactg	tgcacatgtg	13200
tgtgtgcatg	cacacgtgtg	ggaagggcg	gctcacggat	ccctcaggtg	ccccaccac	13260
gcagtctcaa	gtcacaagc	gacagagcag	ccgaggaagg	tctgtgcccc	actggaccct	13320
cgtgaagcca	ccaactctac	ctctgcgccg	tgtcctgcag	actgggctac	cctttgggtg	13380
gggaccagca	tttgatgcaa	gaaaggcaga	cagaaaagga	aaagggcaag	ttcgactcca	13440
gataacacag	acagtaccaa	gccccagggt	ccataaatgc	cacgcagatg	gaagcattta	13500
ctgcgaggcc	acacagcaaa	cgcacggatc	cagggacgga	ggtgcagact	gcggtgcccc	13560
tgagccatga	ccctgcaaat	taccaccatg	ggaagaggag	ctgccaaacc	ccccgacagt	13620
cggctgggct	ggcacagact	cgtggtttcc	atcgagggtg	gaggagggtg	gacgtcccag	13680
cccctcccc	atgccactg	cagagggaag	cggccgtttc	ccctgtgtgg	ttacaaagg	13740
ctcattgttc	ttcctcacag	ggaggaaact	ggaggaccga	gctcagaacg	catttttagaa	13800
ctggcagaaa	agaacatctg	gggaaggaaa	cacatttcag	aaacaaacat	acctttgtac	13860
cagcttttat	tttctttaag	tgttgaaaaa	ataataataa	taaagacatg	ccaaatttat	13920
catcgctcta	caaaatccct	ttattgagca	aaacgtggca	gctctacttt	caaatgatta	13980
ctgttctctg	aaaattgcag	caacgtggat	gccaaggccc	gaaggccgcc	atcagcagcc	14040
aaacaaaaga	tgccacctcg	ggctccgcga	cactgtacca	tgccaggga	ctggacagat	14100
ttggggaatg	ccacggtttg	cctttaaccc	cttgccctct	ggtctcctga	tgcattctcag	14160
aggctaacat	tctttgagga	actggcattt	cttagttgta	aatatgcatg	tgggtttggg	14220
agctgcctgc	aaagtccagt	gttgacgatc	agctttgatt	tccttggaat	caagtttacg	14280
tgtcgagtct	ggaagttaag	agaattttg	agaagctgag	cactatgggt	ttgcaggccc	14340
tgggtgaact	cttccaccaa	gcattcattg	tggactgaca	gcgtgcgagg	ggctctgcag	14400
gcaggtgcac	aggacgaaac	acattccgtc	cgggggaaac	ctgcaggaaa	gctccctctt	14460
cttcctaagg	tgccgggctc	agcttcatgg	gtccctaccc	tccacgctcg	tcacactttc	14520
tgagtctcat	gtgggagctg	cttctgggtc	ctgacttcac	tcagtcctca	taggaggtgg	14580
aactactgtc	accccatttt	acagatgggg	agactgggca	caaggggacc	aagaaaccaa	14640
tgcaaaagtca	cacttggtgg	atcagtgaca	ggggagatca	attcccaggt	tctttctgca	14700
agagttaaat	tgttttcatg	ctgcctaagg	gggggcaact	gaaagaccac	tgcataatctt	14760
tgcaaaaagg	gtcaagcaca	ggagccgcag	ccagtgggtc	agatccgcag	aggcgctggg	14820
gtgacctcc	ccatacctgg	agggatgctt	gtccctcct	ggccttcaact	gggtcccttc	14880
atgacctgg	cctcccagga	cctcagcaca	atcccggtcc	tgtgtctcag	gacaagccct	14940
ccgtcccaaa	gactgtgagg	aaatggaacg	aagaggggct	cgtgcagcc	cagcaccac	15000

032796-132.ST25

actgcccctt	ctcaggggca	agaaccgtcc	tggaggactt	ggctttggag	ggggagcctg	15060
ggaggccagt	aagtcaacaa	gcctctactg	ctcatgggtg	ggatcccacc	gcaggccccc	15120
acctgctggg	gcgggcaggg	acgggcggca	cagcttgccc	agggcagata	acccccacct	15180
tggccagggc	gaaggcagga	cacgtgggct	ccagcctggc	cccaccatcc	ctgcacaaca	15240
ctgggcaaag	tccacgtttt	cctcaactgg	gtgttgacat	ctgcaggaca	ggggcatgga	15300
ggtacagagc	gctgaagcca	cacagcaacc	taggagcgag	actccatgcc	tccccgggga	15360
cccctcccca	ccatgaggac	catgaaggct	tcccatgtgc	cgcaaggact	ctggtgtgga	15420
gacacacgtc	tcctacacag	ccaggcctaa	cgctcttgta	actgggtggt	cccacctggg	15480
ctcacagctg	gagggccagg	agctcaaggc	ttcgcagggt	ctgctctcat	cccagaggcg	15540
atggggagcc	acagcaggct	gcaggagaga	gggtgggccc	cctccacttc	agaggcccca	15600
tctggcccac	agactggaga	gcacatctct	cagcaaccac	ggagcgccaa	ctgcgcacag	15660
ggcctggtcg	tcagagcggg	gcaaaggcac	tgaccgtcac	ggccagggcg	aggggaagacg	15720
ggtgggcagg	gaccttgggc	agagggggaa	gaacctgggtg	cccaggctgg	ccctgccttc	15780
agcagtgaag	ctgagtgggg	aggcgctgat	gcagggggcc	agaaagggct	gctggtcagc	15840
cgggaggagc	ccccacaga	ggaagcagcc	agcccagacg	cagatggcag	ggtcccctca	15900
acaatgtcct	ctgaaaagga	gaggcgggga	ctgctctggt	gacacctaca	aatagatagt	15960
cagccctcag	ccccctgcca	tacttctgac	aaagcagagg	cccccagggg	aggcgcaccc	16020
gaaggtacct	gcacctgtcc	cccagactcc	tagagcccac	ctgaccccat	cccaccaggg	16080
ctccagctac	aaaataaatg	ccgaggccag	ctaggcaagg	acgcacactc	ggtaccgact	16140
gaataggctc	cactgtgtca	tgagcgcaac	ccacaggcca	ccaggccaca	ctatgcagag	16200
ctgagatggt	ttcgcccaag	cagcctctca	gctgagctga	acaagtccag	agtccccggg	16260
gggtcgtcac	tatggagtaa	caattgcat	gcgatggtaa	ccctaacagc	taaccgtcac	16320
tgagccaggc	cctgagctag	gtacttttca	acgtgcctc	tctgcagcct	caggacgagc	16380
ctgtgggagc	ataaagatca	ttccctatca	cggatgggga	aactgagctc	tgaagcagtt	16440
aacgtgcttg	tcccagaccg	cagagctagg	agcaggacac	aacagcaggt	caggcaggaa	16500
cgggtgaggg	gggcctgcat	gggttctct	ggaggctgcg	catacacgca	acccccagga	16560
ccccgacct	gcacctgcag	ctcgtactg	ccccctcagt	gactccagca	aacctcgggg	16620
taggggaagg	aggctgggaa	tacctcgggt	gtccgaaaca	gcagcttctg	cttgagggcc	16680
actgctgcat	aatggttgct	gcccagcaca	ccccaaagcca	cctgtgccac	ctgtggtgac	16740
cttccagcat	gccttgggtga	ccaagctggc	cttaggtgct	gtgggcagcc	agaatagaa	16800
caggggccac	ccctcctctt	cacactaaca	caaagcaaga	ggcgggcact	tcgactgagt	16860
gcatccctct	agctcaaggg	cctcacggat	cacaggggtc	agggcaagat	cccaattctg	16920
cattcccgtc	tgcttttcat	cctgctctgc	caacaacagc	cagtgaaggct	ggggacatcc	16980
ctgaacctgt	ttctcacctg	aaacacatca	taccattgga	ccccagccct	ccgggagagg	17040
ccctaattccc	tgactgtggt	gagatcagat	cactggttaa	gtacccagaa	gggccttggt	17100
caggggatccc	aggggtgggg	ggtgatgggc	gtgtggtgat	cccgtcttgg	gctatagtcc	17160
accctgatgg	aggaggtctg	tggtcagaac	cgggtctgtc	agggcacagg	agcccagagg	17220
gacccccaga	gctcacctgg	tggtctctga	gcagggtctc	ctcaaccctc	agagaaaagc	17280
acagcaagga	ggcgcgccag	agcccagcgc	ctagcaccca	gtggcgtgcc	agacctgcct	17340
ggatcctgga	gatctctcat	caccttccaa	gtcagtcag	cccaacccag	ggaccacag	17400
cccacggggc	cgtgaagggtg	tgctgagtc	aagaaggcct	tcgacactgg	gaagccaagt	17460
ggcacctcct	ggtgtggagc	aggcggaatc	ccaccagcct	ctgctctgcc	agtgggcaca	17520
gctggacgat	gagcagaagg	ggctgttgct	taataaacgt	catttcctta	agaggataaa	17580
acctttcaaa	acagatggaa	atTTTTTTTT	aattaaaact	ggtggccaaa	gagatggaaa	17640
gcaccccttg	tgctccctc	ccatcgtgac	ccatcctctg	cacacctcaa	gctgttcgct	17700
gcccagggtg	ctcctgaggc	actgggggcg	ggtgagaatc	cgtgagccct	cggccagccg	17760
tggctctctg	gagctctgcc	ccaggccatc	agggcacacg	ccgggcaccc	tgggggccac	17820
acagggcaga	gcccagctgg	gtcagcacac	agggccacac	tgggcacaca	agtctctgag	17880
cctcccctgt	ggacgcagct	ctcactatcc	caccccacta	ggtcccgggg	atctgtccca	17940
cagggtgata	tgctgtcaca	gaccactacc	agagccatgg	cctgctgttc	cgcccgcagc	18000
caggtagtca	cttgctccac	agggacaggc	aacgcgcac	ttgggggctg	ctctgcggca	18060
ggactagagc	tccagcagct	cagccctcct	gagaaggaga	actccatgct	ctaagaggca	18120
gacgcagcgg	acggcaccaa	agccaccaca	agccacggg	gccctgcag	gcaggctcag	18180
agtccctgac	cactcgtctc	ttgtaaccag	agctgcagtg	gagtctacga	ggcaaggact	18240
gtgggcggca	gtggccacag	caaatgaatg	agtgtcccaa	gggagcaggc	ggctgcgggg	18300
aggcacagcc	gggacccagg	agtcctccgg	cactgcagca	aactccctgg	gccccctgag	18360
cagcgaccag	gtggcaagtg	catgaactcc	cgggggcata	acctgggagg	gtgacactct	18420

032796-132.ST25

cttcgtgttc	aaattcttga	gaacgcatta	aaaatatcac	tcagtcacct	actctatagt	18480
tttaactcaa	aagtacaaa	gtagccaggc	gcggtggctc	acgcctataa	tcccagtact	18540
ttgggaagct	gaggcaagag	gatcacttaa	gcccaggagt	tccaaatgaa	cctgggcaac	18600
atggagggac	cccatttcta	caaaaaaagt	gttttaaaaa	attacctggg	cctggtggtg	18660
tgtgcctgta	gtcccagcta	ctcaggaggc	tgaggcggga	gaaccacatg	aacccagggg	18720
aggtagaggc	tgcagtaggc	tgtgatggca	ccactgcact	ccagcctggg	taacagagtc	18780
agactctatc	tcaaaaataa	tttaaaaagc	accaagccag	gcttgggtggc	tcacacctgt	18840
aatcccagca	ctcagggagg	ctgaggcaag	tggatcacct	gagtcagaag	ttcgagacca	18900
gcccagccaa	catggtgaaa	ctccatctcc	actaaaaata	caaaaattac	ccaggcgtgg	18960
tggcgggtgc	ctgtaatccc	agctactcag	gaagctgagg	caggagaact	gcttgaaccc	19020
aggaggcaga	ggttgcagtg	agccaagact	gtgctactgc	actcaagcct	gggagacaga	19080
acgagactcc	atctcaaaaa	ataaataaat	caatcaaaac	caccaagact	ttttaatata	19140
aacatttatt	attccataat	tccttttttg	catgattaaa	aatgtttata	taaagtttcc	19200
tgaatgtgt	aagaatgcca	agtgaaggct	gcaaagtccc	aagccccac	cgtggcatct	19260
cacgagctct	gggcccctagg	aggctggtgg	gtaccacgtg	gacccgagac	ttcacagtca	19320
agtccctttg	gggtacactg	ggtttccac	accccagaaa	tatgggctct	tactgcagga	19380
ccatgggggt	cctcacactt	ggcccagaa	ctgtcacata	gccagacagg	tgttctacaa	19440
cctaggctag	agggagctca	tgctccagca	gaattcgagc	cagaggaggt	aaaagatggg	19500
taagatctgc	tccctggaca	gatgaggcct	tggcctcaga	acagttactg	atcatctacc	19560
agacatcaca	ctagaggcag	aggggcccag	acgaagacag	cccctgtcct	caaggccctc	19620
ccaggttggg	tggaccatgg	aaggttccag	acagatctgg	caagagaagt	gcccacacca	19680
ggggcagaag	atgggcaggt	ctgctcaggg	cggcacggcc	tgccaggcca	aaaagttcca	19740
acttcagatg	ctggagaatg	ggcacgactg	tctgagaagg	ggaaggatgt	gatgaaaact	19800
acttggagaa	aaattaatct	ggccagagca	taagataaat	gggcaaaggg	gaggttccag	19860
aaagcaaggga	gaccaagtaa	aagctgatgt	cattggctct	gaatctaggc	tttactgaa	19920
tatgcaccgc	agggcctgta	ggtaaagcct	cagagcccag	ggagtctgag	tggaggagag	19980
ggcaggggac	agagctgggg	cctgtgtcta	cagtgtcag	gaggaatagg	catggacgtc	20040
agctcggagg	ctccagctga	agtgaggagg	cggccagggc	agcacggcca	cgcccggatc	20100
cagactcctt	ttgggaagca	agttcgctct	gggggaaagt	ttggagaaat	ggcctttacc	20160
cgcagaagca	agccccagaa	catatcttgc	tccaaaacta	tctcgtacag	tgaggacgtt	20220
aagcttcagg	tcccctagag	gagacagtct	gctccttcct	ggggcagaac	ccaaggtggc	20280
cagagcctgg	aaggcaccca	gcacccaggc	tgggtgtgtc	cagcccaggc	cacacgtctc	20340
gatagctatt	aatgccccgt	tgagcaatct	cctgagagct	ttgccaggca	ggtaccgcct	20400
ccccatctga	actaatacag	gggtacatcc	caaggaagaa	atgaaagggt	cccacatttt	20460
gctctgggat	taactaggga	ggggagtgat	aattaactca	gtaattatat	ttgccatcgg	20520
gctaattgcta	aaattagtgt	gcattagaat	ttctttcctg	agcagacacc	ggagtgaatt	20580
gggcagcagg	agtggtctcg	gcaagtcggc	acaaagggca	cctccagagc	cttcacaaa	20640
tgtcagcaaa	accacaaat	gtcaaggccg	gtccactgc	acccagcaga	tgaattcact	20700
tccacagcct	gagaccgcca	gctcatcgga	ggccatttaa	aatccagccc	tctgacacct	20760
gctggatatc	accattttacc	gtccccagat	caagagatca	aaggggtgaa	cctgatagga	20820
cggctctgaa	gttcaccaca	aaagcataaa	cgtgcaagca	gagccaatac	gtcttttgaa	20880
aaggacaatg	aggtgggaat	ttacataact	gatcttaaaa	tatgttctga	tgcttcagag	20940
atggagacag	cagcattccg	gtacacaaag	acactcacag	gcagtggagc	acagtgaagg	21000
gtctggaatc	aggacccagg	tgtctgtgga	cactacacat	aaaagagcag	catttacaat	21060
gaatggatag	gatggaccat	cccaccaagg	tgttggaaca	ctccctattc	actggccaga	21120
cccctacctc	ataccatata	caaaaaaaaa	aaaaaaaaaa	aaacccagac	agaataatgt	21180
ctgaatgtaa	aacataaaa	agtaacagtc	ctggaagaaa	ataatggagg	atatatttat	21240
aatctggaga	tggagtaaca	agggatagga	aaaaagccat	agggaaaaag	tagagttatg	21300
attatatgaa	gcttcttaat	atctttatga	taatgtacca	ccagaaacaa	ggatgaagga	21360
ctagctacag	accagcagtg	aaacctgaaa	caaacagaac	aaagaattaa	agtccatacc	21420
aaataaaagac	ctcccacaaa	tctataagaa	aaagataaac	aggctggcac	cgtggcttat	21480
gtctgtaatc	ccagcacttt	gggaggcgga	gatgggttag	tcacttgagg	tcaggagttc	21540
gagacagcc	tggccaacat	ggtgaaaccc	tgtctctacc	aaaaatacaa	aaattagcca	21600
ggcgtggtgg	cgcattgcctg	tagtcccagc	tacttgggag	gctgagccag	gagaacagct	21660
gggaacccggg	aggcagaggt	tgcagtgaac	caagatggca	atcgcgccac	tgactccag	21720
cctggaggac	acagcgagac	tctgtctcaa	aaaaaaaaaa	aaaagaagaa	gaagaaaaaa	21780
gaaaagaaaa	agacaacaga	aaaatgggcc	aaggataagt	gtaggcaatt	tcagaaaaag	21840

032796-132.ST25

taaataccaa	taaaccagaa	atgaggggtg	tgcaaatcaa	aaggtgttat	aatttttaac	21900
caaactggac	caaagaaaac	acaaaaaacc	aaaatcttgt	aattgccagc	atcagagagg	21960
atataggaaa	gtgtgtgttc	tcgtagatgc	ttgcagggtat	gaactgctac	agccttttag	22020
gagttatgta	tgtatgtatg	cttgtatgta	tgtatttgag	acaggggtctc	gctctgttgc	22080
ccaggctaga	tctgttgacg	tgctgtgatc	atggcttact	gcagccttga	cctcctgagc	22140
tcaatagatt	ttcccacctc	agcctttcaa	gtagctgaga	ctacaggagt	gtgcaatcat	22200
actcagctaa	ttttttaaat	tttttgtaga	catggggggt	ctcccaattt	tgcccaggct	22260
ggtctcgaac	tcctggactc	aagtgatcct	cctgcctcaa	cctcccaaag	tgctgggatt	22320
acctggatga	gccactgtgc	ccggcctcaa	tatctttaaa	aacagaaatg	gacacactct	22380
ttgactagga	atgtatccta	taaaaacact	tatacacatg	cagagacaca	cgagcaagca	22440
tgctttgtaa	tagcaatgaa	ggctggaaaa	actcctcaat	caggtaaatg	ctgtcaagtg	22500
cacctgtgta	ctatgaaatg	gcacttggtc	tttaacaaga	gcaaagacag	aaaagcaaaa	22560
gtacaaagta	gggtgtgatg	gcacatgcct	gcagtcccag	ctactcagga	ggctgaggca	22620
ggaagatcct	ttgagcccag	gagttggagg	ccaggagctg	ggcaaatagt	agaaaaaata	22680
aaattaaata	ataataataa	taaaataggc	tgggcacagc	ggctcatgcc	tgtaatccca	22740
acactttggg	aggctgaggt	gggaggatcg	cttgatccca	ggagttcaag	gccagcctgg	22800
gcagcaaagc	aagacaccca	tctcaacgac	aaattttaaa	aaatcagcca	ggcaggctgg	22860
gcatggtggc	tcacgcctgt	aatcccagca	ctttgggagg	ccgaggcagg	cagatcactt	22920
gaggtcagga	gttcgagacc	agcctggcca	acgtggcaaa	accctgtctc	tactaaaaat	22980
acaaaaatta	gctgggcata	gtggcagatg	ctgtgatctc	cagctactga	ggcacaagaa	23040
tcgcttgaac	cagggtggca	gaagttacag	tgagccgaga	tcgtgccacc	gcactccatc	23100
ctgggcgtga	gtgagactcc	tgtctcaaaa	aaaaaaaaaa	aaaaaaaaaca	aggagccagg	23160
cacggtgggg	tgagggaggg	cacagaagca	gcgcctcttc	tgggggcacc	cccaatctct	23220
agcgatccag	aggcctcagg	atcctgaagg	gagaaaaaac	gtgaagctcc	gtgctagaag	23280
agaccataga	gattggaatc	agctggttct	attttacaaa	aaaaggaaac	tgaggccctc	23340
agaaggtgag	tgccctctca	tgccccacag	ggaggcaggg	agagggtctc	gagccctgca	23400
gggccctgga	ttcttgcaat	ggggtggagt	ggagcctgtg	ccgcccccac	caggcacctt	23460
ctcaggagag	gagccgttgt	catatccttg	aaggggtcct	tgagcccctc	aaaaggctaa	23520
aaaccacttt	cctccttgag	tgaaccttca	cctcagttta	accacaagaa	aaactacatt	23580
aaggcccagc	gcagtggctc	atgtctgtaa	tcccagcact	ttgggaggct	gaggtgggtg	23640
gatcgcttga	gcccaggagt	tcaagaccag	cctgggcaac	atagtgaaac	cctgtctcta	23700
caaaaaacaa	caaaatcagc	tgggctgtgt	ggtgcacacc	tgaggtccca	actacttgcg	23760
ggctgaggtg	agaggattgc	ttcagcccag	gaggtagagg	ctgcagtaag	cggtgactga	23820
atcactgcac	tccagcctca	gcaacagagc	aagactcaaa	aaaaaaaaaa	aaagcaggcc	23880
gggtgtgggt	gctcagcctc	gtaatcccag	caccttggtg	ggccgagcgg	gaggtacagg	23940
agatggagac	catcctggct	aacacggtga	aaccccgtct	ctactaaaaa	tgcaaaaaat	24000
tagccgggcg	tgggtggcgg	tgccctgtagt	tccagctact	caggaggctg	aggcaggaga	24060
aaggcgtgac	cctgggagggt	ggagcttgca	gtgagctgag	atcacaccgc	tgactccag	24120
cctgggcgac	agagcaagac	tccatctcaa	aaaaaaaaaa	attaaatctc	aaaaaaaaatt	24180
acattaaggc	aaactaaaag	atgtttaaaa	tatatataat	aaattaaata	cactccaata	24240
gagcaaatac	gaaaataccc	agaaaacaca	atccccgcac	ccccaggaca	acctcccagg	24300
gggtccacag	caagagaccc	caagcacgag	agacagagaa	cagtgtccct	gtggcggaac	24360
ctctggccca	tcaggctcta	ttagaaaata	aggctcttgc	cactgagaga	aagaggcaca	24420
gtcggcccag	agccacgggc	tctggcacac	cacgagtcag	gccagcaaag	tgtcaactgc	24480
cccctacaag	gtgacaaact	aggacaaact	ggaaaccaga	ggctggacct	ggagcacagg	24540
gaccaccaca	tggggctggg	gaatgggcag	ggacctcaga	gcgccacca	catgcctaag	24600
agcagcgctg	atgcgcatgc	ctctgcatgg	cttagggaca	caggagctc	ccccacccc	24660
caaccaggga	aggcagcccc	cactaccag	gtagggaacg	gataggacca	gcaccccggt	24720
ctgctcgtaa	ctcagggtct	caggccccct	cgggggcaac	cagcacagag	ctcagacccc	24780
aaatatcttc	acccacctcc	tggtccccat	ctggacaagg	gtgctgggga	ctggctctca	24840
gtcacaccct	cggggtacct	ttcaaaggac	agctggatgc	cccagggcag	gagcttttgg	24900
ccccagctc	cctcaccctc	gacaccagct	cttgggaccc	caccagcatg	ggcaaggtgg	24960
acaccatcgt	cccgatcttg	cagatgagga	aactgaggct	gagggtgggc	acacggctct	25020
ccagagctga	agagaatgca	gagagcagcc	ggagccagcc	ggtgggtccc	tgaggccggc	25080
tcgtagcaag	ccacagctgc	ctccgcccac	cacacttgga	cctcactggc	cccaggacag	25140
ccctccaggg	cggcctggca	cagagcccac	accctgctgc	ttcctgaaca	aataagtga	25200
caaggccacc	aagccgagga	cctggatgta	gccccggctc	ccgccagggc	ctccccaaca	25260

032796-132.ST25

gactccccat	ttggagagcg	cattaagtgt	ttccaaagcc	tcacaaacca	cagatgtccg	25320
gctgtctcac	ggcttctgta	acctgaactt	ggccctcact	ctgccctccc	agcactcctc	25380
tcagggccca	ggccctcctc	ctgagatgcc	agcactgact	ccccaacttg	tccccatcac	25440
ctggctcggt	cctgaacctc	ggcaggagag	tctcaggcca	gatcctccca	ccagccacct	25500
ccaccaggat	gcaggaggca	tgagacctgc	tcgtgccggc	tgggagatgc	aaccaacca	25560
gatcaatcca	atcagcggat	gaactgacaa	atataatgtg	gtccctccac	acaatggaat	25620
attattcagc	cacaaaaagg	gctgaaatag	gccgggcgtg	atggctcaca	cctgtaatcc	25680
cagcactttg	ggaggccgag	gccggcagct	cacttgaggt	caggagtcca	agaccagcct	25740
ggccaacatg	gtgaaatccc	gtctctacta	aaaatacaaa	aattagctgg	gcgtggtggc	25800
gggcacctgt	aatgcaagct	acttgggagc	ctgaggcagg	agaatcactt	aaaccaggga	25860
ggcagaagtt	gcagtgagcc	aagatcgac	caccgcactc	caacctgggc	aacagagcaa	25920
gactccattt	caaaaaaaaa	ataaaaggct	gaaacaccca	tacgtggtac	tacttggtatg	25980
actcctgaaa	acgttacagt	aaccaaggaa	gtcagccacg	aagacgcatt	gtaagattcc	26040
cttcatgcaa	aatgcccaga	acaggcagaa	ccacagaggc	agaaagtcga	ctggtgttca	26100
ccaggggatc	cggggagagg	gaacgggaag	tcaccgtgta	atgggtatgg	gttttatttt	26160
ggggtgatgg	aaatctctta	taacttgata	gaagagaggg	ttgtaaacac	tgtgaatgta	26220
ccaaatgcct	gccttctata	ctttaatatt	ttatattata	taagtttcac	ctcaatttaa	26280
aaaaaaaaa	actcgacacc	tttcacctag	gaaagatctg	gcttttagctt	gcatttcctg	26340
taactcctgc	ctaaagcctt	ccagaagctt	ccgctgcctt	gtggatcaca	accagactcc	26400
acaccatgat	ctggcctcta	agggcctctc	gcaggacacc	ccgagggtga	aggagcacc	26460
gtggggccac	ctctgcatag	ctgcaaagct	tctttccctg	tcctcccctc	tacatgggaa	26520
gctctgccc	caggggcggg	gccttatctg	ccattctatc	gcactcaacc	ctagcacttc	26580
actcggtagc	agacaccaa	gcaaaacagc	aacagcatta	taccgggcca	ggtgcacgtt	26640
aactcactga	attcatggta	ggaaggattc	tattccatt	ttacaggtga	gaaaactgag	26700
gcacacaaag	gtagcatcag	cttcctaagc	ctcccagcac	aggaagcggc	caggctggaa	26760
tcagaccctg	ggcgagggg	ctctgtccac	agtgtact	aactactcct	gcccccgagg	26820
gctgcagcgg	tgagtgagtg	agtttgtcag	tggactggat	gtccaaggtc	atacaggaaa	26880
aatccagact	attgtaataa	cagcctctag	accggctggg	gccagaaaga	tcgaggacgc	26940
tgacacacaa	ctgcgtcac	tgagctctg	ccagggtatg	ggctaaaggt	ctcacacagg	27000
gcagttaggg	ctccccatag	cctgggagag	gaacggggtg	agataacaga	aactaggtat	27060
ggtgcccga	gtcaaacagc	cactgagcat	gtaaaccag	gtgggtctga	ccccaaaccc	27120
ctccaccccc	atcacccctc	caaccgcctg	ctgcaaggta	gaaagcaact	cagaggcctc	27180
acctgcctac	atccccacc	cgtgtgtgtg	agttctacta	aatgcctgag	cagtgcacac	27240
gcacggctga	aattaaacgg	gttccaaaa	cgacaggaag	cacgaagtga	atctccccag	27300
gaaagtgtctg	aacaaatgct	ggatcgggtt	caccggcgaa	tttcttgga	ctgaagaggg	27360
gagctaaaca	cacggggccc	tgctttggag	gggactctct	cagggtgctc	cacacagcac	27420
ttggttaacc	ccactcagcc	cttctgggct	ctcccagagg	gcccggcctt	ggccttgggc	27480
atctacagga	ggaacctcca	gggggagagg	gggtgcctgg	acaggccggc	cctggaacaa	27540
gcacttgggc	cccagaggaga	gaggactagg	gcttgggagc	tggggaagtt	ctcagcactg	27600
ggaccactag	aacaaagcca	tttccgtgcg	ttcacagctt	ccaattgcaa	caggaagcaa	27660
tcaggaaaaa	taattagcgg	cccacttact	ggcttcgctg	aggtccgagg	catgtatttc	27720
acacagtaaa	accaggggata	taacatcaaa	accgttctgc	agaaagattc	ctccctttcc	27780
ttccatttta	ggcctggatc	accacattca	ctggggctcc	caggccttgc	tgccctaatgt	27840
taaaataatc	aactctattt	ttgcctcaca	cacaactgaa	ctctacagct	ataattcttt	27900
ctcctcaggg	gctcgaacca	catggacgac	aggcatttga	ctccagcaac	atcaccccaa	27960
aacgtgcaca	aaacccaaaa	ctgcaatgag	gtgaaaggca	acgcggtcgg	cctagaaacc	28020
ccccctttta	aacaaacagt	ttccccaaaa	ccccttttgc	ctccttgacc	caggcatttc	28080
cggaaaaaag	agcggcgctg	gcctgtactc	cccagatact	gtcgtgtgtt	tgtcttcacc	28140
ttgttttgct	agctccagac	aaggccccac	aagttaacaa	cgctcctgaa	agaggcagat	28200
ttgggggtgaa	actgtccata	gaatctctag	gcttgggtca	gaggcaggag	gacgtgaaac	28260
aaactccaag	ctcctcctgt	tccccgctgt	ccccacacc	tccaagcaga	ggctgcagcc	28320
tgggggatct	gactacaggg	ccaccccgct	gcaccattca	cactggaaat	attcagggag	28380
acagctgttt	gccttaaggga	ggcccagaca	aaggggcccg	aggtcctccc	cgctaaactg	28440
ccacaaacag	aacaggagcc	gcggcggtga	caggcacttg	cgcccggtgc	acttggccag	28500
ccatactcca	gaaaaacaaa	acacgcacat	ccgaagagaa	tgatttaggt	agcaagaggc	28560
ttgcttgaaa	aaccacatgg	caatctccaa	attaaaagaa	catgtgtagc	gtttcacgac	28620
tgcttaagtt	tcctgagtc	tcctgacctc	aactccaccc	cctgggaaac	acaaaaagtt	28680

032796-132.ST25

ggatgagaaa	gttcccccg	cctacctctc	cccacgggag	tgtacaactg	aggcacaagc	28740
ctgctctccc	cactgccccg	cgatctggga	ccacgtctcc	tccgcgtagc	cgacccgggg	28800
atggacacta	tctggggacc	cggcggccac	acggggcatt	cgggtcgccc	gggcacctgg	28860
caggtgtcag	tccgcttgga	aaccacagc	cacgcggctc	acaggagcag	cgccaccggc	28920
taggccgccc	cgcgcccggg	ctcagaactt	tctcgctgcc	acttcagccc	gtcctcggag	28980
cacgcggggc	ggccgcgcgg	ccgctggaaa	caggcttgcg	aaccggctcc	ccggggccagg	29040
cccgcctccg	cgccccaa	ccccgctcgg	tgcccgcccc	gggccacacg	ggcccagcgc	29100
gggctcggct	cggctccccg	cttcccgcgg	gctcgggcag	gtgaggaccc	gcccgcgccc	29160
cacctggcgg	agcgggcggc	ctcctcgcca	gcccgggacg	cagcgtcccc	ggggaggggc	29220
cgggtgggga	gacaaagggc	ccgcgcgtgg	cggggacgcc	ggggacggca	gggggatccc	29280
gggcgcgcgc	cccaactcgc	tcccaactcg	ccaagtcgct	tccgagacgg	cggcggcgcc	29340
cgcgcacttg	gccgcggggc	cgcccggggc	attgtccgag	caaccgcgg	cccgtcttac	29400
acgccggggc	cgggaaggta	tcgaatcagg				29430

<210> 8

<211> 33769

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (33739), (33749), (33758)

<223> Identity of nucleotide sequences at the above locations are unknown.

<400> 8

cttcccccta	cactggtoct	tcgacccgcc	tcggatgaaa	actgaatggg	tttagcctta	60
gaggctctcg	gtctctaagg	gagggtgggtc	aggatgccgg	ggacagggtc	ctcttcctgg	120
ggcaacgtgg	gggaacgagc	cacctacccc	tccactgaat	tgccctgggg	tgtgggtacc	180
gacggctcat	tcggtgtcca	gggtctgaga	tgtgttgaca	ggaagaatga	aaggggatgg	240
gagggatggg	gcgaaagaag	ccacctgcag	ccccaggaac	tatctggcca	gcacaccgtc	300
accgacggc	ctgagccacc	cctgccagag	ccaggaggag	accctgccaa	tgggtcacca	360
gtgtgcagga	actcagaagg	tcacacagag	taataccctc	catgccccaa	tgtgggaaaa	420
cagggttttt	cacaacaaac	aagataat	ttgttat	ggcaaaagga	ggcagggcag	480
ccccggacac	ctccatccca	cctcatcacc	cagccgcagg	gccccggcca	tccctgcaga	540
cagagtggat	gtcacaacct	ccctgcaccg	aaccaagtgc	agctcccagg	ccacaggcca	600
cccaggaaa	gtccagtggc	ccccggaggc	tcccaccgca	ggcctccac	cacagccggc	660
accaaccag	gatagctgtg	ttctcctggc	ttcttttcac	acgggtagca	gaaagctgag	720
atccggggaa	agctgagatc	cagggaagc	tgagaatcgg	cctctgctgc	ccggacgccc	780
acccccagct	ctgctcccag	ctccagggcc	tccttctcag	gtgcccttac	aggaggcaga	840
gggcttgagc	cacctcctgg	gcctggggca	cgcaggatga	acggggtcac	ggtgcaggcc	900
actgtccact	gcgcagatcc	caaggccata	aacagcctgg	ccacagtggc	ttcccagctg	960
gcaggcggcc	agattat	tggtgtttag	caattgatta	agtttctccg	ctgccccag	1020
gggtaagtgg	tggggcaaat	gccgcaaccg	cagcatttga	cccgggatcc	tgtgccaa	1080
gaccatagg	tcacaaagca	caagggaagt	ggctgggccc	gatgctggct	ctgctggaac	1140
ctgagccgg	ccactgtcac	ctgcacgggtg	cctgggacct	tccagcaagc	acagagaagc	1200
tatggccctc	caggagcagc	tggcaggcac	cttggcctgc	agtcaggggc	tctgtctgct	1260
cagctctaaa	acaggaaagt	cgctgctctg	cctgggggtca	gggcagccag	agagtgacca	1320
agtcagtggc	ggcctcagg	agggacctgc	aggggggtcc	cttctctctc	catccctcgg	1380
tgccagccag	ccccctcgt	ggccccccac	tgccctgctc	tgcccccatg	ccccaccaca	1440
acctcaggcc	catggctgca	tggccactcc	ccaggcaggc	agtggggatg	ggatttcacc	1500
atgttgcca	ggctggtctc	gaactcctga	cctcagggtga	ggagttccta	aagtgtctgg	1560
attacaggcg	tgagccaccg	cgccagccct	ccctgtggta	ctaaacactc	acacccctt	1620
gctggggacc	ctggtgaggg	aacacagcct	cacaagtga	gtgtgggttt	gttgagcaaa	1680
tgacgcctgg	gcagccctct	catctttgcc	taaaactgaa	gaatttaggg	gcgtggatgt	1740

032796-132.ST25

ataaaacagt	tgggtgactta	aatgaaaaag	aaggccacac	tcccccttt	aggcaggcgg	1800
cctaattctt	taaaagccag	cacagggtgc	ctttctgaac	ccaggcacac	agtaggtgtt	1860
caatggacag	cagcggttac	ttgtactgct	catgacaccc	tgtctgtggc	ctctgcagct	1920
ggctccagcc	tgacgcatgg	ctgcgcccct	ccgcaaggcc	accccgggat	acatggaaac	1980
tctgtggaga	aggccttggg	ggcggccag	gacgccaggc	ccagatccca	tctgcgccct	2040
tcctccatag	acctcagcga	gctctcggca	ccatgtgcct	caggcccatt	taagaagtag	2100
ggccggccag	gcatggtggc	tcatgcctgt	aatcccagca	ctttgggagg	cccaagggtg	2160
gtggatcacg	agatggtcag	gagatcgaga	ccatcctggc	taacacggtg	aaaccccatc	2220
tctactaaaa	atacaaaaaa	taagccgagt	gtgggtggcg	gtgcctatag	tccaagctac	2280
tcgggaggct	gaggcaggat	aatcgcttga	gctcagcagg	cagaggttgc	agttagcggg	2340
gatcgcgcca	ttgactcca	gcctaggtga	cagagagaga	ctctgtctca	attaaaaaaa	2400
aaaaaaataa	aaaaaagaag	cagggccagc	cacggacgac	ccctcacaca	gctcccagga	2460
cgcgtgcctg	ggtatagggc	tcaggaccat	gaccgctgca	gtggccccc	agaaacgtta	2520
cttttgtcac	ccaccccgcc	tcagtggcag	tagccaaaat	aacggattag	aatggaacca	2580
tgtgacaatg	ccactgcccc	aactgacaga	agatggctat	cagcagttca	cgcggcccca	2640
cctatcacaa	gtgcagggca	ctctacaact	tatgcatect	tcccagaca	ccgtcctttc	2700
gaccctccca	ggcgcaag	gcacacagg	cctacatttc	acagccacac	agcagagggc	2760
tgaggctgga	actcggtg	tctgatttcc	gttcaatcac	atcccagag	gtggcacaga	2820
gacggggggc	ttctcctgac	aaagtcaaga	aagtcaactgc	cagctccact	gaagaccaaa	2880
gaacctcagc	tctcaaacc	tcttgaaggt	gttaccgaac	tctcccagcc	tgtttctctg	2940
gtcccgatgt	tgggtccctg	ggacacagga	agaggaagaa	gctccctaga	gcagagcctg	3000
gtgcacctgc	cacactctca	gagggctg	cacgggcgga	ggagccgtgt	gcaggagtgg	3060
ggtctggatg	gagggcgct	gtggccggg	gcagggggca	ggggaagggt	gctccagggtg	3120
gtgggcacag	cacgagcagg	ggcagggagg	tccacactca	gatgtgcaca	gggagaaaca	3180
aatcgtgcat	ttccattgga	ataggcggt	aaaggtagaa	aaacagagt	ggggccagga	3240
agggagtcgg	agccttctag	tgtctctctg	caggtgagcg	gcagcccag	gtgtcagctc	3300
agcagacttg	gggtccagg	gccgtgtctt	ctatcactga	ccccagggca	cacggaactg	3360
gggagggaga	gcagaggcac	agggcacggt	cagtgaacg	aaacaaggag	tcacaccaa	3420
atgcggaaa	ggcaaggagt	gcccgcagcc	gcacaagggt	tctgtctggg	caactgggg	3480
gtcccaccag	gccccgcacc	ctgcaagcgc	aaagctcgcc	actgaagata	aagggaagct	3540
gttgagctg	cggagctggt	ctggggctcg	catggagctg	ggcttatgct	gcagtcacaa	3600
gggggacatg	gaagaggctg	caggggacaa	aacagtgac	cacagtctaa	ctctgagcct	3660
gtggaaaagg	gccccagca	ttcacccatc	ccagagtgc	cattccccct	gtgccccgc	3720
tcacggtga	cagcggttct	caggaatatg	atgcgcccct	ctcctcttgc	atcagccctg	3780
acagtgaagta	ttcaggccaa	aaagcagaag	agcacagctg	cgtgggtcca	tttccatgta	3840
gttctggaac	aggcaacgct	aatccaaggt	gatagaagtc	aggagagtgg	tggagggggc	3900
gggggttgag	gatggcaaa	gggcaccggg	aactttccca	gtggtagaaa	tggtctctgt	3960
ctggaccgtg	tggtagttat	gcagacatat	gcagctgtca	aagttaatcc	aatgtacac	4020
gttaaaatgt	gtgcgtttta	ttgcctgcaa	gttatacctc	aattaaaaaa	ataaagttag	4080
cactcaggct	tcttccacaa	cttctgaac	cgtgtgagct	gattttcttg	ctattaaaaa	4140
ttcacggtcc	atggctgaga	acagcagctg	ccttctgttt	gcaaagtcaa	cgccaatcac	4200
tgcccgccg	cggcagactc	ggccccacag	gacctccttt	cttttttccc	tttgacctac	4260
ttccctgata	agtgacaaga	cagccagact	ctgggaacaa	acgcccgta	ttcggccccg	4320
agctgagcgg	gccctgcttc	ctgagctaat	ccgcccggac	agacggagg	acgtgagggg	4380
ctttgccgtc	ggctccagct	gtcagctctg	ccgtcagact	cgacagtggc	cccctctgtt	4440
cctcccgtg	ccccactcc	atccccgact	tctttttgtt	tctgtccct	gacagacgaa	4500
catctgttaa	aactctgtct	gggtgagctg	tggccagcgg	cccacaaatc	cccaagccgc	4560
acccagcct	catctggg	ctgcccggag	cactgcctgg	ccacctctg	gacatagctc	4620
tgagagccac	cggccaggc	acgtgtggcc	cgagtggcat	ggtgcacgcc	gctaagccca	4680
ctgccc aaag	gcccccaagc	aggaggagtg	tcaggaggac	aaaagtcaaa	agaacagggg	4740
cacgttccac	agaggatggg	gctggagggg	tggcagtga	gaacagcagc	ttccgaggat	4800
ggcgtgggca	actcccaaat	aaggcctcac	tctgtctgtt	tttagctcat	tccacataat	4860
tggaaaaaca	tggcagaaac	cgaagccagc	tgtgccttg	gtcctggggc	tgtgtggagg	4920
gggtggggag	gcccggaggcc	caggctctgc	actcgactgc	tggggatgag	agtgactctg	4980
agctgcagag	agcagcatcg	cagccgccat	ggtcccattg	agccccggcc	acgtggggcg	5040
gcagaggctc	gtgggatata	cctgccctgt	ctcatggggg	tcacttcagg	aggggagggg	5100
gagccaggac	acagcccagg	gctagcggtc	accctgcagc	tcagggggca	cgtaaatagt	5160

032796-132.ST25

gccaccttga	aggcacacag	cagtgcgggg	cccccccg	caccaacgca	tccctacctc	5220
taggaggccg	cctgtgtgcc	cctgggaacg	ctgctccctg	tcccttgggg	tccctggtgtg	5280
accaccctct	cagcccttcc	cttggggaag	gcacctgact	ccctacaccc	agctggcttt	5340
catttgcctca	aatcagga	aaagcagaat	tcaagacatc	acagaaatgt	cttcgcctgt	5400
aactccatga	aagataaacg	gtcagacacc	caggaggag	tcccaggac	ccttgagtct	5460
cacctgaggc	tctggcttca	aacctcgaga	tgtttccagc	catgctagcg	ccgcccccca	5520
caacctgccc	cacacagtcc	tcccttggga	actcacagat	ttggccccca	cctgccccgt	5580
ttcttctggt	ggagtgggtg	cgttgggttg	gggtggggct	ggggactctg	gatgtgtctt	5640
aagagtctga	gtgattctga	cacagccagg	ccctgcccc	ctcctgacct	tcgccccaca	5700
ggaaagggag	ccacacgcct	gaagcgccca	gcacacccc	ctccgtcctc	cccaggtcac	5760
ccgctggccg	tgtgagccgt	gtcctccact	gccccctcac	ccaccccagc	tccctcctggc	5820
agcaccacagc	cttggaagct	acttctgatt	acaaccgccc	aaggaagact	cgctccctcg	5880
gcaactgacc	agacagcctg	caccatcacg	ctgctcagca	caaccacac	agccttcctc	5940
caaaccctcat	ggagcgggga	gtataatcac	cccctttcta	ccaacggaca	aactgaagca	6000
cagagaggtt	aagtcacttt	cctaagctcc	caacacgatg	acaaaaata	gaaggtcagc	6060
ccgcaagtgg	aactaggtgc	tccaagtccc	cggctctgcct	gacactgcac	ctcctcgccg	6120
ccacggtccc	gggtccgcct	gacactgcac	ctcctcgccg	ccacggtccc	gggtccgcct	6180
gacactgcac	ctcctcgccg	ccacggtccc	gggtccgcct	gacactgcac	ctcctcgccg	6240
ccacggtccc	gggtccgcct	gacactgcac	ctcctcgccg	ccacggtccc	gggtccgcct	6300
gacactgcac	ctcctcgccg	ccacggtccc	gggtccgcct	gacactgcac	ctcctcgccg	6360
ccacggtccc	gggtctgcct	gacactgcac	ctcctcaaca	ccaccacggt	cccgggtctg	6420
cctgacactg	cacctcctca	ccaccaccac	agtcccgggt	ctgcctgaca	ctgcatttcc	6480
tcatcaccac	agtcccgggt	ctgcctgaca	ctgcatttcc	tcatcaccac	ggtcccgggt	6540
ctgcctgaca	ctgcacctcc	taccgcccac	ggtcccgggt	ctgcctgaca	ctgcatttcc	6600
tcaacaccac	tccctggccg	gtcctcaact	acaaaccaag	ccatgtcttc	catcctgaat	6660
cctcttggcc	taaacatcac	tcacaatgcc	tccctcgcca	acaggcaca	gtcccaccag	6720
cacagcctcc	ttcgttacct	gcgtttccgc	tagcccagg	ccagctccag	agccctcacc	6780
acagagcctc	tatccttcac	ccccggacac	tggacctcac	caaccatag	cctggaggag	6840
atccctgtgt	gaccccagg	cctcctctgc	ccgactctga	atttactgc	ccaacgtgac	6900
acctcggaag	gctctctggg	cactggcagc	cctccatggg	caccgtcctc	tctggccagc	6960
tctgacatcc	cggtctgtga	ggtgccctgc	acgaggcctc	tgcccactgg	gacctcacag	7020
ccgtgctgtc	agctgcaaca	agcgacagaa	tttcacgttt	tcttcacgtt	gcccctgggt	7080
gagcagctcc	aggtagtttt	cagtcgaggc	gaggcgtccc	gtcagcagcc	aggcggcaca	7140
gctaattcat	gcccgcagg	cgcacggccg	caataccaat	gggcacctgc	agcctggaaa	7200
gccacagagg	aagcagaagc	agcgactgtg	ctcaggtgac	aggactgtgg	tcttttaaca	7260
aaacattttc	ctttaacgtg	atattttacg	gcaaggatg	aaacctggag	ggcaggacat	7320
ttggatacta	aagccccagg	ctgccgcgtg	gtctgctttg	tgaagtctga	agcccgccgc	7380
ccatttctggc	cccgtctaca	ggtccggctc	tgactcacca	gcttcaatgc	taggccgtgc	7440
ctgtcctcca	accagaacat	gacttcctta	aggacaaagc	cgtttctcgc	ccatccccat	7500
ctcctctggt	attaagaaat	atgggaagat	cttctagaac	cacctcaa	ttgcagagag	7560
ccatcctggt	gacaaacctc	tgaatgctt	ctaagaagag	tttaggtttc	ttctcaactc	7620
taaaacctct	agaaaactct	atttccacac	cagctgcccc	tgaacactt	cagcttcaaa	7680
agggccaggg	gcaggagagc	ggaggagcca	gcattccacac	cgagcaccag	cctgttaatt	7740
aacgggaagc	gggtggggcc	catctccagg	cagctctgag	gtcagactgg	ggaacctatg	7800
ttacaaaaaa	aagtgaactg	aaacgctcac	gtcctcatgc	aaaaccagac	tcccagttgc	7860
atctttctgt	ctcattgagg	agctttttcc	tccctttgac	agaacaccct	acacacggca	7920
tctggaacca	aagcagaaag	attcaggctc	agagtaaaac	agtccccaca	ctggctgcat	7980
gtggacgttc	ccggcccaga	gtctcgccca	agcagggcct	ataaatgaca	caaaatgttt	8040
ttctcctgcg	tgccagtcac	gtctccactg	agttatgtgt	aaaagtgcct	ctcacggctg	8100
agggcaaaaa	cagttcccc	aagactagag	aaaggtgacc	cctgacggct	gagtctctag	8160
ggagcgtgga	gctcgctgct	cagccctgcg	gcccctgacg	ctctggaatg	gaaaagctat	8220
ccaactggaa	gggcagggct	cgctgctagt	ccacgggtcc	aacccacag	gtgtctgtgg	8280
tgtcagctcc	atgccacaga	gcccagggct	ggggccagag	ccaccaggcc	ccctgccagc	8340
ctgcaggggc	ctcctcctct	gggtagccta	accacccctc	gtgagcgcag	gcagcctcct	8400
ctaatacca	cagggcctgt	ccccccctct	cccccgcttg	caggaaaatg	agccctgagg	8460
actccccagg	gctgctctgg	gcctggacat	ggagactggg	aattacattt	gcagaaggag	8520
cgcaatgccc	ttgaagggtc	cagccacgag	cagccagctc	ccagggtcca	gaaggcccag	8580

032796-132.ST25

ctgttagaac	cctgggagcc	agcaaagagc	caggggctcc	acctaagtct	atagcccctg	8640
cctcttctgg	ttgggaaaga	aatcaacgcc	cctttactgg	ctcccactga	cagcccactc	8700
ccccaggat	gggaggattc	tgggacgatg	caggcaaacc	tggaccctga	gtgaacctgc	8760
cccagctctc	acgggcctgg	caccagccac	agcacctaag	gcgccggtca	tggtgacaac	8820
atgaaggatga	taagggcag	gacagtggac	atggcagctg	gacactgggc	acccactgga	8880
tgccaggcac	ccagcacggc	tccgtcacc	ctggatgagc	agtggccctt	tgcaagccag	8940
ggtagcctgg	gcaagtattt	tgggggtctc	caagcttgct	cagctgtgcg	acttcactga	9000
gccatgagtc	tgggatttta	tcagggccca	caccgcgttc	tggaaactctg	atacgtgagg	9060
gagccacaca	gggaccctta	acaaaagctc	ccagggcaac	atgttctctt	gcctcagtct	9120
cccaaatagc	tgggattaca	ggcgcacgac	taccgcccgg	ctaatttttg	tatttttagt	9180
agagacaggg	tttcaccatg	ttggccaggc	tggtcttgaa	cccctgacct	caaataatcc	9240
ttccactgtt	agggcaaggc	acctgacagg	cacgactgca	cgatctgctt	gttgggggct	9300
gtgtccattc	cccactcctt	cgacaaatgt	ccacaccag	ccttgctttg	acaccccaag	9360
aacagagatg	gtgacacctg	cttcctacat	gccatttgct	ctcccaaggc	agacatcccc	9420
agcagatgca	acacagtgtt	taggcagaca	tcaccaatcg	atggtggcaa	cagacaccag	9480
gccctgctcc	ctctaactcc	agtggccagg	ccccaaagcca	gctctcacct	gcccactccc	9540
aaccacacagc	agcaagactc	agaaatggca	aaaacacaaa	gagaacagaa	acgcccata	9600
gcgggaggat	gactaaaaga	catgtcttga	taagatattg	ttcaggcata	ggccaggcac	9660
agtggctcat	gcctgtgatc	ctagaacttt	aggaggctga	ggtaggtgga	tcacctgagg	9720
ttaggagttc	aagacagccc	tagccaacat	ggtgaaaccc	catctctact	aaacatacaa	9780
aaattagcca	gacatagtag	cgggcgcctg	taatccacgc	tgcttgggag	gctgagccag	9840
gagaattgct	tgaacctggg	aggtggaagc	tgctgtgagc	cactgtactc	caacctggac	9900
aacagagcaa	gactctgtct	caaaaaaaaa	aaaaaaaaaa	gatatacctt	actaaaactc	9960
atgtctttga	tacatattta	cctcctgcaa	tcgcaaatgc	ttctgcagtg	cataaagtga	10020
aataaatagc	aggaagcctt	acggttcgat	caccacacac	gacacacagt	cacatacagg	10080
aaaaacgcag	ggagggctgg	ggaacaaaaa	aacagaagat	aaaatgtgga	gacagacaca	10140
ccaagagagt	aagagaccac	ctccagacct	cccttcagct	tctcaaacac	acgagccggg	10200
cccgttacag	aatttgccgg	gaccgctgca	aaatggaagt	gcagacagcc	ccttactcaa	10260
aaggtaggaa	tttcagggtca	acaacagagc	tcacctcata	tgactacaca	ggtcacacag	10320
cccgtgaagt	cgggtcccaac	accagcatgc	tcctgcctca	aagccgctgc	acgtgctgtt	10380
ccttctcgcc	tttccctctt	ttagtccttc	agatctcagg	cctcctgaga	gagacctctg	10440
acctgccggc	tcaggcgggc	acacccccag	tacaggagtc	tccggctcag	cccctgctgt	10500
gttccgtacc	cgatccagg	ctgtcctatg	tccatctgtg	tgccggcttg	cttccctgaca	10560
tgccccccac	cacacgtgtg	cctcggggca	ggggaacagg	cccgtctcat	taactgcttt	10620
cttctcagat	attttctgga	atatttgttg	atattgggca	acataatg	tccacctttt	10680
tcagtagagc	caggacgagc	tgcatTTTTT	TTTTTTTTT	tttgagacag	ggctctactc	10740
tggtgccag	gctggagtat	agcggcatga	tcttggtctca	gtgcaacctc	cgcctcctag	10800
gctcaagcaa	ttctcctgcc	tcagtctccc	aagtagctgg	gattacaggc	ccgtgccact	10860
actgccagc	taatttttat	attttttagta	gagatggagt	ttcaccatgt	tggccaggct	10920
ggctctgaac	tcctgacctc	aaatgatcca	cctgccttgg	actcccaa	tggtgggatt	10980
acaggcgtga	gccactgcgc	ccggccccag	ctgcctgttt	tacacctttg	ccatattccg	11040
gtgattctct	ctccccctcg	tcccccgcc	ctgactgtgg	tgccactcc	ctgccgtcat	11100
gagcccgat	gtcctcactc	tttccctttc	cgccaggact	tcaaccaaca	ctgcagagcg	11160
caggggtccag	ctccagcact	gagttcagcc	tcttctcacc	aacagacagg	caggaaagaa	11220
aacaaactct	gagaaggcca	aggttcccgg	gcagccagca	agccaagcat	ccttctccgc	11280
tgaggcttgt	gcagccgagg	cacccccctc	tccagggagc	aggcagcgtc	ctggggcagt	11340
ctgcgagggga	gaccaggggc	cttgctccac	cagggcccca	ggatggggg	cagcagcaaa	11400
ctcatggctc	tgggagccag	acccccactg	ctagaacctc	ctatgccacc	tgctgtgggc	11460
aacccccaggc	tggtgacttg	ccctggcctc	ctctgtaaac	aaagggtc	tccaacctgg	11520
tcaaaccact	cctccccctc	aagggtctat	aatcctccct	taacctgctt	gggtccaaacc	11580
cctgggtgtcg	ccaggtcact	caggaggcag	ctcatctgga	ctccttccct	gggtccagtt	11640
tctctctcaa	cattgctttt	gaggccgag	tgaacggtca	acagcgaagg	gccccagagg	11700
tgatggagga	gcgggtgtcc	aagacactca	ccctttctaa	tgactgact	ccctcgtgga	11760
ctcacttgtg	ccgtctcccc	cacccaccca	gccccagagc	ccagagtgcg	agcgcacag	11820
gccccgggatt	ctgtctgcac	cgcggggtcc	ccagtgcctc	ggagcaatgc	cagcaccggg	11880
caagtgttcg	acaaatgcct	gctgaatgag	caaattggatg	gatgaacgaa	tgaatgagca	11940
agcagatgaa	tgaatgggg	gctgtccaga	gccgtgagga	ctaggccgcc	caagtcccca	12000

032796-132.ST25

tttctcaaat	tctcettctc	ccgacttggg	aaacaagatg	cttgggtcggg	gaggtctctcc	12060
aaccatcccc	tgcagcagcc	ggcacagcgg	acagaccctt	tgatgtaaca	gccatgtctt	12120
cattaaagat	gccctgtctc	cagaaagaga	aagacaaata	caaacctgga	aaatcctcac	12180
caaacgcagg	acccctgcca	gggagcagag	aaaagaccca	cacgccacgg	gcgccacgac	12240
cacacacaca	ccccagccgc	tgcacacaaa	cacagaccct	agccagcaag	aacaggggga	12300
ccaggaaact	gttcctaaag	tcaggacccc	catgtgtctc	gacagcagt	agagcaagga	12360
cacttctcca	tccaccggat	gccaggagag	tccttttagg	gggccccaca	ccgagactct	12420
gcccttagga	ctgttcctga	gtgtggaagc	cagcccactt	ggaagcccc	tgccctccc	12480
agtgggacac	cggcacagga	agcaggccct	gtccccacc	actttctgca	agctgggccc	12540
catcacgcta	cagaaacggg	gaggactggt	cccagggatg	gcgctttcct	gacacctctc	12600
gttaccctct	cgcttgccag	gccccagggt	cagcccaga	ggccagactg	gctatcccag	12660
gcccgggagc	atccccgaag	gcgagctgca	tcctgaacgt	gtgtgatttc	ccgaagggcc	12720
cgccccgaac	cgacacctgg	aaagaaagat	cctcagccgg	tgccccagag	gagaagagcc	12780
atgcctcact	gcaacacagt	cccaggaagc	accaaagtgc	tgaggacca	ggcggagagt	12840
aaaaaagtgg	aaaatatctg	gggcaaaaat	aaaacaaaac	aaaacaggat	tgacctcctg	12900
ggctcaagca	atcctcccaa	ctcagcttcc	cgagtagctg	ggaccacaga	cttgaatcac	12960
cacaccgcgc	aagtggatca	tttcgaacgg	gtttgccgag	gttccttctg	gggaccccc	13020
ggcgccgcga	acccattccc	gccaggcccc	gccccgcccg	cccgccccgt	cccgteccac	13080
cgctcaccct	gccttacacg	tcctgccgtt	gtcctgcagc	tgacaccccg	tggggcaggc	13140
gcatgtgtag	aaaggctcgc	ttggggacag	caggcacagg	tgggagcagc	cgccattgtc	13200
ctcctcacag	cgagtgtgga	ctgagaaaac	caggacagac	tgagagaagg	ttccagaaga	13260
ggaccgtcac	ttgtttctga	atgagtcaca	tcctgcctcg	tcctccgtga	cagcctccag	13320
tgtgtccctc	tgcccaaa	tcggcctcaa	gtggcatcag	ggacctcccc	gcgggcacca	13380
ttccacctgc	ctcatcgctg	gccccgtcca	catggggccc	tcagcctggc	cagacggcct	13440
gcaatttccc	caaaaccagc	cgtgaccttc	ctggccaccc	tcacaccag	atgtgacctg	13500
cccattggagt	gacatcctcc	ccatctgctt	cctcccacca	agctcctatg	actagaacac	13560
cctccccagc	tcctcggagc	ccccaaagga	caccctctg	caaaggctgc	ccccacgct	13620
ccaatggccg	gggtcaggac	ctgcctgtgt	ggtagtgaag	ggaaccccag	agacaatggg	13680
ctcctgggca	aaaggcttgt	cttgtctttg	tgctatgtgt	ggaccagca	gcttccatag	13740
gaacactgtc	cttcttgtctg	ggatggccaa	gcttgtcact	ctcccaagcc	ctcctatgac	13800
caacagcaat	tgaacggaac	tcgataaatg	cttcagcac	ctcattcaaa	ccaggggaaa	13860
gctgggtgta	gcagcccaa	aatacggata	taactggaac	aacaaactca	tcaaaatgaa	13920
cctctccctc	cctcatgctg	ccccaaagtgt	agatgggttt	tgtgaccacg	actttctcac	13980
caggaaacag	ctccagagag	ccccaccctc	ctgtgtcctg	ctctgggaac	agctggcacc	14040
cctaggcccc	acatttcaat	tcaaagtcca	aacttccat	aatggcctgg	ccagaaatct	14100
ccatccctgg	tcctgtggg	agtgggccac	tgtccccaga	gccgcagccc	cactgtcaca	14160
gaagctgggtg	catttcccca	tcaggacact	ctgtcacaa	ccagcgtggc	ccccaggctg	14220
agaactgctg	attctgggca	gattattcat	tgataaatac	gcgacttgca	gggccaagca	14280
tggtggctca	tacctgtgac	cccagcactt	tgggaagtca	aggtgtgagg	atcactggag	14340
cccacgagtt	tgagacaagc	ctgggcaacg	tggcaaaatc	tctcatctct	attaaaaata	14400
catacacaca	cacacacaca	cacacacaca	cacatatata	tgtatatata	aataaccata	14460
tatatatata	cacacatacg	tgtatgtgta	tataaatata	tatacacaca	cacacagaca	14520
acttcttctg	ggccttgaaa	acgaggcaac	cttccttgga	aatccccttg	ccactgctga	14580
gcctgaaata	gcccccatga	gctctgcaga	gggtgcctct	gcaggcccgt	gtcccccagc	14640
cagccacaca	cctccctcca	ttgcagcagg	tacccttta	gagagggggc	cccccagagc	14700
atgggcttct	gcagggagg	gtcacctgcc	ccccacccc	accacgccc	gcgcaccccc	14760
acgccccgc	atcctccca	tccctgccc	cgcgcccccg	ctccccccag	ccccctcacc	14820
ctctcccccg	tgccccaa	ggcactcaca	aaaaggctgc	cgctcctggc	tcagcacctg	14880
gatgtccatg	ggtgagtata	gggactcag	gatctccttc	ctcttcccc	cagtgcgctt	14940
gttgacggca	tggatggagc	gggtctgcca	gtctgtccag	tacagagtgt	ccccggagag	15000
cgtcagggcg	aagggtgcg	tcagggtgcc	ctccaccacc	ttctgcctgc	agtcagggaa	15060
gcgggttgga	ggagccatca	ggagggtccc	ccgacagtca	ttgtgtctga	cccaattaat	15120
ttcttttttt	ttttttgaga	tggagtctcg	gtctgtcgcc	caggctggag	tgcaagtgatg	15180
taatctcagc	tcaactgcaac	ctccgcctcc	cgggttcaag	caattatcct	gcctcagcct	15240
cccagtagc	tgggatcact	gatgccacc	actacgccc	gatgattttt	gtatttttag	15300
tagagacagg	gtttcatcat	gttggcaagg	ctggtctcga	actcctgacc	tcaggtgatc	15360
caccacctc	agcctctcaa	agcgtggga	ttacaggcgt	gcgccaccat	gccaggcttc	15420

032796-132.ST25

ccatttgctt	tcaaccagac	aagtgagggc	aggtcaagag	ccccaggagc	tggcgccctc	15480
gtacatttct	cccggcgtgc	acagggcacc	tcccaaacac	agcctgtgat	ggtgacacac	15540
gggctcccc	aggtcaagtg	gcaaagtctc	ccccagggaa	gaaaggagga	agccatgcct	15600
ggcaaaaagc	acacctctcc	tgcccaacgc	tttaacctct	gtatacaa	caggccatgt	15660
gcactcgctc	cttctttacaa	tgtctcataat	ttatactttc	agagtaaagt	aaacttggca	15720
tcaacccgag	aaacagctat	tcttttctag	atgcttacag	tgcccagcaa	atgaggactc	15780
gggtgtaatg	agattatgga	cactggaaac	aggatcataa	tgtgacgtgg	tcggtaatgt	15840
gcagttttat	ttgcttaatg	accctcgccc	cgtgacaggc	tccctgaggg	tgggcctggg	15900
ggcagaggtc	cccgccacgt	ccccagccct	cagcacagtt	gccaggagag	ggtgacactc	15960
atgaagtggc	acagggaaga	tgggagctgt	gggctctgca	gatccaccac	ctcttctgtt	16020
catttttgtt	gatgctgttt	tttaagaaaa	ttattgaagt	aaaattcaca	ggacatacgt	16080
ttactttttt	tttttttttt	ggagatgggg	tctcactctg	tcaccaggt	tggagtgcag	16140
tgggtgatc	tcagctcact	gcaacctctg	cctcccaggt	tcaagcgatt	ctcccacctc	16200
cgctccaga	gtagctggga	ccacaggcgt	gcaccaccac	acccagctaa	tttttggggg	16260
gtatcttttt	ggtagagaca	gggtttcgcc	atgttgccca	aggctggtct	tgaagccctg	16320
agctcaggcg	atccacccgc	cttggcctct	caaagtgtct	ggattacagg	cataagccac	16380
tgcaccagc	ctaaattttac	cacttttaag	tgaatagtgt	tacctagtgc	attcgcaagg	16440
cggtgcagcc	tccacttctg	tctagtcca	aagcacttcc	attgccccac	aggcaaacc	16500
cacaccggc	agcagtcct	ccccagtc	cgccccac	cccggcaaac	acttttgatg	16560
gacttaacta	cacacattct	caacatctca	tataaacgga	atcacaaat	acagcctctg	16620
atgtctgtct	tctttgactt	ggcaccatgt	tttcgaggtt	catccaggct	gtagcatgtc	16680
agtgttcat	cccgttttag	gggtgaacca	tattccagt	tgcagacaga	aaccaatctg	16740
tgcattccatt	cacccactgg	gggacctttg	tgtcatttcc	accctcggct	gttgtgcaca	16800
gtgctgctac	ggacattact	gtccattcac	attttgtgtg	aagacctgtt	ttcgattctt	16860
aagagtatac	agctaggagc	ggaattgctg	ggtcatagct	aatcaatgt	ttacgtctca	16920
aggaatcaac	aaactgtttt	ccacaatgtt	gtcttttttg	tttgttttct	gagacagggg	16980
cttgctctgt	caccagggct	ggagtgcggg	ggtgtgatca	tggctcactg	cagcctcaat	17040
ctcctaagct	caatccatcc	tcctgcctca	gcctcctgag	tagctgggaa	cacaggtatg	17100
taccaccatg	gccagctaat	tttctaattt	tatttttttt	tgtttttgtt	tttttgagac	17160
agagtctcgc	tctgtcgccc	aggctggagt	gcagtgggtc	catctcagct	cactgcaagc	17220
tctgcctccc	gggttcacac	cattctcctg	cctcagcctc	ccgagtggct	gggactatag	17280
tcaccggcca	ccacgcctgg	ctaatttttt	tgtattttta	gtagagatgg	ggtttcaccg	17340
tgttaccag	gatggctctg	atctcctaac	ttcatgatcc	acctgccttg	gcctcccaa	17400
ttcttgggat	tacaggcggt	agccaccacg	ccagacctta	cttttaattt	tttaatttta	17460
ttatttttatt	ttattttttt	tttttttgag	acagagtctc	gctctgtagc	ccaggctgga	17520
gtgcagtggc	gggatctcag	ctcactgcaa	gctccacctc	ccaggttcac	gccattctcc	17580
tgctcagcc	tcccagtag	ctgggactac	aggtgccac	cacgatgccc	ggctaatttt	17640
ttgtattttt	agtagagaca	gggtttcaact	gtgttagcca	ggatgatctc	aatctcctga	17700
cctcgtgatc	cgcccgctc	agcctcccaa	agtgtggga	ttacaggcgt	gagccaccgc	17760
gccagcctt	tttttttttt	tttttttttt	ttttgagata	gagtcttgct	ctgtcgcca	17820
ggctggagt	cagtggcggg	atctcagctc	actgcaagct	ccgcctccca	ggttcacgcc	17880
attctcctgc	ctcagcctcc	cgagttagctg	ggactacagg	caccaccac	cacacctggc	17940
taatgttttg	tatttttagt	agagacgagg	tttcaccgtg	ttagccagga	tggctctgat	18000
ctcctgacct	cgtaatccgc	ccgcctcggc	ctcccaaagt	gctgggatta	cacgcgtaag	18060
ccatggcgcc	cagcccatgt	ggccattttt	cagttagaga	agccagaggc	ccatcactct	18120
cgttgctcc	ctgggcatatg	ctctgcctca	gccagaagca	ctgagggaag	gtcagcctcg	18180
gcccttgccc	cagccacagt	cacagataaa	ggggcctgca	caggctctgtg	tggctccaga	18240
gctcgtcacc	caacacacga	cgcttccatg	tgaatagccc	cagggtgcac	atgaagagcg	18300
atggccgctg	cagaggcaga	agaatcccgc	ggggaagcag	gtgggagaga	ggctgagaac	18360
agaccagacc	ctggagctac	agaccctatg	ttccaacctt	ggctgggact	agctgtgtgg	18420
ctctgggcaa	attcacatgc	ttctctgtgc	acaggggatc	aaaatagcaa	acacaggcta	18480
ggcacagtgg	ttcacacctta	taatcccagt	gctttgagag	gccgaggtgg	acacatggct	18540
taagctcagg	agtttgagac	cagcctgggc	aacatgggtga	aacctcgtct	ctacaaaaaa	18600
aataccaaat	aaattagcca	ggcgtgggtg	tacgtgcctg	tggctcagc	tacttggaag	18660
gctgaggcgg	gaggaacact	tgagcccaag	aagtcaaggc	tgtggcccg	tgtgggtggct	18720
cacgcctgta	atcccagcac	tttgagaggc	tcagggtggg	ggatcacttg	tgatcaggag	18780
ttcaagacca	gcctggccaa	catggtgaaa	ccccgtccct	actaaaaaaa	tacaacaatt	18840

032796-132.ST25

tgccagggcgt	ggtggcgggc	acctgtaatc	ccagctactt	gggaggctga	ggcaggagaa	18900
tagttagaac	ttgggaggtg	gaggttgtag	ttagccaaga	tgggtccgct	gcactccagc	18960
cagggggaca	gagcaagact	ccatcccaaa	aaaaaaaaaa	acaaacaaac	aaacaaaaaa	19020
agaggtcaag	gctgcagtga	accatgattg	tgccaatgca	ctccagcctg	ggtgacaaag	19080
tgagaccctg	cctcaaaaaca	ataaaaatat	aaataaaaaat	aaaacataat	agcaaacggt	19140
tcatagagggt	ggtatgagca	ttaaatgaac	tgataaacgt	ccctggaaaa	cagtaagtgc	19200
tatggaagga	ttcgtctgccc	ccaccgccac	caccattagc	atgtttcaac	ctccatcacc	19260
ctcactgtcc	cctgtcacca	tcctttgacc	agggcactcc	cagctgcagc	ctttctatcc	19320
tcttgtccac	ccttcataac	tgtaagatca	ctcagctccc	aagaaccaca	gtctacaggg	19380
taaccacatt	tccaaatctc	aaaccagacc	cgctgggtctg	cacttccagg	gacaacagga	19440
tattttcaaa	ccagcccaaa	agagatgtgt	ggctcagcat	aagaggaaca	ggagaaactg	19500
aggcctcttg	ccctgagaat	gagcttggaa	gtggatgtcc	cggcctcact	caaacccttca	19560
gatgactgag	gcccagccag	gagcttgagt	gtaccctcag	gtcataccct	gagccagaaq	19620
caccagctta	atccactcct	catcactgac	tccctcccca	taaaaaacct	gtttgctggt	19680
tcaggctggt	aagttgtggg	ctgttttgtt	acacagcaat	ggataactaa	cacacgaggg	19740
ctggcaagtg	tggagcaaaq	ctgcccgaagc	cctcaagtct	gttcatgtgg	gtgttgccct	19800
gtgtttgcag	aatccagcc	actgagtcct	cccagtcagt	cactactgcc	ctctgcacag	19860
acacctgcca	atccctggcc	tgggccagga	gctccactag	tgcaggaatg	gggtctgccg	19920
tcccaggagg	atccctgaca	cctagcacag	ggctagcagc	aggcagcact	tggttagtga	19980
ataaaatgcc	cttcacctgt	acacagaagg	gatgtttcta	taaggggtaa	ttaagtacag	20040
agctgggaag	ctatgctgac	cagaaggctc	taaaagcaat	taaccaacga	gggaaaaacc	20100
cttcctactc	attctcggcc	cattttattg	agcactgacc	atgtggaagg	ccccctggtg	20160
agactgggga	atgcaccaat	aactgagaca	gcttcgggct	gttgccctca	ggatgcctga	20220
gctgggatag	ggccagggtg	gggggtggtgc	gtgtgacagg	gttactgttc	acaaccctgc	20280
cgggccataa	gccctcccca	acaattccaa	aatccaaaac	gctctgaaga	tggaaagctt	20340
ttgttgctca	tctggtgaca	aaacctcatt	tggtgcatgg	gccgggtgcg	gtggctcacg	20400
cctgtaatcc	cagcactctg	ggagccgagg	ggaaggatcc	cttgagctta	ggagttagag	20460
accagcctga	gcaacatgtg	agaccccgtc	tctacaaaaa	atacaaaaat	tagccagggtg	20520
tgggtggcgca	ctcctgtagt	cccagctact	cgggaggctg	aggcgggagg	atcgcttgag	20580
cctgggagggt	gggggctgca	gtgagctgag	attatgacat	tgactccag	cctgggtgaa	20640
agagttagac	tctgtctcaa	aaaaacaaag	ttaaaaaaaa	aaaaactgtg	catgggtgtg	20700
ggctacagat	agtcttttct	gccctactta	gaatgaacgt	gccacatttg	ctatagaaat	20760
attcaagggc	tgggtggcaa	tgccacacag	acctgagctc	tggtccaagt	tctgagaagt	20820
cctgacttcc	tcaggggccc	agagtttcag	agaagagctc	gtaggcctga	gttaagaagg	20880
aacgccttca	aaagccctgg	ggacaaaagg	gaaagggtg	ccccaggact	gcgtgggtac	20940
ctaccggaac	gagccgtcca	ggttggcacg	gtggatgaag	ctgagcttgg	cgtagccca	21000
gtagagcttc	tgctcctcca	ggtcgatggg	cagtcatttg	ggccagtaaa	tgtccgagtc	21060
cacaatgatc	ttccgggtgc	tgccatccat	ccctgccgcg	tcaatccggg	gcgtctcacc	21120
ccagtctgtc	cagtacatgt	acctgtgacg	ggggcagggc	aagagaagca	gctaacacag	21180
atctgttttt	tggtttttgtc	tgcatagatg	cagacatgaa	acaacagaca	gtgaacttgc	21240
cctaaaatct	cacccatcgg	aaataacca	caggtatggt	ttcaggtatt	cctgccttaa	21300
gctgggcaat	caaaatatac	tatttccaac	ttgttctcag	ttaacagtaa	attctgggca	21360
ccttcccttc	ttgtggatag	aaagattcct	tggtcttttg	atgattgcct	agtgtactct	21420
gctgtaagtt	ttttaaaaga	cttcagggtta	tttctgattt	ttttgctacc	atgaaaatgc	21480
tgtaaatgaa	cctctaaaag	gcaattcaaa	acactcagga	tggaaatatta	tttagtggtta	21540
taaagaaatg	agctatcggc	tgggccaggt	ggctcacacc	tctaattcca	gcactttggg	21600
aggccaaggc	gggtggatca	cgaggtcggg	agatcaagac	catcctggct	aacacagtga	21660
aaccccgctc	ctactaaaaa	tacaaaacat	tagccaggcg	tggtagttag	cacctgtagt	21720
ccagctact	taggaggctg	aggcaggaga	atcatttgaa	cccgggaggg	ggaggttgca	21780
gtgagcagaa	atgcacat	tgactccat	cctgggcgac	agagcgagac	tccatctcaa	21840
aaaaaaaaaa	aagaaaagaa	aagaaatgat	ctatcaagcc	atgaaaagac	atggaggaaa	21900
cttaaatgca	tggttagtagg	tgaaaagagcc	aatctgtatg	agtccagttc	taaacactct	21960
ggaaaaagca	aatacacaga	gacagtaaaq	catcagtggg	tgccaggagt	tggagaggag	22020
agggatgaat	gagtgagca	cagaaaatca	gggcagtggg	actatcctgt	atgacatgga	22080
atggtgggtg	catgtcctta	ctcatctgtc	taaaccaaga	atgtacaaat	caagggcgaa	22140
ccctcgtgta	aacgtggatt	ttgggtgatg	gtgcgtcagc	cagctttcat	cagttgtaac	22200
aaatgtacca	ccctgcacag	gatgctgaca	gttggaagg	ctgtgtgggt	gtgaggacag	22260

032796-132.ST25

ggatgtatag	gaactcagta	cctgctgctc	atcaattttg	ctgtgaacct	acaactgttt	22320
gaaaaaatta	agtctattta	aaaacaacaa	aacatggcca	ggcacgatgg	cttgcacctg	22380
taattccagt	acttcgggag	gctgaggtgg	gtgggtcact	tgagccaccc	tgggcaacat	22440
ggcaaatcc	cacctctaca	aaaaataaaa	attaaaaaaa	agttagctgg	gcatggtggc	22500
acactcttgt	agtcccagct	acttgggagg	ctgacgtggg	aggatccctt	cagccctggg	22560
aggtcgaggg	tgcagtgagc	tgtgactgta	ccactgcact	ccagcctgga	tgacagagtg	22620
agaccctgcc	taaaaaaaaa	aaaaaaaaagg	ctgggtgctg	tggctcatgc	ctgtaattcc	22680
agcgctttgg	gaggccgaga	tgggcggatc	acgaggtcag	gagatcgaga	ccatcctggc	22740
taacacggtg	aaaccccgtc	tctactaaaa	gtacaaaaaa	aaaaattagc	cgggcatggt	22800
ggcggacacc	tgtagtca	gctactcggg	aggctgaggg	aggagaatgg	cgtgaacccg	22860
ggaggcggag	cttgagtgta	gccaaagatca	caccactgca	ctctcagcct	gggagacagc	22920
aacactccgt	ctcaaaaaaa	aaagaataaa	acccatggct	gggatggacc	ctgaacctgc	22980
agctgcagct	gttcctgggt	aggtctgtgg	gcgacgtggc	tttgcttctc	catgttccca	23040
agagacaagc	atcacccatc	catgagaaac	aagcacatcc	tcagggcgcc	cttacgtgat	23100
ctctggccaa	tgaaccaaga	caaagtgagc	agacaccagg	tctgggatgg	caggtcccac	23160
ccccaccagt	gcccagtggt	ccctgtttgg	aggtgaccac	aggggtgtgt	cccagaggct	23220
gggcgtgact	ctcagcggag	accagagggg	aaccacacca	gcttgaggga	ctcagttccc	23280
atcccagcca	gctgggatga	gccacaggac	acaagggctg	gcagacctat	tgtgttttgt	23340
ccacccttca	cagcagagaa	aggggacagt	gcccagaatg	tcctctgagg	agcctcctcc	23400
cactcttgg	ccttgtaaaa	tgggtgctgac	tcccttgctc	ccttcttctc	gggggtggcg	23460
gcaaacccca	ttccctcag	ccttagcaag	tgatttagaa	acaggcagct	cgcccaagcc	23520
aggcatgaga	gtgatcccg	gacacaggga	gaacaagccc	cgctttgccc	tctgggggtc	23580
tccattcagc	agaagaggca	aatgacagac	acacagccgc	ctcctcccc	accatggtgc	23640
tctgcagcct	caggagcctc	aggtgcacca	agggccaccc	catccagggg	gccatgcttc	23700
cttgagtgg	atcgcttctg	agcgagtacc	atctccacct	tccagagggg	ctgtgacaag	23760
atcaacaaga	atgagggcat	aggagcctcg	aaccaaacc	gcctcttctc	ctgcagaggc	23820
tgactgcgcc	cagctgctat	caccaagccc	ctgctcctcc	ggccccgtgg	ggacagggtg	23880
agaggggtgt	cacatggaac	agctctccaa	acagtccctc	tcaagctgct	gtctcctgtg	23940
catctagtga	gaacccaacc	aacaaagggg	aggtgggaat	tgctattccc	attaggcaga	24000
tgagaaaact	gaggccccga	aaggctggcc	tgttccaggt	tacaggcgct	gagcggctgc	24060
tctgggaaca	cacttggtgt	ctgctgaggg	cccagagccc	gccatcatat	gactcacctc	24120
tcgccagcaa	agcccgggtg	tgggtgaact	tttcttgcca	gcctgggact	ccaaggtgct	24180
ggcagccagc	ccagggaagg	ctcccgcgtg	cctgcggcag	acgccttgct	ttacctgcac	24240
gtccccacc	ctaggagcct	ggacagagcc	cagaccctcc	gccacctcct	gagaaggtat	24300
caggggcctc	agcttggaat	tgggggggaa	tcacacagag	ccttccccaa	atgctccacc	24360
gtggcccatg	gaaaacgtg	gaaaacgtgc	aggagcagga	gcctccgcat	ggagcataat	24420
tcacattcct	tccccgagtt	tcataacaga	ggcctgctgg	tttctttaa	tggggaattt	24480
gcgagccagt	cggtgaccag	agactggttg	gcgtggacgt	gctcttgag	agtctcaaac	24540
gctaccacaa	gcccagccaa	attccacgga	ggaaaatcga	cttccgaaga	aaagagctgc	24600
agcatggcct	tcgtgcagag	ccagctgcgg	ttgtggttgt	gtgttatttt	agggaagggc	24660
cattttgcat	tttaaagagg	gggttggttt	tcaccctggc	tttaatttga	gacccggggg	24720
ccactgcagc	cccttgctag	gctggtacag	gccggggact	cctcccatgc	taagccagtg	24780
tctttctggc	cccagatcct	cagggggccag	agggtcaccc	ccagagccc	ctctgccacc	24840
cacatgggtg	ccctgggcct	gggagggatg	tgccttccct	caaccctgcc	tggatgtccg	24900
cacggggcca	cctgcattgc	tgaactgca	acgaagtcca	gtctcaggag	gggccccctc	24960
ggctgcaggg	ctcttgatcc	ttttggccac	gtgcacactg	aggtggacgc	tgggaccag	25020
agacccctt	catgatgatg	gccggggcag	gaacccctc	ctctgaggaa	ggaccctggt	25080
gggggacagc	actgcaggag	ggcacaggag	atgacggggg	ctctagcagg	gccgggagga	25140
aggccaagat	gctcctcgca	accgtgtgcc	tgtggccagg	acagaggaca	aacccacct	25200
ccactgtccc	cactctcagg	acagcagtc	tgcgccagga	ctcagcgccc	acacttatgc	25260
ctgaggacca	ctattcaagt	cagtatttgg	cgagcagggg	ttgctgccgc	gggcgctgtg	25320
acaggctgga	atcctctccc	tctccctctc	cctctccgga	gacatggagc	ctacagggac	25380
agagtcagca	cctcagggtg	ggaccatggc	tggcgctc	agcatcactg	gatctgatga	25440
gtgggagccg	gcatctcact	gttttctact	tctcattcaa	atgactggag	caaagggaag	25500
gtgtgggggag	aggcccagga	atcaacacta	aggtcaactt	tgccccaggg	ggcaggggtg	25560
ggagtgaaca	gccacaggtg	tgatcctggg	gagggcttct	gggagagaat	tcagaggcaa	25620
gcatgtagag	gaaccatttc	aaatagttaa	gaaaagccag	agccaaacag	ggacagttgg	25680

032796-132.ST25

ctcgagaga	tgatgcaggc	aaagccagct	cagatctgag	catgggaaa	actactccca	25740
accaagggcc	cagcatctcc	caaccaagca	ccaagtacct	cccaaccaa	tgccaagcac	25800
ctcccaatca	aatacctccc	aaccaagcac	ctagcacctc	tcaactggac	accaactact	25860
cccaaccagg	caccaagtac	ctcccaacca	agtgccaaagc	acctcccaac	caagtaccaa	25920
ttacctccca	accaagcgcc	tagcacctcc	caactgagca	tcatgcacct	cccaacagag	25980
catctagcac	ctcccaactg	atcacctccc	aacctagcac	cgagcacctc	ccaaccaagt	26040
gcagagcacc	tcccaaccaa	gtgccaaagca	cctcccaatc	aaatacctcc	caaccaagca	26100
cctagcacct	ctcaactgga	caccaacaac	tcccaaccaa	gcgccaaagca	cctcctaaca	26160
aagtaccaat	caccttccaa	cagagcacct	agcacctccc	aactgagcat	catgcacctc	26220
ccaacaaatc	acctagcacc	tcccgactga	tcacctccca	acctagcact	gagcacttcc	26280
caaccaacat	agcaaaagcc	ataaagaagt	aaaaagacaa	aaccacgtag	gcatggagac	26340
tggacttctg	gtggcgagga	aagggcattt	ttattataac	gacagctaac	atttggtgaa	26400
ctcacaact	gttcttggtg	ttttcctcat	gacatgcagc	atggtcacgc	ctctgtacag	26460
acaaggatac	tgaggcacag	agtggcaccg	tgccaacctt	gtctcatctt	tttatcgaac	26520
ctacatgcag	agtgccagca	aatccagctg	tcttttctct	tcagaacaga	tcccaaatct	26580
cgccactcct	tacccccaca	agtgaggtgt	ccccgctgct	gctttctgtc	gccaggatcc	26640
cggtataaac	cgtggagagg	gtccttgccc	ccacgccacc	cacccacag	ctcactctcg	26700
ctccagccac	caggggtagc	cttcagcac	gagtcagagc	tgccacctcc	tctgctcgag	26760
acctcatgtg	tccctctccc	acaccttggg	cctgttttcc	ctacattctg	ctacagcccc	26820
tcaaacaggc	ccgcctccaa	accagcccag	ggcctttgca	ctggctgatc	cctctgcttg	26880
gaccgcgctg	ccccagaca	gccacacggt	tctcagctcc	atctgcttcc	agtctcgact	26940
caaaagtcac	caagaggcct	tcccagcacc	tgagctccga	cggaagcccc	tcgccacagc	27000
accaagcac	tgttttatcc	ccctacgcac	acgtcccttt	caaatactat	tcattttacca	27060
tctcctccca	ctcactgaaa	gggccagaga	ctgggctata	cccgtgctgt	ggggagcagg	27120
accaggcgca	agggctcaca	aatgcagtgg	atgcctgggt	gggaggtgag	ggagctgcag	27180
cgaccacgc	tgggagggaa	cgcaatgaca	ggaggagcgc	aggtcctggc	gacacgatgg	27240
ccatggcagc	cgctggtgag	caaccgcagg	ccggccctgg	gagagggctt	ctagcaagct	27300
gctatcttca	gcctctccga	ctactgcaga	tgccccctcc	tagccagaga	caactgtaca	27360
ccagccgacc	cttccaaaaa	gaaggtcagt	aaccccgcca	ctcctggagc	cacagtgcag	27420
ggggagaggg	ctgagagggc	aacagttcac	caagcggaac	agaggctgcc	ccggaggcca	27480
gctggctccc	cggcagctgc	aggggtggct	agccactcgc	gagggcagcg	agggcatacg	27540
aggggctcca	gggatgagtg	gttgcccagc	acagcacccc	tgggagggcg	ggggcacttc	27600
tcaagtagtg	ggggcacgag	gctgctctgg	cctgacctca	gggactcaaa	atactttggc	27660
gataaattcc	accgtgtccc	acccctgctg	gtaccccata	cttacacaca	gactggttca	27720
gatgcagaca	ctctcgcgca	catactcgct	cacacgggca	catacacgtg	cacacacagt	27780
cacatgcgca	cactcagaca	cacacaaata	tccactcaca	cgcatgcatg	cacacacagc	27840
gacacacaca	ggctcacacg	tatgcacgca	tatgcgtgca	cacgcacaca	cacacacaca	27900
cgctcacatc	ctcccaactcc	cacactcagt	tgctcagaca	cacacacgcc	tggctctcac	27960
acaaacctgt	tgggctctga	aaggctccag	cccttcccat	gctcgtcaga	agccagtcaa	28020
tggcttctta	agtcaccaca	cagatcaaag	aggtgaactt	ggccacatgg	caactctgctt	28080
cctgagctcc	caaacaccag	ccttggtgag	gacagaccct	cacccacac	cctcattccc	28140
actaccctgg	gcaggcccag	aggaggggca	tctgcaggat	ctggcaacca	gcccctcccg	28200
cccggctcct	gcagccggca	ccatgggagt	cagggggagg	tactgcaaa	gggcaacagc	28260
aagttggtgg	ccccaggact	agagcccagg	ggtcttcagt	cctactccag	agcttgagca	28320
ctgtcccaca	gggcatggcc	aagggaaggg	cttccagagc	cctgacttca	gggaggaggg	28380
caggcgggct	cctgtggcag	gcctggatgc	atggccgccc	actcctggga	ctttctaacc	28440
tagaataatc	aggtcaggct	gggtgcagtg	gctcacgcct	gcaatcccaa	cactttggga	28500
ggccgaggag	ggtggatcac	ttgaggttag	gagtttgaga	ccagcctggc	caacatggcg	28560
aaacctgtg	tctactaaaa	atacaaaacc	tagccagggtg	tggtagtgca	cgctgtaat	28620
cacagctact	caggaggctg	aggcaggaga	atcacttgaa	ctcgggaggt	ggaggttgca	28680
gtgagctgag	atcgtgccat	tgcgcaaaga	agatctaggc	cggccctcca	accggtgagg	28740
tccaggctgg	cagtgcctgag	agactgtggt	gacactgaat	gaactaacag	gcaaagggct	28800
tccaactgag	cctgggggtg	gtgggaaatg	gctcttggtg	tctagtcaag	acctctgcca	28860
accagttctg	acactgaccc	agcacagaac	ctgacaggtc	agcaagggcc	agggcttagc	28920
acagcccagg	taagggtgtg	tgtacggccc	ccagagtcac	tcccaggctg	caagaaaagg	28980
gacaaaggag	ggacaagggg	tggccaagca	aactgttccc	tctgctcggg	agtctggggg	29040
gacctggcct	agctggccag	tggagctggg	ccacctcccc	ttaaactctc	caccccgagc	29100

032796-132.ST25

ttcgactcca	aagctttcct	gccacccacg	ctctccccac	ctgggatcac	ggccaggccc	29160
tgagccttca	agggcccagg	tgaactcagc	cagactagga	gctgaggagg	acacagggca	29220
gcttccagaa	cggacccgag	aaccactccc	agcaggttct	gcttccagac	aaggagctgc	29280
actttttcag	ccaatgcaat	tagaaagcca	ggagaagggtg	caaattccac	ctgcctgagc	29340
gtccgcactt	cccaggccgc	ccaccataca	cacagcaaag	atgtgtttaa	ccattcaaac	29400
ccatggccaa	ccacatcggt	tgcctcagac	atgcaagttt	taaaaaggaa	cataactatg	29460
ggccaggcac	ggtggttcac	gtctgtaatc	ccagcacttt	gggaggccga	ggtgggtgga	29520
tcacctgagg	tcaggagttc	gagaccagcc	tagacaccat	ggtgaaaccc	catctgtacc	29580
aaaactacaa	aaattagctg	ggcgtggtgg	tgggcgcctg	taatcccagc	tacttgggaa	29640
gctgaggcag	gagaatcact	tgaacccggg	aggcgaaggt	tgcagtgagc	cgagattgtg	29700
ccactgcact	ccagcctggg	caacaaggga	gactccatct	caattaaaaa	aaaaaaaaaa	29760
aaaaaggaac	ataactatgg	agtctcaagg	ggaagtaatt	ccttcaacaa	taacaaatct	29820
tgaagctga	gctctttttt	ttttttgaga	caggatctcc	tactttgtc	gcccaggctg	29880
gagtgcagtg	gtgggatcac	agctcactgc	agcctcgatc	tcccaggctc	aaatgatcct	29940
cctacctcag	cctcccaaga	agctgggatt	acagggtgat	accatcacac	ccgattcatt	30000
tttgtatact	ttgaagagat	ggggtctcac	catgttgccc	agtgtggtct	tgaattcctg	30060
gactcaggtg	atctgcccgc	cttggcctcc	cagagtgcctg	ggattacagg	cctgagccaa	30120
cacccccacg	ggttcatttt	cagagtgcga	ccgagtgcctg	gggttacagg	cctgagccaa	30180
cccccccacg	ggttcatttt	aagagtgcga	ccgagtgcctg	gggttacagg	cctgaaccaa	30240
cccccccacg	agttcatttt	cagagtgcga	ccgagtgcctg	gggttacagg	cctgagccaa	30300
cccccccacg	ggttcatttt	aagagtgcga	ccgagtgcctg	gggttacagg	cctgagccaa	30360
cacccccacg	ggttcatttt	cagagtgcga	ccgagtgcctg	gggttacagg	cctgagccaa	30420
cccccccacg	ggttcatttt	cagagtgcga	ccctttttct	gaaaaacaac	ttgggctcat	30480
gcaaattcga	gagagagatg	gtgacactcc	ccgccccctg	gaccaggtg	gagtgcgagc	30540
agggtttacc	cgtagcgagg	gtccaaggcg	atggccctcg	gctggtcaag	gtcctgccag	30600
aagagcacct	tccgggatgt	gccattgagg	ttggccacct	cgatgcgggt	ggtctctgag	30660
tccgtccagt	acagcttctt	gcccaccacg	tgcaggcgga	ggcgtcggg	agagaccagg	30720
ccggagatga	ccacgttctg	cacggcgggc	cccgtctggt	tcaggtaggt	ctgcttgatg	30780
gcctcctcgc	tcacgtctgt	ccagtacacg	gctcccttgg	aaaactggaa	gtccactgcg	30840
gccgcatacct	ccaggccgct	gaccacgatg	gtggactcca	gcttgactcc	gccggcgtcc	30900
accagccgta	cgccccggcg	gttgccaaat	agcaggagcg	gcgaggctgt	ggggcagaag	30960
caaaccgtga	gggccactgg	ctaagccagc	aagatacaca	gccctgggat	ggagcactat	31020
gcccagagca	ctcctggtac	tgccctgccc	atgcccaga	cctccagttc	cttccctcca	31080
cccctaaggc	gttgtcagga	agttgcctgg	gcagccccgg	cccgcatcat	tcagaggctc	31140
ctgcagcgca	gcaaacagcc	ttcttcccac	attcgggtgac	agcacctgtt	tgtttaccac	31200
ctgttacgtc	tgttccccca	gatatgggtg	acccttctgc	ccatgcccac	aacctcccac	31260
atcgctctcc	acaggctaca	ggggccctgt	cctgttctgc	agagaagcca	catccccttt	31320
gttggcctga	cacaggggat	ggggacatgc	aggcacagca	ctggccatgc	tgctcgctac	31380
agaccagacc	acagggccac	attttttgag	gggttcagag	cccaggccag	acagagcctc	31440
aagattccct	tacaagtctt	tgaccactgt	ccaagctcag	gcccgtttcc	ttggcctggg	31500
catcagcttc	ccatccaccc	ctgtattcca	tgtttctccc	accctgcttc	tggacattcc	31560
tacattttaa	gggtcactct	ggaatgccac	cccttggttc	agacaccttc	cacagctccc	31620
tgtgccagtg	ccatgcagaa	caaggtcaga	ccccctagcc	tggcctccaa	ggccttggcc	31680
tctggcctca	cctacacttc	tctccaccac	cccccccac	gcattcctga	tctgctgcg	31740
gccaggctgg	ctccctcacc	tccctgtgca	ccgcagccct	cagccccttc	tgctgtgca	31800
agaagcctca	tctcacagac	aacggtctca	ttcccacaac	gggctcaatg	agaaatcagg	31860
agaggccttc	agaccatcac	cccaccagac	acctcagacg	tccgaccagg	agggtcagc	31920
aacccccaac	acagactcag	agggactaag	aagccacatg	aggagtgaac	acaagatgtg	31980
gacaggagga	ggttaagggc	ctccaggggag	ctccatcagt	ccgtgttctg	ctgtcagcag	32040
ggttaggctg	ggctggccac	aaacaccccc	aaaaaacatc	tgaagccttg	gcttgaaaca	32100
gctgacattc	ctcatgaaaa	ctgcagaccc	ctgggtcctc	ctgcgcagat	gggggagccc	32160
agccaacccc	acatcccac	cttcaccaag	aaagagaag	ccaaaacaaa	ctcaactcag	32220
ccaatgacaa	tcacagaact	gaatcctgta	gttggttcat	ttgggttcat	ttcagcaggg	32280
gaaagatttg	cagcctctat	gagggtagct	gggaacacaa	agggccagag	catggcccag	32340
gagaccccag	cgcagtgggg	tagatggttc	cgagcacagg	cctccctgcc	aagacaagca	32400
ctggctcaaa	tcctggcccc	tcccattccc	aggagacatg	ctccacagga	tgggaggaca	32460
cacagaggac	ctgaggccag	gaaaatgaca	gcggcgccctc	cgccgccccca	cccgtgctgt	32520

032796-132.ST25

catcatctta	ggtctacagt	tctttgtggc	aacgagggac	actgtgaaag	tcaaacaaca	32580
ggaaggcata	ggccacaaat	aaagacaaac	gggacttcat	gggaagctaa	agatttttgt	32640
catcaaaaga	cactatcgag	agagtaaaaa	ggcaaccac	agaatgagag	aaaatatttc	32700
caaatcatag	atctactaag	agattaatat	ccatgaaata	cagagaactc	ctaaaactca	32760
acaatgagaa	aacaactaag	ccaactcaaa	aatgggcaaa	caacttgaac	agacatttct	32820
ccaaagatga	catataaatg	gccaataaac	acatcaaaac	aggcttaata	tatccctaata	32880
catcagggaa	atgcaaatca	aaactacaat	aagataccat	cttgacacaa	ttaggacggc	32940
tactatcaaa	aaaacaaaaat	agcaagtgtt	ggtgaggatc	tggagcaact	ggaacccttg	33000
tgcaccactg	gcaaaaaatgt	gaaatggtgc	agctactatg	gaaaacagca	tggcagttcc	33060
ccaaaaactt	aaacacagaa	ttaccatatg	acccagcaat	ttcgcttttg	gttatataacc	33120
caaagaact	gaaaacaggg	acacaatcag	atatgcatac	accttggatc	acagcagcat	33180
ccttcccaac	agctaaaaca	tggaggcagc	caggcatggt	ggctcacgcc	tghtaatccca	33240
gcactttggg	aggctgaggc	gggtggatca	cctgaggcca	ggagtccgag	accagcctgg	33300
ccaacatggt	gaaaccccgt	ctctactaaa	atacaaaaat	tagctgggcg	tagtgacggg	33360
cacctgtaat	cccagctact	cacaagtctg	aggcaggaga	atcacttgaa	ccctggaagt	33420
ggacgttgca	gtgagccaag	attgcgccac	tgcattccag	cctgggtgac	acagcgagac	33480
tctgtctcaa	aaaacagcaa	aacaaaaaca	aaaaaacaaa	caaacatgga	agcaacccaa	33540
gcgtccctct	actgagggat	gaatagcggg	gcaaaatctg	ctccatccac	acaatggagt	33600
actattcagt	ctcaaaaagg	aaaaagattc	tggtcaggca	cggtggctca	tgctgtgaat	33660
cccagcactt	ggggaggctg	aggcgggtgg	atcacctgaa	gtcaggaatt	caaggcccgc	33720
ctggccaaga	ctggcaccna	gctacacana	aagtatanng	ccccggaaa		33769

<210> 9

<211> 72049

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (8356), (8385), (38585)

<223> Identity of nucleotide sequences at the above locations are unknown.

<400> 9

tataccttgc	gcggaaccttc	ggctcctgtg	gtgaagacaa	tatgaagaaa	atagaaatta	60
cccataattt	tgccacacag	acttagttgt	gtccatgtat	cttgtgcacc	ttttttctgt	120
ttacggatca	aaatcgactt	ttagggctcag	gcgcggtggc	tcacacctgt	aatcccaaca	180
ctttgggagg	ctggagttgg	ggttgggggg	tggatcactg	aagatcagga	gtttgagacc	240
agcctggcca	acatggcgaa	actccatctc	tactaaaaat	aaaagattag	ccaggcgtgg	300
tggtaggtgc	ctctaattccc	agctactccg	gaggctgagg	caggagaatc	gcttgaaccc	360
aggagacaga	ggttgcagtg	agccaggatc	acgccactgc	actccagcct	ggcaacagag	420
cgagactctg	tctcaaaaaa	aaaaataaaa	ataaaataaa	taaatacata	aattgacttt	480
taggagattg	gttcaaacaa	tgtgtgtaat	gttgtgtctg	agtgtttttc	atttatcggt	540
catgcaaatt	ccgacatcat	tcaactcttct	ccagagtgtg	ctgttttcct	gcctgtgtca	600
tcacccgtca	ccttgaatgc	cctcgtttag	gtaaaataag	tacattttat	tcaaaaatat	660
ttgaggacat	ttgggttgtc	tccaggttct	tggctctgag	ttttgctgtt	cttgtggagc	720
catggtggtg	tctggttgca	ggaacctcca	tgcgttccag	ctgctgcttc	tgectgtggt	780
cttagagagg	aaatgctggg	gtccgcgggt	cccgggctgc	tgaccaggaa	gcctgcgggtg	840
ccttacggcc	cttcacagaag	cgggagatgc	ccccacttaa	gtgtcagaca	ggcctttcca	900
cttcaactggc	agctctgagc	ggctcccttc	tattttcaga	tgactgagaa	gttaccattt	960
tccacgttta	ctgactgtctg	tttctcctgt	taatttgtat	ttatagtctt	cgctaattta	1020
ttgctagggg	tttggtgttg	tccctattga	cttgatgcc	ttttaatttt	ttaaacaaca	1080
ttaatatata	tcattttttt	agagcagttt	taagtttaca	ggaaaattaa	gggacaagta	1140
cagagagttc	cttccacctg	ctgtcctcct	ctcctcctcc	ccaccttccc	tccttcccct	1200
attgtaactt	tctttctgat	attataaaaag	tcaactcatgg	ctgggcgtgg	tggctcacgc	1260

032796-132.ST25

ctgtaatccc	agcacgttgg	gaggcagagg	caggcagatc	acctgaggtc	aggagttcca	1320
gaccagcctg	gccaacatgg	tgaacccccg	tctctactaa	aaacacaaaa	agttagccag	1380
gcgtggtggc	gggcacctgt	aatcccagct	actcaggagg	ctgaggcagg	agaatggcgt	1440
gaacctggga	ggcagaggtt	acagtgaagtc	gagatcgcg	cactgcactc	cagcctgggc	1500
aataagatga	aagcttcgtc	tcaaaaacaa	agtcacacac	gcttcttgta	cgagggtcat	1560
ttggccgagg	ggccagatgg	ctcaccatct	agttgggaca	ggccatgagc	tcggaatgct	1620
ttttacatat	ttacatgggt	gagaagaaaa	tcaggagaat	aatgttttgg	gacatgggaa	1680
aatgacatgg	aattttgcatt	ttagtgtcca	taaatgaagt	tttgtttgct	cccagctgtg	1740
ttgactgagg	caggctggct	tcctacagct	gcggcagagc	tgaggaggcg	ggaaggagac	1800
cgtgcaggcc	gcagcaccca	aaatatttgc	tctctggccc	ttcccagagt	gcttgccgac	1860
ctctgtccga	cagctagaag	gaaggatagg	acccgtccga	cgataaccac	tgttgacatt	1920
tgagcgcgtt	tccttcccgg	cttttgtgtg	agagtggcag	tctgtttgct	tttgtggtcg	1980
ggatctgctg	cacgcacggc	gggctgtttg	catgaggctt	cctggaggat	agggctgggc	2040
tcggagctgc	acgcagtggg	gcgtgtcctg	catgcagtgg	ggcctcagaa	gagagctgtg	2100
gtgggcgggg	cagtgcacac	gctggtgggt	gccaggcctc	cacgctcaga	tcagccccgg	2160
cgacaggttt	gggccaccct	ctctctggcc	tctgtgcagt	ggcccaggcc	gtctgtctctg	2220
cctggcacac	ttgcctctgt	ccttccactg	aagcgtcctt	cttaccctct	gctcccggct	2280
gggtacgttg	aattgtgtcc	ctcaaggaga	tatgctaaa	gtctaaccac	aggaacctgt	2340
gtatgtgatc	taattttgaa	acagggctct	ggctgatgta	atcaagcgag	gatgaggcca	2400
ccctagatga	gggggcctat	atccacgggtg	ctgggtctct	catgagagca	ggtgagcaga	2460
cactgacact	cagggggtgaa	ggctgcattg	agtcagaaca	gggcttagtg	cgatggcggc	2520
cacaagccaa	ggaactccaa	gtatttccctg	caacaccaga	agctggaaga	tgccagggaag	2580
gatcctgccc	tggagccttc	ggagggagtc	tgtccctgca	gacgtcttga	cttttgattg	2640
cagggatgca	tgtcttaggg	tgtgtggggg	ggtgcatttc	tgatgttaga	agccacctgg	2700
ttggtggcga	tgtgtcacgg	gagccctctg	caggttctgc	gtgtccatgt	ggtcggggac	2760
agaggtgggc	agggacggac	ggtgtcgagc	tggacatgtc	catgacgtcg	gccatccctt	2820
gggatggctt	ttttgttttg	aggataaggc	tgcctgccag	gaagctgtgc	cctgcctggc	2880
ccttgcccca	agccccctggc	ctgtgcttgg	cctcgcgga	gggatgtcgc	ccttctctcc	2940
tgcatgctg	cagggaggaa	ggggagaggt	cagcagcccc	cctggaggag	gctcgggcga	3000
ggggaaggtt	tcactttcag	gcaatgttgt	ggggctgttt	aaacaacccc	aaagaaaacc	3060
atttgcccaa	actgttagtt	tccaaacatt	ttacttcctt	ggtgtttaaa	taaattccta	3120
ccaagactct	gtagctggtc	ccagggaagg	agttggcctc	tcttctttat	agccccgcac	3180
agtcagtccc	ctgcacctgc	ccctcccaac	cccaggcctg	cttccccgtg	gccatggctg	3240
ctgcccggac	ctctctacac	acagaacctc	ctggaggcca	gctgtgggca	ccagccttgg	3300
cagggctgag	gcggagccca	ggctgctggt	actctctctg	cagctgctcc	ctgctggcct	3360
ggctggacag	cgtccccacc	accactgggg	tcacctctgt	gctggtcaca	gctcactcag	3420
accttcaggc	aaatgggttg	gatcctgcct	ctctcccagg	tgtctcagtc	tctgcaaaac	3480
tcaaaaacct	cagaggcctt	gcagcctgag	gggtgtcaga	gacacctcct	tcgaatcagt	3540
aaacacctac	agattcaccc	cagcagtga	aggactgctt	cgccacagag	gtttgattta	3600
ctcctaagta	attggaagg	atgccgagaa	taggttcttc	atggtgggac	tagaggccct	3660
ctgctgacct	agttaacaga	gggctagggc	tgggtgtgct	cagcccctga	aggttctagg	3720
cccatttggg	acaccccgcc	agaacctgcc	acaacctgcc	atgtggtgac	agctacctaa	3780
atcccagagg	ctcttgagct	ggagagcaga	cctctcaatc	tcagcaggcc	ccccacacag	3840
accccataac	cctagtctgc	cttcacagta	cagttcgtgg	ctatgtgttc	acggatgggtg	3900
ttgttcacct	aaggtctctg	ccctgtgacc	ccaaggcgct	cctgagggca	gattccaagt	3960
ctgtttcgtc	cacccctcct	tccttagcag	cgggtccagg	gcctggcctg	aactagcttc	4020
ccacagagat	actggtggga	tgatgaaggc	agccaggcgg	caagtgaaaa	acgcacttcc	4080
tgcatgtgct	ggctcctggg	attgaagtgt	ttgaggaagc	aaagtgaagt	gagctttcct	4140
cttgccggctg	tgtgtccttg	ggccgggagc	ctaccctctc	tgagcgttgg	ggtccttgct	4200
agtagaatgg	ggcatcctca	tagctcaagg	ggtggtgtgt	gaaaatttgt	ctattgtgtt	4260
actttaatga	tttttttttt	ttcgagacaa	agcttcaccc	caacgcgcag	gctggagtgc	4320
agtggcgcgga	tctcagctca	ttgcaacctc	tgccctcctg	gttcaagtga	ttctcctgcc	4380
tcagcctccc	aagtagctgg	aattacagga	gtgcgccacc	aggcccggca	tatttttcta	4440
tttttagtag	agaggggggt	ttaccatgtt	ggctaggctg	gtcttgaaact	cctgacctca	4500
ggtgatccac	ctgcctcggc	ctcccaaagt	gctgggatta	caagcatgag	ccaccgcgcc	4560
cggcctactt	tagtgatttc	ttaggaggac	agagggaacg	ggctggcaag	acaggcttgg	4620
aatgtgtttt	gggatcaagt	gccggtttct	gtctggcact	ggcgttctct	gtggggccat	4680

032796-132.ST25

gatggacaca	ctgctgaggt	caagcgtgat	tcgtcttgcg	ctgtgcctgg	cagtctcatt	4740
ggaaagtctt	gtagacatcg	tgtggatggg	gctcttcccc	gccaagccct	tggggacctt	4800
ccaggactgt	gatctcccca	cagtggctgt	taagcagggg	cctttcgtga	agtggagtct	4860
ctgggtccct	ccaagtcata	gctagacagg	gactcgggca	tcgccaagcc	tggctgatta	4920
ttcactggat	gaggagacag	gcccagagag	gggcaggaac	ctgcccagag	tcacccagca	4980
ggccccagag	gtttcgggtc	cggattctcc	ctgctcatcc	ctggatgtag	tgctgctgtg	5040
gatgtgggtc	tgtgctgggg	gctgtggaga	gcagggggct	tgtgccagga	ccccagtgag	5100
ggtggcgccc	tcgccatgag	gccgactggt	ggtatggggc	ggccatccac	tgggggtgtg	5160
ggaggaacag	ctttcctgag	gaggaggtgg	cgggaggaac	agcttccctg	aggaggaggt	5220
ggcgggtgct	tgtgacctgg	gccttgaagg	acaggtccat	tgtcaacaga	acattttggg	5280
agtggagcct	agagggagaa	aattttgttg	aattcagatt	ccccctcccc	taccaataca	5340
caccaaatac	gatgcccctg	accagatcta	aatttggtct	tcagagattt	ccattgtagc	5400
tgggcacttg	gggaaccttc	taagtgtctg	ctctgcctct	ccccagcctg	cctgcctcag	5460
tttccccagc	cctggggccc	tgctgctggt	gccatcacgt	gggcgccctc	tagtggagga	5520
atcagattat	gcaactccgg	gcttgagaca	ggagtccagg	ggggctcctg	tctttccttg	5580
aaacgttgga	tgccgggatc	ctggaacagt	ctctgcattc	ctcctggcga	gaaccagagc	5640
ctgggcacag	gggaccatct	gttgtttgaa	ggctgcagcc	tggcagggca	ctcaggagat	5700
ctggcagttg	gctgcagggc	caggtctagg	ggccagggca	tcagggaggc	tctgggctgg	5760
ttcagccccg	ggcccccttg	cagattgtga	cctgggcccc	tgtgcagggg	catggccaca	5820
ggatgtctgg	aggggtctct	gacctgacc	tctctggctc	tgtgcatcct	tgagaccaga	5880
aaggtctgga	acaaatgagt	agacgatgcc	ctaacctggg	gagggagcca	catcctgata	5940
ccagcaacct	cgggaaggat	ctgtcaggat	tatggggcac	cctggggggc	ccaagtctgc	6000
atgggtctcc	acttgcaatt	tctgtaggaa	gctctgataa	atccaaactg	ggggctcctag	6060
gacacagtca	gaaatgctga	taccgttgtg	tgtggagcct	cggggccctg	gggtcaggag	6120
catgtggagg	gtgggccacg	ggggttcaga	agagaatcct	gtaaccccc	accccccaaa	6180
ctgaagccca	cttgagggcc	atggctgaaa	ggttgggggg	tctccgtgcg	tctgtggag	6240
tgggtggtga	ggagtccttg	ggtttgcacg	cctctggggc	tgagcggcgg	gaccccgcc	6300
acagcggatc	cctggggcct	gttgctcaga	tgctctcaga	gtgttgctgt	ggccacggag	6360
ggagcctgag	ttaagcttct	cttggtgccg	ttgtacgctg	tcaggtcaca	ctggtgagtt	6420
aggcagggca	cagatgcccc	gagcagaggg	aactttcctt	ggggattcaa	cacgtgcaag	6480
tcttaggggc	tggcaaatac	tgccctcagc	tagagagggg	gcttttattt	gagaccagaa	6540
tcacctgagc	atcctcctgt	ccccagctgt	gtccagcctg	tctgcaggga	catcctgaga	6600
ggaccaggct	ctccccctcat	ccacctgcct	aagtgccact	ctgaaccctg	tccacctgtg	6660
ccgtggaggg	gcgtgacctc	aagctgctca	gccagcagca	ggcttggccc	tggggggcag	6720
cagagaccca	ggtggctgtg	gggtgggtgc	ttcgtggcgt	ggttctgaaa	cttcgttgga	6780
agtgtgtgga	cagtgctctg	cctgttctct	gtgggacctt	atttagaaac	gaggtctgag	6840
ttactgtggg	tcatactact	gttctgatgg	cccagctgtg	tggaggccgc	ggtgcagccc	6900
catccaagga	gccaggggcc	tgggtctagc	cgtgaccaga	atgcatgccc	cggagggtgt	6960
tctcatctcg	cacctgtgtt	gcctgggtgt	tcaagtggtc	gtgaaactct	gtgttagctc	7020
ttggtgttcc	tgaagtgccc	ccgggtctct	aggcctcaga	accagggttt	cccttcatct	7080
cgggtggcct	ggagcatctg	ggcagttgag	caaagagggc	gattcacttg	aaggatgtgt	7140
ctggccctgc	ctaggagccc	cccggcacgg	tgctggggcc	tgaagctgcc	ctcgggtggt	7200
ggagaggagg	gagcgatgaa	gtggcgctga	gctgggcagg	aagggtgagc	ccctgcaagg	7260
tgggcatgct	ggggacgctg	agcagcatgg	ccagcagctg	ggtctgcagc	ctggtacccg	7320
gcgggacttg	tgggtggggc	tgggttgtgg	ccaggagagg	ggctggcagg	agacaagggg	7380
gactgtgagg	cagctcccac	ccagcagctg	aagcccaatg	gcctggctgt	gtggctctca	7440
gctgctgca	taacctctca	gtgcttcagt	tctctcattt	gtaaaatgag	gaaacaaaca	7500
gtgccagcct	cccagagggt	tcatgaggat	gaacgagtga	ccatgtagca	tgggctgggt	7560
gcgtgtcacc	taacatcacc	agcctttgca	aggagagccc	tgggggcctg	gctgagtatt	7620
tcccttgccc	ggcccccccc	aggcctagac	ttgtgctgct	tgaggccctt	tgacccctga	7680
ccccattgca	cctgtctcca	caggagccga	ggaggtgctg	ctgctggccc	ggcggacgga	7740
cctacggagg	atctcgctgg	acacgccgga	cttcaccgac	atcgtgctgc	aggtggacga	7800
catccggcac	gccattgcca	tcgactacga	cccgtctagag	ggctatgtct	actggacaga	7860
tgacgagggt	cggggccatcc	gcagggcgta	cctggacggg	tctggggcgc	agacgctggt	7920
caacaccgag	atcaacgacc	ccgatggcat	cgcggtcgac	tgggtggccc	gaaacctcta	7980
ctggaccgac	acgggcacgg	accgcacgga	ggtgacgcgc	ctcaacggca	cctcccgcaa	8040
gatcctggtg	tcggaggacc	tggacgagcc	ccgagccatc	gcactgcacc	ccgtgatggg	8100

032796-132.ST25

gtaagacggg	cgggggctgg	ggcctggagc	cagggccagg	ccaagcacag	gcgagaggga	8160
gattgacctg	gacctgtcat	tctgggacac	tgtcttgcat	cagaaccccg	aggagggctt	8220
gttaaaacac	cggcagctgg	gccccacccc	cagagcgggtg	attcaggagc	tccagggcgg	8280
ggctgaagac	ttgggtttct	aacaagcacc	ccagtgggtcc	ggtgctgctg	ctgggtccat	8340
gcgtagaag	ccctgnaaac	tggaggagc	cctttgtccc	cctgncttca	gtttcctcat	8400
ctgtagaatg	gaacgggtcca	tctgggtgat	ttccaggatg	acagttagtga	cagtaaggggc	8460
agcctctgtg	acactgacca	cagtacaggc	caggcctctt	tttttctttt	tttttttgag	8520
atggagtctc	actctgtcgc	ccaggctgga	gtgcagtggg	gtgatctcag	ctcactacaa	8580
cctctgcctc	ctgggctcaa	gtgattctcc	tgcctcagcc	tcctgagtag	ctgggattac	8640
aggtgcctgc	cactgtgctt	ggctaattgtt	tgtatttttg	gtagagatgg	ggtttcaccg	8700
tcttggccag	gctggctcga	aactcctgac	ctcagggtgat	ccacctgcct	cagcctccca	8760
aagtgtctgg	attacaggca	tgagccacca	cgcccgggtca	ggccaggcct	cttttgaaca	8820
ctttgcacac	catgggtctt	ttcatccagg	ggggtaggta	cagttgtaca	gttgaggaca	8880
ctgaagccca	gagaggctca	gggacttgcc	cagggtcaca	cagcaggatg	tggcagggtg	8940
ggggctgggc	ctggcagcgt	ggctccagct	ttccagcata	gaaatctgtg	aaagcagata	9000
gtttgtcggg	cggtagggga	gactttctga	gacccgcccc	agcggctcag	agggtagtag	9060
ccaggggcct	tcctgggggc	tcataaccga	gaacactgaa	tgggaaaacc	ctgatggagg	9120
aggcgagctg	gagctgtggg	tgccgatggg	aagtcaccga	ggagctggga	ggtcagtagc	9180
gggtgctccc	tctgtggagc	acttagtggg	caccagggtg	gtttccaggt	tcattggccct	9240
gggacctgaa	gctcagaagg	tgaagtaact	tgcccagggc	acccgtcggg	cagcggcggg	9300
cagaggattt	gtgggctgtg	gagcctgtgc	tcgtggccca	gccctggggg	ttgtgagtg	9360
gctggccggg	gagcttttcc	tgaagtggga	ctggtgtcta	ggagccagca	tgtcaggcag	9420
caggcagcgg	gagtgcagca	ggcagcggga	gcacagcagg	cagagggcgg	ggctcgagca	9480
gccatccgtg	gaccctgggg	cacggaggca	tgtgggagag	ggctgctcca	tggcagtggc	9540
tgaagggtctg	ggttgtgccc	cgaggagggt	ggatgagggt	aagaagtggg	gtccccaggg	9600
gctttagcaa	gaggaggccc	aggaactggt	tgccagctac	agtgaaggga	acacggccct	9660
gaggtcagga	gcttgggtcaa	gtcactgtct	acatgggcct	cgggtgcctc	atctgtgaaa	9720
aaggaaaggga	tggggaagct	gactccaagg	cccctcctag	ccctggtttc	atgagtctga	9780
ggatcccagg	gacatgggct	tggcagtctg	acctgtgagg	tcgtggggtc	cagggagggg	9840
caccgagctg	gaagcgggag	gcagaggggc	tggccgggctg	ggtcagacac	agctgaagca	9900
gaggctgtga	cttggggcct	cagaaccttc	acccctgagc	tgccacccca	ggatctgggt	9960
tcctccttg	gggggccccca	gggaacaagt	cacctgtcct	ttgcataggg	gagcccttca	10020
gctatgtgca	gaaggttctg	ctctgcccct	tcctccctct	aggtgctcag	ctcctccagc	10080
ccactagtca	gatgtgaggc	tgccccagac	cctgggcagg	gtcattttctg	tccactgacc	10140
tttgggtagg	gagatgagct	cttggcccct	gagagtccaa	gggctggtgt	ggtgaaaccc	10200
gcacagggtg	gaagtgggca	tcctgtgccc	aggggagccc	ccagggactc	tggtcactgg	10260
gcttgccgct	ggcatgtctca	gtcctccagc	acttactgac	accagcatct	actgacacca	10320
acatttacia	acaccgacat	tgaccgacac	cgacattttac	cgacactgac	atttaccac	10380
actgtttacc	aacactgaca	tctactgaca	ctggcatcta	ccaacactga	catttaccga	10440
cactgacatt	taccaacact	atttaccac	actgacatct	actgacattg	gcacttacca	10500
acaccaacat	ttaccgacac	caacattttac	caacactgaa	atttaccgac	accgacattt	10560
accgacaccg	tttaccacaa	ccgacgttta	ccgacaccga	catttaccga	cactgatatt	10620
taccaacact	gacatctact	gacgttgga	tctactgaca	ccgatgccag	catctaccac	10680
caccgacatt	taccaacact	gacattttacc	aacactgaca	tttaccgaca	ttgacattta	10740
ctgacactga	catctactga	cactggcatc	tactgacact	gacgtttacc	gacactagca	10800
tctactgaca	ctgacattta	ccaacaccag	catctaccac	caccgacatt	taccaacact	10860
gacatttact	gacactgata	tctactgaca	ctggcatcta	ctgacaccaa	catttaccac	10920
caccagcatc	taccaacacc	gacattttacc	aacaccagca	tttaccacaa	ccgatgttta	10980
ccaacgccga	cgtttaccga	cgccagcatc	taccaacact	gacattttacc	gacaccgaca	11040
tttaccgaca	ctgacattta	ctgacactga	catctactga	tactggcatc	taccgacact	11100
gatatttacc	aacgccagca	tctactgaca	ctgatgttta	ccaacaccga	catttadgag	11160
caccgacatt	tactgacacc	aatattttact	gacatcaaca	tttagccatg	tgatgggggc	11220
cggtctgggg	gcaggccttg	ctcttggcac	tggggatgct	gcagagacca	gacagactca	11280
tggggctcatg	gacttctgct	tcttctccag	cctcatgtac	tggacagact	ggggagagaa	11340
ccctaaaatc	gagtgtgcca	acttggatgg	gcaggagcgg	cgtgtgctgg	tcaatgcctc	11400
cctcgggtgg	cccaacggcc	tggccctgga	cctgcaggag	gggaagctct	actggggaga	11460

032796-132.ST25

cgccaagaca	gacaagatcg	agggtgaggct	cctgtggaca	tgtttgatcc	aggaggccag	11520
gccagccac	cccctgcagc	cagatgtacg	tattggcgag	gcaccgatgg	gtgcctgtgc	11580
tctgtatatt	ggccacatgg	aatgcttgag	aaaatagtta	caatactttc	tgacaaaaac	11640
gccttgagag	ggttagcgta	tacaacgtcc	tgtggttacg	taagatgtta	tcattcggcc	11700
agggtcctgt	agacacagct	acttggagac	tgagggtgga	ggatcgctgg	agtccaagag	11760
tttgaggcca	gcccgggcaa	aggggacaca	ggaatcctct	gcactgcttt	tgccacttac	11820
tgtgagattt	aaattatttc	acaatacaaa	attaagacaa	aaagttaatc	acatatccac	11880
tgccctgctt	aagacagaaa	acatgggtgt	tgttgaagcc	agaggcagct	gctggcctga	11940
gtttggtgat	tggttcctaa	gcagttgaag	gcagttttgt	ttttccatag	atgtctgttc	12000
tccctttgct	gggtgcagcc	tcgccctgct	gctgtggctg	ggtttcagtg	gcctcgtccc	12060
gtggacgcag	cctcgccctg	ccgctgtggt	cgggtttcag	tggcctcgtc	ccgtggacgc	12120
agcctcgccc	tgccgctgtg	gtcgggtttc	agtggcctcg	tcccgtggac	gcagcctcgc	12180
cctgccgctg	tggtcggggt	tcagtggcct	cgtcccgtgg	acgcagcctc	gccctgccgc	12240
tgtggtcggg	tttcagtggc	ctcgtcctgt	ggacgcagcc	tcgccctgcc	gctgtggtcg	12300
ggtttcagtg	gcctcgtccc	atgggcgtgc	tttggcagct	ttttgctcac	ctgtggagcc	12360
tctcttgagc	ttttttgttt	gttgtttgtt	tttgtttgat	tttgtttgat	tgtttgtttt	12420
tgttgctggt	gttgttgccc	aggctggagt	gcagtaggcg	gatctcagct	caactgaaac	12480
tctgcctcct	tgggttcctg	ccattctcct	gcctcagcct	cccacatagc	tggtgattaca	12540
agtgcgccgc	accacgcctg	gctaaatttt	gtatttttag	tagacagggg	gtttcaccat	12600
gttgggtcagg	ctgggtctgga	actcctggtc	tcacatgac	cacctgcctc	ggcctcccaa	12660
agtgttggga	ttacaggcgt	gagccaccgc	gccagccctc	ctgttgagca	tattttgagg	12720
ttctcttggt	gccagtgata	tgtacatgtg	tccccatcgc	accatcgtca	cccattgagg	12780
tgacattggt	gcctctcttc	gggttggtatg	cctccctctg	tttcagcaa	cttctgaagg	12840
attttctga	gctgcacag	tccttgttga	cgtcaccatc	gggtcacct	ttgtctcct	12900
cagggctccc	aggggaggcc	cgaatcaggc	agcttgagg	gcagggcagg	atggagaaca	12960
cgagtgtgtg	tctgtgttgc	aggatttcag	accctgcttc	tgagcgggag	gagtttcagc	13020
accttcaggg	tggggaaccc	agggatgggg	gaggctgagt	ggacgccctt	cccacgaaaa	13080
ccctaggagc	tgcaagggtg	gccatttcct	gctggagctc	cttgtaaagt	ttttgttttt	13140
ggcaaggccc	atgtttgagg	gccgctgagg	atgatttgcc	ttcacgcac	cccgtacccc	13200
gtgggagcag	gtcagggaact	cgcgtgtctg	tggcacacca	ggcctgtgac	aggcgttggt	13260
ccatgtactg	tctcagcagt	ggttttcttg	agacagggtc	tcgctcgtc	accagggcga	13320
gagtgagtg	gcgcaatcac	ggctcgtctg	agcctcaatc	tccctgggct	caggtgatcc	13380
tcctgcctca	ccctctgagt	agctgggact	acagacacat	accaccacac	ccagctagtt	13440
tttgtgtatt	ttttgtgggg	ggagatgggg	tttcgctgtg	gtgcccgaagc	tgatctcaaa	13500
ctcctgaggc	acaagcgatc	cacctgcctc	ggcctcccaa	agtgtctggga	tgacaggcat	13560
cagccgtcac	acgcagctca	atgattttat	tgtggtaaaa	taaacatagc	acaaaattga	13620
tgattttaac	cattttaaag	tgaacagttc	aggctgggcg	tgggtggctta	tgcttgtaat	13680
cccagtactt	tgagaggctg	agggtggcag	atcacctgag	gtcaggagtt	tgagaccagc	13740
ctggccaaca	tgatgaaatc	cagtctctac	taaaaatata	aaaattagcc	gggcatggtg	13800
gcaggtgcct	gtaatcccag	ctactcggga	ggctgaggca	ggagaatcgc	ttgagcccgg	13860
gaggtggagg	ttgcagtgat	ctgagatcat	gccactgcac	tccaatctgt	gtgacagagc	13920
aagactctgt	cttgaaaaat	aaataaataa	aaaaaatttt	aaaaagttaa	caattcaggg	13980
catttagtat	gaggacaatg	tgggtgcagg	atctctgcta	ctatctactt	ctagaacact	14040
ttcttctgcc	ctgaaggaaa	ccccatgccc	accggcactc	acgcccattc	tccctctctt	14100
cccagcctct	gtcaaccact	aatctacttt	ctgtctcttg	gggttcactt	cttctggacg	14160
ttttgtgtga	ctggaatcct	gcaatatgtg	gtccctgcgt	gtggcttctt	tccatagcat	14220
tgtgttttcc	agattcacc	acacattgtc	gcacgttatt	agaatctcat	tcctgactgg	14280
gtgcagtggt	ttaggcctgt	aatcctaaca	tcttgaggag	ccaaggcggg	acgatcactt	14340
gaggcaggag	tttgagacca	gcctggccag	cctagcaaga	ccccagctac	caaaaaattt	14400
taaaagttaa	ctgaacgttg	tgggtgtggg	cacttgtggt	tcccagctac	ctgggagggt	14460
gaggttgagg	gatcgcttaa	gcccaggagg	tcaaggctgc	agtgagctat	gatcgacca	14520
ctgcactcca	gcctggacaa	cagagcaaga	ccctgtctga	aaaaaaaaac	aaaaaaaaaa	14580
gttcctttct	ttttgtggct	ggatgacatc	ccattgtatg	gccacagcac	attttgtttg	14640
tctgtttatc	gggtggtggg	cagtgggttc	caccttttgt	ctcctgtgaa	taatgctgct	14700
gtgaacattt	gaattcaagt	ttttgtttga	acacctgttg	tgaattattt	ggatatatgt	14760
gtaggggtag	gattgctgag	tcctatggta	atgttaggtt	tgacttactg	aggaaccatt	14820
aaactgtttt	caacagtggc	tgcgccgttc	tgcattccca	ccggcaggtg	gtgagggttc	14880

032796-132.ST25

tgactttacc	tcttcacaaa	cgcttctttt	ccatttataaa	aaatattcag	ccaggtgctc	14940
tggctcacgc	ctgtaatccc	agcactttgg	gagggcgtgg	cgggcgatc	acctgaggtc	15000
aggagttcga	gacgagcctg	gccaacatgg	tgttaacccca	tctctacca	aaatataaaa	15060
attagccggg	tgtggcagcg	ggcgccgtga	atcccagcta	cttgggaggc	tgaggcagga	15120
gaatcacttg	aaccggggag	gcagaggttg	cagttagcca	agatcgcgcc	actacactcc	15180
agcctgggtg	acaagagtga	aactccatct	aaaataaaa	aaaaataaaa	ataaataaaa	15240
atttattaaa	acattcatca	cagccagcct	agtgggtgtc	ccatgtggct	ttgcctcgca	15300
tttccctgat	aactaggatg	ctgagcgtct	tgtcccaggc	ttgccacacc	tcagcacttt	15360
gagatacgtc	gcacagtccc	catttgcgaa	cgagaaatga	ggttttagga	acagcagctg	15420
tgtcatgtca	cacagcgagc	aggggggtctc	tgagccgtct	gacccacag	ccgaccaagc	15480
tccaatcctt	accgcctcct	agtgttggtg	atgtagccca	gggtgctccc	acatttttca	15540
gatgagaaca	ccgaagctca	aaacaggagc	gttttgtcca	cattggatac	acgatgtctg	15600
tggtttggtc	ctgaagtcac	tttatatctc	agtgtgccag	actggagtag	gacagggggt	15660
tctggggaat	ggggaaggtg	tctcaggtga	aaggaaggaa	ttccagattc	tccatactgt	15720
ccttgggaaag	ttagaagact	cagaggtct	ggcaaagtca	gacaaagcaa	gagaaatgca	15780
gtcaggagga	agcggagctg	tccaggaaca	gggggggtcg	aggagctcac	ccccaggaac	15840
tacacttgct	ggggccttcg	tgtcacaatg	acgtgagcac	tgcgtgttga	ttaccactt	15900
tttttttttt	tttgaggtgg	agtctcgctc	tcttgccag	tctggagtgc	agtggcacga	15960
tctcggtcca	ctgcaagctc	tgccctccgg	gttcagtcca	ttctcctgcc	tcagcctccc	16020
gcgtagctgg	gactacaggc	gcctgccacc	gcgccggct	aatttttgta	tttttagtag	16080
agatgggatt	tactacatt	agccaggatg	gtctcgatct	cctgacctca	tgatccgccc	16140
gtctcggtct	cccaaagtgc	tgggattaca	ggcgtgagcc	accgcgcccc	gcccgatttc	16200
ccactttaag	aatctgtctg	tacatcctca	aagccctata	cacagtgtctg	ggttgctata	16260
gggaatatga	ggcttacagg	ccatggtgct	ggacacacag	aagggacgga	ggtcaggagg	16320
tagaagggcg	gagagaggga	acaggcggag	gtcacatcct	tggctttcaa	aatgggccag	16380
ggagagacac	cctctgagca	tggtaggaca	ggaaagcaag	attggaacac	attgagagca	16440
accgaggtgg	ctgggcgtgg	tggcttacgc	ctgtaatccc	aacactttgg	aaagctgagg	16500
tgggtggatt	gcttgaggcc	aggagttaa	gaccagcctg	gccaacatgg	tgagaccccc	16560
tctctactaa	atatacaaaa	attagccagg	cgtgatggtg	catacctgta	atcccagctg	16620
cttgggaggc	tgaggcagga	gaattgctta	aacctgggag	gcggaggttg	cagttagccc	16680
agatcccgcc	actgcactcc	agcctgggcc	acagagttag	actccatctc	aaaaaaaaaa	16740
aaaaaaaaaga	taaaaagacc	aaccgaggaa	ttgaagtggg	ggggcgctac	agtagcagaa	16800
gggggatcgt	ggagcaggcc	accctgtggt	catgcactgg	aagctcatta	cctgacgatt	16860
tggagctcat	cactgggggc	ctaaggagaa	tagatactga	aggatgagga	gtgatggcgc	16920
ggggcacggg	tgtctttgat	ggccagaact	tggggactgc	tgggggtgcct	cactgcaggc	16980
cttctcagcg	cccttttatg	gcttacacag	gctgtttcta	agagggggat	acattgcata	17040
agcgttttca	gactacctca	tcatgggtcc	ctttctttac	cctctgtggc	cctggtggcg	17100
cactctctgg	gaaggtgcag	gtggatgccc	agacccgccc	tgccatccac	ctgcacgtcc	17160
agagctgact	tagcctcgag	attgctgctg	gcacctcctg	ccccgggaca	cctcggtatg	17220
gcccgtggag	atgctggctc	tgtgttttct	gctggagttt	ggtgcgtctt	ttcctcctgc	17280
aagtggccac	cgctcttggg	tatgtcctca	ggcttctgcg	agtcattggt	gcttctcagg	17340
tccttgccca	gcgccaggag	caaaccctcc	tggcactttg	ttcaggggtg	gatgcgccag	17400
tgttctgct	gtggaccgcc	atctcacatg	agggctcttg	gcctgcaggc	tcgttcagga	17460
aacaccgct	gagtatgcag	tgtgtgccag	ctgtgtccca	ggcaatggcg	gggacagtgg	17520
ctgctgctgg	ggttggtggg	gcttctgggg	actctgggga	cagctgaggt	gcaaggagcc	17580
acggctcctt	gaggatgcag	ttggactcca	ggtggaaggg	atggttgggg	gaggtataaa	17640
tggggtcagg	gaggagacac	atttgaaca	atgggaacat	ttttaagatg	ctatgtcggg	17700
aggcaacaag	gtggccaacc	caggtgctga	ggagcccaca	ccagccctgg	acgtgttttg	17760
ccgctcacct	ttgctgggga	gtggtgggag	agaggattcc	gttccacgtg	gtggtgtgcg	17820
cagctgggct	gtgtggagct	gggcgctagg	aggaaggtgc	tttctgcggg	gctagccggg	17880
ctctgccttt	gaacacaatc	aggctccagg	ttttcagcat	ccagtgcattg	agaggacttc	17940
acgggcagct	tgggctgata	cttgatgaa	ttgggagaag	aacaaaggct	tatgaaatga	18000
ggtttcatgt	agatggcatt	agagacgccc	acaacagatt	tacagagtgg	agcggagacg	18060
gcggatgggt	ctgggaggcc	cctcctgctg	gccttgactg	tgacagctgt	cctgggaatc	18120
agcttccagg	ccgccccagc	agcctgactg	acacacacag	gggttttagc	cccacctcgc	18180
gaccagctgt	tgccatcatc	agtgcagct	gggagtggcg	gtggttccag	ccctgggcac	18240
cctccccacc	tgctggggcc	cacccagggc	agtcctgaca	cctacagggt	gcttggagcc	18300

032796-132.ST25

gcatccgagt	cctgccccac	cacgtgtgaa	gccccagtg	tcgtgggctg	aggccccctg	18360
attgcatccc	cacttccett	ctgcttcaca	tagctgcctc	ttctcacctg	ttttccagcc	18420
tcctgggcta	ggaattccag	tggtgtgctg	gctttgcccc	aggacacctc	cttagccctc	18480
ttcctgagtc	tagagccccg	ggggttgga	gtcctggccc	ctgggacacc	tgcagccaca	18540
ctcagctttc	ctgttgagcc	tccagcatgt	cccccgagga	ccaagccctc	acgttcttgc	18600
ctccccgcgc	acctgggctc	agccagggga	aggcctggct	gggagcgtct	ccccctgccc	18660
ctgccccttc	ccccctctac	cctgcccctc	tctcctctgc	cccgccatgg	cttttatata	18720
ctgtgccaca	agacatggct	gtgtgtgaaa	gtggcagggt	ctggcatctc	tgtgggtctc	18780
tgaggccac	gctccagtgc	cactcttccc	acccgctggc	cgtgccctca	tgtggagggg	18840
acagcccagc	cctctcccga	accccagccc	catgtgccc	gctgcccccg	gccctctccc	18900
ctggaagccg	gggtcactcc	agccgtatgc	catggtgggg	acatcctgct	tccttggcct	18960
tccagggaag	gtcctctttc	caaattggcg	cacctggtcc	ctgcctggag	gctggaagct	19020
gtggcccttg	tatgcccctc	cagggctctg	gcgctcggtt	ggcccgagtt	cccatcaccg	19080
tcatcatcac	catcatcatt	gtcatttcgc	ttgtctgtga	gccggcctgg	tctcccagag	19140
cagagacctt	ctgaggtcca	gcctgagttg	gggtctccgt	gctgacctct	gacggggact	19200
caggacgtac	caggtctggg	tcaggagtga	cccccaaacc	tcgtgccctt	tgacaggcac	19260
ccctgacttt	tgctaagtgg	gtggagggtga	catcacttac	agcgggagtg	atgggacagg	19320
gtctgttggc	tgcactgtgc	tcccagggat	ctggggagag	gctatatccc	tgggcttttg	19380
cactgcagag	ctgtgtgtgt	ttgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	19440
gtgtgtgttt	gcgtgcgcgc	acatgtgtat	aagatctttt	tttattacat	gaagcaagat	19500
aactgtttgt	gtttcccttt	gggtttttgt	ttcaacagag	tggggtactt	cttccctcag	19560
acaacagaac	tctccccctt	aaacacgtgc	tgtcagaggg	tgggtcttgg	gctcatgtct	19620
gtttgcacag	ccgagtcaga	ggaaacacag	ggttcttcat	aaaaaactg	cacagcaggc	19680
gactgtccag	agtcagcctg	caggacggca	gcagccctgc	ccctcagagc	acagctaggg	19740
tgggctgctt	tgggatctcc	cgtcattccc	tcccagctgg	cagccggcgg	ccggcccatt	19800
ccttggtgtg	ctggtcaggg	gggcgtgcgc	ctgctctgct	caccctggga	atgggacaga	19860
agctggcagc	tcggagagga	cagggctgga	cccttgggtg	gcctctggct	ggaccatctc	19920
attgtcctca	gacacagcct	ctcgggtcta	gtttcatttc	ctgaaaaaca	agtgcacaga	19980
actagagcag	gagtcgagag	ctacggcccc	cgggccagat	ccagccctgc	cacctgtttt	20040
cacaccatgc	tcaagctgag	tgggttttac	attttttaat	tacttgaaaa	aaaaaaagcc	20100
aaaggaggtt	tcatgacca	tgaaaattat	atggaattca	aaaaaaaaaa	attatatgga	20160
attcaaat	cagtgtccat	aaataatttc	ttgagacagg	gtctcgctct	gtcaccacag	20220
ctggagtga	gtgctatggc	atggctcgct	gtaccettga	cctcccaggc	tcaagcgatc	20280
ctcctgtctc	agcctcctga	gtagctggga	ctacgggtgt	gtgccaccaa	gcccggttaa	20340
ttttttttta	atttttagta	agacagggtc	tttctatggt	gccagggctt	ttctggaact	20400
ccatcttggc	ctcccaaagt	gctgggatta	cagcctcgag	ccacggagcc	cagcctgttt	20460
ttgttttttc	actgataaag	ttttgccggg	tgtggtagtg	tgtgcctcta	gcgatttggg	20520
aggctgaggt	gggaggatcg	cttaagccca	ggagtttgag	gctgggctca	agtgatcagg	20580
aggatgaact	tgatcatgtc	attgcattcc	agcctgggtg	acagagcaag	aacctatctc	20640
ttaaaaatat	atatttaaaa	agtattgggt	gtgggtggctc	acgcctgtgg	tcccagctac	20700
ttaggcatct	gaggtgggag	gatggcttga	gccagggagt	ttgaggttgc	agcgagccaa	20760
gatcgtgtca	ctacactcta	gcctgggtga	cagagcccag	accctgcctc	tttaaaaaaa	20820
aaaacccaaa	aacatgtatt	ggaacacagc	catgcctgtt	cagtcacgtg	ctctccatgc	20880
tgctttctgc	tccagagacc	cttatggcct	gaaagctgaa	aatattttct	atcctttaca	20940
aaaaagtttg	ctgacctctg	tccctggaaa	ttcatctccc	aagttctctt	ccggcactgg	21000
cgttcctggg	tgtcctaaat	ttggccccctg	ttatttctga	actctgtttt	ggctctgttc	21060
cctcccaggga	gccaggacag	gcacgttctc	tgcattctgt	cccctgacgc	ccagaggctt	21120
ggctcggtc	aggcattctt	ggaaatatct	ggctccagga	aaggcagagg	cctcctgagt	21180
cggcccagag	ggaacctgcc	ccaggtctgg	gggaggcctg	acccagcaga	gtggcttttg	21240
ccgatgggtt	gggcccgtca	agatgtgctg	aaagtgtgcc	tcagaaggcc	actttgggat	21300
tccttctctc	agtattagag	caactgagag	ctgctcattg	caagcctgat	gttttccag	21360
ttggccgggt	ccaccgggtg	ccctgggatt	ctgggactgt	ggtggaaagt	agggggcttg	21420
ggggagtgtc	ctgggttctg	gaatccaggt	gggaagtgtg	gaggttcagg	gagtggcttc	21480
tgagccacca	taggggtctc	tgtgggaggc	tctgccatc	caggagattc	cgcaggccct	21540
gccggcccag	agccagcgtc	ttgcgcttgc	cgaggctaca	gccagcccca	gccgggtgga	21600
acagcccgtc	gcctcctctc	actttgtttt	ggggccacct	gggagtgtgg	agcaagggtg	21660
gagagggagg	aagtggctgc	cggccgctgc	ccagcacctt	tgtttgcctt	gggccctctg	21720

032796-132.ST25

tgggctcctt	tttattgctc	ttcaatgaag	ccagggaaaat	ggacttcctt	gcctcacttc	21780
agttcaacat	gtctggaagt	ttggtattaa	aattaagaaa	gtgtggaat	agagcaagaa	21840
gagaaaaatc	tctccaagag	ataatagtga	cctctgagct	gggcgcggtg	gctcacgcct	21900
gtaaatccca	gtactttggg	aggctgaggc	gggcagatca	cctgaggctg	ggagtttgtg	21960
accggcctga	ccaagatgga	gaaaccccg	ctctactaaa	aataaataaa	taaataaata	22020
aataaataca	aaattagcca	ggcatggtgg	cgctgccta	taatcccagc	taaggcagga	22080
gaatcgcttg	aacctgggag	gcaaagggtg	cagtgaagcca	agatcacgcc	attgcactct	22140
agtctgggca	acaagagtga	aactccgtct	caaaaaaaat	aaataaataa	aaaataaaaa	22200
tagtgacctc	tggccagggtg	tggcagctca	taccgcgtat	cccagcactt	tgggaaggag	22260
gccgagatgg	gcagattgct	ttagcacagg	agtttgagac	cagcctggcc	aacatggtgg	22320
aaccccatct	ctacaaaaat	agaataaaat	ttaagaggta	atagtgcact	tttggtagat	22380
cgaacactgg	attgctttct	ttttctaaat	gctgattcct	ttctttgtgg	tgtttgtgtt	22440
ctgtgccgat	gtccctcccc	cagccctgtt	attgtgagtg	gaagaagggg	aaagggttcg	22500
cccgtactg	tgagccctc	ctctcacgct	gggtgtcctt	ggagaagcct	gcacttcttc	22560
attgtacgcc	agggctgggt	ccctccctgg	agtggttctg	tgctgctggg	atggggccaa	22620
cccctcagat	gttttctgag	tgtcacacac	aggtgtgtgc	attcatggcc	tttgctgtgc	22680
ttcctgttgt	ggaggcaaaa	atgtgaagaa	ccctagatga	ttttgggacc	agggctccat	22740
cacctgctgt	tcattgcaca	ccggagcatc	caggcatggg	tggagagctc	agacttccag	22800
gcacggctcg	agggctgggt	ctaaccatgt	tcccgccgcg	ctgctcgta	gaaccgcctg	22860
ttgggagctg	ttatcatgat	accatacctg	ggccttgggc	tatccgattc	tgacttaatt	22920
gctccaggtt	ggggccaggc	cgttgtttgc	tgttttgttg	ttcttctgt	gacgttagcc	22980
actgggctaa	ctgagcccc	tcagttacag	gtggagaaac	tgagacccat	gggggtgcaa	23040
ggacttgccg	aggaccaga	gccccttggg	ggcagagctg	aggcggggcc	tggctttggg	23100
tcccagagct	tccagtcccc	ttcccgctct	cctaacagct	tttttttttg	agacaagatc	23160
tcacctgtc	accaggtctg	gagtgcattg	gcattgatct	ggctcactgc	aatcttcgct	23220
agctgcgttc	cagcgattct	cctgcctcag	cctcccgagc	agctgggatt	acagggtgtg	23280
gccgccatgc	ccagctcggt	tttttttgta	cttttagtag	agatagggtt	tcacctgtt	23340
ggccaggctg	atctcgaact	cctgacctca	aatgatccgc	ctgcctcggc	ctcccaaagt	23400
gctaggatta	caggctggga	tcacactgtg	cctggcccta	gcagctttgt	cctgtgccat	23460
ccaacaacag	atgaccgaag	tctttgtttc	ttaacatgca	ttccatctgc	cttacagttt	23520
tgccacctgc	aaaacagagg	acttgtcgct	tttctggtaa	gctggaaatg	taatctggta	23580
gcaggaggcc	tgtggaagct	tgcttttaat	ggccttgtgt	ctctttcatc	ctgtcctgag	23640
agccggagaa	cttggtgtt	gcacctaaat	caaccttcct	gttaacatac	agttctgcag	23700
gctcatggat	catcagaacc	acgtcctatc	tcacgcggct	gtatgcttcc	gttggttcag	23760
gtgtttttac	gttgacagta	ttttctcctc	gggtgctttt	gcggtgggtg	cttttaatca	23820
gcattgactc	ttcaagaaaa	atatttagct	gctacatctc	agaggagaca	gggtggaaag	23880
catctgagac	ctgcaggctc	agacttagaa	ccagaagtgc	cctcagagtt	catccggccc	23940
tgaccacgag	ggaaatgagt	tcacagagaa	gcgggagaa	tttgccccag	gccctgccgt	24000
tgctcataac	tgccccagg	ccttacattt	gctccaggct	ctgccccagg	ccctgcagtt	24060
gctcataact	gccccaggct	cttatatttg	ctccaggctc	tgccccagg	cctgcagttg	24120
ctctgtgtgg	tgggtgtgat	ctggagccct	ccgcccattg	ctgcacctgg	ggcaggcatt	24180
gctaattgat	cccaggactc	cttctgcgg	agcacgccct	ggttctccag	gcagccgctg	24240
cctgtcagcc	tgcagtgggt	cgggagagga	cacctgcttg	cctggtctgt	tccaaatctt	24300
gcttctcatc	ccagcacagg	tagggggtgc	tatgggaaag	ggatcctcag	ttggccctgt	24360
cactgctcta	tcagctgggg	acgtggcatc	ctagtgaata	catcatggcc	gggcgcggtg	24420
gctcacgcct	ggaatcccag	cactttggga	ggctgaggag	ggtggatcac	ttgaggtcag	24480
aagttcgaga	ccagcctggt	caacatgggt	aaacccatct	ctactaaaaa	tacaaaaatt	24540
cgccagggtg	ggtggcgggt	acctgtaatc	cgagctactc	gggaggctga	ggcaggagaa	24600
tcgcttgaac	ctgggagggt	gagcttgtag	tgagccgaga	tcttgccact	gcactccagc	24660
ctgggcaaca	gagtgaagag	ctgtctcaaa	atctcaaaaa	aacaaaacaa	caaaaaacaa	24720
acaaacaaag	cgtcatttat	ccagcacccc	tggggaaacca	tgctacctgg	tgttttatgg	24780
tacctggcaa	ggtgcagggt	aagttgctgc	tcttgggcat	tgaacccgtc	ttgtttgggg	24840
cagctcaggc	ccaggcagg	gtccgggttg	gctctcggtg	gtgtggccct	ggcccatcca	24900
gacctatatt	tctgccgtcc	tgcaggtgat	caatgttgat	gggacgaaga	ggcggaacct	24960
cctggaggag	aagctccgcg	acattttcgg	gttcacgctg	ctgggggact	tcatctactg	25020
gactgactgg	cagcgccgca	gcacgagcgc	ggtgcacaag	gtcaaggcca	gccgggacgt	25080
catcattgac	cagctgcccg	acctgatggg	gctcaaaagct	gtgaatgtgg	ccaaggtcgt	25140

032796-132.ST25

cggtagtcc	ggggggtccc	aagccatggc	tcagccatgc	agacttgcat	gaggaggaag	25200
tgacgggtcc	atgcctgggc	ataagtgttg	agctcaggtg	ccccgacctg	gggaagggca	25260
ggacagga	ggtgacagta	tctggccaag	gacagatggg	aagggaacca	gggagctgat	25320
tagggagtgg	ttatggacta	ggaatgtcgg	taacaatggt	tagaaagtga	ctaacttttg	25380
ttgagcacct	gctgtgtgcc	cggccctggc	cgggagcctt	cgtgccca	gtgaccccg	25440
ctgcaaatgt	agttccttgc	cctactcgca	ctggggagca	ggacgcagag	ccgtgcaact	25500
cacaggtgcc	aagctcagga	ctccctcctg	ggtctgcctg	ggctgggctg	tgcttggtgc	25560
ccctgtggcc	cacgcagtgt	caccttccac	ctgaaagcca	ggatcttcag	gacgctcccc	25620
gaggaggtcg	ttgtctggca	caatgatttg	tctcttccctg	aaaagggtgac	agagttacac	25680
tggagagagc	agcatccagg	tgcggcaggg	acaggcctgg	ggctcgcggg	cagggactct	25740
gtgtcctgcc	ggggtcccac	actgcacctg	cttgctcagag	gcaactcagtc	aatctttgct	25800
gatgaaggat	gagaggacag	aggacgtgat	gcttgctgct	gcattgcctg	cagtcctggg	25860
tgagatgcc	gggttgactc	tgtgtcccg	cgggtggatg	tgatgtcaga	tccccggctt	25920
taaaatacga	gggagctggg	aattgagga	gcaggttggg	gcagaaagca	cagccccgctg	25980
gaagcctgga	gctgaggcag	tgtgggcgac	ccctggagca	gtgagtgttt	ccttcattggc	26040
cttcacgcga	ccctgcagtc	ctcatgtagg	ggatgccatc	catgaattta	gttttcccag	26100
cctccttta	aaacgcgttc	atgctggggc	cggggcagtg	cagtggctca	catctgaaat	26160
cccaccactt	tgggaggccg	aggcgggtgg	atcatgaggt	caggagatcg	agaccatcct	26220
ggctaacaag	gtgaaacccc	gtctctacta	aaaatacaaa	aaattagccg	ggtgcggtgg	26280
cgggcgcctg	tagtcccagc	tactcgggag	gctgaggcag	gagaatggcg	tgaacccggg	26340
aagcggagct	tgcagtgcgc	cgagattgcg	ccactgcagt	ccgcagtcg	gcctgggcga	26400
cagagcgaga	ctccgtctca	aaaaaaaaaa	aaaaagtaca	aaaaaaaaaa	aattagtctg	26460
ggtgtggtat	cacgcgccta	taatctcact	actcgagagg	ctgaggcgga	gaattgcttg	26520
aaccaggag	gtagagggtg	tagtgagccc	gtatcgtacc	actgccctcc	acctgggcaa	26580
tagagcgaga	ctctgtctca	aaaagaaaaa	aaaaaaaaaga	acatttatgc	cagggtgtgt	26640
ggctcatgcc	tgaatccca	gaactttgga	agactgaggc	aggaggatca	cttgagccca	26700
gaaatttgag	agtgtcttcc	ctgggcaaca	tagagagacc	tcatctctac	cagaaaaaaa	26760
aaaattagcc	cggcatggtg	gcataccct	gtggtcccag	ctacttaggg	ggctgacgtg	26820
gcaggatcac	ctgagtctgg	aggcagaggt	tgaagtgcgc	tgagatcatg	ccactgcact	26880
ccagcctggg	tgacagacag	agaccctgtc	tcaaaaaaaa	aaaaaaaaaa	aagcatttac	26940
tatccaccat	ggaagggtgag	actgacctgt	gagtgtattgt	tcaagaaca	aaaaataaac	27000
cccagagata	agacaaaagg	gtgcctccat	gggggtgtga	tttaaagctg	agaaattggg	27060
cttcttcccc	ctccctctc	accccggtgt	ttgctaaagg	agatgggaaa	aaggattcct	27120
tttttggtg	aaatatttta	cactaaatta	aagccaattt	taacagcact	ttggttgatg	27180
agtgaatta	acagactggc	caaaaataaa	cagacggtct	gtactatgtg	aaaaagaggc	27240
agctttggcc	atgctggggc	aatgtgagtt	ttcagggttg	ctgggaatgt	ctgtgaatcg	27300
gagggaaggc	ctagctggga	ctctcaggag	ccaaggccct	gaggggcaac	ttgcctgggtc	27360
cctgccctga	ggcggttca	gctttcttcc	tgggccagat	cacaggcccg	gaggctggac	27420
cactgggctg	gcactcttgc	cgagctgctc	cctgacttcc	tgaccatgct	cctttcagca	27480
gccttgctgc	actttagttt	ccttgaatga	aaaatgggga	tgagaatagc	tcctacctcc	27540
aagggtgaatg	gagtgagttc	ggacaggtga	ctccctggga	ccagtgcctg	gcgcctgaca	27600
aggtccagtc	agagcccgcga	ctgctgttac	tgataccctt	ggctgtacca	ggggagaact	27660
tgggtgccat	tgccagggtg	tctcccacca	ccccactac	tgtccctgtt	tgatgtgtgg	27720
cgggaataaa	gctgtgcaca	ttggagcttt	tggcacatcc	tggctttcag	gtgaaagggtg	27780
cgtgtgtgtt	tgagggttta	gcctggccaa	cccagccatg	aggtcggacc	tgacctgggg	27840
gtgagtcctg	agctcggcac	ccctgagctg	tgtggctcac	ggcagcattc	attgtgtggc	27900
ttgggcccga	cccctttccc	tgtgggctg	ttgatgttta	gactggagcc	tctgtgttcg	27960
cttccaggaa	ccaacccgtg	tgcggacagg	aacggggggg	gcagccacct	gtgcttctgc	28020
acacccacg	caacccggtg	tggctgcccc	atcgccctgg	agctgctgag	tgacatgaag	28080
acctgcacg	tgcctgaggc	cttcttggtc	ttcaccagca	gagccgccat	ccacaggatc	28140
tccctcgaga	ccaataacaa	cgacgtggcc	atcccgctca	cgggcgtcaa	ggaggcctca	28200
gccttgga	ttgatgtgtc	caacaaccac	atctactgga	cagacgtcag	cctgaaggta	28260
gcgtgggcca	gaacgtgcac	acaggcgacc	tttatgggaa	aaccttgcc	ctgttcctgc	28320
ctcaaaggct	tcagacactt	ttcttaaagc	actatcgat	ttattgtaac	gcagttcaag	28380
ctaatacaat	atgagcaagc	ctatttaaaa	aaaaaaaaaga	tgattataat	gagcaagtcc	28440
ggtagacaca	cataagggtc	tttgtgaaat	gcttgtgtga	atgtgaaata	tttgtgttcc	28500
gttagagctg	acttcagaca	ccccacccac	tcccttgctg	gtgcccgttt	gctcagcaga	28560

032796-132.ST25

ctctttcttc	atttatagtg	caaagtataa	catccaggac	aaatacagga	agactttttt	28620
ttttttttt	tgagacagag	tcttactctg	ttgccagggc	tgaggtaccg	tagcgtgagc	28680
tcagctcact	gcaacctccg	cctcccagg	tcaagcgatt	cttctgcctc	agcctcctga	28740
gtagctggga	ctacagacat	gcaccaccac	acccagctaa	ttttttttat	atttttagta	28800
gagacaggg	tccatcatgt	tgccaggct	ggtcttgaa	tcctgacctc	aggggaacag	28860
acgggggttg	ctcccaaaag	ggcggaata	acaggggtga	gccaccgttc	ccggcctagg	28920
aaaacttttt	gccttctaaa	gaagagttta	gcaaactagt	ctgtgggctg	gccttctgat	28980
tctgtaaaaga	aagtttgatt	ggtggctggg	tgcggtggct	cacacctgta	atcccagcac	29040
tttgggaggc	cgaggtgggc	agatcacctg	aggctgggag	ttcgagacca	gcctcaccaa	29100
cgtggagaaa	ccccgtctct	actaaaaata	caaaaaaaaa	attaaccggg	catggcggcg	29160
cctgcctgta	atcgagctga	ctcaggaggc	tgaagcagga	gaattgcttg	aacctgggag	29220
gcggagggtg	tggtgagctg	agatggcacc	attgcactcc	agcctgggca	acaaaagtga	29280
aactccgtct	cagaaaaaaa	aaagtttgat	tggtgtaacc	aaagcgcat	tgtttatgga	29340
ttgtctgtgg	cagcttttgt	tctgccgaga	tgagttgtga	cagatctgta	tgggctctaa	29400
agcctaaaac	atgtgccatc	cgccccctta	cagaaaaagt	gtgctgacct	ctgttctaaa	29460
gtattggaca	actacaatgt	ttgtctat	attattctat	gatttgtttt	ctgctttttg	29520
ttgttggtgt	tggttggtgag	atagggtttc	cctctgtcac	tcaggctgga	gtgcagtggt	29580
gtaatttcag	ctcactgcag	cctcgacctc	ctgggctcta	gtgatcctct	catctcagcc	29640
tccctagtag	ctgggactac	aggcacacac	caccactcct	ggctgatttt	ttttttttt	29700
ttttttttt	gtcgagacag	ggtttccgca	tggtgccag	gctggtttca	aactcctagg	29760
ctcaaacacc	cagctcagcc	tcccaaaagt	ctgggattac	aggcgtgagc	caccatgccc	29820
agcctattct	actgtttgta	ttacatagct	ttaaaagatt	ttttatgact	ttaagtca	29880
agggttcttt	gtagaaaaaa	atatatatat	aggaaagtat	aaaaagaaag	taaaaattgt	29940
ccataacctc	tccagccaga	gacgaccgtt	gctgacacct	cagcatattg	cctttaagtc	30000
ttttttctct	aagatagcat	ttctcttcat	cacagtcata	tgctacgcag	aattctgtat	30060
cctgattttt	tcacttgaca	ttacaacagg	tatttgatgg	cgctgtgaca	aactctttgg	30120
cacaatcttt	taaatgtatg	aaatactcca	ctgcacagat	gtttgctttt	aggcttaact	30180
gttcttttat	tttgctgtg	ctggttacag	ccgggcacag	tggctcatgc	ctgtaatcac	30240
aacactttga	gaggggtgag	caggaggatc	acttgagccc	agaagtttga	gaccggcctg	30300
ggcaacatag	tgagacccca	tctctacaaa	aaactttttt	aataagtcgg	gcgtagtggt	30360
gcatagctgt	agtcccagcc	accaaggagg	ctgagttggg	aggattgctt	gagccccagg	30420
aggttgatgc	tgagtgacc	tgagattact	ccactgtact	ccaacctgag	cgacagagca	30480
agacttgctc	ggggaaaaaa	aaaaaaaaaa	tatatatata	tatatatata	tatatacata	30540
tatacatata	cgcacacaca	cataatataa	aaatatatat	ttataaatat	ataatatata	30600
atataaaaat	atataattat	aaataaaaat	tataaattat	atttataagt	aaatatataa	30660
tataataat	aaaaatatat	attatataat	atataataaa	atataataa	taaaaatata	30720
tattttataaa	taatatataa	tacatactta	taagtataa	tttaaaatat	atgtaatgta	30780
tatttttttaa	tgtatgat	ataatataca	tttataaata	cacattttata	ttattttata	30840
taaaatatata	ataaaatctc	caagttgctt	tttccaaaaa	ggtgtcttgc	tgcatttcaa	30900
acattcattt	aaaaacttga	atgctggtga	tctggtccag	aatgtgttca	gtagctgctg	30960
ccagtggcca	agcatctcgg	gagatgtcta	caaaacacgc	tggttctggc	ctggcgtggt	31020
ggctcacgcc	tgtaatctca	gcactttggg	aggctgaggc	agggtgatca	actgaggtct	31080
ggatttcgag	accagccttg	ccagcttggt	gaaaccccat	ctctactaat	aatacaaaaa	31140
aattagccag	gcgtggtggc	atgtgcctgt	aatcccacct	acttgggagg	ctaaggctgg	31200
agaatcgctt	gaacccaggg	ggcagaggtt	gcagtgagcc	gagatcgcac	cattgcactc	31260
caggctgggc	aagaagagcg	aaactccgtc	tcaaaaaaaa	aaaaaaagat	gctggttcc	31320
aaaatgtggc	ccttttccctc	ctcacctgct	gccagaccat	cagccgcgcc	ttcatgaacg	31380
ggagctcggt	ggagcacgtg	gtggagtttg	gccttgacta	ccccgagggc	atggccgttg	31440
actggatggg	caagaacctc	tactgggccg	acactgggac	caacagaatc	gaagtggcgc	31500
ggctggacgg	gcagttccgg	caagtcctcg	tgtggaggga	cttggaaca	ccgaggtcgc	31560
tgccctgga	tcccaccaag	gggtaagtgt	ttgcctgtcc	cgctgcctct	tgtgttcacc	31620
tcgtatgaga	cagtgcgggg	gtgccaaact	ggcaaggtgg	caggctgtcc	gtgtggccct	31680
cagtgattag	agctgtactg	atgtcattag	ccttgatggg	ggccaggact	ggtagggccc	31740
tcagaggtca	tgaggttcct	tcgtggagcg	ggtgctgagg	ctgtatcagg	cacagtgtcg	31800
gctgctttca	cctgggccgt	ctcaccgaag	tgtccatgga	gcctgcgtag	ggtgggtatc	31860
tgtgtcgatt	ttacagatgc	agaaacaggc	tcagagaaac	cgagtgactt	ccctaaggctc	31920
acataccag	ttagagcaga	gctgggccag	gaagtgtctg	ctcaggctcc	tgaccaggctc	31980

032796-132.ST25

tccttgcttt	gcactcttgc	caaaaccatg	atccagaact	gactttgagg	tccccggacc	32040
tcaggctcct	ccgaaatggc	ctcttgagg	ctgctgagcc	acagcttagg	acccacctcg	32100
agaggcaaat	gtgctttgag	ctgccaggcg	tcctgggggc	cctgccttgg	gcacgggggt	32160
cagacaggcc	ccagatgtgt	ggggcgtctt	tctggacttg	agttttcttt	tctgtgtggt	32220
ggacacagtg	ctcaccctt	aaagcacctg	tgatgtgtgc	agcagcccaa	tccctgcctg	32280
tcgcctgttc	tgctaaggaa	ggaaggaata	cttcaggatg	gcaggacaac	agaaagaggt	32340
ccaggtttta	gagcaagggc	aggtcaaact	tagaaaattc	tggaatgagg	atgtgcattt	32400
cctcttctgg	atctgctaaa	agaagagggg	aggaggggct	gctgggggag	gagcccagag	32460
ccgagtttac	atccggatcc	cgcaaggcct	cccctgccct	gaggtcttgt	tttgtgatgt	32520
gcttgtgtcc	atcctggttt	ctgccgtgtc	cccaacatcc	ggccaagctt	aggtggatgt	32580
tccagcacac	actcaccctg	tctgtgcacc	tgtttttgtg	tccgtaagtg	ggtatttact	32640
caccttacga	gtgagccact	gtgggaattc	agggaggtgg	cgcagtgacc	acccctggag	32700
ggatatgtgt	gtggcagggg	tcgagggctc	cgcccttccc	tgcttcctgc	gcgtggcttt	32760
ctccaggacg	gggagggctg	agctgaagag	gtggggacag	ttgcgtcccc	ccgccaccca	32820
ctgtcctgcg	gtgagagcag	actcactgag	cctgcccttc	tcccttgtgc	cttccagcta	32880
catctactgg	accgagtggg	gcggcaagcc	gaggatcgtg	cgggccttca	tggacgggac	32940
caactgcatg	acgctgggtg	acaaggtggg	ccgggccaac	gacctacca	ttgactacgc	33000
tgaccagcgc	ctctactgga	ccgacctgga	caccaacatg	atcgagtcgt	ccaacatgct	33060
gggtgagggc	cgggctgggg	ccttctggtc	atggaggcgg	gggcagccgg	gcgttggcca	33120
ctccccagcc	tcgcgcgacg	taccctgtgg	ctgcgaagtt	ccccaacctg	gcaggagctg	33180
tggccacacc	cacgactgcc	cagcagcctc	accctctgct	gtgggagttg	tccccgtcca	33240
ccctgggtg	cctttgctgc	agttatgtcg	ggagaggctc	tggtgacagc	tgtttctctg	33300
gcacctgctg	ggcactaggt	cccagcta	ccctgtgcca	ggactcta	ttcacccata	33360
cacacatggt	ggttttctatt	gctggggaag	ctgaggcctg	agcacatgac	ttgccttagg	33420
tcacatagct	ggtgagttca	ggatccccc	gagataccag	ggccagcact	cgatccccac	33480
ccagccctga	acccccaccat	gtgctgggat	tgtgctggga	gtgtccacac	gcctgggacc	33540
ccagggtctg	tgctctcatc	tcctttttcc	agatcatgag	aatgaggctc	aggggaagttt	33600
gaaaaaaacc	tatcccaagt	cacacagcaa	caggagcagg	atgtgaacct	agaaaagggg	33660
accgcacact	ctgttctgct	agagtagtta	gctgtcctgg	gtgatatggc	aggtgacagg	33720
ggcaactgtg	cttaacaaag	gaacccccat	ccccctgcc	aagttgggag	actagaaggt	33780
caggggcaga	agctctgaag	ggccagggtg	agtggctgac	acctcta	ccagcacttt	33840
gtgaggccaa	ggcgggcaga	tgatttgagc	ccaggagttc	aagatcagcc	tgggtaatgt	33900
agtgaacgc	catctctaca	aaaaaatttt	ttaaaaatta	gctgggcatg	gtggttcatg	33960
cctgtagtcc	aagctacttg	ggaggctcag	gtgggaggat	tgcttgagcc	caggagggtg	34020
aggttgtggt	gagctgtgat	catgccactg	cactccagcc	tgggcaatag	agtgaagccg	34080
tctccaaaaa	aaaaaaaaga	agaagaaaaa	gaagctctga	ggctccaagt	ccccaggcac	34140
cccttggtct	gagggcagac	aaggaggag	agggtcacct	gggcagccct	gacttttgtc	34200
ccctggcaaa	gggaccttca	gtgaccttgg	ccctaggaga	gcctctgagc	acgtcagcca	34260
tgtcgaaccg	ctcaggaagg	gcagcaagaa	tttggttct	gacctctgcc	tctcctactc	34320
gccatctgca	ctgggtgtgg	ttgtgcccat	tttacagatg	aggaggctgg	ggcatcgacc	34380
agctgaatgc	cttgtcccag	gtactgcgta	ggcagagctg	gcagttgaac	cccgtgtcct	34440
ggttgtcgct	gggggtgggc	tgacccctga	cttgtgaggc	cagtagcaag	gtttgcacgt	34500
gacttcgtga	ccgtcaccga	gctctgcagc	acatcccgtg	accagctca	tccaggccgc	34560
atgcaaacct	gttgccaggc	gagaaaccag	tcaccgcaca	gctgtggttg	cctgaaatga	34620
ttaagctcat	taatcaccct	ggagtggagg	cagactcaga	tgaaaaccag	caaaaagccct	34680
ggaaactcat	gtgaccctgc	caatgagggc	ggccatgtgc	attgcagcct	ggccgtcact	34740
cctcggtacg	tgttttggac	ttaaacgctc	cggatgttta	ctgagtgcct	gattaataac	34800
atggaaggcc	tggtctcatt	gctgtgggag	tgaaggatgc	acagccaggc	ctgacatgat	34860
gagaacaaga	acctggagtc	tcgctgcctg	ggtggtaatc	ctggccctgc	cacttagcaa	34920
ctgtgtgact	gtagccagg	cacttaattt	tgctagatcc	tgccctgcgt	tcagtggatc	34980
ttgtgtggtt	tccaaggtgg	ccaaacactt	taaggcatcc	atgtggtcgc	taggctgcag	35040
ggttgaaccc	tggtcaccct	cgagggcgcc	cgtgtgctct	tgggccctgg	tggtgcctttg	35100
ctgacaccgt	gcccgtgtgt	gttcatgcag	gtcaggagcg	ggctcgtgatt	gccgacgatc	35160
tcccgcaccc	gttcggtctg	acgcagtaca	gcgattatat	ctactggaca	gactggaatc	35220
tgcacagcat	tgagcggggc	gacaagacta	gcggccggaa	ccgcaccctc	atccagggcc	35280
acctggactt	cgtgatggac	atcctggtgt	tccactcctc	ccgccaggat	ggcctcaatg	35340
actgtatgca	caacaacggg	cagtgtgggc	agctgtgcct	tgccatcccc	ggcggccacc	35400

032796-132.ST25

gctgcggtg	cgctcacac	tacacctgg	acccagcag	ccgcaactgc	agccgtaagt	35460
gcctcatggt	ccccgcacc	tcactccctc	gttagatcag	gctggttctg	ggagctgacg	35520
ctgaaaggag	cttctcatct	gggttcctg	ggtgtacata	gatggttggg	taggttgtgc	35580
actgcacaag	ctgcatgatg	ctacctgggg	gtccaggtcc	aggctggatg	gacttgttgc	35640
ttcatcagga	catagataaa	tggccaaaac	tcctcagctg	gaaggtcctg	ggcaggatct	35700
ttgggtgtga	aaaccagtca	caggggaagg	gtgcttgctc	atactgccag	cacagtgtcg	35760
agtgtcttcc	atagcgctcg	tttactcctc	aagcctggag	ggtggggagt	agcatggtcc	35820
catttcacgt	acaaggaacc	cgatgcacag	agaggtgtgg	caacccatcc	aaggccatac	35880
aactggggtg	ggttgagccg	gggttgactg	tggcaggctg	gctcaagagt	ccctgctcct	35940
gaacccttgc	caggcagcct	ggcatcagct	cggggaattt	ttgccctgac	ccttgggaagc	36000
aagtgggcct	ctttgttctc	atgtcagtga	tgagaagagt	gactttccta	tggccccctc	36060
ggagtacagg	tgtttcctgt	tggcgggctc	ttcccccatg	acatcagcag	cgagctgggt	36120
atgattccct	acgcagaact	tgatagttaa	taaagctctt	tgtcatccag	gccccgttgg	36180
agtctcacgc	agacctggtc	gcaggcgggg	ctggtcttgc	ctgtcccagc	tgcattggatg	36240
gggaacttga	ggcttgcaaa	ggttaagggg	ctgttcgagg	cccacgctgg	caggagatgg	36300
gcctgggcca	gagtctggga	cttccccatg	ctgggctgtc	tttggtcctg	ttgctcacca	36360
tccctccctg	gggcatgac	cttagagagc	caaattggagg	tgcaggtaac	ccacggcaag	36420
gaggggttgc	catgactcag	agtccccgtc	ctgtggcccg	cagtacctgg	tgcaacgact	36480
tggatttcag	accagccact	gtagcccgtc	gacgggtgcg	tcgaagtgcc	acagcttctg	36540
aagccaggca	ggactcaggc	caggagactc	tgttagctgt	tgagaggagg	aggccaacgg	36600
atgttctggt	tctgtctagag	agctggttct	tccgactctg	gtaccagtgc	actgagagga	36660
ggcccagctt	gattctgggg	ctgcttgtgt	gtggcatgtg	ctgctcactg	acaccctcga	36720
ggagtgtctt	ctctcgggct	tgttgactgt	gcccgtttt	ccgcagttca	ctggtgcaca	36780
cataggcaca	tagcaaaccg	cacacacagt	cgtgggtatg	agtttacta	cattccacca	36840
ccagtgttca	ctaccattac	ctgccttccg	tcttaagtgt	tcattcattt	aaaataaatt	36900
tattgggctg	gacgcggtgg	ctcatgactg	ttatcccagc	actttgggag	gctgaggcgg	36960
gcagatcacc	tgaggtcagg	agttcaagac	cagcctggcc	aatatggtga	aactccatct	37020
ctactaaaaa	tacaaaatta	gctgggcatg	gtggggcatg	cctataatcc	cagctactca	37080
ggaggctgag	gcaggagaat	ggcgtgaacc	cgagaggcag	agcttacagt	gagcccagat	37140
agcaccactg	cagtccagcg	tgggcaacag	tgcgagactc	catctcaaaa	aaaaataaaa	37200
taaataaaaag	aaaaataaat	ttatgatcta	tttcaaaaat	aacacatgta	ctttgaaaca	37260
gcagagacac	atatgacacg	gagaatgaaa	ttccccatag	cgcaccccca	agagacagcc	37320
ctggtccccc	cgtctttccc	gtggacctcc	agcggggcag	atgctgagcc	gcctgttgtc	37380
gagtggcatg	ctatcccgtc	ctccagctcc	tctgtggctt	acagacaccc	acctgcagcc	37440
ctgtctttgc	ctcctctagc	gcccaccacc	ttcttgtctg	tcagccagaa	atctgccatc	37500
agtcggatga	tcccggacga	ccagcacagc	ccggtactca	tcctgcccct	gcatggactg	37560
aggaacgtca	aagccatcga	ctatgaccca	ctggacaagt	tcattctactg	ggtggatggg	37620
cgccagaaaca	tcaaggcagc	caaggacgac	gggaccagg	cagggtgccct	gtgggaaggg	37680
tgcggggtgt	gcttcccaag	gcgctcctct	tgtgtgttcc	caggctgctg	cccctgtcct	37740
tagcagaggg	aggaaacaga	ggatggctct	gggtgaatga	tgacttgggc	ttcgattatg	37800
tagtcacagg	gtatgaccct	gagatgcgtg	gaaccccgag	actgtgatta	tatgtagaaa	37860
ctgggtttcc	ccgttgttta	agtagtcatg	gtggggtcag	acccacagag	acttttgtct	37920
tttcaagaaa	gaaaatggtc	gtgtgtcatg	caggggtagt	tggtagctgt	taatccaggt	37980
ttatccttta	ttttgtggga	actgtacagt	catttctgct	acaatgctgt	atatgctctt	38040
ctgaaagaca	cctatgcaaa	atcgcacagt	aaaaatgaca	caactcatag	ggaaagcggg	38100
gccagggcac	agccctcaaa	atctccatca	atgacatgta	agaaaagaga	ggaacctggg	38160
aaatagcaaa	gtgccttttg	cacattaaat	ggttagctat	atcccacaat	actgtgcatt	38220
cgtaaacggt	aatgctgcaa	taaatacggc	acttcacctt	gggaagatct	ggagttggct	38280
tatgagtgtg	gaagggtgta	gcgcatgagt	ttttgtgaaa	cactggaagg	aggattgtgg	38340
gaaatcaaat	ggaaagttct	caccccgagg	gtggagaaga	gtgggtcatg	gccccagcag	38400
tgagcccagg	gaggtcagag	acggaggtgt	gtgtgtgggt	gtgacctgc	gcagttccct	38460
gccggctgta	gttttttgca	ttcgcttaat	gtttctcgtg	gaggaaattg	tgcattgagca	38520
aatgtgaaa	cgtgtgtgtc	tcaaattgtc	ctaatcacatc	attgcattgg	aacagattgg	38580
ctttnttttt	tttttttttt	tttttttttt	tttgaaatgg	agtctcactc	tgtcaccagc	38640
ctggagtgca	gtggcatgat	cttggtctac	tgcaaccttt	gcctcctatg	ttcaagtgat	38700
tttctgtcct	cagcctcctg	agtaactggg	attacagggc	atgagccacc	gcggccggcc	38760
agatttgcac	ttttgaaaca	actgctaggc	tgggcgcggt	ggctcacacc	tgtaatccca	38820

032796-132.ST25

gcactgtggg	aggccgaggg	aggtggatca	cctgaggtca	ggggttcgag	accagcctgg	38880
ccaacatggt	gaaaccccgt	ctctactgaa	tatacaaaaa	tcagctgggt	gtggtggcgg	38940
gtgctgttaa	tcccagctac	tcaggaggct	gaggcaggag	aattgcttga	acccaggagg	39000
cagaggttgc	ggtgagccga	gatcacacca	ttgcaactcca	gcctgggcaa	caagagcaaaa	39060
actccatctc	aaaaaataaa	aaatagaaaa	acaagtgtctg	tagcggaaagt	gagcactttg	39120
cggagtcagg	cttgtgtggc	ctgttccaca	aatgatgtgc	tcacgggtggc	ctcaggccca	39180
cctggagtct	gcagcatggg	gcacaacagg	ttcattagtgt	tagaattcca	ggacaggcct	39240
ggctcctaag	cagccttctt	ttacaaaaac	tgacagagcc	gcctgtatcg	tagcactttg	39300
ggaggccgaa	gtgggtggat	cacgaggtca	ggagttcaag	accagcctgg	ccaacatggt	39360
gaaaccccat	ctctactaaa	tatacgaaaa	ttagctgggt	gtggtggcac	gcgcctgtag	39420
tcccagctac	tcgggaggct	gaggcagaat	tgcttgaacc	tgggagggtg	aggttgcagg	39480
gatctgagac	catgtcattg	cactccagcc	tgggcaacag	agcgagacgc	catctcaaaa	39540
aaaaaaaaacc	tacagagcca	cacggcctct	ttctccaccg	agtgttggtg	tgggagcttg	39600
tgttattgtg	gtgaaatctt	ggtactttct	tgaggcagag	agaggctgag	cgcctggaga	39660
gactttcaca	tgggtcgcca	tgtccgccgt	cggtttcgct	gttgtgctcc	ccatctgaag	39720
gctggtgccg	tccagacagg	ctggacgccc	ctttccacca	gatccttcct	cccgcagcag	39780
tttctagtta	cgttgtactg	tgagggtctgt	gtccttggtt	gatggcaaaa	gtcagccgaa	39840
ttgaaattca	gagccatgcc	tggtccctg	gagcttctct	cctgggcagc	tgtgatcatt	39900
gcctctgctg	tgggtgtggg	ggtggaaatg	gattcctttc	atcttgcttg	ctacagggtga	39960
ctgtcacgtg	gagtcctttg	gagagaggga	cgtgttaatt	gatggatgtg	gctcccatgc	40020
tgagaaagct	cctgggcgta	cattgcctta	gagtttcatt	ggagctgctg	tcttttatgg	40080
tgtctgctag	gcagaagtga	tgaagacttg	gaagaaaacc	cagaaggttt	tccacttaat	40140
ttggaaaaatg	tgcttttccc	ctcctgtgtc	ttttgctaag	gtccagcctc	ctgcagcctc	40200
ccgcgtctgt	ggactctggc	tttgattctt	tattaggagt	ccccctgtct	ccccaaaaga	40260
tgggtgtctaa	attatcatcc	aattggccga	ggttttggtt	tctatttaatt	gttttttattt	40320
tttattgtgg	taaatattata	taacataaaa	tttgccattt	taattgtttt	gttattgttg	40380
tttttgagac	agggtctcac	cccagtgcc	aggctggagt	gcagtgggtc	gatcatggct	40440
cactgcagcc	tcagcctcca	gggtccag	gatcctctca	cctcagcctc	tctagtagcc	40500
gggactacag	gcatacacta	ccacatctgg	ctgatttttt	gtattttttt	tttattgtag	40560
agaccgccta	tgttgcccag	gctggtctca	actcctggac	tcaagccatc	ctcccacctc	40620
accctcccaa	agtgtctgga	ttacaggcat	gagccacaac	accagccat	tttaattttt	40680
tttttttttt	ttgagatgga	gtctcactct	atcgcccagg	ctggagtgc	gtggcgtggt	40740
atcaactcac	tgcaacctct	gcctcccagg	ttcaagegac	tctcctgcct	cagcctcctc	40800
ccgagtagct	gggattacag	gtgcccata	ctatgcctgg	ctaatttttg	tatttttttag	40860
cagagacggg	gtttcaccat	gttggccagg	ctggtcttga	actcctaacc	tggatgatccg	40920
cccgcctcgg	cctcccaaaa	tgtgagatt	acagggtgtg	gccaccgtgc	ccggcctttt	40980
tttgtttttg	agacagggtc	ttgcccgtgc	accagactgc	gagtgaatg	gtgggctctt	41040
ggctcactgc	agcctccgcc	tcccaggctc	aagttgtgca	cctccacacc	tggctaactg	41100
tatttttatgt	agagacagat	ttcaccatgt	tgccaggct	gggcttgaaa	tggactcaag	41160
cagtccaccc	acctcagcct	cccaaagtgc	tgagattaca	ggcgcgagcc	accgcaccca	41220
gcccatttta	cctattctgc	agttgacagt	tcagtggcat	tcagtcatgt	cacgaggtaa	41280
ccatcactgc	cattcatctc	cagactactt	caccttctcg	gcagatgtcc	gaaactgtcc	41340
gcattgaaca	cactcctcat	ctccctctga	cagccacat	tctactttgt	atctctctct	41400
gccttctcta	ggtacctcat	gtaagtggaa	ttataccaat	atttgccctt	gtgtgactgg	41460
cttctttcat	gtgacatggt	gtcctcaagg	ttcatctgtg	ttatagcctg	tgtcagaatt	41520
tccttcctta	aagcctgaat	aataacccgt	tgtaaaggct	gggcgcggtg	gctcacaccc	41580
tctaatacca	gcattttggg	agtccgaggt	gggcagatca	cttgaggtca	ggagtttgag	41640
accagcctgg	ccaacatagt	gaaaccctgg	ctctactaaa	agtacaaaat	tagctgggtg	41700
tgggtggcgg	cacctgtaat	cccagttact	caggaggctg	aggcaggaga	atcgcttgta	41760
cccgggaggc	agaggttgca	atgaaccaag	attgtgcctc	tgacgtccag	cctgggtaac	41820
agagtgcagc	ttcctgtctc	aaaaaaaaaa	aaaatcatcg	gatggatgga	cggaccactt	41880
cttgttattt	atccatccac	gggtgctagg	tttcttccac	ctttggttgt	cgtgaataag	41940
gccactatga	acatttccct	ccgtggtgaa	ggttttgtac	tagtgaggaa	aaggcgtgtt	42000
tgtggtgttg	cataggattc	tggttaagaaa	gtttgcacta	accataagta	tttgtactac	42060
attaaaatga	aagctcaggg	gccggggcgcg	gtggctcacg	cctgtaatcc	cagcactttg	42120
ggaggccagg	gcgggaggat	catgaggtca	ggagatcaag	accatcctgg	ccaacatggt	42180

032796-132.ST25

gaaaccccg	ctctactaaa	aataccaaaa	aactagccag	gtgtggtggc	gggcacctgt	42240
agtcccagct	acttgggagg	ctgaggcagg	agaatggcgt	gaacccggga	ggcggagctt	42300
gcggtgagcc	gagatcgctt	cactgcactc	gagcctgggc	aacagagcaa	gactccgtct	42360
cacgcaaaac	tctgtctcac	gcaagactcc	gtctcaaaaa	aaaaaagagt	tcagggttta	42420
tgaactggc	cagccgcgta	aagtttgctg	tgttggtttt	gtgcccggga	ggagtgtggc	42480
cagggtgtca	cgtcacacag	tacacgtttc	tcagatgggtg	gttctccaga	ctgctgtccc	42540
aaagtctgtt	tttgcactcg	gttcccacag	acccaccctc	cacggtgagc	ctgatttttg	42600
ccagggtagc	tggaaatctt	cttgtctttc	agcccggcag	ctgtaccagt	ccagggtcca	42660
cagctagtgg	cttttaggaa	ggaatttggt	cagttggcct	tgacacatgg	ccccctaggg	42720
tccacagctc	tgtagtgtg	tggatgttgt	tatctacaaa	gacacatgat	ccttcgtgtc	42780
cagatgaaag	tgatgatgtc	tttgcagctg	cccagcaagg	ctgtgtgtgt	gtgtgtgtgt	42840
gtgtgtgtgt	gtgtgtgtgg	tgtgtgtgtg	gtgtgtgtgt	gtgtatgggg	gagggaggca	42900
ccctttccat	ctgggggtgt	gtgtgtgtgg	ggtgtgtgtg	tgtgtgtgcg	cgtgtgtgtg	42960
gtgtgtggtg	tgtgtgtgtg	tatgggggag	gcaccctttc	catctgggtc	caagagactg	43020
ggcctgggga	agacgcttct	ttttatctac	ttagagactt	tgttttattt	gtattttttt	43080
gagacagggt	ctcactctgt	caccagggct	ggggtatggt	gatatgagca	tagctcactg	43140
cagcctcggc	ctcccaggct	gaagcgatcc	tcccacctca	gccttctgaa	tagctgggac	43200
tgtaggcgtg	cgtcaccata	ctgagctatt	gttttttttg	tttggttggt	ttaatttttt	43260
ttgatacaga	tggagtcttg	ctatgttgcc	cagactagtc	tcaaactcct	gaactcaagt	43320
gattctccca	cctcagtttc	ccgacattct	gggatcacag	gtgtgagcca	ctgctgtctc	43380
cctgttttat	taagtgtcta	aagacctaga	taaagaaagt	ctgaaaagac	ttactatcag	43440
agcaccatcc	taagatgatt	ccctctgact	caatggagag	ggaggggagc	ttttccttca	43500
ggcctgggtg	gcaggagccc	aggtgctcca	ggccccattt	gccccaggcc	aaatcactcg	43560
ggaacttgga	tgcagctgtc	tttcagggtg	acccaaagga	accagatccc	cgcaggcagt	43620
aggcttctgg	gctgtcctct	cctcctacgt	cagctcagta	agagcccttc	gaagggatgc	43680
tgtgtcggag	gccccaaaag	cccaggctca	tccctgagat	gcacagggtg	ggctgggctt	43740
aggcagcgtc	cgagcatctc	ctggacgggtg	accccagaga	gtgtggagac	ggagagtcct	43800
tgagagtcac	tgagagacgt	ggctgccctg	ccttcccaag	aggggctctg	agtcattccc	43860
cacactcacc	tgcccctacc	caccctcacc	tggccccag	cctcacctac	ccccacatct	43920
gtaccgatcc	ctttaccgcg	accttcccta	cccaccctca	cctcccctgt	accttcacct	43980
ccccactca	ccgcgccctg	caccctcacc	tgtccccac	cttcacctaa	ccccaccctt	44040
cacctgccct	cccctcacct	ggcctccttc	cgttggggaa	ggggttgtaa	ggggcgggcc	44100
ccaaactgtc	tgtcctggtg	ccctgcagag	aaaacagtac	gtgagggccg	cagtcacaaa	44160
gcttgagtcc	tggaaagggtg	aggagacagg	gatgtgttg	gaaggggccc	atggtccttg	44220
atcccttctc	gactgtcaat	ggggccttca	tgggagcgcc	agtctagtga	tgcacagctg	44280
ggtgcccggc	gggtggctga	ggaggcctaa	agtcagaggc	ggcaagagct	cttccagagg	44340
ctgttgtcct	aatcgctctg	gcatactcag	gcgggcacgt	agttaggagc	tgattggaga	44400
ggagagaccc	ccacaccaat	actgggattt	gactttcagg	ctaaacttga	gaagtgtggc	44460
ctctgctgtc	ctgccagagc	tctccagcca	gtgccagggg	ctctccagcc	agtggccggg	44520
ggtctccacc	agtggccggg	ggtctccgcc	agtgccaggg	gtctccgcca	gtgccagggg	44580
gtctccgcca	gtgctcagga	gtcttggttt	ctttgtctta	cagccctttg	ttttgacctc	44640
tctgagccaa	ggccaaaacc	cagacaggca	gccccacgac	ctcagcatcg	acatctacag	44700
ccggacactg	ttctggacgt	gcgaggccac	caataccatc	aacgtccaca	ggctgagcgg	44760
ggaagccatg	ggggtggtgc	tgcgtgggga	ccgcgacaag	cccaggggcca	tcgtcgtcaa	44820
cgcggagcga	gggtaggagg	ccaacgggtg	ggtgggggtg	ctgcccgtcc	aggcgtgccc	44880
gccgtgtctt	ctgccgaatg	ccagcctctc	acaggctggg	gagactttcc	accctgggga	44940
tccaatgggt	ggctttccag	ggtcccaaaa	gcaaacacag	gctctttcac	agccccctcca	45000
ggaaagcaga	aagccccaa	ggctggaagg	gaagggggag	ctctgctgag	aggttacaag	45060
gcagcgtggt	ccgacgggag	ttgcagttga	taggttttgt	atcatccttg	ttaaacttga	45120
accctgtgca	gaaatccctt	ccacggcatg	ggggctgcct	gttgactcgc	tctgtttcca	45180
ccacagggag	ctcctgggct	tcttctctcc	agaggccccc	gacgtcccca	cctgtttggtc	45240
gtcagagctt	ctggttggtg	ggaaggcacc	caggaccttg	aggtctccag	agagaaaagc	45300
cagggaagga	gggagaccga	aacctatgtg	acatgaaact	caggctccaa	actgagcacg	45360
ggaacgtttg	gggacaggag	cgcgatggcc	ttctctcagat	agctgggggg	ctggcatgaa	45420
gacgggagct	acagccagca	caggctctgg	gccgggagcc	cagagattga	gccctgactc	45480
tgtcacttac	tggccacgtg	accttgggcg	ggtggcatag	cctcttgagg	actcagtttc	45540
ctcatttggt	ggagtgacgg	ccacagtggt	gcggcctctg	cagcacacgg	ggggctcggt	45600

032796-132.ST25

gggcggaagc	cccgggtcta	taaggcggct	gtgcaggagc	cagccgagct	ggtctcccaa	45660
cagccagggc	tccgggggtcc	ttagcagctg	tggggggcct	gcacctgttt	cccatggctg	45720
ctgtcagaaa	ttaccagaag	ccagggtggct	gagagtaatg	gacacttggt	ctctcacagt	45780
tcttgagggc	tgaagcccga	gatcgagggtg	tgggcagggc	cctgcgccct	ctgaaggctc	45840
tgagggaacc	tttgggcttc	tgggtggctcc	aggcaccctt	tgacttggtg	tectgtcact	45900
ccagtctctc	tgtctggctg	cacatggcgt	ggcctcttct	gtaccattga	aggacacttc	45960
agttggattt	agggcctacc	ctcacccttt	gtggctcgat	cttgatcctt	catgacattt	46020
gtaaagaccc	tgcttccaaa	taagctcaca	ttctgaggtt	ctgggggtgag	cggaatttg	46080
gagagcattg	ttcaactagt	atagaatgtg	acctgtcagc	ctcgggcagc	cctgagaggc	46140
aggggctttc	cacagcccag	ctgggtgccc	tgggtccgt	gctgtccgag	gagacgcat	46200
ccccacaccc	gtccttcacc	cgccaccctc	ccgcaggtag	ctgtacttca	ccaacatgca	46260
ggaccgggca	gccaagatcg	aacgcgcagc	cctggacggc	accgagcgcg	aggtcctctt	46320
caccaccggc	ctcatccgcc	ctgtggccct	ggtgggtggac	aacacactgg	gcaagctggt	46380
ctgggtggac	gcggacctga	agcgcattga	gagctgtgac	ctgtcaggta	cgcgccccgg	46440
ggcctgccct	aaccgcagac	accgggcctt	cattgtcagt	aatggcagca	gctgccacat	46500
tgtccgagac	ctgccgtgag	cccagtgcgc	cgccaggggc	tttgtgtgta	gcgtgttttg	46560
tcttcacact	gacagctgta	ggctgggggt	ctgagtgagc	cccacagggc	agaggcagaa	46620
aatgagtctc	agagaggggtg	agcgagctgc	ttggggcccc	acagcaggag	atggagcagg	46680
actgcagcct	agcctctgcc	cccagcacct	gcgcaagaag	ctgctctgct	ctggactgtg	46740
ttaggtctcg	agggtctggag	agaaatgaga	gttgtgtgct	agagaggggg	cgcagggtccc	46800
catggctttt	cctcttatga	tgaggtatgat	gggtgaagg	aggggccatg	cttgacgggg	46860
ccagtgaccg	agggccgcgc	ttggaactga	tggccttcac	cccagcgcca	gcccagggtg	46920
gagcagggct	ttccgagggc	ttgtcttggt	tcggcctgct	tccagggaact	ctgctgcagc	46980
tcccaccctt	gtccaaagca	tggaatcccc	caggctccct	ggcagtccct	tcaacctctg	47040
tctcccaag	ctgagtgtgg	ggcaagttct	ggaggtcagc	actgctcagg	ggggcccacg	47100
ggctgcttgc	aggggccaac	cgctgaccc	tggaggacgc	caacatcgtg	cagcctctgg	47160
gcctgaccat	ccttggaag	catctctact	ggatcgaccg	ccagcagcag	atgatcgagc	47220
gtgtggagaa	gaccaccggg	gacaagcgga	ctcgcattca	gggccgtgtc	gcccacctca	47280
ctggcatcca	tgcatgtgag	gaagtcagcc	tggaggagtt	ctgtacgtgg	gggctggcag	47340
tgggggtggc	aggggtggcct	ctaaaccgga	cccctggagg	aggctggagg	ccagtgcaag	47400
atcctgtgtg	gcctcagcca	ggcgggtggc	tctgccagat	gccaaactgtt	gcccgtggg	47460
gttcagcgac	atgtccgaat	gtcccagagg	ctctgaggtt	gttttctttt	gcccagaaac	47520
aatcaccac	gaacagcgtt	ttaagacaac	accaactctt	tttttttttt	ttttttttga	47580
gtcaggatct	tgtctgtttg	cccaggctgg	ggtgcctgtg	tgcaaacaca	gttcaactga	47640
gcctcgacct	ctgggcttaa	ttaagtgaac	accttgccct	agcctcccag	gtagctggga	47700
ctacagttgg	gcaccaccac	acctggctaa	tttttttttg	tagagacggg	gtttccccat	47760
gttgcccaag	ctggtctgca	actcctgggc	acaagctatc	tgccctgctgt	ggcctcccaa	47820
agtgtctagga	ttataggtgt	gagccactgg	cctgacaaca	cccacggatt	gtctctcagt	47880
tctgtaaggc	aaagtccagg	cacagcgtgg	ctcacctggg	ttctctgctc	agggtctcac	47940
ggggccagaa	tcaaggtgtc	aggaacgctg	ggccctcagc	ggaggctctg	tggagaaatt	48000
agcttccttg	ctcactcagc	aggtagcagt	tgtgggatcg	aggttctgtt	ttctctctgg	48060
ttattggctg	gggaccactc	tcagctccta	gaggccaccc	caggteettg	ccccgtggcc	48120
ctctctgcct	cagcagtggg	ggctccctgc	gtcagtcctt	cccgcacctt	gagtctctct	48180
gatttgcttc	taaagggcc	tgtgattcgg	ctcagccacc	tttagattag	gttagcctcc	48240
cctttgatag	actccaagtc	ggctgattaa	taaccttact	cacatctgca	gaatcccttc	48300
tgccacataa	ggtcatgacg	ccgtgctggg	gactgggggtg	ggaaattacg	gggtcattta	48360
ggattctgcc	tgccactgcc	ttgctgtgtc	ccagggtctg	ggggaggggc	ctccacagct	48420
gggaccacag	tccttcctcc	cctccatggt	aacctctga	ggattacttg	agaccagcct	48480
gggcaacatg	gtgagaaccc	atccctacaa	aaaatacaaa	caaaaaggga	ccaggctggg	48540
cttggtggct	catgcctata	atcccagcac	tttgggagac	caaggtgggc	tgatcacttg	48600
aggttgggag	ttcgagacca	gcctgcccga	catagtgaag	tcccgctctc	actaaaaata	48660
caaaaattag	ctgggtgtgg	tggcaggcgc	ctgtattccc	agctactggg	gaggctgagg	48720
tgggagaatt	acttgaacct	gggaggcgga	agttgcagtg	agccaaaatt	acgcactgc	48780
actccagcct	aggcaataga	gtgagactcc	gtctcaaaaa	aaaaaaaggg	ccagggtgtg	48840
tagtgacaaa	gagaccctat	ccccaaaaaa	ccgaacactg	aatccttgag	actgaagtaag	48900
gacactgtga	aatttttctg	ggtggggcag	ggaacagagc	gtcttctgtc	atttcttcca	48960
cctgggtgtg	gtcagctctc	cctccaagct	gcctcctctt	cttctcattg	tccgggtgtt	49020

032796-132.ST25

ggacacattt	ggttaactgg	atagaataac	gcgagttccc	agggacttgg	tccattttgct	49080
attttatttt	attttatttt	attttatttt	atttatttat	ttattttattt	atttattttat	49140
tgagatggag	tttcggtttt	gtcgcccagg	ctggagtgc	gtggcgcgat	ctcggttcac	49200
tgaacctct	gcctcccagg	ttcaagtgat	tctcctacct	cagccttcca	agtaactggg	49260
attacaggca	cccaccacca	taccaggcta	atttttttgt	attttttagta	gagacgggtt	49320
ttcgccattt	tgcccagggt	gggtcttcaac	tcctagcctc	aggtgatcca	cgcacctcgg	49380
cctcccaaag	tgctgggatt	acaggcatga	gccaccacgc	ctggcaccat	ttgctatttt	49440
aattcccatg	tgtattagt	tcccacgggt	gctgtaacaa	atgaccacaa	actggatggc	49500
ttaaagcaac	agaaatggat	tcccccaatg	tgctggagac	cagaagcctg	cgaccaaaact	49560
gttgggagg	ctgtgcttcc	tctgggggct	ccaggaggga	tctatttgtt	ggcccttcca	49620
gtgctgtgg	tgccagcggt	ccacacttgt	ggatgcgcg	cctcaacctc	tgcccatctt	49680
catgtgtcca	tctcctttgt	gtctgcgtct	ttacctcttc	ttcttgtctg	tggtgcctct	49740
tataaggacg	tttgtcattg	ggtttagggc	ccacccaaat	catccgagat	gacctcgtct	49800
tgagatcctt	aacctgcaaa	gacctttttt	ccaaaaaaag	gttatgctca	cagattctag	49860
gccttaagac	atgggtgtat	ctttctgggg	ggcactatcc	aacctcttat	acaatgaaag	49920
acgggaagag	ggccagggtg	ggtagtccac	gcctgtaatc	tcagcacttt	aggaagctga	49980
agcgggagga	tcaacttgagc	ccaggagtgt	acaagtagct	aggcaacatg	atgagacccc	50040
atttctacaa	aaagtaaaaa	aaaaaaaaaa	aaaaaaaaag	ccagggtgtg	tggtcacac	50100
ctgtaatccc	agcacttttg	gaggctgagg	caggcagatc	acgaggtcag	gagattgaga	50160
ccatcctggc	taacacgggt	aaaccccgct	tctactaaaa	atacaaaaaa	ttatggccgg	50220
gcgcagtggt	tccgcctgtg	aatcccagca	ctttgggagg	ccgaggtggg	tgaattacaa	50280
ggtcaagaga	tcgagaccat	cttggtctaac	acggtgaaac	cccatcaaga	tcacaaggct	50340
aagagatgga	gaccatcctg	gctaacacgg	tgaaccccg	tctctactaa	aaatacaaaa	50400
aattagccgg	gcatggtagc	gggcgcctgt	agtcccagct	gctcgggagg	ctgaggcagg	50460
agaatggcgt	gaacccggga	ggcggagctt	gcggtgagcc	gagatcgctc	catgccattg	50520
cactccagcc	tgggtgacag	agtgagactc	cgtctcaaaa	aaaaaaaaaa	aaagaaaatt	50580
agccaggcac	agtggcaggt	gcctattgtc	ccagctactt	gggaggctaa	ggcaggagaa	50640
tggtcatgaac	ccgggaggtg	gagtttgtag	tgagccgaga	tcagccact	gcgctccagc	50700
ctgggcgata	gagcaagact	ctgtctcaaa	aaaaaaaagc	aggcatggtg	gtgcatgcct	50760
gtagtccag	ctactcaaga	ggctgaggca	ggagggttgt	tcgaccacag	gagatcaagg	50820
ctacagttag	ccatgatcgc	accactgcc	tccagcctgg	gtgacagagt	gtgaccctgt	50880
ctcaaagtaa	gtaaatagga	ggagagacaa	gtgggcagtt	cagactgatg	gtatgggcac	50940
agtagagact	ggtgcagaca	ggctggcctg	tgatgtcaag	caacttctgt	aactgtttcc	51000
ggcatccatt	tgtgtgtcaa	tttccgtgtc	agtaggaaga	ctctgtaggc	tgccaagagg	51060
aataagtggg	aggatcctcc	cagagaggcc	gggctgcag	gagggccagt	tctcatgagt	51120
tcttatttgg	ccctaccct	ccaggctgtg	gttctgaggt	gggagacaga	gcctgacctc	51180
tgtttgtctt	gttttgtctt	tgacgagcc	caccatgtgt	cccgtgacaa	tggtggctgc	51240
tcccacatct	gtattgccaa	gggtgatggg	acaccacggt	gctcatgccc	agtccacctc	51300
gtgctcctgc	agaacctgct	gacctgtgga	ggtaggtgtg	acctaggtgc	tcctttgggg	51360
tgatggacag	gtacctgatt	ctctgcctgc	taggtgctg	cctggcatcc	ttttaaaatc	51420
acagtccctg	tggcatccag	tttccaaagc	tgatttgttc	ttcctttgcc	ctcctttctt	51480
ttctactatg	tgcattcggt	gctatgaatt	ttcctctaag	tactgcgttt	cctgcatctc	51540
acaaattttg	ttacattttc	attttcaggt	agtttgaata	tttttact	tctcctgaga	51600
tgacatcttt	ggctcatgtg	ttatttagaa	gtgttgctta	gtttctaaag	agttggggct	51660
tttccagctg	tctctctgca	actgatttct	aatttaattc	tactgtagtc	tgagagctta	51720
ttttatatga	tttctgttat	tttaaagtgt	ttgggtgtgg	tgtttttgtt	gttattgttt	51780
ttgtgtcttt	ttgttttgtt	ttgcttcgtt	tgtttttgtt	ttgagacagt	gtcttgctct	51840
gtcactcagg	ctggagtgc	atggcgcgat	ctcagctcac	cgcaacctct	gcctcccggg	51900
ttcaagtgat	cctcttgctt	cagcctcctg	agtagctggg	attacagggtg	cacgccacca	51960
taccagcta	atttttgtat	tttttagtaga	gacggggttt	caccatgttg	gtcaggctgg	52020
tctcgaactc	ctgacctcgt	gatccgcccc	cctcggcctc	ccaaagtgtc	gggattatag	52080
gcgtgagcca	ctgtgcctgg	ccattagggtg	tgttttatca	cccagcatca	tgacgtttat	52140
cttggtgaat	gttctgtgtg	ctcttgaaaa	gaatgtggat	tctgctgttg	ttgggtggag	52200
tgttccagaa	acatcaatta	gatccagttg	gttaatagt	ctcatcaggt	tgtctctatc	52260
cttccctcct	gactgcctgc	ttgagctgtc	agttattgac	aggggtgtgg	agtctccaac	52320
tctaattggtg	gatttgttta	tttctcctag	tagttctatc	tttttctctc	cttctaccct	52380
tgatcctctt	ctccccctag	ggcttcctgg	tggttggtgg	gggagagtgg	ggtagtgaag	52440

032796-132.ST25

aacctggact	ttagggccaa	agaggccagg	gttcaaatcc	tggctctgtc	acttcccagt	52500
tgagtgaccc	tggctgggtg	ctgaatctct	gtgagcctcc	acttccctcc	ctgtgaaatt	52560
gagagcactt	acctggcagg	ctgtcatggg	catcaagtaa	cagggcactc	cacctggacc	52620
ctgacacgtg	atgcacagga	atgccagctg	ctatgccatg	ggtgtggcag	tagtaataaa	52680
gtgaccatct	gtatcctcac	cacagtgaag	cctgtccagg	gctttctctc	ctatgcccc	52740
atgcctccag	gtggccttgg	atcctgttgg	ttctgtgctc	tgctcagcga	cctttctccc	52800
gtgggagttc	ctgggggttc	agcttcatcc	tacagacagc	agcacacact	ggctgtgcac	52860
cctttttttt	tttttttttt	ttttttttga	gatggagtct	cgcttttttc	gcgcaggctg	52920
aagtgcagtg	gtgtgatctt	ggctcactgc	aacctctacc	tcctgggttc	aagtgatttt	52980
cctgcctcac	cctcccaagt	agctgggatt	acaggctccc	accaccacgc	ccggctaatt	53040
tttgatattt	cagtagagat	ggtgtttcac	catgttggcc	aggatggtct	tgaactcctg	53100
acctcaggtg	atccgcccac	ctcagcctcc	caaagtgcag	ggattacagg	cgtgagccac	53160
cacacccgga	gtgccgggtg	tttttagcag	tttgtcttgt	tcctggagag	actggctcct	53220
gccaggagac	tcggggagta	gggccgcggg	gtgctgcctc	acacctcgag	tttggccgta	53280
agcagagggg	acattttgtg	actgtccccc	tcctgagctt	cccagcagct	tttctccaag	53340
ttacagccca	aaagctcagg	tggatttgca	acccaacggt	gtctgtgcac	ctcccactga	53400
tgcccgaaat	gccctggcca	agaaacgggg	ccgtcagaac	gctgcactaa	ctgcagcctt	53460
gggctccat	gccagaggcc	atgcccttcc	atccaccacc	ccctggcctg	ggccctggcc	53520
ctcctggctc	gggaactcca	ggccccctcc	tcacggatcg	agagacgtgt	atttaccgca	53580
caggtgcttg	tcattctctt	gtggcctctt	ctccagggag	atcacagaag	gacaggccct	53640
cactgaggtc	tcggacatgg	accctttgat	agtggcagga	gccaggctgg	gcaagaggcg	53700
gccacagtca	cctcagcagt	gccatcacca	cgccattca	gcccttccct	gagccgggcg	53760
cgccctggc	tctggcccca	gtgtcccagt	tacagctcac	aggagcttgt	ggtgcccgag	53820
ggctgcttct	gattgagagt	cgaggctcga	ggctttggga	ggctgagagg	ctgctcggtt	53880
tcacaactgc	tgaggagagc	ttgggtccca	tctcaggtct	gccccatgtc	gccctcaacc	53940
tccagccacc	ggtcctccgt	gtcccccatg	gccaggcacg	gcttgacagc	atctgtcggt	54000
ggctcctctc	agcctgtgtg	ggctgacctt	ggcacgtcct	cctgtggctg	agcccagtgg	54060
ggacagctgc	ttccttttat	taccctagaa	ctctcgtctt	tgatcaggcc	ccctccccta	54120
tgccacacag	tcctgtcac	tcgggtgagc	ccagtagtca	tggggaaggc	ctgcgggttc	54180
caaacatcca	aaggcttgcg	tgacagcatg	cagcttgaaa	ccgatgtttt	ttaccttgat	54240
cagatttcag	cttgccgggg	gctttgtctc	gctttcagtg	aggcctgggc	cgatttccca	54300
gcatcccctc	ctgaggccag	cctctgtttc	ctgtgatttt	ctgcacaaag	tgggagggag	54360
gagtccttag	aaatgggggg	ccacctcgaa	acctaggcct	cctctggcct	ctctgtgcca	54420
gtgccccac	gctttgtgtc	tgtgtcccca	gccccatgga	ctgtgttatt	ccctgagtgc	54480
tgccgcatgc	ccagcccgca	ctgaggacgt	ggagccccga	ggggcaggat	ggcctccatg	54540
gtcacagcta	ggaagtggcc	tccacctctc	gatgatcctc	tccccccctc	cctttcagcg	54600
ccttccccgg	gggtgtcatc	agccctcctg	ctctgtcttt	gtcccgtctt	ctgcaggcgc	54660
atgggacgtg	ctgacaggtc	ctctgccggg	ttcctgcctt	gctatgcgca	cgctggtcac	54720
cacagaggcc	tggcccttct	tctgtagcag	tcccacaccc	gcaacagggt	tggctgctga	54780
ccacctgctt	tctgcccctc	tggctctgag	gagggcgcag	tgggcactca	ggcgtggctg	54840
agcagatgtg	tgttgccggg	aggaggaagg	actgctccag	tcagggtgta	atttcccacc	54900
cggagcattt	ctgctgtatt	tgggttagcg	cctgctgctt	aaagctctga	ttcccagttg	54960
gcaccctttc	ccttctgcat	tgaaaaacat	acggatgcat	gtcttcttgc	agtgaatgtg	55020
tattctccca	gcctctcttc	tgggttgggg	ctggaggtgg	agcggcacac	aggagccgca	55080
gcgatggagg	atgtgcgggt	gcagcacccc	gtacagcagg	gatgccaaac	ccgcgctgag	55140
tcctctctaa	cttctgcttt	gaagcccagt	cacgccattg	cctgggtttt	gctgggcggg	55200
gctgcatgtg	atgttctcct	ctgtccctcc	cccagagccg	cccacctgct	ccccggacca	55260
gtttgcatgt	gccacagggg	agatcgactg	tatccccggg	gcctggcgct	gtgacggctt	55320
tcccagtgct	gatgaccaga	gcgacgagga	gggctgcccc	gtgtgctccg	ccgcccagtt	55380
ccctgcgcg	cggggtcagt	gtgtggacct	gcgcctgcgc	tgcgacggcg	aggcagactg	55440
tcaggaccgc	tcagacgagg	tggactgtga	cggtagggcc	ctccccgtca	aggctctgcc	55500
aagacccttg	ccctgcccct	cgggatacga	gcttggggct	gcctccggcc	tcacaggagt	55560
aggggctctg	aaaacctttg	cttgacggga	gattggccaag	tctgtctttt	aggcccaaca	55620
aggaaaactc	tgcagttcca	cccatcctgt	cccaccagg	agtgtggctt	gaaggcagac	55680
tgtgagggtc	tatctcacct	tcctgcatta	ggtcaggagt	ttcacagaaa	cctgaggcac	55740
attcaggggt	gggctgcaga	ggtccatggc	tcacaccctg	gaaaatccgc	ccccaaaaga	55800
cagtgtgtgc	tccactgacc	agtctgtggg	atagtgtcta	agcctgagtg	gtttctatca	55860

032796-132.ST25

acatgtagaa	tcaggaggta	taaagagatt	tgctcaggca	tcctggggccc	tctctgacca	55920
gcaggatcct	ccttttagatc	ttgacagtga	aacacatctc	ttctgtgccc	cctgtgagtt	55980
ttctttcatt	cattcattca	ttcattcatt	cattcattca	ttcgagacag	agtcttgctc	56040
tgtcacccag	gctggagtgc	cctggtgtaa	tctcggctca	ctgcaacctc	tgccctccagg	56100
gttcaatcga	ttctcctgcc	tcagcctccc	gagtagctgg	gatgacaggt	gcgcaccacc	56160
atgcctggct	aatttttgta	tttttagtag	agacagggtt	tcaccatgtt	ggccaggctg	56220
gtctcgaact	cctgacctca	ggtgatccgc	ccgcctcagc	ctcccaaagt	gctgggatta	56280
caggcatgag	ccaccgcgcc	cggcctgagt	tttcctttta	tgaaggacct	gcttggttgg	56340
ttgcctgcca	catgttgtca	gcaccatggg	cccaggactg	ctgaggagct	gttgatgcc	56400
tcgctctccc	agagccaccg	gctctgttag	ataattcaca	tgcagtctgg	ccactgtcct	56460
acgtcctcat	tcacaaagag	cagacatttc	gtagaagatg	agggcctggg	agtaacctcc	56520
ctgcatgttt	ttctataaag	gcatagtggg	taagtccctc	cagctcattg	accattggag	56580
aattttatgg	aggctgtaga	ctaggggctg	gtaaactaag	ggcccagggg	ccaaatccag	56640
cctgccacct	acttttgtaa	ataaagtttt	cttggtgcac	agccatgccc	attcattcat	56700
ttgcacaatg	tctgtggctg	ctttcatgcc	aaaagcagga	gaactgagtg	gttatgctgg	56760
agacctacgg	ccttcaaagc	cccagacctc	acgtctggcc	cttgacagac	agagcttccc	56820
cagccctgct	gcgcacccctg	gcccagcatg	tgctgtgtgt	gtgatttcag	cttgaggag	56880
ccgtggttag	gaattgtccc	tgtgttggtc	cattttgcat	tgctatgaag	gagcacctga	56940
ggccgggtag	attatgaagg	aaagaggctc	gtctggctca	tggttctgta	ggcagcacca	57000
gtatggcacc	cgcacctgct	cagcttctag	tgaggtctca	ggaagctttg	actcatggtg	57060
gaagtgcgaag	cgggagcagg	tgcatcacat	ggtgagagag	ggagcaacgg	agagagagag	57120
agagagagag	agagcgcctc	tccctcttgc	cctcaccttg	agaggagatg	ccaggctcct	57180
ttaagtaacc	agctcccatg	tgaactcaca	gtgagagccc	atttgctact	gcggagaggg	57240
caccaggcat	ctgctcccat	gacccaaaca	ctgcccacca	ggccctacct	ccaaccttgg	57300
ggtcataatt	tattctgttc	tatgctatgc	tatgctatgc	catgccatgc	catgccatgc	57360
tattcctatt	ctattatttg	agacagaatc	tcgctctgtt	gcccaggctg	gagtgcagtg	57420
gcatgatcct	ggctcactgc	aacctccacc	tcccaggctc	aagcgattct	cctgcctcag	57480
cctcccgagt	agctgggatt	acaggcacac	accaccacac	ccgggtaatt	tttgtatttt	57540
caatagagat	gggggtttcac	catgttggcc	aggctggtct	caaactcctg	gcctcaagtg	57600
atccacttac	ctcggcctcc	caaagtgcc	tgattacaga	tgtgagtcac	tgcgcccagt	57660
gagggtcaca	tttccgttga	gatttgagg	ggcagacgtt	ggagccatct	gagccccctc	57720
gtcccgtctc	agcttctcct	cccgtgtgcc	ccgcggtgct	ggtggcaggc	ccttacgccg	57780
gttctggctg	cacgctctgt	tccagaagct	ttcttccttg	cttggttacc	agaaaatcat	57840
cccattccatt	acaaggacag	ggtcccctta	tctcccattc	ccagggcagg	acaccggggg	57900
caggggcagg	ggggaactga	gcaagtcttc	tgggggcagg	cgtggctatg	gctccctctg	57960
ggtgggcgct	tggggagggg	tggaggcagc	cgtcagcgcc	ctggcttgct	cttccctccct	58020
ggccagagac	tgtggccttg	tgtgctccc	gtgtggctg	cctgcacctc	cagtgggttg	58080
tgctccctcc	cctccctcc	cctcaagctc	tgctgagcac	cactgccttc	cacagcccc	58140
actctcgga	ggcgaggctc	ctcgtggcca	ttcctgtcct	tggcaccac	ccccccacca	58200
acctggtaga	gccttgggag	gggtctgtta	ctccttgcat	ggcgtagacc	tccccacagt	58260
aggcacctga	cacataacct	ctggggggca	ggcaggaggt	gcgttgaggt	ctcagccctg	58320
gcagtccttc	ccctgcgtgg	cataggcctc	gccacagggt	catcgagggt	gggtggagac	58380
tgtactagac	cactccccgc	tggtcctaga	aagggtccca	tctgtctgct	ctctgttttg	58440
agtccagacc	ttggttgctg	tgccctgcat	ggtgggctgg	ggggcaccct	ccagcctctc	58500
tgagtgcag	gcctctcctt	gcagccatct	gcctgcccac	ccagttccgg	tgtgcgagcg	58560
gccagtgtgt	cctcatcaaa	cagcagtgcg	actccttccc	cgactgtatc	gacggctccg	58620
acgagctcat	gtgtggtgag	ccagcttctg	gcacggggaa	ggggcgctccg	ggctgggttc	58680
ccccaggaac	gtggagttaa	ggggaggaga	cgtgccttcc	cagcggggct	gggggctgtg	58740
tgggagactc	aggcggtctg	gaggctcctt	gcgggaggca	gggaagcctt	tcccagggca	58800
gcggccagga	ggacagactg	tgagctgtgg	gctcggcggc	tacagagtct	gcctcagtgg	58860
gcgggctgga	tgggtgtccag	gtgcctgcag	cacgcacca	cccacgggac	cttgctgagc	58920
agcgtctgtc	attaccgcaag	attaccgag	ggctgcagtg	gtcctgttcc	ctggcagctt	58980
actgtctggc	tgaggaggag	tgatgttcac	atatgcacac	atgtcatgtg	cacacacatg	59040
tacatgacaa	catcccacat	gctcctcaaa	tagcatgacc	tgtacagtca	cggatatagg	59100
gcctagggga	taggaggcca	agacagtcag	ggaagacttt	ccagaggcag	tggctcctga	59160
aaggctgtct	gattcaggca	ggaagggagc	tgagttcaga	taggaagtag	caatgagtc	59220
ttgtgtctgg	ggacatggcc	actccttcgc	tgacagaggga	cctgggctga	gagctcctct	59280

032796-132.ST25

cttatggctg	cagtcgggag	agaagtctgt	tggggggaga	agggggcttc	ctcaagggac	59340
tcctgtgccc	ctttggcacc	ttcgtgccag	gtcaggcttg	aggcctgaag	gcagtgggtg	59400
gggccaccaa	gggtcgccctc	ctctgctggg	caagtcccca	gtctgacggg	cctgtgccgt	59460
gggccccagc	tgtggggggcg	ctgttgatgc	gcagccaggc	ctcgccgcca	gagcccgcac	59520
gcttcatttc	cgctgacttc	atcgacgccc	tcaggatcgc	tggggccggcc	ctgtgggaga	59580
gtgaatgtgg	cttttgccaa	agttgagtct	ggagcctgga	aacttcacct	tgggcagcct	59640
tgatagtggg	gtggcccaag	gagcccaccc	agccgaccct	gccccctccg	tggctgggtg	59700
gcggcaccag	gggtgacctg	gctttgctcg	ttcaccaaca	tcacccgggc	tggccagggc	59760
gcgctcactt	ctgccaccac	cgagggccct	gggcgaagga	gtgaatacca	ggctgccttg	59820
gcagggatgt	gttgagggct	gtggggagtc	ggacagcggc	gggggtcaga	ggaggaggag	59880
ggtgcaccgt	gcaggctgaa	gggccacgtt	accctgaggt	tggccaggct	ccccaggcct	59940
agcctcccag	ctccccact	ttctccccac	cctccaccag	tggcaaagcc	agccccctca	60000
gggcgcacgg	tgtctgcccc	caaggagggc	ccattccgtt	ggggttaatg	ttggccacct	60060
ctttctgttt	gtctctggca	gaaatcacca	agccgcccctc	agacgcacagc	ccggcccaca	60120
gcagtgccat	cgggcccgtc	attggcatca	tcctctctct	cttcgtcatg	ggtggtgtct	60180
attttgtgtg	ccagcgcgtg	gtgtgccagc	gctatgcggg	ggccaacggg	cccttcccgc	60240
acgagtatgt	cagcgggacc	ccgcacgtgc	ccctcaattt	catagccccg	ggcggttccc	60300
agcatggccc	cttcacaggt	aaggagcctg	agatatggaa	tgatctggag	gaggcaggag	60360
agtgcttggtg	gcagcttttg	ggagtggagc	agggatgtgc	taccccaggc	cctcttgcac	60420
atgtggcaga	cattgctaag	cgatcacagc	attcagcctt	tccactgag	cctgtgcttg	60480
gcatacagaat	ccttcaacac	agaggcctgc	atggctgtag	caacccaccc	tttggcactg	60540
taggtgtgga	gaaagctcct	tggacttgac	cttcatattc	tagtaggaca	tgtgctgtgt	60600
tgtccacaaa	tcctcatgta	ccctagaaat	gaatgtgggg	gcggctgggc	tctctccaga	60660
gctgaaggaa	tcactctgta	ccatacagca	gctttgtctt	gagtgcagct	gggatttgtg	60720
gctgagcagt	tacaattcct	acgtggccca	ggcaccagga	acgcaggctg	tgttttaga	60780
tggctgggca	gccgcaccgc	agagctgcac	catgctggtt	tgtatcacat	gggtgaccat	60840
ggtatgtcta	agaaggtgga	gtccctgtga	ggtctgcagg	tgccccaca	gctccaggcc	60900
accttgagga	ttgcctctgc	ctgcccagcc	ctgagttccc	tctcccctgt	cctgtcccac	60960
tgtcacccca	agccggcctc	attgggagcc	tgttggatgg	cagggtataag	atgtaacctg	61020
attctctctg	gggagcgggg	ttatctggct	tctcaagagc	tcctaggagc	ccacagtggg	61080
ggcaccatca	cagtcgcagc	agccccaga	gaacgcggcc	ctgtctgttc	ctggcgtgct	61140
ctgtgctgcc	ccgctgggt	tccttgcccc	agtcgcaggc	cccttgagg	aggtaccatg	61200
tgtctcccgt	ttcacagatg	agccccgggg	agctcactct	agtagtggcc	agagaggcct	61260
gcggctcagg	gagcggggca	catttccaac	aggacacacc	gccctggtct	gagtctcgtg	61320
ggtagtggga	gcagaggaga	gcgcctatg	tctgtggggc	ggcttggtg	agcctggaag	61380
ccacctgacc	tccccgctcc	cttccctgcc	aggcatcgca	tgcggaaggt	ccatgatgag	61440
ctccgtgagc	ctgatggggg	gccggggcgg	ggtgcccctc	tacgaccgga	accacgtcac	61500
aggggcctcg	tccagcagct	cgtccagcac	gaaggccacg	ctgtacccgc	cggtgagggg	61560
cggggccggg	gagggggcgg	gcgggatggg	gctgtggggc	cctcccaccg	tcagtgtctg	61620
ccaccggagg	cttcccgggt	tcctgggggc	tgtgccaccg	cctctgaggc	atgcttgctt	61680
tcttcccttt	tcaaaccctt	ctgcttcctt	ctttaatgac	attgttgatt	gtggataatc	61740
tgaaaactac	acaaaaatat	aaagagccaa	aatctcacc	aaatccacct	cctagagtgg	61800
ctgttgggct	ccgtcagcat	ccaggcggcc	gtctgtgttc	cgcacggccc	agcccatcga	61860
tagccgcctg	caccaggcct	gtctgccctc	tgtgagcctc	cccacagggt	tcctccaca	61920
aacaccctgt	tctcccaccc	agggctggct	gcttcctgga	aaacagctgg	atggttttgt	61980
gcatgacaga	caaacacagg	gtgattttcg	tggctaaaat	actccctgga	gcttttgga	62040
gggtgagggg	ctggctccag	ctgagccacg	ccttgagtga	aatgactgtg	aggagaataa	62100
actgccgtg	ccctccagga	tcactggggc	tggctgggga	gaacccccgt	ttctgggagc	62160
acagtccag	gatgccaaag	cgagcttggt	gccagatgt	gaactcctga	gtgtaaacag	62220
cgggggctga	cttgacatgc	tttgtatgct	tttcatttgt	tcctgcagct	gtatgcccct	62280
aaggtgagtc	cagccccctt	ctgcttcctc	tggggcctcg	ccagtgagcc	ccaccttgct	62340
ggggctgggt	cctcctgccc	ttctgggtat	ccctcacatc	tggggctctg	tcttcttggt	62400
ttatttttct	tttttttttg	agacggagtt	tcacttttgt	tgcccaggct	tcagtgcaat	62460
ggtgtgatct	ctaggtcac	cgcaacctct	gcctcccagg	ttcaagcagt	tctcctgctt	62520
cagcctccct	agtagctggg	attacaggca	tgtgccacca	cgcccagcta	attttgtatt	62580
tttagtagag	atgggggttc	tccatggttg	tcaggctgat	cttgaactcc	ctacctcagg	62640
tgatccgccc	accttgccct	cccaaagtgc	tgggattaca	ggcgtgagcc	accgcacctg	62700

032796-132.ST25

gcctttttct	tttcttttct	tttctttttt	ctgagacagg	gtctcgcctc	gtcaccacagg	62760
ctggagtgc	atggtgtcat	catggctaac	tgcagcctct	accttctagg	ctcaagcaat	62820
cctcccatct	cagccctaa	gtagctagga	ctgcacgc	gcaccccat	gccagctaa	62880
tatttacatt	ttttgtagag	atgaagtctc	actatattgc	ccaggctgg	ctccaactcc	62940
tggactcgag	cgatcctcct	gcctcggcct	ccccaggtgc	tgggattaca	ggcgtgagcc	63000
accgtgcctg	gcctggggta	ttgtcttctt	atggcacctg	actgtgggtg	gccctgggaa	63060
ggaagtagca	gaagagggtt	cttcttggtt	tcctggacag	taactgagt	ttctggaggc	63120
cccaggccct	ggctttgttt	agggacaaag	ggaactggta	accagaagcc	gagagttaa	63180
acacccactg	cccttcttcc	ctgctcctgc	tgctgcaacc	cagcttaacc	agccaggagt	63240
gctaggaacc	caagcagggc	ccccgagcac	acagcaggca	gctcacgaat	tctcttttcc	63300
tggtctccct	tgggagctgg	gaggatctta	atcaggcaat	aagagatggc	actgagcagc	63360
cagctaattt	tttaaatac	tttattgttt	aacctatga	ctcaccact	taaaaagg	63420
tacagttcag	tgggttttag	tgtattcaca	gatgtgtgca	acctcacca	cagttaattt	63480
tagaacattt	tcctgcccct	aaaagaaact	ctgcatgaag	ccagctgttt	ttaaattagc	63540
aaagtatttt	tgcacctctt	aaatatatgt	tcatggtaca	aaattcaaaa	gatacagaag	63600
agtcctcagt	ccaaagagac	tcgccccca	tgacgcaaag	caggactccc	tgggaggcat	63660
ggcctcctgc	agtgtgtttc	ttctatgtcc	ccccagggtg	catctgtaca	tatgcaagca	63720
tacaagagcg	tggactttgt	tttccaagcc	agaagataat	tgtagattta	tgtgcagttg	63780
tgagaaagag	cacagaccca	tttactctct	gcctgggtttc	ccccagtgtc	gcctgccatc	63840
ttgcatgact	tcattccta	tcataagcaa	gacactgata	acgattcttt	caccttattc	63900
agattgacat	aagtgttttt	tggttggtct	tgagacaaac	ttcctctgtc	accagtgagg	63960
agtgcagtg	cacaatcaca	gctcactgca	gcctcaaact	cctgggctca	agcgattctc	64020
ctgcctcagt	ccctcaagt	agctcagatg	gcaggtgtgc	accatcatgc	caggctaatt	64080
tttaaatttt	ttgtggaggt	gaggcctcac	taaatttcct	gggctagtct	tgaactcctg	64140
agctaaagt	atcctcctgc	ctcagcctcc	caaagtggta	ggattacagg	catgagccac	64200
tgcgccctgg	ctgacatatg	tgttttcgta	agcccgaag	atagcatctg	aagagtcaac	64260
attgagcctt	gccttttgct	gctaatagat	tataaaagct	gctgttctga	gcatttcgga	64320
ggctcccagc	tgcggtgtgc	acctgccta	gagctctacc	gtaacccatc	tcggggagga	64380
ggtgctattg	ttttcctcat	tttgcaacaa	ggaggctgaa	gaactgagca	tgaaccactg	64440
gcctgggtcg	ttcggttggt	aggcagtggt	gccaggccat	ccaactcaca	accaccttct	64500
actctgcttc	ccccgcacc	tgaagtttgt	tctgttttga	ggacacagcc	gtcacattct	64560
tggtggctga	acagcactcc	ttgtcaggtg	tggtcgggcc	cccactggag	ggcatcatgg	64620
tcctctctcc	tgctgcggtt	gaaccttggc	tgtttcgaac	actcctgcca	agtggccctc	64680
tgaaggggac	agtccatctt	ttctcagcag	agggccacac	tggcaaaaacg	gtccctggca	64740
ccctttctct	ccacctgtct	aatatagagt	aaaaatggta	tcattgttaag	atcttcattt	64800
atatattatt	tatcatgaat	gatgtaagca	tcattttgtg	tgtttaagaa	cctttgggcc	64860
cagcgtgatg	gcttgacagt	gtaatctcag	cacttttagga	ggctgagatg	agcgatcac	64920
ttgaggccgg	gagtttgaga	ccagcctggc	caacatggag	aaaccccgtc	tctagtataa	64980
atttaaaaat	tagccgggta	tggtgatccc	agctacttgg	gagtctgaag	catgagaatt	65040
gcttgaacat	gggaggcgga	ggttgacagt	agccgagatc	gcgccattgc	actccagcct	65100
gggcgacaga	gcgagactct	gtctcacaaa	aaaaaaaaaa	aaagaaaaga	aaagaaatta	65160
tcaatctcct	cttttatggc	atatatatat	atatatatat	atatatatat	ttatttccct	65220
ttcttggtta	tgttcataaa	ggcctcccct	gctctgatca	taaaaacaa	cttattttca	65280
cactctctct	cttttttttt	tgagacagag	ttttgctcct	gttgcccagg	ctggagtgc	65340
gtggcgcaat	ctcagctcac	tgtaacctcc	gcctcccggg	ttggagtgat	tctcctgcct	65400
taccttccc	agtagctggg	attataggca	tgaccacca	tgctggcta	attttgtact	65460
tttagtagag	acgggggttt	ctccatgttg	gtcaggctgg	tctcgaactc	gcgacctcag	65520
gtgatccacc	cacctcgccc	tcccaaagt	ctgggattac	agacgtgagc	caccatggcc	65580
agcccacact	ctctttctta	acgtcctcct	cctttcggtt	tacgttcaca	tctttaattc	65640
ttctgggatg	taattagatt	tgatgagcaa	gggtggcatc	cagcttggtt	cttggctgat	65700
ggcttatggg	tggcgtgaat	tagtcggggt	ctatcaggag	gcagaaactc	tatgagaatt	65760
tgaacagaga	aagttccgtc	tacaggctta	ttaccaggga	ctggaatagc	agaaattgaa	65820
cagttagatg	tacagagaac	tctaagaatg	caggaatagg	ccaggcatgg	tggctcacac	65880
ctgtcatccc	agcactttgg	gagaccaagg	cgggtggatc	acctgaggtc	aggagttcga	65940
gaccagcctg	gccaacatag	tgaaccccca	tctctactaa	aaatacaaaa	aaattagctg	66000
ggtgtggtgg	cgcatgcctg	taatcccagc	ttctcgggag	tctgaggctg	gagaatcact	66060
tgaacctggg	aggcagaggt	tgtagtgagc	cgagatcatg	ccattgtact	ccagcctggg	66120

032796-132.ST25

caacaagagc	gagactcagt	caaaacaaca	acaacgcagg	aatagcagat	gagccgaggt	66180
ggggcctccc	cagccccac	ccccacccc	gcaccctggg	ccgagatcca	gtcctctttg	66240
aataggccct	gggctgtgtt	cacgggacat	ctgagacatt	gccgaggcgc	tgcactgggtg	66300
gatcttgcca	gaagtctgcc	cagtgcagat	ttgggcagaa	tctcaaactg	ccttgggatg	66360
taggagagaa	accaggcctg	gtcaagttca	tgggaagagg	tggaaacaga	cccatagggc	66420
tggggcttgg	gcagctgtag	gaagccctct	ctgctgcctc	cctgcctgct	ctctgctttg	66480
aagcatcttc	cccagtcccc	ccagtctcat	gccctctcaa	cgttgggggtc	aaatcctgag	66540
gaataccag	actggctctc	tgggcaaag	aggaccctct	ccagaaagag	cagggcccag	66600
tgcggcttcc	taaagggcag	gggaagggcc	tggccactcc	ccagaggcta	ctcaccagcc	66660
atcaggatag	ccccaggaag	caggccttct	cgagccatt	ttattacttt	attttattat	66720
tttatttaat	tttaaattta	ttttttgaga	cagagtctca	ctctgttgcc	caggctggag	66780
tgcagtgggtg	cgatctcaac	ccactgcagc	ctctgcctcc	agggttcaag	ggattctccc	66840
acctcagcct	cccaagtagc	tgggattaca	ggtgcccgcc	accacacccg	gctaattttc	66900
atatttttag	tagagacgag	gtttcaccat	gttgccagg	ctggtctcga	actcctgacc	66960
tcaagtgate	cgcccgctc	ggcctcccaa	agtgttaggt	caagccatt	ttaaagttga	67020
agaaactgag	gctgaggtaa	attccctccc	cagggatcct	gctgcagcca	gaaggtggta	67080
aaacaggact	tcaccgggt	ctgtctggcg	tgaaggcag	tgttcttgta	ccaccctagg	67140
gggcctgaga	gactagttc	cctcgggcat	aactgacagt	tctgttccca	ttattccgca	67200
ggggctcgga	tctggctgta	tgctttccag	gatggccttg	gagaccaca	taagccctac	67260
accctttggg	aagctgcatg	ttgggttggg	gtgccgtcag	tggcacttgt	ggaaggtgca	67320
gacctgtgtg	ggtgtgtggg	cccagggccc	ctggtccctt	cctccctttg	tagggctggg	67380
tgtgtgctgc	ctggacctgg	ggggcacgtt	cacgtggtga	atttgtctat	ttactatccc	67440
cgctttgggg	ctggtgccag	cacaggccct	tgtgaagggg	gtgcctttgt	ctggagtggg	67500
actgtggccc	ctccctcagc	gtggtgactt	ctgtgtcagg	gcttcagcag	ggacgcagag	67560
cccctgagtg	ttcggaacaa	gggcgtcatt	gcaggagtta	gactgtgtgt	gatggaggga	67620
ggagggggcag	gaggaaaggt	cagaaggaga	gttcctggga	aggtccctga	ggagcctggg	67680
gaggtgctaa	ctggtgtgga	ggacactcag	ggcctgtggg	gacatctcct	actgctgggg	67740
gccagccaca	aagggaactg	gccgaagtcc	tgtccccgcc	ttcacagccc	agcatctggt	67800
cacaaggcag	gtacttgga	gggcgcgggc	acctgggcca	aaagtgcctg	ggttcccttt	67860
gcctttcact	gagatgacct	tcggggcagg	tggctgtgc	ctccccctcct	gtccccagg	67920
tttgccaaact	ggccagagga	aggggtcctg	ggaagcaggg	gggccagaag	ccctctctgc	67980
aaggaaagcc	cgaggggtgt	gggaggaagg	aaggatgcc	caggctggcg	aggctctaag	68040
tcaccctggc	ttggctctcc	tcagatcctg	aaccgcgcgc	cctccccggc	cacggacccc	68100
tcctgttaca	acatggacat	gttctactct	tcaaacattc	cgccactgc	gagaccgtac	68160
aggtaggaca	tcccctgcag	ccctccatgg	ccattgggtt	cccgccagcc	cgtggtggag	68220
gggcctaate	cccatgccac	tgatgagggg	aggtattctg	ggtgctagt	ggcaggtgcc	68280
ggggccagcc	ctgcctccct	ctgctctgcc	aaccacacta	ggctgcctcc	ccagacaagc	68340
tcagcgggca	ctgcatgttg	ggttcagaaa	tcagcagaac	tccacgttct	gagctgctct	68400
tcaagttgct	cctatggggg	ttacttttaa	gctgggaaat	ggctgtggcg	tcgaggggcc	68460
gggggcttgg	gctccaaact	ctgactgtgt	gtttgagtcc	ggctgtggaa	acctagccat	68520
tgagatgccc	cctcttggtg	gctctgtcct	cttaggatgg	gacaagtctg	tgaaggctgc	68580
tgcagcacc	accgtagacc	cctaatcgtg	tgacgtcacc	aggatggtcc	gggctgctca	68640
cttgccacag	tggcctgttt	gagcccggga	agccaacggg	gctgctcagc	tggacaccag	68700
ccccccgagc	tgcccatggt	ggggtcacag	gccccacctc	cctggttggg	gaggggcaac	68760
tgagagtgtg	gagaggtggg	acccaggtgt	gctggtctcc	gcaggggctg	gatcagagcc	68820
tgggatgggc	agggtagacc	tcctgacctt	taaccagtg	gtgtcaggca	acgtggccca	68880
cccgccagcc	gcaccaggcc	ccaccccgcg	aggtgaagg	gtgggatagg	ctgggcctgg	68940
gccagagcac	ctctggacca	cgcattcctc	attgcttggg	tccctggagc	agcagggcct	69000
cccagatgtg	gtgcgcctg	ccacctagt	gccatttcca	cgaactcca	ggcctggctg	69060
gggagccgga	actgcagcct	ccatttccac	cccactccgg	gtcgggccac	ctccctgatg	69120
cctcagtatt	atatcaaact	gtcacagtct	gtcccacagc	cttacagacc	actgtctcca	69180
gaatggtcac	atccacactg	ggcagcccag	tctcgctagt	tcctcgctcc	acctcctgcc	69240
tttgctcatg	cccgctctgc	tctgggcccc	ccgcggacac	atcttcccc	cgcccgcctg	69300
ctgacctcac	agcagctggg	ccccaaagag	agtatcctgt	cctgctgcac	ttttctcaac	69360
acccggtgtt	ggctgcacct	tcccacccat	tgcaggcccc	tctgtgacag	gacgggggct	69420
cctaaacaca	ccacagttcc	gagtctgaac	tcacacagt	ggatgcggcg	tttctgggcc	69480
acagttgggt	gcaggtagcc	tctgggagga	tgggaggtca	ggagccatct	tgcgagtcag	69540

032796-132.ST25

gttgcttgaa	ctcaggatgg	aagtgttccg	ggcccattgg	ttgctgtatt	agcctgttct	69600
cacgctgcta	ataaaagacat	acccaagact	gggtaattgt	aaaggaaaga	ggtttaacgg	69660
actcacagtt	ccacctgcct	gggggtggcct	cacaatcatg	gtagaagaca	aggaggagca	69720
agtcacatct	tacatggctt	cagggaacag	acagcatgag	aaccaagcga	aaggggttct	69780
cccttgtaaa	accatcaagt	ctagtgaagt	ttattcacta	ccacgagaac	agtatggggg	69840
gaaccacccc	catgattcaa	tcatctccca	ctgggtccct	cccacagcac	gtgggaatta	69900
tgggagtaca	attcaagatg	agatttgggt	ggggacacag	ccaaacccta	tcggttgcca	69960
acatttacag	taacagtgtt	aggtgaacag	ttgtccagtc	tctgtttttg	tcggacactg	70020
tttctagcac	cttccaggca	gaatctcatg	tatccttcac	tttcgaaatg	ggtactatct	70080
catccccact	tttatcaatg	agaaactaaa	gctcgaagag	gtcaagtaag	ttcctggcca	70140
aggtcagcta	gcaggctcta	gaggcctcgt	tctccttaga	ggcagccttg	ccaggggcca	70200
ggcttggcag	gctgcagggc	aggtgcgggc	atgcccatgg	tagagggtgg	accattgagg	70260
ctcagagagg	gtaagtgatg	agccctggcg	acacagcggg	gtgggtccag	agtccggcct	70320
gcatcttctg	gagctggcca	gtggacaggc	ctttcccgtt	cacagccccg	gggctgctgt	70380
gccaccagg	gcggatgtgc	ctaccgaatc	ccactcctct	gtgtgtgtcc	ctttcaggcc	70440
ctacatcatt	cgaggaatgg	cgcccccgac	gacgccctgc	agcaccgacg	tgtgtgacag	70500
cgactacagc	gccagccgct	ggaaggccag	caagtactac	ctggatttga	actcggactc	70560
agacccttat	ccacccccac	ccacgccccca	cagccagtag	ctgtcggcgg	aggacagctg	70620
cccgccctcg	cccgccaccg	agaggagcta	cttccatctc	ttcccgcgcc	ctccgtcccc	70680
ctgcacggac	tcatcctgac	ctcggccggg	ccactctggc	ttctctgtgc	ccctgtaaat	70740
agttttaaat	atgaacaaag	aaaaaaatat	attttatgat	ttaaaaaata	aatataattg	70800
ggattttaaa	aacatgagaa	atgtgaactg	tgatggggtg	ggcagggtctg	ggagaacttt	70860
gtacagtgga	gaaatattta	taaacttaat	tttgtaaaac	agaactgccca	ttctttttgtg	70920
ccctgtgtgc	atttgagttg	tgtgtccccg	tggagggaat	gccgaccccc	ggaccaccat	70980
gagagtcctc	ctgcaccccg	gcgtccctct	gtccggctcc	tgcagggaag	ggctggggcc	71040
ttgggcagag	gtggatatct	cccctgggat	gcatccctga	gctgcaggcc	gggcccggctt	71100
tatgtgcgtg	tggcctgtgc	cgtcagaaag	ggccctgggc	ttcatcacgc	tgttgctgtt	71160
cgtcttcttc	agattcttag	tctttttttt	tttttttttt	ttttgagacg	gagtcctttct	71220
ctgtcatcca	ggctggagtg	cagtgggtaca	atctcagctc	actgcaagct	ccgactccca	71280
ggttcaagtg	agtctcctgc	ctcagcctcc	cgagtagctg	ggactacagg	tgcgcgccac	71340
cacaccgcgc	cagctaattt	ttgtattttt	agtagagatg	gggtttcacc	atgttgacca	71400
ggatgatctc	gatctcttga	cctcgtgatc	cgcccacctc	ggcctcccaa	agtgtctgga	71460
ttataggcat	gagccactgt	acccagctga	ctcttagtca	cttttaagaa	ggggactgtg	71520
ccttcatttt	tactggggcc	ctgcagaata	tatgcctggg	ctctgggctc	ttctgaacct	71580
gtgttggtt	ccatctgacc	tctctgtgcc	agcccaaggc	tgtgtctctt	cctgagggca	71640
aggagcccca	tgactgcgtg	ttgactcgtt	ggatggggct	gctgagccca	ctctgccaca	71700
ccacgtgccc	ctggcaggga	gggaatccct	gggtcctcac	aggaacagtc	agcaagccac	71760
acctgacgcc	tgtgtggggc	ccatccctgc	ggtgctggag	aagacagaca	aggcctggtc	71820
actgcctctg	caggggtccc	agtccgtgga	aggagacagt	aatctaggca	ttttcggttg	71880
ggaagctgag	ctgttctcgt	gtcctgaagg	ccaggcgggg	acagccgtct	tcagagggaa	71940
gggagaaaat	gcacatcgca	tcagtggaga	agggcctgac	ttccctcagc	atggtggagg	72000
gaggtcagaa	aacagtcaag	cttgagtatt	ctatagtgtc	acctaaata		72049

<210> 10

<211> 8705

<212> DNA

<213> Homo sapiens

<400> 10

ggactcaggg	gcagcagggg	ggtacaccca	tggttagtgg	gcggaccata	gggggtaatg	60
agagggtgaa	tcgatggaac	ctggggggaca	caatcgaagt	ggttccagag	tcgggctgta	120
ctaattaaag	agacggggca	gtggacaggc	attttcagtt	gactgcccag	ggagtgttct	180
gcccaacagg	gaggatatgc	gtacagaatc	atactcgatc	agcatgagtc	caattcagac	240
cgtacatcag	tggagatatg	ggtcccccgga	tgactccgtg	gaacactgat	gtttgtgaca	300
ggggagtaca	gcaccagcca	tcagcaggcc	agtaaatacat	accggcctgc	gaaattggac	360

032796-132.ST25

tcagaccg	atccaccctg	accgacgtcc	caagccccc	ccccccacc	cccaccatgg	420
gccgagatcc	agtccctctt	gaatagggcc	tggccgtggt	tcacgggaca	tctgagacat	480
tgccgaggcg	ctgcattggg	ggatcttgcc	agaagtttgc	ccagtgcaga	tttgggcaga	540
atctcaaact	gccttgggat	gtaggagaga	aaccaggcct	ggtcaagttc	atgggaagag	600
gtggaacag	accccatagg	ctggggcttg	ggcagctgta	ggaagccctc	tctgctgcct	660
ccctgcctgc	tctctgcttt	gaagcatctt	ccccagtgcc	ccagtctca	tgccctctca	720
acgttggggt	caaatcctga	ggaataccca	gactggctct	ctggggccaaa	gaggaccctc	780
tccagaaaga	gcagggccca	gtgcggcttc	ctaaagggca	ggggaagggc	ctggccactc	840
cccagaggct	actcaccagc	catcaggata	gccccaggaa	gcaggccttc	tcgagcccat	900
tttattactt	tattttatta	ttttatttaa	ttttaaat	atTTTTtgag	acagagtctc	960
actctgttgc	ccaggctgga	gtgcagtggg	gcgatctcaa	cccactgcag	cctctgcctc	1020
caggggtcaa	gggattctcc	cacctcagcc	tccaagtag	ctgggattac	aggtgcccg	1080
caccacaccc	ggctaatttt	catattttta	gtagagatga	ggtttcacca	tgttgccag	1140
gctggtctcg	aactcctgac	ctcaagtgat	ccgcccgcct	cggcctccca	aagtgctagg	1200
tcaagcccat	tttaaagttg	aagaaactga	ggctgaggta	aattccctcc	ccagggatcc	1260
tgctgcagcc	agaaggtggt	aaaacaggac	ttcaccggg	tctgtctggc	gtgaaaggca	1320
gtgttcttgt	accaccctag	ggggcctgag	agaactgagt	ccctcgggca	taactgacag	1380
ttctgttccc	ataattccg	aggggctcgg	atctggctgt	atgctttcca	ggatggcctt	1440
ggagaccac	ataagcccta	caccctttgg	gaagctgcat	gttgggttgg	ggtgccgtca	1500
gtggcacttg	tggaagggtc	agacctgtgt	gggtgtgtgg	gcccaggggc	cctggtccct	1560
tcctcccttt	gtagggtctg	ttgtgtgctg	cctggacctg	gggggcacgt	tcacgtggtg	1620
aatttgtcta	tttactatcc	ccgctttggg	gctggtgcca	gcacaggccc	ttgtgaaggg	1680
ggtgcctttg	tctggagtgg	gactgtggcc	cctccctcag	cgtggtgact	tctgtgtcag	1740
ggcttcagca	gggacgcaga	gcccctgagt	gttcggaaca	agggcgcat	tcagaggagt	1800
agactgtgtg	tgatggaggg	aggaggggca	ggaggaaagg	tcagaaggag	agttcctggg	1860
aaggctccctg	aggagcctgg	tgagggtcta	actggtgtgg	aggacactca	gggcctgtgg	1920
ggacatctcc	tactgctggg	ggccagccac	aaagggaact	ggccgaagtc	ctgtccccgc	1980
cttcacagcc	cagcatctgg	tcacaaggca	ggtacttgga	agggcgcggg	cacctgggccc	2040
aaaagtgcct	gggttccctt	tgcccttcac	tgagatgacc	ttcggggcag	gtggctgctg	2100
cctccctcc	tgtccccagg	ttttgccaac	tgccagagg	aaggggctct	gggaagcagg	2160
ggggccagaa	gcctctctg	caaggaaagc	ccgaggggtg	tgggaggaag	gaaggaatgc	2220
ccaggctggc	gaggtctaa	gtcaccctgg	cttggtctct	ctcagatcct	gaaccgcgg	2280
ccctcccg	ccagggacc	ctccctgtac	aacatggaca	tgttctactc	ttcaaactt	2340
ccggccactg	cgagaccgta	caggtaggac	atccctgca	gccctccatg	gccattgggt	2400
tcggccagc	ccgtggtgga	ggggccta	ccccatgcca	ctgatgaggg	gaggatttct	2460
gggtgcta	gggcagggtc	ggggccagc	cctgcctccc	tctgctctgc	caaccacact	2520
aggctgcctc	cccagacaag	ctcagcgggc	actgcatgtt	gggttcagaa	atcagcagaa	2580
ctccacgttc	tgagctgtc	ttcaagttgc	tcctatgggg	gttactttta	agctgggaaa	2640
tggctgtggc	gtcgaggggc	cgggggcttg	ggctccagag	tctgactgtg	tgtttgagtc	2700
cggctgtgga	aacctagcca	ttgagatgcc	ccctcttggt	ggctctgtcc	tcttaggatg	2760
ggacaagtct	gtgaaggctg	ctgcagcacc	caccgtagac	ccctaatacgt	gtgacgtcac	2820
caggatggtc	cgggctgtc	acttgccaca	gtggcctgtt	tgagcccggg	aagccaacgg	2880
ggctgctcag	ctggacacca	gccccccgag	ctgcccattgt	tggggtcaca	ggccccacct	2940
ccctggttgg	ggaggggcaa	ctgagagtgt	ggagagggtg	gaccaggtg	tgtggtctc	3000
cgcaggggct	ggatcagagc	ctgggatggg	cagggtgagc	ctcctgacct	ttaaccagct	3060
ggtgtcaggc	aacgtggccc	acccgccagc	cgcaccaggc	cccaccccg	caggtgaagg	3120
ggtgggatag	gctgggcctg	ggccaggaca	cctctggacc	acgcattcct	cattgcttgg	3180
gtccctggag	cagcagggcc	tcccagagtgt	ggtgcgcgct	gccacctagt	ggccatttcc	3240
acgaactccc	aggcctggct	ggggagccgg	aactgcagcc	tccattttcca	ccccactccg	3300
ggtcgggcca	ccctccctgat	gcctcagtat	tatatcaa	tgtcacagtc	tgtcccacag	3360
ccttacagac	cactgtctcc	agaatggtca	catccacact	gggcagccca	gtctcgctag	3420
ttcctcgtcc	cacctctctc	ctttgctcat	gcccgtcctg	ctctggggcc	accgcggaca	3480
catcttcccc	ccgcccgcgg	tctgacctca	cagcagctgg	gccccaaagag	gagtatcctg	3540
tctgtgtgca	cttttctcaa	cacccggtgt	tggctgcacc	ttcccaccca	ttgcaggccc	3600
ctctgtgaca	ggacgggggc	tcctaaacac	accacagttc	cgagtctgaa	ctcacacagt	3660
gggatgcggc	gtttctgggc	cacagttggg	tgcaggtagc	ctctgggagg	atgggagggtc	3720
aggagccatc	ttgcgagtca	ggttgcttga	actcaggatg	gaagtgttcc	ggggccattg	3780

032796-132.ST25

gttgctgtat	tagcctgttc	tcacgtctgt	aataaagaca	taccaagac	tgggtaattg	3840
taaaggaag	aggtttaacg	gactcacagt	tccacctgcc	tgggggtggcc	tcacaatcat	3900
ggtagaagac	aaggaggagc	aagtcacatc	ttacatggct	tcaggggaaca	gacagcatga	3960
gaaccaagcg	aaaggggttt	ccccttgtaa	aacctatcaag	tctagtgaga	tttattcact	4020
accacagaa	cagtatgggg	ggaaccaccc	ccatgattca	atcatctccc	actgggtccc	4080
tcccacagca	cgtgggaatt	atgggagtac	aattcaagat	gagatttggg	tggggacaca	4140
gccaaccct	atcggttgcc	aacattttaca	gtaacagtgt	taggtgaaca	gttgtccagt	4200
ctcctgtttt	gtcggacact	gtttctagca	ccttccaggc	agaatctcat	gtatccttca	4260
ctttcgaaat	gggtactatt	tcatccccac	ttttatcaat	gagaaactaa	agctcgaaga	4320
ggtcaagtaa	gttcctggcc	aaggtcagct	agcaggctct	agaggcctcg	ttctccttag	4380
aggcagcctt	gccagggccc	aggcttgga	ggctgcaggg	cagggtgcggg	catgcccag	4440
gtagaggtgg	gaccattgag	gctcagagag	ggtaagtgat	gagccctggc	gacacagcgg	4500
ggtgggtcca	gagtccggcc	tgcatcttct	ggagctggcc	agtggacagg	cctttcccgt	4560
tcacagcccc	ggggctgctg	tgcccaccag	ggcggatgtg	cctaccgaat	cccactcctc	4620
tgtgtgtgtc	cctttcaggc	cctacatcat	tcgaggaatg	gcgccccga	cgacgccctg	4680
cagcaccgac	gtgtgtgaca	gcgactacag	cgccagccgc	tggaaggcca	gcaagtacta	4740
cctggatttg	aactcggact	cagaccccta	tccaccccca	cccacgcccc	acagccagta	4800
ccgtgcggcg	gaggacagct	gcccgccttc	gcccgcacc	gagaggagct	acttccatct	4860
cttccccgcc	cctccgtccc	cctgcacgga	ctcctctga	cctcggccgg	gccactctgg	4920
cttctctgtg	ccccgtgaaa	tagtttttaa	tatgaacaaa	gaaaaaaata	tattttatga	4980
tttaaaaaat	aaatataatt	gggattttta	aaacatgaga	aatgtgaact	gtgatggggt	5040
gggcagggct	gggagaactt	tgtacagtgg	agaaatattt	ataaacttaa	ttttgtaaaa	5100
cagaactgcc	attctttcgt	gccctgtgtg	catttgagtt	gtgtgtcccc	gtggagggaa	5160
tgccgacccc	cggaccacca	tgagagtcct	cctgcacccg	ggcgtccctc	tgtccggctc	5220
ctgcagggaa	gggctggggc	cttgggcaga	ggtggatatc	tcccctggga	tgcacccctg	5280
agctgcaggc	cgggccggct	ttatgtgcgt	gtggcctgtg	ccgtcagaaa	gggccctggg	5340
cttcatcacg	ctgttgctgt	tcgtcttctt	cagattctta	gtcttttttt	tttttttttt	5400
ttttttgaga	cggagtcttt	ctctgtcatc	caggctggag	tgacgtggta	caatctcagc	5460
tcactgcaag	ctccgactcc	caggttcaag	tgagtctcct	gcctcagcct	cccagtagac	5520
tgggactaca	ggtgcgcgcc	accacacccg	cccagctaatt	ttttgtattt	ttagtagaga	5580
tggggtttca	ccatgttggc	caggatgata	tcgatctctt	gacctcgtga	tccgcccacc	5640
tcggcctccc	aaagtgtctg	gattatagcg	atgagccact	gtaccagact	gactcttagt	5700
cacttttaag	aaggggactg	tgccttctatt	tttactggg	ccctgcagaa	tatatgcctg	5760
ggctctgggc	tcttctgaac	ctgtgttggc	ttccatctga	cctctctgtg	ccagcccaag	5820
gctgtctgtc	ttcctgaggg	caaggagccc	catgactgcg	tgttgactcg	ctggatgggg	5880
ctgctgagcc	cactctgccca	caccacgtgc	ccctggcagg	gagggaaatc	ctgggtcctc	5940
acaggaacag	tcagcaagcc	acacctgacg	cctgctgtgg	gcccacccct	gcggtgctgg	6000
agaagacaga	caaggcctgg	tcactgcctc	tgcagggtcc	ccagtcctgt	gaaggagaca	6060
gtaatctagg	cattttcggc	ggggaagctg	agctgttctc	gtgtcctgaa	ggccaggcgg	6120
gaacagccgt	cttcagaggg	aaggagagaa	atgcacatcg	catcagtgga	gaagggcctg	6180
acttccctca	gcatggtgga	gggaggtcag	aaaacagtca	agcttggtgc	tgggtgacag	6240
tgcatttaat	aatcaaaaata	taggctgggt	acggtggctc	atgcctgtaa	tcccagcact	6300
ttgggaggct	gaggcaggtg	gatcacttga	ggccaggagt	ttgagaccgg	cctggccaac	6360
atggcaaaac	ctcaactact	aaaatacaaa	aactagccgg	gcgtgggtgt	gcacgcctgt	6420
aatcccagct	acttgggagg	ctgaggcagg	agaattgctt	gaacctggga	ggcggaggct	6480
gcagttagcc	gagattgtgc	cactgcactc	cagcctgggc	aacagagcaa	gactctgtct	6540
caaaaaaaaa	aaaaaaaaaa	gcaatacaaa	atacaaatat	cactttcact	aaaagaaggg	6600
atggaagacc	caaaaacaaac	agaaaaacaa	aaaatggcag	gagtaagtcc	ccacttatca	6660
ataataacat	tgactgtaaa	taggctaagc	tctgcaatca	aaagagtggg	ccaggagcgg	6720
tggctcacgc	ctgtaattcc	aacgctttgg	gaggctgagg	cggatggatc	atttgatgtc	6780
acgagtttta	agaccagcct	ggccaacaag	gtgaaacccc	atctgtacta	aaaatacaaa	6840
aattagccag	gcggtagtgg	cacgcacctg	taatcccagc	tacttgtgag	gctgaggcag	6900
gagaatcact	ggaggctggg	aagcggagggt	tgctgtgagc	caagatggag	ccactgcact	6960
cccacctggg	cgacagagtg	agatcctgtc	ttaagaaaaa	aaagagtgga	tgaatggatc	7020
aaaaaacaag	acccaaccat	ctcttgcata	caagaaacac	actttaccta	taaaaacaca	7080
ctaggccagg	tgtgggtggc	cacacctgta	atcccagccc	tttgggaggc	ctgactggca	7140
gatcacctga	ggccaggagt	ttcagaccag	cttgaccgac	atggcaaaac	cccatctctc	7200

032796-132.ST25

ctaaaaatac	aaaaaaacaa	aaaaaagaaa	aaggctggaa	gtagtgatgt	gtgcctgtag	7260
ccccagctac	ttgggaggct	gaggcaggag	aattgcttga	atccgggaag	tggaggttgc	7320
agtgagccag	gatggtgcca	ctgcactcca	gcctgggtga	cagagcgaga	ccctgtcata	7380
aaaaaaaaaa	gaaaagaaaa	gaaaaacgag	aaaaacaaac	acaaaattag	tagaagaaaa	7440
gaaataataa	agatcagaac	aggccaggct	catgggcaca	gtggctcaac	tcctacctgc	7500
tcaggagttt	gagaccagtc	tggccaacat	ggcaaaaccc	catctctcct	aaaaatatga	7560
aaaaaaaaaa	ataggctgga	tgtggtgatg	tgtgtgtgcc	tgtagcccca	gctacttggtg	7620
aggctgaggt	gggagaatca	cttgagccca	ggaagtggag	gctgcagcga	gtcatgaatg	7680
cacctgcac	tctagctggg	taactggagt	gagattctgt	ctcaaaaaag	caaagaccag	7740
agcagaaata	aatgaaatgg	aaatgaagga	aacaatgcaa	aatgatacaa	aaagtttttt	7800
cgaaaagata	aacaaaatca	acaaaccttt	agccagatta	agaaaaaaag	agagaagacc	7860
caaataaata	aaatccgaga	ttaaaaagga	gacattacca	ctgataccac	agaaattcaa	7920
aggatcatta	gaggcaacta	tgtgcaacta	tatgctaata	aactggaaaa	cctagaagaa	7980
ctgggtaaat	ttctagacac	atacaaccta	tcaagattga	accatgaaga	aatccaaaac	8040
ctgaacaggc	cgggcacggt	ggcttacgcc	tgtaatccca	gcactttgga	aggcctgaga	8100
tcaggagttc	gagaccagcc	tggccaacat	ggtgaaaccc	catctctact	gaaaaaatat	8160
aaaaattagc	cgggcggtgt	ggcggtgcc	tctaattgtca	gccactcggg	aggctgaggtc	8220
aggaaaatca	cttgaacctg	ggaggcatag	gttgacgaga	gccgaggttg	caccactgca	8280
ctccagcctt	ggcgacagag	ccagactcca	tctcaaaaaa	attaaaataa	caaaaaacctg	8340
aacagaccaa	taacaagtaa	tgcgatgaaa	actgtaataa	aatgtttccc	aacaaaagaaa	8400
gccaggaac	aatggcttc	actgctgaat	tttaccaaaac	atTTTTTTTT	ttttgagacg	8460
gagtcctcgt	ctgtcgccca	ggctggagtg	cagtgggtga	acctcggttc	gctggtaact	8520
tatgcctctc	aggctgcaag	tgattttcct	gcttcaggcc	ccccgagtg	ctggaaatta	8580
gatggtactt	gtcaacaacg	gcctggctaa	atttctatat	ttccttcaag	tagaagatgt	8640
gcttccaaca	aagggtgggt	tacggctggc	ttctgaaaat	cttggatttc	aaggctcccc	8700
aaaag						8705

<210> 11

<211> 66933

<212> DNA

<213> Homo sapiens

<400> 11

tataatcaag	cgcgttccgt	ccagtcgggt	gggaagattt	tcgatatgct	tcgtgatctg	60
ctcaagaacg	ttgatcttaa	agggttcgag	cctgatgtac	gtattttgct	taccaaatac	120
agcaatagta	atggctctca	gtccccgtgg	atggaggagc	aaattcggga	tgcctgggga	180
agcatggttc	taaaaaatgt	tgtacgtgaa	acggatgaag	ttggtaaagg	tcagatccgg	240
atgagaactg	tttttgaaca	ggccattgat	caacgctctt	caactggtgc	ctggagaaat	300
gctctttcta	tttggaacc	tgtctgcaat	gaaattttcg	atcgtctgat	taaaccacgc	360
tgggagatta	gataatgaag	cgtgcgcctg	ttattccaaa	acatacgctc	aatactcaac	420
cggttgaaga	tacttcgtta	tcgacaccag	ctgccccgat	ggtggattcg	ttaattgcgc	480
gcgtaggagt	aatggctcgc	ggtaatgcca	ttactttgcc	tgtatgtggt	cgggatgtga	540
agtttactct	tgaagtgtc	cggggtgata	gtgttgagaa	gacctctcgg	gtatggtcag	600
gtaatgaacg	tgaccaggag	ctgcttactg	aggacgcact	ggatgatctc	atcccttctt	660
ttctactgac	tgggtcaacag	acaccggcgt	tcggtcgaag	agtatctggt	gtcatagaaa	720
ttgccgatgg	gagtcgccgt	cgtaaagctg	ctgcacttac	cgaaagtgat	tatcgtgttc	780
tggttggcga	gctggatgat	gagcagatgg	ctgcattatc	cagattgggt	aacgattatc	840
gccaacaacg	tgcttatgaa	cgtggtcagc	gttatgcaag	ccgattgcag	aatgaatttg	900
ctggaaatat	ttctgcgctg	gctgatgcgg	aaaatatctc	acgtaagatt	attacccgct	960
gtatcaacac	cgccaaattg	cctaaatcag	ttgttgctct	tttttctcac	cccgggtgaac	1020
tatctgcccc	gtcagggtgat	gcacttcaaa	aagcctttac	agataaagag	gaattactta	1080
agcagcaggc	atctaacctt	catgagcaga	aaaaagctgg	ggtgatattt	gaagctgaag	1140
aagttatcac	tcttttaact	tctgtgctta	aaacgtcatc	tgcatacaaga	actagtttaa	1200
gctcacgaca	tcagtttgct	cctggagcga	cagtattgta	taagggcgat	aaaatggtgc	1260
ttaacctgga	caggctctcgt	gttccaactg	agtgtataga	gaaaattgag	gccattctta	1320

032796-132.ST25

aggaacttga	aaagccagca	ccctgatgcg	accacgtttt	agtctacgtt	tatctgtctt	1380
tacttaatgt	cctttgttac	aggccagaaa	gcataactgg	cctgaatatt	ctctctgggc	1440
ccactgttcc	acttgatcgt	tcggtctgat	aatcagactg	ggaccacggt	cccactcgta	1500
tcgtcggctc	gattattagt	ctggggaccac	gggtcccactc	gtatcgtcgg	tctgattatt	1560
agtctgggac	cacggtccca	ctcgtatcgt	cggctctgata	atcagactgg	gaccacggtc	1620
ccactcgtat	cgtcggctctg	attattagtc	tgggaccatg	gtcccactcg	tatcgtcggg	1680
ctgattatta	gtctgggacc	acggtccac	tcgtatcgtc	ggctctgatta	ttagtctgga	1740
accacggtcc	cactcgtatc	gtcggctctga	ttattagtc	gggaccacgg	tcccactcgt	1800
atcgtcggtc	tgattattag	tctgggacca	cgatcccact	cgtgttgctc	gtctgattat	1860
cggctcggga	ccacggtccc	acttgatttg	tcgatcagac	tatcagcgtg	agactacgat	1920
tccatcaatg	cctgtcaagg	gcaagtattg	acatgtcgtc	gtaacctgta	gaacggagta	1980
acctcgggtg	gcggttgat	gcctgctgtg	gattgctgct	gtgtcctgct	tatccacaac	2040
atthttgcga	cggttatgtg	gacaaaatac	ctggttacct	aggccgtgcc	ggcacgttaa	2100
ccgggctgca	tccgatgcaa	gtgtgtcgtc	gtcgcagagc	tcgcgagctc	ggacatgagg	2160
ttgccccgta	ttcagtgtcg	ctgatttgta	ttgtctgaag	ttgtttttac	gttaagttga	2220
tgcatgcaa	ttaatcacat	acctgcgtca	taattgatta	tttgacgtgg	tttgatggcc	2280
tccacgcacg	ttgtgatatg	tagatgataa	tcattatcac	tttacgggtc	ctttccgggtg	2340
atccgacagg	ttacggggcg	gcgacctcgc	gggttttcgc	tatttatgaa	aattttccgg	2400
tttaaggcgt	ttccgttctt	cttcgtcata	acttaatgtt	ttattttaaa	ataccctctg	2460
aaaagaaagg	aaacgcacag	tgctgaaagc	gagctttttg	gcctctgtcg	tttcctttct	2520
ctgtttttgt	ccgtggaatg	aacaatggaa	gtccgagctc	atcgctaata	acttcgtata	2580
gcatacatta	tacgaagtta	tattcgatgc	ggccgcaagg	ggttcgcgtc	agcgggtgtt	2640
ggcgggtgtc	ggggctggct	taactatgct	gcacagagc	agattgtact	gagagtgcac	2700
catatgcggt	gtgaaatacc	gcacagatgc	gtaaggagaa	aataccgcat	caggcgccat	2760
tcgccattca	ggctgcgcaa	ctgttgggaa	gggcgatcgg	tgccggcctc	ttcgtatta	2820
cgccagctgg	cgaaaggggg	atgtgctgca	aggcgattaa	gttgggtaac	gccaggggtt	2880
tcccagtcac	gacgttgtaa	aacgacggcc	agtgaattgt	aatacgactc	actatagggc	2940
gaattcgagc	tcggtacctg	gggatcctct	agagtgcacc	tgacggcatg	caagcttctc	3000
ttgtgccggt	tgtacgctgt	caggtcacac	tggtagatta	ggcagggcac	agatgccag	3060
agcagaggga	actttccttg	gggattcaac	acgtgcaagt	cttaggggct	ggcaaactct	3120
gccctcagct	agagaggggt	cttttatttg	agaccagaat	cacctgagca	tcctcctgtc	3180
cccagctgtg	tccagcctgt	ctgcagggac	atcctgagag	gaccaggctc	tcccctcatc	3240
cacctgccta	agtgccactc	tgaacctgt	ccacctgtgc	cgtggagggg	cgtgacctca	3300
agctgctcag	ccagcagcag	gcttgccct	ggggggcagc	agagaccag	gtggctgtgg	3360
ggtgggtgct	tcgtggcgtg	gttctgaaac	ttcgttgga	gtgtgtggac	agtgccttgc	3420
ctgttctctg	tgggacctta	tttagaaacg	aggtctgagt	tactgggggt	catcactgtg	3480
ttctgatggc	ccagctgtgt	ggaggccgct	gtgcagcccc	atccaaggag	ccagggccct	3540
gggtctagcc	gtgaccagaa	tgcatgcccc	ggaggtgttt	ctcatctcgc	acctgtgttg	3600
cctggtgtgt	caagtggctg	tgaactctg	tgtagctct	tggtgttcct	gaaagtgcc	3660
ccgggtctca	ggcctcagaa	ccagggtttc	ccttcatctc	ggtggcctgg	gagcatctgg	3720
gcagttgagc	aaagagggcg	attcacttga	aggatgtgtc	tggccctgcc	taggagcccc	3780
ccggcacggt	gctggggcct	gaagctgccc	tcgggtggtg	gagaggaggg	agcgatgaag	3840
tggcgtcgag	ctgggcagga	agggtgagcc	cctgcaagg	gggcatgctg	gggacgctga	3900
gcagcatggc	cagcagctgg	gtctgcagcc	tggtagccgg	cgggacttgt	ggttggggct	3960
ggtttgtggc	caggagaggg	gctggcagga	gacaaggggg	actgtgaggc	agctcccacc	4020
cagcagctga	agcccaatgg	cctggctgtg	tggctctcag	ctgcgtgcat	aacctctcag	4080
tgcttcagtt	ctctcatattg	taaaatgagg	aaacaaacag	tgccagcctc	ccagaggtgt	4140
catgaggatg	aacgagtgc	catgtagcat	gggctgggtg	cgtgtcacct	aacatcacca	4200
gcctttgcaa	ggagagccct	gggggcctgg	ctgagtattt	cccttgccc	gcccacccca	4260
ggcctagact	tgtgcctgct	gcaggccctt	gaccttgac	cccattgcac	ctgtctccac	4320
aggagccgag	gaggtgctgc	tgtggcccg	gcggacggac	ctacggagga	tctcgtgga	4380
cacgcccggac	ttcaccgaca	tcgtgctgca	ggtggacgac	atccggcacg	ccattgccat	4440
cgactacgac	ccgctagagg	gctatgtcta	ctggacagat	gacgaggtgc	gggccatccg	4500
cagggcgtag	ctggacgggt	ctggggcgca	gacgctggtc	aacaccgaga	tcaacgaccc	4560
cgatggcatc	gcggtcgact	gggtggccc	aaacctctac	tggaccgaca	cgggcacgga	4620
ccgcatcgag	gtgacgcgcc	tcaacggcac	ctcccgcaag	atcctggtgt	cggaggacct	4680
ggacgagccc	cgagccatcg	cactgcaccc	cgtgatgggg	taagacgggc	gggggctggg	4740

032796-132.ST25

gcctggagcc	agggccaggc	caagcacagg	cgagagggag	attgacctgg	acctgtcatt	4800
ctgggacact	gtcttgcata	agaaccggga	ggagggcttg	ttaaaacacc	ggcagctggg	4860
ccccaccccc	agagcgggtga	ttcaggagct	ccagggcggg	gctgaagact	tgggtttcta	4920
acaagcacc	cagtgggtccg	gtgctgctgc	tgggtccatg	cgtagaaagc	cctggagacc	4980
tggagggagc	ccttgtttcc	cctggcttca	gtttcctcat	ctgtagaatg	gaacgggtcca	5040
tctgggtgat	ttccaggatg	acagtagtga	cagtaagggc	agcctctgtg	acactgacca	5100
cagtacaggc	caggcctctt	tttttctttt	tttttttttg	agatggagtc	tcactctgtc	5160
gcccaggctg	gagtgcagtg	gtgtgatctc	agctcactac	aacctctgcc	tcctgggctc	5220
aagtgattct	cctgcctcag	cctcctgagt	agctgggatt	acaggtgcct	gccactgtgc	5280
ttggctaata	tttgtatttt	tggtagagat	ggggtttcac	cgtcttgccc	aggctggctg	5340
caaactcctg	acctcagggt	atccacctgc	ctcagcctcc	caaagtgtct	ggattacagg	5400
catgagccac	cacgcccggg	caggccaggc	ctcttttgaa	cactttgcac	accatgggtc	5460
ttttcatcca	ggggggtagg	tacagtgtga	cagttgagga	cactgaagcc	cagagaggct	5520
cagggaactg	cccagggtca	cacagcagga	tgtggcagggt	gtggggctgg	gcctggcagc	5580
gtggctccag	ctttccagca	tagaaatctg	tgaagcaga	tagtttgtcg	gtcggtaggg	5640
gagactttct	gagacccgcc	ccagcggctc	agagggtagt	agccaggggc	cttcctgggg	5700
gctcataacc	cagaacactg	aatgggaaaa	ccctgatgga	ggaggcgag	tggagctgtg	5760
ggtgccgatg	ggaagtccca	gaggagctgg	gaggtcagta	gcggtgctgc	cctctgtgga	5820
gcacttagtg	ggcaccagggt	gtgtttccag	gttcattggcc	ctgggacctg	aagctcaaaa	5880
ggtgaagtaa	cttgcccagg	gcacccgtcg	ggcagcggcg	ggcagaggat	ttgtgggctg	5940
tggagcctgt	gctcgtggcc	cagccctggg	ggttgtgagt	gtgctggccg	gggagctttt	6000
cctgcaagtg	gactggtgtc	taggagccag	catgtcaggc	agcaggcagc	gggagtgcag	6060
caggcagcgg	gagcacagca	ggcagagggc	ggggctcgag	cagccatccg	tggaccctgg	6120
ggcacggagg	catgtgggag	agggctgctc	catggcagtg	gctgaagggc	tgggttgtgc	6180
cccagggagg	gtggatgagg	gtaagaagtg	gggtccccag	gggctttagc	aagaggaggc	6240
ccaggaactg	gttgccagct	acagtgaagg	gaacacggcc	ctgaggctag	gagcttggct	6300
aagtcactgt	ctacatgggc	ctcgggtgtc	tcactctgtg	aaaagggaag	gatggggaag	6360
ctgactccaa	ggccctcctt	agccctgggt	tcactgagct	gaggatccca	gggacatggg	6420
cttggcagtc	tgacctgtga	ggtcgtgggg	tccagggagg	ggcaccgagc	tggagcggg	6480
aggcagaggg	gctggcgggc	tgggtcagac	acagctgaag	cagaggctgt	gacttggggc	6540
ctcagaacct	tcacccctga	gctgccaccc	caggatctgg	gttcctcctt	tggggggccc	6600
cagggaaaca	gtcacctgtc	ctttgcatag	gggagccctt	cagctatgtg	cagaagggtt	6660
tgetctgccc	cttcctccct	ctaggtgtct	agctcctcca	gcccactagt	cagatgtgag	6720
gctgccccag	accctgggca	gggtcatttc	tgtccactga	cctttgggat	gggagatgag	6780
ctcttggccc	ctgagagtcc	aagggctggt	gtggtgaaac	ccgcacaggg	tggaggtggg	6840
catccctgtc	ccaggggagc	ccccagggac	tctggctact	gggcttgccg	ctggcatgct	6900
cagtccctca	gcacttactg	acaccagcat	ctactgacac	caacattttac	aaacaccgac	6960
attgaccgac	accgacattt	accgacactg	acattttacca	acactgttta	ccaacactga	7020
catctactga	cactggcatc	taccaacact	gacattttacc	gacactgaca	tttaccaaca	7080
ctattttacca	acactgacat	ctactgacat	tggcatctac	caacaccaac	attttaccgac	7140
accaacattt	accaacactg	aaattttaccg	acaccgacat	ttaccgacac	cgtttaccaaa	7200
caccgacgtt	taccgacacc	gacattttacc	gacactgata	tttaccaaca	ctgacatcta	7260
ctgacgttgg	catctactga	caccgatgcc	agcatctacc	aacaccgaca	tttaccaaca	7320
ctgacattta	ctgacactga	tatctactga	cactggcatc	tactgacacc	aacattttacc	7380
aacaccagca	tctaccaaca	ccgacattta	ccaacaccag	cattttacca	caccgatgtt	7440
taccaacgcc	gacgttttacc	gacgccagca	tctaccaaca	ctgacattta	ccgacaccga	7500
cattttaccga	cactgacatt	tactgacact	gacatctact	gatactggca	tctaccgaca	7560
ctgatattta	ccaacgccag	catctactga	cactgatgtt	taccaacacc	gacattttacg	7620
agcaccgaca	tttactgaca	ccaatattta	ctgacatcaa	cattttagcca	tgtgatgggg	7680
gccggcttgg	gggcaggcct	tgtctttggc	actggggatg	ctgcagagac	cagacagact	7740
catggggtca	tggacttctg	cttctttctc	agcctcatgt	actggacaga	ctggggagag	7800
aaccctaaaa	togagtgtgc	caacttggat	gggcaggagc	ggcgtgtgct	ggtcaatgcc	7860
tccctcgggt	ggcccaacgg	cctggccctg	gacctgcagg	aggggaagct	ctactgggga	7920
gacgccaaga	cagacaagat	cgaggtgagg	ctcctgtgga	catgtttgat	ccaggaggcc	7980
aggccagacc	acccctgca	gccagatgta	cgtattggcg	aggcaccgat	gggtgcctgt	8040
gctctgctat	ttggccacat	ggaatgcttg	agaaaatagt	tacaatactt	tctgacaaaa	8100
acgccttgag	agggtagcgc	tatacaacgt	cctgtgggtta	cgtaagatgt	tatcattcgg	8160

032796-132.ST25

ccaggtgcct	gtagacacag	ctacttggag	actgaggtgg	gaggatcgct	ggagtccaag	8220
agtttgaggc	cagcccgggc	aaaggggaca	caggaatcct	ctgcactgct	tttgccactt	8280
actgtgagat	ttaaattatt	tcacaatata	aaattaagac	aaaaagttaa	tcacatatcc	8340
actgccctgc	ttaagacaga	aaacatgggt	gttgttgaag	ccagaggcag	ctgctggcct	8400
gagtttggtg	attggttcct	aagcagttga	aggcagtttt	gtttttccat	agatgtctgt	8460
tctccctttg	ctgggtgcag	cctcgccctg	ctgctgtggt	cgggtttcag	tggcctcgtc	8520
ccgtggacgc	agcctcgccc	tgcgctgtg	gtcgggtttc	agtggcctcg	tcccgtggac	8580
gcagcctcgc	cctgctgctg	tggtcgggtt	tcagtggcct	cgtcccgtgg	acgcagcctc	8640
gccctgccgc	tgtggtcggg	tttcagtggc	ctcgtcccgt	ggacgcagcc	tcgccctgcc	8700
gctgtggtcg	ggtttcagtg	gcctcgtccc	atgggcgtgc	tttggcagct	ttttgctcac	8760
ctgtggagcc	tctcttgagc	ttttttgttt	gttgtttgtt	tttgtttgat	tttgtttgat	8820
tgtttgtttt	tgtttgtcgt	gttgtttgcc	aggctggagt	gcagtggcgc	gatctcagct	8880
cactgaaacc	tctgcctcct	tgggttcatt	ccattctcct	gcctcagcct	cccacatagc	8940
tgggattaca	agtgcgcgcc	accacgcctg	gctaaatttt	gtatttttag	tagacagggg	9000
gtttcaccat	gttggtcagg	ctggtctgga	actcctggtc	tcacatgata	cacctgcctc	9060
ggcctcccaa	agtgttggga	ttacaggcgt	gagccaccgc	gcccagcctc	tgttgagcat	9120
attttgaggt	tctcttgggt	ccagtgtat	gtacatgtgt	ccccatcgca	ccatcgctac	9180
ccattgaggt	gacattgggt	cctctcctcg	gggtggatgt	ctccctctgt	ttccagcaac	9240
ttctgaagga	ttttcctgag	ctgcatcagt	ccttgttgac	gtcaccatcg	gggtcacctt	9300
tgtctcctc	agggctccca	ggggaggccc	gaatcaggca	gcttgacagg	cagggcagga	9360
tggagaacac	gagtgtgtgt	ctgtgttgca	ggatttcaga	ccctgcttct	gagcgggagg	9420
agtctcagca	ccttcagggt	ggggaaccca	gggatggggg	aggctgagtg	gacgcccttc	9480
ccacgaaaac	cctaggagct	gcaggtgtgg	ccatttctcg	ctggagctcc	ttgtaaatgt	9540
tttgtttttg	gcaaggccca	tgtttgcggg	ccgctgagga	tgatttgcct	tcacgcatac	9600
ccgctaccgg	tgggagcagg	tcagggaactc	gcgtgtctgt	ggcacaccag	gcctgtgaca	9660
ggcgttggtc	catgtactgt	ctcagcagtg	gttttcttga	gacagggtct	cgctcgctca	9720
cccaggcgag	agtgcagtg	cgcaatcacg	gctcgtgtga	gcctcaatct	ccctgggctc	9780
aggtgatcct	cctgcctcac	cctctgagta	gctgggacta	cagacacata	ccaccacacc	9840
cagctagttt	ttgtgtattt	tttgtggggg	gagatggggg	ttcgtgtgtg	tgcccaagct	9900
gatctcaaac	tcttgaggca	caagcgatcc	acctgcctcg	gcctcccaaa	gtgctgggat	9960
gacaggcata	agccgtcaca	cgcagctcaa	tgattttatt	gtggtaaaaa	aaacatagca	10020
caaaattgat	gatttttaacc	attttaaaagt	gaacagttca	ggctgggcgt	ggtggcttat	10080
gcttgaatac	ccagtacttt	gagaggctga	gggtggcgca	tcacctgagg	tcaggagt	10140
gagaccagcc	tggccaacat	gatgaaatcc	agtctctact	aaaaatacaa	aaattagccg	10200
ggcatggtgg	caggtgcctg	taatcccagc	tactcgggag	gctgaggcag	gagaatcgct	10260
tgagcccggg	aggtggaggt	tgcagtgatc	tgagatcatg	ccactgcact	ccaatctgtg	10320
tgacagagca	agactctgtc	ttgaaaaata	aataaataaa	aaaaatttta	aaaagtgaac	10380
aattcagggc	atttagtagt	aggacaatgt	ggtgcaggta	tctctgctac	tatctacttc	10440
tagaacactt	tcttctgccc	tgaaggaaac	cccatgccca	ccggcactca	cgcccattct	10500
cccctctctc	ccagcctctg	tcaaccacta	atctactttc	tgtctctggg	ggttcacttc	10560
ttctggacgt	tttgtgtgac	tggaaatcctg	caatatgtgg	tccctgcgtg	tggcttcttt	10620
ccatagcatt	gtgttttcca	gattcaccca	cacattgtcg	cacgttatca	gaatctcatt	10680
cctgactggg	tgcagtgggt	taggcctgta	atcctaaccat	tctgggaggc	caaggcggga	10740
cgatcacttg	aggcaggagt	ttgagaccag	cctggccagc	ctagcaagac	cccagctacc	10800
aaaaaatttt	aaaagttaac	tgaacgtggt	ggtggtgggc	acttgtggtt	cccagctacc	10860
tgggagcttg	aggtgggagg	atcgcttaag	ccagaggagt	caaggctgca	gtgagctatg	10920
atcgaccac	tgcactccag	cctggacaac	agagcaagac	cctgtctgaa	aaaaaaaaa	10980
aaaaaaaaaag	ttcctttctt	tttgtggctg	gatgacatcc	cattgtatgg	ccacagcaca	11040
ttttgtttgt	ctgttttatcg	ggtggtgggc	agtgttttcc	accttttgtc	tcctgtgaat	11100
aatgctgctg	tgaacatttg	aattcaagtt	tttgtttgaa	cacctgttgt	gaattatttg	11160
gatatatgtg	taggggtagg	attgctgagt	cctatggtaa	tgtaggttt	gacttactga	11220
ggaaccatta	aactgttttc	aacagtggct	gcgccgttct	gcatccccac	cggcagtggt	11280
tgagggttct	gactttacct	cctcacaac	gcttcttttc	catttaaaaa	aatattcagc	11340
caggtgctct	ggctcacgcc	tgtaatccca	gcactttggg	aggccgtggc	gggcggatca	11400
cctgaggtca	ggagttcgag	acgagcctgg	ccaacatggt	gtaaccccat	ctctacccaa	11460
aatataaaaa	ttagccgggt	gtggcagcgg	gcgcctgtaa	tcccagctac	ttgggaggct	11520
gaggcaggag	aatcacttga	accggggagg	cagaggttgc	agtgagccaa	gatcgcgcca	11580

032796-132.ST25

ctacactcca	gcctgggtga	caagagtga	actccatcta	aaataaaaca	aaaataaaaa	11640
taaataaaaa	tttattaaaa	cattcatcac	agccagccta	gtgggtgtcc	catgtggctt	11700
tgcctcgcat	ttccctgata	actaggatgc	tgagcgtctt	gtcccaggct	tgccacacct	11760
cagcactttg	agatacgtcg	cacagtcctc	atttgcgaac	gagaaatgag	gtttagggaa	11820
cagcagctgt	gtcatgtcac	acagcgagca	gggggtctct	gagccgtctg	acccacacag	11880
cgaccaagct	ccaatcctta	ccgcctccta	gtgttggtga	tgtagcccag	ggtgctccca	11940
cattttttcag	atgagaacac	cgaagctcaa	aacaggagcg	ttttgtccac	attggataca	12000
cgatgtctgt	ggtttggtcc	tgaagtcact	ttatatctca	gtggtccaga	ctggagtagg	12060
acaggggggt	ctggggaatg	gggaaggtgt	ctcaggtgaa	aggaaggaat	tccagattct	12120
ccatactgtc	cttgggaagt	tagaagactc	agaggggtctg	gcaaagtcag	acaaagcaag	12180
agaaatgcag	tcaggaggaa	gcggagctgt	ccaggaacag	gggggtcgca	ggagctcacc	12240
cccaggaact	acacttgctg	gggccttcgt	gtcacaatga	cgtgagcact	gcgtgttgat	12300
taccacattt	tttttttttt	ttgaggtgga	gtctcgctct	cttgcccagt	ctggagtgc	12360
gtggcacgat	ctcggtcac	tgaagctct	gcctcccggg	ttcatgccat	tctcctgcct	12420
cagcctcccg	cgtagctggg	actacaggcg	cctgccaccg	cgcccggcta	atttttgtat	12480
ttttagtaga	gatgggattt	cactacatta	ggcaggatgg	tctcgatctc	ctgacctcat	12540
gatccgcccc	tctcggtctc	ccaaagtgtc	gggattacag	gcgtgagcca	ccgcgcccgg	12600
cccgatttcc	cactttaaga	atctgtctgt	acatcctcaa	agccctatac	acagtgtctg	12660
gttgctatag	ggaatatgag	gcttacaggc	catggtgtctg	gacacacaga	agggacggag	12720
gtcaggaggt	agaaggcg	agagagggaa	caggcggagg	tcacatcctt	ggctttcaaa	12780
atgggccagg	gagagacacc	ctctgagcat	ggtaggacag	gaaagcaaga	ttggaacaca	12840
ttgagagcaa	ccgaggtggc	tgggcgtggg	ggcttacgcc	tgtaatccca	acactttgga	12900
aagctgaggt	gggtggattg	cttgaggcca	ggagttcaag	accagcctgg	ccaacatggt	12960
gagacccccgt	ctctactaaa	tatacaaaaa	ttagccaggc	gtgatggtgc	atacctgtaa	13020
tcccagctgc	ttgggaggct	gaggcaggag	aattgcttaa	acctgggagg	cggaggttgc	13080
agttagccga	gatcccccca	ctgcaactcca	gcctgggcca	cagagtgaga	ctccatctca	13140
aaaaaaaaaa	aaaaaaaaaga	taaaaagacc	aaccgaggaa	ttgaagtggg	ggggcgctcac	13200
agtagcagaa	gggggatcgt	ggagcaggcc	accctgtggg	catgcaactg	aagctcatta	13260
cctgacgatt	tggagctcat	cactgggggc	ctaaggagaa	tagatactga	aggatgagga	13320
gtgatggcgc	ggggcacggg	tgtctttggg	ggccagaact	tggggactgc	tgggggtgcct	13380
cactgcaggc	cttctcagcg	ccctttatat	gcttacacag	gctgtttcta	agagggggat	13440
acattgcata	agcgttttca	gactacctca	tcattgggtcc	ctttctttac	cctctgtggc	13500
cctggtggcg	cactctctgg	gaaggtgcag	gtggatgcc	agaccgccc	tgccatccac	13560
ctgcacgtcc	agagctgact	tagcctcgag	attgctgctg	gcacctctg	ccccgggaca	13620
cctcgatgt	gcccgtggag	atgctggctc	tgtgttttct	gctggagtgt	ggtgcgtctt	13680
ttcctcctgc	aagtggccac	cgctcttggg	tatgtcctca	ggcttctgcg	agtcattggt	13740
gcttctcagg	tccttgccca	gcgccaggag	caaaccctcc	tggcactttg	ttcaggggtg	13800
gatgcgccag	tgttcctgct	gtggaccccc	atctcacatg	agggctcttg	gcctgcaggc	13860
tcgttcagga	aacaccgct	gagtacgcag	tgtgtgccag	ctgtgtccca	ggcaatggcg	13920
gggacagtgg	ctgctgctgg	ggttgtggtg	gcttctgggg	actctgggga	cagctgaggt	13980
gcaaggagcc	acggctcctt	gaggatgcag	ttggactcca	ggtggaagg	atggttgggg	14040
gaggtataaa	tggggtcagg	gaggagacac	atttggaaca	atgggaacat	ttttaagatg	14100
ctatgtcggg	aggcaacaag	gtggccaacc	caggtgctga	ggagcccaca	ccagccctgg	14160
acgtgttttg	ccgctcacct	ttgctgggga	gtggtgggag	agaggattcc	gttccacgtg	14220
gtggtgtgcg	cagctgggct	gtgtggagct	gggcgctagg	aggaaggtgc	tttctgcggg	14280
gctagccggg	ctctgccttt	gaacacaatc	aggctccagg	ttttcagcat	ccagtgcattg	14340
agaggacttc	acgggcagct	gtggctgata	ccttgatgaa	ttgggagaag	aacaaaggtc	14400
tatgaaatga	ggtttcatgt	agatggcatt	agagacgccc	acaacagatt	tacagagtgg	14460
agcggagacg	gcggatgggt	ctgggaggcc	cctcctgctg	gccttgactg	tgacagctgt	14520
cctgggaatc	agcttccagg	ccgccccagc	agcctgactg	acacacacag	gggttttagc	14580
cccactcctgc	gaccagctgt	tgccatcatc	agtgcagct	gggagtggcg	gtggttccag	14640
ccctgggcac	cctccccacc	tgtgtgggccc	caccagggc	agtcctgaca	cctacaggtt	14700
gcttgagacc	gcattccgagt	cctgccccac	cacgtgtgaa	gcccagtggt	tcgtgggctg	14760
aggtcccctg	attgcatccc	cacttccctt	ctgcttcaca	tagctgcctc	ttctcacctg	14820
ttttccagcc	tcctgggcta	ggaattccag	tgttgtgctg	gctttgcccc	aggacacctc	14880
cttagccctc	ttcctgagtc	tagagccccg	ggggttgga	gttctggccc	ctgggacacc	14940
tgcagccaca	ctcagcttct	cctgtgagcc	tccagcatgt	cccctcagga	ccaagccctc	15000

032796-132.ST25

acgttcttgc	ctccccgccc	acctgggctc	agccagggga	aggcctggct	gggagcgtct	15060
ccctcttgc	ctgcccttct	cccccttacc	ctgcccttct	ctcctctgcc	ccgccatggc	15120
ttttatatcc	tgtagccaaa	gacatggctg	ttgtgtgaaag	tggcaggggc	tggcatctct	15180
gtgggtctct	gagggccacg	ctccagtgcc	actcttccca	cccgttgccc	gtgccctcat	15240
gctggaggga	cagcccagcc	ctctcccgaa	ccccagcccc	atgtgccag	ctgcccccg	15300
ccctctcccc	tggaaagccg	ggctactcca	gccgtatgcc	atgggtggga	catcctgctt	15360
ccttggcctt	ccagggaagg	tctcttttcc	aaatggcgac	acctgggtccc	tgcttgagg	15420
ctggaagctg	tggcccttgt	atgccccctc	agggctctgtg	cgctcggttg	gcccagagttc	15480
ccatcaccgt	catcatcacc	atcatcattg	tcatttctgt	tgtctgtgag	ccggcctggt	15540
ctcccagagc	agagaccctc	tgagggtccag	cctgagttgg	ggtctccgtg	ctgaccctctg	15600
acggggactc	aggacgtacc	aggtctgggt	caggagtgc	ccccaacct	cgtgcccttt	15660
gacaggcacc	cctgactttt	gctaagtggg	tggaggtgac	atcacttaca	gcgggagtg	15720
tgggacagg	tctgttggct	gcaactgtgt	cccagggatc	tggggagagg	ctatatccct	15780
gggctttggc	actgcagagc	tgtgtgtgtt	tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	15840
tgtgtgtgtg	tgtgtgtgtg	tttgcgtgcg	cgcacatgtg	tataagatct	ttttttatta	15900
catgaagcaa	gataactgtt	gctgtttcct	tttgggtttt	gtgttcaaca	gagtggggtg	15960
cttcttccct	cagacaacag	aactctcccc	tttaaacacg	tgctgtcaga	gggtgggtct	16020
tgggctcatg	tctgtttgca	cagccgagtc	agaggaaaca	cagggttctt	cataaaaaa	16080
ctgcacagca	ggcgactgtc	cagagtgcgc	ctgcaggacg	gcagcagccc	tgccccctcag	16140
agcacagcta	gggtgggctg	ctttgggata	tcccgctcatt	ccctcccagc	tggcagccgg	16200
cggccggccc	attccttggg	gtgctgggtc	ggggggcggtg	cgctgctct	gctcaccctg	16260
ggaatgggac	agaagctggc	agctcggaga	ggacagggct	ggacccttgg	gtggcctctg	16320
gctggaccat	ctcattgtcc	tcagacacag	cctctcgggt	ctagtttcat	ttcctgaaaa	16380
acaagtgcac	agaactagag	caggagtgcg	gagctacggc	ccccgggcca	gatccagccc	16440
tgccacctgt	tttcacacca	tgctcaagct	gagtggtttt	tacatttttt	aattacttga	16500
aaaaaaaaaa	gccaaggag	gtttcatgac	ccatgaaaat	tatatggaat	tcaaaaaaaaa	16560
aaaattatat	ggaattcaaa	tttcagtgtc	cataaataat	ttcttgagac	agggtctcgc	16620
tctgtcacc	aggctggagt	gcagtgtcat	ggcatggctc	gctgtaccct	tgacctccca	16680
ggctcaagcg	atcctcctgt	ctcagcctcc	tgaagtacgtg	ggactacggg	tgtgtgccac	16740
caagcccgcc	taattttttt	tttaattttag	taaagacagg	gtctttctat	gttgcccagg	16800
cttttctgga	actccatctt	ggcctcccaa	agtgtcggga	ttacaggctc	gagccacgga	16860
gcccagcctg	tttttgtttt	ttcaactgata	aagttttgcc	gggtgtggta	gtgtgtgcct	16920
ctagcgattt	gggaggctga	gggtgggagg	tcgcttaagc	ccaggagttt	gaggctgggc	16980
tcaagtgatc	aggaggtgaa	ctatgatcat	gtcattgcat	tccagcctgg	gtgacagagc	17040
aagaacctat	ctcttaaaaa	tatatattta	aaaagtattg	ggtgtgggtg	ctcacgcctg	17100
tgggtcccagc	tacttaggca	tctgaggtgg	gaggatggct	tgagcccagg	agtttgaggt	17160
tgacgcgagc	caagatcggt	tcactacact	ctagcctggg	tgacagagcc	cagaccctgc	17220
ctctttaaaa	aaaaaaaacca	aaaaacatgt	attggaacac	agccatgcct	gttcagtcac	17280
gtgctctcca	tgctgctttc	tgctccagag	acccttatgg	cctgaaagct	gaaaaatattt	17340
tctatccttt	acaaaaaagt	ttgtgtacct	ctgtcctgga	aaattcatct	cccaagttct	17400
cttccggcac	tggcggttct	gggtgtccta	aatttggccc	ctgttatttc	tgaactctgt	17460
tttggctctg	ttccctccca	ggagccagga	caggcacggt	ctctgcatct	tgtccctga	17520
cgcccagagg	cttggctcgg	ctcaggcatt	cttggaaata	tctggctcca	ggaaaggcag	17580
aggctcctg	agtcagccca	gagggaacct	gccccaggtc	tgggggaggc	ctgaccacgc	17640
agagtggctt	ttggccgatg	gttgggccc	tcaagatgtg	ctgaaaagttg	tcctcagaag	17700
gccactttgg	gattccttcc	tccagtatta	gagcaactga	gagctgctca	ttgcaagcct	17760
gatgttttcc	cagttggccg	gggtccaccg	gtgccctggg	attctgggat	ctgggtggaa	17820
agtagggggc	ttgggggagt	gtcctgggtt	ctggaatcca	gggtggcaagt	ggtgaggttc	17880
agggagtggc	ttctgagcca	ccataggggt	ctctgtggga	ggctctgccc	atccaggaga	17940
ttccgcaggc	cctgccggcc	cagagccagc	gtcttgcgct	tgccgaggct	acagccagcc	18000
ccagccgggt	ggaacagccc	gtcgccctct	ctcactttgt	tttggggcca	cctgggagtg	18060
tggagcaagg	gtagagaggg	aggaagtggc	tgccggccgc	tgcccagcac	ccttgtttgc	18120
cttggggcct	ctgtgggctc	ctttttattg	ctcttcaatg	aagccaggga	aatggacttc	18180
cttgccctac	ttcagttcaa	catgtctgga	agtttggtat	taaaattaag	aaagtgtgga	18240
aatagagcaa	gaagagaaaa	atctctccaa	gagataatag	tgacctctga	gctgggcgcg	18300
gtggctcacg	cctgtaaatc	ccagtacttt	gggaggctga	ggcgggcaga	tcacctgagg	18360
tcgggagttt	gtgaccggcc	tgaccaagat	ggagaaaccc	cgtctctact	aaaaataaat	18420

032796-132.ST25

aaataaataa	ataaataaat	acaaaattag	ccaggcatgg	tggcgctgc	ctataatccc	18480
agctaaggca	ggagaatcgc	ttgaacctgg	gaggcaaagg	ttgcagtgg	ccaagatcac	18540
gccattgcac	tctagtctgg	gcaacaagag	tgaaactccg	tctcaaaaaa	aataaataaa	18600
taaaaaataa	aaatagtgc	ctctggccag	gtgtggcagc	tcatacccg	aatcccagca	18660
ctttggaagg	aaggccgaga	tgggcagatt	gcttttagcac	aggagtgtga	gaccagcctg	18720
gccaacatgg	tggaaaccca	tctctacaaa	aatagaataa	aatttaagag	gtaatagtga	18780
ccttttggtg	gatcgaaacc	tggattgctt	tctttttcta	aatgctgatt	cttttctttg	18840
tgggtgttgt	gttctgtgcc	gatgtccctc	ccccagccct	gttattgtga	gtggaagaag	18900
gggaaaggg	tcgcccgcga	ctgtgagccc	ctcctctcac	gctgggtgtc	cttgagagaag	18960
cctgcacttc	ttcattgtac	gccagggtcg	ggtccctccc	tggagtgggt	ctgtgctgct	19020
gggatggggc	caaccctca	gatgttttct	gagtgtcaca	cacaggtgtg	tgcattcatg	19080
gcctttgcgt	gtcttctctg	tgtggaggca	aaaatgtgaa	gaaccctaga	tgattttggg	19140
accagggtcg	catcacctgc	tgttcattgc	acaccggagc	atccaggcat	gggtggagag	19200
ctcagacttc	caggcacggg	cgaggggcat	ggtctaacca	tgttcccggc	cgctgctcg	19260
tcagaaccgc	ctgttgaggag	ctgttatcat	gataccatac	ctgggcccctg	ggctatccga	19320
ttctgactta	attgctccag	gttggggcca	ggcgttgttt	tgctgttttg	ttgtttcttc	19380
tgtgacgtta	gccactgggc	taatctgagc	ccctcagtta	caggtggaga	aactgagacc	19440
catgggggtg	caaggacttg	ccgaggacct	agagcccctt	gggggcagag	ctgaggcggg	19500
gcctggcttt	gggtcccaga	gcttccagtc	cccttcccgc	tctcctaaca	gctttttttt	19560
ttgagacaag	atctcacctc	gtcacccagg	ctggagtgc	atggcatgat	ctcggtcac	19620
tgcaatcttc	gctagctgcg	ttccagcgat	tctcctgcct	cagcctcccg	agcagctggg	19680
attacaggtg	tgtgccgcca	tgcccagctc	gttttttttt	gtacttttag	tagagatagg	19740
gtttcaccat	gttgccagg	ctgatctcga	actcctgacc	tcaaatagatc	cgctgcctc	19800
ggcctcccaa	agtgttagga	ttacaggctg	ggatcacact	gtgcctggcc	ctagcagctt	19860
tgtcctgtgc	catccaacaa	cagatgaccg	aagtctttgt	ttcttaacat	gcattccatc	19920
tgcttacag	ttttgccacc	tgcaaaacag	aggactgttc	gcttttctgg	taagctggaa	19980
atgtaatctg	gtagcaggag	gcctgtggaa	gcttgccctt	aatggccttg	tgtctctttc	20040
atcctgtcct	gagagccgga	gaacttggat	gttgaccta	actcaacctt	cctgttaaca	20100
tacagtctctg	caggctcatg	gatcatcaga	accacgtcct	atctcacgcg	gctgtatgct	20160
tccgttggtt	cagggtgtttt	taccttgaca	gtattttctc	ctcgggtggc	tttgcgggtg	20220
ttgcttttaa	tcagcattga	ctcttcaaga	aaaatatatta	gctgctacat	ctcagaggag	20280
acagggtgga	aagcatctga	gacctgcagg	ctcagactta	gaaccagaag	tgccctcaga	20340
gttcatccgg	ccctgaccca	gcgggaaatg	agttcacaga	gaagcgggag	aactttgccc	20400
caggccctgc	cgttgctcat	aactgcccc	ggtccttaca	tttgctccag	gtcctgcccc	20460
aggccctgca	gttgctcata	actgccccag	gtccttatat	ttgctccagg	tcctgcccc	20520
ggtcctgcag	ttgctctgtg	tgggtgggtg	gatctggagc	cctccgcca	ttgctgcacc	20580
tggggcaggc	attgctaatt	gatcccagga	ctccttccctg	cggagcacgc	cctgggtctc	20640
caggcagccg	ctgcctgtca	gcctgcagtg	gttcgggaga	ggacacctgc	ttgcctgggtc	20700
tgttccaaat	cttgcttctc	atcccagcac	aggtaggggg	tgctatggga	aagggtacct	20760
cagttggccc	tgtcactgct	ctatcagctg	gggacgtggc	atcctagtga	aaacatcatg	20820
gccgggcgcg	gtggctcacg	cctggaatcc	cagcactttg	ggaggctgag	gagggtggat	20880
cacttgaggt	cagaagttcg	agaccagcct	ggtcaacatg	gtgaaacca	tctctactaa	20940
aaatacaaaa	attcgccagg	tgtggtggcg	gttacctgtg	atccgagcta	ctcgggaggg	21000
tgaggcagga	gaatcgcttg	aacctgggag	tgggagcttg	cagtgagccg	agatcttgcc	21060
actgcactcc	agcctgggca	acagagttag	acgctgtctc	aaaatctcaa	acaaacaaac	21120
aaacaaaaaa	caaacaaaca	aagcgtcatt	tatccagcac	ccctggggaa	ccatgctacc	21180
tgggtgttta	tggtagcttg	caagggtgcag	gtgaagtgtc	tgctcttggg	cattgaaccc	21240
gtcttggttg	gggcagctca	ggccccaggc	agggtccggg	ttggctctcg	ttgggtgtggc	21300
cctggcccat	ccagacctat	atttctgccg	tcctgcaggt	gatcaatgtt	gatgggacga	21360
agaggcgagc	cctcctggag	gacaagctcc	cgacattttt	cgggttcacg	ctgctggggg	21420
acttcatcta	ctggactgac	tggcagcgcc	gcagcatcga	gcgggtgcac	aagggtcaagg	21480
ccagccggga	cgtcatcatt	gaccagctgc	ccgacctgat	ggggctcaaa	gctgtgaatg	21540
tggccaaggt	cgtcgggtgag	tcgggggggt	cccaagccat	ggctcagcca	tgacagacttg	21600
catgaggagg	aagtgcaggg	tccatgcctg	ggcataagtg	ttgagctcag	gtgccccgac	21660
ctgggggaagg	gcaggacagg	aaaggtgaca	gtatctggcc	aaggacagat	gggaagggac	21720
caagggagct	gattagggag	tggttatgga	ctaggaatgt	cggttaacaat	ggttagaaag	21780
tgactaacat	ttgttgagca	cctgctgtgt	gcccgccct	ggccgggagc	cttcgtgccc	21840

032796-132.ST25

acagtgaccc	cgtctgcaaa	tgtagtctct	tgcctactc	gcactgggga	gcaggacgca	21900
gagccgtgca	tctcacaggt	gccaaagctca	ggactccctc	ctgggtctgc	ctgggtctggg	21960
ctgtgcttgt	tgccctgtg	gccacgcgat	gtgcaccttc	cacctgaaag	ccaggatctt	22020
caggacgctc	cccaggagg	tcgttgtctg	gcacaatgat	ttgtctcttc	ctgaaaaggt	22080
gacagagtta	cactggagag	agcagcatcc	aggtgcgga	gggacaggcc	tggggctcgc	22140
gggcagggac	tctgtgtcct	gccgggggtcc	cacactgcac	ctgcttgtca	gaggcactca	22200
gtcaatcttt	gctgatgaag	gatgagagga	cagaggacgt	gatgcttgct	gctgcattgc	22260
ctgcagtcc	gggtgagatg	cccgggttga	ctctgtgcc	cgtcgggtgg	atgtgatgtc	22320
agatccccgg	ctttaaaata	cgaggagct	gggaattgag	ggagcagggt	ggggcagaaa	22380
gcacagcccc	gtggaagcct	ggagctgagg	cagtgtgggc	gacccctgga	gcagtgagt	22440
cttccctcat	ggccttcac	gcaccctgca	gtcctcatgt	aggggatgcc	atccatgaat	22500
ttagtcttcc	cagcctcctt	taaaaacgcg	ttcatgtctg	ggccggggca	gtgcagtggc	22560
tcacatctga	aatcccacca	ctttgggagg	ccgaggcggg	tggatcatga	ggtcaggaga	22620
tcgagaccat	cctggctaac	aaggtgaaac	cccgtctcta	ctaaaaatac	aaaaaattag	22680
ccgggtgcgg	tggcgggcgc	ctgtagtccc	agctactcgg	gaggctgagg	caggagaatg	22740
gcgtgaaccc	gggaagcggg	gcttgcaagt	agccgagatt	gcgccactgc	agtcgcgagt	22800
ccggcctggg	cgacagagcg	agactccgtc	tcaaaaaaaa	aaaaaaaagt	acaaaaaaa	22860
aaaaattagt	ctgggtgtgg	tatcacgcgc	ctataatctc	actactcgag	aggctgaggc	22920
ggagaattgc	ttgaaccag	gaggtagagg	ttgtagttag	cccgtatcgt	accactgcc	22980
tccacctggg	caatagagcg	agactctgtc	tcaaaaagaa	aaaaaaaaaa	agaacattta	23040
tgccagggtgt	ggtggctcat	gcctgaaatc	ccagaacttt	ggaagactga	ggcaggagga	23100
tcacttgagc	ccagaaattt	gagagtgtct	tccctgggca	acatagagag	acctcatctc	23160
taccagaaaa	aaaaaaatta	gcccggcatg	gtggcatatc	cctgtgggtcc	cagctactta	23220
gggggctgac	gtggcaggat	cacctgagtc	tggaggcaga	ggttgaagtg	agctgagatc	23280
atgccactgc	actccagcct	gggtgacaga	cagagaccct	gtctcaaaaa	aaaaaaaaaa	23340
aaaaagcatt	tactatccac	catggaaggt	gagactgacc	tgtgagtgat	tgttcaaaga	23400
acaaaaata	aacccagag	ataagacaaa	aggtgacctc	catgggggtg	tgatttaaag	23460
ctgagaaatt	gggtctcttc	cccctcccct	ctcaccctgt	ggtttgctaa	aggagatggg	23520
aaaaaggatt	cttttttttg	ctgaaatatt	taacactaaa	ttaaagccaa	ttttaacagc	23580
actttgggtg	atgagtgaag	ttaacagact	ggccaaaaat	aaacgaacgg	tctgtactat	23640
gtgaaaaaga	ggcagctttg	gccatgctgg	gccaatgtga	gttttcaggg	ttgctgggaa	23700
tgtctgtgaa	tcggaggaag	ggcctagctg	ggactctcag	gagccaaggc	cctgaggggc	23760
aacttgccctg	gtccctgccc	tgaggcgttc	actgctttct	tcctgggcca	gatcacaggc	23820
ccggaggctg	gacctgagg	ctggcactct	tgccgagctg	ctccctgact	tcctgaccat	23880
gctcctttca	gcagccttgc	tgcactttag	tttccttgaa	tgaaaaatgg	ggatgagaat	23940
agctcctacc	tccaagggtga	atggagttag	ttcggacagg	tgactccctg	ggaccagtgc	24000
ctggcgccctg	acaagggtcca	gtcagagccc	gcactgctgt	tactgatacc	cttggctgta	24060
ccaggggaga	acttggttgc	cattgccagg	tgttctccca	ccacccccac	tactgtccct	24120
gtttgatgtg	tggcgggaat	aaagctgtgc	acattggagc	ttttggcaca	tcctggcttt	24180
caggtgaaag	gtgcgtgtgt	gtttgagggt	ttagcctggc	caaccagacc	atgaggctcg	24240
acctgacctg	gggtgagtc	ctgagctcgg	caccctgag	ctgtgtggct	cacggcagca	24300
ttcattgtgt	ggcttgccg	cacccttcc	cctgctgggc	tgttgatgtt	tagactggag	24360
cctctgtgtt	cgcttccagg	aaccaaccgc	tgtgcggaca	ggaacggggg	gtgcagccac	24420
ctgtgcttct	tcacacccca	cgcaaccggg	tgtggctgcc	ccatcggcct	ggagctgtctg	24480
agtacatga	agacctgcat	cgtgcctgag	gccttcttgg	tcttcaccag	cagagccgcc	24540
atccacagga	tctccctcga	gaccaataac	aacgacgtgg	ccatcccgct	cacgggcgtc	24600
aaggaggcct	cagccctgga	ctttgatgtg	tccaacaacc	acatctactg	gacagacgtc	24660
agcctgaagg	tagcgtgggc	cagaacgtgc	acacaggcag	cctttatggg	aaaaccttgc	24720
ctctgttct	gcctcaaagg	cttcagacac	ttttcttaaa	gcactatcgt	atttattgta	24780
acgcagttca	agctaataca	atatgagcaa	gcctatttaa	aaaaaaaaaa	gatgattata	24840
atgagcaagt	ccggtagaca	cacataaggg	cttttgtgaa	atgcttgtgt	gaatgtgaaa	24900
tatttgttgt	ccgttgagct	tgacttcaga	cacccaccc	actcccttgt	cggtgcccg	24960
ttgctcagca	gactctttct	tcatttatag	tgcaaatgta	aacatccagg	acaaatacag	25020
gaagactttt	ttttttttt	tttgagacag	agtcttactc	tgttgcccag	gctggagtag	25080
cgtagcgtga	gctcagctca	ctgcaacctc	cgctcccgag	gttcaagcga	ttcttctgcc	25140
tcagcctcct	gagtagctgg	gactacagac	atgcaccacc	acaccagct	aattttttt	25200
atatttttag	tagagacagg	gtttcatcat	gttgccagg	ctggtcttga	actcctgacc	25260

032796-132.ST25

tcaggtgatc	tgcccgcctc	ggcctcccaa	agtgctgaga	taacaggtgt	gagccaccgt	25320
tcccggcata	ggaaaacttt	ttgccttcta	aagaagagtt	tagcaaacta	gtctgtgggc	25380
tggccttctg	attctgtaaa	gaaagtttga	ttggtggctg	gggtgcggtg	ctcacacctg	25440
taatcccatc	actttgggag	gccgacgtgg	gcataatcacc	tgatgtcggg	acttcgagac	25500
cagcctcacc	aacgtggaga	aaccccgctc	ctactaaaaa	tacaaaaaaa	aaattaaccg	25560
ggcatggcgg	cgcctgcctg	taatcgcagc	tactcaggag	gctgaagcag	gagaattgct	25620
tgaacctggg	aggcggaggt	tgtggtgagc	tgagatggca	ccattgcact	ccagcctggg	25680
caacaaaagt	gaaactccgt	ctcagaaaaa	aaaaagtttg	attggtgtaa	ccaaagcgca	25740
tttgtttatg	gattgtctgt	ggcagctttt	gttctgccga	gatgagttgt	gacagatctg	25800
tatgggctct	aaagcctaaa	acatgtgcc	tccgcccctt	tacagaaaaa	gtgtgctgac	25860
ctctgttcta	aagtattgga	caactacaat	gtttgtctcat	ttattattct	atgatttggt	25920
ttctgctttt	tgttggtgtt	gttggtgttg	agatagggtt	tccctctgtc	actcaggctg	25980
gagtgcagtg	gtgtaatctc	agctcactgc	agcctcgacc	tcctgggctc	tagtgatcct	26040
ctcatctcag	cctccctagt	agctgggact	acaggcacac	accaccactc	ctggctgatt	26100
tttttttttt	tttttttttt	ttgtggagac	agggtttccg	catgttgccc	aggctggttt	26160
caaactccta	ggctcaaaca	cccacctcag	cctcccaaa	tgctgggatt	acaggcgtga	26220
gccaccatgc	ccagcctatt	ctactgtttg	tattacatat	ctttaaaaga	ttttttatga	26280
ctttaagtca	caagggttct	ttgtagaaaa	aaatatatat	ataggaaa	ataaaaaaga	26340
agtaaaaatt	gtccataacc	tctccagcca	gagacgaccg	ttgctgacac	ctcagcatat	26400
tgcccttaag	tcttttttct	ctaagatagc	atttctcttc	atcacagtca	tatgctacgc	26460
agaattctgt	atcctgattt	tttcaactga	cattacaaca	ggtatttgat	ggcgtgtga	26520
caaactcttt	ggcacaatct	tttaaagtga	tgaaatactc	cactgcacag	atgtttgctt	26580
ttaggcttaa	ctgttctttt	atgttgctg	tgctggttac	agccgggcac	agtggctcat	26640
gcctgtaatc	acaacacttt	gagagggtga	ggcaggagga	tcacttgagc	ccagaagtgt	26700
gagaccggcc	tgggcaacat	agtgagacc	catctctaca	aaaaactttt	ttaataagtc	26760
gggcgtagtg	gtgcatagct	gtagtccag	ccaccaagga	ggctgagttg	ggaggattgc	26820
ttgagcccca	ggaggttgat	gctgcagtga	cctgagatta	ctccactgta	ctccaacctg	26880
agcgacagag	caagacttgt	ctggggaaaa	aaaaaaaaaa	aatatatata	tatatatata	26940
tatatataca	tatatacata	cacgcacaca	cacataatat	aaaaatatat	atttataaat	27000
atataatata	taataataaaa	atatatatatt	ataaataaaa	tttataaatt	atatttataa	27060
gtaaatatat	aatatataat	ataaaaaat	atattatata	atatataata	aaatatataa	27120
tataaaaaata	tatatattata	aataatatat	aatacatact	tataagtata	tatttataat	27180
atatgtaatg	tatatattttt	aatgtatgat	atataatata	catttataaa	tacacattta	27240
tattattttta	tataaaatat	atataaaatc	tccaagttgc	tttttccaaa	aagggtgtctt	27300
gctgcatttc	aaacattcat	ttaaaaactt	gaatgctggt	gatctggtcc	agaatgtgtt	27360
cagtagctgc	tgccagtggc	caagcatctc	gggagatgtc	tacaaaacac	gctggttctg	27420
gcctggcgtg	gtggctcacg	cctgtaatct	cagcactttg	ggaggctgag	gcagggtgat	27480
caactgaggt	ctggatttcg	agaccagcct	tgccagcttg	gtgaaacccc	atctctacta	27540
agaatacaaa	aaaattagcc	aggcgtggtg	gcatgtgcct	gtaatccac	ctacttggga	27600
ggctaaggct	ggagaatcgc	ttgaaccag	ggggcagagg	ttgcagtga	ccgagatcgc	27660
accattgcac	tccaggctgg	gcaagaagag	cgaaactccg	tctcaaaaaa	aaaaaaaaag	27720
atgctgggtc	ctaaaatgtg	gcccttttcc	tcctcacctg	ctgccagacc	atcagccgcg	27780
ccttcatgaa	cgggagctcg	gtggagcacg	tgggtgagtt	tggccttgac	taccccgagg	27840
gcatggccgt	tgactggatg	ggcaagaacc	tctactgggc	cgacactggg	accaacagaa	27900
tcgaagtggc	gcggtgggac	gggcagttcc	ggcaagtcc	cgtgtggagg	gacttggaca	27960
acccgaggtc	gctggccctg	gatcccacca	aggggttaagt	gtttgcctgt	cccgtgcgtc	28020
cttgtgttca	cctcgtatga	gacagtgcgg	gggtgccaac	tgggcaaggt	ggcaggctgt	28080
ccgtgtggcc	ctcagtgtat	agagctgtac	tgatgtcatt	agccttgatg	gtggccagga	28140
ctggttagggc	cctcagaggt	catggagtcc	cttcgtggag	cgggtgctga	ggctgtatca	28200
ggcacagtgc	tggctgcttt	cacctgggcc	gtctcaccga	agtgtccatg	gagcctgcgt	28260
agggtgggta	tctgtgtcga	ttttacagat	gcagaaacag	gctcagagaa	accgagtga	28320
ttccctaagg	tcacataccc	agttagagca	gagctgggccc	aggaagtgtc	gtctcaggct	28380
cctgaccagg	tctccttgc	ttgcactctt	gccaaaacca	tgatccagaa	ctgactttga	28440
ggtccccgga	cctcaggctc	ctccgaaatg	gcctcttgga	ggctgctgag	ccacagctta	28500
ggaccacact	cgagaggcaa	atgtgctttg	agctgccagg	cgtcctgggg	gccctgcctt	28560
gggcacgggg	ttcagacagg	ccccagatgt	gtggggcgctc	tttctggact	tgagttttct	28620
tttctgtgtg	gtggacacag	tgctcacccc	ttaaagcacc	tgtgatgtgt	gcagcagccc	28680

032796-132.ST25

aatccctgcc	tgtcgccctgt	tctgctaggg	aaggaaggaa	gacttcagga	tggcaggaca	28740
acagaaagag	gtccagggtt	tagagcaagg	gcagggtcaaa	cttagaaaaat	tctggaatga	28800
ggatgtgcat	ttcctcttct	ggatctgcta	aaagaagagg	gaaggagggg	ctgctggggg	28860
aggagcccag	agccgagttt	acatccggat	cccgaaggc	ctcccctgcc	ctgaggtctt	28920
gttttgtgat	gtgcttgtgt	ccatcctggt	ttctgccgtg	tccccaacat	ccggccaagc	28980
ttaggtggat	gttccagcac	acactcacc	tgtctgtgca	cctgtttttg	tgtccgtaag	29040
tgggtattta	ctcaccttac	gagtgaacca	ctgtgggaat	tcaggagagt	ggcgagtg	29100
ccaccctgg	agggatatgt	gtgtggcagg	ggtcgagggt	ctcgcccttc	cctgcttcct	29160
gcgcgtggct	ttctccagga	cggggagggc	tgagctgaag	aggtggggac	agttgcgtcc	29220
ccccgccacc	cactgtcctg	cggtgagagc	agactcactg	agcctgccct	tctcccttgt	29280
gccttccagc	tacatctact	ggaccgagt	gggaggcaag	ccgaggatcg	tgcgggcctt	29340
catggacggg	accaactgca	tgacgctggt	ggacaagggt	ggccgggcca	acgacctcac	29400
cattgactac	gctgaccagc	gcctctactg	gaccgacctg	gacaccaaca	tgatcgagtc	29460
gtccaacatg	ctgggtgagg	gccgggctgg	ggccttctgg	tcattggagg	cggggcagcc	29520
gggcgttggc	cacctcccag	cctcgccgca	cgtacctgt	ggcctgcaag	ttccccaacc	29580
tggcaggagc	tgtggccaca	cccagcactg	cccagcagcc	tcacctctg	ctgtgggagt	29640
tgtccccgtc	cacctctggg	tgcctttgct	gcagttatgt	cgggagaggc	tctggtgaca	29700
gctgtttcct	gtgcacctgc	tgggcactag	gtcccagcta	atccctgtgc	caggactcta	29760
atttcacctt	aacacacatg	gtggttttca	ttgctgggga	agctgaggcc	tgagcacatg	29820
acttgcttta	ggtcacatag	ctgggtgagtt	caggatcccc	cagagatacc	agggccagca	29880
ctcgatcccc	acccagccct	gaaccccacc	atgtgctggg	attgtgctgg	gagtgtccac	29940
acgcctggga	ccccagggct	ggtgctctca	tctccttttt	ccagatcatg	agaatgaggc	30000
tcagggaagt	ttgaaaaaaa	cctatcccaa	gtcacacagc	aacaggagca	ggatttgaac	30060
ccagaaaagg	ggaccgcaca	ctctgttctg	ctagagtagt	tagctgtcct	gggtgatatg	30120
gcaggtgaca	ggggcaactg	tgtttaacaa	aggaaccccc	atccccctg	ccaagttggg	30180
agactagaag	gtcaggggca	gaagctctga	agggccagggt	gcagtggctg	acacctctaa	30240
tcccagcact	ttgtgaggcc	aaggcgggca	gatgatttga	gccaggagt	tcaagatcag	30300
cctgggtaat	gtagtgaagc	gccatctcta	caaaaaaatt	ttttaaaaaat	tagctgggca	30360
tgggtgttca	tgcctgtagt	ccaagctact	tgggaggctc	aggtgggagg	attgcttgag	30420
cccaggagggt	tgaggttgtg	gtgagctgtg	atcatgccac	tgactccag	cctgggcaat	30480
agagtgaagc	cgtctccaaa	aaaaaaaaaa	gaagaagaaa	aagaagctct	gaggctccaa	30540
gtccccaggc	accccttggc	ttgaggggcag	acaaggagg	agagggtcac	ctgggcagcc	30600
ctgacttttg	tcccctggca	aagggacctt	cagtgcacct	ggccctagga	gagcctctga	30660
gcacgtcagc	catgtcgaa	cgtcaggaa	gggcagcaag	aatttggtct	ctgacctctg	30720
cctctcctac	tcgccatctg	cactgggtgt	ggttgtgccc	attttacaga	tgaggaggct	30780
ggggcatcga	ccagctgaat	gccttgtccc	aggtactgcg	taggcagagc	tggcagttga	30840
accccggtgc	ctgggtgtcg	ctgggggtgg	gctgcaccct	gacttgtgag	gccagtagca	30900
aggtttgcac	gtgacttcgt	gaccgtcacc	cagctctgca	gcacatccc	tgaccagct	30960
catccaggcc	gcatgcaaac	ctgttgccag	gcgagaaacc	agtcaccgca	cagctgtggt	31020
tgcctgaaat	gattaaagctc	attaatcacc	ccggagtga	gacagactca	gatgaaaacc	31080
agcaaaagcc	ctggaaactc	atgtgacct	gccaatgagg	gcggccatgt	gcattgcagc	31140
ctggccgtca	ctcctcggt	cgtgttttg	acttaaacgc	tccggatgtt	tactgagtgc	31200
ttgattaata	acatggaagg	cctggtctca	ttgctgtggg	agtgaaggat	gcacagccag	31260
gctgacatg	atgagaacaa	gaacctggag	tctcgctgcc	tgggtggtaa	tcctggccct	31320
gccacttagc	aactgtgtga	ctgtagccag	gtcacttaat	tttgctagat	cctgcctgcg	31380
cctcagtgga	tcttgctggt	tttccaaggt	ggccaaacac	tttaaggcat	tcatgtggtc	31440
gctaggctgc	agggttgaac	cctggctcac	cccgcagggc	gccgtgtgct	ctgtggcctg	31500
gctgtgcctt	tgtgacacc	gtgcccgtgt	gtgttcatgc	aggtcaggag	cggtctgtga	31560
ttgccgacga	tctccgcac	ccgttcgggtc	tgacgcagta	cagcgattat	atctactgga	31620
cagactggaa	tctgcacagc	attgagcggg	ccgacaagac	tagcgccggg	aaccgcaccc	31680
tcacccaggg	ccacctggac	ttcgtgatgg	acatcctggt	gttccactcc	tcccgcagg	31740
atggcctcaa	tgactgtatg	cacaacaacg	ggcagtggtg	gcagctgtgc	cttgccatcc	31800
ccggcgccca	ccgtgcggc	tgcgcctcac	actacaccct	ggaccccagc	agccgcaact	31860
gcagccgtaa	gtgcctcatg	gtcccccgca	cctcactccc	tcgttagatc	aggctgggtc	31920
tgggagctga	cgctgaaaagg	agcttctcat	ctggggttcc	tgggtgtaca	tagatgggtg	31980
ggtaggttgt	gcactgcaca	agctgcatga	tgtacctgg	gggtccagggt	ccaggctgga	32040
tggacttgtt	gcttcatcag	gacatagata	aatggccaaa	actcctcagc	tgggaaggtcc	32100

032796-132.ST25

tgggcaggat	ctttgggtgt	gaaaaccagt	cacaggggaa	gggtgcttgc	tcatactgcc	32160
agcacagtgc	tgagtgcctt	ccatagcgct	cgtttactcc	tcaagcctgg	aggggtggga	32220
gtagcatggg	cccatttcac	gtacaaggaa	cccgatgcac	agagaggtgt	ggcaaccctat	32280
ccaaggccat	acaactgggg	tgggttgagc	cgggggtgac	tgtggcaggc	tggctcaaga	32340
gtccctgctc	ctgaaccctt	gccaggcagc	ctggcatcag	ctcggggaat	ttttgccctg	32400
acccttggaa	gcaagtgggc	ctctttgttc	tcatgtcagt	gatgagaaga	gtgactttcc	32460
tatggccctt	ctggagtaca	ggtgtttcct	gttggcgggc	tcttcccca	tgacatcagc	32520
agcgagctgg	ttatgattcc	ctacgcagaa	cttgatagtt	tataaagctc	tttgtcatcc	32580
aggccccgtt	ggagtctcac	gcagacctgg	tcgcaggcgg	ggctggtcct	gcctgtccca	32640
gctgcatgga	tggggaactt	gaggcttgca	aaggttaagg	ggctgttcga	ggcccaggct	32700
ggcaggagat	gggcctgggc	cagagtctgg	gacttcccat	gcctgggctg	tctttggtcc	32760
tgttgctcac	catccctccc	tggggccatg	accttagaga	gccaatgga	ggtgcaggta	32820
accacggca	aggaggggtt	gccatgactc	agagtccccg	tcctgtggcc	ggcagtacct	32880
ggtgcaacga	cttgatttcc	agaccagcca	ctgtagcccg	ctgacgggtg	gctcgaagtg	32940
ccacagcttc	tgaagccagg	caggactcag	gccaggagac	tctgttagct	gttgagaggg	33000
agaggccaac	ggatgttctg	gttctgtcag	agagctgggt	cttcggatcc	tggtaccagt	33060
gcactgagag	gaggcccagc	ttgattctgg	ggctgccttg	tgggtggcatg	tgctgctcac	33120
tgacaccctc	gaggagtgtc	ttctctcggg	cttggtgact	gtgcccgggt	ttccgcagtt	33180
cactggtgca	cacataggca	catagcaaac	cgcacacaca	gtcgtgggta	tgagtttcac	33240
tacattccac	caccagtgtt	cactaccatt	acctgccttc	cgtcttaagt	gttcattcatt	33300
taaaaataaa	tttattgggc	tggacgcggt	ggctcatgac	tgttatccca	gcactttggg	33360
aggctgaggc	gggcagatca	cctgaggtca	ggagttcaag	accagcctgg	ccaatatggt	33420
gaaactccat	ctctactaaa	aatacaaaat	tagctgggca	tgggtgggca	tgccctataat	33480
cccagctact	caggaggctg	aggcaggaga	atggcgtgaa	cccagagaggc	agagcttaca	33540
gtgagcccag	atagcaccac	tgcagtccag	cgtgggcaac	agtgcgagac	tccatctcaa	33600
aaaaaaaaata	aataaataaa	agaaaaataa	atztatgatc	tatttcaaaa	ataacacatg	33660
tactttgaaa	cagcagagac	acatatgaca	cggagaatga	aattccccc	agcgcacccc	33720
caagagacag	ccctggtccc	ccgtcttttc	ccgtggacct	ccagcggggc	agatgctgag	33780
ccgctgttg	tcgagtggcg	tgctatcccg	tcctccagct	cctctgtggc	ttacagacac	33840
ccacctgcag	ccctgtcctt	gcctcctcta	gcgccacca	ccttcttgct	gttcagccag	33900
aaatctgcc	tcagtccgat	gatcccggac	gaccagcaca	gcccgatct	catcctgccc	33960
ctgcatggac	tgaggaacgt	caaagccatc	gactatgacc	cactggacaa	gttcattctac	34020
tgggtggatg	ggcgccagaa	catcaagcga	gccaaggacg	acgggaccca	ggcagggtgcc	34080
ctgtgggaag	ggtgcggggt	gtgcttccca	aggcgctcct	cttgctggtt	tccaggtgc	34140
tgccctgtc	cttagcagag	ggaggaaaca	gaggatggct	ctgggtgaat	gatgacttgg	34200
gcttcgatta	tgtagtca	gggtatgacc	ctgagatgcg	tggaacccc	agactgtgat	34260
tatatgtaga	aactgggttt	ccccgttggt	taagtagtca	tgggtgggtc	agaccccaca	34320
ggacttttgt	cttttcaaga	aagaaaatgg	tcgtgtgtca	tgaggggta	gttggtactg	34380
gttaatccag	gtttatcctt	tattttgtgg	gaactgtaca	gtcatttctg	ctacaatgct	34440
gtatatgctc	ttctgaaaga	cacctatgca	aaatcgcaca	gtaaaaatga	cacaactcat	34500
agggaaagcg	gggccagggc	acagccctca	aaatctccat	caatgacatg	taagaaaaga	34560
gaggaacctg	ggaaatagca	aagtgccttt	tgcacattaa	atggttagct	atatcccaca	34620
atactgtgca	ttcgtaaacg	ttaatgctgc	aataaatacg	gcacttcacc	ttgggaagat	34680
ctggagttgg	cttatgagtg	tggaaagggtg	tagcgcata	gtttttgtga	aacactggaa	34740
ggaggttgg	gggaaatcaa	atggaaagtt	ctcaccacag	gcgtggagaa	gagtgggtca	34800
tggccccagc	agtgagccca	gggaggtcag	agacggaggt	gtgtgtgtgg	gtgtgaccct	34860
gcgcagttcc	ctgccggctg	tagttttttg	cattcgctta	atgtttctcg	tggaggaat	34920
tgtgcatgag	caaagtgtga	accgtgctgt	gctcaaattg	tcctaataca	tcattgcatt	34980
ggaacagatt	ggcttttttt	tttttttttt	tttttttttt	tttttgagat	ggagtctcac	35040
tctgtcacca	gcctggagtg	cagtggcatg	atcttggtc	actgcaacct	ttgcctccta	35100
tgttcaagtg	atcttctgc	ctcagcctcc	tgagtaactg	ggattacagg	catgagccac	35160
cgcggccggc	cagatttgca	tttttgaaac	aactgctagg	ctgggcgcgg	tggctcacac	35220
ctgtaatccc	agcactgtgg	gaggccgagg	caggtggatc	acctgaggtc	aggggttcga	35280
gaccagcctg	gccaacatgg	tgaacccccg	tctctactga	atatacaaaa	atcagctggg	35340
tgtggtggcg	ggtgcctgta	atcccagcta	ctcaggaggc	tgaggcagga	gaattgcttg	35400
aaccaggag	gcagagggtt	cggtgagccg	agatcacacc	attgcactcc	agcctgggca	35460
acaagagcaa	aactccatct	caaaaaataa	aaaatagaaa	aacaagtgct	gtagcggagg	35520

032796-132.ST25

tgagcacttt	gcggagtcag	gcttgtgtgg	cctgttccac	aaatgatgtg	ctcacggtgg	35580
cctcaggccc	acctggagtc	tgcagcatgg	ggcacaacag	gttcattagt	gtagaattcc	35640
aggacaggcc	tggctcctaa	gcagccttct	tttacaaaaa	ctgcagagcc	cgctgtatc	35700
ctagcacttt	gggaggccga	agtgggtgga	tcacgaggtc	aggagttcaa	gaccagcctg	35760
gccaacatgg	tgaaacccca	tctctactaa	atatacgaaa	attagctggg	tgtggtggca	35820
cgcgctgtga	gtcccagcta	ctcgggagge	tgaggcagaa	ttgcttgaac	ctgggaggtg	35880
gaggttgcag	ggatctgaga	ccatgtcatt	gcactccagc	ctgggcaaca	gagcgagacg	35940
ccatctcaaa	aaaaaaaaac	ctacagagcc	acacggcctc	tttctccacc	gagtgttggg	36000
gtgggagctt	gtgttattgt	ggtgaaatct	tggacttttc	ttgaggcaga	gagaggctga	36060
gcgcctggag	agactttcac	atgggtcgcc	atgtccgcgc	tcggtttcgc	tgttgtgtct	36120
cccacttgaa	ggctggtgcc	gtccagacag	gctggacgcc	cctttccacc	agatccttcc	36180
tcccgcagca	gtttctagtt	acgttgtact	gtgaggtctg	tgtccttggt	tgatggcaaa	36240
agtcagccga	attgaaattc	agagccatgc	ctggctccct	ggagcttctc	tcctgggcag	36300
ctgtgatcat	tgcctctgct	gtggtgtggg	tgggtgaaat	ggattccttt	catcttgctt	36360
gctacagggtg	actgtcacgt	ggagtccttt	ggagagaggg	acgtgttaat	tgatggatgt	36420
ggctcccattg	ctgagaaagc	tcctgggcgt	acattgcctt	agagtttcat	tggagctgcg	36480
ttcgttttat	gtgtctgcta	ggcagaagtg	atgaagactt	ggaagaaaa	ccagaagggt	36540
ttccacttaa	tttggaatat	gtgcttttcc	cctcctgtgt	cttttgctaa	ggccagcct	36600
cctgcagcct	ccccgctctg	tggactctgg	ctttgattct	ttattaggag	ttcccctgct	36660
cccccaaaag	atggtgtcta	aattatcatc	caattggccg	aggttttggt	ttctattaat	36720
tgtttttatt	ttttattgtg	gtaaatatat	ataacataaa	atttgccatt	ttaattgttt	36780
tgttattggt	gtttttgaga	cagggtctca	ccccagtgcc	caggctggag	tgcagtgggtg	36840
cgatcatggc	tactgcagc	ctcagcctcc	agggctccag	tgatcctctc	acctcagcct	36900
ctctagtagc	cgggactaca	ggcatacact	accacatctg	gctgattttt	tgtatttttt	36960
ttttattgta	gagaccogct	atgttgccca	ggctggtctc	aactcctgga	ctcaagccat	37020
cctcccacct	cacctccca	aagtgtctgg	attacaggca	tgagccacaa	caccagccca	37080
ttttaatttt	ttttttttt	tttgagatgg	agtctcactc	tatcgcccag	gctggagtgc	37140
agtggcgtgg	tatcaactca	ctgcaacctc	tgcctcccag	gttcaagcga	ctctcctgcc	37200
tcagcctcct	cccagtagtc	tgggattaca	ggtgcccac	actatgcctg	gctaattttt	37260
gtatttttta	gcagagacgg	ggtttcacca	tgttgccag	gctggtcctg	aactcctaac	37320
ctggtgatcc	gcccgcctctg	gcctcccaaa	atgtgagat	tacagggtgtg	agccaccgtg	37380
cccggccttt	ttttgttttt	gagacagggt	cttgccctgt	caccagact	ggagtgcatt	37440
gggtggctct	tggctcactg	cagcctccgc	ctcccaggct	caagtgtgtc	acctccacac	37500
ctggctaact	gtattttatg	tagagacaga	tttcaccatg	ttgccaggc	tgggcttgaa	37560
atggactcaa	gcagtccacc	cacctcagcc	tcccaaagtg	ctgagattac	aggcgcgagc	37620
caccgcaccc	agcccatttt	acctattctg	cagttgacag	ttcagtggca	ttcagtcagt	37680
tcacgaggta	accatcactg	ccattcatct	ccagactact	tcaccttctc	ggcagatgtc	37740
cgaaactgtc	cgcattgaac	acactcctca	tctcctctg	acagccacca	ttctactttg	37800
tatctctctc	tgccttctct	aggtacctca	tgtaaagtga	attataccaa	tatttgccct	37860
tgtgtgactg	gcttctttca	tgtgacatgg	tgtcctcaag	gttcatctgt	gttatagcct	37920
gtgtcagaat	ttccttccct	aaagcctgaa	taataaccgc	ttgtaaaggc	tgggcgcggt	37980
ggctcacacc	ctctaattccc	agcatttttg	gagtcagagg	tgggcagatc	acttgaggtc	38040
aggagtttga	gaccagcctg	gccaacatag	tgaaaccttg	gctctactaa	aagtacaaaa	38100
ttagctgggt	gtggtggcgc	gcacctgtaa	tcccagttac	tcaggaggct	gaggcaggag	38160
aatcgcttgt	acccgggagg	cagaggttgc	agtgaaccaa	gattgtgcct	ctgcagtcca	38220
ccctgggtaa	cagagtgaga	cttctctgtc	caaaaaaaat	ggtgtggtgg	ggtgtggtgg	38280
acggaccact	tcttggttat	tatccatcca	cgggtgctag	gtttcttcca	cctttggttg	38340
tcgtgaataa	ggccactatg	aacatttcc	tccgtgggtga	aggttttgta	ctagtgaagg	38400
aaaggcgtgt	ttgtggtgtt	gcataaggatt	ctggtaagaa	agtttgact	aaccataagt	38460
atttgtacta	cattaaaaatg	aaagctcagg	ggcggggcgc	ggtggctcac	gcctgtaatc	38520
ccagcacttt	gggaggccag	ggcgggcgga	tcatgaggtc	aggagatcaa	gaccatcctg	38580
gccaacatgg	tgaacccccg	tctctactaa	aaataccaaa	aaactagcca	ggtgtggtgg	38640
cgggcacctg	tagtcccagc	tacttgggag	gctgaggcag	gagaatggcg	tgaacccggg	38700
aggcggagct	tgcggtgagc	cgagatcgct	tactgcact	cgagcctggg	caacagagca	38760
agactccgtc	tcacgcaaaa	ctctgtctca	cgcaagactc	cgtctcaaaa	aaaaaaagag	38820
ttcagggttt	atgaaactgg	ccagccgcgt	aaagtttgct	gtgttggttt	tgtgcccggg	38880
aggagtgtgg	ccagggtgtc	acgtcacaca	gtacacgttt	ctcagatggt	ggttctccag	38940

032796-132.ST25

actgctgtcc	caaagtctgt	ttttgcatct	ggttcccaca	gacccaccct	ccacggtgag	39000
cctgattttg	gccagggtag	ctggaatctt	gcttgtcttt	cagcccggca	gctgtaccag	39060
tccagggtcc	acagctagt	gcttttagga	aggaatttgt	tcagttggct	ttgacacatg	39120
gccccctagg	gtccacagct	ctgtagtgat	gtggatgttg	ttatctacaa	agacacatga	39180
tccttcgtgt	ccagatgaaa	gtgatgatgt	ctttgcagct	gcccagcaag	gctgtgtgtg	39240
tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	tgggtgtgtg	gtgggtgtgtg	tgtgtgtatg	39300
ggggaggagg	gcaccctttc	catctggggg	tgtgtgtgtg	tgggggtgtg	gtgtgtgtgt	39360
gcgcgtgtgt	gtgggtgtgtg	gtgtgtgtgt	gtgtatgggg	gaggcaccct	ttccatctgg	39420
gtccaagaga	ctgggcctgg	ggaagacgct	tctttttatc	tacttagaga	ctttgtttta	39480
tttgtatttt	tttgagacag	ggtctcactc	tgtcaccag	gctgggggat	ggtgatatga	39540
gcatagctca	ctgcagcctc	ggcctcccag	gctgaagcga	tcctcccacc	tcagccttct	39600
gaatagctgg	gactgtaggc	gtgcgtcacc	atactgagct	attgtttttt	ttgtttgggt	39660
ggtttaattt	tttttgatac	agatggagtc	ttgctatgtt	gcccagacta	gtctcaaact	39720
cctgaactca	agtgattctc	ccacctcagt	ttcccagacat	tctgggatca	cagggtgtgag	39780
ccactgctgt	ctccctgttt	tattaactgc	tgaagacct	agataaagaa	agtctgaaaa	39840
gacttactat	ccagacacca	tcctaagatg	attccctctg	actcaatgga	gagggagggg	39900
agcttttctt	tcaggcctgg	gtggcaggag	cccaggtgct	ccaggcccca	tttgccccag	39960
gccaaatcac	tcgggaactt	ggatgcagct	gtctttcagg	gtaacccaaa	ggaaccagat	40020
ccccgcaggc	agtaggcttc	tgggctgtcc	tctcctccta	cgtcagctca	gtaagagccc	40080
ttcgaagggg	tgtgtgtgtg	gaggcccca	aagcccaggc	tcacccctga	gatgcacagg	40140
gtgggctggg	cttaggcagc	gctcgagcat	ctcctggacg	gtgaccccag	agagtgtgga	40200
gacggagagt	ccttgagagt	cactgagaga	cgtggctgcc	ctgccttccc	aagaggggct	40260
ctgagtcatt	ccccacactc	acctgcccct	accaccctc	acctggcccc	cagcctcacc	40320
tacccccaca	tctgtaccga	tccctttacc	cgcaccttcc	ctacccaccc	tcacctcccc	40380
tgtaccttca	cctccccccac	tcacccgccc	ctgcaccctc	acctgtcccc	caccttcacc	40440
taacccccac	cctcacctgc	cctccccctca	cctggcctcc	ttccgttggg	gaaggggttg	40500
taaggggcgg	cccccaaaact	gtctgtcctg	gtgccttgca	gagaaaacag	tacgtgaggg	40560
ccgcagtcca	aaagcttgag	tcttgaaggg	tggaggagac	agggatgtgt	tgggaagggc	40620
cccattggtct	tggatccctt	ctcgactgtc	aatggggcct	tcattgggagc	gccagtctag	40680
tgatgcacag	ctgggtgccc	ggcgggtggc	tgaggaggcc	taaagtccga	ggcggcaaga	40740
gctcttcacg	aggtgttgtt	cctaactcgt	ctggcatact	caggcgggga	cgtagttagg	40800
agctgattgg	agaggagaga	ccccacacc	aatactggga	tttgactttc	aggctaaact	40860
tgagaagtgt	ggcctctgct	gtcctgccag	agctctccag	ccagtgccca	gggctctcca	40920
gccagtgtcc	gggggtctcc	accagtgtcc	gggggtctcc	gccagtgtcc	gggggtctccg	40980
ccagtgtcca	gggtgtctcg	ccagtgtctca	ggagtcttgg	tttctttgtc	ttacagccct	41040
ttgttttgac	ctctctgagc	caaggccaaa	accagacag	gcagccccac	gacctcagca	41100
tcgacatcta	cagccggaca	ctgttctgga	cgtgcgaggc	caccaatacc	atcaacgtcc	41160
acaggctgag	cggggaagcc	atgggggtgg	tgtgtcgtgg	ggaccgagac	aagcccaggg	41220
ccatcgtcgt	caacgcggag	cgagggtagg	aggccaacgg	gtgggtgggg	gtgctgtccc	41280
tccaggcgtg	cccgcggtgt	cttatgccga	atgccagcct	ctcacaggct	ggggagactt	41340
tccacctggg	gatccaatgg	gtggctttcc	agggtcccaa	aagcaaacac	aggtttttca	41400
cagcccgtcc	gggaaagcag	aaagccccaa	ggggctggaa	ggggaaaggg	ggagctctgc	41460
tgagaggtta	caaggcagcg	ctggccgacg	ggagtgtcag	ttgatagggt	ttgtatcatc	41520
cttgttaaac	ttgaacctgt	tgcagaaatc	ccttccacgg	catgggggct	gcctgttgac	41580
tcgctcctgt	tccaccacag	ggagctcctg	ggcttcttcc	tcccagaggc	ccccgacgct	41640
cccacctgtt	ggtcgtcaga	gcttctggtt	ggtgggaagg	caccagggac	cttgaggtct	41700
ccagagagaa	aagccaggga	aagagggaga	ccgaaaccca	tgtgacatga	aactcaggct	41760
ccaaactgag	cacgggaacg	tttggggaca	ggagcgcgat	ggccttctct	agatagctgg	41820
ggggctggca	tgaagacggg	agctacagcc	agcacaggtc	ctgggcccgg	agcccagaga	41880
ttgagccctg	actctgtcac	ttactggcca	cgtgaccttg	ggcgggtggc	atagcctctt	41940
ggagactcag	tttccctcatt	ggtaggagtg	acggccacag	tgggtgcggcc	tctgcagcac	42000
acggggggct	cgggtggcg	aagccccggg	tctataaggc	ggctgtgcag	gagccagccg	42060
agctggtctc	ccaacagcca	gggctccggg	gtccttagca	gctgtggggg	gcctgcacct	42120
gtttcccatg	gctgctgtca	gaaattacca	gaagccaggt	ggctgagagt	aatggacact	42180
tgttctctca	cagttcctga	gggctgaagc	ccgagatcga	ggtgtgggca	gggccctgcg	42240
ccctctgaag	gctctgaggg	aacctttggg	cttctggtgg	ctccaggcac	cccttgactt	42300
gtggtcctgt	cactccagtc	tctctgtctg	gctgcacatg	gcgtggcctc	ttctgtacca	42360

032796-132.ST25

ttgaaggaca	cttcagttgg	atthagggcc	taccctcacc	cattgtgggc	gtatcttgat	42420
ccttcatgac	atttgtaaaag	accctgcttc	caaataagct	cacattctga	ggttctgggg	42480
tgagcgggaa	tttgagagac	attgttcaac	tagtatagaa	tgtgacctgt	cagcctcggg	42540
cagccctgag	aggcaggggc	tttccacagc	ccagctgggt	gccctgggct	ccgtgctgtc	42600
cgaggagacg	ccatccccac	accctgcctt	caccgcacac	cctcccgag	gtacctgtac	42660
ttcaccaaca	tgcaggaccg	ggcagccaag	atcgaacgcg	cagccctgga	cggcaccgag	42720
cgcgaggtcc	tcttcaccac	cggcctcatc	cgcctgtgg	ccctgggtgg	agacaacaca	42780
ctgggcaagc	tgttctgggt	ggacgcggac	ctgaagcgca	ttgagagctg	tgacctgtca	42840
ggtacgcgcc	ccggggcctg	ccctaaccgc	agacacccgg	ccttcattgt	cagtaatggc	42900
agcagctgcc	acattgtccg	agacctgccg	tgagcccagt	gccgcgccag	gggctttgtg	42960
tgtagcgtgt	tttgtcctca	cactgacagc	tgtaggctgg	ggttctgagt	gagccccaca	43020
gggcagaggc	agaaaatgag	tctcagagag	ggtgagcgag	ctgcttgggg	ccccacagca	43080
ggagatggag	caggactgca	gcctagcctc	tgcccccagc	acctgcgcaa	gaagctgctc	43140
tgctctggac	tgtgttaggc	tgcgagggct	ggagagaaat	gagagttggg	gcttagagag	43200
ggggcgcagg	tccccatggc	tttctctctt	atgatgaggt	agatgggtga	agggaggggc	43260
catgcttgca	ggggccagtg	accgaggccc	gccgttgga	ctgatggcct	tcatcccag	43320
cccagcccag	gtgggagcag	ggctttccga	gggcttgtct	tgggtcggcc	tgcttccagg	43380
gactctgctg	cagctcccac	ccctgtccaa	agcatggaat	ccccaggct	ccctggcagt	43440
cctgtcaacc	tctgtcctcc	caagctgagt	gtggggcaag	ttctggaggt	cagcactgct	43500
cagggggggc	cacgggctgc	ttgcaggggc	caaccgcctg	accctggagg	acgccaacat	43560
cgtgcagcct	ctgggcctga	ccatccttgg	caagcatctc	tactggatcg	accgccagca	43620
gcagatgac	gagcgtgtgg	agaagaccac	cggggacaag	cggactcgca	tccagggccg	43680
tgtcgcccac	ctcactggca	tccatgcagt	ggaggaagtc	agcctggagg	agttctgtac	43740
gtgggggctg	gcagtggggg	gggcagggtg	gcctctaacc	ccgacccctg	gaggaggctg	43800
gaggccagtg	caagatcctg	tgtggcctca	gccaggcggt	ggtctctgcc	agatgccaac	43860
tgttgccgc	tggggttcag	cgacatgtcc	gaatgtcccg	aggcctctga	ggttggtttc	43920
ttttgccgca	gaacaaatca	ccacgaacag	cgttttaaga	caacaccaac	tctttttttt	43980
tttttttttt	tgagtcagga	tcttgctctg	ttgccaggc	tggggtgcc	tggtgcaaac	44040
acagttcact	gcagcctcga	cctctgggct	taattaagt	aacaccttgc	ctcagcctcc	44100
caggtagctg	ggactacagg	tgggcaccac	cacacctggc	taattttttt	ttgtagagac	44160
ggggtttccc	catgttgccc	aggctggtct	gcaactcctg	ggcacaagct	atctgcctgc	44220
tgtggcctcc	caaagtgtca	ggattatagg	tgtgagccac	tggcctgaca	acacccacgg	44280
attgtctctc	agttctgtaa	ggcaaaagtc	aggcagacgc	tggctcacct	gggttctctg	44340
ctcaggggtc	cacggggcca	gaatcaaggt	gtcaggaacg	ctggggccctc	agcggaggct	44400
ctgtggagaa	attagcttcc	ttgctcactc	agcaggtagc	agttgtggga	tcgaggttct	44460
gttttctctc	tggttatttg	tcggggacca	ctctcagctc	ctagaggcca	ccacaggctc	44520
ttgccccgtg	gccctctctg	cctcagcagt	gggggctccc	tgctgcagtc	cctcccacac	44580
cttgagtctc	tctgatttgc	ttctaaaggg	ccctgtgatt	cggctcagcc	acctttagat	44640
taggttagcc	tcccctttga	tagactccaa	gtcggctgat	taataacctt	aatcacatct	44700
gcagaatccc	ttctgccaca	taaggtcatg	acgccgtgct	ggggactggg	gtgggaaatt	44760
acggggctcat	ttaggattct	gcctgccact	gccttgctgt	gtcccagggc	ttgggggagg	44820
ggcctccaca	gctgggacca	cagtccttcc	tcccctccat	ggttaaccatc	tgaggattac	44880
ttgagaccag	cctgggcaac	atggtgagaa	cccatcccta	caaaaaatac	aaacaaaaag	44940
ggaccaggct	gggcttggtg	gctcatgcct	ataatcccag	cactttggga	gaccaagggtg	45000
ggctgatcac	ttgaggttgg	gagttcgaga	ccagcctgcc	caacatagtg	aaatcccgtc	45060
tctactaaaa	atacaaaaaa	tagctgggtg	tgggtgcagg	cgcctgtatt	cccagctact	45120
ggggaggctg	aggtgggaga	attacttgaa	ctggggaggc	ggaagttgca	gtgagccaaa	45180
attacgccac	tgactccag	cctaggcaat	agatgtgagac	tccgtctcaa	aaaaaaaaaa	45240
gggccagggg	tggtagtgac	aaagagaccc	tatcccaaaa	aaaccgaaca	ctgaatcctt	45300
gagactgagt	aaggacactg	tgaatttttt	ctgggtgggg	cagggaacag	agcgtcttct	45360
gtcatttctt	ccacctgggt	gtggtcagct	ctccctccaa	gctgcctcct	cttcttctca	45420
ttgtccgggt	gttgacacaca	tttggttaac	tggatagaat	aacgcgagtt	cccagggact	45480
tgggtccattt	gctatttttat	tttattttat	tttattttat	tttattttatt	tattttattta	45540
tttattttatt	tattgagatg	gagtttcgtt	tttgtcggcc	aggctggagt	gcagtggcgc	45600
gatctcgggt	cactgcaacc	tctgcctccc	aggttcaagt	gattctccta	cctcagcctt	45660
ccaagtaact	gggattacag	gcacccacca	ccataccagg	ctaatttttt	tgtatttttta	45720
gtagagacgg	gttttcgcca	ttttgcccg	gctggtcttc	aactcctagc	ctcaggtgat	45780

032796-132.ST25

ccacgcacct	cggcctccca	aagtgtctggg	attacaggca	tgagccacca	cgcttgccac	45840
catttgctat	tttaattccc	atgtgtatta	gtgtcccacg	gctgtctgta	caaataacca	45900
caaactggat	ggcttaaagc	aacagaaatg	gattccccca	atgtgtctgga	gaccagaagc	45960
ctgcgaccaa	actgttgagg	gggtgtgtct	tcctctgggg	gctccaggga	ggatctattt	46020
gttggtccct	ccagtgtgtg	gggtgccagc	gttccacact	tgtggatgcg	ccgcctcaac	46080
ctctgcccac	cttcatgtgt	ccatctcctt	tgtgtctgct	tttttacctc	ttcttcttgt	46140
ctgtgttgcc	tcttataagg	acgtttgtca	ttgggtttag	ggccccacca	aatcatccga	46200
gatgacctcg	tcttgagatc	cttaacctgc	aaagaccctt	tttccaaaaa	aaggttatgc	46260
tcacagattc	taggccttaa	gacatgggtg	tatctttctg	gggggcacta	tccaaccctt	46320
tatacaatga	aagacgggaa	gagggccagg	tgtggtagtt	cacgcctgta	atctcagcac	46380
tttaggaagc	tgaagcggga	ggatcacttg	agcccaggag	tttacaagta	gctaggcaac	46440
atgatgagac	cccatttcta	caaaaagtga	aaaaaaaaaa	aaaaaaaaaa	aagccagggtg	46500
tggtggctca	cacctgtaat	cccagcactt	tgggaggctg	aggcaggcag	atcacgagggt	46560
caggagattg	agaccatcct	ggctaacacg	gtgaaacccc	gtctctacta	aaaatacaaa	46620
aaattatggc	cgggcgcagt	ggctcccgcc	tgtaatccca	gcactttggg	aggccgagggt	46680
gggtgaatta	caaggtcaag	agatcgagac	catcttggtc	aacacggtga	aaccccatca	46740
agatcacaag	gtcaagagat	ggagaccatc	ctggctaaca	cggtgaaacc	ccgtctctac	46800
taaaaataca	aaaaattagc	cgggcatggt	agcggcgccc	tgtagtccca	gctgctcggg	46860
aggctgaggg	aggagaatgg	cgtgaacccg	ggaggcggag	cttgcggtga	gccgagatcg	46920
ctccatgcca	ctgcactcca	gcctgggtga	cagagtgaga	ctccgtctca	aaaaaaaaaa	46980
aaaaaaaaaa	aaaaaaagaa	aattagccag	gcacagtggc	aggtgcctat	tgtcccagct	47040
acttgggagg	ctaaggcagg	agaatggcat	gaacccggga	ggtggagttt	gcagtgagcc	47100
gagatcatgc	cactgcgctc	cagcctgggc	gatagagcaa	gactctgtct	caaaaaaaaaa	47160
agccaggcat	ggtggtgcat	gcctgtagtc	ccagctactc	aagaggctga	ggcaggagggt	47220
ttgttcgacc	cacggagatc	aaggctacag	tgagccatga	tcgcaccact	gccctccagc	47280
ctgggtgaca	gagtgtgacc	ctgtctcaaa	gtaagtaaata	aggaggagag	acaagtgggc	47340
agttcagact	gatggtatgg	gcacagtaga	gactggtgca	gacaggctgg	cctgtgatgt	47400
caagcaactt	ctgtaattgt	ttccggcatc	catttgtgtg	tcaatttccg	tgtcagtagg	47460
aagactctgt	aggctgccaa	gaggaataag	tgggaggatc	ctcccagaga	ggccgggcct	47520
gcaggagggc	cagttctcat	gagttctcat	tttggccccta	ccctccaggc	tgtggttctg	47580
agggtggaga	caagcctgga	cctctgtttg	tcttgttttg	tctttgcagc	agcccaccca	47640
tgtgcccgtg	acaatggtgg	ctgctcccac	atctgtattg	ccaagggtga	tgggacacca	47700
cgggtgctcat	gcccagttca	cctcgtgctc	ctgcagaacc	tgctgacctg	tggaggtagg	47760
tgtgacctag	gtgtcctttt	ggggtgatgg	acaggtaacct	gattctctgc	ctgctaggct	47820
gctgcctggc	atccttttaa	aatcacagtc	cctgtggcat	ccagtttcca	aagctgattg	47880
tgtcttcctt	tgccctcctt	tcttttctac	tatgtgcatt	cgggtgctatg	aattttcctc	47940
taagtactgc	gtttcctgca	tctcacaat	tttgttacat	tttcattttc	aggtagtttg	48000
aatattttta	cacttctcct	gagatgacat	ctttggtcca	tgtgttattt	agaagtgttg	48060
cttagtttct	aaagagttgg	ggcttttcca	gctgtctctc	tgcaactgat	ttctaattta	48120
attctactgt	agtctgagag	cttattttat	atgatttctg	ttattttaaa	tgtgttgggt	48180
gtggtgtttt	tgttgttatt	gtttttgtgt	ctttttgttt	tgttttgctt	cgtttgtttt	48240
gtttttgaga	cagtgtcttg	ctctgtcact	caggctggag	tgcaatggcg	cgatctcagc	48300
tcaccgcaac	ctctgcctcc	cgggttcaag	tgatcctctt	gcctcagcct	cctgagtagc	48360
tgggattaca	ggtgcacgcc	accataccca	gctaattttt	gtatttttag	tagagacggg	48420
gtttcaccat	gttggtcagg	ctggtctcga	actcctgacc	tcgtgatccg	cccacctcgg	48480
cctcccaaac	tgctgggatt	ataggcgtga	gccactgtgc	ctggccatta	ggtgtgtttt	48540
atcacccagc	atcatgcagt	ttatcttggg	gaaatgttctg	tgtactcttg	aaaagaatgt	48600
ggattctgct	gttgtttggg	ggagtgttcc	agaaacatca	attagatcca	gttgggttaat	48660
agtgtctatc	aggttgtctc	tatccttctt	tcctgactgc	ctgcttgagc	tgtcagttat	48720
tgacaggggt	gtggagtctc	caactctaata	ggtggatttg	tttatttctc	ctagtagttc	48780
tatctttttc	tctccttcta	cccttgatcc	tcttctcccc	ctagggcttc	ctggtgttag	48840
tgggtggaga	gtggggtagt	gaagaacctg	gacttttaggg	ccaaagaggc	cagggttcaa	48900
atcctggctc	tgtcacttcc	cagttgagtg	accctggctg	gtgcctgaat	ctctgtgagc	48960
ctccacttcc	tcctctgtga	aattgagagc	acttacctgg	caggctgtca	tgggcatcaa	49020
gtaacagggc	actccacctg	gaccctgaca	cgtgatgcac	aggaatgcc	gctgctatgc	49080
catgggtgtg	gcagtagtaa	taaagtgacc	atctgtatcc	tcaccacagt	gaagcctgtc	49140
cagggctttc	tctcctatgc	ccccatgcct	ccagggtggc	ttggatcctg	ttggttctgt	49200

032796-132.ST25

gctctgctca	gcgacctttc	tcccgtggga	gttcctgggg	gttcagcttc	atcctacaga	49260
cagcagcaca	cactggctgt	gcacctttt	ttttttttt	ttttttttt	tgagatggag	49320
tctcgctttt	ttcgcgagg	ctgaagtga	gtggtgtgat	cttggtcac	tgcaacctct	49380
acctcctggg	ttcaagtga	tttctgctt	cacctccca	agtagctggg	attacagget	49440
cccaccacca	cgcccggcta	atttttgtat	tttcagtaga	gatggtgtt	caccatgttg	49500
gccaggatgg	tcttgaactc	ctgacctcag	gtgatccgcc	cacctcagcc	tcccaaagtg	49560
cagggattac	aggcgtgagc	caccacaccc	ggagtgcgg	ttgtttttag	cagtttgtct	49620
tgttcctgga	gagactggct	cctgcccagg	agctcgggga	gtagggccgc	ggggtgctgc	49680
ctcacacctc	gagtttgccc	gtaagcagag	gggacatttt	gtgactgtcc	ccctcctgag	49740
cttcccagca	gctttttctc	aagttacagc	ccaaaagctc	aggtggattt	gcaacccaac	49800
ggtgtctgtg	cacctccac	tgatgccga	actgccctgg	ccaagaaacg	gggccgtcag	49860
aacgctgcac	taactgcagc	cttgggcctc	catgccagag	gccatgccct	tccatccacc	49920
acccctggc	ctgggcccctg	ggccctcctg	gctcgggaac	tccaggcccc	ttcctcacgg	49980
ctcgagagac	gtgtatttac	cgcacagggtg	cttgtcattc	tcttgtggcc	tcttctccag	50040
ggagatcaca	gaaggacagg	gcctcactga	ggtctcggac	atggaccctt	tgatagtggc	50100
aggagccagg	ctgggcaaga	ggcggccaca	gtcacctcag	cagtgccatc	accaccgcca	50160
ttcagccctt	ccctgagccg	ggcgcgcccc	tggtctctggc	cccagtgtcc	cagttacagc	50220
tcacaggagc	ttgtggtgcc	cagcggctgc	ttctgattga	gagtcgaggt	cggaggcttt	50280
gggaggctga	gaggtgcttc	ggtttcacaa	ctgctgaggg	agacttgggc	tccatctcag	50340
gtatgcccc	tgctgccttc	aacctccagc	caccggctct	ccgtgtcccc	catggccagg	50400
cacggcttgc	agacatctgt	cgttggctcc	tctcagccgt	cgtgggctga	ccctggcacg	50460
tcctcctgtg	gctgagccca	gtggggacag	ctgcttctct	ttattacctt	agaactctcg	50520
tctttgatca	ggccccctcc	cctatgccac	acagtccctg	tactcgggt	gagcccagta	50580
gtcatgggga	aggcctgcgg	gttccaaaca	tccaaaggct	tgcgtgcagc	atgacagctt	50640
gaaaccgatg	ttttttacct	tgatcagatt	tcagcttggc	gggggctttg	ctcagctttc	50700
agtgaggcct	gggcccattt	cccagcatcc	cctcctgagg	ccagcctctg	tttctgtga	50760
ttttctgcac	aaagtgggag	ggaggagtcc	taggaaatgg	ggggccacct	cgaagcctag	50820
gcctcctctg	gcttctctgt	gccagtggcc	ccacgctttg	tgtctgtgtc	cccagcccat	50880
gggactctgc	tattccctga	gtgctgcgc	atgccagacc	cgcactgagg	acgtggagcc	50940
ccgaggggca	ggatggcctc	catggtcaca	cgtaggaagt	ggcctccacc	ctccgatgat	51000
cctctccctc	ctccctttca	gcgcccctcc	cgggggtgtc	ctcagccctc	ctgectgtgc	51060
tttgtcccgt	cttctgcagg	cgcctgggac	gtgctgacag	gtcctctgcc	ggctcctgcc	51120
ttgtctatgc	cacgctggtc	accacagagg	cctggccctt	cttctgtagc	agtcccacac	51180
ccgcaacagg	tgtggctgct	gaccaacctgc	tttctgcccc	tctggtcctg	aggaggcgcc	51240
agtgggcaact	caggcgtggc	tgagcagatg	tgtgttgccg	ggaggaggaa	ggactgctcc	51300
agtcagggct	gaatttccca	cccggagcat	ttctgctgta	tttgggtgag	cgcctgctgc	51360
ttaaagctct	gattcccagt	tggcaccctt	tcccttctgc	attgaaaaac	atagggatgc	51420
atgtcttctt	gcagtgaatg	tgtattctcc	cagcctctct	tctgggttgg	ggctggaggt	51480
ggagcggcac	acaggagccg	cagcgatgga	ggatgtgcgg	gtgcagcacc	ccgtacagca	51540
gggatgccaa	acccgcgtcg	agtcctctct	aacttctgct	ttgaagccca	gtcacgccat	51600
tgccctgggt	ttgctgggcg	gggctgcgtg	tgatgttctc	ctctgtccct	ccccagagc	51660
cgccacacctg	ctccccggac	cagtttgcat	gtgccacagg	ggagatcgac	tgtatccccg	51720
gggcctggcg	ctgtgacggc	tttcccagat	gcgatgacca	gagcgacgag	gagggctgcc	51780
ccgtgtgctc	cgcgcgccag	ttcccctgcg	cgcgggggtca	gtgtgtggac	ctgcgcctgc	51840
gctgcgacgg	cgaggcagac	tgtcaggacc	gctcagacga	ggcggactgt	gacggtgagg	51900
ccctccccgt	caaggctctg	ccaagaccct	ggccctgccc	tccgggatac	gagcttgggg	51960
ctgcctccgg	cctcacagga	gtaggggctc	tgaaaacctt	tgcttgacag	gagattgcca	52020
agtctgtctt	ttaggcccaa	caaggaaaac	tctgacgttc	cacctatcct	gtcccaccag	52080
gtagtgtggc	ttgaaggcag	actgtgaggg	tctatctcac	cttctgcat	taggtcagga	52140
gtttcacaga	aacctgaggg	acattcaggg	gtgggctgca	gaggtccatg	gctcacaccc	52200
tggaaaatcc	gcccccaaaa	gacagtgtct	tctccactga	ccagtctgtg	ggatagtgtc	52260
taagcctgag	tggtttctat	caacatgtag	aatcaggagg	tataaagaga	tttgctcagg	52320
catcctgggc	cctctctgac	cagcaggatc	ttcctttaga	tcttgacagt	gaaacacatc	52380
tcttctgtgc	cccctgtgag	ttttctttca	ttcattcatt	cattcattca	ttcattcatt	52440
cattcattcg	agacagagtc	ttgctctgtc	accagggctg	gagtgcctct	gtgtaatctc	52500
ggctcactgc	aacctctgcc	tccaggggtc	aatcgattct	cctgcctcag	cctcccaggt	52560
agctgggatg	acaggtgcgc	accaccatgc	ctggctaatt	tttgtatttt	tagtagagac	52620

032796-132.ST25

agggtttcac	catgttggcc	aggctggtct	cgaactcctg	acctcaggtg	atccgcccgc	52680
ctcagcctcc	caaagtgtctg	ggattacagg	catgagccac	cgcgcccggc	ctgagttttc	52740
cttttatgaa	ggacctgctt	ggttggttgc	ctgccacatg	ttgtcagcac	catgggcccc	52800
ggactgctga	ggagctgttg	atgccctcgc	tctcccagag	ccaccggctc	tgtagataa	52860
ttcacatgca	gtctggccac	tgctctacgt	cctcattcac	aaagagcaga	catttcgtag	52920
aagatgaggg	cctgggagta	acctccctgc	atgtttttct	ataaaggcat	agtggttaag	52980
tccttccagc	tcattgacca	ttggagaatt	ttatggaggc	tgtagactag	gggctggtaa	53040
actaagggcc	caggggccaa	atccagcctg	ccacctactt	ttgtaaataa	agttttcttg	53100
gtgcacagcc	atgccatttc	attcatttgc	acaatgtctg	tggtgtcttt	catgccaaaa	53160
gcaagagaac	tgagtggtta	tgctggagac	ctacggcctt	caaagcccca	gacctcacgt	53220
ctggcccttg	acagacagag	cttccccagc	cctgtctgcg	atcctggccc	agcatgtgct	53280
gtgtgtgtga	tttcagcttg	caggagccgt	ggtaggaat	tgctccctgt	ttgggtccatt	53340
ttgcattgct	atgaaggagc	acctgaggcc	gggtagatta	tgaaggaaag	aggtctgtct	53400
ggctcatggt	tctgtaggca	gcaccagtat	ggcaccgcga	tctgtctcagc	ttctagttag	53460
gtctcaggaa	gctttgactc	atgggtgaaag	tcgaagcggg	agcaggtgca	tcacatgggt	53520
agagagggag	caacggagag	agagagagag	cgcctctccc	tcttgccctc	accttgagag	53580
gagatgccag	gctcctttta	gtaaccagct	cccattgtgaa	ctcacagtga	gagcccatth	53640
gctactgcgg	agagggcacc	aggcatctgc	tcccatgacc	caaacactgc	ccaccaggcc	53700
ctacctccaa	ccttggggtc	atattttatt	ctgttctatg	ctatgctatg	ctatgccatg	53760
ccatgccatg	ccatgctatt	cctattctat	tatttgagac	agaatctcgc	tctgttgccc	53820
aggctggagt	gcagtggcat	gatcttggtc	cactgcaacc	tccacctccc	aggttcaagc	53880
gattctcctg	tatcagcctc	ccgagtagct	gggattacag	gcacacacca	ccacaccggg	53940
ctaatttttg	tattttcaat	agagatgggg	tttcaccatg	ttggccaggc	tggtctcaaa	54000
ctcctggcct	caagtgatcc	acctacctcg	gcctcccaaa	gtgcatgat	tacagatgtg	54060
agtcactgcg	cccagttagg	gtcacatttc	cggttagatt	tgagggggca	gacgttgag	54120
ccatctgagc	cccctcgtcc	cgctctagct	tctcctcccg	tggtgcccgc	ggtgctgggt	54180
gcaggccctt	acgcgggttc	tggtgcatg	ctctgttcca	gaagctttct	tccctgcttg	54240
gttaccagaa	aatcatccca	tccattacaa	ggacagggtc	cccttatctc	ccattcccag	54300
ggcaggacac	cgggggcagg	gcagggtggg	aactgagcaa	gttctctggg	ggcaggcggt	54360
gctatggctc	cctctgggtg	ggcgtctggg	gaggggtgga	ggcagccgtc	agcgccctgg	54420
cttgctcttc	ctccctggcc	agagactgtg	gccttgtgct	gctcccgtgt	gggctgcctg	54480
cacctccagt	gggttggtct	ccctcccctc	ccctcccctc	aagctctgct	gagcaccact	54540
gccttccaca	gccccactc	tcgggaggcg	aggctcctcg	tgccattcc	tgctcttggc	54600
acccaccccc	ccaccaacct	ggtagagcct	tgggcggggg	ctgttactcc	ttgcatggcg	54660
tagacctccc	cacagtaggc	acctgacaca	tacctcctgg	ggggcaggca	ggagggtcgt	54720
tgagggtctca	gcccgtggcag	tccctcccct	gcgtggcata	ggcctcgcca	cagggtcatc	54780
gagggtgggt	ggagactgta	ctagaccact	ccccgctggg	cctagaaagg	gtcccactct	54840
tctgctctct	gtttggagtc	cagaccttgg	ttgtgtgccc	ctgcatgggt	ggctgggggg	54900
cacctccag	cctctctgag	tgcatggcct	ctccttgtag	ccatctgcct	gcccaccag	54960
ttccggtgtg	cgagcggcca	gtgtgtcctc	atcaaacagc	agtgcgactc	cttccccgac	55020
tgatcgacg	gctccgacga	gctcatgtgt	ggtagccag	cttctggcac	ggggaagggg	55080
cgctccgggt	gggttcccc	aggaacgtgg	agtttagggg	aggagacgtg	cctttccagc	55140
ggggctgggg	gctgtgtggg	agactcaggc	ggctgggagg	ctccttgccg	gaggcaggga	55200
agcctttccc	agggcagcgg	ccaggaggac	agactgtgag	ctgtgggctc	ggcggctaca	55260
gagctgcct	cagtgggcgg	ggctgatggt	gtccagggtg	ctgcagcacg	caccacccca	55320
cgggaccttg	ctgagcagcg	tctgtcaggc	agcaagatta	cccaggggct	gcagtggctc	55380
tgttccctgg	cagcttactg	tctggctgag	gaggagtgtat	gttcacatat	gcacacatgt	55440
catgtgcaca	cacatgtaca	tgacaacatc	ccacatgtct	ctcaaatagc	atgacctgta	55500
cagtcacgga	tatagggcct	aggggatagg	aggccaagac	agtcagggaa	gactttccag	55560
aggcagtggc	tcctgaaagg	ctgtctgatt	caggcaggaa	gggagctgag	ttcagatagg	55620
aagtagcaat	gagtcattgt	gtctggggac	atggccactc	cttcgctgca	gagggacctg	55680
ggctgagagc	tcctctctta	tggtgtcagt	cgggagagaa	gtctgttggg	gggagaaggg	55740
ggcttccctca	agggactccc	tgtgcccttt	ggcaccttcg	tgccagggtca	ggcttgaggc	55800
ctgaaggcag	tgggtggggc	caccaagggt	cgcctcctct	gctgggcaag	ttcccagctc	55860
gacgggcctg	tgccgtgggc	cccagctgtg	ggggcgctgt	tgatgcgcag	ccaggcctcg	55920
ccgccagagc	ccgcacgctt	ccattccgct	gacttcacgt	acgccctcag	gatcgctggg	55980
ccggccctgt	gggagagtga	atgtggcttt	tgccaaagtt	gagctctggag	cctggaaact	56040

032796-132.ST25

tccctatggg	cagccttgat	agtggagtgg	cccaaggagc	ccaccagacc	gaccctgccc	56100
ctcccgtggc	tgggtggcgg	caccaggggc	tgcctggcct	tgctcgttca	ccaacatcac	56160
ctgggctggc	cagggcgcg	tcaattctgc	caccaccgag	ggccctgggc	gaaggagtga	56220
ataccaggct	gccttggcag	ggatgtgttg	agggctgtgg	ggagtcggac	agcggcgggg	56280
gtcagaggag	gaggaggggtg	caccgtgcag	gctgaagggc	cacgttacc	tgaggttggc	56340
caggctcccc	aggcctagcc	tcccagctcc	cccactttct	ccccaccctc	caccagtggc	56400
aaagccagcc	ccttcagggc	gcacgggtgc	tgcccccaag	gagggcccat	tccgttgggg	56460
ttaatgttgg	ccacctcttt	ctgtttgtct	ctggcagaaa	tcaccaagcc	gccctcagac	56520
gacagcccgg	cccacagcag	tgccatcggg	cccgtcattg	gcatcatcct	ctctctcttc	56580
gtcatgggtg	gtgtctatct	tgtgtgccag	cgcgtgggtg	gccagcgcta	tgcgggggcc	56640
aacggggcct	tcccgcacga	gtatgtcagc	gggaccccg	acgtgcccct	caatttcata	56700
gccccggcg	gttcccagca	tggccccttc	acaggtaagg	agcctgagat	atggaatgat	56760
ctggaggagg	caggagagta	gtctgggcag	ctttggggag	tggagcaggg	atgtgctacc	56820
ccaggccctc	ttgcacatgt	ggcagacatt	gctaatcgat	cacagcattc	agcctttccc	56880
actgagcctg	tgcctggcat	cagaatcctt	caacacagag	gcctgcatgg	ctgtagcaac	56940
ccaccctttg	gcactgtagg	tgtggagaaa	gctccttgga	cttgaccttc	atattctagt	57000
aggacatgtg	ctgtgttgtc	cacaaatcct	catgtaccct	agaaatgaat	gtggggcgcg	57060
ctgggctctc	tccagagctg	aaggaaatcac	tctgtaccat	acagcagctt	tgtcttgagt	57120
gcagctggga	tttgtggctg	agcagttaca	attcctacgt	ggcccaggca	ccaggaaacgc	57180
aggctgtgtt	tgtagatggc	tgggcagccg	caccgcagag	ctgcaccatg	ctgggttgta	57240
tcacatgggt	gaccatggta	tgtctaagaa	ggtggagtcc	ctgtgaggtc	tgcagggtgcc	57300
cccacagctc	caggccacct	tgaggattgc	ctctgcctgc	ccagccctga	gttccctctc	57360
ccctgtcctg	tcccactgtc	accccaagcc	ggcctcattg	ggagcctgtt	ggatggcagg	57420
gtatagatgt	aacctgattc	tctctgggga	gcgggggtat	ctggcttctc	aagagctcct	57480
aggagcccac	agtgggtggca	ccatcacagt	cgcagcagcc	cccagagaac	gcggccctgt	57540
ctgttcctgg	cgtgctctgt	gctgccccgc	ctgggttccc	tgccccagtc	gcaggcccct	57600
tggaggagggt	accatgtgtc	tcccgtttca	cagatgagcc	ccggggagct	cactctagta	57660
gtggccagag	aggcctgceg	ctcagggagc	ggggcacatt	tccaacagga	cacaccgccc	57720
tggctctgagt	ctcgtgggta	gtgggagcag	aggagagcgc	cctatgtctg	tggggcgget	57780
tggctgagcc	tggaaagccac	ctgacctccc	ccgtcccttc	cctgccaggc	atcgcatgcg	57840
gaaagtccat	gatgagctcc	gtgagcctga	tggggggccg	gggcgggggtg	cccctctacg	57900
accggaacca	cgtcacaggg	gcctcgtcca	gcagctcgtc	cagcacgaag	gccacgctgt	57960
accggccgggt	tgaggggcgg	gccggggagg	ggcggggcgg	gatggggctg	tgggcccctc	58020
ccaccgtcag	tgctggccac	cggaggcttc	ccgggttcct	gggggctgtg	ccaccgcctc	58080
tgaggcatgc	ttgctttctt	cccttttcaa	acccttctgc	ttccttcttt	aatgacattg	58140
ttgattgtgg	ataatctgaa	aactacacaa	aaatataaag	agccaaaatc	tcacccaaat	58200
ccacctccta	gagtggctgt	tgggtccgt	cagcatccag	gcggccgtct	gtgttccgca	58260
cggcccagcc	catcgatagc	cgctgcacc	aggcctgtct	gccctctgtg	agcctcccca	58320
cagggttccc	tccacaaaca	ccctgttctc	ccaccaggg	ctggctgctt	cctggaaaac	58380
agctggatgg	ttttgtgcat	gacagacaaa	cacagggtga	ttttcgtggc	taaaatactc	58440
cctggagctt	ttggcaggggt	gaggggctgg	ctccagctga	gccacgcctt	gagtgaatg	58500
actgtgagga	gaataaactg	ccgctgccct	ccaggatcac	tggggctggc	tggggagaac	58560
ccccgtttct	gggagcacag	tcccaggatg	ccaaggcgag	cttggtgccg	agatgtgaac	58620
tcttgatgtg	aaacagcggg	ggctgacttg	acatgctttg	tatgcttttc	atttgttctt	58680
gcagctgtat	gcccctaagg	tgagtccagc	ccccttctgc	ttcctctggg	gcctcgccag	58740
tgagccccac	cttgctgggg	ctggttcttc	ctgcccttct	gggtatccct	cacatctggg	58800
gtcttgtctt	cttggtttct	ttttcttttt	tttttgagac	ggagtttcac	ttttgttgcc	58860
caggcttcag	tgcaatgggt	tgatctctag	gctcaccgca	acctctgcct	cccaggttca	58920
agcagttccc	ctgcctcagc	ctccctagta	gctgggatta	caggcatgtg	ccaccacgcc	58980
cagctaattt	tgtattttta	gtagagatgg	ggtttctcca	tgttggtcag	gctgatcttg	59040
aactccctac	ctcagggtgat	ccgcccacct	tggcctccca	aagtgctggg	attacaggcg	59100
tgagccaccg	caactggcct	ttttcttttc	ttttcttttc	tttttctga	gacagggctt	59160
cgtctgttca	cccaggctgg	agtgaatgg	tgtcatcatg	gctaactgca	gcctctacct	59220
tctaggctca	agcaatcctc	ccatctcagc	ccctaagtag	ctaggactgc	acgcatgcat	59280
ccccatgccc	agctaataatt	tacatttttt	gtagagatga	agtttacta	tattgcccag	59340
gctggctctc	aactcctgga	ctcgagcgat	cctcctgcct	cggcctcccc	aggtgctggg	59400
attacaggcg	tgagccaccg	tgcctggcct	ggggatttgt	cttcttatgg	cacctgactg	59460

032796-132.ST25

tggtgggccc	tgggaaggaa	gtagcagaag	agggttcttc	ttggtttcct	ggacagtaac	59520
tgagtgttct	ggaggcccca	gggcctggct	ttgttttagg	acaaagggaa	ctggtaacca	59580
gaagccgaga	gtttaaacac	ccactgccct	tcttccctgc	tcctgctgct	gcaaccacagc	59640
ttaaccagcc	aggagtgcta	ggaacccaag	cagggccccc	gagcacacag	caggcagctc	59700
acgaattctc	ttttcctggt	ctcccttggg	agctgggagg	atcttaataca	ggcaataaga	59760
gatggcactg	agcagccagc	taatttttta	aatcacttta	ttgtttaacc	atatgactca	59820
cccacttaaa	aaagggtaaca	gttcagtggt	ttttagtgt	ttcacagatg	tgtgcaacc	59880
tcaccacagt	taattttaga	acattttcct	gcccctaaaa	gaaactctgc	atgaagccag	59940
ctgtttttta	attagcaaaag	ttattttgca	tcctttaaat	atatgttcat	ggtacaaaat	60000
tcaaaagata	cagaagagtc	tgcagtcct	agagactccg	cccccatgac	gccaaagcagg	60060
catccctggg	aggcatggcc	tctgagtg	tggttcttct	atgtccccc	aggggtcatc	60120
tgtacatatg	caagcatata	agagcgtgga	ctttgttttc	caagccagaa	gataattgta	60180
gatttatgtg	cagttgtgag	aaagagcaca	gaccatttta	tcctctgcct	ggtttcccc	60240
agtgtctgct	gccatcttgc	atgacttcca	ttcctatcat	aagcaagaca	ctgataacga	60300
ttctttcacc	ttattcagat	tgacataagt	gttttttgtt	tgttcttgag	acaaacttcc	60360
tctgtcacc	agtgggagtg	cagtggcaca	atcacagctc	actgcagcct	caaactcctg	60420
ggctcaagcg	attctcctgc	ctcagtcctc	tcaagtagct	cagatggcag	gtgtgcacca	60480
tcatgccagg	ctaattttta	aattttttgt	ggaggtgagg	cctcactaaa	tttctctggg	60540
tagtcttgaa	ctcctgagct	aaagtgatcc	ctctgcctca	gcctcccaa	gtggtaggat	60600
tacaggcatg	agccagctgc	cctgggctga	catatgtgtt	ttcgttaagcc	cgaaagatag	60660
catctgaaga	gtcaacattg	agccttgctt	tttctgtcta	acgatgtata	aaagctgctg	60720
ttctgagcat	ttcggaggct	cccagctgcc	gtgtgcacc	tgcttagagc	tctaccgtaa	60780
cccatctccg	ggaggagggtg	ctattgtttt	cctcattttg	caacaaggag	gctgaagaac	60840
tgagcatgaa	ccactggcct	gggtcgttcg	gttggtaggc	agtggggcca	ggccatccaa	60900
ctcacaacca	ccttctactc	tgcttcccc	gcaccctgaa	gtttgttctg	ttttgaggac	60960
acagccgtca	cattcttggt	ggctgaacag	cactccttgt	caggcgtggc	tgggccccca	61020
ctggaggggca	tcatggctct	ctctcctgct	gcggttgaa	cttggctgtt	tcaaccactc	61080
ctgccaaagt	gcccctctgaa	agggacagtc	catcttttct	cagcagaggg	ccacactggc	61140
aaaacgggtc	ctggcaccct	ttctctccac	ctgtctaata	tagagtaaaa	atggtatcat	61200
gttaagatct	tcattttatat	ttattttatc	atgaatgatg	taagcatcat	tttgtgtgtt	61260
taagaacctt	tgggcccagc	gtgatggctt	gcagctgtaa	tctcagcact	ttaggaggct	61320
gagatgagcg	gatcacttga	ggccgggagt	ttgagaccag	cctggccaac	atggagaaac	61380
cccgtctcta	gtaaaaaatt	aaaaattagc	cgggtatggt	gatcccagct	acttgggagt	61440
ctgaagcatg	agaattgctt	gaacatggga	ggcggaggtt	gcagtgaagg	gagatcgcg	61500
cattgcactc	cagcctgggc	gacagagcga	gactctgtct	caaaaaaaaa	aaaaaaaaaag	61560
aaaagaaaag	aaattatcaa	tctcctcttt	tatggcatat	atatatatat	atatatatat	61620
atatatatat	atatatatat	tttttttttg	gttatgttca	gaaaggcctt	ccctgctctg	61680
atcataaaaa	acaacttatt	ttcacactct	ctctcttttt	tttttgagac	agagttttgc	61740
tcctgttgcc	caggctggag	tgcagtggcg	caatctcagc	tcactgtaac	ctccgcctcc	61800
cgggttgag	tgattctcct	gccttacctt	cccagtagtc	tgggattata	ggcatgcacc	61860
accatgcctg	gctaattttg	tacttttagt	agagacgggg	gtttctccat	gttggtcagg	61920
ctggtctcga	actcgcgacc	tcaggtgata	caccacctc	ggcctcccaa	agtgtctggg	61980
ttacagacgt	gagccaccat	gcccagccca	cactctcttt	cttaacgtcc	tcctcctttc	62040
gttttacgtt	cacatcttta	attcttcttg	gatgtaatta	gatttgatga	gcaaggtggg	62100
catccagctt	gtttcttggc	tgatggctta	tgggtggcgt	gaattagtcg	gggtctatca	62160
ggaggcagaa	actctatgag	aatttgaaca	gagaaagttc	cgtctacagg	cttattacca	62220
gggactggaa	tagcagaaat	tgaacagtga	gatgtacaga	gaactctaag	aatgcaggaa	62280
taggccaggc	atggtggctc	acacctgtca	tcccagcact	ttgggagacc	aaggcgggtg	62340
gataccctga	ggtcaggagt	tcgagaccag	cctggccaac	atagtgaaac	cccatctcta	62400
ctaaaaatac	aaaaaaatta	gctgggtgtg	ctgtgcgcatg	cctgtaatcc	cagctactcg	62460
ggaggctgag	gcaggagaat	cacttgaacc	tgggaggcag	aggttgagct	gagccgagat	62520
catgccactg	tactccagcc	tgggtggaag	agcggaaact	tgtctgaaaa	aaaaaaaaaa	62580
aacaagaagt	tcaacttgaa	gggaaaaaat	ccgtattgtc	tttccctttg	ttatgtcacc	62640
agggcacagt	ccatcccagg	ctggcgctga	tccacgggct	ggagaggggc	tgccccagaa	62700
gaggacatgc	cagggaaggc	ttggctgggt	ttcaggagcc	caggccaggt	caggtcaaga	62760
ggtgttgagg	ctggacggga	gaggccagct	aggggctcat	gtaggatatg	aggggtcggc	62820
ccatttcaac	gtggaaactg	agctcttctg	cttctctttc	ttcttctactg	cattaagatt	62880

032796-132.ST25

caataccgct	tgggaagcag	gtatttcctt	tcctataaag	gatggttggg	agcctgagtg	62940
ttgggagaaa	gtgtagccgc	tgagttacta	acaactaggg	ctgccgtcaa	gcctatgggg	63000
aaagagagaa	gaggacattt	ggaaggagag	agatcaagct	gtggcaccct	gggagaggac	63060
cacagaaaag	aggccagtga	gggggttccc	cgggtggcatc	tgaaggtgtg	gccaaccag	63120
gaggtccaga	ggctgccagc	cgagtggccc	aggagaggga	acctcacagg	ggctgagtg	63180
gaccaagcc	ctatccaccg	tcctaaccac	ccacatttct	cgggaacaag	acctcccaca	63240
gtggcctccc	cggcagtggg	aatagccaaa	ctggcaacat	ggactttctt	caactgccc	63300
ggcgatgctg	cctcagtgcc	ccagggcagg	cagggaagctc	ccacacccat	tctggaatga	63360
ggggttggag	gaaggctgag	ctgagcaaa	gacccatctc	tgtctgtggt	ggtggggagg	63420
gagccatta	tacaagagac	ccctcagggc	tcagttaggg	gtgacagaga	cttggggagt	63480
agtggctgtc	actgcagagg	tgagagggtt	tggagagaag	gtacatgcct	ttttggccac	63540
attgagtagc	acctggtagc	cagttagtaa	cgtgtattgg	ataaataaaa	gattaaacgg	63600
atgcaaaaaa	aaatgttggc	tttgcttctt	tttaccctaa	cctcagttcc	ctcaagtaga	63660
ttctgggaac	acccctacc	tggctggact	gttgtgaagt	ttaaataagc	caggttaact	63720
tcacctcctc	ctttaagaca	cagctcagac	actgcctcct	ccaagaagcc	ccctctggct	63780
tctgtgtga	atatgacggc	cctctgggct	ctagggtatc	ttagaacaat	gcttccttat	63840
ggctttggaa	ccccgctgtc	tcttgattg	ggagcaaatg	caggggagga	gccacacctg	63900
actaatctct	gggtctccca	gcacataagt	ggcataaggg	cagggtctgt	cccgtctcag	63960
gcacttactg	aaggatgtac	ttggcagagg	gtaggcagcc	ggcggatgag	ccctcactc	64020
tccccagctg	actgcgtggg	cgggaaaggc	gggttcagga	gacccagcct	ccctgggctg	64080
tcaccacctc	tgcacatcca	gccccattga	tcaagggttc	aatttttggg	gtcctgttgg	64140
gaggccagga	gactctctcc	aggcacttct	tccagggtctt	tgtgttaggg	tgtgtgtgtg	64200
tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtt	gttttatttt	atttatttat	ttatttattt	64260
atttatttat	ttatttattt	tgagacgcag	tctcgctctg	ttgccagggt	tgagggtgtg	64320
tggcatgac	tcggctcact	gcaagctccg	cctcccgggt	tcacgccatt	ctcctgcctc	64380
actcttctctg	agtagccgga	ttacaggcgc	acgcaccatg	cctggctaata	tattttgttt	64440
ttttagtaga	gacagggttt	cgccacgttg	cccaggctgg	tcttgaatcc	ctggcctcaa	64500
gcgatccgcc	cgcctcagcc	tcccaaagtg	ctgggattac	aggcgtgagc	caccgtgcc	64560
gccagcccta	ggggtacatg	aaactttttt	tttttttttt	ttgagacaga	gtttcactct	64620
gtcctcaggg	tggagtgcag	tggcgtgatc	tcggcgtact	gcaatctccg	cctcccgggt	64680
caagcgattc	tcctgcctca	gcctcccag	tagctgggat	tgcaggcacg	cgccaccaca	64740
cccagctaata	ttttgtattt	ttagtagaga	cgggctttca	ccatgtggga	caggatggtc	64800
tcgatctcct	gacctcgtga	tcggcccgc	tcagcctccg	aaagtgtctg	gattacaggc	64860
ctgagccacc	gtgcccagcc	atgatgtttt	gatacaggga	tataacgtat	aataatcaca	64920
tcagggtaaa	tgatgtaacc	atcacatcaa	gcatttatcc	tttgtgttac	aaaaaaaaat	64980
ctaattatac	tttcctactt	attctttttt	tttttttttt	ttgagacgga	gtctccctca	65040
gtcgcccagg	ctggagtgca	gtggcatgat	ctcagttcac	tgcaagctct	gcctcctagc	65100
tctgcctcct	gggttcatgc	cattctcctg	tctcagcctc	gcgagtagct	gggactacag	65160
gcgcctgcca	ccgtgcccg	ctaatttttt	ttttgtatt	tttggttagag	acagggtttc	65220
accgtgttag	ccaggatgg	ctcgatctcc	tgacctcata	atccgcccgt	ctcgccctcc	65280
caaagtgtctg	ggattacagg	catgagccac	cgccccagc	ctatttatcc	ttaaatgtac	65340
aataaattat	tgttgactcc	agtcaccctg	ctgtgtctacc	aaatacggat	cttcttcatt	65400
ctatctaact	gtattttctgt	acctgttaac	catctctcct	ccacctcacc	ccccaaaccc	65460
actacccttc	tcagcctctg	gtaaccatcc	ttctactctc	tatctctatg	agttcaattg	65520
tattaatttt	tagctccccg	gccgggcacg	gtggctcacg	cctgtaatcc	cagcacttca	65580
ggaggctgag	gcagggtgat	cacgaggtca	ggagtttgag	accagcctgg	ccaacatggt	65640
ggaaccccat	ctctactaaa	aacacaaaaa	ttagctgggc	gtggtggtgg	gcgctttag	65700
tcccagctac	ttgggaggct	gaggcaggag	aatcgcttga	aactgggagg	cagagggttc	65760
agttagccaa	gattgcgcca	ctgcactcca	gtctgggtga	cagagtaaga	ttccatcccc	65820
aaaaaaaaaa	agtttagctc	ccacaaaata	gtgagaacac	gtgaagtctc	tctttctgtg	65880
cctcgcttgt	ttcacttaac	ataatgacct	ccagttccat	ccacgttgtt	gctttgttat	65940
aatgacagg	atcttgggtca	ggcgagtg	ctcatgcctg	taatcccagc	actttgggag	66000
gctgagggtg	actgatcatg	aggtcaagag	atcgagacca	tcctggctaa	cacagtga	66060
ccccgtctct	actaaaaata	caagaaatta	gccgggcgtg	gtggtgggca	cccatttccg	66120
ccccttctcg	ggacgctgat	gcacgacata	ttaccatcc	ccggaagact	aatcctcccc	66180
cactctatat	tgtacctctt	cctttctcct	ccacgcgatt	ccccgagtaa	cccgtcttcc	66240
ctccctcctc	ggattacgct	cacctttccg	cttcaatcac	gttgctccgt	ccccttcccc	66300

032796-132.ST25

attcgtacca	ctcctcaett	togtcttct	acccccacta	tcccttttcg	tcctctctat	66360
tccttactta	ctcctcccc	ttctcttcat	acttcattcc	ctccgctctt	cccactcgcg	66420
ctcccacttt	cacctagtgt	ccctcaccta	cgttgccatc	tcgccccttc	ttcagctctc	66480
ggcctctcac	ccatctgtcc	tctctcttac	ctctctcctc	atctcgctca	gacatctctc	66540
tagactatcc	ctcactttac	cttctcagtc	gtcttcttcc	tatccttcgt	tctccatgat	66600
cttcacgtcg	ccatctcttt	togccccctt	catatgtctc	tcttcatgtt	ctcactatca	66660
ttctcatgat	cactatcggt	ctcactactt	atcactcccc	tctttcttca	tcaattcctc	66720
tccgtcattc	togtctctct	cttacaaccg	ccttccttgt	gctatctaac	tcaaccatgc	66780
ctctcctact	ctctctctat	cgcccctcca	tcgcttatgc	atcctcttct	attgcacacc	66840
cgcccctcca	tcgcttatgc	atcctcttct	attgcacacc	gccctccat	cgcttatgca	66900
tcctcttcta	ttgcacatcc	tcttctattg	cac			66933

<210> 12
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 12
 ctgagcggaa ttcgtgagac c 21

<210> 13
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 13
 ttggtctcac gtattccgct cga 23

<210> 14
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 14
 ctcgagaatt ctggatcctc 20

<210> 15
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

032796-132.ST25

<400> 15
ttgaggatcc agaattctcg ag 22

<210> 16
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 16
tgtatgcgaa ttcgctgcgc g 21

<210> 17
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 17
ttcgcgcagc gaattcgcac aca 23

<210> 18
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 18
gtccactgaa ttctcagtga g 21

<210> 19
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 19
ttgtcactga gaattcagtg gac 23

<210> 20
<211> 21
<212> DNA
<213> Artificial Sequence

032796-132.ST25

<220>

<223> Primer

<400> 20

gaatccgaat tcctggtcag c

21

<210> 21

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 21

ttgctgacca ggaattcgga ttc

23

<210> 22

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 22

cuacuacuac uactgagcgg aattcgtgag acc

33

<210> 23

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 23

cuacuacuac uactcgagaa ttctggatcc tc

32

<210> 24

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 24

cuacuacuac uatgtatgcg aattcgctgc gcg

33

<210> 25

032796-132.ST25

<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 25
cuacuacuac uagtcactg aattctcagt gag 33

<210> 26
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 26
cuacuacuac uagaatccga attcctgggc agc 33

<210> 27
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 27
aactggaaga attcgcggcc gcaggaattt tttttttttt ttttt 45

<210> 28
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 28
aattcggcac gag 13

<210> 29
<211> 9
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 29
ctcgtgccg 9

032796-132.ST25

<210> 30
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 30
gtacgacggc cagt

14

<210> 31
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 31
aacagctatg accatg

16

<210> 32
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 32
ccaagttctg agaagtcc

18

<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 33
aatacctgaa accatacctg

20

<210> 34
<211> 57
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

032796-132.ST25

<400> 34
agctgctcgt agctgtctct ccctggatca cgggtacatg tactggacag actgggt 57

<210> 35
<211> 56
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 35
tgagacgccc ggattgagcg ggcagggata gcttattccc tgtgccgcat tacggc 56

<210> 36
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 36
agctgctcgt agctgtctct ccctgga 27

<210> 37
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 37
gccgtaatgc ggcacagga ataagct 27

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 38
gagaggctat atccctgggc 20

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

032796-132.ST25

<220>

<223> Primer

<400> 39

acagcacgtg tttaaagggg

20

<210> 40

<211> 163

<212> DNA

<213> Homo sapiens

<400> 40

actaaagcgc	cgccgccgcg	ccatggagcc	cgagtgaact	cgccgccggc	ccgtccggcc	60
gccggacaac	atggaggcag	ctccgcccg	gccgccgtgg	ccgtgctgc	tgctgctgct	120
gctgctgctg	gcgctgtgcg	gctgcccgcc	ccccgccgcg	gcc		163

<210> 41

<211> 419

<212> DNA

<213> Homo sapiens

<400> 41

gccccacagc	ctcgccgctc	ctgctatttg	ccaaccgccg	ggacgtacgg	ctggtggacg	60
ccggcggagt	caagctggag	tccaccatcg	tggtcagcgg	cctggaggat	gcggccgcag	120
tggacttcca	gttttccaag	ggagccgtgt	actggacaga	cgtgagcgag	gaggccatca	180
agcagaccta	cctgaaccag	acgggggccg	ccgtgcagaa	cgtggtcac	tccggcctgg	240
tctctcccga	cggcctcgcc	tgcgactggg	tgggcaagaa	gctgtactgg	acggactcag	300
agaccaaccg	catcgagggtg	gccaacctca	atggcacatc	ccggaagggtg	ctcttctggc	360
aggaccttga	ccagccgagg	gccatcgcc	tggaccccg	tcacgggtaa	accctgctg	419

<210> 42

<211> 221

<212> DNA

<213> Homo sapiens

<400> 42

ccccgtcaca	ggtacatgta	ctggacagac	tggggtgaga	cgccccggat	tgagcgggca	60
gggatggatg	gcagcaccgc	gaagatcatt	gtggactcgg	acatttactg	gccaatgga	120
ctgaccatcg	acctggagga	gcagaagctc	tactgggctg	acgccaagct	cagcttcac	180
caccgtgcc	acctggacgg	ctcgttcccg	taggtaccca	c		221

<210> 43

<211> 221

<212> DNA

<213> Homo sapiens

<400> 43

tccctgactg	caggcagaag	gtggtggagg	gcagcctgac	gcaccccttc	gccctgacgc	60
tctccgggga	cactctgtac	tggaacagact	ggcagaccgc	ctccatccat	gcctgcaaca	120
agcgactgg	ggggaagagg	aaggagatcc	tgagtgccct	atactcacc	atggacatcc	180
aggtgctgag	ccaggagcgg	cagccttttt	gtgagtgccg	g		221

032796-132.ST25

<210> 44
 <211> 156
 <212> DNA
 <213> Homo sapiens

<400> 44
 tttctcagtc cacactcgct gtgaggagga caatggcggc tgggtcccacg tgtgcctgct 60
 gtccccaagc gagccttttt acacatgcgc ctgccccacg ggtgtgcaga tgcaggacaa 120
 cggcaggacg tgtaaggcag gtgaggcggg gggacg 156

<210> 45
 <211> 416
 <212> DNA
 <213> Homo sapiens

<400> 45
 ctccacagga gccgaggagg tgctgctgct ggcccggcgg acggacctac ggaggatctc 60
 gctggacacg ccggacttca ccgacatcgt gctgcagggtg gacgacatcc ggcacgccat 120
 tgccatcgac tacgaccgcg tagagggcta tgtctactgg acagatgacg aggtgcgggc 180
 catccgcagg gcgtacctgg acgggtctgg ggccgcagacg ctggtcaaca ccgagatcaa 240
 cgaccccgat ggcatcgcgg tcgactgggt ggcccgaac ctctactgga ccgacacggg 300
 cacggaccgc atcgagggtga cgcgcctcaa cggcacctcc cgcaagatcc tgggtgtcga 360
 ggacctggac gagccccgag ccacgcgact gcaccccggt atggggtaag acgggc 416

<210> 46
 <211> 198
 <212> DNA
 <213> Homo sapiens

<400> 46
 ttcttctcca gcctcatgta ctggacagac tggggagaga accctaaaat cgagtgtgcc 60
 aacttgatg ggcaggagcg gcgtgtgctg gtcaatgcct ccctcgggtg gcccacggc 120
 ctggccctgg acctgcagga ggggaagctc tactggggag acgccaagac agacaagatc 180
 gaggtgaggc tcctgtgg 198

<210> 47
 <211> 244
 <212> DNA
 <213> Homo sapiens

<400> 47
 ccgtcctgca ggtgatcaat gttgatggga cgaagaggcg gaccctcctg gaggacaagc 60
 tcccgcatat ttctcgggttc acgctgctgg gggacttcat ctactggact gactggcagc 120
 gccgcagcat cgagcgggtg cacaagggtca aggccagccg ggacgtcatc attgaccagc 180
 tgcccagacct gatggggctc aaagctgtga atgtggccaa ggctcgtcggg gagtccgggg 240
 ggtc 244

<210> 48
 <211> 313
 <212> DNA
 <213> Homo sapiens

032796-132.ST25

<400> 48
 gttcgttcc aggaaccaac ccgtgtgctg acaggaacgg ggggtgcagc cacctgtgct 60
 tctgcacacc ccacgcaacc cgggtgtggct gccccatcgg cctggagctg ctgagtgcaca 120
 tgaagacctg catcgtgcct gaggcctttt tggctctcac cagcagagcc gccatccaca 180
 ggatctccct cgagaccaat aacaacgacg tggccatccc gtcacgggc gtcaaggagg 240
 cctcagccct ggactttgat gtgtccaaca accacatcta ctggacagac gtcagcctga 300
 aggtagcgtg ggc 313

<210> 49
 <211> 255
 <212> DNA
 <213> Homo sapiens

<400> 49
 cctgtgcca gaccatcagc cgcgccttca tgaacgggag ctggtggag cacgtggtgg 60
 agtttggcct tgactacccc gagggcatgg ccgttgactg gatgggcaag aacctctact 120
 gggccgacac tgggaccaac agaatcgaag tggcgcggt ggacgggcag ttccggcaag 180
 tcctcgtgtg gagggacttg gacaaccga ggtcgtggt cctggatccc accaaggggt 240
 aagtgtttgc ctgtc 255

<210> 50
 <211> 210
 <212> DNA
 <213> Homo sapiens

<400> 50
 gtgccttcca gctacatcta ctggaccgag tggggcggca agccgaggat cgtgcggggc 60
 ttcattgacg ggaccaactg catgacgctg gtggacaagg tgggccgggc caacgacctc 120
 accattgact acgctgacca gcgcctctac tggaccgacc tggacaccaa catgatcgag 180
 tcgtccaaca tgctgggtga gggccggggt 210

<210> 51
 <211> 352
 <212> DNA
 <213> Homo sapiens

<400> 51
 gtgttcatgc aggtcaggag cgggtcgtga ttgccgacga tctcccgcac ccgttcgggtc 60
 tgacgcagta cagcgattat atctactgga cagactggaa tctgcacagc attgagcggg 120
 ccgacaagac tagcggccgg aaccgcaccc tcatccaggg ccacctggac ttcgtgatgg 180
 acatcctggt gttccactcc tcccgccagg atggcctcaa tgactgtatg cacaacaacg 240
 ggcagtgtgg gcagctgtgc cttgccatcc ccggcgcca ccgctgcggc tgcgcctcac 300
 actacaccct ggacccacgc agccgcaact gcagccgtaa gtgcctcatg gt 352

<210> 52
 <211> 225
 <212> DNA
 <213> Homo sapiens

<400> 52
 gcctcctcta cgcccaccac cttcttctgt ttcagccaga aatctgccat cagtcggatg 60
 atcccgacg accagcacag cccggatctc atcctgcccc tgcattggact gaggaacgtc 120
 aaagccatcg actatgaccc actggacaag ttcattctact ggttgatgg gcgccagaac 180

032796-132.ST25

atcaagcgag ccaaggacga cgggacccag gcaggtgccc tgtgg 225

<210> 53
 <211> 235
 <212> DNA
 <213> Homo sapiens

<400> 53
 ctttgtctta cagccctttg ttttgacctc tctgagccaa ggccaaaacc cagacaggca 60
 gccccacgac ctcagcatcg acatctacag ccggacactg ttctggacgt gcgaggccac 120
 caataccatc aacgtccaca ggctgagcgg ggaagccatg ggggtggtgc tgcgtgggga 180
 ccgcgacaag cccagggccca tcgtcgtcaa cgcgagcga gggtaggagg ccaac 235

<210> 54
 <211> 218
 <212> DNA
 <213> Homo sapiens

<400> 54
 ccaccctccc gcaggtacct gtacttcacc aacatgcagg accgggcagc caagatcgaa 60
 cgcgcagccc tggacggcac cgagcgcgag gtcctcttca ccaccggcct catccgccct 120
 gtggccctgg tgggtggacaa cacactgggc aagctgttct ggggtggacgc ggacctgaag 180
 cgcattgaga gctgtgacct gtcaggtacg cgccccgg 218

<210> 55
 <211> 234
 <212> DNA
 <213> Homo sapiens

<400> 55
 ggctgcttgc aggggccaaac cgctgacctc tggaggacgc caacatcgtg cagcctctgg 60
 gcctgaccat ccttggaag catctctact ggatcgaccg ccagcagcag atgatcgagc 120
 gtgtggagaa gaccaccggg gacaagcgga ctcgcatcca gggccgtgc gccaccta 180
 ctggcatcca tgcagtggag gaagtcagcc tggaggagtt ctgtacgtgg gggc 234

<210> 56
 <211> 157
 <212> DNA
 <213> Homo sapiens

<400> 56
 ttgtctttgc agcagccac ccatgtgccc gtgacaatgg tggctgctcc cacatctgta 60
 ttgccaagggt tgatgggaca ccacgggtgt catgccagtt ccacctcgtg ctctgcaga 120
 acctgctgac ctgtggaggt aggtgtgacc taggtgc 157

<210> 57
 <211> 272
 <212> DNA
 <213> Homo sapiens

<400> 57
 gttctcctct gtccctcccc cagagccgcc cacctgctcc ccggaccagt ttgcatgtgc 60

032796-132.ST25

cacaggggag	atcgactgta	tccccggggc	ctggcgctgt	gacggctttc	ccgagtgcga	120
tgaccagagc	gacgaggagg	gctgccccgt	gtgctccgcc	gcccagttcc	cctgcgcgcg	180
gggtcagtg	gtggacctgc	gcctgcgctg	cgacggcgag	gcagactgtc	aggaccgctc	240
agacgagg	gactgtgacg	gtgaggccct	cc			272

<210> 58

<211> 134

<212> DNA

<213> Homo sapiens

<400> 58

tctccttgca	gccatctgcc	tgcccaacca	gttccggtgt	gcgagcggcc	agtgtgtcct	60
catcaaacag	cagtgcgact	ccttccccga	ctgtatcgac	ggctccgacg	agctcatgtg	120
tggtgagcca	gctt					134

<210> 59

<211> 274

<212> DNA

<213> Homo sapiens

<400> 59

gtttgtctct	ggcagaaatc	accaagccgc	cctcagacga	cagcccggcc	cacagcagtg	60
ccatcgggcc	cgtcattggc	atcatcctct	ctctcttcgt	catgggtggg	gtctattttg	120
tgtgccagcg	cgtgggtgtg	cagcgctatg	cgggggccaa	cgggcccttc	ccgcacgagt	180
atgtcagcgg	gaccccgcac	gtgcccctca	atttcatagc	cccgggcggg	tcccagcatg	240
gccccttcac	aggtaaggag	cctgagatat	ggaa			274

<210> 60

<211> 164

<212> DNA

<213> Homo sapiens

<400> 60

cttccctgcc	aggcatcgca	tgcggaaggt	ccatgatgag	ctccgtgagc	ctgatggggg	60
gccggggcgg	gggtgccctc	tacgaccgga	accacgtcac	aggggcctcg	tccagcagct	120
cgtccagcac	gaaggccacg	ctgtaccgcg	cgggtgagggg	cggg		164

<210> 61

<211> 130

<212> DNA

<213> Homo sapiens

<400> 61

ttggctctcc	tcagatcctg	aacccgcccgc	cctccccggc	cacggacccc	tccctgtaca	60
acatggacat	gttctactct	tcaaacattc	cggccactgc	gagaccgtac	aggtaggaca	120
tcccctgcag						130

<210> 62

<211> 496

<212> DNA

<213> Homo sapiens

032796-132.ST25

<400> 62

tcaaacattc	cggccactgc	gagaccgtac	aggccctaca	tcattcgagg	aatggcgccc	60
ccgacgacgc	cctgcagcac	cgacgtgtgt	gacagcgact	acagcgccag	ccgctggaag	120
gccagcaagt	actacctgga	tttgaactcg	gactcagacc	cctatccacc	cccaccacg	180
ccccacagcc	agtacctgtc	ggcggaggac	agctgcccgc	cctcgcccgc	caccgagagg	240
agctacttcc	atctcttccc	gccccctccg	tccccctgca	cggactcatc	ctgacctcgg	300
ccgggccact	ctggcttctc	tgtgcccctg	taaatagttt	taaaatgaa	caaagaaaaa	360
aatatatatt	atgattttaa	aaataaatat	aattgggatt	ttaaaaacat	gagaaatgtg	420
aactgtgatg	gggtgggcag	ggctgggaga	actttgtaca	gtggagaaat	atttataaac	480
ttaattttgt	aaaaca					496

<210> 63

<211> 3081

<212> DNA

<213> Homo sapiens

<400> 63

cccgccagcc	cagcccagcc	caaccctact	ccctcccccac	gccagggcag	cagccgtttgc	60
tcagagagaa	ggtggaggaa	gaaatccaga	ccctagcacg	cgcgacccat	catggaccat	120
tatgattctc	agcaaaccaa	cgattacatg	cagccagaag	aggactggga	ccgggacctg	180
ctcctggacc	cggcctggga	gaagcagcag	agaaagacat	tcacggcatg	gtgtaactcc	240
cacctccgga	aggcggggac	acagatcgag	aacatcgaag	aggacttccg	ggatggcctg	300
aagctcatgc	tgctgttgga	ggctatctca	ggtgaacgct	tggccaagcc	agagcgaggc	360
aagatgagag	tgcacaagat	ctccaacgtc	aacaaggccc	tggatttcat	agccagcaaa	420
ggcgtcaaac	tgggtgtccat	cggagccgaa	gaaatcgtgg	atgggaatgt	gaagatgacc	480
ctgggcatga	tctggaccat	catcctgcgc	tttgccatcc	aggacatctc	cgtggaagag	540
acttcagcca	aggaagggct	gtcctctgtg	tgtcagagaa	agacagcccc	ttacaaaaat	600
gtcaacatcc	agaacttcca	cataagctgg	aaggatggcc	tcggttcttg	tgttttgatc	660
caccgacacc	ggcccagagct	gattgactac	gggaagctgc	ggaaggatga	tccactcaca	720
aatctgaata	cggcttttga	cgtggcagag	aagtacctgg	acatcccaa	gatgctggat	780
gccgaagaca	tcgttggaa	tgcccagccg	gatgagaaag	ccatcatgac	ttacgtgtct	840
agcttctacc	acgccttctc	tggagcccag	aaggcggaga	cagcagccaa	tcgcatctgc	900
aagggtgttg	ccgtcaacca	ggagaacgag	cagcttatgg	aagactacga	gaagctggcc	960
agtgatctgt	tggagtggat	ccgcgcaca	atcccgtggc	tggagaaccg	ggtgcccag	1020
aacaccatgc	atgccatgca	acagaagctg	gaggacttcc	gggactaccg	gcgcctgcac	1080
aagccgcccc	aggtgcagga	gaagtgccag	ctggagatca	acttcaacac	gctgcagacc	1140
aagctgcggc	tcagcaaccg	gcctgccttc	atgccctctg	agggcaggat	ggtctcggac	1200
atcaacaatg	cctggggctg	cctggagcag	gtggagaagg	gctatgagga	gtggttgctg	1260
aatgagatcc	ggaggctgga	gcgactggac	cacctggcag	agaagttccg	gcagaaggcc	1320
tccatccacg	aggcctggac	tgacggcaaa	gaggccatgc	tgcgacagaa	ggactatgag	1380
accgccaccc	tctcggagat	caaggccttg	ctcaagaagc	atgaggcctt	cgagagtgc	1440
ctggctgccc	accaggaccg	tgtggagcag	attgccgcca	tcgcacagga	gctcaatgag	1500
ctggactatt	atgactcacc	cagtgtcaac	gcccgttgcc	aaaagatctg	tgaccagtgg	1560
gacaatctgg	gggccctaac	tcagaagcga	agggaagctc	tggagcggac	cgagaaactg	1620
ctggagacca	ttgaccagct	gtacttggag	tatgccaaag	gggctgcacc	cttcaacaac	1680
tggatggagg	gggccatgga	ggacctgcag	gacaccttca	ttgtgcacac	cattgaggag	1740
atccagggac	tgaccacagc	ccatgagcag	ttcaaggcca	ccctccctga	tgccgacaag	1800
gagcgcttg	ccatcctggg	catccacaat	gagggtgtcca	agattgtcca	gacctaccac	1860
gtcaatatgg	cgggcaccaa	cccctacaca	accatcacgc	ctcaggagat	caatggcaaa	1920
tgggaccacg	tgcggcagct	ggtgcctcgg	agggaccaag	ctctgacgga	ggagcatgcc	1980
cgacagcagc	acaatgagag	gctacgcaag	cagtttggag	cccaggccaa	tgtcatcggg	2040
ccctggatcc	agaccaagat	ggaggagatc	gggaggatct	ccattgagat	gcatgggacc	2100
ctggaggacc	agctcagcca	cctgcggcag	tatgagaaga	gcatcgtcaa	ctacaagcca	2160
aagattgatc	agctggaggg	cgaccaccag	ctcatccagg	agggcgtcat	cttcgacaac	2220
aagcacacca	actacaccat	ggagcacatc	cgtgtgggct	gggagcagct	gctcaccacc	2280
atcgccagga	ccatcaatga	ggtagagaac	cagatcctga	cccgggatgc	caagggcac	2340

032796-132.ST25

agccaggagc	agatgaatga	gttccgggcc	tccttcaacc	actttgaccg	ggatcaactcc	2400
ggcacactgg	gtccccgagga	gttcaaagcc	tgccctcatca	gcttgggtta	tgatattggc	2460
aacgaccccc	agggagaagc	agaatttgcc	cgcacatga	gcattgtgga	ccccaaccgc	2520
ctgggggtag	tgacattcca	ggccttcatt	gacttcatgt	cccgcgagac	agccgacaca	2580
gatacagcag	accaagtcac	ggcttccttc	aagatcctgg	ctgggggacaa	gaactacatt	2640
accatggacg	agctgcgcgc	cgagctgcc	cccgaaccag	ctgagtactg	catcgcgcg	2700
atggccccct	acaccggccc	cgactccgtg	ccaggtgctc	tggactacat	gtccttctcc	2760
acggcgctgt	acggcgagag	tgacctctaa	tccaccccg	ccggccgccc	tctgtctgtg	2820
cgcctgtccc	acagatgtga	aatgaatgta	atctaataga	agcctaataca	gcccaccatg	2880
ttctccactg	aaaaatcctc	tttctttggg	gtttttcttt	ctttcttttt	tgattttgca	2940
ctggacgggtg	acgtcagcct	gtacaggctc	ccaggggtgg	cgtcaaatgc	tattgaaatt	3000
gcgctgaatc	gtatgctttt	tccttttgat	aaataaaca	tgtaaaaatg	tttcaaaaac	3060
ctaataaaat	aaataaatac	g				3081

<210> 64

<211> 1324

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)...(1324)

<223> n = A,T,C or G

<400> 64

ggcgcgcccg	cgccccagc	agnccgagcc	ggggcgacaca	gncggggcg	agccccgcgc	60
ccccgcgcgc	attgacatga	tgtttccaca	aagcaggcat	tggggtcct	cgacacctacc	120
ccagcaactc	aaattcacca	cctcggactc	ctgcgaccgc	atcaaagacg	aatttcagct	180
actgcaagct	cagtaccaca	gcctcaagct	cgaatgtgac	aagttggcca	gtgagaagtc	240
agagatgcag	cgtcactatg	tgatgtacta	cgagatgtcc	tacggcttga	acatcgagat	300
gcacaaacag	gctgacatcg	tcaaaaggct	gaacgggatt	tgtgcccagg	tcctgcctta	360
cctctcccaa	gagcaccagc	agcaggctct	gggagccatt	gagagggcca	agcaggtcac	420
cgctcccgag	ctgaactcta	tcatccgaca	gcagctccaa	gcccaccagc	tgteccagct	480
gcaggccctg	gccctgccct	tgacccccact	acccgtgggg	ctgcagccgc	cttegtgtgc	540
ggcggtcagc	gcaggcaccg	gcctcctctc	gctgtccgcg	ctgggttccc	aggccacct	600
ctccaaggaa	gacaagaacg	ggcacgatgg	tgacaccac	caggaggatg	atggcgagaa	660
gtcggattag	cagggggccg	ggacaggag	gttgggagg	gggacagagg	ggagacagag	720
gcacggagag	aaaggaatgt	ttagcacaag	acacagcgga	gctcgggatt	ggctaattct	780
ccatagtatt	tatggtggcg	ccggcggggc	cccagcccag	cttgaggcc	acctctagct	840
ttcttctctac	cccattecg	cttccctcct	cctccctgc	agcctgggtta	ggtggataacc	900
tgccctgaca	tgtgaggcaa	gctaaggcct	ggagggtcag	atgggagacc	aggtcccaag	960
ggagcaagac	ctgcgaagcg	cagcagcccc	ggcccttccc	ccgttttgaa	catgtgtaac	1020
cgacagtctg	ccctgggcca	cagccctctc	accctgttac	tgcatgcacg	caatgctagc	1080
tgcccccttc	ccgtcctggg	caccccgagt	ctccccgcac	cccgggtccc	aggtatgtct	1140
ccacctccac	ctgccccact	caccacctct	gctagtcca	gacacctcca	cgccccctg	1200
gtcctctccc	atcgcccaca	aaaggggggg	cacgaggag	gagcttagct	gagctgggag	1260
gagcagggtg	agggtgggag	acccaggatt	ccccctcccc	ttcccaaata	aagatgaggg	1320
tact						1324

<210> 65

<211> 2377

<212> DNA

<213> Homo sapiens

<400> 65

ggtgacaaag	agccaacaga	gacaatagga	gacttgtcaa	tttgtcttga	tgggctacag	60
------------	------------	------------	------------	------------	------------	----

032796-132.ST25

ttagagtctg	aagttgttac	caatggtgaa	actacatgtt	cagaaagtgc	ttctcagaat	120
gatgatggct	ccagatccaa	ggatgaaaca	agagttagca	caaattggatc	agatgaccct	180
gaagatgcag	gagctgggtga	aaataggaga	gtcagtgagg	ataattctcc	atcactctca	240
aatgggtggt	ttaaaccttc	tagacctcca	agaccttcac	gaccaccacc	acccacccca	300
cgtagaccag	catctgtcaa	tggttcacca	tctgccactt	ctgaaagtga	tgggtctagt	360
acaggctctc	tgccgccgac	aaatacaaat	acaaatacat	ctgaaggagc	aacatctgga	420
ttaataattc	ctcttactat	atctggaggc	tcaggcccta	ggccattaaa	tcctgtaact	480
caagctccct	tgccacctgg	ttgggagcag	agagtggacc	agcacgggcg	agtttactat	540
gtagatcatg	ttgagaaaag	aacaacatgg	gatagaccag	aacctctacc	tcctggctgg	600
gaacggcggg	ttgacaacat	gggacgtatt	tattatgttg	accatttcac	aagaacaaca	660
acgtggcaga	ggccaacact	ggaatccgtc	cggaaactatg	aacaatggca	gctacagcgt	720
agtcagcttc	aaggagcaat	gcagcagttt	aaccagagat	tcatttatgg	gaatcaagat	780
ttatttgcta	catcacaaag	taaagaattt	gatcctcttg	gtccattgcc	acctggatgg	840
gagaagagaa	cagacagcaa	tggcagagta	tatttcgtca	accacaacac	acgaattaca	900
caatgggaag	accccgagaag	tcaaggtcaa	ttaaatgaaa	agcccttacc	tgaaggttgg	960
gaaatgagat	tcacagtggg	tgggaattcca	tattttgtgg	accacaatag	aagaactacc	1020
acctatatag	atccccgcac	aggaaaatct	gccctagaca	atggacctca	gatagcctat	1080
gttcgggact	tcaaagcaaa	ggttcagtat	ttccggttct	ggtgtcagca	actggccatg	1140
ccacagcaca	taaagattac	agtgacaaga	aaaacattgt	ttgaggattc	ctttcaacag	1200
ataatgagct	tcagtcccca	agatctgcga	agacgtttgt	gggtgatttt	tccaggagaa	1260
gaaggttttag	attatggagg	tgtagcaaga	gaatggttct	ttcttttgtc	acatgaagtg	1320
ttgaacccaa	tgtattgcct	gtttgaatat	gcagggaagg	ataactactg	cttgacagata	1380
aaccccgctt	cttacatcaa	tccagatcac	ctgaaatatt	ttcgttttat	tggcagattt	1440
attgccatgg	ctctgttcca	tgggaaattc	atagacacgg	gtttttcttt	accattctat	1500
aagcgtatct	tgaacaaacc	agttggactc	aaggatttag	aatctattga	tccagaattt	1560
tacaattctc	tcactctggg	taaggaaaac	aattattgag	aatgtgattt	ggaaatgtac	1620
ttctccggtg	acaaagaaat	tctaggtgaa	attaagagtc	atgatctgaa	acctaattgg	1680
ggcaatattc	ttgtaacaga	agaaaataaa	gaggaatata	tcagaatggt	agctgagtg	1740
agggtgtctc	gaggtgttga	agaacagaca	caagctttct	ttgaaggctt	taatgaaatt	1800
cttccccagc	aatatttgca	atactttgat	gcaaaggaaat	tagaggctct	tttatgtgga	1860
atgcaagaga	ttgatattgaa	tgactggcaa	agacattgcca	tctaccgtca	ttatgcaagg	1920
accagcaaac	aaatcatgtg	gttttggcag	tttgttaaag	aaattgataa	tgagaagaga	1980
atgagacttc	tgcagtttgt	tactggaaac	tgccgattgc	cagtaggagg	atttgctgat	2040
ctcatgggga	gcaatggacc	acagaaatcc	tgcattgaaa	aagttgggaa	agaaaattgg	2100
ctaccagaa	gtcatacctg	ttttaatcgc	ctggacctgc	caccatacaa	gagctatgag	2160
caactgaagg	aaaagctgtt	gtttgccata	gaagaaacag	aaggatttgg	acaagagtaa	2220
cttctgagaa	cttgaccat	gaatgggcaa	gaacttattt	gcaatgtttg	tccttctctg	2280
cctgttgac	atcttgtaaa	attggacaat	ggctcttttag	agagttatct	gagtgttaagt	2340
aaattaatgt	tctcatttaa	aaaaaaaaaa	aaaaaaa			2377

<210> 66

<211> 1295

<212> DNA

<213> Homo sapiens

<400> 66

ggggcgccgc	ccaccggggc	cttgccctcta	cctcagtcgt	tgccccccga	ttttcggtg	60
gagcccacgg	ccccggccct	cagccccgc	tctagcttcg	ccagtagctc	ggccagcgac	120
gcgagcaagc	cgtccagccc	ccggggcagc	ctgctgctgg	acggggcggg	ggctggcgga	180
gctggaggta	gccggccctg	cagcaatcgc	accagcgcca	tcagcatggg	ctacgaccag	240
cgccacggga	gccccttgcc	agcggggccg	tgctgtttg	gcccaccctt	ggccggagca	300
ccggcagget	attctcccgg	aggggtcccg	tccgcctacc	cggagctcca	cgccgccctg	360
gaccgattgt	acgctcagcg	gcccgcgggg	ttcggtgcc	aggaaagccg	ccactcgtat	420
cccccgccc	tgggcagccc	tggagctcta	gccggggccc	gagtgggagc	ggcggggccc	480
ttggagagac	ggggggcgca	acccggacga	cactctgtga	ccggctacgg	ggactgcgcc	540
gtgggcgccc	ggtaccagga	cgagctaaca	gctttgcttc	gcctgacggt	gggcaccggt	600
gggcgagaag	ccggagcccc	cggagaaccc	tccgggattg	agccgtcggg	tctggaggag	660

032796-132.ST25

ccaccaggctc	ctttcggttcc	ggaggccgcc	cgggcccggga	tgcgggagcc	agaggccagg	720
gaggactact	tcggcacctg	tatcaagtgc	aacaaaggca	tctatgggca	gagcaatgcc	780
tgccaggccc	tggacagcct	ctaccacacc	cagtgccttg	tttgctgctc	ttgtgggcga	840
actttgctgt	gcaaggcttt	ctacagtgtc	aatggctctg	tgtactgtga	ggaagattat	900
ctgttttcag	ggtttcagga	ggcagctgag	aatgctgtg	tctgtggtca	cttgattttg	960
gagaagatcc	tacaagcaat	ggggaagtcc	tatcatccag	gctgtttccg	atgcattggt	1020
tgaacaagt	gcctggatgg	catcccttc	acagtggact	tctccaacca	agtatactgt	1080
gtcaccgact	accacaaaaa	ttatgctcct	aagtgtgcag	cctgtggcca	acccatcctc	1140
ccctctgagg	gctgtgagga	catcgtgagg	gtgatatcca	tggaccggga	ttatcacttt	1200
gagtgtctacc	actgtgagga	ctgccggatg	cagctgagtg	atgaggaagg	ctgctgctgt	1260
ttccctctgg	atgggcactt	gctctgccat	ggttg			1295

<210> 67

<211> 3411

<212> DNA

<213> Homo sapiens

<400> 67

gggcccgggg	tcccgccacc	accgcgcgcg	ggacagattg	attcactttg	gagctgtaag	60
tactgatgta	ttaggggtgca	gcgtcattg	ttcattgacg	cagagtccca	aaatgaatat	120
ccaagagcag	ggtttccct	tggacctcgg	agcaagtttc	accgaagatg	ctccccgacc	180
cccagtgcct	ggtgaggagg	gagaactggt	gtccacagac	ccgaggcccg	ccagctacag	240
tttctgctcc	gggaaagggtg	ttggcattaa	aggtgagact	tcgacggcca	ctccgaggcg	300
ctcggatctg	gacctgggggt	atgagcctga	gggcagtgcc	tccccaccc	caccatactt	360
gaagtgggct	gagtcactgc	attccctgct	ggatgaccaa	gatgggataa	gcctgttcag	420
gactttcctg	aagcaggagg	gctgtgccga	cttgctggac	ttctggtttg	cctgcactgg	480
cttcaggaag	ctggagccct	gtgactcgaa	cgaggagaag	aggctgaagc	tggcgagagc	540
catctaccga	aagtacattc	ttgataacaa	tggcatcgtg	tcccggcaga	ccaagccagc	600
caccaagagc	ttcataaagg	gctgcatcat	gaagcagctg	atcgatcctg	ccatgtttga	660
ccaggcccg	accgaaatcc	aggccactat	ggaggaaaac	acctatccct	ccttccttaa	720
gtctgatatt	tatttggaat	atacgaggac	aggctcggag	agccccaaag	tctgtagtga	780
ccagagctct	gggtcaggga	cagggaagg	catatctgga	tacctgccga	ccttaaatga	840
agatgaggaa	tggaaagtgtg	accaggacat	ggacgaggac	gatggcagag	acgctgctcc	900
ccccggaaga	ctccctcaga	agctgtcct	ggagacagct	gccccgagg	tctcctccag	960
tagacggtac	agcgaaggca	gagagttcag	gtatggatcc	tggcgggagc	cagtcaaccc	1020
ctattatgtc	aatgccggct	atgccctggc	cccagccacc	agtgccaacg	acagcgagca	1080
gcagagcctg	tccagcgatg	cagacaccct	gtccctcacg	gacagcagcg	tggatgggat	1140
ccccccatac	aggatccgta	agcagcaccc	caggagagatg	caggagagcg	cgaggtcaa	1200
tgggcgggtg	cccctacctc	acattccccg	cacgtaccgg	gtgccgaagg	aggtccgcgt	1260
ggagcctcag	aagttcgcg	aggagctcat	ccaccgcctg	gaggctgtgc	agcgcacgcg	1320
ggaggccgag	gagaagctgg	aggagcggt	gaagcgcgtg	cgatggagg	aggaaggtga	1380
ggacggcgat	ccatcgtcag	ggcccccagg	gccgtgtcac	aagctgcctc	ccgccccgc	1440
ttggcaccac	ttcccgcccc	gcttgtgttg	gacatgggct	tgtgccgggc	tccgggatgc	1500
acacgaggag	aaccctgaga	gcaccttgga	cgagcacgta	cagcgtgtgc	tgaggacaac	1560
tggccgccag	tcgcctgggc	ctggccatcg	ctccccggac	agtgggcacg	tggccaagat	1620
gccagtggca	ctgggggggtg	ccgcctcggg	gcacgggaag	cacgtaccca	agtcaggggc	1680
gaagctggac	gcggccggcc	tgcaccacca	ccgacacgtc	caccaccacg	tccaccacag	1740
cacagcccgg	cccaaggagc	aggtggaggc	cgaggccacc	cgaggggccc	agagcagctt	1800
cgcttggggc	ctggaaccac	acagccatgg	ggcaagggtc	cgaggctact	cagagagtgt	1860
tggcgtgcc	cccaacgcca	gtgatggcct	cgccacagct	gggaagggtg	gcgttgctgt	1920
caaaagaaat	gccaagaagg	ctgagtcggg	gaagagcgcc	agcaccgagg	tgccaggtgc	1980
ctcggaggat	gcggagaaga	accagaaaat	catgcagtgg	atcattgagg	gggaaaagga	2040
gatcagcagg	caccgcagga	ccggccacgg	gtcttcgggg	acgaggaagc	cacagcccca	2100
tgagaactcc	agaccyttgt	cccttgagca	cccctggggc	ggccctcagc	tccggacctc	2160
cgtgcagccc	tcccacctct	tcatccaaga	ccccaccatg	ccacccacc	cagctcccaa	2220
ccccctaacc	cagctggagg	aggcgcgcgc	acgtctggag	gaggaagaaa	agagagccag	2280
ccgagcaccc	tccaagcaga	ggtatgtgca	ggaggttatg	cggcggggac	gcgcctgcgt	2340

032796-132.ST25

caggccagcg	tgcgcgccgg	tgctgcacgt	ggtaccagcc	gtgtcggaca	tggagctctc	2400
cgagacagag	acaagatcgc	agaggaaggt	gggcggcggg	agtgccagc	cggtgtgacag	2460
catcgttgtg	gcgtactact	tctgcgggga	acccatcccc	taccgcaccc	tgggtgagggg	2520
ccgcgctgtc	accctggggc	agttcaagga	gctgctgacc	aaaaaggcca	gctacagata	2580
ctacttcaag	aaagtgagcg	acgagtttga	ctgtggggtg	gtgtttgagg	aggttcgaga	2640
ggacgagggc	gtcctgcccg	tctttgagga	gaagatcatc	ggcaaagtgg	agaagggtgga	2700
ctgataggct	ggtgggctgg	ccgctgtgcc	aggcgaggcc	cttggcgggc	acgggtgtca	2760
cggccaggca	gatgacctcg	tactcaggag	cccgatgggg	aacagtgttg	ggtgtaccac	2820
ccatccctgt	ggtctacccg	tgtctagagg	caggtagggg	gtccctccaa	gtggtccaca	2880
agcttctgtc	ctgcccccaa	ggaggcagcc	tggaccactc	ctcatagcaa	tacttggagg	2940
gccagcccca	agtgaggcag	ccgaggtccc	tgctgccagc	tcagggtgac	cccccccat	3000
cccccggcac	ctcccttggg	cacgtgtgct	gggatctact	ttccctctgg	gatttgccca	3060
cgtaccacag	tctggctggg	gcccaggccc	ggatgcagag	gcctgcaggg	cctctgtcaa	3120
ttgtacgcgc	caccaagtgc	cttcaacaca	gcttgtctct	tgctgccac	tgtgtgaatc	3180
ggcgacggag	cactgcacct	gcctccagcc	gccggtgtg	cagtcctggg	tcctcctttc	3240
tgagggcccg	tgtaaatatg	tacatttctc	aggctagggc	cagcaggggc	tgcccagatc	3300
tgtttttcat	gcgatgacac	ttgtacaatt	atcttttcaa	aggtacttgg	ataataatga	3360
aataaaactg	tttttgaacc	tgaataaaaa	aaaaaaaaaa	aaaaaaaaaa	a	3411

<210> 68

<211> 3140

<212> DNA

<213> Homo sapiens

<400> 68

ggctgcgagt	acctccatgg	tcccgggtggc	tgtgacggcg	gcagtggcgc	ctgtcctgtc	60
cataaacagc	gattttctcag	atttgcgga	aattaaaaag	caactgctgc	ttattgcggg	120
ccttaccggg	gagcggggcc	tactacacag	tagcaaattg	tcggcggagt	tggctttctc	180
tctccctgca	ttgcctctgg	ccgagctgca	accgcctccg	cctattacag	aggaagatgc	240
ccaggatatg	gatgcctata	ccctggccaa	ggcctacttt	gacgttaaag	agtatgatcg	300
ggcagcacat	tctctgcatg	gctgcaatag	caagaaaagc	tattttctgt	atatgtattc	360
cagatatctg	tctggagaaa	aaaagaagga	cgatgaaaca	gttgatagct	taggccccct	420
ggaaaaagga	caaggagaaa	atgaggcgct	tagagaattg	agagtggagc	tcagcaaaaa	480
acaccaagct	cgagaacttg	atggatttgg	actttatctg	tatggtgtgg	tgcttcgaaa	540
actggacttg	gttaaagagg	ccattgatgt	gtttgtggaa	gctactcatg	ttttgccctt	600
gcattgggga	gcctgggttag	aactctgtaa	cctgatcaca	gacaaagaga	tgctgaagtt	660
cctgtctttg	ccagacacct	ggatgaaaga	gttttttctg	gctcatatat	acacagagtt	720
gcagttgata	gaggaggccc	tgcaaaagta	tcagaatctc	attgatgtgg	gcttctctaa	780
gagctcgtat	attgtttccc	aaattgcagt	tgcctatcac	aatatcagag	atattgacaa	840
agccctctcc	atttttaatg	agctaaggaa	acaagaccct	tacaggattg	aaaatatgga	900
cacattctcc	aaccttcttt	atgtcaggag	catgaaatcg	gagttgagtt	atctggctca	960
taacctctgt	gagattgata	aataccgtgt	agaaacgtgc	tgtgtaattg	gcaattatta	1020
cagtttacgt	tctcagcatg	agaaagcagc	cttatatttc	cagagagccc	tgaaattaaa	1080
tcctcggtat	cttgggtgct	ggacactaat	gggacatgag	tacatggaga	tgaagaacac	1140
gtctgtgtct	atccaggctt	atagacatgc	cattgaggtc	aacaaacggg	actacagagc	1200
ttggtatggc	ctcgggcaga	cctatgaaat	ccttaagatg	ccattttact	gcctttatta	1260
ttatagacgg	gcccaccagc	ttcgacccaa	tgattctcgc	atgctgggtg	ctttaggaga	1320
atgttacgag	aaactcaatc	aactagtggg	agccaaaaag	tgttattgga	gagcttacgc	1380
cgtgggagat	gtggagaaaa	tggctctggt	gaaactggca	aagcttcatg	aacagttgac	1440
tgagtacagaa	caggctgccc	agtgttacat	caaatatatc	caagatatct	attcctgtgg	1500
ggaaatagta	gaacacttgg	aggaaagcac	tgcccttcgc	tatctggccc	agtactatct	1560
taagtgcaaa	ctgtgggatg	aagcttcaac	ttgtgcacaa	aagtgttgtg	catttaatga	1620
taccggggaa	gaaggtaagg	ccttactccg	gcaaataccta	cagcttcgga	accaaggcga	1680
gactcctacc	accgaggtgc	ctgtccctt	tttccctacct	gcttactctc	ctgctaacaa	1740
tacccccaca	cgcagagttt	ctccactcaa	cttgtcttct	gtcacgcat	agttggctac	1800
tctcaagcca	gcacattggt	agacccatct	taattaagcc	ttacctccat	gtaaagaaca	1860
gcacgtctgt	tccaaggacc	tcagctcttc	ttgtttctac	agatggcaac	agctccatag	1920

032796-132.ST25

ggacagcttg	tataattacc	ttcagaggcc	aactgacaga	atcctggcag	gaacagacat	1980
tatcttgcca	gttagaagta	cttctgtctc	acttatgtcc	aaagagtggc	tatagatctt	2040
ggccttcttc	cctgaatgct	tttttttttt	ggccccaag	aaagtccctt	ttatagcact	2100
ttagcacagg	caatgctaca	ggaacaaagt	ttcaatgctg	ctgagagtga	aagaaaggag	2160
gaaagtctgc	cactctaccc	tgagctggca	gtagggcact	gagtaccctt	aggaagaagt	2220
cagagcaatg	gatacaaatg	accttgctct	tggatttgct	gagcatgac	cctattctga	2280
tgtcagagat	taggtttaaa	tggaatagag	ctatccattt	gttcttactc	tctagggaga	2340
caatcttcca	aaacagtttt	gggggggtct	tctaaagctt	tcaaattgga	agtaacttta	2400
ttcaactaga	gttgaataaa	agaagggcaa	aaataatctc	acagagcttg	gaactgctga	2460
tagcccttac	tgagggcaaa	agatggctat	attgttagct	atactcctac	caaagcaagc	2520
aaggagatag	gattatagat	aatttcacgg	acatttgga	ataacattgg	tgattataca	2580
gacaagaata	aactcacttc	aagctggtct	gttttaataa	attttcaacg	taattgtcta	2640
ttttttccc	tcccatctgc	aacagaatac	atttttttca	gcctttatct	agatgaggta	2700
aagggaatca	ttcttatggt	gctcttgag	agtttcaggc	ctgtgcatgt	gtgtacagca	2760
ggaggaata	tgctataatg	tctgctgtaa	tatatgtgca	cagtagatgc	tatggatcat	2820
tctgagctca	gggtccagac	tttattctta	ttcccagaat	tttgtgttac	gtttttacct	2880
cctaaccatg	gacacttcac	cttatattaa	ggaaggttta	gaatatctaa	tacgacttga	2940
attcatttgt	tactaagcct	tctcaggcaa	cggtgatact	agttactgg	ctccactgcc	3000
atgccttttc	aaggttccca	tggtccagaa	tgatgtttga	ttcttaattt	ttctgtccct	3060
tttataattt	gttttaatga	ttttgctaca	tttggaattc	aataaaaaat	gtgaacaata	3120
ataaaaaaaaa	aaaaaaaaaa					3140

<210> 69

<211> 3513

<212> DNA

<213> Homo sapiens

<400> 69

ccgtgtacca	ggtgctgcta	gtgggaagca	cgctgctgaa	ggaagtgcct	tccgggctgc	60
agctggagca	gttgccttct	cagagcctgc	tgaccacat	cccaacggcg	gggctgccc	120
cttcgctagg	aggaggcctg	ccttactgcc	accaggcctg	gctggatttc	cgaaggcggc	180
tggaagctct	actacagaac	tgccaggcag	cttggtgcc	gctccagggg	gccatcgaaa	240
gtgtgaaggc	tgtgccccag	cccatggagc	ctggggaggt	cggtcagctg	ctacagcaga	300
cagaggtcct	gatgcagcag	gtgctagact	cgccatggct	ggcatggcta	caatgccagg	360
ggggccggga	gctgacatgg	ctgaagcaag	aggtcccaga	ggtgaccctg	agcccagact	420
acaggacggc	aatggacaag	gctgacgagc	tatatgaccg	ggtggatgga	ttgctgcacc	480
aactgaccct	gcagagcaac	cagcgaatac	aggccctaga	gttgggtcaa	acactggagg	540
cccgggaaag	cggactgcac	cagattgaag	tgtggctgca	gcaggtgggc	tgccagcac	600
tggaggaggc	tggggagccc	tcgctggaca	tgctgctcca	ggcccaaggc	tcttttcagg	660
agctgtacca	ggttgcccag	gagcaggtca	ggcaagggga	gaagtttctg	cagccgctga	720
ctggctggga	ggcggctgaa	ctggaccccc	ctggggcacg	ctttctggcc	ctgcgagccc	780
agctgactga	attctctagg	gcttttgccc	agcgggtgcca	gcggctggcg	gatgctgaga	840
ggctgtttca	gctcttcagg	gaggccttga	cgtgggctga	ggaggggcag	cgagtgttg	900
cagagctgga	gcaggaacgc	ccgggggttg	tgttgacgca	gctgcagctg	cactggacca	960
ggcaccctga	cttgccctcct	gcccacttcc	gaaagatgtg	ggctctggcc	acggggctgg	1020
gctcagaggc	catccgccag	gagtgccgct	gggcctgggc	gcgggtgccag	gacacctggc	1080
tggccctgga	ccaaaagctt	gaggcttcac	tgaagctacc	accggtgggc	agcacagcta	1140
gcctgtgtgt	cagccaggtc	cccgtgcac	ctgcccaccc	tcccctgagg	aaggcctaca	1200
gcttcgatcg	gaatctgggg	cagagtctca	gtgaacctgc	ctgccactgc	caccatgcgg	1260
ccactattgc	tgccctgccg	agaccagagg	ctggaggagg	tgccctgccc	caggcatccc	1320
ctactgtgcc	tccaccaggc	agctctgacc	ccaggagcct	caacaggcta	cagctggtgc	1380
tggcagagat	ggtggccacg	gagcgggagt	atgtccgggc	tctagagtac	actatggaga	1440
actatttccc	cgagctggat	cgccccgatg	tgccccaggg	cctccgcggt	cagcgtgccc	1500
acctctttgg	caacctggag	aagctgcggg	acttccactg	ccacttcttc	ctgcgtgagc	1560
tggaggcttg	cacccggcac	ccaccacgag	tggcctatgc	cttcctgcgc	catagggtgc	1620
agtttgggat	gtacgcgctc	tacagcaaga	ataagcctcg	ctccgatgcc	ctgatgtcaa	1680
gctatgggca	caccttcttc	aaggacaagc	agcaagcact	gggggaccac	ctggacctgg	1740

032796-132.ST25

cctcctacct	gctaaagccc	atccagcgca	tgggcaagta	cgcactgctg	ctgcaggagc	1800
tggcacgggc	ctgcgggggc	cccacgcagg	agctcagtg	gctgcgggag	gcccagagcc	1860
ttgtgcactt	ccagctgcgg	cacggaaacg	acctgctggc	catggacgcc	atccagggtc	1920
gtgatgttaa	cctcaaggaa	caggggcagc	tgggtgcgaca	ggatgagttt	gtggtgcgca	1980
ctggggcgcca	caagtccgtg	cgccgcctct	tcctttttga	ggagctgctg	ctcttcagca	2040
agcctcgcca	tggggccaca	ggggttgaca	catttgccta	caagcgctcc	ttcaagatgg	2100
cagaccttgg	tctcactgag	tgtgtggga	acagcaacct	gcgcttcgag	atctgggtcc	2160
gccgcgcaa	ggccagggac	acctttgtgc	tgcaggcctc	cagcctggct	atcaagcagg	2220
cctggacagc	tgacatctcc	cacctgcttt	ggaggcaggc	cgccacaac	aaggagggtgc	2280
gcatggctga	gatggtgtcc	atgggtgtgg	ggaacaaggc	cttccgagac	attgctccca	2340
gcgaggaaagc	catcaacgac	cgcaccgtca	actatgtcct	gaagtgccga	gaagttcgct	2400
ctcgggcgtc	cattgccgta	gccccgtttg	accatgacag	cctctacctg	ggggcctcga	2460
actcccttcc	tggagaccct	gcctcttgct	ctgttctggg	gtccctcaac	ctgcacctgt	2520
acagagaccc	agctcttctg	ggtctccgct	gtcccttgta	tcccagcttc	ctagaggaag	2580
cagcactgga	ggctgaggca	gagctgggag	gccagccctc	tttgactgct	gaggactcag	2640
agatctcgct	ccaatgcccc	tcagccagtg	gctccagtg	ctctgacagc	agctgtgtgt	2700
cagggcaggc	cctgggtagg	ggcctggagg	acttaccctg	tgtctgagcc	cgggactgga	2760
cgagcagtag	atccagcagc	ctgcagctcc	aaggaacatt	gcctctctgg	atctgctgtg	2820
accagggtgt	ggtgtgacac	tgggtacct	ccaacctaca	tgtgcaacgc	tgttgactac	2880
cctttctgat	gtgtgtggcc	attggactaa	ctggcacggg	gcctctctag	ggaagtctgg	2940
ttgtagagcc	tgaataggct	cctggcccca	tgaccccttc	tcctgtcccc	agctcccatc	3000
ccagtgtgg	gttaagaata	ggctagagca	gacattgggt	gtttccatgc	tgtaggctgg	3060
tgggggacca	tgtgcctcta	ggcagtga	agggtgcccc	cacccctcag	gaagaacaca	3120
ggtgggctcc	tagcagctga	tcccaatgc	ctggccttaa	agccgagctc	agttaccata	3180
gggacaggctc	cacctctact	gggccctcat	gcttgccttt	cctggccccc	aggcccagcc	3240
cctttttact	ggggcagttt	cgttatattt	acttgatgcc	ttttgaataa	ctttcaatag	3300
aattgtctaa	aattatctta	ctggttggtt	ggcctttggt	gtctcagaga	aggagtctag	3360
gtctttgatg	tgtgatttaa	tcttttattt	gtttataata	aaaaatagac	tgattttgtaa	3420
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	3480
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaa			3513

<210> 70

<211> 3597

<212> DNA

<213> Homo sapiens

<400> 70

catgccagtt	acttcctcag	gaaaatattt	tcttgccctc	ttcttttcagt	atggttttaa	60
atttgggaac	agtggataac	ccaagtgtcc	cacaggccaa	ggtatattcc	aatggcagca	120
tgatccctgc	acccaaagcc	agcccctaaa	gcctaccctc	tgtgcacccg	cagcctggta	180
agtgagcttg	gctgcttggt	aggagctaca	agtgaagag	aagttatttt	aaataaatcc	240
caaagtgtga	ggcagactgt	ccaggactgt	tcccaggaag	aagcaggagt	taccacacagg	300
aaaagtctct	gacctgggtc	cctcaggccc	agctacctgc	gcccaccagc	agtgaagggt	360
gatgtactgg	cccagcatct	ccacctcccc	catgcaacca	ggtccctggt	accgtgtctc	420
ccgttgcatg	tctggcttct	gcctgtgtct	ctcctgccac	gagcatcctc	cctgtccctc	480
ctcattccac	cgtgtctctc	ctgcacacat	agcctctgtc	ccagggcgat	ttatccactt	540
gagtacagga	gctgctcaga	cctctcagcc	cagccctctg	tgactgcccc	agccccatcc	600
tacccacccc	aaagctgcct	tcttggtgtg	aggagctccc	tcgtctagcc	aaggccctat	660
gggtcccat	ccgaggatcc	acaagcaatg	acttcccaaa	tgacctccac	tgcaagaaga	720
atccttacca	ctgtttccag	agccgtgaac	gatgctgtga	tggcccagg	ctcagcacca	780
ccctctgtga	cctaaaaaga	aaagctcaat	ttccatctgt	cttctttccc	aggaccaagg	840
ggacacagta	atgtgaagtc	aaatacttaa	ccgagcaaag	ggccagtgtt	gttatcagtc	900
aaggacaaac	ctcccacctc	acagacagcc	aagcagtga	ggaaagacag	acagacatag	960
gtaggaagg	gctctgcagg	cacaaggccc	agagaagccc	ctctccggga	acttcccctg	1020
ctccttccag	gaacagtga	cccagtga	agtcccagcc	agctcttcaa	ggccttcaag	1080
gggtctttcc	atgactgagt	cacctccagg	agctcacctg	acccccagag	aagacctacc	1140
ccaggcagct	ccgtgcccctg	gcttctcccc	atgccccaaa	tccccccag	ccatccctcc	1200

032796-132.ST25

tggtcctcgt	ctacatcaag	ggcctcttcc	cctcttctcc	ccagctctca	ggacaggtga	1260
ctggggagacc	ttgaaccctc	agcctcttcc	tttaaaaaaa	acaaaacaaa	acaaaactgt	1320
gggccattta	tttgggattt	tggagttggt	tgggttttgt	ttttatatct	taatagtctg	1380
aaagtaagaa	gggagccctg	ctatggatgt	taagtccaaa	ttactcgggt	agtgggagca	1440
aaacctatga	cttccaaggg	gatgaggaga	ggttcagagg	acaggaggag	cctcccccac	1500
tgaaaaaaaaa	aaaatgggtc	aggacattcc	ctggatgagg	acaatgctag	gggtggcatc	1560
tcacatggct	gctgctattc	ctggtgcttc	cccacacttt	tgacagatgg	agtccttctc	1620
ctaccgcctc	ctgccacctc	accctacagg	cattctctat	gtaggaaaca	agagccttat	1680
cttatagagt	ggggagctga	gacacagcct	caggtaacac	tgacacagct	cccgaatgag	1740
gctgggacac	tctgcaaacc	tctcctcatg	gtgctaaggg	tggcatgctc	ttgacaggaa	1800
acctaaatga	ccactcctct	catttggaaa	gtaatccact	gcagtaaaag	tttcagacat	1860
gcaagagaga	gttttttttt	ttttttacta	caaatttttg	ctcccccata	aaattatttt	1920
tttattagag	ggagtatcca	agttttaaaa	gtatatagaa	ttttttgggt	gtaagagaaa	1980
tacatactca	ttaggatccc	gattaaattc	cttgagtaga	ctggtgccta	ccagaaagca	2040
aagcaaaagt	aaacaaaacg	aaacaaaatc	cttcataatac	aaaaagaact	ttctgtttgt	2100
attggcagag	gtagtgaagt	gattcaggta	ggctgaaaat	cctgggttgc	gggagcctca	2160
ctttattcca	ttcccaccog	ctttgatgtc	tatgcttggc	tctctgggct	gcccctggta	2220
ctgccgaatc	ctacacatct	cttatcagct	ttcctcaaac	tttaaggagg	ctctgtgagg	2280
gatgggtcat	gggaagaccc	aagctttccc	tccgccagga	ttgcaaaagc	aagtagactt	2340
ggtctatgca	gctcttcttc	caacaatttc	tttatttgga	attagaactt	cctttgttag	2400
tatctttgat	cttttgactc	aagcacattt	tgggaagggt	cccttataaa	agtagaattt	2460
aaaacagagg	atacagttaa	agagcaaccc	aaaggacgct	taagaaaccg	agaccacttc	2520
accgaacagg	actaagggaac	actttcgtgc	acagaagtca	gccgcaatcc	aggcacagga	2580
cgaagatggg	atacacgtgc	tcatctgtct	gtcctccttt	cctctccctc	cccgcagttc	2640
tagttagctt	gttgacttgt	taaaccttct	gttcttaaaa	tgaaaagcta	gcttacctca	2700
aagaatcttg	tttccattcg	gaaaccaacg	attttgtgtt	ttagaatgga	cagccctccc	2760
ctcaccactc	cctaccttgg	cctggtgtcc	ttgagacata	cggctcttgc	ttagtcgtgt	2820
gttggtgct	ttgagcagga	acgaggcctc	caggccctga	ggtgggaagg	aaggattgga	2880
tgccactgcc	ctcctcccca	cttttagcatg	taggggccag	cccatctctt	ccagcagggt	2940
cctgctgagt	taccatagca	accagcaact	ccagggtacc	acaacagaca	atggctcagc	3000
gagccgacgt	gtggggatga	tgcagggggt	ttggcccagc	cagaggaccc	agagttgagc	3060
ttcaaatgct	agagaagggg	agaaacagga	tggaaagggtg	gtttaaggaa	ctggcagggg	3120
tctttgagtc	acatagagaa	gccgttgaag	gaggtagggc	aggttatctc	tgttccagtc	3180
accccccttc	agcccatcc	cacttctgtt	tcaaactaaa	gctcccacct	cgaacattga	3240
ccctttgtta	gaacaaagca	aagcatatct	ttaaacaaca	gtgttaaaat	gagcctcaaa	3300
tgtatgtgga	tgagatctct	aagaagaggg	tcttctgggt	ttgattttta	aagaagagta	3360
tcctagtaaa	atattaaaaa	aaaattaaaa	agttttttaa	aaggaaacct	atgctattta	3420
aattggagcc	cagttgtaac	ttggtaaagg	caagcttctg	tacctttgtt	ataattaatt	3480
gtatacctgt	gtatgtaaat	ataaggcatt	cctattttgc	agttcagaac	aaaaaaaaact	3540
tatttgaat	atagaataaa	gtttattaaa	aaataagaaa	aaaaaaaaaa	aaaaaaa	3597

<210> 71

<211> 855

<212> DNA

<213> Homo sapiens

<400> 71

cgctcaatta	tctactcgag	tctagactcg	aggcgccgc	ccattgtgca	ctaaagcagg	60
ggatagcaac	ggcgtccctc	ctccccgctc	agctgcagcc	cgcagtcctc	acagtggtaa	120
catgccacgt	ggtagtctct	gtccatggac	accacacgga	tggttgtctc	gcagccctgt	180
gcaggaggga	taggacgggc	acaggaggcg	cattttgggtg	caaaaaccgt	gtgatagtct	240
cgcacgcagt	agatgttgtt	ctccacgtcc	acggtgaagg	gaaccccgctc	caggcactca	300
ttgcacacgg	agcaccggaa	gcagcctggg	tggtaggact	tgcccagggc	ctgcaggatc	360
atttccatga	tgagatgtcc	acacacgctg	catttgtcgg	ccgtctgctg	gaacccggag	420
tacaggaagt	cctcctggca	gtacactttc	tcacccacgt	tgtagaacgc	cttcccacgg	480
agtcgtctcc	cacacgagtc	gcaggtgaag	cagtcagtg	gataaagact	ccccattgcc	540
tggcacgcct	gctgggctcc	gtagatgcc	agccacact	tgatgcaaat	gccgaagtag	600

032796-132.ST25

tcccgcgcgcg	tgcgcgcctc	gagcgccecg	tccagctccc	gggtgagcgc	ctccagccgc	660
cgctcggccg	cgcttgggcc	gccctcccgg	ccagggggca	gcgggagtc	aggcagcggg	720
aagggggccg	gccccgcagg	ctccggggag	cgagcgggcg	cggggcaggc	gccgggcggg	780
aggaagtacg	cgtaggcttt	agtgcacaat	gggaattcgg	atccggtcga	cactagttct	840
aggatctctt	ttttt					855

<210> 72

<211> 3791

<212> DNA

<213> Homo sapiens

<400> 72

acagacggcg	ggtgaacatg	gcgtcctcga	cttggctctga	gacgtgatag	gcctgccttc	60
tggttgaaga	tgtggcgagt	gaaaaaactg	agcctcagcc	tgtcgccttc	gccccagacg	120
ggaaaacat	ctatgagaac	tcctctccgt	gaacttaccc	tgagccccg	tgccctcacc	180
acctctggaa	aaagatcccc	cgcttgctcc	tcgctgacct	catcactgtg	caagctgggg	240
ctgcaggaa	gcagcaacaa	ctcgtctcca	aagtgttttg	taaataacaa	gaggacagac	300
ttatcttcag	aacatttcag	tcattcctca	aagtggctag	aaacttgtca	gcatgaatca	360
gatgagcagc	ctctagatcc	aattcccca	attagctcta	ctcctaaaac	gtctgaggaa	420
gcagtagacc	cactgggcaa	ttatatgggt	aaaaccatcg	tccttgtagc	atctccactg	480
gggcagcaac	aagacatgat	atgtgaggcc	cgtttagata	ccatggcaga	gacaaacagc	540
atatcttta	atggaccttt	gagaacagac	gatctgggtg	gagaggaggt	ggcaccctgc	600
atgggagaca	ggttttcaga	agttgctgct	gtatctgaga	aacctatctt	tcaggaatct	660
ccgtcccac	tccttagagga	gtctccacca	aatccctgtt	ctgaacaact	acattgctcc	720
aaggaaaagg	tgagcagtag	aactgagggt	gtgcgtgagg	acttagtacc	ttctgaaagt	780
aacgccttct	tgcccttcctc	tggttctctg	ctttccctct	caactgcctt	ggcagcagat	840
ttccgtgtca	atcatgtgga	cccagaggag	gaaattgtag	agcatggagc	tatggaggaa	900
agagaaatga	ggtttcccac	acatcctaag	gagctctgaa	cagaagatca	agcacttgct	960
tcaagtgtgg	aagatattct	gtccacatgc	ctgacaccaa	atctagtaga	aatggaatcc	1020
caagaagctc	caggcccagc	agtagaagat	gttggttaga	ttcttggtct	tgatacagag	1080
tcttgtagtg	ccccactggc	ctggctggaa	aaaggtgtaa	atacctccgt	catgctggaa	1140
aatctccgcc	aaagcttata	ccttccctcg	atgcttcggg	atgctgcaat	tggcactacc	1200
cctttctcta	cttgctcggg	ggggacttgg	tttactcctt	cagcaccaca	ggaaaagagt	1260
acaaacacat	cccagacagg	cctgggtggc	accaagcaca	gtacttctga	gacagagcag	1320
ctcctgtgtg	gccggcctcc	agatctgact	gccttgcttc	gacatgactt	ggaagataac	1380
ctgctgagct	ctcttgatca	tgtggagttt	ctctcccgcc	agcttcggga	ctggaagagc	1440
cagctggctg	tcctcaccac	agaaacccag	gacagtagca	cacagactga	cacatctcac	1500
agtgggataa	ctaataaact	tcagcatctt	aaggagagcc	atgagatggg	acaggcccta	1560
cagcaggcca	gaaatgtcat	gcaatcatgg	gtgcttatct	ctaaagagct	gatatccttg	1620
cttcacctat	ccctgttgca	tttagaagaa	gataagacta	ctgtgaatca	ggagtctcgg	1680
cgtgcagaaa	cattgggtctg	ttgctgtttt	gatttgctga	agaaattgag	ggcaaagctc	1740
cagagcctca	aagcagaaa	ggaggaggca	aggcacagag	aggaaatggc	tctcagaggc	1800
aaggatgcgg	cagagatagt	gttgagggtc	ttctgtgcac	acgccagcca	gcgcatcagc	1860
cagctggaac	aggacctagc	atccatgcgg	gaattcagag	gccttctgaa	ggatgccag	1920
acccaactgg	tagggcttca	tgccaagcaa	gaagagctgg	ttcagcagac	agtgaagtctt	1980
acttctacgt	tgcaacaaga	ctggagggtc	atgcaactgg	attatacaac	atggacagct	2040
ttgctgagtc	ggtcccagca	actcacagag	aaactcacag	tcaagagcca	gcaagccctg	2100
caggaaactg	atgtggcaat	tgaggaaaag	caggagggtt	ctagggtgct	ggaacaagtc	2160
tctgcccagt	tagaggagtg	caaaggccaa	acagaacaac	tggagttgga	aaacattcgt	2220
ctagcaacag	atctccgggc	tcagttgcag	attctggcca	acatggacag	ccagctaaaa	2280
gagctacaga	gtcagcatat	ccattgtgcc	caggacctgg	ctatgaagga	tgagttactc	2340
tgccagctta	cccagagcaa	tgaggagcag	gctgctcaat	gcgtaaagga	agagatggca	2400
ctaaaacaca	tgagggcaga	actgcagcag	caacaagctg	tcctggccaa	agaggtgcgg	2460
gacctgaaag	agaccttgga	gtttgcagac	caggagaatc	aggttgctca	cctggagctg	2520
ggtcaggttg	agtgtcaatt	gaaaaccaca	ctggaagtgc	tccgggagcg	cagcttgtag	2580
tgtgagaacc	tcaaggacac	tgtagagaac	ctaaccgcta	aactggccag	caccatagca	2640
gataaccagg	agcaagatct	ggagaaaaca	cggcagtagt	ctcaaaagct	agggtgctg	2700

032796-132.ST25

actgagcaac	tacagagcct	gactctcttt	ctacagacaa	aactaaagga	gaagactgaa	2760
caagagaccc	ttctgctgag	tacagcctgt	cctcccaccc	aggaacaccc	tctgcctaata	2820
gacaggacct	tcctgggaag	catcttgaca	gcagtggcag	atgaagagcc	agaatcaact	2880
cctgtgccct	tgcttggaag	tgacaagagt	gctttcaccc	gagtagcatc	aatgggttcc	2940
cttcagcccc	cagagacccc	aggcatggag	gagagcctgg	cagaaatgag	tattatgact	3000
actgagcttc	agagtctttg	ttccctgcta	caagagtcta	aagaagaagc	catcaggact	3060
ctgcagcgaa	aaatttggtga	gctgcaagct	aggctgcagg	cccaggaaga	acagcatcag	3120
gaagtccaga	aggcaaaaga	agcagacata	gagaagctga	accaggcctt	gtgcttgccg	3180
tacaagaatg	aaaaggagct	ccaggaagtg	atacagcaga	atgagaagat	cctagaacag	3240
atagacaaga	gtggcgagct	cataagcctt	agagaggagg	tgaccacact	taccgctca	3300
cttcggcggtg	cggagacaga	gaccaaagtg	ctccaggagg	cctggcaggc	cagctggact	3360
ccaactgccca	gcctatggcc	accaattgga	tccaggagaa	agtgtggctc	tctcaggagg	3420
tggaacaaact	gagagtgatg	ttcctggaga	tgaaaaatga	gaagggaaaac	tcctgatcaa	3480
gttccagagc	ccatagaaat	atcctagagg	agaaccttcg	gcgctctgac	aaggagttag	3540
aaaaactaga	tgacattggt	cagcatatct	ataagacctt	gctctctatt	ccagagggtg	3600
tgaggggagtg	caaagaacta	cagggattgc	tggaatttct	gagctaagaa	actgaaagcc	3660
agaatttggt	tcacctgttt	ttacctgcaa	tacctcctta	ccccaatacc	aagaccaact	3720
ggcatagagc	caactgagat	aaatgctatt	taaataaagt	gtattttaatg	aaaaaaaaaa	3780
aaaaaaaaaa	a					3791

<210> 73

<211> 1683

<212> DNA

<213> Homo sapiens

<400> 73

ctctgagtgt	ccagtgggtca	gttgccccag	gatggggacc	acagccagag	cagccttggt	60
cttgacctat	ttggctggtg	cttctgctgc	ctctgaggga	ggcttcacgg	ctacaggaca	120
gaggcagctg	aggccagagc	actttcaaga	agttggctac	gcagctcccc	cctccccacc	180
cctatcccga	agcctcccca	tgatcacccc	tgactcctct	cagcatggcc	ctccctttga	240
gggacagagt	caagtgcagc	cccctccctc	tcaggaggcc	acccctctcc	aacaggaaaa	300
gctgctacct	gccccactcc	ctgctgaaaa	ggaagtgggt	ccccctctcc	ctcagggaagc	360
tgtccccctc	caaaaagagc	tgccctctct	ccagcacccc	aatgaacaga	aggaagggaac	420
gccagctcca	tttgggggacc	agagccatcc	agaacctgag	tcctgggaatg	cagcccagca	480
ctgccaacag	gaccggtccc	aagggggctg	gggccaccgg	ctggatggct	tccccctgg	540
gcggccttct	ccagacaatc	tgaacaaat	ctgccttctt	aaccgtcagc	atgtggtata	600
tggtccctgg	aacctaccac	agtccagcta	ctccacctc	actcgccagg	gtgagaccct	660
caatttcctg	gagattggat	attcccgtg	ctgccactgc	cgcagccaca	caaaccgcct	720
agagtgtgcc	aaacttgtgt	gggaggaagc	aatgagccga	ttctgtgagg	ccgagttctc	780
ggtcaagacc	cgaccccaact	ggtgctgcac	gcggcagggg	gaggctcgg	tctcctgctt	840
ccaggaggaa	gctccccagc	cacactacca	gctccggggc	tgccccagcc	atcagcctga	900
tatttcctcg	ggtcttgagc	tgcttttccc	tcctgggggtg	cccacatttg	acaatatcaa	960
gaacatctgc	cacctgaggc	gcttcogctc	tgtgccacgc	aacctgccag	ctactgacct	1020
cctacaaaagg	gagctgctgg	cactgatcca	gctggagagg	gagttccagc	gctgctgccg	1080
ccagggggaa	aatcacacct	gtacatggaa	ggcctgggag	gatacccttg	acaaatactg	1140
tgaccgggag	tatgctgtga	agacccacca	ccacttgtgt	tgccgcccacc	ctcccagccc	1200
tactcgggat	gagtgcctttg	cccgtcgggc	tccttaccct	aactatgacc	gggacatctt	1260
gaccattgac	atcagtcgag	tcacccccaa	cctcatgggc	cacctctgtg	gaaaccaaag	1320
agttctcacc	aagcataaac	atattcctgg	gctgatccac	aacatgactg	cccgtgctg	1380
tgacctgcca	tttccagaac	aggcctgctg	tgagaggag	gagaaattaa	ccttcatcaa	1440
tgatctgtgt	ggtccccgac	gtaacatctg	gcgagaccct	gcctctgct	gttacctgag	1500
tcctggggat	gaacagggtca	actgcttcaa	catcaattat	ctgaggaacg	tggtctagt	1560
gtctggagac	actgagaacg	ccaagggcca	gggggagcag	ggctcaactg	gaggaacaaa	1620
tatcagctcc	acctctgagc	ccaaggaaga	atgagtcacc	ccagagccct	agagggtcag	1680
atg						1683

<210> 74

032796-132.ST25

<211> 1696

<212> DNA

<213> Homo sapiens

<400> 74

cacctaaaag	ccaaaatggg	aaaggaaaag	actcatatca	acattgtcgt	cattggacac	60
gtagattcgg	gcaagtccac	cactactggc	catctgatct	ataaatgcgg	tggcatcgac	120
aaaagaacca	ttgaaaaatt	tgagaaggag	gctgctgaga	tgggaaaggg	ctccttcaag	180
tatgcctggg	tcttggataa	actgaaagct	gagcgtgaac	gtggatcac	cattgatatc	240
tccttgtgga	aatttgagac	cagcaagtac	tatgtgacta	tcattgatgc	cccaggacac	300
agagacttta	tcaaaaacat	gattacaggg	acatctcagg	ctgactgtgc	tgtcctgatt	360
gttgctgctg	gtgttgggtg	atttgaagct	ggtatctcca	agaatgggca	gacccgagag	420
catgcccttc	tggcttacac	actgggtgtg	aaacaactaa	ttgtcgggtg	taacaaaatg	480
gattccactg	agccacccta	cagccagaag	agatatgagg	aaattgttaa	ggaagtcagc	540
acttacatta	agaaaattgg	ctacaacccc	gacacagtag	catttgtgcc	aatttctggt	600
tggaatgggtg	acaacatgct	ggagccaagt	gctaacatgc	cttgggtcaa	gggatggaaa	660
gtcacccgta	aggatggcaa	tgccagtggg	accacgtctg	ttgaggctgt	ggactgcatc	720
ctaccaccaa	ctcgtccaac	tgacaagccc	ttgcgcctgc	ctctccagga	tgtctacaaa	780
attggtggta	ttggtactgt	tcctgttggc	cgagtggaga	ctgggtgttct	caaaccgggt	840
atgggtggta	cctttgctcc	agtcaacggt	acaacggaag	taaaatctgt	cgaaatgcac	900
catgaagctt	tgagtgaagc	tcttcctggg	gacaatgtgg	gcttcaatgt	caagaatgtg	960
tctgtcaagg	atgttcgtcg	tggcaacggt	gctggtgaca	gcaaaaatga	cccaccaatg	1020
gaagcagctg	gcttcactgc	tcaggtgatt	atcctgaacc	atccaggcca	aataagcgcc	1080
ggctatgccc	ctgtattgga	ttgccacacg	gctcacattg	catgcaagtt	tgctgagctg	1140
aaggaaaaga	ttgatcgccg	ttctggtaaa	aagctggaag	atggccctaa	attcttgaag	1200
tctggtgatg	ctgccattgt	tgatatgggt	cctggcaagc	ccatgtgtgt	tgagagcttc	1260
tcagactatc	cacctttggg	tcgctttgct	gttcgtgata	tgagacagac	agttgcgggtg	1320
ggtgtcatca	aagcagtgga	caagaaggct	gctggagctg	gcaaggtcac	caagtctgcc	1380
cagaaaagctc	agaaggctaa	atgaatatta	tccctaatac	ctgccacccc	actcttaatc	1440
agtggtgga	gaacggtctc	agaactgttt	gtttcaattg	gccatttaag	tttagtagta	1500
aaagactgggt	taatgataac	aatgcacgtg	aaaaccttca	gaaggaaagg	agaatgtttt	1560
gtggaccact	ttggttttct	tttttgcgtg	tggcagtttt	aagttattag	tttttaaaat	1620
cagtactttt	taatggaaac	aacttgacca	aaaatttgtc	acagaatttt	gagacccatt	1680
aaaaaagtta	aatgag					1696

<210> 75

<211> 7680

<212> DNA

<213> Homo sapiens

<400> 75

gaagagcaag	aggcaggctc	agcaaattggt	tcagccccag	tccccgggtg	ctgtcagtc	60
aagcaagccc	ggttgttatg	acaatggaaa	acactatcag	ataaatcaac	agtgggagcg	120
gacctaccta	ggtaatgtgt	tggtttgtac	ttgttatgga	ggaagccgag	gttttaactg	180
cgaaagtaaa	cctgaagctg	aagagacttg	ctttgacaag	tacactggga	acacttaccg	240
agtgggtgac	acttatgagc	gtcctaaaga	ctccatgac	tgggactgta	cctgcatcgg	300
ggctgggcga	gggagaataa	gctgtaccat	cgcaaaccgc	tgccatgaag	ggggtcagtc	360
ctacaagatt	ggtgacacct	ggaggagacc	acatgagact	ggtggttaca	tgtagagtgtg	420
tgtgtgtcct	ggtaattgga	aaggagaatg	gacctgcaag	cccatagctg	agaagtgttt	480
tgatcatgct	gctgggactt	cctatgtggt	cggagaaacg	tgggagaagc	cctaccaagg	540
ctggatgatg	gtagattgta	cttgcctggg	agaaggcagc	ggacgcatca	cttgcacttc	600
tagaaataga	tgcaacgata	aggacacaag	gacatcctat	agaattggag	acacctggag	660
caagaaggat	aatcgaggaa	acctgctcca	gtgcatctgc	acaggcaacg	gccgaggaga	720
gtggaagtgt	gagaggcaca	cctctgtgca	gaccacatcg	agcggatctg	gccccttcac	780
cgatgttcgt	gcagctgttt	accaaccgca	gcctcaccac	cagcctcctc	cctatggcca	840
ctgtgtcaca	gacagtgggtg	tggtctactc	tgtggggatg	cagtgggttg	agacacaagg	900
aaataagcaa	atgcttttga	cgtgcctggg	caacggagtc	agctgccaag	agacagctgt	960

032796-132.ST25

aacccagact	tacggtggca	acttaaattg	agagccatgt	gtcttaccat	tcacctacaa	1020
tggcaggacg	ttctactcct	gcaccacgga	agggcgacag	gacggacatc	tttggtgcag	1080
cacaacttcg	aattatgagc	aggaccagaa	atactctttc	tgcacagacc	acactgtttt	1140
ggttcagact	caaggaggaa	attccaattg	tgccttgtgc	cacttcccct	tcctatacaa	1200
caaccacaat	tacactgatt	gcacttctga	gggcagaaga	gacaacatga	agtgggtgtg	1260
gaccacacag	aactatgatg	ccgaccagaa	gtttgggttc	tgccccatgg	ctgcccacga	1320
ggaaatctgc	acaaccaatg	aaggggtcat	gtaccgcatt	ggagatcagt	gggataagca	1380
gcatgacatg	ggtcacatga	tgaggtgcac	gtgtgttggg	aatggtcgtg	gggaatggac	1440
atgcattgcc	tactcgcaac	ttcgagatca	gtgcattgtt	gatgacatca	cttacaatgt	1500
gaacgacaca	ttccacaagc	gtcatgaaga	ggggcacatg	ctgaactgta	catgcttcgg	1560
tcagggtcgg	ggcaggtgga	agtgtgatcc	cgtcgaccaa	tgccaggatt	cagagactgg	1620
gacgttttat	caaattggag	attcatggga	gaagtatgtg	catggtgtca	gataccagtg	1680
ctactgctat	ggccgtggca	ttggggagt	gcattgccaa	cctttacaga	cctatccaag	1740
ctcaagtgg	cctgtcgaag	tatttatcac	tgagactccg	agtcagccca	actcccaccc	1800
catccagtgg	aatgcaccac	agccatctca	catttccaag	tacattctca	ggtggagacc	1860
taaaaattct	gtaggccgtt	ggaagggaagc	taccatacca	ggccacttaa	actcctacac	1920
catcaaaggc	ctgaagcctg	gtgtggtata	cgagggccag	ctcatcagca	tccagcagta	1980
cggccacca	gaagtgcctc	gctttgactt	caccaccacc	agcaccagca	cacctgtgac	2040
cagcaacacc	gtgacaggag	agacgactcc	cttttctcct	cttgtggcca	cttctgaatc	2100
tgtgaccgaa	atcacagcca	gtagctttgt	ggtctcctgg	gtctcagctt	ccgacaccgt	2160
gtcgggattc	cgggtggaat	atgagctgag	tgaggaggga	gatgagccac	agtacctgga	2220
tcttccaagc	acagccactt	ctgtgaacat	ccctgacctg	cttctctggc	gaaaatacat	2280
tgtaaatgtc	tatcagatat	ctgaggatgg	ggagcagagt	ttgatcctgt	ctacttcaca	2340
aacaacagcg	cctgatgccc	ctcctgacct	gactgtggac	caagttgatg	acacctcaat	2400
tgttgttcgc	tggagcagac	cccaggctcc	catcacaggg	tacagaatag	tctattcgcc	2460
atcagtagaa	ggtagcagca	cagaactcaa	ccttcctgaa	actgcaaact	ccgtcaccct	2520
cagtgacttg	caacctggtg	ttcagtataa	catcactatc	tatgctgtgg	aagaaaatca	2580
agaaagtaca	cctgttgtca	ttcaacaaga	aaccactggc	acccacgct	cagatacagt	2640
gccctctccc	agggacctgc	agtttgtgga	agtgcagac	gtgaaggtea	ccatcatgtg	2700
gacaccgct	gagagtgcag	tgaccggcta	ccgtgtggat	gtgatccccg	tcaacctgcc	2760
tggcgagcac	gggcagaggc	tgcccacag	caggaacacc	tttgcagaag	tcaccgggct	2820
gtcccctggg	gtcacctatt	acttcaaagt	ctttgcagtg	agccatggga	gggagagcaa	2880
gcctctgact	gtcacaacaga	caaccaaact	ggatgctccc	actaacctcc	agtttgtcaa	2940
tgaactgat	tctactgtcc	tggtagatg	gactccacct	cggggcccaga	taacaggata	3000
ccgactgacc	gtgggcctta	cccgaagagg	ccagcccagg	cagtacaatg	tgggtccctc	3060
tgtctccaag	tacccctga	ggaatctgca	gcctgcatct	gagtacaccg	tatccctcgt	3120
ggccataaag	ggcaaccaag	agagcccaa	agccactgga	gtctttacca	cactgcagcc	3180
tgggagctct	attccacctt	acaacaccga	ggtgactgag	accaccatcg	tgatcacatg	3240
gacgcctgct	ccaagaattg	gttttaagct	gggtgtacga	ccaagccagg	gaggagaggc	3300
accacgagaa	gtgacttcag	actcaggaag	catcgttgtg	tccggcttga	ctccaggagt	3360
agaatacgtc	tacaccatcc	aagtcctgag	agatggacag	gaaagagatg	cgccaattgt	3420
aaacaaagt	gtgacaccat	tgtctccacc	aacaaacttg	catctggagg	caaaccctga	3480
cactggagt	ctcacagtct	cctgggagag	gagcaccacc	ccagacatta	ctggttatag	3540
aattaccaca	acccctacaa	acggccagca	gggaattct	ttggaagaag	tgggtccatgc	3600
tgatcagagc	tcctgcactt	ttgataacct	gagtcocggc	ctggagtaca	atgtcagtgt	3660
ttacactgtc	aaggatgaca	aggaaagtgt	ccctatctct	gataccatca	tcccagctgt	3720
tcctcctccc	actgacctgc	gattcaccaa	cattggtcca	gacaccatgc	gtgtcacctg	3780
ggctccaccc	ccatccattg	atttaaccaa	cttcctgggtg	cgttactcac	ctgtgaaaaa	3840
tgaggaaagt	ggtgcagagt	tgtcaatttc	tccttcagac	aatgcagtgg	tcttaacaaa	3900
tctctgcct	ggtacagaat	atgtagttag	tgtctccagt	gtctacgaac	aacatgagag	3960
cacacctctt	agaggaagac	agaaaacagg	tcttgattcc	ccaactggca	ttgacttttc	4020
tgatattact	gccaactctt	ttactgtgca	ctggattgct	cctcgagcca	ccatcactgg	4080
ctacaggatc	cgccatcatc	ccgagcactt	cagtgggaga	cctcgagaag	atcgggtgcc	4140
ccactctcgg	aattccatca	ccctcaccaa	cctcactcca	ggcacagagt	atgtggtcag	4200
catcgttgct	cttaattggca	gagaggaaag	tcccttattg	attggccaac	aatcaacagt	4260
ttctgatgtt	ccgagggacc	tggaaagtgt	tgctgcgacc	cccaccagcc	tactgatcag	4320
ctgggatgct	cctgctgtca	cagttagata	ttacaggatc	acttacggag	aaacaggagg	4380

032796-132.ST25

aaatagccct	gtccaggagt	tactgtgcc	tgggagcaag	tctacagcta	ccatcagcgg	4440
ccttaaacct	ggagttgatt	ataccatcac	tgtgtatgct	gtcactggcc	gtggagacag	4500
ccccgcaagc	agcaagccaa	tttccattaa	ttaccgaaca	gaaattgaca	aaccatccca	4560
gatgcaagt	accgatgttc	aggacaacag	cattagtgtc	aagtggctgc	cttcaagttc	4620
ccctgttact	ggttacagag	taaccaccac	tcccaaaaa	ggaccaggac	caacaaaaac	4680
taaaactgca	gggtccagatc	aaacagaaat	gactattgaa	ggcttgacgc	ccacagtgga	4740
gtatgtgggt	agtgtctatg	ctcagaatcc	aagcggagag	agtcagcctc	tggttcagac	4800
tgcagtaacc	aacattgatc	gccctaaagg	actggcattc	actgatgtgg	atgtcgattc	4860
catcaaaatt	gcttgggaaa	gccacagggt	gcaagtttcc	aggtacagggt	tgacctactc	4920
gagccctgag	gatggaatcc	atgagctatt	ccctgcacct	gatggtgaag	aagacactgc	4980
agagctgcaa	ggcctcagac	cgggttctga	gtacacagtc	agtgtggttg	ccttgcacga	5040
tgatatggag	agccagcccc	tgattggaac	ccagtccaca	gctattcctg	caccaactga	5100
cctgaagtgc	actcaggtca	caccacaaag	cctgagcgcc	cagtggacac	cacccaatgt	5160
tcagctcact	ggatatcgag	tgcgggtgac	ccccaggag	aagaccggac	caatgaaaga	5220
aatcaacctt	gtccttgaca	gtcatccgt	ggttgtatca	ggacttatgg	tggccaccaa	5280
atatgaagt	agtgtctatg	ctcttaagga	cactttgaca	agcagaccag	ctcagggtgt	5340
tgaccacct	ctggagaatg	tcagcccacc	aagaagggtc	cgtgtgacag	atgctactga	5400
gaccaccatc	accattagct	ggagaaccaa	gactgagacg	atcactggct	tccaagttga	5460
tgccgttcca	gccaatggcc	agactccaat	ccagagaacc	atcaagccag	atgtcagaag	5520
ctacaccatc	acaggtttac	aaccaggcac	tgactacaag	atctacctgt	acaccttgaa	5580
tgacaatgct	cggagctccc	ctgtggtcat	cgacgcctcc	actgccattg	atgcaccatc	5640
caacctgcgt	ttcctggcca	ccacacccaa	ttccttgctg	gtatcatggc	agccgccacg	5700
tgccaggatt	accggctaca	tcataagta	tgagaagcct	gggtctcctc	ccagagaagt	5760
gggtccctcg	ccccgccttg	gtgtcacaga	ggctactatt	actggcctgg	aaccgggaac	5820
cgaatatata	atttatgtca	ttgccctgaa	gaataatcag	aagagcgagc	ccctgattgg	5880
aaggaaaaag	acagacgagc	ttccccaact	ggtaaccctt	ccacacccca	atcttcatgg	5940
accagagatc	ttggatgttc	cttccacagt	tcaaaagacc	cctttcgtca	cccaccctgg	6000
gtatgacact	ggaaatggta	ttcagcttcc	tggcacttct	ggtcagcaac	ccagtgttgg	6060
gcaacaaatg	atctttgagg	aacatggttt	taggcggacc	acaccgcca	caacggccac	6120
ccccataagg	cataggccaa	gaccataccc	gccgaatgta	ggacaagaag	ctctctctca	6180
gacaaccatc	tcattggccc	cattccagga	cacttctgag	tacatcattt	catgtcatcc	6240
tgttggcact	gatcagaagc	ccttacagtt	cagggttctc	ggaacttcta	ccagtgccac	6300
tctgacaggc	ctcaccagag	gtgccacctc	caactctata	gtggaggcac	tgaagacca	6360
gcagaggcat	aagggttcggg	aagaggttgt	taccgtgggc	aactctgtca	acgaaggctt	6420
gaaccaacct	acggatgact	cgtgctttga	cccctacaca	gtttcccat	atgccgttgg	6480
agatgagtgg	gaacgaatgt	ctgaatcagg	ctttaaactg	ttgtgccagt	gcttaggctt	6540
tggaaagtgg	catttcagat	gtgattcatc	tagatgggtc	catgacaatg	gtgtgaacta	6600
caagattgga	gagaagtggg	accgtcagggt	agaaaatggc	cagatgatga	gctgcacatg	6660
tcttgggaac	ggaaaaggag	aattcaagt	tgacctcat	gaggcaacgt	gttacgatga	6720
tgggaagaca	taccacgtag	gagaacagt	gcagaaggaa	tatctcgggt	ccatttgctc	6780
ctgcacatgc	tttggaggcc	agcggggctg	gcgctgtgac	aaetgccgca	gacctggggg	6840
tgaacccagt	cccgaaggca	ctactggcca	gtcctacaac	cagtattctc	agagatacca	6900
tcagagaaca	aacactaatg	ttaattgccc	aattgagtgc	ttcatgcctt	tagatgtaca	6960
ggctgacaga	gaagattccc	gagagtaaat	catctttcca	atccagagga	acaagcatgt	7020
ctctctgcca	agatccatct	aaactggagt	gatgttagca	gaccagctt	agagttcttc	7080
tttctttctt	aagccctttg	ctctggagga	agttctccag	cttcagctca	actcacagct	7140
tctccaagca	tcaccctggg	agtttctctga	gggttttctc	ataaatgagg	gctgcacatt	7200
gcctgttctg	cttogaagta	ttcaataccg	ctcagttatt	taaatgaagt	gattctaaga	7260
tttgggttgg	gaatcaatag	aaagcatatg	cagccaacca	agatgcaa	gttttgaaat	7320
gatgatgacca	aaattttaag	taggaaagtc	acccaaacac	ttctgcttcc	acttaagtgt	7380
ctggcccgcga	atactgtagg	aacaagcatg	atcttggtac	tgtgatattt	taaatatcca	7440
cagtactcac	tttttccaaa	tgatcctagt	aattgcctag	aaatatcttt	ctcttacctg	7500
ttatttatca	atttttccca	gtatttttat	acggaaaaaa	ttgtattgaa	aacacttagt	7560
atgcagttga	taagaggaat	ttggtataat	tatgggtgggt	gattattttt	tatactgtat	7620
gtgccaaagc	tttactactg	tggaaagaca	actgttttaa	taaaagattt	acattccaca	7680

032796-132.ST25

<210> 76
 <211> 1316
 <212> DNA
 <213> Homo sapiens

<400> 76
 tcctaatacgc actcactata gggctcgagc ggccgcccgc gcagggtcgaa tgcaggcgac 60
 ttgcgagctg ggagcgattt aaaacgcttt ggattccccc ggcttgggtg gggagagcga 120
 gctgggtgcc ccctagattc cccgccccgc cacctcatga gccgaccctc ggctccatgg 180
 agcccggcaa ttatgccacc ttggatggag ccaaggatat cgaaggcttg ctgggagcgg 240
 gagggggggcg gaatctggtc gccactccc ctctgaccag ccaccagcg gcgcctacgc 300
 tgatgcctgc tgtcaactat gccccttgg atctgccagg ctcggcggag ccgccaaagc 360
 aatgccaccc atgccctggg gtgcccagg ggacgtcccc agctcccgtg ccttatggtt 420
 actttggagg cgggtactac tectgccgag tgtcccgag ctcgctgaaa ccctgtgccc 480
 aggcagccac cctggccgcg taccgcgcg agactccac ggccggggaa gagtaccca 540
 gtcgcccac tgagtttgcc ttctatccg gatattccgg aacctaccac gctatggcca 600
 gttacctgga cgtgtctgtg gtgcagactc tgggtgctcc tggagaaccg cgacatgact 660
 ccctgttgcc tgtggacagt taccagtctt gggctctcgc tgggtggctg aacagccaga 720
 tgtgttgcca gggagaacag aaccaccag gtcccttttg gaaggcagca tttgcagact 780
 ccagcgggca gcacctcct gacgcctgcg cctttcgtcg cgcccgcaag aaacgcattc 840
 cgtacagcaa ggggcagttg cgggagctgg agcgggagta tgcggctaac aagttcatca 900
 ccaaggacaa gaggcgcaag atctcggcag ccaccagcct ctcgagcgc cagattacca 960
 tctggtttca gaaccgccg gtcaaagaga agaaggttct cgccaagggtg aagaacagcg 1020
 ctaccctta agagatctcc ttgcctgggt gggaggagcg aaagtggggg tgtcctgggg 1080
 agaccagaaa cctgccaaag ccaggctggg gccaaaggact ctgctgagag gcccttagag 1140
 acaacaccct tcccaggcca ctggctgctg gactgttcct caggagcggc ctgggtaccc 1200
 agtatgtgca gggagacgga acccatgtg acaggccac tccaccaggg ttcccaaaga 1260
 acctggccca gtcataatca ttcactctca cagtggcaat aatcacgata accagt 1316

<210> 77
 <211> 566
 <212> DNA
 <213> Homo sapiens

<400> 77
 cccaccaaac ccataaagag ggtgggtcga cccacgcgtc cgccgacgcg tgggaaatta 60
 ttgaattgga aacagaaata gaaaagttta aagctgagaa cgcatcttta gctaaacttc 120
 gcattgaacg agaaagtgc ttggaaaaac tcaggaaaga aattgcagac ttcgaacaac 180
 agaaagcaaa agaattagct cgaatagaag agtttaaaaa ggaggagatg aggaagctac 240
 aaaaggaaacg taaagttttt gaaaagtata ctacagctgc aagaactttt ccagataaaa 300
 aggaacgtga agaaatacag acttttaaac agcaaatagc agatttacgg gaagatttga 360
 aaagaaagga gaccaaatgg tcaagtacac acagccgtct cagaagccag atacaaatgt 420
 tagtcagaga gaacacagac ctccgggaag aaataaaagt gatggaaaga ttccgactgg 480
 atgcctggaa gagagcagaa gccatagaga gcagcctcga ggtggagaag aaggacaagc 540
 ttgcgaacac atctgttcga tttcaa 566

<210> 78
 <211> 5067
 <212> DNA
 <213> Homo sapiens

<400> 78
 gcccgacac ctgtctgcag catggataag tatgacgacc tgggcctgga ggccagtaaa 60
 ttcactcagg acctgaacat gtatgaggcc tctaaggatg ggctcttccg agtggacaag 120
 ggtgcaggca acaacccccg gtttgaggaa actcgcaggg tgctcgccac caagatggcc 180
 aaaatccacc tccagcagca gcagcagcag ctctgcagg aggagactct gccagggggg 240
 agtagaggcc ctgtcaatgg agggggccgc ctgggcccac aggcccggtt ggaagttgtg 300

032796-132.ST25

ggcagcaagc	tgactgtgga	tgggtgctgcc	aagcctcctc	ttgctgcctc	gacaggggca	360
cctggggcag	tcaccaccct	cgctgctggg	cagcccccg	acccaccgca	ggagcagaga	420
tccaggccat	acctgcatgg	cacgagggat	ggcagccagg	actgtgggtc	cagggagagc	480
ctggcgactt	ctgagatgtc	tgctttccac	cagccaggcc	cctgtgagga	tccttcctgc	540
ctcactcatg	gagactatta	tgacaacctc	tccttgga	gccccaaagt	gggtgacaaa	600
ccaggagtgt	ccccagcat	cgccctgagt	gtagggagt	gggtggcctag	ctccccggg	660
agtgaccac	cactgcccc	accctgcg	gaccatcccc	taaataccg	acagctctcc	720
ctgagctcca	gcaggtcttc	tgagggtagc	ctcggtggtc	agaatagtgg	cattgggtggc	780
cgcagcagcg	agaagccaac	aggcctttgg	tcactgcct	cctcccagcg	ggtagaccct	840
ggcctgcctt	ccccaaactt	ggagaacgga	gcaccagctg	tggggcctgt	tcagcccagg	900
actccttctg	tgtcagcacc	cttggccctg	agctgcccc	ggcaaggagg	tcttccaaga	960
tcaaactcgg	ggctgggggg	tgaggtttca	ggtgtgatgt	ccaaacccaa	tgtggacccc	1020
caacctggt	tccaggatgg	gccccaatct	tacctttcca	gttctgcccc	gtcatcctcg	1080
ccagctggcc	tggacggttc	acagcagggt	gcggtccctg	ggctggggcc	gaagcctggc	1140
tgacagacc	ttggcactgg	tcccaagctc	agccccacca	gtcttgcca	tccagtgtg	1200
tccaccctgc	ctgagttatc	ttgtaaagag	ggtccccctg	gctggtcttc	tgatggtagc	1260
ctgggactctg	tgctcctgga	cagccccage	tcccctagg	taaggtgccc	ctgccagccc	1320
ctcgtcccag	gtcctgagct	gagacctctc	gctgctgagt	tgaattaga	agccctcacc	1380
caacgtctgg	agcgagagat	ggatgctcac	ccgaaggctg	attactttgg	agcctgtgtg	1440
aatgcagca	aagggtgtt	tggggtggc	caggcctgtc	aggccatggg	gaacctctac	1500
catgacacat	gcttcacctg	tgacgcttgc	agccggaagc	tgagaggaaa	agccttttat	1560
tttgtcaacg	gcaaagtgtt	ttgtgaagaa	gacttcctgt	actctggttt	ccagcagtcg	1620
gctgacaggt	gttttctttg	tgacatctg	atcatggaca	tgatcctgca	agccctgggg	1680
aagtcctacc	accccggtg	ttccgctgt	gtcatctgta	atgagtgttt	ggatggggtg	1740
cccttcaccg	tggactcaga	gaacaagatc	tactgtgtcc	gagattacca	caaggtgctg	1800
gccccaaagt	gtgcagcctg	tgggcttccc	atccttccac	ctgagggtc	agatgagacc	1860
atcctgtctg	tgtccatgga	cagagactac	cacgtggagt	gttaccactg	cgaggactgt	1920
ggtctggagc	tcaatgatga	agatggccac	cgctgttatc	cgctggagga	ccacctgttc	1980
tgtactcct	gccacgtgaa	gaggctggag	aagagaccct	catctacagc	ccttcaccag	2040
caccacttct	agccagagcc	acttgacagc	atcacggcag	gggatgagga	gccggggttg	2100
ctgctgctgc	ttccggtggc	ccctggggtg	gaagtgggtg	aggggaagag	gaggggcagg	2160
aggagaggtt	cctgtgagca	tgtggggggt	gcctttcctt	taaccaggga	ggtgaacact	2220
acctgcctcc	tgcgtgtatt	ttccaagtgc	ttttctctgt	tgccacattt	tcctcaggtt	2280
actcaggaaa	atgtccagc	atgtgcgagc	acatgacctg	aggttgcac	atagcaccaa	2340
aggaatcctc	ctgtccctc	tgggaacatt	tcagtcttca	gaggagagg	ttttatttga	2400
gcttggttca	caatatcccc	ttgaagggac	agctcagctg	ccaatacatt	caaccctttc	2460
tcttccttca	ggaaaatacc	tatacccaaa	tgttccctcc	cccacatat	atcatggcat	2520
gacttaaggc	ttcttttcac	ctgagagctt	cagttcttct	gcagaatggc	tgcaaattta	2580
attgcattaa	ggcaagaagg	aagctcta	gtgtgctttg	tatcctaaga	taaatttgct	2640
tagaaaacca	gagtcaagat	ttgaaatagg	tgaggcagg	tttcctcctt	agacactgac	2700
agcattctcc	gtaccccttc	aaatccttac	tctcctaaag	gcagctgagt	ccgcgacaga	2760
aatttgccct	atgggagtaa	aacatacttt	gggagaagaa	cttgggtgag	gcaccaggat	2820
ttttttttt	gcccacgtgt	ttgcgctgtt	tttctctgga	gttctcaaga	gttgggtgact	2880
tgaaggccg	cttctgcaag	gcaagtctca	ggaacccatg	caggtacatc	gcttgacact	2940
gttttttagt	tatttaatga	cgggcttttg	ggaagagctg	ccgcatact	gagagacagc	3000
ttcttataaa	caaggagagt	ttttgtgtgt	gcgagatctc	taagccagcg	tgggagggag	3060
cgcctcagga	taagttatta	tattcatttc	gttgggttct	ctcctgccc	attcttggca	3120
caggcattat	gtttgaagaa	accaggataa	ggtacactgc	ttttgtctgt	ttaatttttt	3180
tagttgtttc	ccttcacttt	cagtcttcca	cacacaaaaa	atacctcaca	gagcttcacc	3240
aatcacaga	ttcaggagga	atttggcttt	cacactggac	tcagatacct	tcttcagtgt	3300
gttggaatc	actggcttca	cacaggccca	actccaactg	gtcagggcag	agtgatcgta	3360
actaaaggtc	agtggggaat	agatccgatt	cagtgttttt	gccttatgca	tttcagcatc	3420
ctggctcccc	aggggtggcag	gagctgagga	agggccacac	actggcaaga	tttcaagacc	3480
actctctgca	ctgaagaggt	aaaatttgca	ctgcaagtca	catccctgag	gccagaggtc	3540
agtacccttt	ggtatttcga	ttagaagaag	ctgcaaaaga	aaggcagccc	attttaccat	3600
tgccagccag	gccggggaca	caggagccgg	tgtgtgca	ctgcctccta	acattgcacc	3660
cagagcaaga	ggactgggtg	ctgggctgca	gaggccggtc	agtggagccc	ctagcacgtg	3720

032796-132.ST25

tgaactcagg	cttttcattg	ggccccggctc	cacttctagg	ccatgttttg	actcatttgg	3780
taaccattgc	ctgtaagcag	cacagaattg	gtgccatgga	ttatcttttc	catgttgatg	3840
gaattcattc	tggtggaatc	ctttggccag	atgtcacttc	agccagggtg	tgcatcatca	3900
ttgggttctt	ttcacaggct	gagcctcctg	aaaacccatg	aacgctgggg	ctgggggaagt	3960
gaaccctgag	gtgggggacc	tctcttccca	tcaaatacatc	cagctcagtg	tggggcgtgg	4020
caggggggta	aatgaagcca	gccaatgtgt	taacctgtct	ctgtcaacct	aagaatgttg	4080
gccttactga	cacacctttg	ctccatgttc	aagaccagaa	gtagctggga	tttgtttgca	4140
aattgggtaa	ttagttttaa	aatctgtgat	tacattttta	aatgaaattt	tcaaagtggc	4200
ctagattgag	gtgattcaga	taggtttgcg	aataaccat	tttatattgt	tgagaaagaa	4260
caaaaaggga	atttcagat	gtcctagaaa	tcctagcaac	agatttctct	ggttgtcagt	4320
ttccctggag	aaggcgccag	ataggaatct	ccaatcagtt	gtttttctct	tcgcttcagg	4380
cccttacaca	aaagccatga	agagatgttc	acctaccgg	tattttaaat	gttctgtaaa	4440
ttattagcca	aatagaactg	taatgggggt	gtatttatgg	gcgcctagaa	agaaaacaca	4500
aggacttggg	aggccaggaa	gaaaagattt	taaaatttag	aatgaatagc	ccttctgggt	4560
tttctttttg	acaattcttg	gacttgaggt	aaaacaagga	ggattgtggc	cggatttcag	4620
atcccaaagc	cagcctccat	cttaggcctt	tgccctcattg	tgcccttttag	gttttcttac	4680
ccaccgtctc	ctgttttgtc	ttttttttct	ttctctctac	ccctatcttg	ggacattcag	4740
aaactgcctg	ggtgggttga	gaagagacaa	ccaagttaga	tctgcaatac	aaggatccat	4800
tcgtaatctc	tctctcactg	atgttattcc	cccatctgcc	gtcttggttc	atctcaccac	4860
agaagggcat	ttagtccctac	ccagccatcg	gctgcggtat	gacagcagga	tggcacttcc	4920
catttctctg	tggttagtgc	tcgagtgaag	acctctttca	gctgagtcct	ctgaggttct	4980
gctgttgagt	cctgggtggc	tgatggaatg	attgaggagg	tctggtcacc	ctcaagcgcc	5040
gtcatcgctc	tgtttccatg	ggcttct				5067

<210> 79

<211> 950

<212> DNA

<213> Homo sapiens

<400> 79

tcgaccggat	ccgaattccc	attgtgcact	aaagcgtctc	cctgctccgc	ggccccgggct	60
ggcggggcgg	cgctcggtcg	gcggctgcag	cagcagaggg	agaccgcgg	caaccgccggc	120
aaccagggc	tcggcgctgc	tgccaccatg	acgggaagca	atatgtcgga	cgccttgccc	180
aacgcccgtg	gccagcgtcg	ccaggcccgc	ttctcccccg	ccgagcgcag	tgtcaacagc	240
aatggggagc	tgtaccatga	gcaactgttc	gtgtgtgccc	agtgttccg	gcccttcccc	300
gaggggctct	tctatgagtt	tgaaggccgg	aagtactgcg	aacacgactt	ccaaatgctg	360
tttgctccgt	gctgtggatc	ctgcggtgag	ttcatcattg	gccgcgtcat	caaggccatg	420
aacaacaact	ggcaccggg	ctgcttccgc	tgcgagctgt	gtgatgtgga	gctggctgac	480
ctgggctttg	tgaagaatgc	cggcaggcat	ctctgccggc	cttgccacaa	ccgtgagaag	540
gccaagggcc	tgggcaagta	catctgccag	cggtgccacc	tggtcatcga	cgagcagccc	600
ctcatgttca	ggagcgacgc	ctaccacctt	gaccacttca	actgcaccca	ctgtgggaag	660
gagctgacag	ccgaggcccc	cgagctgaag	ggtgagctct	actgcctgcc	ctgccatgac	720
aagatgggcg	ttcccatctg	cggggcctgc	cgccggccca	tcgagggccg	agtggtaaac	780
gcgctgggca	agcagtggca	cgtggagcac	tttgtctgtg	ccaagtgtga	gaagccattc	840
ctggggcacc	ggcactatga	gaagaagggc	ctggcctact	gcgagcttta	gtgcacaatg	900
ggcggccgcc	tcgagtctag	actcgagtag	ataattgagc	ggaatttctt		950

<210> 80

<211> 2346

<212> DNA

<213> Homo sapiens

<400> 80

ccgcccgtcgc	ccccgcctcc	ccctgcctca	gcggtgtccc	ccgccagcgg	gccgcccgcct	60
cccccgggcc	ttgcagcggg	ccccggcccc	gctggagggg	ccccgacccc	agctctgggtg	120
gcgggcagca	gcgccgcggc	ccccttccct	cacggggact	cggccctgaa	cgagcaggag	180

032796-132.ST25

aaggagttgc	agcggcggct	gaagcgtctc	taccgggccc	tggacgaaca	agagacgccg	240
ctgcctcggg	cctggagccc	gaaggacaag	ttcagctaca	tcggcctctc	tcagaacaac	300
ctgcgggtgc	actacaaagg	tcatggcaaa	accccaaaag	atgccgcgtc	agttcgagcc	360
acgcattcaa	taccagcagc	ctgtgggatt	tattattttg	aagtaaaaat	tgtagtaag	420
ggaagagatg	gttacatggg	aattgggtctt	tctgctcaag	gtgtgaacat	gaatagacta	480
ccaggttggg	ataagcattc	atatgggttac	catggggatg	atggacattc	gttttgttct	540
tctggaactg	gacaacctta	tggaccaact	ttcactactg	gtgatgtcat	tggctgttgt	600
gttaatctta	tcaacaatac	ctgctttttac	accaagaatg	gacatagttt	aggtattgct	660
ttcactgacc	taccgcaaaa	tttgtatcct	actgtggggc	ttcaaacacc	aggagaagtg	720
gtcgatgcca	attttgggca	acatcctttc	gtgttttgata	tagaagacta	tatgcgggag	780
tggagaacca	aatccaggc	acagatagat	cgatttccta	tcggagatcg	agaaggagaa	840
tggcagacca	tgatacaaaa	aatgggtttca	tcttatttag	tccaccatgg	gtactgtgcc	900
acagcagagg	cctttgccag	atctacagac	cagaccgttc	tagaagaatt	agcttccatt	960
aagaatagac	aaagaattca	gaaatttggt	ttagcaggaa	gaatgggaga	agccattgaa	1020
acaacacaac	agttataccc	aagtttactt	gaaagaaatc	ctaattctcct	tttcacatta	1080
aaagtgcgtc	agtttataga	aatgggtgaat	ggtacagata	gtgaagtacg	atgtttggga	1140
ggccgaagtc	caaagtctca	agacagttat	cctgttagtc	ctcgaccttt	tagtagtcca	1200
agtatgagcc	ccagccatgg	aatgaatatc	cacaatttag	catcaggcaa	aggaagcacc	1260
gcacattttt	caggttttga	aagttgtagt	aatgggtgaa	tatcaaataa	agcacatcaa	1320
tcatattgcc	atagtaataa	acaccagtca	tccaacttga	atgtaccaga	actaaacagt	1380
ataaatatgt	caagatcaca	gcaagttaat	aacttcacca	gtaatgatgt	agacatggaa	1440
acagatcact	actccaatgg	agttggagaa	acttcaccca	atggtttcct	aaatggtagc	1500
tctaaacatg	accacgaaat	ggaagattgt	gacaccgaaa	tggagttga	ttcaagttag	1560
ttgagacgcc	agttgtgtgg	aggaagttag	gccgccatag	aaagaatgat	ccactttgga	1620
cgagagctgc	aagcaatgag	tgaacagcta	aggagagact	gtggcaagaa	cactgcaaac	1680
aaaaaaatgt	tgaaggatgc	attcagtcta	ctagcatatt	cagatccctg	gaacagccca	1740
gttggaatc	agcttgaccc	gattcagaga	gaacctgtgt	gctcagctct	taacagtgca	1800
atattagaaa	cccacaatct	gccaaagcaa	cctccacttg	ccctagcaat	gggacaggcc	1860
acacaatgtc	taggactgat	ggctcgatca	ggaattggat	cctgcgcatt	tgccacagtg	1920
gaagactacc	tacattagct	atgcatttca	agagctcaca	cttatattgt	ggcatatagt	1980
caacatggaa	gtagaccagc	tctgctgatt	tgaaatttag	attttttaaa	ttatgtactg	2040
gggacagggt	tttgtcgctt	tacattgtct	cctagtttac	agcatgatgc	aaatgatttt	2100
ctaaacttag	gttaggagaa	attattttcc	atctttaacc	tcttagttgt	ctaagagtta	2160
aatattactg	aatttcagac	gttcaaattg	atcatcacia	atcctttaaa	acaattacct	2220
aaaagaaacc	aaaaatcctg	ccttctttgt	gggggagggg	ggagagaggg	gaaggaaatg	2280
gaacaagttg	tgtttgtgtt	agcatgtggg	tgatgtaaac	ttcaaattgg	gagatgttcc	2340
gacccc						2346

<210> 81

<211> 2512

<212> DNA

<213> Homo sapiens

<400> 81

caatgcactg	acggatatga	gtgggatacct	gtgagacagc	aatgcaaaga	tattgatgaa	60
tgtgacattg	tcccagacgc	ttgtaaaggt	ggaatgaagt	gtgtcaacca	ctatggagga	120
tacctctgcc	ttccgaaaaa	agcccagatt	attgtcaata	atgaacagcc	tcagcaggaa	180
acacaaccag	cagaaggaaac	ctcaggggca	accaccgggg	ttgtagctgc	cagcagcatg	240
gcaaccagtg	gagtgttgcc	cggggggtgt	tttgtggcca	gtgctgctgc	agtcgcaggc	300
cctgaaatgc	agactggccg	aaataacttt	gtcatccggc	ggaaccacgc	tgaccctcag	360
cgatttcctt	ccaacccttc	ccaccgtatc	cagtgtgcag	caggctacga	gcaaagtga	420
cacaacgtgt	gccaagacat	agacgagtgc	actgcaggga	cgcacaaactg	tagagcagac	480
caagtgtgca	tcaatttacg	gggatccttt	gcatgtcagt	gccctcctgg	atatcagaag	540
cgaggggagc	agtgcgtaga	catagatgaa	tgtaccatcc	ctccatattg	ccaccaaaaga	600
tgcgtgaata	caccaggctc	attttattgc	cagtgcagtc	ctgggtttca	attggcagca	660
aacaactata	cctgcgtaga	tataaatgaa	tgtgatgcc	gcaatcaatg	tgctcagcag	720
tgtacaaca	ttcttggttc	attcatctgt	cagtgcacac	aaggatatga	gctaagcagt	780

032796-132.ST25

gacaggetca	actgtgaaga	cattgatgaa	tgcagaacct	caagctacct	gtgtcaatat	840
caatgtgtca	atgaacctgg	gaaattctca	tgtatgtgcc	cccaggata	ccaagtgggtg	900
agaagtagaa	catgtcaaga	tataaatgag	tgtgagacca	caaatgaatg	ccgggaggat	960
gaaatgtgtt	ggaattatca	tggcggcttc	cggtgttatc	cacgaaatcc	ttgtcaagat	1020
ccctacattc	taacaccaga	gaaccgatgt	gtttgcccag	tctcaaatgc	catgtgccga	1080
gaactgcccc	agtcaatagt	ctacaaatc	atgagcatcc	gatctgatag	gtctgtgcc	1140
tcagacatct	tccagataca	ggccacaact	atttatgcc	acaccatcaa	tacttttcgg	1200
attaaatctg	gaaatgaaaa	tggagagttc	tacctacgac	aaacaagtcc	tgtaagtgc	1260
atgcttgtgc	tctgaagtc	attatcagga	ccaagagaac	atatcgtgga	cctggagatg	1320
ctgacagtca	gcagtatagg	gaccttccgc	acaagctctg	tgtaagatt	gacaataata	1380
gtggggccat	tttcatttta	gtcttttcta	agagtcaacc	acaggcattt	aagtcagcca	1440
aagaatattg	ttaccttaaa	gcactatttt	atttatagat	atatctagt	catctacatc	1500
tctatactgt	acactcacc	ataacaaaca	attacacat	ggtataaagt	gggcatttaa	1560
tatgtaaaga	ttcaaagttt	gtctttatta	ctatatgtaa	attagacatt	aatccactaa	1620
actggtcttc	ttcaagagag	ctaagtatac	actatctggt	gaaacttgga	ttctttccta	1680
taaaagtggg	accaagcaat	gatgatcttc	tgtggtgctt	aaggaaactt	actagagctc	1740
actaacagt	ctcataagga	ggcagccatc	ataaccattg	aatagcatgc	aagggtgaaga	1800
atgagttttt	aactgctttg	taagaaaatg	gaaaaggcca	ataaagatat	atttcttttag	1860
aaaatgggga	tctgccat	ttgtgttggt	ttttattttc	atatccagcc	ttaaagggtgt	1920
tggtttattat	atagtaataa	atcattgctg	tacaacatgc	tggtttctgt	agggattttt	1980
taattttgtc	agaaatttta	gattgtgaat	attttgtaaa	aaacagtaag	caaaattttc	2040
cagaattccc	aaaatgaacc	agataccccc	tagaaaatta	tactattgag	aaatctatgg	2100
ggaggatatg	agaaaataaa	ttccttctaa	accacattgg	aactgacctg	aagaagcaaa	2160
ctcggaat	ataataacat	ccctgaattc	aggcattcac	aagatgcaga	acaaaatgga	2220
taaaagggtat	ttcactggag	aagttttaat	ttctaagtaa	aatttaaatc	ctaacacttc	2280
actaatttat	aactaaaatt	tctcatcttc	gtacttgatg	ctcacagagg	aagaaaatga	2340
tgatggtttt	tattcctggc	atccagagtg	acagtgaact	taagcaaatt	accctcctac	2400
ccaattctat	ggaatatttt	atacgtctcc	ttgtttaaaa	tctgactgct	ttactttgat	2460
gtatcatatt	tttaataaaa	aataaatatt	cctttagaag	atcactctaa	aa	2512

<210> 82

<211> 2306

<212> DNA

<213> Homo sapiens

<400> 82

gggcgggagc	tgcacgcgcc	gtggctccgg	atctcttcgt	ctttgcagcg	tacgcccag	60
tcgggtcagcg	ccggaggacc	tcagcagcca	tgtcgaagcc	ccatagtga	gccgggactg	120
ccttcattca	gacccagcag	ctgcacgcag	ccatggctga	cacattcctg	gagcacatgt	180
gccgcctgga	cattgattca	ccacccatca	cagcccgga	cactggcatc	atctgtacca	240
ttggcccagc	ttcccgatca	gtggagacgt	tgaaggagat	gattaagtct	ggaatgaatg	300
tggctcgtct	gaacttctct	catggaactc	atgagtacca	tgccggagacc	atcaagaatg	360
tgcgcacagc	cacggaaagc	tttgcttctg	acccctacct	ctaccggccc	gttgctgtgg	420
ctctagacac	taaaggacct	gagatccgaa	ctgggctcat	caagggcagc	ggcactgcag	480
agctggagct	gaagaaggga	gccactctca	aatcacgct	ggataacgcc	tacatggaaa	540
agtgtgacga	gaacatcctg	tggctggact	acaagaacat	ctgcaagggtg	gtggaagtgg	600
gcagcaagat	ctacgtggat	gatgggctta	tttctctcca	ggtgaagcag	aaagggtgccg	660
acttcctggg	gacggagggtg	gaaaatgggtg	gctccttggtg	cagcaagaag	ggtgtgaacc	720
ttcctggggc	tgctgtggac	ttgcctgctg	tgtcggagaa	ggacatccag	gatctgaagt	780
ttggggtcga	gcaggatgtt	gatatgggtg	ttgcgtcatt	catccgcaag	gcatctgatg	840
tccatgaagt	taggaaggctc	ctgggagaga	agggaagaa	catcaagatt	atcagcaaaa	900
tcgagaatca	tgagggggtt	cggagggttg	atgaaatcct	ggaggccagt	gatgggatca	960
tgggtggctcg	tggatgacta	ggcattgaga	ttcctgcaga	gaaggctctc	cttgctcaga	1020
agatgatgat	tggacgggtgc	aaccgagctg	ggaagcctgt	catctgtgct	actcagatgc	1080
tggagagcat	gatcaagaag	ccccgcccc	ctcgggctga	aggcagtgat	gtggccaatg	1140
cagtcctgga	tggagccgac	tgcacatgc	tgtctggaga	aacagccaaa	ggggactatc	1200
ctctggaggc	tgtgcgcatg	cagcacctga	ttgcccgtga	ggcagaggct	gccatctacc	1260

032796-132.ST25

acttgcaatt	atttgaggaa	ctccgcccgc	tggcgcccat	taccagcgac	cccacagaag	1320
ccaccgccgt	gggtgccgtg	gaggcctcct	tcaagtgcgtg	cagtggggcc	ataatcgtcc	1380
tcaccaagtc	tggcaggtct	gtccaccagg	tggccagata	ccgcccacgt	gcccccatca	1440
ttgctgtgac	ccggaatccc	cagacagctc	gtcaggccca	cctgtaccgt	ggcatcttcc	1500
ctgtgctgtg	caaggaccca	gtccaggagg	cctgggctga	ggacgtggac	ctccgggtga	1560
actttgcat	gaatgttggc	aaggcccag	gcttcttcaa	gaaggagat	gtggtcattg	1620
tgctgaccgg	atggcgccct	ggctccggct	tcaccaacac	catgcgtgtt	gttcctgtgc	1680
cgtgatggac	cccagagccc	ctcctccagc	ccctgtccca	cccccttccc	ccagcccac	1740
cattaggcca	gcaacgcttg	tagaactcac	tctgggctgt	aacgtggcac	tggtaggttg	1800
ggacaccagg	gaagaagatc	aacgcctcac	tgaacatgg	ctgtgtttgc	agcctgctct	1860
agtgggacag	cccagagcct	ggctgcccac	catgtggccc	cacccaatca	agggaagaag	1920
gaggaatgct	ggactggagg	cccctggagc	cagatggcaa	gagggtgaca	gcttcctttc	1980
ctgtgtgtac	tctgtccagt	tccttttagaa	aaaatggatg	cccagaggac	tcccaaccct	2040
ggcttggggt	caagaaacag	ccagcaagag	ttaggggcct	tagggcactg	ggctgtgtgt	2100
ccattgaagc	cgactctggc	cctggccctt	acttgcttct	ctagctctct	aggcctctcc	2160
agtttgacc	tgtccccacc	ctccactcag	ctgtcctgca	gcaaacactc	caccctccac	2220
cttccatttt	cccccactac	tgcagcacct	ccaggcctgt	tgctatagag	cctacctgta	2280
tgtcaataaa	caacagctga	agcacc				2306

<210> 83

<211> 2656

<212> DNA

<213> Homo sapiens

<400> 83

gaattcgcg	ccgcagagtc	cccgggcca	gatggctgcg	cggtgctcca	cacgctgggt	60
gctggtggt	gtggggaccc	cgcggtgcc	ggctatatcg	ggtagagggg	cccggccgcc	120
cagggagggc	gtggtggggg	catggctgag	ccgcaagctg	agcgtccccg	cctttgcgtc	180
ttccctgacc	tcttgccggc	ccgagcgct	gctgacattg	agacctgggt	tcagccttac	240
aggaacaaaa	cataaccctt	tcatttgtac	tgccctcttc	cacacgagtg	cccctttggc	300
caaagaagat	tattatcaga	tattaggagt	gcctcgaaat	gccagccaga	aagagatcaa	360
gaaagcctat	tatcagcttg	ccaagaagta	tcaccctgac	acaaataagg	atgatcccaa	420
agccaaggag	aagttctccc	agctggcaga	agcctatgag	gttttgagtg	atgaggtgaa	480
gaggaagcag	tacgatgcct	acggctctgc	aggcttcgat	cctggggcca	gcggctccca	540
gcatagctac	tgggaaggag	gccccactgt	ggaccccgag	gagctgttca	ggaagatctt	600
tggcgagttc	tcatectctt	catttgagga	tttccagacc	gtgtttgatc	agcctcagga	660
atacttcatg	gagttgacat	tcaatcaagc	tgcaaagggg	gtcaacaagg	agttcaccgt	720
gaacatcatg	gacacgtgtg	agcgtgcaa	cggcaagggg	aacgagcccc	gcaccaaggt	780
gcagcattgc	cactactgtg	gcggctccgg	catggaaacc	atcaacacag	gcccttttgt	840
gatgcgttcc	acgtgtagga	gatgtggtgg	ccgcggctcc	atcatcatat	cgccctgtgt	900
ggtctgcagg	ggagcaggac	aagccaagca	gaaaaagcga	gtgatgatcc	ctgtgcctgc	960
aggagtcgag	gatggccaga	ccgtgaggat	gcctgtggga	aaaagggaaa	ttttcattac	1020
gttcagggtg	cagaaaagcc	ctgtgttccg	gagggacggc	gcagacatcc	actccgacct	1080
ctttatttct	atagctcagg	ctcttcttgg	gggaacagcc	agagcccagg	gcctgtacga	1140
gacgatcaac	gtgacgatcc	cccctgggac	tcagacagac	cagaagattc	ggatgggtgg	1200
gaaaggcatc	ccccggatta	acagctacgg	ctacggagac	cactacatcc	acatcaagat	1260
acgagttcca	aagaggctaa	cgagccggca	gcagagcctg	atcctgagct	acgccgagga	1320
cgagacagat	gtggaggggg	cggtgaacgg	cgctaccctc	accagctctg	gtggcagcac	1380
catggatagc	tccgcaggaa	gcaaggctag	cgctgaggct	ggggaggacg	aggagggatt	1440
cctttccaaa	cttaagaaaa	tgtttacctc	atgatatccc	agccgaggaa	aaagatccac	1500
tggaaactag	gccgggaagc	agcagccctt	ccaagggcca	gggcacctgg	gagacgggag	1560
gattccagaa	cagcagcact	gagctccac	ccgcagagcc	tctggacggc	cttggcaaca	1620
gcaaaatcat	gggacaacac	ctctctccac	ggaaaggtca	cagtggacag	cccgggcagt	1680
aggatgcagc	cccagaggct	ggtggcagtt	tcctgtccat	tggtaggtga	cggccccctg	1740
gtcagcagag	gagagggttag	atcttgacag	ctaaaactct	aatttggaat	tgaatattgt	1800
ggatatctta	gttaaaggcc	atgcttacag	cttagaaatg	aagccttaag	ctgcatcaag	1860
ttacgaagtg	attaatttcc	ttctcagcaa	acctccggga	ggttccagaa	tgagttcttc	1920

032796-132.ST25

ctgacaggtt	gtcttctactg	ggagcgtggg	gccccagggc	cccaccagca	ccgtcctccc	1980
ctaagtgggg	gccctgccga	ggcatcagct	gctctgctca	gttagttttt	attcccgggg	2040
taccaagcag	ctgcacagtc	gggtgcctggg	aagcacgtta	aaggcccaga	gagatcctgg	2100
gggttctgct	ctgaccgtgt	gggtggtgat	ccttgctcagg	atgtacagtc	cttgtctcca	2160
ccccatccgg	gatggccggc	tgccctgac	tattgagtc	tggtgttgta	agccaggcat	2220
ggagggtctc	tgcccttctg	ctgagccaca	gcccattgca	gcaactgtgct	ggccagactt	2280
cagctgcctt	gggaactgaa	gccctgccac	tggtgctagt	caggggcttg	gttctccac	2340
ttacactgtt	gacatctatt	ttctgaagtg	tggttaaat	attcagtgtc	aatcattgtt	2400
ttttcctttg	taaatgttga	ttcagaaaag	gaaagcacag	gctaagcagt	tgaaggttcc	2460
ccaccattca	gtgagagcag	aacccccatt	ccccagctc	tgctggtagc	atgtcgcagt	2520
ttccatgtgt	ttcaggatct	tcgggctgtc	gttagacagg	ttaatgaaga	acacttctca	2580
acagtttctt	ttttgttttc	ctttataatt	cactaaaata	aagcatctat	tagtgtctga	2640
aaaaaaaaaa	aaaaaa					2656

<210> 84

<211> 2217

<212> DNA

<213> Homo sapiens

<400> 84

gcggaccggg	cgccgaggcg	gccaccgag	acggggcgcg	cacgtccgg	cctgcgcagc	60
ccggcccggc	catggcgggc	ccccgccgt	ctccgcgat	ctccgtttcg	gtctcggtc	120
cggttttta	cgccccgag	aagaagtctg	gccctgtggt	ggcccaaag	cccaaagtga	180
atcccttccg	gcccggggac	agcgagcctc	ccccggcacc	cgggggccag	cgcgcacaga	240
tgggccgggt	gggcgagatt	ccccgcgcg	ccccggaaga	ctttcccctg	cctccacctc	300
cccttgctgg	ggatggcgac	gatgcagagg	gtgctctggg	aggtgccttc	ccgccgccc	360
ctcccccgat	cgaggaatca	tttccccctg	cgcctctgga	ggaggagatc	ttcccttccc	420
cgccgcctcc	tccggaggag	gagggagggc	ctgaggcccc	cataccgccc	ccaccacagc	480
ccagggagaa	ggtgagcagt	attgattttg	agatcgactc	tctgtcctca	ctgctggatg	540
acatgaccaa	gaatgatcct	ttcaaagccc	gggtgtcatc	tgatgatgtg	ccccaccag	600
tggccactcc	attcagttcc	aagtccagta	ccaagcctgc	agccgggggc	acagcacccc	660
tgctccttg	gaagtccctt	tccagctccc	agcctctgcc	ccaggttccg	gctccggctc	720
agagccagac	acagttccat	gttcagcccc	agccccagcc	caagcctcag	gtccaactcc	780
atgtccagtc	ccagaccag	cctgtgtctt	tggctaacac	ccagccccga	gggccccag	840
cctcatctcc	ggctccagcc	cctaagtttt	ctccagtgc	tcctaagttt	actcctgtgg	900
cttccaagtt	cagtcctgga	gccccagggtg	gatctgggtc	acaaccaa	caaaaattgg	960
ggcaccgccg	agctctttct	gctggcacag	gctccctca	acctccagc	ttcacctatg	1020
cccagcagag	ggagaagccc	cgagtgcagg	agaagcagca	ccccgtgcc	ccaccggctc	1080
agaacaaaaa	ccaggtgcgc	tcccctgggg	ccccagggcc	cctgactctg	aaggaggtgg	1140
aggagctgga	gcagctgacc	cagcagctaa	tgcaggacat	ggagcatcct	cagaggcaga	1200
atgtggtgtg	caacgaactc	tgcggccgat	gccatcaacc	cctggcccgg	gcgcagccag	1260
ccgtccgcgc	tctagggcag	ctgttccaca	tcgcctgctt	cacctgccac	cagtgtgcgc	1320
agcagctcca	gggccagcag	ttctacagtc	tggagggggc	gccgtactgc	gagggctgtt	1380
acactgacac	cctggagaag	tgtaacacct	gcggggagcc	catcactgac	cgcatgtga	1440
gggccacggg	caaggcctat	caccgcact	gcttcacctg	tgtggtctgc	gcccgecccc	1500
tggagggcac	ctccttcac	gtggaccagg	ccaaccggcc	ccactgtgtc	cccgaactac	1560
acaagcagta	cgccccgagg	tgctccgtct	gctctgagcc	catcatgcct	gagcctggcc	1620
gagatgagac	tgtgcgagtg	gtcgccctgg	acaagaactt	ccacatgaag	tggtacaagt	1680
gtgaggactg	cggaagccc	ctgtcgattg	aggcagatga	caatggctgc	ttccccctgg	1740
acggtcacgt	gctctgtcgg	aagtgccaca	ctgctagagc	ccagacctga	gtgaggacag	1800
gccctcttca	gaccgcagtc	catgccccat	tgtggaccac	ccacactgag	accacctgcc	1860
cccacctcag	ttattgtttt	gatgtctagc	ccctccatt	tccaacccct	ccctagcatc	1920
ccaggtgccc	tgaccagga	cccaacatgg	tctagggatg	caggatcccc	gccctgggggt	1980
ctggtcctcg	cccatcctgc	agggattgcc	caccgtcttc	cagacacccc	acctgagggg	2040
ggcaccagggt	ttagtgctgc	tgctttcact	gctgcacccg	cgccctcggc	cggccccccg	2100
agcagccttt	gtactctgct	tgcggagggc	tgggagaccc	tccaggacat	tcccaccctc	2160
ccccatgctg	ccaagttgta	gctatagcta	caaataaaaa	aaaaccttgt	tttccag	2217

032796-132.ST25

<210> 85

<211> 8906

<212> DNA

<213> Homo sapiens

<400> 85

gaggcgccca	aggacctggc	cgacatcgcg	gccttcttcc	gatccggggt	tcgaaaaaac	60
gatgaaatga	aagctatgga	tgttttacca	attttgaagg	aaaaagttgc	atacctttca	120
ggtgggagag	ataaacgtgg	aggtcccatt	ttaacgtttc	cggcccgcag	caatcatgac	180
agaatacgac	aggaggatct	caggagactc	atttcctatc	tagcctgtat	tcccagcgag	240
gaggtctgca	agcgtggctt	cacggtgatc	gtggacatgc	gtgggtccaa	gtgggactcc	300
atcaagcccc	ttctgaagat	cctgcaggag	tccttcccct	gctgcatcca	tgtggccctg	360
atcatcaagc	cagacaactt	ctggcagaaa	cagaggacta	attttggcag	ttctaaattt	420
gaatttgaga	caaatatggt	ctcttttagaa	ggccttacca	aagtagttga	tccttctcag	480
ctaactcctg	agtttgatgg	ctgcctggaa	tacaaccacg	aagaatggat	tgaaatcaga	540
gttgcttttg	aagactaacg	tagcaatgcc	acccacatgc	tgtctcggct	ggaggaaactt	600
caggacatcc	tagctaagaa	ggagctgcct	caggatttag	agggggctcg	gaatatgatc	660
gaggaacatt	ctcagctgaa	gaagaagggtg	attaaggccc	ccatcgagga	cctggatttg	720
gaggacaga	agctgcttca	gaggatacag	agcagtgaaa	gctttcccaa	aaagaactca	780
ggctcaggca	atgcggacct	gcagaacctc	ttgcccaagg	tgtccaccat	gctggaccgg	840
ctgcactcga	cacggcagca	tctgcaccag	atgtggcatg	tgaggaagct	gaagctggac	900
cagtgttcc	agctgaggct	gtttgaacag	gatgtcgaga	agatgtttga	ctggatcaca	960
cacaacaaag	gcctgtttct	aaacagctac	acagagattg	ggaccagcca	ccctcatgcc	1020
atggagcttc	agacgcagca	caatcacttt	gccatgaact	gtatgaacgt	gtatgtaaat	1080
ataaaccgca	tcatgtcggg	ggccaatcgt	ctggtggagt	ctggccacta	tgcctcgag	1140
cagatcaggc	agatcgcgag	tcagctggag	caggagtggg	aggcgtttgc	ggcagccctg	1200
gatgagcgga	gcaccttgct	ggacatgtcc	tccattttcc	accagaaggc	cgaaaagtat	1260
atgagcaacg	tggattcatg	gtgtaaagct	tgcgggtgag	tagaccttcc	ctcagagctg	1320
caggacctag	aagatgccat	tcatcaccac	cagggaatat	atgaacatat	cactcttgct	1380
tattctgagg	tcagccaaga	tgggaagtct	ctccttgaca	agctccagcg	gcccttgact	1440
cccggcagct	ccgattccct	gacagcctct	gccaaactact	ccaaggccgt	gcaccatgtc	1500
ctggatgtca	tccacgaggt	gctgcaccac	cagcggcacg	tgagaacaat	ctggcaacac	1560
cgcaaggtcc	ggctgcatca	gaggctgcag	ctgtgtgttt	tccagcagga	agttcagcag	1620
gtgctagact	ggatcgagaa	ccacggagaa	gcatttctga	gcaaacatac	aggtgtgggg	1680
aaatctcttc	atcggggccag	agcattgcag	aaacgtcatg	aagattttga	agaagtggca	1740
cagaacacat	acaccaatgc	ggataaatta	ctggaagcag	cagaacagct	ggctcagact	1800
ggggaatgtg	accccgaaag	gatttatcag	gctgcccac	agctggaaga	ccggattcaa	1860
gatttcgttc	ggcgtgttga	gcagcgaaag	atcctactgg	acatgtcagt	gtcctttcac	1920
acccatgtga	aagagctgtg	gacgtggctg	gaggagctgc	agaaggagct	gctggacgac	1980
gtgtatgccg	agtcggtgga	ggccgtgcag	gacctcatca	agcgcttttg	ccagcagcag	2040
cagaccacc	tgcaggtgac	tgtcaacgtg	atcaaggaag	gggaggacct	catccagcag	2100
ctcagggact	ctgccatctc	cagtaacaag	acccccaca	acagctccat	caaccacatt	2160
gagacggtgc	tgcagcagct	ggacgaggcg	cagtcgcaga	tggaggagct	cttcaggag	2220
cgcaagatca	agctggagct	cttcctgcac	gtgcgcactc	tcgagaggga	cgccatcgac	2280
attatctcag	acctcgagtc	ttggaatgat	gagctttctc	agcaaataaa	tgacttcgac	2340
acagaagatc	tcacgattgc	agagcagcgc	ctccagcacc	atgcagacaa	agccttgacc	2400
atgaacaact	tgacttttga	cgtcattccac	caagggaag	atcttctgca	gtatgtcaat	2460
gaggtcagg	cctctggtgt	ggagctgctg	tgtgatagag	atgtagacat	ggcaactcgg	2520
gtccaggacc	tgctggagtt	tcttcatgaa	aaacagcag	aattggattt	agccgcagag	2580
cagcatcgga	aacacctgga	gcagtgcgtg	cagctgcgcc	acctgcaggc	agaagtgaag	2640
caggtgctgg	gttggatccg	caacggagag	tccatgttaa	atgccggact	tatcacagcc	2700
agctcgttac	aagaggcaga	gcagctccag	cgagagcacg	agcagttcca	gcatgccatt	2760
gagaaaacac	atcagagcgc	gctgcagggtg	cagcagaagg	cagaagccat	gctacaggcc	2820
aaccactacg	acatggacat	gatccgggac	tgcgccgaga	aggtggcgctc	tcactggcaa	2880
cagctcatgc	tcaagatgga	agatcgccctc	aagctcgtca	acgcctctgt	cgctttctac	2940
aaaacctcag	agcaggtctg	cagcgtcctc	gagagcctgg	aacaggagta	caagagagaa	3000

032796-132.ST25

gaagactggt	gtggcggggc	ggataagctg	ggcccaaact	ctgagacgga	ccacgtgacg	3060
cccatgatca	gcaagcacct	ggagcagaag	gaggcattcc	tgaaggcttg	cacccttgct	3120
cggaggaatg	cagacgtctt	cctgaaatac	ctgcacagga	acagcgtgaa	catgccagga	3180
atggtgacgc	acatcaaagc	tcctgaacag	caagtgaaaa	atatcttgaa	tgaactcttc	3240
caacgggaga	acaggggtatt	gcattactgg	accatgagga	agagacggct	ggaccagtgt	3300
cagcagtacg	tgggtctttga	gaggagtgcc	aagcaggctt	tggaatggat	ccatgacaat	3360
ggcaggttct	acctttccac	acacacctcc	acgggtcca	gtatacagca	caccaggaag	3420
ctcctgaaag	agcacgagga	gttccagata	actgcaaagc	aaaccaaaga	gagagtgaag	3480
ctattgatac	agctggctga	tggcttttgt	gaaaaagggc	atgcccatgc	ggcagagata	3540
aaaaaatgtg	ttactgctgt	ggataagagg	tacagagatt	tctctctgcg	gatggagaag	3600
tacaggacct	ctttggaaaa	agccctgggg	atttcttcag	attccaacaa	atcgagtaaa	3660
agtctccagc	tagatatcat	tccagccagt	atccctggct	cagaggtgaa	acttcgagat	3720
gctgctcatg	aacttaatga	agagaagcgg	aaatctgccc	gcaggaaaga	gttcataatg	3780
gctgagctca	ttcaaactga	aaaggcttat	gtaagagacc	tccgggaatg	tatggatacg	3840
tacctgtggg	aaatgaccag	tggcgtggaa	gagattccac	ctggcattgt	aaacaaagaa	3900
ctcatcatct	tcggaaacat	gcaagaaatc	tacgaatttc	ataataacat	attcctaaag	3960
gagctggaaa	aatatgaaca	gttgccagag	gatgttggac	attgttttgt	tacttgggca	4020
gacaaagtct	acatatgtg	cacatattgc	aaaaataagc	ctgattctac	tcagctgata	4080
ttggaacatg	caggggtccta	ttttgacgag	atacagcagc	gacatggatt	agccaattcc	4140
atttcttctt	accttattaa	accagttcag	cgaataacga	aatatcagct	ccttttaaaa	4200
gagctgctga	cgtgctgtga	ggaaggaaaag	ggagagatta	aagatggcct	ggaggtgatg	4260
ctcagcgtgc	cgaagcgagc	caatgacgcc	atgcacctca	gcatgctgga	agggtttgat	4320
gaaaacattg	agtctcaggg	agaactcatc	ctacaggaat	ccttccaagt	gtgggaccca	4380
aaaaccttaa	ttcgaaaggg	tcgagaacgg	catctcttcc	tttttgaaat	gtccttagta	4440
tttagtaaaag	aagtgaagaa	ttccagtggg	agaagcaagt	acctttataa	aagcaaattg	4500
tttacctcag	agttgggtgt	cacagaacat	gttgaaggag	acccttgcaa	atttgactg	4560
tgggtggggg	gaacaccaac	ttcagataat	aaaattgtcc	ttaaggcttc	cagcatagag	4620
aacaagcagg	actggataaa	gcataatccgc	gaagtcatcc	aggagcggac	gatccacctg	4680
aagggagccc	tgaaggagcc	cattcacatc	cctaagaccg	ctcccgccac	aagacagaag	4740
ggaaggaggg	atggagagga	tctggacagc	caaggagacg	gcagcagcca	gcctgatacg	4800
atttccatcg	cctcacggac	gtctcagaac	acgctggaca	gcgataagct	ctctggtggc	4860
tgtgagctga	cagtggtgat	catgacttcc	accgcttgca	acagcaacga	gtgaccatc	4920
cgacggggcc	agaccgtgga	agttctggag	cggccgcgatg	acaagcctga	ctggtgtctg	4980
gtcgcgacca	ctgaccgctc	cccagcggca	gaaggcctgg	tcccctgtgg	ttcactgtgc	5040
atcgcccact	ccagaagtag	catggaaatg	gagggcatct	tcaaccacaa	agactcgctc	5100
tccgtctcca	gcaatgacgc	cagtcacccc	gcatacgtgg	cttccctcca	gccccacatg	5160
atcgggggccc	agagctcgcc	gggccccaaag	cggccgggca	acaccctgcg	caagtggctc	5220
accagccccg	tgcggcggct	cagcagcggc	aaggccgacg	ggcacgtgaa	gaagctggcg	5280
cacaagcaca	agaagagccg	cgaggtccgc	aagagcggcg	acgccggctc	gcagaaggac	5340
tccgacgaca	gtcgcgccac	cccgcaggac	gagacggctg	aggagagagg	ccggaacgag	5400
ggcctgagca	gcggtactct	ctccaaatcc	tcctcctcgg	ggatgcagag	ctgtggagaa	5460
gaggaaggcg	aggagggggc	cgacgccgtg	cccctgccgc	cacccatggc	catccagcag	5520
cacagcctcc	tccagccaga	ctcacaggat	gacaaggcct	cttctcggtt	attagtccgc	5580
cccaccagct	ccgaaacacc	gagtgcagcc	gagctcgtca	gtgcaattga	ggaactcgtg	5640
aaaagcaaga	tggcactgga	ggatcgcccc	agctcactcc	ttgttgacca	gggagatagt	5700
agcagccctt	ccttcaaac	ttcggataat	tccttctctc	cttctctctc	gcccattgat	5760
gagatggaaag	aaaggaaatc	cagctcttta	aagagaagac	actacgtttt	gcaagaacta	5820
gtggagacag	agcgtgacta	tgtgcgggac	cttggtatg	tgggtgaggg	ctacatggca	5880
cttatgaaag	aagatgggtg	tcctgatgac	atgaaaggaa	aagacaaaat	tgtgttcggc	5940
aacatccatc	agattttacga	ctggcacaga	gacttttttt	taggagagtt	agagaagtgc	6000
cttgaagatc	cagaaaaact	aggatccctt	tttgttaaac	acgagagaag	gttgacatg	6060
tacatagctt	attgtcaaaa	taaaccaaag	tctgagcaca	ttgtctcaga	atacattgat	6120
accttttttg	aggacttaaa	gcagcgtctt	ggccacaggt	tacagctcac	agatctgttg	6180
atcaaaccag	tgcagagaat	catgaagtat	cagctgttac	tgaaggactt	cctcaagtat	6240
tccaaaagg	ccagcctgga	tacatcagaa	ttagagagag	ctgtggaagt	catgtgcata	6300
gtacccaggc	ggtgcaacga	catgatgaac	gtggggcggc	tgaaggattt	cgacgggaaa	6360
atcggttgccc	agggtaaaact	gctcttgcat	gacacattct	tggtcacaga	ccaagatgca	6420

032796-132.ST25

ggacttctgc	ctcgtctgag	agagaggcgc	atcttctctt	ttgagcagat	cgtcatattc	6480
agcgaaccac	ttgataaaaa	gaagggttct	tccatgccgg	gattcctgtt	taagaacagt	6540
atcaagggtga	gttgcctttg	cctggaggaa	aatgtggaaa	atgatccctg	taaatttgct	6600
ctgacatcga	ggacgggtga	cgtggtagag	accttcattt	tgcatcctc	tagtccaagt	6660
gtccggcaaa	cttggatcca	tgaaatcaac	caaattttag	aaaaccagcg	caatttttta	6720
aatgccttga	catcgccaat	cgagtaccag	aggaaccaca	gcgggggcgg	cggcggcggc	6780
ggcagcgggg	cagcggcggg	ggtgggggca	gcggcggcgg	cggggccccc	agtggcggca	6840
gcggccacag	tggcggcccc	agcagctgcg	gcggcggccc	cagcacgagc	aggagccggc	6900
cctcccggat	cccccagcct	gtccgacacc	acccccccgt	gctggtctcc	tctgcagcct	6960
cgagccaggc	agaggcagac	aagatgtcag	agtgaagca	gcagcagtag	caacatctcc	7020
accatgttgg	tgacacacga	ttacacggca	gtgaaggagg	atgagatcaa	cgtctaccaa	7080
ggagaggctg	ttcaaattct	ggccagcaac	cagcagaaca	tgtttctggt	gttccgagcc	7140
gccactgacc	agtgcctcgc	agctgagggc	tggattccag	gctttgtcct	gggccacacc	7200
agtgcagtca	tcgtggagaa	cccggacggg	actctcaaga	agtcaacatc	ttggcacaca	7260
gcactccgtt	taaggaaaaa	atctgagaaa	aaagataaag	acggcaaaaag	ggaaggcaag	7320
ttagagaacg	gttatcggaa	gtcacgggaa	ggactcagca	acaaggatc	tgtgaagctt	7380
ctcaatccca	actacattta	tgacgttccc	ccagaattcg	tcattccatt	gagtgaagtc	7440
acgtgtgaga	caggggagac	cgttgttctt	agatgtcgag	tctgtggccg	ccccaaagcc	7500
tcaattacct	ggaagggccc	tgaacacaa	accttgaaca	acgatggtca	ctacagcatc	7560
tcctacagtg	acctgggaga	ggccacgctg	aagattgtgg	gcgtgaccac	ggaagatgac	7620
ggcatctaca	cgtgcctcgc	tgtcaatgac	atgggttcag	cctcatcctc	ggccagcctg	7680
agggtcctag	gtccagggat	ggatgggatc	atgggtgacct	ggaaagacaa	ctttgactcc	7740
ttctacagtg	aagtggctga	gcttggcagg	ggcagattct	ctgtcgttaa	gaaatgtgat	7800
cagaaaggaa	ccaagcgagc	agtggccact	aagtttgtga	acaagaagtt	gatgaagcgc	7860
gaccaggtca	cccatgagct	tggcatcctg	cagagcctcc	agcaccctcc	gcttgtcggc	7920
ctcctcgaca	cctttgagac	ccccaccagc	tacatcctgg	tcttagaaat	ggctgaccag	7980
ggtcgctctc	tggactgcgt	ggtgcgatgg	ggaagcctca	ctgaagggaa	gatcaggggc	8040
cacctggggg	aggttcttga	agctgtccgg	tacctgcaca	actgcaggat	agcacacctg	8100
gacctaaagc	ctgagaatat	cctggtggat	gagagtttag	ccaagccaac	catcaaactg	8160
gctgactttg	gagatgctgt	tcagctcaac	acgacctact	acatccacca	gttactgggg	8220
aacctgaat	tcgcagcccc	tgaaatcctc	ctcggaacc	ctgtctccct	gacctcggat	8280
acgtggagtg	ttggagtgtc	cacatacgta	cttcttagtg	gcgtgtcccc	cttcctggat	8340
gacagtgtgg	aagagacctg	cctgaacatt	tgccgcttag	acttttagctt	cccagatgac	8400
tactttaaag	gagtgaagcca	gaaggccaag	gagttcgtgt	gcttcctcct	gcaggaggac	8460
cccgccaagc	gtccctcggc	tgcgtggccc	ctccaggagc	agtggctgca	ggccggcaac	8520
ggcagaagca	cgggcgtcct	cgacacgtcc	agactgactt	ccttcattga	gcggcgcaaa	8580
caccagaatg	atgttcgacc	tatccgtagc	attaaaaact	ttctgcagag	caggcttctg	8640
cctagagttt	gacctatcca	gaagttcttt	ctcattctct	ttcacctgcc	aatcagctgt	8700
taatctgaat	tttcaagaga	aaacaagcaa	acataactga	tcagctgccg	gtatgttcat	8760
cgtgtgaaat	tgcatcccaa	gtgagctgtg	ctcagcagtg	cttggacaca	gagctgcaag	8820
ctgcgtggg	gtggaggacc	gtcacttaca	ctctgccaag	gacggaggtc	gcattgtctgt	8880
atcacagtat	tttttacgga	tttctg				8906

<210> 86

<211> 1204

<212> DNA

<213> Homo sapiens

<400> 86

tcggcggcgg	tggatatcggc	ggcagctgtg	aggggggttcc	gggaagatgg	tgctgatcaa	60
ggaattccgt	gtggttttgc	catgttctgt	tcaggagtat	cagggttggc	agctttactc	120
tgttgacaga	gctagtaaga	atgagactgg	tgggtggaga	ggaattgaag	tcttaaagaa	180
tgaaccttat	gagaaggatg	gagaaaaggg	acagtatacg	cacaaaattt	atcacctaaa	240
gagcaaagtg	cctgcattcg	tgaggatgat	tgctcccgag	ggctccttgg	tgtttcatga	300
gaaagcctgg	aatgcgtacc	cctactgtag	aacaattgta	acgaatgaat	atatgaaaga	360
tgatttcttc	attaaaaatcg	aaacatggca	caaaccagac	ttgggaacat	tagaaaatgt	420

032796-132.ST25

```

acatggttta gatccaaaca catggaaaac tgttgaaatt gtccatatag atattgcaga 480
tagaagtcaa gttgaaccag cagactacaa agctgatgaa gaccagcat tattccagtc 540
agtcaagacc aagagaggcc ctttgggacc caactggaag aaggagctgg caaacagccc 600
tgactgtccc cagatgtgtg cctataagct ggtgaccatc aaattcaagt ggtggggact 660
gcaaagcaaa gtagaaaact tcattcaaaa gcaagaaaaa cggatattta caaacttcca 720
tcgccagctt ttttgttgga ttgacaagtg gatcgatctc acgatggaag acattaggag 780
aatggaagac gagactcaga aagaactaga aacaatgcgt aagaggggtt ccgttcgagg 840
cacgtcggct gctgatgtct agatgagtc cctgtagggt cagagacaat gtcaaactgt 900
ttacgtaatc aaggtcaagt gaggggaaca agcgcagcca gtgatgagtg aacaacaatc 960
tgaccagtat cttgcagtgt tgacgtttcc cagatgtgtg cttgtgatga tacacacaca 1020
tgcacaggtt ctcaaccacg tgtgtatata tgtatgtgtg catatgtctg tagctgtata 1080
taaagcgcat gtagagctac agatccagat acacacactt gtgtatatat gtacatacag 1140
acatactgaa gggattagta caatttctcc aaagtactgt acctatcttc agcaagaatg 1200
caaa 1204

```

<210> 87

<211> 892

<212> PRT

<213> Homo sapiens

<400> 87

```

Met Asp His Tyr Asp Ser Gln Gln Thr Asn Asp Tyr Met Gln Pro Glu
1      5      10      15
Glu Asp Trp Asp Arg Asp Leu Leu Leu Asp Pro Ala Trp Glu Lys Gln
20      25      30
Gln Arg Lys Thr Phe Thr Ala Trp Cys Asn Ser His Leu Arg Lys Ala
35      40      45
Gly Thr Gln Ile Glu Asn Ile Glu Glu Asp Phe Arg Asp Gly Leu Lys
50      55      60
Leu Met Leu Leu Leu Glu Val Ile Ser Gly Glu Arg Leu Ala Lys Pro
65      70      75      80
Glu Arg Gly Lys Met Arg Val His Lys Ile Ser Asn Val Asn Lys Ala
85      90      95
Leu Asp Phe Ile Ala Ser Lys Gly Val Lys Leu Val Ser Ile Gly Ala
100     105     110
Glu Glu Ile Val Asp Gly Asn Val Lys Met Thr Leu Gly Met Ile Trp
115     120     125
Thr Ile Ile Leu Arg Phe Ala Ile Gln Asp Ile Ser Val Glu Glu Thr
130     135     140
Ser Ala Lys Glu Gly Leu Leu Leu Trp Cys Gln Arg Lys Thr Ala Pro
145     150     155     160
Tyr Lys Asn Val Asn Ile Gln Asn Phe His Ile Ser Trp Lys Asp Gly
165     170     175
Leu Gly Phe Cys Ala Leu Ile His Arg His Arg Pro Glu Leu Ile Asp
180     185     190
Tyr Gly Lys Leu Arg Lys Asp Asp Pro Leu Thr Asn Leu Asn Thr Ala
195     200     205
Phe Asp Val Ala Glu Lys Tyr Leu Asp Ile Pro Lys Met Leu Asp Ala
210     215     220
Glu Asp Ile Val Gly Thr Ala Arg Pro Asp Glu Lys Ala Ile Met Thr
225     230     235     240
Tyr Val Ser Ser Phe Tyr His Ala Phe Ser Gly Ala Gln Lys Ala Glu
245     250     255
Thr Ala Ala Asn Arg Ile Cys Lys Val Leu Ala Val Asn Gln Glu Asn
260     265     270
Glu Gln Leu Met Glu Asp Tyr Glu Lys Leu Ala Ser Asp Leu Leu Glu
275     280     285

```

032796-132.ST25

Trp Ile Arg Arg Thr Ile Pro Trp Leu Glu Asn Arg Val Pro Glu Asn
 290 295 300
 Thr Met His Ala Met Gln Lys Leu Glu Asp Phe Arg Asp Tyr Arg
 305 310 315 320
 Arg Leu His Lys Pro Pro Lys Val Gln Glu Lys Cys Gln Leu Glu Ile
 325 330 335
 Asn Phe Asn Thr Leu Gln Thr Lys Leu Arg Leu Ser Asn Arg Pro Ala
 340 345 350
 Phe Met Pro Ser Glu Gly Arg Met Val Ser Asp Ile Asn Asn Ala Trp
 355 360 365
 Gly Cys Leu Glu Gln Val Glu Lys Gly Tyr Glu Glu Trp Leu Leu Asn
 370 375 380
 Glu Ile Arg Arg Leu Glu Arg Leu Asp His Leu Ala Glu Lys Phe Arg
 385 390 395 400
 Gln Lys Ala Ser Ile His Glu Ala Trp Thr Asp Gly Lys Glu Ala Met
 405 410 415
 Leu Arg Gln Lys Asp Tyr Glu Thr Ala Thr Leu Ser Glu Ile Lys Ala
 420 425 430
 Leu Leu Lys Lys His Glu Ala Phe Glu Ser Asp Leu Ala Ala His Gln
 435 440 445
 Asp Arg Val Glu Gln Ile Ala Ala Ile Ala Gln Glu Leu Asn Glu Leu
 450 455 460
 Asp Tyr Tyr Asp Ser Pro Ser Val Asn Ala Arg Cys Gln Lys Ile Cys
 465 470 475 480
 Asp Gln Trp Asp Asn Leu Gly Ala Leu Thr Gln Lys Arg Arg Glu Ala
 485 490 495
 Leu Glu Arg Thr Glu Lys Leu Leu Glu Thr Ile Asp Gln Leu Tyr Leu
 500 505 510
 Glu Tyr Ala Lys Arg Ala Ala Pro Phe Asn Asn Trp Met Glu Gly Ala
 515 520 525
 Met Glu Asp Leu Gln Asp Thr Phe Ile Val His Thr Ile Glu Glu Ile
 530 535 540
 Gln Gly Leu Thr Thr Ala His Glu Gln Phe Lys Ala Thr Leu Pro Asp
 545 550 555 560
 Ala Asp Lys Glu Arg Leu Ala Ile Leu Gly Ile His Asn Glu Val Ser
 565 570 575
 Lys Ile Val Gln Thr Tyr His Val Asn Met Ala Gly Thr Asn Pro Tyr
 580 585 590
 Thr Thr Ile Thr Pro Gln Glu Ile Asn Gly Lys Trp Asp His Val Arg
 595 600 605
 Gln Leu Val Pro Arg Arg Asp Gln Ala Leu Thr Glu Glu His Ala Arg
 610 615 620
 Gln Gln His Asn Glu Arg Leu Arg Lys Gln Phe Gly Ala Gln Ala Asn
 625 630 635 640
 Val Ile Gly Pro Trp Ile Gln Thr Lys Met Glu Glu Ile Gly Arg Ile
 645 650 655
 Ser Ile Glu Met His Gly Thr Leu Glu Asp Gln Leu Ser His Leu Arg
 660 665 670
 Gln Tyr Glu Lys Ser Ile Val Asn Tyr Lys Pro Lys Ile Asp Gln Leu
 675 680 685
 Glu Gly Asp His Gln Leu Ile Gln Glu Ala Leu Ile Phe Asp Asn Lys
 690 695 700
 His Thr Asn Tyr Thr Met Glu His Ile Arg Val Gly Trp Glu Gln Leu
 705 710 715 720
 Leu Thr Thr Ile Ala Arg Thr Ile Asn Glu Val Glu Asn Gln Ile Leu
 725 730 735
 Thr Arg Asp Ala Lys Gly Ile Ser Gln Glu Gln Met Asn Glu Phe Arg

032796-132.ST25

```

      740      745      750
Ala Ser Phe Asn His Phe Asp Arg Asp His Ser Gly Thr Leu Gly Pro
      755      760      765
Glu Glu Phe Lys Ala Cys Leu Ile Ser Leu Gly Tyr Asp Ile Gly Asn
      770      775      780
Asp Pro Gln Gly Glu Ala Glu Phe Ala Arg Ile Met Ser Ile Val Asp
785      790      795      800
Pro Asn Arg Leu Gly Val Val Thr Phe Gln Ala Phe Ile Asp Phe Met
      805      810      815
Ser Arg Glu Thr Ala Asp Thr Asp Thr Ala Asp Gln Val Met Ala Ser
      820      825      830
Phe Lys Ile Leu Ala Gly Asp Lys Asn Tyr Ile Thr Met Asp Glu Leu
      835      840      845
Arg Arg Glu Leu Pro Pro Asp Gln Ala Glu Tyr Cys Ile Ala Arg Met
850      855      860
Ala Pro Tyr Thr Gly Pro Asp Ser Val Pro Gly Ala Leu Asp Tyr Met
865      870      875      880
Ser Phe Ser Thr Ala Leu Tyr Gly Glu Ser Asp Leu
      885      890

```

<210> 88

<211> 197

<212> PRT

<213> Homo sapiens

<400> 88

```

Met Met Phe Pro Gln Ser Arg His Ser Gly Ser Ser His Leu Pro Gln
1      5      10      15
Gln Leu Lys Phe Thr Thr Ser Asp Ser Cys Asp Arg Ile Lys Asp Glu
20      25      30
Phe Gln Leu Leu Gln Ala Gln Tyr His Ser Leu Lys Leu Glu Cys Asp
35      40      45
Lys Leu Ala Ser Glu Lys Ser Glu Met Gln Arg His Tyr Val Met Tyr
50      55      60
Tyr Glu Met Ser Tyr Gly Leu Asn Ile Glu Met His Lys Gln Ala Glu
65      70      75      80
Ile Val Lys Arg Leu Asn Gly Ile Cys Ala Gln Val Leu Pro Tyr Leu
85      90      95
Ser Gln Glu His Gln Gln Gln Val Leu Gly Ala Ile Glu Arg Ala Lys
100      105      110
Gln Val Thr Ala Pro Glu Leu Asn Ser Ile Ile Arg Gln Gln Leu Gln
115      120      125
Ala His Gln Leu Ser Gln Leu Gln Ala Leu Ala Leu Pro Leu Thr Pro
130      135      140
Leu Pro Val Gly Leu Gln Pro Pro Ser Leu Pro Ala Val Ser Ala Gly
145      150      155      160
Thr Gly Leu Leu Ser Leu Ser Ala Leu Gly Ser Gln Ala His Leu Ser
165      170      175
Lys Glu Asp Lys Asn Gly His Asp Gly Asp Thr His Gln Glu Asp Asp
180      185      190
Gly Glu Lys Ser Asp
195

```

<210> 89

<211> 739

<212> PRT

<213> Homo sapiens

032796-132.ST25

<400> 89

Gly Asp Lys Glu Pro Thr Glu Thr Ile Gly Asp Leu Ser Ile Cys Leu
 1 5 10 15
 Asp Gly Leu Gln Leu Glu Ser Glu Val Thr Asn Gly Glu Thr Thr
 20 25 30
 Cys Ser Glu Ser Ala Ser Gln Asn Asp Asp Gly Ser Arg Ser Lys Asp
 35 40 45
 Glu Thr Arg Val Ser Thr Asn Gly Ser Asp Asp Pro Glu Asp Ala Gly
 50 55 60
 Ala Gly Glu Asn Arg Arg Val Ser Gly Asn Asn Ser Pro Ser Leu Ser
 65 70 75 80
 Asn Gly Gly Phe Lys Pro Ser Arg Pro Pro Arg Pro Ser Arg Pro Pro
 85 90 95
 Pro Pro Thr Pro Arg Arg Pro Ala Ser Val Asn Gly Ser Pro Ser Ala
 100 105 110
 Thr Ser Glu Ser Asp Gly Ser Ser Thr Gly Ser Leu Pro Pro Thr Asn
 115 120 125
 Thr Asn Thr Asn Thr Ser Glu Gly Ala Thr Ser Gly Leu Ile Ile Pro
 130 135 140
 Leu Thr Ile Ser Gly Gly Ser Gly Pro Arg Pro Leu Asn Pro Val Thr
 145 150 155 160
 Gln Ala Pro Leu Pro Pro Gly Trp Glu Gln Arg Val Asp Gln His Gly
 165 170 175
 Arg Val Tyr Tyr Val Asp His Val Glu Lys Arg Thr Thr Trp Asp Arg
 180 185 190
 Pro Glu Pro Leu Pro Pro Gly Trp Glu Arg Arg Val Asp Asn Met Gly
 195 200 205
 Arg Ile Tyr Tyr Val Asp His Phe Thr Arg Thr Thr Thr Trp Gln Arg
 210 215 220
 Pro Thr Leu Glu Ser Val Arg Asn Tyr Glu Gln Trp Gln Leu Gln Arg
 225 230 235 240
 Ser Gln Leu Gln Gly Ala Met Gln Gln Phe Asn Gln Arg Phe Ile Tyr
 245 250 255
 Gly Asn Gln Asp Leu Phe Ala Thr Ser Gln Ser Lys Glu Phe Asp Pro
 260 265 270
 Leu Gly Pro Leu Pro Pro Gly Trp Glu Lys Arg Thr Asp Ser Asn Gly
 275 280 285
 Arg Val Tyr Phe Val Asn His Asn Thr Arg Ile Thr Gln Trp Glu Asp
 290 295 300
 Pro Arg Ser Gln Gly Gln Leu Asn Glu Lys Pro Leu Pro Glu Gly Trp
 305 310 315 320
 Glu Met Arg Phe Thr Val Asp Gly Ile Pro Tyr Phe Val Asp His Asn
 325 330 335
 Arg Arg Thr Thr Tyr Ile Asp Pro Arg Thr Gly Lys Ser Ala Leu
 340 345 350
 Asp Asn Gly Pro Gln Ile Ala Tyr Val Arg Asp Phe Lys Ala Lys Val
 355 360 365
 Gln Tyr Phe Arg Phe Trp Cys Gln Gln Leu Ala Met Pro Gln His Ile
 370 375 380
 Lys Ile Thr Val Thr Arg Lys Thr Leu Phe Glu Asp Ser Phe Gln Gln
 385 390 395 400
 Ile Met Ser Phe Ser Pro Gln Asp Leu Arg Arg Arg Leu Trp Val Ile
 405 410 415
 Phe Pro Gly Glu Glu Gly Leu Asp Tyr Gly Gly Val Ala Arg Glu Trp
 420 425 430
 Phe Phe Leu Leu Ser His Glu Val Leu Asn Pro Met Tyr Cys Leu Phe

032796-132.ST25

```

      435      440      445
Glu Tyr Ala Gly Lys Asp Asn Tyr Cys Leu Gln Ile Asn Pro Ala Ser
450      455      460
Tyr Ile Asn Pro Asp His Leu Lys Tyr Phe Arg Phe Ile Gly Arg Phe
465      470      475      480
Ile Ala Met Ala Leu Phe His Gly Lys Phe Ile Asp Thr Gly Phe Ser
      485      490      495
Leu Pro Phe Tyr Lys Arg Ile Leu Asn Lys Pro Val Gly Leu Lys Asp
500      505      510
Leu Glu Ser Ile Asp Pro Glu Phe Tyr Asn Ser Leu Ile Trp Val Lys
515      520      525
Glu Asn Asn Ile Glu Glu Cys Asp Leu Glu Met Tyr Phe Ser Val Asp
530      535      540
Lys Glu Ile Leu Gly Glu Ile Lys Ser His Asp Leu Lys Pro Asn Gly
545      550      555      560
Gly Asn Ile Leu Val Thr Glu Glu Asn Lys Glu Glu Tyr Ile Arg Met
565      570      575
Val Ala Glu Trp Arg Leu Ser Arg Gly Val Glu Glu Gln Thr Gln Ala
580      585      590
Phe Phe Glu Gly Phe Asn Glu Ile Leu Pro Gln Gln Tyr Leu Gln Tyr
595      600      605
Phe Asp Ala Lys Glu Leu Glu Val Leu Leu Cys Gly Met Gln Glu Ile
610      615      620
Asp Leu Asn Asp Trp Gln Arg His Ala Ile Tyr Arg His Tyr Ala Arg
625      630      635      640
Thr Ser Lys Gln Ile Met Trp Phe Trp Gln Phe Val Lys Glu Ile Asp
645      650      655
Asn Glu Lys Arg Met Arg Leu Leu Gln Phe Val Thr Gly Thr Cys Arg
660      665      670
Leu Pro Val Gly Gly Phe Ala Asp Leu Met Gly Ser Asn Gly Pro Gln
675      680      685
Lys Phe Cys Ile Glu Lys Val Gly Lys Glu Asn Trp Leu Pro Arg Ser
690      695      700
His Thr Cys Phe Asn Arg Leu Asp Leu Pro Pro Tyr Lys Ser Tyr Glu
705      710      715      720
Gln Leu Lys Glu Lys Leu Leu Phe Ala Ile Glu Glu Thr Glu Gly Phe
725      730      735
Gly Gln Glu

```

<210> 90

<211> 431

<212> PRT

<213> Homo sapiens

<400> 90

```

Gly Pro Pro Pro Thr Arg Ala Leu Pro Leu Pro Gln Ser Leu Pro Pro
1      5      10      15
Asp Phe Arg Leu Glu Pro Thr Ala Pro Ala Leu Ser Pro Arg Ser Ser
20      25      30
Phe Ala Ser Ser Ser Ala Ser Asp Ala Ser Lys Pro Ser Ser Pro Arg
35      40      45
Gly Ser Leu Leu Leu Asp Gly Ala Gly Ala Gly Gly Ala Gly Gly Ser
50      55      60
Arg Pro Cys Ser Asn Arg Thr Ser Gly Ile Ser Met Gly Tyr Asp Gln
65      70      75      80
Arg His Gly Ser Pro Leu Pro Ala Gly Pro Cys Leu Phe Gly Pro Pro

```

032796-132.ST25

```

      85              90              95
Leu Ala Gly Ala Pro Ala Gly Tyr Ser Pro Gly Gly Val Pro Ser Ala
      100              105              110
Tyr Pro Glu Leu His Ala Ala Leu Asp Arg Leu Tyr Ala Gln Arg Pro
      115              120              125
Ala Gly Phe Gly Cys Gln Glu Ser Arg His Ser Tyr Pro Pro Ala Leu
      130              135              140
Gly Ser Pro Gly Ala Leu Ala Gly Ala Arg Val Gly Ala Ala Gly Pro
      145              150              155
Leu Glu Arg Arg Gly Ala Gln Pro Gly Arg His Ser Val Thr Gly Tyr
      165              170              175
Gly Asp Cys Ala Val Gly Ala Arg Tyr Gln Asp Glu Leu Thr Ala Leu
      180              185              190
Leu Arg Leu Thr Val Gly Thr Gly Gly Arg Glu Ala Gly Ala Arg Gly
      195              200              205
Glu Pro Ser Gly Ile Glu Pro Ser Gly Leu Glu Glu Pro Pro Gly Pro
      210              215              220
Phe Val Pro Glu Ala Ala Arg Ala Arg Met Arg Glu Pro Glu Ala Arg
      225              230              235
Glu Asp Tyr Phe Gly Thr Cys Ile Lys Cys Asn Lys Gly Ile Tyr Gly
      245              250              255
Gln Ser Asn Ala Cys Gln Ala Leu Asp Ser Leu Tyr His Thr Gln Cys
      260              265              270
Phe Val Cys Cys Ser Cys Gly Arg Thr Leu Arg Cys Lys Ala Phe Tyr
      275              280              285
Ser Val Asn Gly Ser Val Tyr Cys Glu Glu Asp Tyr Leu Phe Ser Gly
      290              295              300
Phe Gln Glu Ala Ala Glu Lys Cys Cys Val Cys Gly His Leu Ile Leu
      305              310              315
Glu Lys Ile Leu Gln Ala Met Gly Lys Ser Tyr His Pro Gly Cys Phe
      325              330              335
Arg Cys Ile Val Cys Asn Lys Cys Leu Asp Gly Ile Pro Phe Thr Val
      340              345              350
Asp Phe Ser Asn Gln Val Tyr Cys Val Thr Asp Tyr His Lys Asn Tyr
      355              360              365
Ala Pro Lys Cys Ala Ala Cys Gly Gln Pro Ile Leu Pro Ser Glu Gly
      370              375              380
Cys Glu Asp Ile Val Arg Val Ile Ser Met Asp Arg Asp Tyr His Phe
      385              390              395
Glu Cys Tyr His Cys Glu Asp Cys Arg Met Gln Leu Ser Asp Glu Glu
      405              410              415
Gly Cys Cys Cys Phe Pro Leu Asp Gly His Leu Leu Cys His Gly
      420              425              430

```

<210> 91

<211> 900

<212> PRT

<213> Homo sapiens

<400> 91

```

Gly Pro Gly Ser Arg His His Arg Ala Arg Asp Arg Leu Ile His Phe
  1              5              10              15
Gly Ala Val Ser Thr Asp Val Leu Gly Cys Ser Ala His Cys Ser Leu
      20              25              30
Thr Gln Ser Pro Lys Met Asn Ile Gln Glu Gln Gly Phe Pro Leu Asp
      35              40              45
Leu Gly Ala Ser Phe Thr Glu Asp Ala Pro Arg Pro Pro Val Pro Gly

```

032796-132.ST25

50	55	60
Glu Glu Gly Glu Leu Val Ser Thr Asp Pro Arg Pro Ala Ser Tyr Ser		
65	70	75
Phe Cys Ser Gly Lys Gly Val Gly Ile Lys Gly Glu Thr Ser Thr Ala		80
	85	90
Thr Pro Arg Arg Ser Asp Leu Asp Leu Gly Tyr Glu Pro Glu Gly Ser		95
	100	105
Ala Ser Pro Thr Pro Pro Tyr Leu Lys Trp Ala Glu Ser Leu His Ser		110
	115	120
Leu Leu Asp Asp Gln Asp Gly Ile Ser Leu Phe Arg Thr Phe Leu Lys		125
	130	135
Gln Glu Gly Cys Ala Asp Leu Leu Asp Phe Trp Phe Ala Cys Thr Gly		140
145	150	155
Phe Arg Lys Leu Glu Pro Cys Asp Ser Asn Glu Glu Lys Arg Leu Lys		160
	165	170
Leu Ala Arg Ala Ile Tyr Arg Lys Tyr Ile Leu Asp Asn Asn Gly Ile		175
	180	185
Val Ser Arg Gln Thr Lys Pro Ala Thr Lys Ser Phe Ile Lys Gly Cys		190
	195	200
Ile Met Lys Gln Leu Ile Asp Pro Ala Met Phe Asp Gln Ala Gln Thr		205
	210	215
Glu Ile Gln Ala Thr Met Glu Glu Asn Thr Tyr Pro Ser Phe Leu Lys		220
225	230	235
Ser Asp Ile Tyr Leu Glu Tyr Thr Arg Thr Gly Ser Glu Ser Pro Lys		240
	245	250
Val Cys Ser Asp Gln Ser Ser Gly Ser Gly Thr Gly Lys Gly Ile Ser		255
	260	265
Gly Tyr Leu Pro Thr Leu Asn Glu Asp Glu Glu Trp Lys Cys Asp Gln		270
	275	280
Asp Met Asp Glu Asp Asp Gly Arg Asp Ala Ala Pro Pro Gly Arg Leu		285
	290	295
Pro Gln Lys Leu Leu Leu Glu Thr Ala Ala Pro Arg Val Ser Ser Ser		300
305	310	315
Arg Arg Tyr Ser Glu Gly Arg Glu Phe Arg Tyr Gly Ser Trp Arg Glu		320
	325	330
Pro Val Asn Pro Tyr Tyr Val Asn Ala Gly Tyr Ala Leu Ala Pro Ala		335
	340	345
Thr Ser Ala Asn Asp Ser Glu Gln Gln Ser Leu Ser Ser Asp Ala Asp		350
	355	360
Thr Leu Ser Leu Thr Asp Ser Ser Val Asp Gly Ile Pro Pro Tyr Arg		365
	370	375
Ile Arg Lys Gln His Arg Arg Glu Met Gln Glu Ser Ala Gln Val Asn		380
385	390	395
Gly Arg Val Pro Leu Pro His Ile Pro Arg Thr Tyr Arg Val Pro Lys		400
	405	410
Glu Val Arg Val Glu Pro Gln Lys Phe Ala Glu Glu Leu Ile His Arg		415
	420	425
Leu Glu Ala Val Gln Arg Thr Arg Glu Ala Glu Glu Lys Leu Glu Glu		430
	435	440
Arg Leu Lys Arg Val Arg Met Glu Glu Glu Gly Glu Asp Gly Asp Pro		445
	450	455
Ser Ser Gly Pro Pro Gly Pro Cys His Lys Leu Pro Pro Ala Pro Ala		460
465	470	475
Trp His His Phe Pro Pro Arg Leu Cys Trp Thr Trp Ala Cys Ala Gly		480
	485	490
Leu Arg Asp Ala His Glu Glu Asn Pro Glu Ser Ile Leu Asp Glu His		495
	500	505
		510

032796-132.ST25

Val Gln Arg Val Leu Arg Thr Thr Gly Arg Gln Ser Pro Gly Pro Gly
 515 520 525
 His Arg Ser Pro Asp Ser Gly His Val Ala Lys Met Pro Val Ala Leu
 530 535 540
 Gly Gly Ala Ala Ser Gly His Gly Lys His Val Pro Lys Ser Gly Ala
 545 550 555 560
 Lys Leu Asp Ala Ala Gly Leu His His His Arg His Val His His His
 565 570 575
 Val His His Ser Thr Ala Arg Pro Lys Glu Gln Val Glu Ala Glu Ala
 580 585 590
 Thr Arg Arg Ala Gln Ser Ser Phe Ala Trp Gly Leu Glu Pro His Ser
 595 600 605
 His Gly Ala Arg Ser Arg Gly Tyr Ser Glu Ser Val Gly Ala Ala Pro
 610 615 620
 Asn Ala Ser Asp Gly Leu Ala His Ser Gly Lys Val Gly Val Ala Cys
 625 630 635 640
 Lys Arg Asn Ala Lys Lys Ala Glu Ser Gly Lys Ser Ala Ser Thr Glu
 645 650 655
 Val Pro Gly Ala Ser Glu Asp Ala Glu Lys Asn Gln Lys Ile Met Gln
 660 665 670
 Trp Ile Ile Glu Gly Glu Lys Glu Ile Ser Arg His Arg Arg Thr Gly
 675 680 685
 His Gly Ser Ser Gly Thr Arg Lys Pro Gln Pro His Glu Asn Ser Arg
 690 695 700
 Pro Leu Ser Leu Glu His Pro Trp Ala Gly Pro Gln Leu Arg Thr Ser
 705 710 715 720
 Val Gln Pro Ser His Leu Phe Ile Gln Asp Pro Thr Met Pro Pro His
 725 730 735
 Pro Ala Pro Asn Pro Leu Thr Gln Leu Glu Glu Ala Arg Arg Arg Leu
 740 745 750
 Glu Glu Glu Glu Lys Arg Ala Ser Arg Ala Pro Ser Lys Gln Arg Tyr
 755 760 765
 Val Gln Glu Val Met Arg Arg Gly Arg Ala Cys Val Arg Pro Ala Cys
 770 775 780
 Ala Pro Val Leu His Val Val Pro Ala Val Ser Asp Met Glu Leu Ser
 785 790 795 800
 Glu Thr Glu Thr Arg Ser Gln Arg Lys Val Gly Gly Gly Ser Ala Gln
 805 810 815
 Pro Cys Asp Ser Ile Val Val Ala Tyr Tyr Phe Cys Gly Glu Pro Ile
 820 825 830
 Pro Tyr Arg Thr Leu Val Arg Gly Arg Ala Val Thr Leu Gly Gln Phe
 835 840 845
 Lys Glu Leu Leu Thr Lys Lys Gly Ser Tyr Arg Tyr Tyr Phe Lys Lys
 850 855 860
 Val Ser Asp Glu Phe Asp Cys Gly Val Val Phe Glu Glu Val Arg Glu
 865 870 875 880
 Asp Glu Ala Val Leu Pro Val Phe Glu Glu Lys Ile Ile Gly Lys Val
 885 890 895
 Glu Lys Val Asp
 900

<210> 92

<211> 591

<212> PRT

<213> Homo sapiens

<400> 92

032796-132.ST25

Met	Val	Pro	Val	Ala	Val	Thr	Ala	Ala	Val	Ala	Pro	Val	Leu	Ser	Ile
1				5					10					15	
Asn	Ser	Asp	Phe	Ser	Asp	Leu	Arg	Glu	Ile	Lys	Lys	Gln	Leu	Leu	Leu
			20					25					30		
Ile	Ala	Gly	Leu	Thr	Arg	Glu	Arg	Gly	Leu	Leu	His	Ser	Ser	Lys	Trp
		35					40					45			
Ser	Ala	Glu	Leu	Ala	Phe	Ser	Leu	Pro	Ala	Leu	Pro	Leu	Ala	Glu	Leu
	50					55					60				
Gln	Pro	Pro	Pro	Pro	Ile	Thr	Glu	Glu	Asp	Ala	Gln	Asp	Met	Asp	Ala
65					70					75					80
Tyr	Thr	Leu	Ala	Lys	Ala	Tyr	Phe	Asp	Val	Lys	Glu	Tyr	Asp	Arg	Ala
				85					90					95	
Ala	His	Phe	Leu	His	Gly	Cys	Asn	Ser	Lys	Lys	Ala	Tyr	Phe	Leu	Tyr
			100					105					110		
Met	Tyr	Ser	Arg	Tyr	Leu	Ser	Gly	Glu	Lys	Lys	Lys	Asp	Asp	Glu	Thr
		115					120					125			
Val	Asp	Ser	Leu	Gly	Pro	Leu	Glu	Lys	Gly	Gln	Val	Lys	Asn	Glu	Ala
	130					135					140				
Leu	Arg	Glu	Leu	Arg	Val	Glu	Leu	Ser	Lys	Lys	His	Gln	Ala	Arg	Glu
145					150						155				160
Leu	Asp	Gly	Phe	Gly	Leu	Tyr	Leu	Tyr	Gly	Val	Val	Leu	Arg	Lys	Leu
				165					170					175	
Asp	Leu	Val	Lys	Glu	Ala	Ile	Asp	Val	Phe	Val	Glu	Ala	Thr	His	Val
			180					185					190		
Leu	Pro	Leu	His	Trp	Gly	Ala	Trp	Leu	Glu	Leu	Cys	Asn	Leu	Ile	Thr
	195						200					205			
Asp	Lys	Glu	Met	Leu	Lys	Phe	Leu	Ser	Leu	Pro	Asp	Thr	Trp	Met	Lys
	210					215					220				
Glu	Phe	Phe	Leu	Ala	His	Ile	Tyr	Thr	Glu	Leu	Gln	Leu	Ile	Glu	Glu
225					230						235				240
Ala	Leu	Gln	Lys	Tyr	Gln	Asn	Leu	Ile	Asp	Val	Gly	Phe	Ser	Lys	Ser
				245					250					255	
Ser	Tyr	Ile	Val	Ser	Gln	Ile	Ala	Val	Ala	Tyr	His	Asn	Ile	Arg	Asp
			260					265					270		
Ile	Asp	Lys	Ala	Leu	Ser	Ile	Phe	Asn	Glu	Leu	Arg	Lys	Gln	Asp	Pro
	275						280					285			
Tyr	Arg	Ile	Glu	Asn	Met	Asp	Thr	Phe	Ser	Asn	Leu	Leu	Tyr	Val	Arg
	290					295					300				
Ser	Met	Lys	Ser	Glu	Leu	Ser	Tyr	Leu	Ala	His	Asn	Leu	Cys	Glu	Ile
305					310					315					320
Asp	Lys	Tyr	Arg	Val	Glu	Thr	Cys	Cys	Val	Ile	Gly	Asn	Tyr	Tyr	Ser
				325					330				335		
Leu	Arg	Ser	Gln	His	Glu	Lys	Ala	Ala	Leu	Tyr	Phe	Gln	Arg	Ala	Leu
			340					345					350		
Lys	Leu	Asn	Pro	Arg	Tyr	Leu	Gly	Ala	Trp	Thr	Leu	Met	Gly	His	Glu
	355						360					365			
Tyr	Met	Glu	Met	Lys	Asn	Thr	Ser	Ala	Ala	Ile	Gln	Ala	Tyr	Arg	His
	370					375					380				
Ala	Ile	Glu	Val	Asn	Lys	Arg	Asp	Tyr	Arg	Ala	Trp	Tyr	Gly	Leu	Gly
385					390					395					400
Gln	Thr	Tyr	Glu	Ile	Leu	Lys	Met	Pro	Phe	Tyr	Cys	Leu	Tyr	Tyr	Tyr
				405					410					415	
Arg	Arg	Ala	His	Gln	Leu	Arg	Pro	Asn	Asp	Ser	Arg	Met	Leu	Val	Ala
			420					425					430		
Leu	Gly	Glu	Cys	Tyr	Glu	Lys	Leu	Asn	Gln	Leu	Val	Glu	Ala	Lys	Lys
	435						440				445				
Cys	Tyr	Trp	Arg	Ala	Tyr	Ala	Val	Gly	Asp	Val	Glu	Lys	Met	Ala	Leu

032796-132.ST25

```

      450      455      460
Val Lys Leu Ala Lys Leu His Glu Gln Leu Thr Glu Ser Glu Gln Ala
465      470      475      480
Ala Gln Cys Tyr Ile Lys Tyr Ile Gln Asp Ile Tyr Ser Cys Gly Glu
      485      490      495
Ile Val Glu His Leu Glu Glu Ser Thr Ala Phe Arg Tyr Leu Ala Gln
      500      505      510
Tyr Tyr Phe Lys Cys Lys Leu Trp Asp Glu Ala Ser Thr Cys Ala Gln
      515      520      525
Lys Cys Cys Ala Phe Asn Asp Thr Arg Glu Glu Gly Lys Ala Leu Leu
      530      535      540
Arg Gln Ile Leu Gln Leu Arg Asn Gln Gly Glu Thr Pro Thr Thr Glu
545      550      555      560
Val Pro Ala Pro Phe Phe Leu Pro Ala Ser Leu Ser Ala Asn Asn Thr
      565      570      575
Pro Thr Arg Arg Val Ser Pro Leu Asn Leu Ser Ser Val Thr Pro
      580      585      590

```

<210> 93

<211> 914

<212> PRT

<213> Homo sapiens

<400> 93

```

Val Tyr Gln Val Leu Leu Val Gly Ser Thr Leu Leu Lys Glu Val Pro
1      5      10      15
Ser Gly Leu Gln Leu Glu Gln Leu Pro Ser Gln Ser Leu Leu Thr His
      20      25      30
Ile Pro Thr Ala Gly Leu Pro Thr Ser Leu Gly Gly Gly Leu Pro Tyr
      35      40      45
Cys His Gln Ala Trp Leu Asp Phe Arg Arg Arg Leu Glu Ala Leu Leu
      50      55      60
Gln Asn Cys Gln Ala Ala Cys Ala Leu Leu Gln Gly Ala Ile Glu Ser
65      70      75      80
Val Lys Ala Val Pro Gln Pro Met Glu Pro Gly Glu Val Gly Gln Leu
      85      90      95
Leu Gln Gln Thr Glu Val Leu Met Gln Gln Val Leu Asp Ser Pro Trp
      100      105      110
Leu Ala Trp Leu Gln Cys Gln Gly Gly Arg Glu Leu Thr Trp Leu Lys
      115      120      125
Gln Glu Val Pro Glu Val Thr Leu Ser Pro Asp Tyr Arg Thr Ala Met
      130      135      140
Asp Lys Ala Asp Glu Leu Tyr Asp Arg Val Asp Gly Leu Leu His Gln
145      150      155      160
Leu Thr Leu Gln Ser Asn Gln Arg Ile Gln Ala Leu Glu Leu Val Gln
      165      170      175
Thr Leu Glu Ala Arg Glu Ser Gly Leu His Gln Ile Glu Val Trp Leu
      180      185      190
Gln Gln Val Gly Trp Pro Ala Leu Glu Glu Ala Gly Glu Pro Ser Leu
      195      200      205
Asp Met Leu Leu Gln Ala Gln Gly Ser Phe Gln Glu Leu Tyr Gln Val
210      215      220
Ala Gln Glu Gln Val Arg Gln Gly Glu Lys Phe Leu Gln Pro Leu Thr
225      230      235      240
Gly Trp Glu Ala Ala Glu Leu Asp Pro Pro Gly Ala Arg Phe Leu Ala
      245      250      255
Leu Arg Ala Gln Leu Thr Glu Phe Ser Arg Ala Leu Ala Gln Arg Cys

```

032796-132.ST25

										260						265						270			
Gln	Arg	Leu	Ala	Asp	Ala	Glu	Arg	Leu	Phe	Gln	Leu	Phe	Arg	Glu	Ala										
										275			280			285									
Leu	Thr	Trp	Ala	Glu	Glu	Gly	Gln	Arg	Val	Leu	Ala	Glu	Leu	Glu	Gln										
										290			295			300									
Glu	Arg	Pro	Gly	Val	Val	Leu	Gln	Gln	Leu	Gln	Leu	His	Trp	Thr	Arg										
305											310			315			320								
His	Pro	Asp	Leu	Pro	Pro	Ala	His	Phe	Arg	Lys	Met	Trp	Ala	Leu	Ala										
										325			330			335									
Thr	Gly	Leu	Gly	Ser	Glu	Ala	Ile	Arg	Gln	Glu	Cys	Arg	Trp	Ala	Trp										
										340			345			350									
Ala	Arg	Cys	Gln	Asp	Thr	Trp	Leu	Ala	Leu	Asp	Gln	Lys	Leu	Glu	Ala										
										355			360			365									
Ser	Leu	Lys	Leu	Pro	Pro	Val	Gly	Ser	Thr	Ala	Ser	Leu	Cys	Val	Ser										
370											375			380											
Gln	Val	Pro	Ala	Ala	Pro	Ala	His	Pro	Pro	Leu	Arg	Lys	Ala	Tyr	Ser										
385											390			395			400								
Phe	Asp	Arg	Asn	Leu	Gly	Gln	Ser	Leu	Ser	Glu	Pro	Ala	Cys	His	Cys										
										405			410			415									
His	His	Ala	Ala	Thr	Ile	Ala	Ala	Cys	Arg	Arg	Pro	Glu	Ala	Gly	Gly										
										420			425			430									
Gly	Ala	Leu	Pro	Gln	Ala	Ser	Pro	Thr	Val	Pro	Pro	Pro	Gly	Ser	Ser										
										435			440			445									
Asp	Pro	Arg	Ser	Leu	Asn	Arg	Leu	Gln	Leu	Val	Leu	Ala	Glu	Met	Val										
450											455			460											
Ala	Thr	Glu	Arg	Glu	Tyr	Val	Arg	Ala	Leu	Glu	Tyr	Thr	Met	Glu	Asn										
465											470			475			480								
Tyr	Phe	Pro	Glu	Leu	Asp	Arg	Pro	Asp	Val	Pro	Gln	Gly	Leu	Arg	Gly										
										485			490			495									
Gln	Arg	Ala	His	Leu	Phe	Gly	Asn	Leu	Glu	Lys	Leu	Arg	Asp	Phe	His										
										500			505			510									
Cys	His	Phe	Leu	Arg	Glu	Leu	Glu	Ala	Cys	Thr	Arg	His	Pro	Pro											
										515			520			525									
Arg	Val	Ala	Tyr	Ala	Phe	Leu	Arg	His	Arg	Val	Gln	Phe	Gly	Met	Tyr										
530											535			540											
Ala	Leu	Tyr	Ser	Lys	Asn	Lys	Pro	Arg	Ser	Asp	Ala	Leu	Met	Ser	Ser										
545											550			555			560								
Tyr	Gly	His	Thr	Phe	Phe	Lys	Asp	Lys	Gln	Gln	Ala	Leu	Gly	Asp	His										
										565			570			575									
Leu	Asp	Leu	Ala	Ser	Tyr	Leu	Leu	Lys	Pro	Ile	Gln	Arg	Met	Gly	Lys										
										580			585			590									
Tyr	Ala	Leu	Leu	Leu	Gln	Glu	Leu	Ala	Arg	Ala	Cys	Gly	Gly	Pro	Thr										
										595			600			605									
Gln	Glu	Leu	Ser	Ala	Leu	Arg	Glu	Ala	Gln	Ser	Leu	Val	His	Phe	Gln										
610											615			620											
Leu	Arg	His	Gly	Asn	Asp	Leu	Leu	Ala	Met	Asp	Ala	Ile	Gln	Gly	Cys										
625											630			635			640								
Asp	Val	Asn	Leu	Lys	Glu	Gln	Gly	Gln	Leu	Val	Arg	Gln	Asp	Glu	Phe										
										645			650			655									
Val	Val	Arg	Thr	Gly	Arg	His	Lys	Ser	Val	Arg	Arg	Ile	Phe	Leu	Phe										
										660			665			670									
Glu	Glu	Leu	Leu	Leu	Phe	Ser	Lys	Pro	Arg	His	Gly	Pro	Thr	Gly	Val										
										675			680			685									
Asp	Thr	Phe	Ala	Tyr	Lys	Arg	Ser	Phe	Lys	Met	Ala	Asp	Leu	Gly	Leu										
690											695			700											
Thr	Glu	Cys	Cys	Gly	Asn	Ser	Asn	Leu	Arg	Phe	Glu	Ile	Trp	Phe	Arg										
705											710			715			720								

032796-132.ST25

```

Arg Arg Lys Ala Arg Asp Thr Phe Val Leu Gln Ala Ser Ser Leu Ala
      725      730      735
Ile Lys Gln Ala Trp Thr Ala Asp Ile Ser His Leu Leu Trp Arg Gln
      740      745      750
Ala Val His Asn Lys Glu Val Arg Met Ala Glu Met Val Ser Met Gly
      755      760      765
Val Gly Asn Lys Ala Phe Arg Asp Ile Ala Pro Ser Glu Glu Ala Ile
      770      775      780
Asn Asp Arg Thr Val Asn Tyr Val Leu Lys Cys Arg Glu Val Arg Ser
785      790      795      800
Arg Ala Ser Ile Ala Val Ala Pro Phe Asp His Asp Ser Leu Tyr Leu
      805      810      815
Gly Ala Ser Asn Ser Leu Pro Gly Asp Pro Ala Ser Cys Ser Val Leu
      820      825      830
Gly Ser Leu Asn Leu His Leu Tyr Arg Asp Pro Ala Leu Leu Gly Leu
      835      840      845
Arg Cys Pro Leu Tyr Pro Ser Phe Leu Glu Glu Ala Ala Leu Glu Ala
      850      855      860
Glu Ala Glu Leu Gly Gly Gln Pro Ser Leu Thr Ala Glu Asp Ser Glu
865      870      875      880
Ile Ser Ser Gln Cys Pro Ser Ala Ser Gly Ser Ser Gly Ser Asp Ser
      885      890      895
Ser Cys Val Ser Gly Gln Ala Leu Gly Arg Gly Leu Glu Asp Leu Pro
      900      905      910
Cys Val

```

<210> 94

<211> 277

<212> PRT

<213> Homo sapiens

<400> 94

```

Leu Asn Tyr Leu Leu Glu Ser Arg Leu Glu Ala Ala Ala His Cys Ala
 1      5      10      15
Leu Lys Gln Gly Ile Ala Thr Ala Ser Leu Leu Pro Ala Gln Leu Gln
      20      25      30
Pro Ala Val Leu Thr Val Val Thr Cys His Val Val Val Ser Val His
      35      40      45
Gly His His Thr Asp Gly Cys Leu Ala Ala Leu Cys Arg Glu Asp Arg
      50      55      60
Thr Gly Thr Gly Gly Ala Phe Trp Cys Lys Asn Arg Val Ile Val Ser
65      70      75      80
His Ala Val Asp Val Val Leu His Val His Gly Glu Gly Asn Pro Val
      85      90      95
Gln Ala Leu Ile Ala His Gly Ala Pro Glu Ala Ala Trp Val Val Gly
      100      105      110
Leu Ala Gln Gly Leu Gln Asp His Phe His Asp Glu Met Ser Thr His
      115      120      125
Ala Ala Phe Val Gly Arg Leu Leu Glu Pro Gly Val Gln Glu Val Leu
      130      135      140
Leu Ala Val His Phe Leu Thr His Val Val Glu Arg Leu Pro Thr Glu
      145      150      155      160
Ser Ser Pro Thr Arg Val Ala Gly Glu Ala Val Ser Val Ile Lys Thr
      165      170      175
Pro His Cys Leu Ala Arg Leu Leu Gly Ser Val Asp Ala Lys Pro Thr
      180      185      190

```

032796-132.ST25

Leu Asp Ala Asn Ala Glu Val Val Pro Arg Arg Ala Arg Leu Glu Arg
 195 200 205
 Pro Leu Gln Leu Pro Gly Glu Arg Leu Gln Pro Pro Leu Gly Arg Ala
 210 215 220
 Trp Ala Ala Leu Pro Ala Arg Gly Gln Arg Glu Cys Arg Gln Arg Glu
 225 230 235 240
 Gly Gly Arg Pro Arg Arg Leu Arg Gly Ala Ser Gly Arg Gly Ala Gly
 245 250 255
 Ala Gly Arg Glu Glu Val Ser Val Gly Phe Ser Ala Gln Trp Glu Phe
 260 265 270
 Gly Ser Gly Arg His
 275

<210> 95

<211> 1120

<212> PRT

<213> Homo sapiens

<400> 95

Met Trp Arg Val Lys Lys Leu Ser Leu Ser Leu Ser Pro Ser Pro Gln
 1 5 10 15
 Thr Gly Lys Pro Ser Met Arg Thr Pro Leu Arg Glu Leu Thr Leu Gln
 20 25 30
 Pro Gly Ala Leu Thr Thr Ser Gly Lys Arg Ser Pro Ala Cys Ser Ser
 35 40 45
 Leu Thr Pro Ser Leu Cys Lys Leu Gly Leu Gln Glu Gly Ser Asn Asn
 50 55 60
 Ser Ser Pro Val Asp Phe Val Asn Asn Lys Arg Thr Asp Leu Ser Ser
 65 70 75 80
 Glu His Phe Ser His Ser Ser Lys Trp Leu Glu Thr Cys Gln His Glu
 85 90 95
 Ser Asp Glu Gln Pro Leu Asp Pro Ile Pro Gln Ile Ser Ser Thr Pro
 100 105 110
 Lys Thr Ser Glu Glu Ala Val Asp Pro Leu Gly Asn Tyr Met Val Lys
 115 120 125
 Thr Ile Val Leu Val Pro Ser Pro Leu Gly Gln Gln Gln Asp Met Ile
 130 135 140
 Phe Glu Ala Arg Leu Asp Thr Met Ala Glu Thr Asn Ser Ile Ser Leu
 145 150 155 160
 Asn Gly Pro Leu Arg Thr Asp Asp Leu Val Arg Glu Glu Val Ala Pro
 165 170 175
 Cys Met Gly Asp Arg Phe Ser Glu Val Ala Ala Val Ser Glu Lys Pro
 180 185 190
 Ile Phe Gln Glu Ser Pro Ser His Leu Leu Glu Glu Ser Pro Pro Asn
 195 200 205
 Pro Cys Ser Glu Gln Leu His Cys Ser Lys Glu Ser Leu Ser Ser Arg
 210 215 220
 Thr Glu Ala Val Arg Glu Asp Leu Val Pro Ser Glu Ser Asn Ala Phe
 225 230 235 240
 Leu Pro Ser Ser Val Leu Trp Leu Ser Pro Ser Thr Ala Leu Ala Ala
 245 250 255
 Asp Phe Arg Val Asn His Val Asp Pro Glu Glu Glu Ile Val Glu His
 260 265 270
 Gly Ala Met Glu Glu Arg Glu Met Arg Phe Pro Thr His Pro Lys Glu
 275 280 285
 Ser Glu Thr Glu Asp Gln Ala Leu Val Ser Ser Val Glu Asp Ile Leu
 290 295 300

032796-132.ST25

```

Ser Thr Cys Leu Thr Pro Asn Leu Val Glu Met Glu Ser Gln Glu Ala
305                               310           315           320
Pro Gly Pro Ala Val Glu Asp Val Gly Arg Ile Leu Gly Ser Asp Thr
                               325           330           335
Glu Ser Trp Met Ser Pro Leu Ala Trp Leu Glu Lys Gly Val Asn Thr
                               340           345           350
Ser Val Met Leu Glu Asn Leu Arg Gln Ser Leu Ser Leu Pro Ser Met
                               355           360           365
Leu Arg Asp Ala Ala Ile Gly Thr Thr Pro Phe Ser Thr Cys Ser Val
                               370           375           380
Gly Thr Trp Phe Thr Pro Ser Ala Pro Gln Glu Lys Ser Thr Asn Thr
385                               390           395           400
Ser Gln Thr Gly Leu Val Gly Thr Lys His Ser Thr Ser Glu Thr Glu
                               405           410           415
Gln Leu Leu Cys Gly Arg Pro Pro Asp Leu Thr Ala Leu Ser Arg His
                               420           425           430
Asp Leu Glu Asp Asn Leu Leu Ser Ser Leu Val Ile Val Glu Phe Leu
                               435           440           445
Ser Arg Gln Leu Arg Asp Trp Lys Ser Gln Leu Ala Val Pro His Pro
                               450           455           460
Glu Thr Gln Asp Ser Ser Thr Gln Thr Asp Thr Ser His Ser Gly Ile
465                               470           475           480
Thr Asn Lys Leu Gln His Leu Lys Glu Ser His Glu Met Gly Gln Ala
                               485           490           495
Leu Gln Gln Ala Arg Asn Val Met Gln Ser Trp Val Leu Ile Ser Lys
                               500           505           510
Glu Leu Ile Ser Leu Leu His Leu Ser Leu Leu His Leu Glu Glu Asp
                               515           520           525
Lys Thr Thr Val Asn Gln Glu Ser Arg Arg Ala Glu Thr Leu Val Cys
                               530           535           540
Cys Cys Phe Asp Leu Leu Lys Lys Leu Arg Ala Lys Leu Gln Ser Leu
545                               550           555           560
Lys Ala Glu Arg Glu Glu Ala Arg His Arg Glu Glu Met Ala Leu Arg
                               565           570           575
Gly Lys Asp Ala Ala Glu Ile Val Leu Glu Ala Phe Cys Ala His Ala
                               580           585           590
Ser Gln Arg Ile Ser Gln Leu Glu Gln Asp Leu Ala Ser Met Arg Glu
                               595           600           605
Phe Arg Gly Leu Leu Lys Asp Ala Gln Thr Gln Leu Val Gly Leu His
                               610           615           620
Ala Lys Gln Glu Glu Leu Val Gln Gln Thr Val Ser Leu Thr Ser Thr
625                               630           635           640
Leu Gln Gln Asp Trp Arg Ser Met Gln Leu Asp Tyr Thr Thr Trp Thr
                               645           650           655
Ala Leu Leu Ser Arg Ser Arg Gln Leu Thr Glu Lys Leu Thr Val Lys
                               660           665           670
Ser Gln Gln Ala Leu Gln Glu Arg Asp Val Ala Ile Glu Glu Lys Gln
675                               680           685           690
Glu Val Ser Arg Val Leu Glu Gln Val Ser Ala Gln Leu Glu Glu Cys
                               695           700           705
Lys Gly Gln Thr Glu Gln Leu Glu Leu Glu Asn Ile Arg Leu Ala Thr
705                               710           715           720
Asp Leu Arg Ala Gln Leu Gln Ile Leu Ala Asn Met Asp Ser Gln Leu
                               725           730           735
Lys Glu Leu Gln Ser Gln His Thr His Cys Ala Gln Asp Leu Ala Met
                               740           745           750
Lys Asp Glu Leu Leu Cys Gln Leu Thr Gln Ser Asn Glu Glu Gln Ala

```

032796-132.ST25

```

      755              760              765
Ala Gln Cys Val Lys Glu Glu Met Ala Leu Lys His Met Gln Ala Glu
 770              775              780
Leu Gln Gln Gln Gln Ala Val Leu Ala Lys Glu Val Arg Asp Leu Lys
 785              790              795              800
Glu Thr Leu Glu Phe Ala Asp Gln Glu Asn Gln Val Ala His Leu Glu
      805              810              815
Leu Gly Gln Val Glu Cys Gln Leu Lys Thr Thr Leu Glu Val Leu Arg
      820              825              830
Glu Arg Ser Leu Gln Cys Glu Asn Leu Lys Asp Thr Val Glu Asn Leu
      835              840              845
Thr Ala Lys Leu Ala Ser Thr Ile Ala Asp Asn Gln Glu Gln Asp Leu
      850              855              860
Glu Lys Thr Arg Gln Tyr Ser Gln Lys Leu Gly Leu Leu Thr Glu Gln
 865              870              875              880
Leu Gln Ser Leu Thr Leu Phe Leu Gln Thr Lys Leu Lys Glu Lys Thr
      885              890              895
Glu Gln Glu Thr Leu Leu Leu Ser Thr Ala Cys Pro Pro Thr Gln Glu
      900              905              910
His Pro Leu Pro Asn Asp Arg Thr Phe Leu Gly Ser Ile Leu Thr Ala
      915              920              925
Val Ala Asp Glu Glu Pro Glu Ser Thr Pro Val Pro Leu Leu Gly Ser
      930              935              940
Asp Lys Ser Ala Phe Thr Arg Val Ala Ser Met Val Ser Leu Gln Pro
 945              950              955              960
Ala Glu Thr Pro Gly Met Glu Glu Ser Leu Ala Glu Met Ser Ile Met
      965              970              975
Thr Thr Glu Leu Gln Ser Leu Cys Ser Leu Leu Gln Glu Ser Lys Glu
      980              985              990
Glu Ala Ile Arg Thr Leu Gln Arg Lys Ile Cys Glu Leu Gln Ala Arg
      995              1000              1005
Leu Gln Ala Gln Glu Glu Gln His Gln Glu Val Gln Lys Ala Lys Glu
      1010              1015              1020
Ala Asp Ile Glu Lys Leu Asn Gln Ala Leu Cys Leu Arg Tyr Lys Asn
 1025              1030              1035              1040
Glu Lys Glu Leu Gln Glu Val Ile Gln Gln Asn Glu Lys Ile Leu Glu
      1045              1050              1055
Gln Ile Asp Lys Ser Gly Glu Leu Ile Ser Leu Arg Glu Glu Val Thr
      1060              1065              1070
His Leu Thr Arg Ser Leu Arg Arg Ala Glu Thr Glu Thr Lys Val Leu
      1075              1080              1085
Gln Glu Ala Trp Gln Ala Ser Trp Thr Pro Thr Ala Ser Leu Trp Pro
      1090              1095              1100
Pro Ile Gly Ser Arg Arg Lys Cys Gly Ser Leu Arg Arg Trp Thr Asn
 1105              1110              1115              1120

```

<210> 96

<211> 540

<212> PRT

<213> Homo sapiens

<400> 96

```

Met Gly Thr Thr Ala Arg Ala Ala Leu Val Leu Thr Tyr Leu Ala Val
 1              5              10              15
Ala Ser Ala Ala Ser Glu Gly Gly Phe Thr Ala Thr Gly Gln Arg Gln
      20              25              30
Leu Arg Pro Glu His Phe Gln Glu Val Gly Tyr Ala Ala Pro Pro Ser

```

032796-132.ST25

35	40	45
Pro Pro Leu Ser Arg Ser Leu Pro Met Asp His Pro Asp Ser Ser Gln		
50	55	60
His Gly Pro Pro Phe Glu Gly Gln Ser Gln Val Gln Pro Pro Pro Ser		
65	70	75
Gln Glu Ala Thr Pro Leu Gln Gln Glu Lys Leu Leu Pro Ala Gln Leu		
85	90	95
Pro Ala Glu Lys Glu Val Gly Pro Pro Leu Pro Gln Glu Ala Val Pro		
100	105	110
Leu Gln Lys Glu Leu Pro Ser Leu Gln His Pro Asn Glu Gln Lys Glu		
115	120	125
Gly Thr Pro Ala Pro Phe Gly Asp Gln Ser His Pro Glu Pro Glu Ser		
130	135	140
Trp Asn Ala Ala Gln His Cys Gln Gln Asp Arg Ser Gln Gly Gly Trp		
145	150	155
Gly His Arg Leu Asp Gly Phe Pro Pro Gly Arg Pro Ser Pro Asp Asn		
165	170	175
Leu Asn Gln Ile Cys Leu Pro Asn Arg Gln His Val Val Tyr Gly Pro		
180	185	190
Trp Asn Leu Pro Gln Ser Ser Tyr Ser His Leu Thr Arg Gln Gly Glu		
195	200	205
Thr Leu Asn Phe Leu Glu Ile Gly Tyr Ser Arg Cys Cys His Cys Arg		
210	215	220
Ser His Thr Asn Arg Leu Glu Cys Ala Lys Leu Val Trp Glu Glu Ala		
225	230	235
Met Ser Arg Phe Cys Glu Ala Glu Phe Ser Val Lys Thr Arg Pro His		
245	250	255
Trp Cys Cys Thr Arg Gln Gly Glu Ala Arg Phe Ser Cys Phe Gln Glu		
260	265	270
Glu Ala Pro Gln Pro His Tyr Gln Leu Arg Ala Cys Pro Ser His Gln		
275	280	285
Pro Asp Ile Ser Ser Gly Leu Glu Leu Pro Phe Pro Pro Gly Val Pro		
290	295	300
Thr Leu Asp Asn Ile Lys Asn Ile Cys His Leu Arg Arg Phe Arg Ser		
305	310	315
Val Pro Arg Asn Leu Pro Ala Thr Asp Pro Leu Gln Arg Glu Leu Leu		
325	330	335
Ala Leu Ile Gln Leu Glu Arg Glu Phe Gln Arg Cys Cys Arg Gln Gly		
340	345	350
Asn Asn His Thr Cys Thr Trp Lys Ala Trp Glu Asp Thr Leu Asp Lys		
355	360	365
Tyr Cys Asp Arg Glu Tyr Ala Val Lys Thr His His His Leu Cys Cys		
370	375	380
Arg His Pro Pro Ser Pro Thr Arg Asp Glu Cys Phe Ala Arg Arg Ala		
385	390	395
Pro Tyr Pro Asn Tyr Asp Arg Asp Ile Leu Thr Ile Asp Ile Ser Arg		
405	410	415
Val Thr Pro Asn Leu Met Gly His Leu Cys Gly Asn Gln Arg Val Leu		
420	425	430
Thr Lys His Lys His Ile Pro Gly Leu Ile His Asn Met Thr Ala Arg		
435	440	445
Cys Cys Asp Leu Pro Phe Pro Glu Gln Ala Cys Cys Ala Glu Glu Glu		
450	455	460
Lys Leu Thr Phe Ile Asn Asp Leu Cys Gly Pro Arg Arg Asn Ile Trp		
465	470	475
Arg Asp Pro Ala Leu Cys Cys Tyr Leu Ser Pro Gly Asp Glu Gln Val		
485	490	495

032796-132.ST25

Asn Cys Phe Asn Ile Asn Tyr Leu Arg Asn Val Ala Leu Val Ser Gly
 500 505 510
 Asp Thr Glu Asn Ala Lys Gly Gln Gly Glu Gln Gly Ser Thr Gly Gly
 515 520 525
 Thr Asn Ile Ser Ser Thr Ser Glu Pro Lys Glu Glu
 530 535 540

<210> 97

<211> 462

<212> PRT

<213> Homo sapiens

<400> 97

Met Gly Lys Glu Lys Thr His Ile Asn Ile Val Val Ile Gly His Val
 1 5 10 15
 Asp Ser Gly Lys Ser Thr Thr Thr Gly His Leu Ile Tyr Lys Cys Gly
 20 25 30
 Gly Ile Asp Lys Arg Thr Ile Glu Lys Phe Glu Lys Glu Ala Ala Glu
 35 40 45
 Met Gly Lys Gly Ser Phe Lys Tyr Ala Trp Val Leu Asp Lys Leu Lys
 50 55 60
 Ala Glu Arg Glu Arg Gly Ile Thr Ile Asp Ile Ser Leu Trp Lys Phe
 65 70 75 80
 Glu Thr Ser Lys Tyr Tyr Val Thr Ile Ile Asp Ala Pro Gly His Arg
 85 90 95
 Asp Phe Ile Lys Asn Met Ile Thr Gly Thr Ser Gln Ala Asp Cys Ala
 100 105 110
 Val Leu Ile Val Ala Ala Gly Val Gly Glu Phe Glu Ala Gly Ile Ser
 115 120 125
 Lys Asn Gly Gln Thr Arg Glu His Ala Leu Leu Ala Tyr Thr Leu Gly
 130 135 140
 Val Lys Gln Leu Ile Val Gly Val Asn Lys Met Asp Ser Thr Glu Pro
 145 150 155 160
 Pro Tyr Ser Gln Lys Arg Tyr Glu Glu Ile Val Lys Glu Val Ser Thr
 165 170 175
 Tyr Ile Lys Lys Ile Gly Tyr Asn Pro Asp Thr Val Ala Phe Val Pro
 180 185 190
 Ile Ser Gly Trp Asn Gly Asp Asn Met Leu Glu Pro Ser Ala Asn Met
 195 200 205
 Pro Trp Phe Lys Gly Trp Lys Val Thr Arg Lys Asp Gly Asn Ala Ser
 210 215 220
 Gly Thr Thr Leu Leu Glu Ala Val Asp Cys Ile Leu Pro Pro Thr Arg
 225 230 235 240
 Pro Thr Asp Lys Pro Leu Arg Leu Pro Leu Gln Asp Val Tyr Lys Ile
 245 250 255
 Gly Gly Ile Gly Thr Val Pro Val Gly Arg Val Glu Thr Gly Val Leu
 260 265 270
 Lys Pro Gly Met Val Val Thr Phe Ala Pro Val Asn Val Thr Thr Glu
 275 280 285
 Val Lys Ser Val Glu Met His His Glu Ala Leu Ser Glu Ala Leu Pro
 290 295 300
 Gly Asp Asn Val Gly Phe Asn Val Lys Asn Val Ser Val Lys Asp Val
 305 310 315 320
 Arg Arg Gly Asn Val Ala Gly Asp Ser Lys Asn Asp Pro Pro Met Glu
 325 330 335
 Ala Ala Gly Phe Thr Ala Gln Val Ile Ile Leu Asn His Pro Gly Gln
 340 345 350

032796-132.ST25

```

Ile Ser Ala Gly Tyr Ala Pro Val Leu Asp Cys His Thr Ala His Ile
      355              360              365
Ala Cys Lys Phe Ala Glu Leu Lys Glu Lys Ile Asp Arg Arg Ser Gly
      370              375              380
Lys Lys Leu Glu Asp Gly Pro Lys Phe Leu Lys Ser Gly Asp Ala Ala
      385              390              395              400
Ile Val Asp Met Val Pro Gly Lys Pro Met Cys Val Glu Ser Phe Ser
      405              410              415
Asp Tyr Pro Pro Leu Gly Arg Phe Ala Val Arg Asp Met Arg Gln Thr
      420              425              430
Val Ala Val Gly Val Ile Lys Ala Val Asp Lys Lys Ala Ala Gly Ala
      435              440              445
Gly Lys Val Thr Lys Ser Ala Gln Lys Ala Gln Lys Ala Lys
      450              455              460

```

<210> 98

<211> 2328

<212> PRT

<213> Homo sapiens

<400> 98

```

Lys Ser Lys Arg Gln Ala Gln Gln Met Val Gln Pro Gln Ser Pro Val
  1              5              10              15
Ala Val Ser Gln Ser Lys Pro Gly Cys Tyr Asp Asn Gly Lys His Tyr
      20              25              30
Gln Ile Asn Gln Gln Trp Glu Arg Thr Tyr Leu Gly Asn Val Leu Val
      35              40              45
Cys Thr Cys Tyr Gly Gly Ser Arg Gly Phe Asn Cys Glu Ser Lys Pro
      50              55              60
Glu Ala Glu Glu Thr Cys Phe Asp Lys Tyr Thr Gly Asn Thr Tyr Arg
      65              70              75              80
Val Gly Asp Thr Tyr Glu Arg Pro Lys Asp Ser Met Ile Trp Asp Cys
      85              90              95
Thr Cys Ile Gly Ala Gly Arg Gly Arg Ile Ser Cys Thr Ile Ala Asn
      100              105              110
Arg Cys His Glu Gly Gly Gln Ser Tyr Lys Ile Gly Asp Thr Trp Arg
      115              120              125
Arg Pro His Glu Thr Gly Gly Tyr Met Leu Glu Cys Val Cys Leu Gly
      130              135              140
Asn Gly Lys Gly Glu Trp Thr Cys Lys Pro Ile Ala Glu Lys Cys Phe
      145              150              155              160
Asp His Ala Ala Gly Thr Ser Tyr Val Val Gly Glu Thr Trp Glu Lys
      165              170              175
Pro Tyr Gln Gly Trp Met Met Val Asp Cys Thr Cys Leu Gly Glu Gly
      180              185              190
Ser Gly Arg Ile Thr Cys Thr Ser Arg Asn Arg Cys Asn Asp Gln Asp
      195              200              205
Thr Arg Thr Ser Tyr Arg Ile Gly Asp Thr Trp Ser Lys Lys Asp Asn
      210              215              220
Arg Gly Asn Leu Leu Gln Cys Ile Cys Thr Gly Asn Gly Arg Gly Glu
      225              230              235              240
Trp Lys Cys Glu Arg His Thr Ser Val Gln Thr Thr Ser Ser Gly Ser
      245              250              255
Gly Pro Phe Thr Asp Val Arg Ala Ala Val Tyr Gln Pro Gln Pro His
      260              265              270
Pro Gln Pro Pro Pro Tyr Gly His Cys Val Thr Asp Ser Gly Val Val
      275              280              285

```

032796-132.ST25

Tyr	Ser	Val	Gly	Met	Gln	Trp	Leu	Lys	Thr	Gln	Gly	Asn	Lys	Gln	Met	290	295	300
Leu	Cys	Thr	Cys	Leu	Gly	Asn	Gly	Val	Ser	Cys	Gln	Glu	Thr	Ala	Val	305	310	315
Thr	Gln	Thr	Tyr	Gly	Gly	Asn	Leu	Asn	Gly	Glu	Pro	Cys	Val	Leu	Pro	320	325	330
Phe	Thr	Tyr	Asn	Gly	Arg	Thr	Phe	Tyr	Ser	Cys	Thr	Thr	Glu	Gly	Arg	335	340	345
Gln	Asp	Gly	His	Leu	Trp	Cys	Ser	Thr	Thr	Ser	Asn	Tyr	Glu	Gln	Asp	350	355	360
Gln	Lys	Tyr	Ser	Phe	Cys	Thr	Asp	His	Thr	Val	Leu	Val	Gln	Thr	Gln	365	370	375
Gly	Gly	Asn	Ser	Asn	Gly	Ala	Leu	Cys	His	Phe	Pro	Phe	Leu	Tyr	Asn	380	385	390
Asn	His	Asn	Tyr	Thr	Asp	Cys	Thr	Ser	Glu	Gly	Arg	Arg	Asp	Asn	Met	400	405	410
Lys	Trp	Cys	Gly	Thr	Thr	Gln	Asn	Tyr	Asp	Ala	Asp	Gln	Lys	Phe	Gly	415	420	425
Phe	Cys	Pro	Met	Ala	Ala	His	Glu	Glu	Ile	Cys	Thr	Thr	Asn	Glu	Gly	430	435	440
Val	Met	Tyr	Arg	Ile	Gly	Asp	Gln	Trp	Asp	Lys	Gln	His	Asp	Met	Gly	445	450	455
His	Met	Met	Arg	Cys	Thr	Cys	Val	Gly	Asn	Gly	Arg	Gly	Glu	Trp	Thr	460	465	470
Cys	Ile	Ala	Tyr	Ser	Gln	Leu	Arg	Asp	Gln	Cys	Ile	Val	Asp	Asp	Ile	475	480	485
Thr	Tyr	Asn	Val	Asn	Asp	Thr	Phe	His	Lys	Arg	His	Glu	Glu	Gly	His	490	495	500
Met	Leu	Asn	Cys	Thr	Cys	Phe	Gly	Gln	Gly	Arg	Gly	Arg	Trp	Lys	Cys	505	510	515
Asp	Pro	Val	Asp	Gln	Cys	Gln	Asp	Ser	Glu	Thr	Gly	Thr	Phe	Tyr	Gln	520	525	530
Ile	Gly	Asp	Ser	Trp	Glu	Lys	Tyr	Val	His	Gly	Val	Arg	Tyr	Gln	Cys	535	540	545
Tyr	Cys	Tyr	Gly	Arg	Gly	Ile	Gly	Glu	Trp	His	Cys	Gln	Pro	Leu	Gln	550	555	560
Thr	Tyr	Pro	Ser	Ser	Ser	Gly	Pro	Val	Glu	Val	Phe	Ile	Thr	Glu	Thr	565	570	575
Pro	Ser	Gln	Pro	Asn	Ser	His	Pro	Ile	Gln	Trp	Asn	Ala	Pro	Gln	Pro	580	585	590
Ser	His	Ile	Ser	Lys	Tyr	Ile	Leu	Arg	Trp	Arg	Pro	Lys	Asn	Ser	Val	595	600	605
Gly	Arg	Trp	Lys	Glu	Ala	Thr	Ile	Pro	Gly	His	Leu	Asn	Ser	Tyr	Thr	610	615	620
Ile	Lys	Gly	Leu	Lys	Pro	Gly	Val	Val	Tyr	Glu	Gly	Gln	Leu	Ile	Ser	625	630	635
Ile	Gln	Gln	Tyr	Gly	His	Gln	Glu	Val	Thr	Arg	Phe	Asp	Phe	Thr	Thr	640	645	650
Thr	Ser	Thr	Ser	Thr	Pro	Val	Thr	Ser	Asn	Thr	Val	Thr	Gly	Glu	Thr	655	660	665
Thr	Pro	Phe	Ser	Pro	Leu	Val	Ala	Thr	Ser	Glu	Ser	Val	Thr	Glu	Ile	670	675	680
Thr	Ala	Ser	Ser	Phe	Val	Val	Ser	Trp	Val	Ser	Ala	Ser	Asp	Thr	Val	685	690	695
Ser	Gly	Phe	Arg	Val	Glu	Tyr	Glu	Leu	Ser	Glu	Glu	Gly	Asp	Glu	Pro	700	705	710
Gln	Tyr	Leu	Asp	Leu	Pro	Ser	Thr	Ala	Thr	Ser	Val	Asn	Ile	Pro	Asp	715	720	725
																730	735	

			740					745					750			
Leu	Leu	Pro	Gly	Arg	Lys	Tyr	Ile	Val	Asn	Val	Tyr	Gln	Ile	Ser	Glu	
		755					760					765				
Asp	Gly	Glu	Gln	Ser	Leu	Ile	Leu	Ser	Thr	Ser	Gln	Thr	Thr	Ala	Pro	
	770					775					780					
Asp	Ala	Pro	Pro	Asp	Pro	Thr	Val	Asp	Gln	Val	Asp	Asp	Thr	Ser	Ile	
785					790					795					800	
Val	Val	Arg	Trp	Ser	Arg	Pro	Gln	Ala	Pro	Ile	Thr	Gly	Tyr	Arg	Ile	
				805					810						815	
Val	Tyr	Ser	Pro	Ser	Val	Glu	Gly	Ser	Ser	Thr	Glu	Leu	Asn	Leu	Pro	
			820					825					830			
Glu	Thr	Ala	Asn	Ser	Val	Thr	Leu	Ser	Asp	Leu	Gln	Pro	Gly	Val	Gln	
		835					840					845				
Tyr	Asn	Ile	Thr	Ile	Tyr	Ala	Val	Glu	Glu	Asn	Gln	Glu	Ser	Thr	Pro	
	850					855					860					
Val	Val	Ile	Gln	Gln	Glu	Thr	Thr	Gly	Thr	Pro	Arg	Ser	Asp	Thr	Val	
865					870					875					880	
Pro	Ser	Pro	Arg	Asp	Leu	Gln	Phe	Val	Glu	Val	Thr	Asp	Val	Lys	Val	
				885					890						895	
Thr	Ile	Met	Trp	Thr	Pro	Pro	Glu	Ser	Ala	Val	Thr	Gly	Tyr	Arg	Val	
			900					905					910			
Asp	Val	Ile	Pro	Val	Asn	Leu	Pro	Gly	Glu	His	Gly	Gln	Arg	Leu	Pro	
		915					920					925				
Ile	Ser	Arg	Asn	Thr	Phe	Ala	Glu	Val	Thr	Gly	Leu	Ser	Pro	Gly	Val	
	930					935					940					
Thr	Tyr	Tyr	Phe	Lys	Val	Phe	Ala	Val	Ser	His	Gly	Arg	Glu	Ser	Lys	
945				950						955					960	
Pro	Leu	Thr	Ala	Gln	Gln	Thr	Thr	Lys	Leu	Asp	Ala	Pro	Thr	Asn	Leu	
				965					970						975	
Gln	Phe	Val	Asn	Glu	Thr	Asp	Ser	Thr	Val	Leu	Val	Arg	Trp	Thr	Pro	
			980					985					990			
Pro	Arg	Ala	Gln	Ile	Thr	Gly	Tyr	Arg	Leu	Thr	Val	Gly	Leu	Thr	Arg	
		995				1000						1005				
Arg	Gly	Gln	Pro	Arg	Gln	Tyr	Asn	Val	Gly	Pro	Ser	Val	Ser	Lys	Tyr	
	1010					1015					1020					
Pro	Leu	Arg	Asn	Leu	Gln	Pro	Ala	Ser	Glu	Tyr	Thr	Val	Ser	Leu	Val	
1025					1030					1035					1040	
Ala	Ile	Lys	Gly	Asn	Gln	Glu	Ser	Pro	Lys	Ala	Thr	Gly	Val	Phe	Thr	
				1045					1050						1055	
Thr	Leu	Gln	Pro	Gly	Ser	Ser	Ile	Pro	Pro	Tyr	Asn	Thr	Glu	Val	Thr	
			1060					1065					1070			
Glu	Thr	Thr	Ile	Val	Ile	Thr	Trp	Thr	Pro	Ala	Pro	Arg	Ile	Gly	Phe	
	1075						1080									

032796-132.ST25

Asp Gln Ser Ser Cys Thr Phe Asp Asn Leu Ser Pro Gly Leu Glu Tyr
 1205 1210 1215
 Asn Val Ser Val Tyr Thr Val Lys Asp Asp Lys Glu Ser Val Pro Ile
 1220 1225 1230
 Ser Asp Thr Ile Ile Pro Ala Val Pro Pro Pro Thr Asp Leu Arg Phe
 1235 1240 1245
 Thr Asn Ile Gly Pro Asp Thr Met Arg Val Thr Trp Ala Pro Pro Pro
 1250 1255 1260
 Ser Ile Asp Leu Thr Asn Phe Leu Val Arg Tyr Ser Pro Val Lys Asn
 1265 1270 1275 1280
 Glu Glu Asp Val Ala Glu Leu Ser Ile Ser Pro Ser Asp Asn Ala Val
 1285 1290 1295
 Val Leu Thr Asn Leu Leu Pro Gly Thr Glu Tyr Val Val Ser Val Ser
 1300 1305 1310
 Ser Val Tyr Glu Gln His Glu Ser Thr Pro Leu Arg Gly Arg Gln Lys
 1315 1320 1325
 Thr Gly Leu Asp Ser Pro Thr Gly Ile Asp Phe Ser Asp Ile Thr Ala
 1330 1335 1340
 Asn Ser Phe Thr Val His Trp Ile Ala Pro Arg Ala Thr Ile Thr Gly
 1345 1350 1355 1360
 Tyr Arg Ile Arg His His Pro Glu His Phe Ser Gly Arg Pro Arg Glu
 1365 1370 1375
 Asp Arg Val Pro His Ser Arg Asn Ser Ile Thr Leu Thr Asn Leu Thr
 1380 1385 1390
 Pro Gly Thr Glu Tyr Val Val Ser Ile Val Ala Leu Asn Gly Arg Glu
 1395 1400 1405
 Glu Ser Pro Leu Leu Ile Gly Gln Gln Ser Thr Val Ser Asp Val Pro
 1410 1415 1420
 Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr Ser Leu Leu Ile Ser
 1425 1430 1435 1440
 Trp Asp Ala Pro Ala Val Thr Val Arg Tyr Tyr Arg Ile Thr Tyr Gly
 1445 1450 1455
 Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe Thr Val Pro Gly Ser
 1460 1465 1470
 Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys Pro Gly Val Asp Tyr Thr
 1475 1480 1485
 Ile Thr Val Tyr Ala Val Thr Gly Arg Gly Asp Ser Pro Ala Ser Ser
 1490 1495 1500
 Lys Pro Ile Ser Ile Asn Tyr Arg Thr Glu Ile Asp Lys Pro Ser Gln
 1505 1510 1515 1520
 Met Gln Val Thr Asp Val Gln Asp Asn Ser Ile Ser Val Lys Trp Leu
 1525 1530 1535
 Pro Ser Ser Ser Pro Val Thr Gly Tyr Arg Val Thr Thr Thr Pro Lys
 1540 1545 1550
 Asn Gly Pro Gly Pro Thr Lys Thr Lys Thr Ala Gly Pro Asp Gln Thr
 1555 1560 1565
 Glu Met Thr Ile Glu Gly Leu Gln Pro Thr Val Glu Tyr Val Val Ser
 1570 1575 1580
 Val Tyr Ala Gln Asn Pro Ser Gly Glu Ser Gln Pro Leu Val Gln Thr
 1585 1590 1595 1600
 Ala Val Thr Asn Ile Asp Arg Pro Lys Gly Leu Ala Phe Thr Asp Val
 1605 1610 1615
 Asp Val Asp Ser Ile Lys Ile Ala Trp Glu Ser Pro Gln Gly Gln Val
 1620 1625 1630
 Ser Arg Tyr Arg Val Thr Tyr Ser Ser Pro Glu Asp Gly Ile His Glu
 1635 1640 1645
 Leu Phe Pro Ala Pro Asp Gly Glu Glu Asp Thr Ala Glu Leu Gln Gly

032796-132.ST25

1650	1655	1660
Leu Arg Pro Gly Ser Glu Tyr Thr Val Ser Val Val Ala Leu His Asp		
1665	1670	1675
Asp Met Glu Ser Gln Pro Leu Ile Gly Thr Gln Ser Thr Ala Ile Pro		1680
	1685	1690
Ala Pro Thr Asp Leu Lys Phe Thr Gln Val Thr Pro Thr Ser Leu Ser		1695
	1700	1705
Ala Gln Trp Thr Pro Pro Asn Val Gln Leu Thr Gly Tyr Arg Val Arg		1710
	1715	1720
Val Thr Pro Lys Glu Lys Thr Gly Pro Met Lys Glu Ile Asn Leu Ala		1725
	1730	1735
Pro Asp Ser Ser Ser Val Val Val Ser Gly Leu Met Val Ala Thr Lys		1740
1745	1750	1755
Tyr Glu Val Ser Val Tyr Ala Leu Lys Asp Thr Leu Thr Ser Arg Pro		1760
	1765	1770
Ala Gln Gly Val Val Thr Thr Leu Glu Asn Val Ser Pro Pro Arg Arg		1775
	1780	1785
Ala Arg Val Thr Asp Ala Thr Glu Thr Thr Ile Thr Ile Ser Trp Arg		1790
	1795	1800
Thr Lys Thr Glu Thr Ile Thr Gly Phe Gln Val Asp Ala Val Pro Ala		1805
	1810	1815
Asn Gly Gln Thr Pro Ile Gln Arg Thr Ile Lys Pro Asp Val Arg Ser		1820
1825	1830	1835
Tyr Thr Ile Thr Gly Leu Gln Pro Gly Thr Asp Tyr Lys Ile Tyr Leu		1840
	1845	1850
Tyr Thr Leu Asn Asp Asn Ala Arg Ser Ser Pro Val Val Ile Asp Ala		1855
	1860	1865
Ser Thr Ala Ile Asp Ala Pro Ser Asn Leu Arg Phe Leu Ala Thr Thr		1870
	1875	1880
Pro Asn Ser Leu Leu Val Ser Trp Gln Pro Pro Arg Ala Arg Ile Thr		1885
	1890	1895
Gly Tyr Ile Ile Lys Tyr Glu Lys Pro Gly Ser Pro Pro Arg Glu Val		1900
1905	1910	1915
Val Pro Arg Pro Arg Pro Gly Val Thr Glu Ala Thr Ile Thr Gly Leu		1920
	1925	1930
Glu Pro Gly Thr Glu Tyr Thr Ile Tyr Val Ile Ala Leu Lys Asn Asn		1935
	1940	1945
Gln Lys Ser Glu Pro Leu Ile Gly Arg Lys Lys Thr Asp Glu Leu Pro		1950
	1955	1960
Gln Leu Val Thr Leu Pro His Pro Asn Leu His Gly Pro Glu Ile Leu		1965
1970	1975	1980
Asp Val Pro Ser Thr Val Gln Lys Thr Pro Phe Val Thr His Pro Gly		1985
	1990	1995
Tyr Asp Thr Gly Asn Gly Ile Gln Leu Pro Gly Thr Ser Gly Gln Gln		2000
	2005	2010
Pro Ser Val Gly Gln Gln Met Ile Phe Glu Glu His Gly Phe Arg Arg		2015
	2020	2025
Thr Thr Pro Pro Thr Thr Ala Thr Pro Ile Arg His Arg Pro Arg Pro		2030
	2035	2040
Tyr Pro Pro Asn Val Gly Gln Glu Ala Leu Ser Gln Thr Thr Ile Ser		2045
	2050	2055
Trp Ala Pro Phe Gln Asp Thr Ser Glu Tyr Ile Ile Ser Cys His Pro		2060
2065	2070	2075
Val Gly Thr Asp Glu Glu Pro Leu Gln Phe Arg Val Pro Gly Thr Ser		2080
	2085	2090
Thr Ser Ala Thr Leu Thr Gly Leu Thr Arg Gly Ala Thr Tyr Asn Ile		2095
	2100	2105
		2110

032796-132.ST25

Ile Val Glu Ala Leu Lys Asp Gln Gln Arg His Lys Val Arg Glu Glu
 2115 2120 2125
 Val Val Thr Val Gly Asn Ser Val Asn Glu Gly Leu Asn Gln Pro Thr
 2130 2135 2140
 Asp Asp Ser Cys Phe Asp Pro Tyr Thr Val Ser His Tyr Ala Val Gly
 2145 2150 2155 2160
 Asp Glu Trp Glu Arg Met Ser Glu Ser Gly Phe Lys Leu Leu Cys Gln
 2165 2170 2175
 Cys Leu Gly Phe Gly Ser Gly His Phe Arg Cys Asp Ser Ser Arg Trp
 2180 2185 2190
 Cys His Asp Asn Gly Val Asn Tyr Lys Ile Gly Glu Lys Trp Asp Arg
 2195 2200 2205
 Gln Gly Glu Asn Gly Gln Met Met Ser Cys Thr Cys Leu Gly Asn Gly
 2210 2215 2220
 Lys Gly Glu Phe Lys Cys Asp Pro His Glu Ala Thr Cys Tyr Asp Asp
 2225 2230 2235 2240
 Gly Lys Thr Tyr His Val Gly Glu Gln Trp Gln Lys Glu Tyr Leu Gly
 2245 2250 2255
 Ala Ile Cys Ser Cys Thr Cys Phe Gly Gly Gln Arg Gly Trp Arg Cys
 2260 2265 2270
 Asp Asn Cys Arg Arg Pro Gly Gly Glu Pro Ser Pro Glu Gly Thr Thr
 2275 2280 2285
 Gly Gln Ser Tyr Asn Gln Tyr Ser Gln Arg Tyr His Gln Arg Thr Asn
 2290 2295 2300
 Thr Asn Val Asn Cys Pro Ile Glu Cys Phe Met Pro Leu Asp Val Gln
 2305 2310 2315 2320
 Ala Asp Arg Glu Asp Ser Arg Glu
 2325

<210> 99

<211> 188

<212> PRT

<213> Homo sapiens

<400> 99

His Gln Thr His Lys Glu Gly Gly Ser Thr His Ala Ser Ala Asp Ala
 1 5 10 15
 Trp Glu Ile Ile Glu Leu Glu Thr Glu Ile Glu Lys Phe Lys Ala Glu
 20 25 30
 Asn Ala Ser Leu Ala Lys Leu Arg Ile Glu Arg Glu Ser Ala Leu Glu
 35 40 45
 Lys Leu Arg Lys Glu Ile Ala Asp Phe Glu Gln Gln Lys Ala Lys Glu
 50 55 60
 Leu Ala Arg Ile Glu Glu Phe Lys Lys Glu Glu Met Arg Lys Leu Gln
 65 70 75 80
 Lys Glu Arg Lys Val Phe Glu Lys Tyr Thr Thr Ala Ala Arg Thr Phe
 85 90 95
 Pro Asp Lys Lys Glu Arg Glu Glu Ile Gln Thr Leu Lys Gln Gln Ile
 100 105 110
 Ala Asp Leu Arg Glu Asp Leu Lys Arg Lys Glu Thr Lys Trp Ser Ser
 115 120 125
 Thr His Ser Arg Leu Arg Ser Gln Ile Gln Met Leu Val Arg Glu Asn
 130 135 140
 Thr Asp Leu Arg Glu Glu Ile Lys Val Met Glu Arg Phe Arg Leu Asp
 145 150 155 160
 Ala Trp Lys Arg Ala Glu Ala Ile Glu Ser Ser Leu Glu Val Glu Lys
 165 170 175

032796-132.ST25

Lys Asp Lys Leu Ala Asn Thr Ser Val Arg Phe Gln
 180 185

<210> 100

<211> 284

<212> PRT

<213> Homo sapiens

<400> 100

Met Glu Pro Gly Asn Tyr Ala Thr Leu Asp Gly Ala Lys Asp Ile Glu
 1 5 10 15
 Gly Leu Leu Gly Ala Gly Gly Gly Arg Asn Leu Val Ala His Ser Pro
 20 25 30
 Leu Thr Ser His Pro Ala Ala Pro Thr Leu Met Pro Ala Val Asn Tyr
 35 40 45
 Ala Pro Leu Asp Leu Pro Gly Ser Ala Glu Pro Pro Lys Gln Cys His
 50 55 60
 Pro Cys Pro Gly Val Pro Gln Gly Thr Ser Pro Ala Pro Val Pro Tyr
 65 70 75 80
 Gly Tyr Phe Gly Gly Gly Tyr Tyr Ser Cys Arg Val Ser Arg Ser Ser
 85 90 95
 Leu Lys Pro Cys Ala Gln Ala Ala Thr Leu Ala Ala Tyr Pro Ala Glu
 100 105 110
 Thr Pro Thr Ala Gly Glu Glu Tyr Pro Ser Arg Pro Thr Glu Phe Ala
 115 120 125
 Phe Tyr Pro Gly Tyr Pro Gly Thr Tyr His Ala Met Ala Ser Tyr Leu
 130 135 140
 Asp Val Ser Val Val Gln Thr Leu Gly Ala Pro Gly Glu Pro Arg His
 145 150 155 160
 Asp Ser Leu Leu Pro Val Asp Ser Tyr Gln Ser Trp Ala Leu Ala Gly
 165 170 175
 Gly Trp Asn Ser Gln Met Cys Cys Gln Gly Glu Gln Asn Pro Pro Gly
 180 185 190
 Pro Phe Trp Lys Ala Ala Phe Ala Asp Ser Ser Gly Gln His Pro Pro
 195 200 205
 Asp Ala Cys Ala Phe Arg Arg Gly Arg Lys Lys Arg Ile Pro Tyr Ser
 210 215 220
 Lys Gly Gln Leu Arg Glu Leu Glu Arg Glu Tyr Ala Ala Asn Lys Phe
 225 230 235 240
 Ile Thr Lys Asp Lys Arg Arg Lys Ile Ser Ala Ala Thr Ser Leu Ser
 245 250 255
 Glu Arg Gln Ile Thr Ile Trp Phe Gln Asn Arg Arg Val Lys Glu Lys
 260 265 270
 Lys Val Leu Ala Lys Val Lys Asn Ser Ala Thr Pro
 275 280

<210> 101

<211> 676

<212> PRT

<213> Homo sapiens

<400> 101

Met Asp Lys Tyr Asp Asp Leu Gly Leu Glu Ala Ser Lys Phe Ile Glu
 1 5 10 15
 Asp Leu Asn Met Tyr Glu Ala Ser Lys Asp Gly Leu Phe Arg Val Asp
 20 25 30
 Lys Gly Ala Gly Asn Asn Pro Glu Phe Glu Glu Thr Arg Arg Val Phe

		35								40							45					
Ala 50	Thr	Lys	Met	Ala	Lys	Ile 55	His	Leu	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Leu						
Leu 65	Gln	Glu	Glu	Thr	Leu	Pro	Arg	Gly	Ser	Arg	Gly	Pro	Val	Asn	Gly							
Gly	Gly	Arg	Leu	Gly	Pro	Gln	Ala	Arg	Trp	Glu	Val	Val	Gly	Ser	Lys							
Leu	Thr	Val	Asp	Gly	Ala	Ala	Lys	Pro	Pro	Leu	Ala	Ala	Ser	Thr	Gly							
Ala	Pro	Gly	Ala	Val	Thr	Thr	Leu	Ala	Ala	Gly	Gln	Pro	Pro	Tyr	Pro							
Pro	Gln	Glu	Gln	Arg	Ser	Arg	Pro	Tyr	Leu	His	Gly	Thr	Arg	His	Gly							
Ser	Gln	Asp	Cys	Gly	Ser	Arg	Glu	Ser	Leu	Ala	Thr	Ser	Glu	Met	Ser							
Ala	Phe	His	Gln	Pro	Gly	Pro	Cys	Glu	Asp	Pro	Ser	Cys	Leu	Thr	His							
Gly	Asp	Tyr	Tyr	Asp	Asn	Leu	Ser	Leu	Ala	Ser	Pro	Lys	Trp	Gly	Asp							
Lys	Pro	Gly	Val	Ser	Pro	Ser	Ile	Gly	Leu	Ser	Val	Gly	Ser	Gly	Trp							
Pro	Ser	Ser	Pro	Gly	Ser	Asp	Pro	Pro	Leu	Pro	Lys	Pro	Cys	Gly	Asp							
His	Pro	Leu	Asn	His	Arg	Gln	Leu	Ser	Leu	Ser	Ser	Ser	Arg	Ser	Ser							
Glu	Gly	Ser	Leu	Gly	Gly	Gln	Asn	Ser	Gly	Ile	Gly	Gly	Arg	Ser	Ser							
Glu	Lys	Pro	Thr	Gly	Leu	Trp	Ser	Thr	Ala	Ser	Ser	Gln	Arg	Val	Ser							
Pro	Gly	Leu	Pro	Ser	Pro	Asn	Leu	Glu	Asn	Gly	Ala	Pro	Ala	Val	Gly							
Pro	Val	Gln	Pro	Arg	Thr	Pro	Ser	Val	Ser	Ala	Pro	Leu	Ala	Leu	Ser							
Cys	Pro	Arg	Gln	Gly	Gly	Leu	Pro	Arg	Ser	Asn	Ser	Gly	Leu	Gly	Gly							
Glu	Val	Ser	Gly	Val	Met	Ser	Lys	Pro	Asn	Val	Asp	Pro	Gln	Pro	Trp							
Phe	Gln	Asp	Gly	Pro	Lys	Ser	Tyr	Leu	Ser	Ser	Ser	Ala	Pro	Ser	Ser							
Ser	Pro	Ala	Gly	Leu	Asp	Gly	Ser	Gln	Gln	Gly	Ala	Val	Pro	Gly	Leu							
Gly	Pro	Lys	Pro	Gly	Cys	Thr	Asp	Leu	Gly	Thr	Gly	Pro	Lys	Leu	Ser							
Pro	Thr	Ser	Leu	Val	His	Pro	Val	Met	Ser	Thr	Leu	Pro	Glu	Leu	Ser							
Cys	Lys	Glu	Gly	Pro	Leu	Gly	Trp	Ser	Ser	Asp	Gly	Ser	Leu	Gly	Ser							
Val	Leu	Leu	Asp	Ser	Pro	Ser	Ser	Pro	Arg	Val	Arg	Leu	Pro	Cys	Gln							
Pro	Leu	Val	Pro	Gly	Pro	Glu	Leu	Arg	Pro	Ser	Ala	Ala	Glu	Leu	Lys							
Leu	Glu	Ala	Leu	Thr	Gln	Arg	Leu	Glu	Arg	Glu	Met	Asp	Ala	His	Pro							
Lys	Ala	Asp	Tyr	Phe	Gly	Ala	Cys	Val	Lys	Cys	Ser	Lys	Gly	Val	Phe							
Gly	Ala	Gly	Gln	Ala	Cys	Gln	Ala	Met	Gly	Asn	Leu	Tyr	His	Asp	Thr							

032796-132.ST25

Cys Phe Thr Cys Ala Ala Cys Ser Arg Lys Leu Arg Gly Lys Ala Phe
 500 505 510
 Tyr Phe Val Asn Gly Lys Val Phe Cys Glu Glu Asp Phe Leu Tyr Ser
 515 520 525
 Gly Phe Gln Gln Ser Ala Asp Arg Cys Phe Leu Cys Gly His Leu Ile
 530 535 540
 Met Asp Met Ile Leu Gln Ala Leu Gly Lys Ser Tyr His Pro Gly Cys
 545 550 555 560
 Phe Arg Cys Val Ile Cys Asn Glu Cys Leu Asp Gly Val Pro Phe Thr
 565 570 575
 Val Asp Ser Glu Asn Lys Ile Tyr Cys Val Arg Asp Tyr His Lys Val
 580 585 590
 Leu Ala Pro Lys Cys Ala Ala Cys Gly Leu Pro Ile Leu Pro Pro Glu
 595 600 605
 Gly Ser Asp Glu Thr Ile Arg Val Val Ser Met Asp Arg Asp Tyr His
 610 615 620
 Val Glu Cys Tyr His Cys Glu Asp Cys Gly Leu Glu Leu Asn Asp Glu
 625 630 635 640
 Asp Gly His Arg Cys Tyr Pro Leu Glu Asp His Leu Phe Cys His Ser
 645 650 655
 Cys His Val Lys Arg Leu Glu Lys Arg Pro Ser Ser Thr Ala Leu His
 660 665 670
 Gln His His Phe
 675

<210> 102

<211> 296

<212> PRT

<213> Homo sapiens

<400> 102

Ser Thr Gly Ser Glu Phe Pro Leu Cys Thr Lys Ala Ser Pro Cys Ser
 1 5 10 15
 Ala Ala Arg Ala Gly Gly Arg Ala Leu Gly Trp Arg Leu Gln Gln
 20 25 30
 Arg Glu Thr Arg Gly Asn Pro Gly Asn Pro Gly Leu Gly Val Ala Ala
 35 40 45
 Thr Met Thr Gly Ser Asn Met Ser Asp Ala Leu Ala Asn Ala Val Cys
 50 55 60
 Gln Arg Cys Gln Ala Arg Phe Ser Pro Ala Glu Arg Ile Val Asn Ser
 65 70 75 80
 Asn Gly Glu Leu Tyr His Glu His Cys Phe Val Cys Ala Gln Cys Phe
 85 90 95
 Arg Pro Phe Pro Glu Gly Leu Phe Tyr Glu Phe Glu Gly Arg Lys Tyr
 100 105 110
 Cys Glu His Asp Phe Gln Met Leu Phe Ala Pro Cys Cys Gly Ser Cys
 115 120 125
 Gly Glu Phe Ile Ile Gly Arg Val Ile Lys Ala Met Asn Asn Asn Trp
 130 135 140
 His Pro Gly Cys Phe Arg Cys Glu Leu Cys Asp Val Glu Leu Ala Asp
 145 150 155 160
 Leu Gly Phe Val Lys Asn Ala Gly Arg His Leu Cys Arg Pro Cys His
 165 170 175
 Asn Arg Glu Lys Ala Lys Gly Leu Gly Lys Tyr Ile Cys Gln Arg Cys
 180 185 190
 His Leu Val Ile Asp Glu Gln Pro Leu Met Phe Arg Ser Asp Ala Tyr
 195 200 205

032796-132.ST25

His Pro Asp His Phe Asn Cys Thr His Cys Gly Lys Glu Leu Thr Ala
 210 215 220
 Glu Ala Arg Glu Leu Lys Gly Glu Leu Tyr Cys Leu Pro Cys His Asp
 225 230 235 240
 Lys Met Gly Val Pro Ile Cys Gly Ala Cys Arg Arg Pro Ile Glu Gly
 245 250 255
 Arg Val Val Asn Ala Leu Gly Lys Gln Trp His Val Glu His Phe Val
 260 265 270
 Cys Ala Lys Cys Glu Lys Pro Phe Leu Gly His Arg His Tyr Glu Lys
 275 280 285
 Lys Gly Leu Ala Tyr Cys Glu Leu
 290 295

<210> 103

<211> 500

<212> PRT

<213> Homo sapiens

<400> 103

Met Gly Ile Gly Leu Ser Ala Gln Gly Val Asn Met Asn Arg Leu Pro
 1 5 10 15
 Gly Trp Asp Lys His Ser Tyr Gly Tyr His Gly Asp Asp Gly His Ser
 20 25 30
 Phe Cys Ser Ser Gly Thr Gly Gln Pro Tyr Gly Pro Thr Phe Thr Thr
 35 40 45
 Gly Asp Val Ile Gly Cys Cys Val Asn Leu Ile Asn Asn Thr Cys Phe
 50 55 60
 Tyr Thr Lys Asn Gly His Ser Leu Gly Ile Ala Phe Thr Asp Leu Pro
 65 70 75 80
 Pro Asn Leu Tyr Pro Thr Val Gly Leu Gln Thr Pro Gly Glu Val Val
 85 90 95
 Asp Ala Asn Phe Gly Gln His Pro Phe Val Phe Asp Ile Glu Asp Tyr
 100 105 110
 Met Arg Glu Trp Arg Thr Lys Ile Gln Ala Gln Ile Asp Arg Phe Pro
 115 120 125
 Ile Gly Asp Arg Glu Gly Glu Trp Gln Thr Met Ile Gln Lys Met Val
 130 135 140
 Ser Ser Tyr Leu Val His His Gly Tyr Cys Ala Thr Ala Glu Ala Phe
 145 150 155 160
 Ala Arg Ser Thr Asp Gln Thr Val Leu Glu Glu Leu Ala Ser Ile Lys
 165 170 175
 Asn Arg Gln Arg Ile Gln Lys Leu Val Leu Ala Gly Arg Met Gly Glu
 180 185 190
 Ala Ile Glu Thr Thr Gln Gln Leu Tyr Pro Ser Leu Leu Glu Arg Asn
 195 200 205
 Pro Asn Leu Leu Phe Thr Leu Lys Val Arg Gln Phe Ile Glu Met Val
 210 215 220
 Asn Gly Thr Asp Ser Glu Val Arg Cys Leu Gly Gly Arg Ser Pro Lys
 225 230 235 240
 Ser Gln Asp Ser Tyr Pro Val Ser Pro Arg Pro Phe Ser Ser Pro Ser
 245 250 255
 Met Ser Pro Ser His Gly Met Asn Ile His Asn Leu Ala Ser Gly Lys
 260 265 270
 Gly Ser Thr Ala His Phe Ser Gly Phe Glu Ser Cys Ser Asn Gly Val
 275 280 285
 Ile Ser Asn Lys Ala His Gln Ser Tyr Cys His Ser Asn Lys His Gln
 290 295 300

032796-132.ST25

Ser Ser Asn Leu Asn Val Pro Glu Leu Asn Ser Ile Asn Met Ser Arg
 305 310 315 320
 Ser Gln Gln Val Asn Asn Phe Thr Ser Asn Asp Val Asp Met Glu Thr
 325 330 335
 Asp His Tyr Ser Asn Gly Val Gly Glu Thr Ser Ser Asn Gly Phe Leu
 340 345 350
 Asn Gly Ser Ser Lys His Asp His Glu Met Glu Asp Cys Asp Thr Glu
 355 360 365
 Met Glu Val Asp Ser Ser Gln Leu Arg Arg Gln Leu Cys Gly Gly Ser
 370 375 380
 Gln Ala Ala Ile Glu Arg Met Ile His Phe Gly Arg Glu Leu Gln Ala
 385 390 395 400
 Met Ser Glu Gln Leu Arg Arg Asp Cys Gly Lys Asn Thr Ala Asn Lys
 405 410 415
 Lys Met Leu Lys Asp Ala Phe Ser Leu Leu Ala Tyr Ser Asp Pro Trp
 420 425 430
 Asn Ser Pro Val Gly Asn Gln Leu Asp Pro Ile Gln Arg Glu Pro Val
 435 440 445
 Cys Ser Ala Leu Asn Ser Ala Ile Leu Glu Thr His Asn Leu Pro Lys
 450 455 460
 Gln Pro Pro Leu Ala Leu Ala Met Gly Gln Ala Thr Gln Cys Leu Gly
 465 470 475 480
 Leu Met Ala Arg Ser Gly Ile Gly Ser Cys Ala Phe Ala Thr Val Glu
 485 490 495
 Asp Tyr Leu His
 500

<210> 104

<211> 387

<212> PRT

<213> Homo sapiens

<400> 104

Met Ala Thr Ser Gly Val Leu Pro Gly Gly Gly Phe Val Ala Ser Ala
 1 5 10 15
 Ala Ala Val Ala Gly Pro Glu Met Gln Thr Gly Arg Asn Asn Phe Val
 20 25 30
 Ile Arg Arg Asn Pro Ala Asp Pro Gln Arg Ile Pro Ser Asn Pro Ser
 35 40 45
 His Arg Ile Gln Cys Ala Ala Gly Tyr Glu Gln Ser Glu His Asn Val
 50 55 60
 Cys Gln Asp Ile Asp Glu Cys Thr Ala Gly Thr His Asn Cys Arg Ala
 65 70 75 80
 Asp Gln Val Cys Ile Asn Leu Arg Gly Ser Phe Ala Cys Gln Cys Pro
 85 90 95
 Pro Gly Tyr Gln Lys Arg Gly Glu Gln Cys Val Asp Ile Asp Glu Cys
 100 105 110
 Thr Ile Pro Pro Tyr Cys His Gln Arg Cys Val Asn Thr Pro Gly Ser
 115 120 125
 Phe Tyr Cys Gln Cys Ser Pro Gly Phe Gln Leu Ala Ala Asn Asn Tyr
 130 135 140
 Thr Cys Val Asp Ile Asn Glu Cys Asp Ala Ser Asn Gln Cys Ala Gln
 145 150 155 160
 Gln Cys Tyr Asn Ile Leu Gly Ser Phe Ile Cys Gln Cys Asn Gln Gly
 165 170 175
 Tyr Glu Leu Ser Ser Asp Arg Leu Asn Cys Glu Asp Ile Asp Glu Cys
 180 185 190

032796-132.ST25

Arg Thr Ser Ser Tyr Leu Cys Gln Tyr Gln Cys Val Asn Glu Pro Gly
 195 200 205
 Lys Phe Ser Cys Met Cys Pro Gln Gly Tyr Gln Val Val Arg Ser Arg
 210 215 220
 Thr Cys Gln Asp Ile Asn Glu Cys Glu Thr Thr Asn Glu Cys Arg Glu
 225 230 235 240
 Asp Glu Met Cys Trp Asn Tyr His Gly Gly Phe Arg Cys Tyr Pro Arg
 245 250 255
 Asn Pro Cys Gln Asp Pro Tyr Ile Leu Thr Pro Glu Asn Arg Cys Val
 260 265 270
 Cys Pro Val Ser Asn Ala Met Cys Arg Glu Leu Pro Gln Ser Ile Val
 275 280 285
 Tyr Lys Tyr Met Ser Ile Arg Ser Asp Arg Ser Val Pro Ser Asp Ile
 290 295 300
 Phe Gln Ile Gln Ala Thr Thr Ile Tyr Ala Asn Thr Ile Asn Thr Phe
 305 310 315 320
 Arg Ile Lys Ser Gly Asn Glu Asn Gly Glu Phe Tyr Leu Arg Gln Thr
 325 330 335
 Ser Pro Val Ser Ala Met Leu Val Leu Val Lys Ser Leu Ser Gly Pro
 340 345 350
 Arg Glu His Ile Val Asp Leu Glu Met Leu Thr Val Ser Ser Ile Gly
 355 360 365
 Thr Phe Arg Thr Ser Ser Val Leu Arg Leu Thr Ile Ile Val Gly Pro
 370 375 380
 Phe Ser Phe
 385

<210> 105

<211> 531

<212> PRT

<213> Homo sapiens

<400> 105

Met Ser Lys Pro His Ser Glu Ala Gly Thr Ala Phe Ile Gln Thr Gln
 1 5 10 15
 Gln Leu His Ala Ala Met Ala Asp Thr Phe Leu Glu His Met Cys Arg
 20 25 30
 Leu Asp Ile Asp Ser Pro Pro Ile Thr Ala Arg Asn Thr Gly Ile Ile
 35 40 45
 Cys Thr Ile Gly Pro Ala Ser Arg Ser Val Glu Thr Leu Lys Glu Met
 50 55 60
 Ile Lys Ser Gly Met Asn Val Ala Arg Leu Asn Phe Ser His Gly Thr
 65 70 75 80
 His Glu Tyr His Ala Glu Thr Ile Lys Asn Val Arg Thr Ala Thr Glu
 85 90 95
 Ser Phe Ala Ser Asp Pro Tyr Leu Tyr Arg Pro Val Ala Val Ala Leu
 100 105 110
 Asp Thr Lys Gly Pro Glu Ile Arg Thr Gly Leu Ile Lys Gly Ser Gly
 115 120 125
 Thr Ala Glu Leu Glu Leu Lys Lys Gly Ala Thr Leu Lys Ile Thr Leu
 130 135 140
 Asp Asn Ala Tyr Met Glu Lys Cys Asp Glu Asn Ile Leu Trp Leu Asp
 145 150 155 160
 Tyr Lys Asn Ile Cys Lys Val Val Glu Val Gly Ser Lys Ile Tyr Val
 165 170 175
 Asp Asp Gly Leu Ile Ser Leu Gln Val Lys Gln Lys Gly Ala Asp Phe
 180 185 190

032796-132.ST25

```

Leu Val Thr Glu Val Glu Asn Gly Gly Ser Leu Gly Ser Lys Lys Gly
195 200 205
Val Asn Leu Pro Gly Ala Ala Val Asp Leu Pro Ala Val Ser Glu Lys
210 215 220
Asp Ile Gln Asp Leu Lys Phe Gly Val Glu Gln Asp Val Asp Met Val
225 230 235 240
Phe Ala Ser Phe Ile Arg Lys Ala Ser Asp Val His Glu Val Arg Lys
245 250 255
Val Leu Gly Glu Lys Gly Lys Asn Ile Lys Ile Ile Ser Lys Ile Glu
260 265 270
Asn His Glu Gly Val Arg Arg Phe Asp Glu Ile Leu Glu Ala Ser Asp
275 280 285
Gly Ile Met Val Ala Arg Gly Asp Leu Gly Ile Glu Ile Pro Ala Glu
290 295 300
Lys Val Phe Leu Ala Gln Lys Met Met Ile Gly Arg Cys Asn Arg Ala
305 310 315 320
Gly Lys Pro Val Ile Cys Ala Thr Gln Met Leu Glu Ser Met Ile Lys
325 330 335
Lys Pro Arg Pro Thr Arg Ala Glu Gly Ser Asp Val Ala Asn Ala Val
340 345 350
Leu Asp Gly Ala Asp Cys Ile Met Leu Ser Gly Glu Thr Ala Lys Gly
355 360 365
Asp Tyr Pro Leu Glu Ala Val Arg Met Gln His Leu Ile Ala Arg Glu
370 375 380
Ala Glu Ala Ala Ile Tyr His Leu Gln Leu Phe Glu Glu Leu Arg Arg
385 390 395 400
Leu Ala Pro Ile Thr Ser Asp Pro Thr Glu Ala Thr Ala Val Gly Ala
405 410 415
Val Glu Ala Ser Phe Lys Cys Cys Ser Gly Ala Ile Ile Val Leu Thr
420 425 430
Lys Ser Gly Arg Ser Ala His Gln Val Ala Arg Tyr Arg Pro Arg Ala
435 440 445
Pro Ile Ala Val Thr Arg Asn Pro Gln Thr Ala Arg Gln Ala His
450 455 460
Leu Tyr Arg Gly Ile Phe Pro Val Leu Cys Lys Asp Pro Val Gln Glu
465 470 475 480
Ala Trp Ala Glu Asp Val Asp Leu Arg Val Asn Phe Ala Met Asn Val
485 490 495
Gly Lys Ala Arg Gly Phe Phe Lys Lys Gly Asp Val Val Ile Val Leu
500 505 510
Thr Gly Trp Arg Pro Gly Ser Gly Phe Thr Asn Thr Met Arg Val Val
515 520 525
Pro Val Pro
530

```

<210> 106

<211> 480

<212> PRT

<213> Homo sapiens

<400> 106

```

Met Ala Ala Arg Cys Ser Thr Arg Trp Leu Leu Val Val Val Gly Thr
1 5 10 15
Pro Arg Leu Pro Ala Ile Ser Gly Arg Gly Ala Arg Pro Pro Arg Glu
20 25 30
Gly Val Val Gly Ala Trp Leu Ser Arg Lys Leu Ser Val Pro Ala Phe
35 40 45

```

032796-132.ST25

Ala Ser Ser Leu Thr Ser Cys Gly Pro Arg Ala Leu Leu Thr Leu Arg
 50 55 60
 Pro Gly Val Ser Leu Thr Gly Thr Lys His Asn Pro Phe Ile Cys Thr
 65 70 75 80
 Ala Ser Phe His Thr Ser Ala Pro Leu Ala Lys Glu Asp Tyr Tyr Gln
 85 90 95
 Ile Leu Gly Val Pro Arg Asn Ala Ser Gln Lys Glu Ile Lys Lys Ala
 100 105 110
 Tyr Tyr Gln Leu Ala Lys Lys Tyr His Pro Asp Thr Asn Lys Asp Asp
 115 120 125
 Pro Lys Ala Lys Glu Lys Phe Ser Gln Leu Ala Glu Ala Tyr Glu Val
 130 135 140
 Leu Ser Asp Glu Val Lys Arg Lys Gln Tyr Asp Ala Tyr Gly Ser Ala
 145 150 155 160
 Gly Phe Asp Pro Gly Ala Ser Gly Ser Gln His Ser Tyr Trp Lys Gly
 165 170 175
 Gly Pro Thr Val Asp Pro Glu Glu Leu Phe Arg Lys Ile Phe Gly Glu
 180 185 190
 Phe Ser Ser Ser Phe Gly Asp Phe Gln Thr Val Phe Asp Gln Pro
 195 200 205
 Gln Glu Tyr Phe Met Glu Leu Thr Phe Asn Gln Ala Ala Lys Gly Val
 210 215 220
 Asn Lys Glu Phe Thr Val Asn Ile Met Asp Thr Cys Glu Arg Cys Asn
 225 230 235 240
 Gly Lys Gly Asn Glu Pro Gly Thr Lys Val Gln His Cys His Tyr Cys
 245 250 255
 Gly Gly Ser Gly Met Glu Thr Ile Asn Thr Gly Pro Phe Val Met Arg
 260 265 270
 Ser Thr Cys Arg Arg Cys Gly Gly Arg Gly Ser Ile Ile Ile Ser Pro
 275 280 285
 Cys Val Val Cys Arg Gly Ala Gly Gln Ala Lys Gln Lys Lys Arg Val
 290 295 300
 Met Ile Pro Val Pro Ala Gly Val Glu Asp Gly Gln Thr Val Arg Met
 305 310 315 320
 Pro Val Gly Lys Arg Glu Ile Phe Ile Thr Phe Arg Val Gln Lys Ser
 325 330 335
 Pro Val Phe Arg Arg Asp Gly Ala Asp Ile His Ser Asp Leu Phe Ile
 340 345 350
 Ser Ile Ala Gln Ala Leu Leu Gly Gly Thr Ala Arg Ala Gln Gly Leu
 355 360 365
 Tyr Glu Thr Ile Asn Val Thr Ile Pro Pro Gly Thr Gln Thr Asp Gln
 370 375 380
 Lys Ile Arg Met Gly Gly Lys Gly Ile Pro Arg Ile Asn Ser Tyr Gly
 385 390 395 400
 Tyr Gly Asp His Tyr Ile His Ile Lys Ile Arg Val Pro Lys Arg Leu
 405 410 415
 Thr Ser Arg Gln Gln Ser Leu Ile Leu Ser Tyr Ala Glu Asp Glu Thr
 420 425 430
 Asp Val Glu Gly Thr Val Asn Gly Val Thr Leu Thr Ser Ser Gly Gly
 435 440 445
 Ser Thr Met Asp Ser Ser Ala Gly Ser Lys Ala Arg Arg Glu Ala Gly
 450 455 460
 Glu Asp Glu Glu Gly Phe Leu Ser Lys Leu Lys Lys Met Phe Thr Ser
 465 470 475 480

<210> 107

<211> 572

032796-132.ST25

<212> PRT

<213> Homo sapiens

<400> 107

```

Met Ala Ala Pro Arg Pro Ser Pro Ala Ile Ser Val Ser Val Ser Ala
 1          5          10          15
Pro Ala Phe Tyr Ala Pro Gln Lys Lys Phe Gly Pro Val Val Ala Pro
 20          25          30
Lys Pro Lys Val Asn Pro Phe Arg Pro Gly Asp Ser Glu Pro Pro Pro
 35          40          45
Ala Pro Gly Ala Gln Arg Ala Gln Met Gly Arg Val Gly Glu Ile Pro
 50          55          60
Pro Pro Pro Pro Glu Asp Phe Pro Leu Pro Pro Pro Pro Leu Ala Gly
 65          70          75          80
Asp Gly Asp Asp Ala Glu Gly Ala Leu Gly Gly Ala Phe Pro Pro Pro
 85          90          95
Pro Pro Pro Ile Glu Glu Ser Phe Pro Pro Ala Pro Leu Glu Glu Glu
100          105          110
Ile Phe Pro Ser Pro Pro Pro Pro Glu Glu Glu Gly Gly Pro Glu
115          120          125
Ala Pro Ile Pro Pro Pro Pro Gln Pro Arg Glu Lys Val Ser Ser Ile
130          135          140
Asp Leu Glu Ile Asp Ser Leu Ser Ser Leu Leu Asp Asp Met Thr Lys
145          150          155          160
Asn Asp Pro Phe Lys Ala Arg Val Ser Ser Gly Tyr Val Pro Pro Pro
165          170          175
Val Ala Thr Pro Phe Ser Ser Lys Ser Ser Thr Lys Pro Ala Ala Gly
180          185          190
Gly Thr Ala Pro Leu Pro Pro Trp Lys Ser Pro Ser Ser Ser Gln Pro
195          200          205
Leu Pro Gln Val Pro Ala Pro Ala Gln Ser Gln Thr Gln Phe His Val
210          215          220
Gln Pro Gln Pro Gln Pro Lys Pro Gln Val Gln Leu His Val Gln Ser
225          230          235          240
Gln Thr Gln Pro Val Ser Leu Ala Asn Thr Gln Pro Arg Gly Pro Pro
245          250          255
Ala Ser Ser Pro Ala Pro Ala Pro Lys Phe Ser Pro Val Thr Pro Lys
260          265          270
Phe Thr Pro Val Ala Ser Lys Phe Ser Pro Gly Ala Pro Gly Gly Ser
275          280          285
Gly Ser Gln Pro Asn Gln Lys Leu Gly His Pro Glu Ala Leu Ser Ala
290          295          300
Gly Thr Gly Ser Pro Gln Pro Pro Ser Phe Thr Tyr Ala Gln Gln Arg
305          310          315          320
Glu Lys Pro Arg Val Gln Glu Lys Gln His Pro Val Pro Pro Pro Ala
325          330          335
Gln Asn Gln Asn Gln Val Arg Ser Pro Gly Ala Pro Gly Pro Leu Thr
340          345          350
Leu Lys Glu Val Glu Glu Leu Glu Gln Leu Thr Gln Gln Leu Met Gln
355          360          365
Asp Met Glu His Pro Gln Arg Gln Asn Val Ala Val Asn Glu Leu Cys
370          375          380
Gly Arg Cys His Gln Pro Leu Ala Arg Ala Gln Pro Ala Val Arg Ala
385          390          395          400
Leu Gly Gln Leu Phe His Ile Ala Cys Phe Thr Cys His Gln Cys Ala
405          410          415
Gln Gln Leu Gln Gly Gln Gln Phe Tyr Ser Leu Glu Gly Ala Pro Tyr

```


032796-132.ST25

										420								425								430			
Cys	Glu	Gly	Cys	Tyr	Thr	Asp	Thr	Leu	Glu	Lys	Cys	Asn	Thr	Cys	Gly														
																435				440				445					
Glu	Pro	Ile	Thr	Asp	Arg	Met	Leu	Arg	Ala	Thr	Gly	Lys	Ala	Tyr	His														
																450				455				460					
Pro	His	Cys	Phe	Thr	Cys	Val	Val	Cys	Ala	Arg	Pro	Leu	Glu	Gly	Thr														
																465				470				475					
Ser	Phe	Ile	Val	Asp	Gln	Ala	Asn	Arg	Pro	His	Cys	Val	Pro	Asp	Tyr														
																485				490				495					
His	Lys	Gln	Tyr	Ala	Pro	Arg	Cys	Ser	Val	Cys	Ser	Glu	Pro	Ile	Met														
																500				505				510					
Pro	Glu	Pro	Gly	Arg	Asp	Glu	Thr	Val	Arg	Val	Val	Ala	Leu	Asp	Lys														
																515				520				525					
Asn	Phe	His	Met	Lys	Cys	Tyr	Lys	Cys	Glu	Asp	Cys	Gly	Lys	Pro	Leu														
																530				535				540					
Ser	Ile	Glu	Ala	Asp	Asn	Gly	Cys	Phe	Pro	Leu	Asp	Gly	His	Val															
																545				550				555					
Leu	Cys	Arg	Lys	Cys	His	Thr	Ala	Arg	Ala	Gln	Thr																		
																565				570									

<210> 108

<211> 2861

<212> PRT

<213> Homo sapiens

<400> 108

Met	Lys	Ala	Met	Asp	Val	Leu	Pro	Ile	Leu	Lys	Glu	Lys	Val	Ala	Tyr																
																1				5				10				15			
Leu	Ser	Gly	Gly	Arg	Asp	Lys	Arg	Gly	Gly	Pro	Ile	Leu	Thr	Phe	Pro																
																20				25				30							
Ala	Arg	Ser	Asn	His	Asp	Arg	Ile	Arg	Gln	Glu	Asp	Leu	Arg	Arg	Leu																
																35				40				45							
Ile	Ser	Tyr	Leu	Ala	Cys	Ile	Pro	Ser	Glu	Glu	Val	Cys	Lys	Arg	Gly																
																50				55				60							
Phe	Thr	Val	Ile	Val	Asp	Met	Arg	Gly	Ser	Lys	Trp	Asp	Ser	Ile	Lys																
																65				70				75				80			
Pro	Leu	Leu	Lys	Ile	Leu	Gln	Glu	Ser	Phe	Pro	Cys	Cys	Ile	His	Val																
																85				90				95							
Ala	Leu	Ile	Ile	Lys	Pro	Asp	Asn	Phe	Trp	Gln	Lys	Gln	Arg	Thr	Asn																
																100				105				110							
Phe	Gly	Ser	Ser	Lys	Phe	Glu	Phe	Glu	Thr	Asn	Met	Val	Ser	Leu	Glu																
																115				120				125							
Gly	Leu	Thr	Lys	Val	Val	Asp	Pro	Ser	Gln	Leu	Thr	Pro	Glu	Phe	Asp																
																130				135				140							
Gly	Cys	Leu	Glu	Tyr	Asn	His	Glu	Glu	Trp	Ile	Glu	Ile	Arg	Val	Ala																
																145				150				155				160			
Phe	Glu	Asp	Tyr	Ile	Ser	Asn	Ala	Thr	His	Met	Leu	Ser	Arg	Leu	Glu																
																165				170				175							
Glu	Leu	Gln	Asp	Ile	Leu	Ala	Lys	Lys	Glu	Leu	Pro	Gln	Asp	Leu	Glu																
																180				185				190							
Gly	Ala	Arg	Asn	Met	Ile	Glu	Glu	His	Ser	Gln	Leu	Lys	Lys	Lys	Val																
																195				200				205							
Ile	Lys	Ala	Pro	Ile	Glu	Asp	Leu	Asp	Leu	Glu	Gly	Gln	Lys	Leu	Leu																
																210				215				220							
Gln	Arg	Ile	Gln	Ser	Ser	Glu	Ser	Phe	Pro	Lys	Lys	Asn	Ser	Gly	Ser																
																225				230				235				240			
Gly	Asn	Ala	Asp	Leu	Gln	Asn	Leu	Leu	Pro	Lys	Val	Ser	Thr	Met	Leu																

032796-132.ST25

Leu Asp Glu Ala Gln Ser Gln Met Glu Glu Leu Phe Gln Glu Arg Lys
 705 710 715 720
 Ile Lys Leu Glu Leu Phe Leu His Val Arg Ile Phe Glu Arg Asp Ala
 725 730 735
 Ile Asp Ile Ile Ser Asp Leu Glu Ser Trp Asn Asp Glu Leu Ser Gln
 740 745 750
 Gln Met Asn Asp Phe Asp Thr Glu Asp Leu Thr Ile Ala Glu Gln Arg
 755 760 765
 Leu Gln His His Ala Asp Lys Ala Leu Thr Met Asn Asn Leu Thr Phe
 770 775 780
 Asp Val Ile His Gln Gly Gln Asp Leu Leu Gln Tyr Val Asn Glu Val
 785 790 795 800
 Gln Ala Ser Gly Val Glu Leu Leu Cys Asp Arg Asp Val Asp Met Ala
 805 810 815
 Thr Arg Val Gln Asp Leu Leu Glu Phe Leu His Glu Lys Gln Gln Glu
 820 825 830
 Leu Asp Leu Ala Ala Glu Gln His Arg Lys His Leu Glu Gln Cys Val
 835 840 845
 Gln Leu Arg His Leu Gln Ala Glu Val Lys Gln Val Leu Gly Trp Ile
 850 855 860
 Arg Asn Gly Glu Ser Met Leu Asn Ala Gly Leu Ile Thr Ala Ser Ser
 865 870 875 880
 Leu Gln Glu Ala Glu Gln Leu Gln Arg Glu His Glu Gln Phe Gln His
 885 890 895
 Ala Ile Glu Lys Thr His Gln Ser Ala Leu Gln Val Gln Gln Lys Ala
 900 905 910
 Glu Ala Met Leu Gln Ala Asn His Tyr Asp Met Asp Met Ile Arg Asp
 915 920 925
 Cys Ala Glu Lys Val Ala Ser His Trp Gln Gln Leu Met Leu Lys Met
 930 935 940
 Glu Asp Arg Leu Lys Leu Val Asn Ala Ser Val Ala Phe Tyr Lys Thr
 945 950 955 960
 Ser Glu Gln Val Cys Ser Val Leu Glu Ser Leu Glu Gln Glu Tyr Lys
 965 970 975
 Arg Glu Glu Asp Trp Cys Gly Gly Ala Asp Lys Leu Gly Pro Asn Ser
 980 985 990
 Glu Thr Asp His Val Thr Pro Met Ile Ser Lys His Leu Glu Gln Lys
 995 1000 1005
 Glu Ala Phe Leu Lys Ala Cys Thr Leu Ala Arg Arg Asn Ala Asp Val
 1010 1015 1020
 Phe Leu Lys Tyr Leu His Arg Asn Ser Val Asn Met Pro Gly Met Val
 1025 1030 1035 1040
 Thr His Ile Lys Ala Pro Glu Gln Gln Val Lys Asn Ile Leu Asn Glu
 1045 1050 1055
 Leu Phe Gln Arg Glu Asn Arg Val Leu His Tyr Trp Thr Met Arg Lys
 1060 1065 1070
 Arg Arg Leu Asp Gln Cys Gln Gln Tyr Val Val Phe Glu Arg Ser Ala
 1075 1080 1085
 Lys Gln Ala Leu Glu Trp Ile His Asp Asn Gly Glu Phe Tyr Leu Ser
 1090 1095 1100
 Thr His Thr Ser Thr Gly Ser Ser Ile Gln His Thr Gln Glu Leu Leu
 1105 1110 1115 1120
 Lys Glu His Glu Glu Phe Gln Ile Thr Ala Lys Gln Thr Lys Glu Arg
 1125 1130 1135
 Val Lys Leu Leu Ile Gln Leu Ala Asp Gly Phe Cys Glu Lys Gly His
 1140 1145 1150
 Ala His Ala Ala Glu Ile Lys Lys Cys Val Thr Ala Val Asp Lys Arg

032796-132.ST25

1155	1160	1165
Tyr Arg Asp Phe Ser Leu	Arg Met Glu Lys Tyr	Arg Thr Ser Leu Glu
1170	1175	1180
Lys Ala Leu Gly Ile Ser	Ser Asp Ser Asn Lys	Ser Ser Lys Ser Leu
1185	1190	1195
Gln Leu Asp Ile Ile	Pro Ala Ser Ile	Pro Gly Ser Glu Val Lys Leu
1205	1210	1215
Arg Asp Ala Ala His	Glu Leu Asn Glu Glu	Lys Arg Lys Ser Ala Arg
1220	1225	1230
Arg Lys Glu Phe Ile	Met Ala Glu Leu Ile	Gln Thr Glu Lys Ala Tyr
1235	1240	1245
Val Arg Asp Leu Arg	Glu Cys Met Asp Thr	Tyr Leu Trp Glu Met Thr
1250	1255	1260
Ser Gly Val Glu Glu	Ile Pro Pro Gly Ile	Val Asn Lys Glu Leu Ile
1265	1270	1275
Ile Phe Gly Asn Met	Gln Glu Ile Tyr	Glu Phe His Asn Asn Ile Phe
1285	1290	1295
Leu Lys Glu Leu Glu	Lys Tyr Glu Gln	Leu Pro Glu Asp Val Gly His
1300	1305	1310
Cys Phe Val Thr Trp	Ala Asp Lys Phe	Gln Met Tyr Val Thr Tyr Cys
1315	1320	1325
Lys Asn Lys Pro Asp	Ser Thr Gln Leu Ile	Leu Glu His Ala Gly Ser
1330	1335	1340
Tyr Phe Asp Glu Ile	Gln Gln Arg His	Gly Leu Ala Asn Ser Ile Ser
1345	1350	1355
Ser Tyr Leu Ile Lys	Pro Val Gln Arg	Ile Thr Lys Tyr Gln Leu Leu
1365	1370	1375
Leu Lys Glu Leu Leu	Thr Cys Cys Glu	Glu Gly Lys Gly Glu Ile Lys
1380	1385	1390
Asp Gly Leu Glu Val	Met Leu Ser Val	Pro Lys Arg Ala Asn Asp Ala
1395	1400	1405
Met His Leu Ser Met	Leu Glu Gly Phe	Asp Glu Asn Ile Glu Ser Gln
1410	1415	1420
Gly Glu Leu Ile Leu	Gln Glu Ser Phe	Gln Val Trp Asp Pro Lys Thr
1425	1430	1435
Leu Ile Arg Lys Gly	Arg Glu Arg His	Leu Phe Leu Phe Glu Met Ser
1445	1450	1455
Leu Val Phe Ser Lys	Glu Val Lys Asp	Ser Ser Gly Arg Ser Lys Tyr
1460	1465	1470
Leu Tyr Lys Ser Lys	Leu Phe Thr Ser	Glu Leu Gly Val Thr Glu His
1475	1480	1485
Val Glu Gly Asp Pro	Cys Lys Phe Ala	Leu Trp Val Gly Arg Thr Pro
1490	1495	1500
Thr Ser Asp Asn Lys	Ile Val Leu Lys	Ala Ser Ser Ile Glu Asn Lys
1505	1510	1515
Gln Asp Trp Ile Lys	His Ile Arg Glu	Val Ile Gln Glu Arg Thr Ile
1525	1530	1535
His Leu Lys Gly Ala	Leu Lys Glu Pro	Ile His Ile Pro Lys Thr Ala
1540	1545	1550
Pro Ala Thr Arg Gln	Lys Gly Arg Asp	Gly Glu Asp Leu Asp Ser
1555	1560	1565
Gln Gly Asp Gly Ser	Ser Gln Pro Asp	Thr Ile Ser Ile Ala Ser Arg
1570	1575	1580
Thr Ser Gln Asn Thr	Leu Asp Ser Asp	Lys Leu Ser Gly Gly Cys Glu
1585	1590	1595
Leu Thr Val Val Ile	His Asp Phe Thr	Ala Cys Asn Ser Asn Glu Leu
1605	1610	1615

032796-132.ST25

Thr Ile Arg Arg Gly Gln Thr Val Glu Val Leu Glu Arg Pro His Asp
 1620 1625 1630
 Lys Pro Asp Trp Cys Leu Val Arg Thr Thr Asp Arg Ser Pro Ala Ala
 1635 1640 1645
 Glu Gly Leu Val Pro Cys Gly Ser Leu Cys Ile Ala His Ser Arg Ser
 1650 1655 1660
 Ser Met Glu Met Glu Gly Ile Phe Asn His Lys Asp Ser Leu Ser Val
 1665 1670 1675 1680
 Ser Ser Asn Asp Ala Ser Pro Pro Ala Ser Val Ala Ser Leu Gln Pro
 1685 1690 1695
 His Met Ile Gly Ala Gln Ser Ser Pro Gly Pro Lys Arg Pro Gly Asn
 1700 1705 1710
 Thr Leu Arg Lys Trp Leu Thr Ser Pro Val Arg Arg Leu Ser Ser Gly
 1715 1720 1725
 Lys Ala Asp Gly His Val Lys Lys Leu Ala His Lys His Lys Lys Ser
 1730 1735 1740
 Arg Glu Val Arg Lys Ser Ala Asp Ala Gly Ser Gln Lys Asp Ser Asp
 1745 1750 1755 1760
 Asp Ser Ala Ala Thr Pro Gln Asp Glu Thr Val Glu Glu Arg Gly Arg
 1765 1770 1775
 Asn Glu Gly Leu Ser Ser Gly Thr Leu Ser Lys Ser Ser Ser Ser Gly
 1780 1785 1790
 Met Gln Ser Cys Gly Glu Glu Glu Gly Glu Glu Gly Ala Asp Ala Val
 1795 1800 1805
 Pro Leu Pro Pro Pro Met Ala Ile Gln Gln His Ser Leu Leu Gln Pro
 1810 1815 1820
 Asp Ser Gln Asp Asp Lys Ala Ser Ser Arg Leu Leu Val Arg Pro Thr
 1825 1830 1835 1840
 Ser Ser Glu Thr Pro Ser Ala Ala Glu Leu Val Ser Ala Ile Glu Glu
 1845 1850 1855
 Leu Val Lys Ser Lys Met Ala Leu Glu Asp Arg Pro Ser Ser Leu Leu
 1860 1865 1870
 Val Asp Gln Gly Asp Ser Ser Ser Pro Ser Phe Asn Pro Ser Asp Asn
 1875 1880 1885
 Ser Leu Leu Ser Ser Ser Ser Pro Ile Asp Glu Met Glu Glu Arg Lys
 1890 1895 1900
 Ser Ser Ser Leu Lys Arg Arg His Tyr Val Leu Gln Glu Leu Val Glu
 1905 1910 1915 1920
 Thr Glu Arg Asp Tyr Val Arg Asp Leu Gly Tyr Val Val Glu Gly Tyr
 1925 1930 1935
 Met Ala Leu Met Lys Glu Asp Gly Val Pro Asp Asp Met Lys Gly Lys
 1940 1945 1950
 Asp Lys Ile Val Phe Gly Asn Ile His Gln Ile Tyr Asp Trp His Arg
 1955 1960 1965
 Asp Phe Phe Leu Gly Glu Leu Glu Lys Cys Leu Glu Asp Pro Glu Lys
 1970 1975 1980
 Leu Gly Ser Leu Phe Val Lys His Glu Arg Arg Leu His Met Tyr Ile
 1985 1990 1995 2000
 Ala Tyr Cys Gln Asn Lys Pro Lys Ser Glu His Ile Val Ser Glu Tyr
 2005 2010 2015
 Ile Asp Thr Phe Glu Asp Leu Lys Gln Arg Leu Gly His Arg Leu
 2020 2025 2030
 Gln Leu Thr Asp Leu Leu Ile Lys Pro Val Gln Arg Ile Met Lys Tyr
 2035 2040 2045
 Gln Leu Leu Leu Lys Asp Phe Leu Lys Tyr Ser Lys Lys Ala Ser Leu
 2050 2055 2060
 Asp Thr Ser Glu Leu Glu Arg Ala Val Glu Val Met Cys Ile Val Pro

032796-132.ST25

2065	2070	2075	2080
Arg Arg Cys Asn Asp Met Met Asn Val Gly Arg Leu Gln Gly Phe Asp			
	2085	2090	2095
Gly Lys Ile Val Ala Gln Gly Lys Leu Leu Leu Gln Asp Thr Phe Leu			
	2100	2105	2110
Val Thr Asp Gln Asp Ala Gly Leu Leu Pro Arg Cys Arg Glu Arg Arg			
	2115	2120	2125
Ile Phe Leu Phe Glu Gln Ile Val Ile Phe Ser Glu Pro Leu Asp Lys			
	2130	2135	2140
Lys Lys Gly Phe Ser Met Pro Gly Phe Leu Phe Lys Asn Ser Ile Lys			
2145	2150	2155	2160
Val Ser Cys Leu Cys Leu Glu Glu Asn Val Glu Asn Asp Pro Cys Lys			
	2165	2170	2175
Phe Ala Leu Thr Ser Arg Thr Gly Asp Val Val Glu Thr Phe Ile Leu			
	2180	2185	2190
His Ser Ser Ser Pro Ser Val Arg Gln Thr Trp Ile His Glu Ile Asn			
	2195	2200	2205
Gln Ile Leu Glu Asn Gln Arg Asn Phe Leu Asn Ala Leu Thr Ser Pro			
	2210	2215	2220
Ile Glu Tyr Gln Arg Asn His Ser Gly Gly Gly Gly Gly Gly Ser			
2225	2230	2235	2240
Gly Ala Ala Ala Gly Val Gly Ala Ala Ala Ala Gly Pro Pro Val			
	2245	2250	2255
Ala Ala Ala Ala Thr Val Ala Ala Pro Ala Ala Ala Ala Ala Pro Pro			
	2260	2265	2270
Ala Arg Ala Gly Ala Gly Pro Pro Gly Ser Pro Ser Leu Ser Asp Thr			
	2275	2280	2285
Thr Pro Pro Cys Trp Ser Pro Leu Gln Pro Arg Ala Arg Gln Arg Gln			
	2290	2295	2300
Thr Arg Cys Gln Ser Glu Ser Ser Ser Ser Ser Asn Ile Ser Thr Met			
2305	2310	2315	2320
Leu Val Thr His Asp Tyr Thr Ala Val Lys Glu Asp Glu Ile Asn Val			
	2325	2330	2335
Tyr Gln Gly Glu Val Val Gln Ile Leu Ala Ser Asn Gln Gln Asn Met			
	2340	2345	2350
Phe Leu Val Phe Arg Ala Ala Thr Asp Gln Cys Pro Ala Ala Glu Gly			
	2355	2360	2365
Trp Ile Pro Gly Phe Val Leu Gly His Thr Ser Ala Val Ile Val Glu			
	2370	2375	2380
Asn Pro Asp Gly Thr Leu Lys Lys Ser Thr Ser Trp His Thr Ala Leu			
2385	2390	2395	2400
Arg Leu Arg Lys Lys Ser Glu Lys Lys Asp Lys Asp Gly Lys Arg Glu			
	2405	2410	2415
Gly Lys Leu Glu Asn Gly Tyr Arg Lys Ser Arg Glu Gly Leu Ser Asn			
	2420	2425	2430
Lys Val Ser Val Lys Leu Leu Asn Pro Asn Tyr Ile Tyr Asp Val Pro			
	2435	2440	2445
Pro Glu Phe Val Ile Pro Leu Ser Glu Val Thr Cys Glu Thr Gly Glu			
	2450	2455	2460
Thr Val Val Leu Arg Cys Arg Val Cys Gly Arg Pro Lys Ala Ser Ile			
2465	2470	2475	2480
Thr Trp Lys Gly Pro Glu His Asn Thr Leu Asn Asn Asp Gly His Tyr			
	2485	2490	2495
Ser Ile Ser Tyr Ser Asp Leu Gly Glu Ala Thr Leu Lys Ile Val Gly			
	2500	2505	2510
Val Thr Thr Glu Asp Asp Gly Ile Tyr Thr Cys Ile Ala Val Asn Asp			
	2515	2520	2525

032796-132.ST25

Met Gly Ser Ala Ser Ser Ser Ala Ser Leu Arg Val Leu Gly Pro Gly
 2530 2535 2540
 Met Asp Gly Ile Met Val Thr Trp Lys Asp Asn Phe Asp Ser Phe Tyr
 2545 2550 2555 2560
 Ser Glu Val Ala Glu Leu Gly Arg Gly Arg Phe Ser Val Val Lys Lys
 2565 2570 2575
 Cys Asp Gln Lys Gly Thr Lys Arg Ala Val Ala Thr Lys Phe Val Asn
 2580 2585 2590
 Lys Lys Leu Met Lys Arg Asp Gln Val Thr His Glu Leu Gly Ile Leu
 2595 2600 2605
 Gln Ser Leu Gln His Pro Leu Leu Val Gly Leu Leu Asp Thr Phe Glu
 2610 2615 2620
 Thr Pro Thr Ser Tyr Ile Leu Val Leu Glu Met Ala Asp Gln Gly Arg
 2625 2630 2635 2640
 Leu Leu Asp Cys Val Val Arg Trp Gly Ser Leu Thr Glu Gly Lys Ile
 2645 2650 2655
 Arg Ala His Leu Gly Glu Val Leu Glu Ala Val Arg Tyr Leu His Asn
 2660 2665 2670
 Cys Arg Ile Ala His Leu Asp Leu Lys Pro Glu Asn Ile Leu Val Asp
 2675 2680 2685
 Glu Ser Leu Ala Lys Pro Thr Ile Lys Leu Ala Asp Phe Gly Asp Ala
 2690 2695 2700
 Val Gln Leu Asn Thr Thr Tyr Tyr Ile His Gln Leu Leu Gly Asn Pro
 2705 2710 2715 2720
 Glu Phe Ala Ala Pro Glu Ile Ile Leu Gly Asn Pro Val Ser Leu Thr
 2725 2730 2735
 Ser Asp Thr Trp Ser Val Gly Val Leu Thr Tyr Val Leu Leu Ser Gly
 2740 2745 2750
 Val Ser Pro Phe Leu Asp Asp Ser Val Glu Glu Thr Cys Leu Asn Ile
 2755 2760 2765
 Cys Arg Leu Asp Phe Ser Phe Pro Asp Asp Tyr Phe Lys Gly Val Ser
 2770 2775 2780
 Gln Lys Ala Lys Glu Phe Val Cys Phe Leu Leu Gln Glu Asp Pro Ala
 2785 2790 2795 2800
 Lys Arg Pro Ser Ala Ala Leu Ala Leu Gln Glu Gln Trp Leu Gln Ala
 2805 2810 2815
 Gly Asn Gly Arg Ser Thr Gly Val Leu Asp Thr Ser Arg Leu Thr Ser
 2820 2825 2830
 Phe Ile Glu Arg Arg Lys His Gln Asn Asp Val Arg Pro Ile Arg Ser
 2835 2840 2845
 Ile Lys Asn Phe Leu Gln Ser Arg Leu Leu Pro Arg Val
 2850 2855 2860

<210> 109

<211> 271

<212> PRT

<213> Homo sapiens

<400> 109

Met Val Leu Ile Lys Glu Phe Arg Val Val Leu Pro Cys Ser Val Gln
 1 5 10 15
 Glu Tyr Gln Val Gly Gln Leu Tyr Ser Val Ala Glu Ala Ser Lys Asn
 20 25 30
 Glu Thr Gly Gly Gly Glu Gly Ile Glu Val Leu Lys Asn Glu Pro Tyr
 35 40 45
 Glu Lys Asp Gly Glu Lys Gly Gln Tyr Thr His Lys Ile Tyr His Leu
 50 55 60

032796-132.ST25

Lys Ser Lys Val Pro Ala Phe Val Arg Met Ile Ala Pro Glu Gly Ser
 65 70 75 80
 Leu Val Phe His Glu Lys Ala Trp Asn Ala Tyr Pro Tyr Cys Arg Thr
 85 90 95
 Ile Val Thr Asn Glu Tyr Met Lys Asp Phe Phe Ile Lys Ile Glu
 100 105 110
 Thr Trp His Lys Pro Asp Leu Gly Thr Leu Glu Asn Val His Gly Leu
 115 120 125
 Asp Pro Asn Thr Trp Lys Thr Val Glu Ile Val His Ile Asp Ile Ala
 130 135 140
 Asp Arg Ser Gln Val Glu Pro Ala Asp Tyr Lys Ala Asp Glu Asp Pro
 145 150 155 160
 Ala Leu Phe Gln Ser Val Lys Thr Lys Arg Gly Pro Leu Gly Pro Asn
 165 170 175
 Trp Lys Lys Glu Leu Ala Asn Ser Pro Asp Cys Pro Gln Met Cys Ala
 180 185 190
 Tyr Lys Leu Val Thr Ile Lys Phe Lys Trp Trp Gly Leu Gln Ser Lys
 195 200 205
 Val Glu Asn Phe Ile Gln Lys Gln Glu Lys Arg Ile Phe Thr Asn Phe
 210 215 220
 His Arg Gln Leu Phe Cys Trp Ile Asp Lys Trp Ile Asp Leu Thr Met
 225 230 235 240
 Glu Asp Ile Arg Arg Met Glu Asp Glu Thr Gln Lys Glu Leu Glu Thr
 245 250 255
 Met Arg Lys Arg Gly Ser Val Arg Gly Thr Ser Ala Ala Asp Val
 260 265 270

<210> 110

<211> 233

<212> PRT

<213> Homo sapiens

<400> 110

Asn Ser Val Leu Asn Ser Asn Ala Ile Lys Asn Leu Pro Pro Pro Leu
 1 5 10 15
 Gly Gly Ala Ala Gly His Pro Gly Ser Ala Val Ser Ala Ala Pro Gly
 20 25 30
 Ile Leu Tyr Pro Gly Gly Asn Lys Tyr Gln Thr Ile Asp Asn Tyr Gln
 35 40 45
 Pro Tyr Pro Cys Ala Glu Asp Glu Glu Cys Gly Thr Asp Glu Tyr Cys
 50 55 60
 Ala Ser Pro Thr Arg Gly Gly Asp Ala Gly Val Gln Ile Cys Leu Ala
 65 70 75 80
 Cys Arg Lys Arg Arg Lys Arg Cys Met Arg His Ala Met Cys Cys Pro
 85 90 95
 Gly Asn Tyr Cys Lys Asn Gly Ile Cys Val Ser Ser Asp Gln Asn His
 100 105 110
 Phe Arg Gly Glu Ile Glu Glu Thr Ile Thr Glu Ser Phe Gly Asn Asp
 115 120 125
 His Ser Thr Leu Asp Gly Tyr Ser Arg Arg Thr Thr Leu Ser Ser Lys
 130 135 140
 Met Tyr His Thr Lys Gly Gln Glu Gly Ser Val Cys Leu Arg Ser Ser
 145 150 155 160
 Asp Cys Ala Ser Gly Leu Cys Cys Ala Arg His Phe Trp Ser Lys Ile
 165 170 175
 Cys Lys Pro Val Leu Lys Glu Gly Gln Val Cys Thr Lys His Arg Arg
 180 185 190

032796-132.ST25

Lys Gly Ser His Gly Leu Glu Ile Phe Gln Arg Cys Tyr Cys Gly Glu
 195 200 205
 Gly Leu Ser Cys Arg Ile Gln Lys Asp His His Gln Ala Ser Asn Ser
 210 215 220
 Ser Arg Leu His Thr Cys Gln Arg His
 225 230

<210> 111
 <211> 212
 <212> PRT
 <213> Homo sapiens

<400> 111
 Asn Ser Val Leu Asn Ser Asn Ala Ile Lys Asn Leu Pro Pro Pro Leu
 1 5 10 15
 Gly Gly Ala Ala Gly His Pro Gly Ser Ala Val Ser Ala Ala Pro Gly
 20 25 30
 Ile Leu Tyr Pro Gly Gly Asn Lys Tyr Gln Thr Ile Asp Asn Tyr Gln
 35 40 45
 Pro Tyr Pro Cys Ala Glu Asp Glu Glu Cys Gly Thr Asp Glu Tyr Cys
 50 55 60
 Ala Ser Pro Thr Arg Gly Gly Asp Ala Gly Val Gln Ile Cys Leu Ala
 65 70 75 80
 Cys Arg Lys Arg Arg Lys Arg Cys Met Arg His Ala Met Cys Cys Pro
 85 90 95
 Gly Asn Tyr Cys Lys Asn Gly Ile Cys Val Ser Ser Asp Gln Asn His
 100 105 110
 Phe Arg Gly Glu Ile Glu Glu Thr Ile Thr Glu Ser Phe Gly Asn Asp
 115 120 125
 His Ser Thr Leu Asp Gly Tyr Ser Arg Arg Thr Thr Leu Ser Ser Lys
 130 135 140
 Met Tyr His Thr Lys Gly Gln Glu Gly Ser Val Cys Leu Arg Ser Ser
 145 150 155 160
 Asp Cys Ala Ser Gly Leu Cys Cys Ala Arg His Phe Trp Ser Lys Ile
 165 170 175
 Cys Lys Pro Val Leu Lys Glu Gly Gln Val Cys Thr Lys His Arg Arg
 180 185 190
 Lys Gly Ser His Gly Leu Glu Ile Phe Gln Arg Cys Tyr Cys Gly Glu
 195 200 205
 Gly Leu Ser Cys
 210

<210> 112
 <211> 149
 <212> PRT
 <213> Homo sapiens

<400> 112
 Asn Ser Val Leu Asn Ser Asn Ala Ile Lys Asn Leu Pro Pro Pro Leu
 1 5 10 15
 Gly Gly Ala Ala Gly His Pro Gly Ser Ala Val Ser Ala Ala Pro Gly
 20 25 30
 Ile Leu Tyr Pro Gly Gly Asn Lys Tyr Gln Thr Ile Asp Asn Tyr Gln
 35 40 45
 Pro Tyr Pro Cys Ala Glu Asp Glu Glu Cys Gly Thr Asp Glu Tyr Cys

032796-132.ST25

```

      50              55              60
Ala Ser Pro Thr Arg Gly Gly Asp Ala Gly Val Gln Ile Cys Leu Ala
65              70              75              80
Cys Arg Lys Arg Arg Lys Arg Cys Met Arg His Ala Met Cys Cys Pro
      85              90              95
Gly Asn Tyr Cys Lys Asn Gly Ile Cys Val Ser Ser Asp Gln Asn His
      100             105             110
Phe Arg Gly Glu Ile Glu Glu Thr Ile Thr Glu Ser Phe Gly Asn Asp
      115             120             125
His Ser Thr Leu Asp Gly Tyr Ser Arg Arg Thr Thr Leu Ser Ser Lys
      130             135             140
Met Tyr His Thr Lys
145

```

```

<210> 113
<211> 170
<212> PRT
<213> Homo sapiens

```

```

<400> 113
Cys Ala Ser Pro Thr Arg Gly Gly Asp Ala Gly Val Gln Ile Cys Leu
1      5      10      15
Ala Cys Arg Lys Arg Arg Lys Arg Cys Met Arg His Ala Met Cys Cys
      20      25      30
Pro Gly Asn Tyr Cys Lys Asn Gly Ile Cys Val Ser Ser Asp Gln Asn
      35      40      45
His Phe Arg Gly Glu Ile Glu Glu Thr Ile Thr Glu Ser Phe Gly Asn
      50      55      60
Asp His Ser Thr Leu Asp Gly Tyr Ser Arg Arg Thr Thr Leu Ser Ser
65      70      75      80
Lys Met Tyr His Thr Lys Gly Gln Glu Gly Ser Val Cys Leu Arg Ser
      85      90      95
Ser Asp Cys Ala Ser Gly Leu Cys Cys Ala Arg His Phe Trp Ser Lys
      100     105     110
Ile Cys Lys Pro Val Leu Lys Glu Gly Gln Val Cys Thr Lys His Arg
      115     120     125
Arg Lys Gly Ser His Gly Leu Glu Ile Phe Gln Arg Cys Tyr Cys Gly
      130     135     140
Glu Gly Leu Ser Cys Arg Ile Gln Lys Asp His His Gln Ala Ser Asn
145     150     155     160
Ser Ser Arg Leu His Thr Cys Gln Arg His
      165     170

```

```

<210> 114
<211> 128
<212> PRT
<213> Homo sapiens

```

```

<400> 114
Val Ser Ser Asp Gln Asn His Phe Arg Gly Glu Ile Glu Glu Thr Ile
1      5      10      15
Thr Glu Ser Phe Gly Asn Asp His Ser Thr Leu Asp Gly Tyr Ser Arg
      20      25      30
Arg Thr Thr Leu Ser Ser Lys Met Tyr His Thr Lys Gly Gln Glu Gly
      35      40      45

```

032796-132.ST25

```

Ser Val Cys Leu Arg Ser Ser Asp Cys Ala Ser Gly Leu Cys Cys Ala
 50          55          60
Arg His Phe Trp Ser Lys Ile Cys Lys Pro Val Leu Lys Glu Gly Gln
65          70          75          80
Val Cys Thr Lys His Arg Arg Lys Gly Ser His Gly Leu Glu Ile Phe
          85          90          95
Gln Arg Cys Tyr Cys Gly Glu Gly Leu Ser Cys Arg Ile Gln Lys Asp
          100          105          110
His His Gln Ala Ser Asn Ser Ser Arg Leu His Thr Cys Gln Arg His
          115          120          125

```

<210> 115

<211> 84

<212> PRT

<213> Homo sapiens

<400> 115

```

Gly Gln Glu Gly Ser Val Cys Leu Arg Ser Ser Asp Cys Ala Ser Gly
 1          5          10          15
Leu Cys Cys Ala Arg His Phe Trp Ser Lys Ile Cys Lys Pro Val Leu
          20          25          30
Lys Glu Gly Gln Val Cys Thr Lys His Arg Arg Lys Gly Ser His Gly
          35          40          45
Leu Glu Ile Phe Gln Arg Cys Tyr Cys Gly Glu Gly Leu Ser Cys Arg
          50          55          60
Ile Gln Lys Asp His His Gln Ala Ser Asn Ser Ser Arg Leu His Thr
65          70          75          80
Cys Gln Arg His

```

<210> 116

<211> 149

<212> PRT

<213> Homo sapiens

<400> 116

```

Cys Ala Ser Pro Thr Arg Gly Gly Asp Ala Gly Val Gln Ile Cys Leu
 1          5          10          15
Ala Cys Arg Lys Arg Arg Lys Arg Cys Met Arg His Ala Met Cys Cys
          20          25          30
Pro Gly Asn Tyr Cys Lys Asn Gly Ile Cys Val Ser Ser Asp Gln Asn
          35          40          45
His Phe Arg Gly Glu Ile Glu Glu Thr Ile Thr Glu Ser Phe Gly Asn
          50          55          60
Asp His Ser Thr Leu Asp Gly Tyr Ser Arg Arg Thr Thr Leu Ser Ser
65          70          75          80
Lys Met Tyr His Thr Lys Gly Gln Glu Gly Ser Val Cys Leu Arg Ser
          85          90          95
Ser Asp Cys Ala Ser Gly Leu Cys Cys Ala Arg His Phe Trp Ser Lys
          100          105          110
Ile Cys Lys Pro Val Leu Lys Glu Gly Gln Val Cys Thr Lys His Arg
          115          120          125
Arg Lys Gly Ser His Gly Leu Glu Ile Phe Gln Arg Cys Tyr Cys Gly
          130          135          140
Glu Gly Leu Ser Cys
145

```

032796-132.ST25

<210> 117
 <211> 107
 <212> PRT
 <213> Homo sapiens

<400> 117
 Val Ser Ser Asp Gln Asn His Phe Arg Gly Glu Ile Glu Glu Thr Ile
 1 5 10 15
 Thr Glu Ser Phe Gly Asn Asp His Ser Thr Leu Asp Gly Tyr Ser Arg
 20 25 30
 Arg Thr Thr Leu Ser Ser Lys Met Tyr His Thr Lys Gly Gln Glu Gly
 35 40 45
 Ser Val Cys Leu Arg Ser Ser Asp Cys Ala Ser Gly Leu Cys Cys Ala
 50 55 60
 Arg His Phe Trp Ser Lys Ile Cys Lys Pro Val Leu Lys Glu Gly Gln
 65 70 75 80
 Val Cys Thr Lys His Arg Arg Lys Gly Ser His Gly Leu Glu Ile Phe
 85 90 95
 Gln Arg Cys Tyr Cys Gly Glu Gly Leu Ser Cys
 100 105

<210> 118
 <211> 15
 <212> PRT
 <213> Homo sapiens

<400> 118
 Gly Asn Lys Tyr Gln Thr Ile Asp Asn Tyr Gln Pro Tyr Pro Cys
 1 5 10 15

<210> 119
 <211> 22
 <212> PRT
 <213> Homo sapiens

<400> 119
 Leu Asp Gly Tyr Ser Arg Arg Thr Thr Leu Ser Ser Lys Met Tyr His
 1 5 10 15
 Thr Lys Gly Gln Glu Gly
 20

<210> 120
 <211> 21
 <212> PRT
 <213> Homo sapiens

<400> 120
 Arg Ile Gln Lys Asp His His Gln Ala Ser Asn Ser Ser Arg Leu His
 1 5 10 15
 Thr Cys Gln Arg His
 20

032796-132.ST25

<210> 121
<211> 15
<212> PRT
<213> Homo sapiens

<400> 121
Arg Gly Glu Ile Glu Glu Thr Ile Thr Glu Ser Phe Gly Asn Asp
1 5 10 15

<210> 122
<211> 19
<212> PRT
<213> Homo sapiens

<400> 122
Glu Ile Phe Gln Arg Cys Tyr Cys Gly Glu Gly Leu Ser Cys Arg Ile
1 5 10 15
Gln Lys Asp

<210> 123
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> LRP5/HBM amino acid sequence

<400> 123
Met Tyr Trp Thr Asp Trp Val Glu Thr Pro Arg Ile Glu
1 5 10

<210> 124
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> LRP5/HBM amino acid sequence

<400> 124
Met Tyr Trp Thr Asp Trp Gly Glu Thr Pro Arg Ile Glu
1 5 10

<210> 125
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> LRP5/HBM amino acid sequence

032796-132.ST25

<400> 125

Lys Arg Thr Gly Gly Lys Arg Lys Glu Ile Leu Ser Ala
 1 5 10

<210> 126

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> LRP5/HBM amino acid sequence

<400> 126

Glu Arg Val Glu Lys Thr Thr Gly Asp Lys Arg Thr Arg Ile Gln Gly
 1 5 10 15
 Arg

<210> 127

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> LRP5/HBM amino acid sequence

<400> 127

Lys Gln Gln Cys Asp Ser Phe Pro Asp Cys Ile Asp Gly Ser Asp Glu
 1 5 10 15

<210> 128

<211> 266

<212> PRT

<213> Homo sapiens

<400> 128

Met Met Ala Leu Gly Ala Ala Gly Ala Thr Arg Val Phe Val Ala Met
 1 5 10 15
 Val Ala Ala Ala Leu Gly Gly His Pro Leu Leu Gly Val Ser Ala Thr
 20 25 30
 Leu Asn Ser Val Leu Asn Ser Asn Ala Ile Lys Asn Leu Pro Pro Pro
 35 40 45
 Leu Gly Gly Ala Ala Gly His Pro Gly Ser Ala Val Ser Ala Ala Pro
 50 55 60
 Gly Ile Leu Tyr Pro Gly Gly Asn Lys Tyr Gln Thr Ile Asp Asn Tyr
 65 70 75 80
 Gln Pro Tyr Pro Cys Ala Glu Asp Glu Glu Cys Gly Thr Asp Glu Tyr
 85 90 95
 Cys Ala Ser Pro Thr Arg Gly Gly Asp Ala Gly Val Gln Ile Cys Leu
 100 105 110
 Ala Cys Arg Lys Arg Arg Lys Arg Cys Met Arg His Ala Met Cys Cys
 115 120 125
 Pro Gly Asn Tyr Cys Lys Asn Gly Ile Cys Val Ser Ser Asp Gln Asn
 130 135 140

032796-132.ST25

```

His Phe Arg Gly Glu Ile Glu Glu Thr Ile Thr Glu Ser Phe Gly Asn
145                150                155                160
Asp His Ser Thr Leu Asp Gly Tyr Ser Arg Arg Thr Thr Leu Ser Ser
                165                170                175
Lys Met Tyr His Thr Lys Gly Gln Glu Gly Ser Val Cys Leu Arg Ser
                180                185                190
Ser Asp Cys Ala Ser Gly Leu Cys Cys Ala Arg His Phe Trp Ser Lys
                195                200                205
Ile Cys Lys Pro Val Leu Lys Glu Gly Gln Val Cys Thr Lys His Arg
                210                215                220
Arg Lys Gly Ser His Gly Leu Glu Ile Phe Gln Arg Cys Tyr Cys Gly
225                230                235                240
Glu Gly Leu Ser Cys Arg Ile Gln Lys Asp His His Gln Ala Ser Asn
                245                250                255
Ser Ser Arg Leu His Thr Cys Gln Arg His
                260                265

```

<210> 129
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> complementary synthetic oligonucleotide

<400> 129
 tggtcagcgg cctggaggat gtggccgcag tggacttcc 39

<210> 130
 <211> 39
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> complementary synthetic oligonucleotide

<400> 130.
 ggaagtccac tgcggccaca tcctccaggc cgctgacca 39

<210> 131
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> complementary synthetic oligonucleotide

<400> 131
 aagctgtact ggacggactc agtgaccaac cgcacgcagg 40

<210> 132
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> complementary synthetic oligonucleotide

032796-132.ST25

<400> 132
cctcgatgcg gttggtcact gagtccgtcc agtacagctt 40

<210> 133
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide

<400> 133
atgtactgga cagactggaa ggagacgccc cggtattgagc g 41

<210> 134
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide

<400> 134
cgctcaatcc ggggcgtctc cttccagtct gtccagtaca t 41

<210> 135
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide

<400> 135
atgtactgga cagactgggtt tgagacgccc cggtattgagc g 41

<210> 136
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide

<400> 136
cgctcaatcc ggggcgtctc aaaccagtct gtccagtaca t 41

<210> 137
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide

<400> 137

032796-132.ST25

atgtactgga cagactggat tgagacgccc cggattgagc g 41

<210> 138
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide
<400> 138
cgctcaatcc ggggcgtctc aatccagtct gtccagtaca t 41

<210> 139
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide
<400> 139
atgtactgga cagactggca ggagacgccc cggattgagc g 41

<210> 140
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide
<400> 140
cgctcaatcc ggggcgtctc ctgccagtct gtccagtaca t 41

<210> 141
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide
<400> 141
cggacattta ctggcccaat gtactgacca tcgacctgga gg 42

<210> 142
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide
<400> 142
cctccagggtc gatggtcagt acattggggc agtaaattgc cg 42

<210> 143

032796-132.ST25

<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide

<400> 143
agctctactg ggctgacgtc aagctcagct tcatccaccg 40

<210> 144
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide

<400> 144
cggtggatga agctgagctt gacgtcagcc cagtagagct 40

<210> 145
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide

<400> 145
gagtgccctc tactcaccg tggacatcca ggtgctgagc c 41

<210> 146
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide

<400> 146
ggctcagcac ctggatgtcc acgggtgagt agagggcact c 41

<210> 147
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide

<400> 147
catgtactgg acagactggg tagagaaccc taaaatcgag tgtgc 45

<210> 148
<211> 45
<212> DNA
<213> Artificial Sequence

032796-132.ST25

<220>
<223> complementary synthetic oligonucleotide

<400> 148
gcacactcga ttttaggggt ctctaccag tctgtccagt acatg 45

<210> 149
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide

<400> 149
catctactgg accgagtggg tcggcaagcc gaggatcgtg cg 42

<210> 150
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide

<400> 150
cgcacgatcc tcggcttgcc gaccactcg gtccagtaga tg 42

<210> 151
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide

<400> 151
gtacttcacc aacatggtgg accgggcagc caagatcgaa cg 42

<210> 152
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> complementary synthetic oligonucleotide

<400> 152
cgttcgatct tggctgcccg gtccaccatg ttggtgaagt ac 42

<210> 153
<211> 42
<212> DNA
<213> Artificial Sequence

<220>

032796-132.ST25

<223> complementary synthetic oligonucleotide

<400> 153

gtactggaca gactgggtag aagtgccaaa gatagaacgt gc

42

<210> 154

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> complementary synthetic oligonucleotide

<400> 154

gcacgttcta tctttggcac ttctaccag tctgtccagt ac

42

<210> 155

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 155

ttttttgtcg accaattcca acgctatcaa g

31

<210> 156

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 156

ttttttgtcg acctgcgcta gtcccacccg c

31

<210> 157

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 157

ttttttgtcg accgtgtctt ctgatcaaaa tc

32

<210> 158

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

032796-132.ST25

<400> 158
ttttttgtcg accggacaag aaggttctgt ttg 33

<210> 159
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 159
ttttttgcgg ccgcttattt ggtgtgatac atttttg 37

<210> 160
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 160
ttttttgcgg ccgcttagca agacagacct tctcc 35

<210> 161
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 161
ttttttgcgg ccgcttagtg tctctgacaa gtgtg 35

<210> 162
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 162
cagtgaattc accatgcaaa acaccacttt gttc 34

<210> 163
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 163
cagttgcggc cgctcatctc cgggtggcctc tg 32

032796-132.ST25

<210> 164
 <211> 39
 <212> DNA
 <213> Homo sapiens

<220>
 <223> primer

<400> 164
 caatagtcga cgaattcacc atggctctgg gcgcagcgg 39

<210> 165
 <211> 42
 <212> DNA
 <213> Homo sapiens

<220>
 <223> primer

<400> 165
 gtattgcggc cgctctagat tagtgtctct gacaagtgtg aa 42

<210> 166
 <211> 32
 <212> DNA
 <213> Homo sapiens

<220>
 <223> primer

<400> 166
 ctaacggatc caccatggcc gcgttgatgc gg 32

<210> 167
 <211> 33
 <212> DNA
 <213> Homo sapiens

<220>
 <223> primer

<400> 167
 gattcgaatt ctcaaatttt ctgacacaca tgg 33

<210> 168
 <211> 690
 <212> DNA
 <213> Homo sapiens

<400> 168
 aattccaacg ctatcaagaa cctgccccca ccgctgggcg gcgctgcggg gcacccaggc 60
 tctgcagtca gcgcccgcgc ggaatcctg taccggggcg ggaataagta ccagaccatt 120
 gacaactacc agccgtaccc gtgcgcagag gacgaggagt gcggcactga tgagtactgc 180
 gctagtccca cccgcggagg ggacgcgggc gtgcaaact gtctcgctg caggaagcgc 240
 cgaaaacgct gcatgcgtca cgctatgtgc tgccccggga attactgcaa aaatggaata 300
 tgtgtgtctt ctgatcaaaa tcatttccga ggagaaattg aggaaaccat cactgaaagc 360
 tttggtaatg atcatagcac cttggatggg tattccagaa gaaccacctt gtcttcaaaa 420

032796-132.ST25

```

atgtatcaca ccaaaggaca agaaggttct gtttgtctcc ggtcatcaga ctgtgcctca 480
ggatttgtgt gtgctagaca cttctgggcc aagatctgta aacctgtcct gaaagaaggt 540
caagtgtgta ccaagcatag gagaaaaggc tctcatggac tagaaatatt ccagcgttgt 600
tactgtggag aaggtctgtc ttgccggata cagaaagatc accatcaagc cagtaattct 660
tctaggcttc acacttgtca gagacactaa                               690

```

<210> 169

<211> 1226

<212> DNA

<213> Homo sapiens

<400> 169

```

ctcatctgac ccctgcatgg actgaggaac gtcaaagcca tcgactatga cccactggac 60
aagttcatct actgggtgga tgggcgccag aacatcaagc gagccaagga cgacgggacc 120
cagccctttg ttttgacctc tctgagccaa ggccaaaacc cagacaggca gccccacgac 180
ctcagcatcg acatctacag ccggacactg ttctggacgt gcgaggccac caataccatc 240
aacgtccaca ggctgagcgg ggaagccatg ggggtggtgc tgcgtgggga ccgcgacaag 300
cccagggccca tcgtcgtcaa cgcggagcga ggggtacctg acttcaccaa catgcaggac 360
cgggcagcca agatcgaacg cgcagccctg gacggcaccg agcgcgaggt cctcttcacc 420
accggcctca tccgccctgt ggccctgggt gtagacaaca cactgggcaa gctgttctgg 480
gtggagcggg acctgaagcg cattgagagc tgtgacctgt caggggcca cccgctgacc 540
ctggaggacg ccaacatcgt gcagcctctg ggcctgacca tccttgcaa gcatctctac 600
tggatcgacc gccagcagca gatgatcgag cgtgtggaga agaccaccgg ggacaagcgg 660
actcgcatcc agggcctgtg cgcacacctc actggcatcc atgcagtggg ggaagtcagc 720
ctggaggagt tctcagccca cccatgtgcc cgtgacaatg gtggctgctc ccacatctgt 780
attgccaaag gtgatgggac accacggtgc tcatgccag tccacctcgt gtcctgcag 840
aacctgctga cctgtggaga gccgccacc tgcctcccgg accagtttgc atgtgccaca 900
ggggagatcg actgtatccc cggggcctgg cgtgtgacg gctttcccga gtgcgatgac 960
cagagcgacg aggagggctg ccccgctgtg tccgcgcgcc agttcccctg cgcgcggggg 1020
cagtgtggtg gacctgcgcc tgcgtgcga cggcgaggca gactgtcagg accgctcaga 1080
cgaggcggac tgtgacgcca tctgcctgcc caaccagttc cgggtgtgca gcggccagt 1140
tgtcctcatc aaacagccag tgcgactcct tccccgactg tatcgacggc tccgacgagc 1200
tcatgtgtga aatcaccaag ccgccc                               1226

```

<210> 170

<211> 934

<212> DNA

<213> Homo sapiens

<400> 170

```

agggccatcg tcgtcaacgc ggagcgaggg tacctgtact tcaccaacat gcaggaccgg 60
gcagccaaga tcgaacgcgc agccctggac ggcaccgagc gcgaggtcct cttcaccacc 120
ggcctcatcc gccctgtggc cctggtggtg gacaacacac tgggcaagct gttctgggtg 180
gacgcggacc tgaagcgcac tgagagctgt gacctgtcag gggccaaccg cctgaccctg 240
gaggacgcca acatcgtgca gcctctgggc ctgaccatcc ttggcaagca tctctactgg 300
atcgaccgcc agcagcagat gatcgagcgt gtggagaaga ccaccgggga caagcggact 360
cgcattccagg gccgtgtgcg ccacctcact ggcattccatg cagtggagga agtcagcctg 420
gaggagtctc cagcccaccc atgtgcccgt gacaatggtg gctgctccca catctgtatt 480
gccaagggtg atgggacacc acggtgtcga tgcccagtc acctcgtgct cctgcagaac 540
ctgctgacct gtggagagcc gccacacctg tccccggacc agtttgcatg tgccacaggg 600
gagatcgact gtatccccgg ggccctggcg tgtgacggct ttcccagtg cgatgaccag 660
agcagcaggg aggggtgccg cgtgtgcctc cgccgcccag ttcccctgcg cgcgggggtc 720
gtgtgtggac cctgcgcctg cgtgcgacgg cgaggcagac tgtcaggacc gctcagacga 780
ggcggactgt gacgccatct ggccctgccc accagttccg gtgtgcgagc ggccagtgtg 840
tcctcatcaa acagcagtg gactccttcc ccgactgtat cgacggctcc gacgagctca 900
tgtgtgaaat caccaagccg ccctaagcgg ccgc                               934

```

032796-132.ST25

<210> 171
<211> 16
<212> PRT
<213> Homo sapiens

<400> 171
Ser Val Gly Cys Leu Leu Cys Ala Gly Leu Gly Val Trp Ser Leu Ser
1 5 10 15

<210> 172
<211> 19
<212> PRT
<213> Homo sapiens

<400> 172
Trp Cys Cys Cys Gly Leu Phe Arg Gly Val Cys Val Trp Ser Cys Gly
1 5 10 15
Ala Asp Asp

<210> 173
<211> 16
<212> PRT
<213> Homo sapiens

<400> 173
Gly Trp Arg Arg Cys Asp Trp Cys Gly Cys Val Ser Trp Cys Trp Val
1 5 10 15

<210> 174
<211> 32
<212> PRT
<213> Homo sapiens

<400> 174
Met Pro Gly Ser Val Ser His Cys Trp Gly Gly Ile Cys Glu Ala Leu
1 5 10 15
Ser Cys Cys Ala Val Asp Val Cys Leu Arg Cys Gly Gly Trp Phe Arg
20 25 30

<210> 175
<211> 16
<212> PRT
<213> Homo sapiens

<400> 175
Ser Cys Cys Ala Val Asp Val Cys Leu Arg Cys Gly Gly Trp Phe Arg
1 5 10 15

<210> 176
<211> 16
<212> PRT

032796-132.ST25

<213> Homo sapiens

<400> 176

Ser Val Leu Gly Thr Cys Cys Cys Cys Gly Gly Trp Ile Leu Cys Glu
1 5 10 15

<210> 177

<211> 16

<212> PRT

<213> Homo sapiens

<400> 177

Val Leu Ser Val Cys Glu Val Cys Gly Gly Val Phe Val Arg Arg Cys
1 5 10 15

<210> 178

<211> 15

<212> PRT

<213> Homo sapiens

<400> 178

Gly Met Trp Tyr Trp Ser Gly Arg Asp Cys Ala Leu Cys Trp Leu
1 5 10 15

<210> 179

<211> 16

<212> PRT

<213> Homo sapiens

<400> 179

Cys Thr Ala Val Met Trp Gly Val Gly Ser Val Ala Tyr Leu Gly Glu
1 5 10 15

<210> 180

<211> 13

<212> PRT

<213> Homo sapiens

<400> 180

Val Val Cys Trp Trp Cys Gly Cys Arg Gly Trp Trp Arg
1 5 10

<210> 181

<211> 16

<212> PRT

<213> Homo sapiens

<400> 181

Cys Val Cys Ala Ser Phe Cys Cys Cys Val Cys Gly Leu Arg Leu Leu
1 5 10 15

032796-132.ST25

<210> 182
<211> 16
<212> PRT
<213> Homo sapiens

<400> 182
Thr Tyr Glu Val Cys Glu Glu Cys Gly Gly Arg Val Arg Met Trp Val
1 5 10 15

<210> 183
<211> 16
<212> PRT
<213> Homo sapiens

<400> 183
Val Val Val Cys Ala Ser Cys Gly Gln Val Trp His Gly Ser Gly Ala
1 5 10 15

<210> 184
<211> 16
<212> PRT
<213> Homo sapiens

<400> 184
Cys Cys Arg Cys Cys His Cys Trp Asp Cys Glu Trp His Met Cys Val
1 5 10 15

<210> 185
<211> 16
<212> PRT
<213> Homo sapiens

<400> 185
Phe Cys Ala Ser Cys Cys Trp Cys Gly Cys Asp Cys Phe Gly Trp Val
1 5 10 15

<210> 186
<211> 16
<212> PRT
<213> Homo sapiens

<400> 186
Cys Asp Tyr Cys Trp Ser Cys Gly Val Trp Cys Pro Ser Ser Trp Leu
1 5 10 15

<210> 187
<211> 16
<212> PRT
<213> Homo sapiens

<400> 187
Val Tyr Leu Cys Val Trp Cys Gly Ala Ala Arg Phe Gly Cys Tyr Gly

032796-132.ST25

1 5 10 15

<210> 188
<211> 16
<212> PRT
<213> Homo sapiens

<400> 188
Phe Cys Val Cys Gly Cys Cys Trp Cys Trp Cys Ala Ala Cys Trp Cys
1 5 10 15

<210> 189
<211> 16
<212> PRT
<213> Homo sapiens

<400> 189
Val Val Leu Cys Ser Arg Cys Gly Arg Leu Trp Arg Trp Ser Cys Gly
1 5 10 15

<210> 190
<211> 16
<212> PRT
<213> Homo sapiens

<400> 190
Glu Val Arg Gln Val Thr Cys Ile Arg Cys Arg Arg Gly Phe Leu Leu
1 5 10 15

<210> 191
<211> 15
<212> PRT
<213> Homo sapiens

<400> 191
Gly Gly Gly Gly Met Trp Glu Ala Trp Ser Cys Tyr Ala Cys Gly
1 5 10 15

<210> 192
<211> 16
<212> PRT
<213> Homo sapiens

<400> 192
Gly Trp Arg Trp Cys Gly Arg Cys Gly Ala Leu Trp Trp Arg Arg Val
1 5 10 15

<210> 193
<211> 485
<212> DNA
<213> Homo sapiens

032796-132.ST25

<400> 193

```

aagcttgcca ccatggagac agacacactc ctgctatggg tactgctgct ctgggttcca 60
ggttccactg gtgacggatc catgagcgat aaaattattc acctgactga cgacagtttt 120
gacacggatg tactcaaagc ggacggggcg atcctcgtcg atttctgggc agagtgggtg 180
ggtccgaatt ccgtggttct gtgttcgcgt tgtgggcgtt tgtggcgggtg gtcgtgtggg 240
actagtggtc cgtgcaaaa actgaacatc attctggatg aaatcgctga cgaatatcag 300
ggcaaaactga ccgttgcaaa actgaacatc gatcaaaacc ctggcactgc gccgaaatat 360
ggcatccgtg gtatcccgac tctgctgctg ttcaaaaacg gtgaagtggc ggcaacccaa 420
gtgggtgcac tgtctaaagg tcagttgaaa gagttcctcg acgctaacct ggcgtaagcg 480
gccgc

```

<210> 194

<211> 485

<212> DNA

<213> Homo sapiens

<400> 194

```

aagcttgcca ccatggagac agacacactc ctgctatggg tactgctgct ctgggttcca 60
ggttccactg gtgacggatc catgagcgat aaaattattc acctgactga cgacagtttt 120
gacacggatg tactcaaagc ggacggggcg atcctcgtcg atttctgggc agagtgggtg 180
ggtccgaatt ccgggtggcg gtggtgtggt cgggtgtggg ctgtgtgtgtg gcggcgtgtt 240
actagtggtc cgtgcaaaa actgaacatc attctggatg aaatcgctga cgaatatcag 300
ggcaaaactga ccgttgcaaa actgaacatc gatcaaaacc ctggcactgc gccgaaatat 360
ggcatccgtg gtatcccgac tctgctgctg ttcaaaaacg gtgaagtggc ggcaacccaa 420
gtgggtgcac tgtctaaagg tcagttgaaa gagttcctcg acgctaacct ggcgtaagcg 480
gccgc

```

<210> 195

<211> 485

<212> DNA

<213> Homo sapiens

<400> 195

```

aagcttgcca ccatggagac agacacactc ctgctatggg tactgctgct ctgggttcca 60
ggttccactg gtgacggatc catgagcgat aaaattattc acctgactga cgacagtttt 120
gacacggatg tactcaaagc ggacggggcg atcctcgtcg atttctgggc agagtgggtg 180
ggtccgaatt ccgaggtgctg gcaggttacg tgtattaggt gtcgtcggg ttttctgttg 240
actagtggtc cgtgcaaaa actgaacatc attctggatg aaatcgctga cgaatatcag 300
ggcaaaactga ccgttgcaaa actgaacatc gatcaaaacc ctggcactgc gccgaaatat 360
ggcatccgtg gtatcccgac tctgctgctg ttcaaaaacg gtgaagtggc ggcaacccaa 420
gtgggtgcac tgtctaaagg tcagttgaaa gagttcctcg acgctaacct ggcgtaagcg 480
gccgc

```

<210> 196

<211> 485

<212> DNA

<213> Homo sapiens

<400> 196

```

aagcttgcca ccatggagac agacacactc ctgctatggg tactgctgct ctgggttcca 60
ggttccactg gtgacggatc catgagcgat aaaattattc acctgactga cgacagtttt 120
gacacggatg tactcaaagc ggacggggcg atcctcgtcg atttctgggc agagtgggtg 180
ggtccgaatt ccgggtggtg ggggatgatt tgggaggctt ggagttgtta tgcgtgtggg 240
actagtggtc cgtgcaaaa actgaacatc attctggatg aaatcgctga cgaatatcag 300
ggcaaaactga ccgttgcaaa actgaacatc gatcaaaacc ctggcactgc gccgaaatat 360
ggcatccgtg gtatcccgac tctgctgctg ttcaaaaacg gtgaagtggc ggcaacccaa 420

```

032796-132.ST25

gtgggtgcac tgtctaaagg tcagttgaaa gagttcctcg acgctaacct ggcgtaagcg 480
gccgc 485

<210> 197

<211> 485

<212> DNA

<213> Homo sapiens

<400> 197

aagcttgcca ccatggagac agacacactc ctgctatggg tactgctgct ctgggttcca 60
ggttccactg gtgacggatc catgagcgat aaaattattc acctgactga cgacagtttt 120
gacacggatg tactcaaagc ggacggggcg atcctcgtcg atttctgggc agagtgggtg 180
ggtccgaatt ccttgtggat tgggccgggt gatcagggtc tgtttcggcg ttttgttttt 240
actagtggtc cgtgcaaaat gatcgccccg attctggatg aaatcgctga cgaatatcag 300
ggcaaaactga ccgttgcaaa actgaacatc gatcaaaacc ctggcactgc gccgaaatat 360
ggcatccgtg gtatcccgac tctgctgctg ttcaaaaacg gtgaagtggc ggcaaccaaa 420
gtgggtgcac tgtctaaagg tcagttgaaa gagttcctcg acgctaacct ggcgtaagcg 480
gccgc 485

<210> 198

<211> 476

<212> DNA

<213> Homo sapiens

<400> 198

aagcttgcca ccatggagac agacacactc ctgctatggg tactgctgct ctgggttcca 60
ggttccactg gtgacggatc cgtgtcttct gatcaaaatc atttccgagg agaaattgag 120
gaaaccatca ctgaaagctt tggtaatgat catagcacct tggatgggta ttccagaaga 180
accaccttgt cttcaaaaat gtatcacacc aaaggacaag aagggttctgt ttgtctccgg 240
tcatcagact gtgcctcagg attgtgttgt gctagacact tctgggtccaa gatctgtaaa 300
cctgtcctga aagaaggatc agtgtgtacc aagcatagga gaaaaggctc tcatggacta 360
gaaatattcc agcgttggtt ctgtggagaa ggtctgtctt gccggatata gaaagatcac 420
catcaagcca gtaattcttc taggcttcac acttgtcaga gacactaagc ggccgc 476

<210> 199

<211> 539

<212> DNA

<213> Homo sapiens

<400> 199

aagcttgcca ccatggagac agacacactc ctgctatggg tactgctgct ctgggttcca 60
ggttccactg gtgacggatc ctgcgctagt cccaccgcg gaggggacgc ggcggtgcaa 120
atctgtctcg cctgcaggaa gcgccgaaaa cgctgcatgc gtcacgctat gtgctgcccc 180
gggaattact gcaaaaatgg aatatgtgtg tcttctgctc aaaatcattt ccgaggagaa 240
attgaggaaa ccatcactga aagcttttgt aatgatcata gcaccttggg tgggtattcc 300
agaagaacca ccttgtcttc aaaaatgtat cacaccaaaag gacaagaagg ttctgtttgt 360
ctccggtcat cagactgtgc ctcaggattg tgttgtgcta gacacttctg gtccaagatc 420
tgtaaacctg tcctgaaaga aggtcaagtg tgtaccaagc ataggagaaa aggtctctcat 480
ggactagaaa tattccagcg ttgttactgt ggagaaggctc tgtcttgcta agcggccgc 539

<210> 200

<211> 416

<212> DNA

<213> Homo sapiens

<400> 200

aagcttgcca ccatgggcca taaaattatt cacctgactg acgacagttt tgacacggat 60

032796-132.ST25

```

gtactcaaag cggacggggc gatcctcgtc gatttctggg cagagtgggt cgggccgaat 120
tcctatgcgt ggttggtttc ttgtagtagg ttaggtgggt ggttgccctg gactagtggg 180
ccgtgcaaaa tgatcgcccc gattctggat gaaatcgctg acgaatatca gggcaaactg 240
accgttgcaa aactgaacat cgatcaaaac cctggcactg cgccgaaata tggcatccgt 300
ggtatcccgga ctctgctgct gttcaaaaac ggtgaagtgg cggcaaccaa agtgggtgca 360
ctgtctaaaag gtcagttgaa agagttcctc gacgctaacc tggcgtaagc ggccgc 416

```

<210> 201

<211> 416

<212> DNA

<213> Homo sapiens

<400> 201

```

aagcttgcca ccatgggcca taaaattatt cacctgactg acgacagttt tgacacggat 60
gtactcaaac gccacggggc gatcctcgtc gatttctggg cagagtgggt cgggccgaat 120
tccatttggt aggttggtgag gttgtggagt cggatcctt ggtcttgggt gactagtggg 180
ccgtgcaaaa tgatcgcccc gattctggat gaaatcgctg acgaatatca gggcaaactg 240
accgttgcaa aactgaacat cgatcaaaac cctggcactg cgccgaaata tggcatccgt 300
ggtatcccgga ctctgctgct gttcaaaaac ggtgaagtgg cggcaaccaa agtgggtgca 360
ctgtctaaaag gtcagttgaa agagttcctc gacgctaacc tggcgtaagc ggccgc 416

```

<210> 202

<211> 422

<212> DNA

<213> Homo sapiens

<400> 202

```

aagcttgcca ccatgggcca taaaattatt cacctgactg acgacagttt tgacacggat 60
gtactcaaaag cggacggggc gatcctcgtc gatttctggg cagagtgggt cgggccgaat 120
tccggttgta ctagtgcggg gtgtgggtgct tgggctgagg cgggtagggt ttattgtact 180
agtgggccgt gcaaaatgat cgccccgatt ctggatgaaa tcgctgacga atatcagggc 240
aaactgaccg ttgcaaaact gaacatcgat caaaaccctg gactgcgcc gaaatatggc 300
atccgtggta tcccgaactc gctgctgttc aaaaacgggt aagtggcggc aaccaaagt 360
ggtgcactgt ctaaaggtca gttgaaagag ttcctcgacg ctaacctggc gtaagcggcc 420
gc 422

```

<210> 203

<211> 416

<212> DNA

<213> Homo sapiens

<400> 203

```

aagcttgcca ccatgggcca taaaattatt cacctgactg acgacagttt tgacacggat 60
gtactcaaaag cggacggggc gatcctcgtc gatttctggg cagagtgggt cgggccgaat 120
tccttggtgga ttgggccggg tgatcagggg ctgtttcggc gttttgttt tactagtggg 180
ccgtgcaaaa tgatcgcccc gattctggat gaaatcgctg acgaatatca gggcaaactg 240
accgttgcaa aactgaacat cgatcaaaac cctggcactg cgccgaaata tggcatccgt 300
ggtatcccgga ctctgctgct gttcaaaaac ggtgaagtgg cggcaaccaa agtgggtgca 360
ctgtctaaaag gtcagttgaa agagttcctc gacgctaacc tggcgtaagc ggccgc 416

```

<210> 204

<211> 154

<212> PRT

<213> Homo sapiens

<400> 204

032796-132.ST25

```

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
 1           5           10           15
Gly Ser Thr Gly Asp Gly Ser Met Ser Asp Lys Ile Ile His Leu Thr
 20           25           30
Asp Asp Ser Phe Asp Thr Asp Val Leu Lys Ala Asp Gly Ala Ile Leu
 35           40           45
Val Asp Phe Trp Ala Glu Trp Cys Gly Pro Asn Ser Val Val Leu Cys
 50           55           60
Ser Arg Cys Gly Arg Leu Trp Arg Trp Ser Cys Gly Thr Ser Gly Pro
 65           70           75           80
Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp Glu Tyr Gln
 85           90           95
Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn Pro Gly Thr
 100          105          110
Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu Leu Phe Lys
 115          120          125
Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu Ser Lys Gly Gln
 130          135          140
Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala
 145          150

```

<210> 205

<211> 154

<212> PRT

<213> Homo sapiens

<400> 205

```

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
 1           5           10           15
Gly Ser Thr Gly Asp Gly Ser Met Ser Asp Lys Ile Ile His Leu Thr
 20           25           30
Asp Asp Ser Phe Asp Thr Asp Val Leu Lys Ala Asp Gly Ala Ile Leu
 35           40           45
Val Asp Phe Trp Ala Glu Trp Cys Gly Pro Asn Ser Gly Trp Arg Trp
 50           55           60
Cys Gly Arg Cys Gly Ala Leu Trp Trp Arg Arg Val Thr Ser Gly Pro
 65           70           75           80
Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp Glu Tyr Gln
 85           90           95
Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn Pro Gly Thr
 100          105          110
Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu Leu Phe Lys
 115          120          125
Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu Ser Lys Gly Gln
 130          135          140
Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala
 145          150

```

<210> 206

<211> 154

<212> PRT

<213> Homo sapiens

<400> 206

```

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
 1           5           10           15

```

032796-132.ST25

Gly Ser Thr Gly Asp Gly Ser Met Ser Asp Lys Ile Ile His Leu Thr
 20 25 30
 Asp Asp Ser Phe Asp Thr Asp Val Leu Lys Ala Asp Gly Ala Ile Leu
 35 40 45
 Val Asp Phe Trp Ala Glu Trp Cys Gly Pro Asn Ser Glu Val Arg Gln
 50 55 60
 Val Thr Cys Ile Arg Cys Arg Arg Gly Phe Leu Thr Ser Gly Pro
 65 70 75 80
 Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp Glu Tyr Gln
 85 90 95
 Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn Pro Gly Thr
 100 105 110
 Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu Leu Phe Lys
 115 120 125
 Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu Ser Lys Gly Gln
 130 135 140
 Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala
 145 150

<210> 207
 <211> 154
 <212> PRT
 <213> Homo sapiens

<400> 207
 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
 1 5 10 15
 Gly Ser Thr Gly Asp Gly Ser Met Ser Asp Lys Ile Ile His Leu Thr
 20 25 30
 Asp Asp Ser Phe Asp Thr Asp Val Leu Lys Ala Asp Gly Ala Ile Leu
 35 40 45
 Val Asp Phe Trp Ala Glu Trp Cys Gly Pro Asn Ser Gly Gly Gly Gly
 50 55 60
 Met Ile Trp Glu Ala Trp Ser Cys Tyr Ala Cys Gly Thr Ser Gly Pro
 65 70 75 80
 Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp Glu Tyr Gln
 85 90 95
 Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn Pro Gly Thr
 100 105 110
 Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu Leu Phe Lys
 115 120 125
 Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu Ser Lys Gly Gln
 130 135 140
 Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala
 145 150

<210> 208
 <211> 154
 <212> PRT
 <213> Homo sapiens

<400> 208
 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
 1 5 10 15
 Gly Ser Thr Gly Asp Gly Ser Met Ser Asp Lys Ile Ile His Leu Thr

032796-132.ST25

```

      20      25      30
Asp Asp Ser Phe Asp Thr Asp Val Leu Lys Ala Asp Gly Ala Ile Leu
  35      40      45
Val Asp Phe Trp Ala Glu Trp Cys Gly Pro Asn Ser Leu Trp Ile Gly
  50      55      60
Pro Gly Asp Gln Gly Leu Phe Arg Arg Phe Val Phe Thr Ser Gly Pro
  65      70      75      80
Cys Lys Met Ile Ala Pro Ile Leu Asp Glu Ile Ala Asp Glu Tyr Gln
      85      90      95
Gly Lys Leu Thr Val Ala Lys Leu Asn Ile Asp Gln Asn Pro Gly Thr
      100      105      110
Ala Pro Lys Tyr Gly Ile Arg Gly Ile Pro Thr Leu Leu Leu Phe Lys
      115      120      125
Asn Gly Glu Val Ala Ala Thr Lys Val Gly Ala Leu Ser Lys Gly Gln
      130      135      140
Leu Lys Glu Phe Leu Asp Ala Asn Leu Ala
145      150

```

<210> 209

<211> 151

<212> PRT

<213> Homo sapiens

<400> 209

```

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
  1      5      10      15
Gly Ser Thr Gly Asp Gly Ser Val Ser Ser Asp Gln Asn His Phe Arg
      20      25      30
Gly Glu Ile Glu Glu Thr Ile Thr Glu Ser Phe Gly Asn Asp His Ser
      35      40      45
Thr Leu Asp Gly Tyr Ser Arg Arg Thr Thr Leu Ser Ser Lys Met Tyr
      50      55      60
His Thr Lys Gly Gln Glu Gly Ser Val Cys Leu Arg Ser Ser Asp Cys
      65      70      75      80
Ala Ser Gly Leu Cys Cys Ala Arg His Phe Trp Ser Lys Ile Cys Lys
      85      90      95
Pro Val Leu Lys Glu Gly Gln Val Cys Thr Lys His Arg Arg Lys Gly
      100      105      110
Ser His Gly Leu Glu Ile Phe Gln Arg Cys Tyr Cys Gly Glu Gly Leu
      115      120      125
Ser Cys Arg Ile Gln Lys Asp His His Gln Ala Ser Asn Ser Ser Arg
      130      135      140
Leu His Thr Cys Gln Arg His
145      150

```

<210> 210

<211> 172

<212> PRT

<213> Homo sapiens

<400> 210

```

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
  1      5      10      15
Gly Ser Thr Gly Asp Gly Ser Cys Ala Ser Pro Thr Arg Gly Gly Asp
      20      25      30
Ala Gly Val Gln Ile Cys Leu Ala Cys Arg Lys Arg Arg Lys Arg Cys

```

032796-132.ST25

```

      35              40              45
Met Arg His Ala Met Cys Cys Pro Gly Asn Tyr Cys Lys Asn Gly Ile
  50              55              60
Cys Val Ser Ser Asp Gln Asn His Phe Arg Gly Glu Ile Glu Glu Thr
  65              70              75              80
Ile Thr Glu Ser Phe Gly Asn Asp His Ser Thr Leu Asp Gly Tyr Ser
      85              90              95
Arg Arg Thr Thr Leu Ser Ser Lys Met Tyr His Thr Lys Gly Gln Glu
      100              105              110
Gly Ser Val Cys Leu Arg Ser Ser Asp Cys Ala Ser Gly Leu Cys Cys
      115              120              125
Ala Arg His Phe Trp Ser Lys Ile Cys Lys Pro Val Leu Lys Glu Gly
      130              135              140
Gln Val Cys Thr Lys His Arg Arg Lys Gly Ser His Gly Leu Glu Ile
      145              150              155              160
Phe Gln Arg Cys Tyr Cys Gly Glu Gly Leu Ser Cys
      165              170

```

<210> 211
 <211> 131
 <212> PRT
 <213> Homo sapiens

```

<400> 211
Met Gly Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp
  1              5              10              15
Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp
      20              25              30
Cys Gly Pro Asn Ser Tyr Ala Trp Leu Phe Ser Cys Ser Arg Cys Arg
  40              45
Trp Trp Leu Pro Trp Thr Ser Gly Pro Cys Lys Met Ile Ala Pro Ile
      50              55              60
Leu Asp Glu Ile Ala Asp Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys
  65              70              75              80
Leu Asn Ile Asp Gln Asn Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg
      85              90              95
Gly Ile Pro Thr Leu Leu Leu Phe Lys Asn Gly Glu Val Ala Ala Thr
      100              105              110
Lys Val Gly Ala Leu Ser Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala
      115              120              125
Asn Leu Ala
      130

```

<210> 212
 <211> 131
 <212> PRT
 <213> Homo sapiens

```

<400> 212
Met Gly Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp
  1              5              10              15
Val Leu Lys Arg His Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp
      20              25              30
Cys Gly Pro Asn Ser Ile Cys Glu Val Val Arg Leu Trp Ser Arg Tyr
      35              40              45
Pro Trp Ser Trp Val Thr Ser Gly Pro Cys Lys Met Ile Ala Pro Ile

```

032796-132.ST25

```

      50              55              60
Leu Asp Glu Ile Ala Asp Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys
65              70              75              80
Leu Asn Ile Asp Gln Asn Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg
      85              90              95
Gly Ile Pro Thr Leu Leu Leu Phe Lys Asn Gly Glu Val Ala Ala Thr
      100              105              110
Lys Val Gly Ala Leu Ser Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala
      115              120              125
Asn Leu Ala
      130

```

<210> 213
 <211> 133
 <212> PRT
 <213> Homo sapiens

```

<400> 213
Met Gly Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp
1              5              10              15
Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp
      20              25              30
Cys Gly Pro Asn Ser Gly Cys Thr Ser Ala Val Cys Gly Ala Trp Ala
      35              40              45
Glu Ala Gly Arg Phe Tyr Cys Thr Ser Gly Pro Cys Lys Met Ile Ala
      50              55              60
Pro Ile Leu Asp Glu Ile Ala Asp Glu Tyr Gln Gly Lys Leu Thr Val
65              70              75              80
Ala Lys Leu Asn Ile Asp Gln Asn Pro Gly Thr Ala Pro Lys Tyr Gly
      85              90              95
Ile Arg Gly Ile Pro Thr Leu Leu Leu Phe Lys Asn Gly Glu Val Ala
      100              105              110
Ala Thr Lys Val Gly Ala Leu Ser Lys Gly Gln Leu Lys Glu Phe Leu
      115              120              125
Asp Ala Asn Leu Ala
      130

```

<210> 214
 <211> 131
 <212> PRT
 <213> Homo sapiens


```

<400> 214
Met Gly Asp Lys Ile Ile His Leu Thr Asp Asp Ser Phe Asp Thr Asp
1              5              10              15
Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp Phe Trp Ala Glu Trp
      20              25              30
Cys Gly Pro Asn Ser Leu Trp Ile Gly Pro Gly Asp Gln Gly Leu Phe
      35              40              45
Arg Arg Phe Val Phe Thr Ser Gly Pro Cys Lys Met Ile Ala Pro Ile
      50              55              60
Leu Asp Glu Ile Ala Asp Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys
65              70              75              80
Leu Asn Ile Asp Gln Asn Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg
      85              90              95

```

032796-132.ST25

Gly Ile Pro Thr Leu Leu Leu Phe Lys Asn Gly Glu Val Ala Ala Thr
100 105 110
Lys Val Gly Ala Leu Ser Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala
115 120 125
Asn Leu Ala
130



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number
WO 02/092015 A3

(51) International Patent Classification⁷: **A61K 39/395**,
39/00, 39/38

19335 (US). **YAWORSKY, Paul, J.** [US/US]; 13 Hobart Lane, Rockland, MA 02370 (US).

(21) International Application Number: PCT/US02/15982

(74) Agents: **REA, Teresa, Stanek et al.**; Burns, Doane, Swecker & Mathis L.L.P., P.O. Box 1404, Alexandria, VA 22313-1404 (US).

(22) International Filing Date: 17 May 2002 (17.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/291,311 17 May 2001 (17.05.2001) US
60/353,058 1 February 2002 (01.02.2002) US
60/361,293 4 March 2002 (04.03.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*):
GENOME THERAPEUTICS CORPORATION [US/US]; 100 Beaver Street, Waltham, MA 02453 (US).
WYETH [US/US]; Five Giralda Farms, Madison, NJ 07928 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ALLEN, Kristina** [US/US]; 11 Oliver Lane, Hopkinton, MA 01748-3108 (US). **ANISOWICZ, Anthony** [US/US]; 50 Upham Street, West Newton, MA 02465 (US). **BHAT, Bheem, M.** [IN/US]; 1214 Mayapple Lane, West Chester, PA 19380 (US). **DAMAGNEZ, Veronique** [FR/US]; 125 Water Street, Framingham, MA 01701 (US). **ROBINSON, John, Allen** [US/US]; 23 Webb Road, Downingtown, PA

Published:

— with international search report

(88) Date of publication of the international search report:
23 October 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: REAGENTS AND METHODS FOR MODULATING DKK-MEDIATED INTERACTIONS

(57) Abstract: The present invention provides reagents, compounds, compositions, and methods relating to novel interactions of the extracellular domain of LRP5, HBM (a variant of LRP5), and/or LRP6 with Dkk, including Dkk-1. The various nucleic acids, polypeptides, antibodies, assay methods, diagnostic methods, and methods of treatment of the present invention are related to and impact on Dkk, LRP5, LRP6, HBM, and Wnt signaling. Dkk, LRP5, LRP6, HBM, and Wnt are implicated in bone and lipid cellular signaling. Thus, the present invention provides reagents and methods for modulating lipid levels and/or bone mass and is useful in the treatment and diagnosis of abnormal lipid levels and bone mass disorders, such as osteoporosis.

WO 02/092015 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/15982

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 39/395, 00, 38

US CL : 424/130.1, 184.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/130.1, 184.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GONG, Y et al. LDL RECEPTOR-RELATED PROTEIN 5 (LRP-5) AFFECTS BONE ACCRUAL AND EYE DEVELOPMENT, CELL, 2001 VOL. 107, PAGES 513-523	1-11 and 13-23
	ZORN A. WNT SIGNALLING: ANTAGONISTIC DICKKOPFS, CURRENT BIOLOGY, 2001, VOL. 11, No. 15, PAGES R592-R595	1-11 and 13-23
A	WO 9846743 A1 (THE WELL-COME TRUST LIMITED), 22 OCTOBER 1998 (22.10.98) see entire document.	1-11 and 13-23

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

18 March 2003 (18.03.2003)

Date of mailing of the international search report

08 AUG 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized Officer

Valerie Bell-Hanno
Michael A. Belyavsky

Telephone No. 703/308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/15982

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-11 and 13-23

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

I. Claims 1-11 and 13-23, drawn to a method of regulating LRP5 activity in a subject, comprising administering a composition which inhibits Dkk binding to LRP5.

II. Claims 1-11 and 13-20, drawn to a method of regulating LRP5 activity in a subject, comprising administering a composition which inhibits Dkk binding to LRP6.

III. Claims 1-11 and 13-20, drawn to a method of regulating LRP5 activity in a subject, comprising administering a composition which inhibits Dkk binding to HBM.

IV. Claims 1-10, 12-14 and 16-23 drawn to a method of regulating LRP5 activity in a subject, comprising administering a composition which enhances Dkk binding to LRP5.

V. Claims 1-10, 12-14 and 16-20, drawn to a method of regulating LRP5 activity in a subject, comprising administering a composition which enhances Dkk binding to LRP6.

VI. Claims 1-10, 12-14 and 16-20, drawn to a method of regulating LRP5 activity in a subject, comprising administering a composition which enhances Dkk binding to HBM.

VII. Claims 2 - 4, 7-11, 13-20, 21-27, drawn to a method of regulating Dkk-Wnt pathway activity, comprising administering a composition which modulates Dkk activity, or interaction with LRP5, wherein said composition inhibits Dkk binding to LRP5.

VIII. Claims 2 - 4, 7-11, 13-20, 24-27, drawn to a method of regulating Dkk-Wnt pathway activity, comprising administering a composition which modulates Dkk activity, or interaction with LRP6, wherein said composition inhibits Dkk binding to LRP6.

IX. Claims 2 - 4, 7-11, 13-20, 24-27, drawn to a method of regulating Dkk-Wnt pathway activity, comprising administering a composition which modulates Dkk activity, or interaction with HBM, wherein said composition inhibits Dkk binding to HBM.

X. Claims 2 - 4, 7-10, 12-27, drawn to a method of regulating Dkk-Wnt pathway activity, comprising administering a composition which modulates Dkk activity, or interaction with LRP5, wherein said composition enhances Dkk binding to LRP5.

XI. Claims 2 - 4, 7-10, 12-20, 24-27, drawn to a method of regulating Dkk-Wnt pathway activity, comprising administering a composition which modulates Dkk activity, or interaction with LRP6, wherein said composition enhances Dkk binding to LRP6.

XII. Claims 2 - 4, 7-10, 12-20, 24-27, drawn to a method of regulating Dkk-Wnt pathway activity, comprising administering a composition which modulates Dkk activity, or interaction with HBM, wherein said composition enhances Dkk binding to HBM.

XIII. Claims 2 - 4, 7-11, 13-23, 28-32 drawn to a method of modulating bone mass in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP5, wherein said composition inhibits Dkk binding to LRP5.

XIV. Claims 2 - 4, 7-11, 13-23, 28-32 drawn to a method of modulating bone mass in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP6, wherein said composition inhibits Dkk binding to LRP6.

XV. Claims 2 - 4, 7-11, 13-23, 28-32 drawn to a method of modulating bone mass in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with HBM, wherein said composition inhibits Dkk binding to HBM.

INTERNATIONAL SEARCH REPORT

XVI. Claims 2 - 4, 7-10, 12-23, 28-32 drawn to a method of modulating bone mass in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP5, wherein said composition enhances Dkk binding to LRP5.

XIV. Claims 2 - 4, 7-10, 12-20, 28-32 drawn to a method of modulating bone mass in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP6, wherein said composition enhances Dkk binding to LRP6.

XV. Claims 2 - 4, 7-10, 12-20, 28-32 drawn to a method of modulating bone mass in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with HBM, wherein said composition enhances Dkk binding to HBM.

XVI. Claims 2 - 4, 7-11, 13-23, 33-35 drawn to a method of modulating lipid levels in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP5, wherein said composition inhibits Dkk binding to LRP5.

XVII. XVI. Claims 2 - 4, 7-11, 13-23, 33-35 drawn to a method of modulating lipid levels in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP6, wherein said composition inhibits Dkk binding to LRP6.

XVIII. Claims 2 - 4, 7-11, 13-23, 33-35 drawn to a method of modulating lipid levels in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with HBM, wherein said composition inhibits Dkk binding to HBM.

XIX. Claims 2 - 4, 7-10, 12-23, 33-35 drawn to a method of modulating lipid levels in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP5, wherein said composition enhances Dkk binding to LRP5.

XX. Claims 2 - 4, 7-10, 12-20, 33-35 drawn to a method of modulating lipid levels in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP6, wherein said composition enhances Dkk binding to LRP6.

XXI. Claims 2 - 4, 7-10, 12-20, 33-35 drawn to a method of modulating lipid levels in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with HBM, wherein said composition enhances Dkk binding to HBM.

XXII. Claims 2, 35 and 36 drawn to a method of diagnosing low or high bone mass and /or high or low lipid levels in a subject comprising examining expression of Dkk.

XXIII. Claims 2, 35 and 36 drawn to a method of diagnosing low or high bone mass and /or high or low lipid levels in a subject comprising examining expression of LRP5.

XXIV. Claims 2, 35 and 36 drawn to a method of diagnosing low or high bone mass and /or high or low lipid levels in a subject comprising examining expression of LRP6.

XXV. Claims 2, 35 and 36 drawn to a method of diagnosing low or high bone mass and /or high or low lipid levels in a subject comprising examining expression of HBM.

XXVI. Claims 2, 37-43, 44-47, drawn to a method of screening for a compound which modulates the interaction of DKK with LRP5.

XXVII. Claims 2, 37-43, 47, drawn to a method of screening for a compound which modulates the interaction of DKK with LRP6.

XXVIII. Claims 2, 37-43, 47, drawn to a method of screening for a compound which modulates the interaction of DKK with HBM.

XXIX. Claims 2, 41-43, 48-49, drawn to a method of screening for a compound which modulates the interaction of Dkk with a Dkk interacting proteins.

INTERNATIONAL SEARCH REPORT

PCT/US02/15982

XXX. Claims 50-63 drawn to a composition comprising a LRP5 and a pharmaceutical acceptable carrier thereof.

XXXI. Claims 50- 59, 63 drawn to a composition comprising a LRP6 and a pharmaceutical acceptable carrier thereof.

XXXII. Claims 50- 59, 63 drawn to a composition comprising a HBM and a pharmaceutical acceptable carrier thereof.

XXXIII. Claims 2 and 64 drawn to a method for identifying compound which modulate Dkk and LRP5 interaction.

XXXIV. Claims 2 and 64 drawn to a method for identifying compound which modulate Dkk and LRP6 interaction.

XXXV. Claims 2 and 64 drawn to a method for identifying compound which modulate Dkk and HBM interaction.

XXXVI. Claims 2 and 65 drawn to a method of identifying binding partners for a Dkk protein.

XXXVII. Claims 66-68 drawn to a nucleic acid and a vector encoding a Dkk interacting protein.

XXXVIII. Claims 69-90, drawn to a method of detecting a modulatory activity of a compound, wherein the first peptide is a Dkk peptide and the second peptide is a LRP5.

XXXIX. Claims 69-87, drawn to a method of detecting a modulatory activity of a compound, wherein the first peptide is a Dkk peptide and the second peptide is a LRP6.

XL. Claims 69-87, drawn to a method of detecting a modulatory activity of a compound, wherein the first peptide is a Dkk peptide and the second peptide is a HBM.

XLI. Claims 91-92 drawn to a transgenic animal.

XLII. Claims 2 and 93 drawn to a method for identifying potential compound which modulate Dkk activity.

XLIII - LXII. Claim 94, drawn to one specific peptide aptamer of one specific SEQ ID NOs : 171-88; 189-192.

LXIII- LXXIX. Claims 95-97, drawn to an antibody which specifically recognizes and binds to specific peptides of SEQ ID NOs : 110-127.

LXXX . Claims 2, 98-100 , drawn to a method of identifying Dkk interacting protein which modulate the interaction of Dkk with Wnt signaling pathway.

LXXXI. Claims 2, 25 and 101-104, drawn to a method for identifying Dkk interacting proteins.

LXXXII. Claims 2, 105-106, drawn to a method for identifying compounds which modulate Dkk and LRP5 interaction.

LXXXIII. Claims 2, 105-106, drawn to a method for identifying compounds which modulate Dkk and LRP6 interaction.

LXXXIV. Claims 2, 105-106, drawn to a method for identifying compounds which modulate Dkk and HBM interaction.

LXXXV. Claims 2, 25, 107-110, drawn to a method for identifying compound which modulate the interaction of Dkk with Wnt signaling pathway.

LXXXVI. Claims 2, 111, drawn to a method of testing compounds that modulate Dkk-mediated activity in a mammal.

LXXXVII. Claims 2, 112, 113, drawn to method of screening for compound or composition which modulate the interaction of Dkk and Dkk interacting protein.

LXXXVIII-CIX. Claim 114 drawn to antibody which recognizes and binds to one specific SEQ ID NOs: 171-192.

INTERNATIONAL SEARCH REPORT

PCT/US02/15982

The inventions listed as Groups 1-109 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The invention listed as groups 1-109 do not related to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, hey lack the same or corresponding special technical features for the following reasons:

The special technical features of Group I is considered a method of regulating LRP5 activity in a subject, comprising administering a composition which inhibits Dkk binding to LRP5.

The special technical features of Group II is considered a method of regulating LRP5 activity in a subject, comprising administering a composition which inhibits Dkk binding to LRP6.

The special technical features of Group III is considered a method of regulating LRP5 activity in a subject, comprising administering a composition which inhibits Dkk binding to HBM.

The special technical features of Group IV is considered a method of regulating LRP5 activity in a subject, comprising administering a composition which enhances Dkk binding to LRP5.

The special technical features of Group V is considered a method of regulating LRP5 activity in a subject, comprising administering a composition which enhances Dkk binding to LRP6.

The special technical features of Group VI is considered a method of regulating LRP5 activity in a subject, comprising administering a composition which enhances Dkk binding to HBM.

INTERNATIONAL SEARCH REPORT

PCT/US02/15982

The special technical features of Group VII is considered a method of regulating Dkk-Wnt pathway activity, comprising administering a composition which modulates Dkk activity, or interaction with LRP5, wherein said composition inhibits Dkk binding to LRP5.

The special technical features of Group VIII is considered a method of regulating Dkk-Wnt pathway activity, comprising administering a composition which modulates Dkk activity, or interaction with LRP6, wherein said composition inhibits Dkk binding to LRP6.

The special technical features of Group IX is considered a method of regulating Dkk-Wnt pathway activity, comprising administering a composition which modulates Dkk activity, or interaction with HBM, wherein said composition inhibits Dkk binding to HBM.

The special technical features of Group X is considered a method of regulating Dkk-Wnt pathway activity, comprising administering a composition which modulates Dkk activity, or interaction with RP5, wherein said composition enhances Dkk binding to LRP5.

The special technical features of Group XI is considered a method of regulating Dkk-Wnt pathway activity, comprising administering a composition which modulates Dkk activity, or interaction with LRP6, wherein said composition enhances Dkk binding to LRP6.

The special technical features of Group XII is considered a method of regulating Dkk-Wnt pathway activity, comprising administering a composition which modulates Dkk activity, or interaction with HBM, wherein said composition enhances Dkk binding to HBM.

The special technical features of Group XIII is considered a method of modulating bone mass in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP5, wherein said composition inhibits Dkk binding to LRP5.

The special technical features of Group XIV is considered a method of modulating bone mass in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP6, wherein said composition inhibits Dkk binding to LRP6.

The special technical features of Group XV is considered a method of modulating bone mass in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with HBM, wherein said composition inhibits Dkk binding to HBM.

The special technical features of Group XVI is considered a method of modulating bone mass in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP5, wherein said composition enhances Dkk binding to LRP5.

The special technical features of Group XIV is considered a method of modulating bone mass in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP6, wherein said composition enhances Dkk binding to LRP6.

The special technical features of Group XV is considered a method of modulating bone mass in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with HBM, wherein said composition enhances Dkk binding to HBM.

The special technical features of Group XVI is considered a method of modulating lipid levels in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP5, wherein said composition inhibits Dkk binding to LRP5.

The special technical features of Group XVII is considered a method of modulating lipid levels in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP6, wherein said composition inhibits Dkk binding to LRP6.

The special technical features of Group XVIII is considered a method of modulating lipid levels in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with HBM, wherein said composition inhibits Dkk binding to HBM.

The special technical features of Group XIX is considered a method of modulating lipid levels in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP5, wherein said composition enhances Dkk binding to LRP5.

INTERNATIONAL SEARCH REPORT

PCT/US02/15982

The special technical features of Group XX is considered a method of modulating lipid levels in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with LRP6, wherein said composition enhances Dkk binding to LRP6.

The special technical features of Group XXI is considered a method of modulating lipid levels in a subject comprising administering to the subject a composition which modulates DKK activity or interaction with HBM, wherein said composition enhances Dkk binding to HBM.

The special technical features of Group XXII is considered a method of diagnosing low or high bone mass and /or high or low lipid levels in a subject comprising examining expression of Dkk.

The special technical features of Group XXIII is considered a method of diagnosing low or high bone mass and /or high or low lipid levels in a subject comprising examining expression of LRP5.

The special technical features of Group XXIV is considered a method of diagnosing low or high bone mass and /or high or low lipid levels in a subject comprising examining expression of LRP6.

The special technical features of Group XXV is considered a method of diagnosing low or high bone mass and /or high or low lipid levels in a subject comprising examining expression of HBM.

The special technical features of Group XXVI is considered a method of screening for a compound which modulates the interaction of DKK with LRP5.

The special technical features of Group XXVII is considered a method of screening for a compound which modulates the interaction of DKK with LRP6.

The special technical features of Group XXVIII is considered a method of screening for a compound which modulates the interaction of DKK with HBM.

The special technical features of Group XXIX is considered a method of screening for a compound which modulates the interaction of Dkk with a Dkk interacting proteins.

The special technical features of Group XXX is considered a composition comprising a LRP5 and a pharmaceutical acceptable carrier thereof.

The special technical features of Group XXXI is considered a composition comprising a LRP6 and a pharmaceutical acceptable carrier thereof.

The special technical features of Group XXXII is considered a composition comprising a HBM and a pharmaceutical acceptable carrier thereof.

The special technical features of Group XXXIII is considered a method for identifying compound which modulate Dkk and LRP5 interaction.

The special technical features of Group XXXIV is considered a method for identifying compound which modulate Dkk and LRP6 interaction.

The special technical features of Group XXXV is considered a method for identifying compound which modulate Dkk and HBM interaction.

The special technical features of Group XXXVI is considered a method of identifying binding partners for a Dkk protein.

The special technical features of Group XXXVII is considered a nucleic acid and a vector encoding a Dkk interacting protein.

The special technical features of Group XXXVIII is considered a method of detecting a modulatory activity of a compound, wherein the first peptide is a Dkk peptide and the second peptide is a LRP5.

INTERNATIONAL SEARCH REPORT

PCT/US02/15982

The special technical features of Group XXXIX is considered a method of detecting a modulatory activity of a compound, wherein the first peptide is a Dkk peptide and the second peptide is a LRP6.

The special technical features of Group XL is considered a method of detecting a modulatory activity of a compound, wherein the first peptide is a Dkk peptide and the second peptide is a HBM.

The special technical features of Group XLI is considered a transgenic animal.

The special technical features of Group XLII is considered a method for identifying potential compound which modulate Dkk activity.

The special technical features of Group XLIII - LXII is considered one specific peptide aptamer of one specific SEQ ID NOs : 171-88; 189-192.

The special technical features of Group LXIII- LXXIX is considered an antibody which specifically recognizes and binds to specific peptides of SEQ ID NOs : 110-127.

The special technical features of Group LXXX is considered a method of identifying Dkk interacting protein which modulate the interaction of Dkk with Wnt signaling pathway.

The special technical features of Group LXXXI is considered a method for identifying Dkk interacting proteins.

The special technical features of Group LXXXII is considered a method for identifying compounds which modulate Dkk and LRP5 interaction.

The special technical features of Group LXXXIII is considered a method for identifying compounds which modulate Dkk and LRP6 interaction.

The special technical features of Group LXXXIV is considered a method for identifying compounds which modulate Dkk and HBM interaction.

The special technical features of Group LXXXV is considered a method for identifying compound which modulate the interaction of Dkk with Wnt signaling pathway.

The special technical features of Group LXXXVI is considered a method of testing compounds that modulate Dkk-mediated activity in a mammal.

The special technical features of Group LXXXVII is considered a method of screening for compound or composition which modulate the interaction of Dkk and Dkk interacting protein.

The special technical features of Group LXXXVIII-CIX. is considered an antibody which recognizes and binds to one specific SEQ ID NOs: 171-192.

Accordingly, Groups I-CIX are not so linked by the same or corresponding special technical feature within meaning of PCT Rule 13.2 so as to form a single general inventive concept.

Continuation of B. FIELDS SEARCHED Item 3:

INTERNATIONAL SEARCH REPORT

PCT/US02/15982

Biosis, CAPLUS, SciSearch, Medline, EMBASE, WEST, USPATFULL, PCTFULL
search terms; Allen K; Anisowicz, A; Bhat, B; Damagnez, V, Robinson, J; Yaworsky, P; DKK, Dkk1, LRP5, SEQ ID NO:28, protein
OST262; osteoporosis.